0001564590-21-042834.txt : 20210810 0001564590-21-042834.hdr.sgml : 20210810 20210809213252 ACCESSION NUMBER: 0001564590-21-042834 CONFORMED SUBMISSION TYPE: 10-Q PUBLIC DOCUMENT COUNT: 86 CONFORMED PERIOD OF REPORT: 20210630 FILED AS OF DATE: 20210810 DATE AS OF CHANGE: 20210809 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Fulgent Genetics, Inc. CENTRAL INDEX KEY: 0001674930 STANDARD INDUSTRIAL CLASSIFICATION: SERVICES-MEDICAL LABORATORIES [8071] IRS NUMBER: 812621304 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 10-Q SEC ACT: 1934 Act SEC FILE NUMBER: 001-37894 FILM NUMBER: 211158177 BUSINESS ADDRESS: STREET 1: 4978 SANTA ANITA AVENUE, SUITE 205 CITY: TEMPLE CITY STATE: CA ZIP: 91780 BUSINESS PHONE: 626-350-0537 MAIL ADDRESS: STREET 1: 4978 SANTA ANITA AVENUE, SUITE 205 CITY: TEMPLE CITY STATE: CA ZIP: 91780 FORMER COMPANY: FORMER CONFORMED NAME: Fulgent Diagnostics, Inc. DATE OF NAME CHANGE: 20160517 10-Q 1 flgt-10q_20210630.htm 10-Q flgt-10q_20210630.htm
false Q2 0001674930 --12-31 0.20 0.24 0.16 0.11 true us-gaap:AccountingStandardsUpdate201613Member true true true true 0.20 0.24 flgt:TestingServicesMember flgt:TestingServicesMember flgt:TestingServicesMember flgt:TestingServicesMember us-gaap:OtherAssetsNoncurrent us-gaap:OtherAssetsNoncurrent us-gaap:OtherLiabilitiesCurrent us-gaap:OtherLiabilitiesCurrent us-gaap:OtherLiabilitiesNoncurrent us-gaap:OtherLiabilitiesNoncurrent 0001674930 2021-01-01 2021-06-30 xbrli:shares 0001674930 2021-08-01 iso4217:USD 0001674930 2021-06-30 0001674930 2020-12-31 iso4217:USD xbrli:shares 0001674930 2021-04-01 2021-06-30 0001674930 2020-04-01 2020-06-30 0001674930 2020-01-01 2020-06-30 0001674930 us-gaap:CommonStockMember 2020-12-31 0001674930 us-gaap:AdditionalPaidInCapitalMember 2020-12-31 0001674930 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2020-12-31 0001674930 us-gaap:RetainedEarningsMember 2020-12-31 0001674930 us-gaap:ParentMember 2020-12-31 0001674930 us-gaap:AdditionalPaidInCapitalMember 2021-01-01 2021-03-31 0001674930 us-gaap:ParentMember 2021-01-01 2021-03-31 0001674930 2021-01-01 2021-03-31 0001674930 us-gaap:CommonStockMember 2021-01-01 2021-03-31 0001674930 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2021-01-01 2021-03-31 0001674930 srt:CumulativeEffectPeriodOfAdoptionAdjustmentMember us-gaap:RetainedEarningsMember 2020-12-31 0001674930 srt:CumulativeEffectPeriodOfAdoptionAdjustmentMember us-gaap:ParentMember 2020-12-31 0001674930 srt:CumulativeEffectPeriodOfAdoptionAdjustmentMember 2020-12-31 0001674930 us-gaap:RetainedEarningsMember 2021-01-01 2021-03-31 0001674930 us-gaap:CommonStockMember 2021-03-31 0001674930 us-gaap:AdditionalPaidInCapitalMember 2021-03-31 0001674930 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2021-03-31 0001674930 us-gaap:RetainedEarningsMember 2021-03-31 0001674930 us-gaap:ParentMember 2021-03-31 0001674930 2021-03-31 0001674930 us-gaap:AdditionalPaidInCapitalMember 2021-04-01 2021-06-30 0001674930 us-gaap:ParentMember 2021-04-01 2021-06-30 0001674930 us-gaap:CommonStockMember 2021-04-01 2021-06-30 0001674930 us-gaap:NoncontrollingInterestMember 2021-04-01 2021-06-30 0001674930 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2021-04-01 2021-06-30 0001674930 us-gaap:RetainedEarningsMember 2021-04-01 2021-06-30 0001674930 us-gaap:CommonStockMember 2021-06-30 0001674930 us-gaap:AdditionalPaidInCapitalMember 2021-06-30 0001674930 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2021-06-30 0001674930 us-gaap:RetainedEarningsMember 2021-06-30 0001674930 us-gaap:ParentMember 2021-06-30 0001674930 us-gaap:NoncontrollingInterestMember 2021-06-30 0001674930 flgt:NovemberTwoThousandTwentyEquityDistributionAgreementMember 2021-03-31 0001674930 flgt:NovemberTwoThousandTwentyEquityDistributionAgreementMember 2021-06-30 0001674930 us-gaap:CommonStockMember 2019-12-31 0001674930 us-gaap:AdditionalPaidInCapitalMember 2019-12-31 0001674930 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2019-12-31 0001674930 us-gaap:RetainedEarningsMember 2019-12-31 0001674930 2019-12-31 0001674930 us-gaap:AdditionalPaidInCapitalMember 2020-01-01 2020-03-31 0001674930 2020-01-01 2020-03-31 0001674930 us-gaap:CommonStockMember 2020-01-01 2020-03-31 0001674930 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2020-01-01 2020-03-31 0001674930 us-gaap:RetainedEarningsMember 2020-01-01 2020-03-31 0001674930 us-gaap:CommonStockMember 2020-03-31 0001674930 us-gaap:AdditionalPaidInCapitalMember 2020-03-31 0001674930 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2020-03-31 0001674930 us-gaap:RetainedEarningsMember 2020-03-31 0001674930 2020-03-31 0001674930 us-gaap:AdditionalPaidInCapitalMember 2020-04-01 2020-06-30 0001674930 us-gaap:CommonStockMember 2020-04-01 2020-06-30 0001674930 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2020-04-01 2020-06-30 0001674930 us-gaap:RetainedEarningsMember 2020-04-01 2020-06-30 0001674930 us-gaap:CommonStockMember 2020-06-30 0001674930 us-gaap:AdditionalPaidInCapitalMember 2020-06-30 0001674930 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2020-06-30 0001674930 us-gaap:RetainedEarningsMember 2020-06-30 0001674930 2020-06-30 0001674930 us-gaap:AccountingStandardsUpdate201409Member 2021-01-01 2021-06-30 0001674930 flgt:FFGeneBiotechMember 2021-01-01 2021-06-30 flgt:Customer 0001674930 us-gaap:CustomerConcentrationRiskMember us-gaap:SalesRevenueNetMember 2021-04-01 2021-06-30 0001674930 us-gaap:CustomerConcentrationRiskMember us-gaap:SalesRevenueNetMember 2021-01-01 2021-06-30 xbrli:pure 0001674930 us-gaap:CustomerConcentrationRiskMember us-gaap:SalesRevenueNetMember flgt:CustomerOneMember 2021-04-01 2021-06-30 0001674930 us-gaap:CustomerConcentrationRiskMember us-gaap:SalesRevenueNetMember flgt:CustomerOneMember 2021-01-01 2021-06-30 0001674930 us-gaap:CustomerConcentrationRiskMember us-gaap:SalesRevenueNetMember flgt:CustomerTwoMember 2021-04-01 2021-06-30 0001674930 us-gaap:CustomerConcentrationRiskMember us-gaap:SalesRevenueNetMember flgt:CustomerTwoMember 2021-01-01 2021-06-30 0001674930 us-gaap:CustomerConcentrationRiskMember us-gaap:SalesRevenueNetMember 2020-04-01 2020-06-30 0001674930 us-gaap:CustomerConcentrationRiskMember us-gaap:SalesRevenueNetMember 2020-01-01 2020-06-30 0001674930 us-gaap:CustomerConcentrationRiskMember us-gaap:SalesRevenueNetMember flgt:CustomerOneMember 2020-04-01 2020-06-30 0001674930 us-gaap:CustomerConcentrationRiskMember us-gaap:SalesRevenueNetMember flgt:CustomerOneMember 2020-01-01 2020-06-30 0001674930 us-gaap:CustomerConcentrationRiskMember us-gaap:AccountsReceivableMember 2020-01-01 2020-12-31 0001674930 us-gaap:CustomerConcentrationRiskMember us-gaap:AccountsReceivableMember 2021-01-01 2021-06-30 0001674930 us-gaap:CustomerConcentrationRiskMember us-gaap:AccountsReceivableMember srt:MinimumMember 2020-01-01 2020-12-31 0001674930 us-gaap:AccountingStandardsUpdate201409Member 2021-04-01 2021-06-30 0001674930 us-gaap:AccountingStandardsUpdate201409Member 2020-04-01 2020-06-30 0001674930 us-gaap:AccountingStandardsUpdate201409Member 2020-01-01 2020-06-30 0001674930 flgt:ClinicalInstitutionalContractsMember us-gaap:AccountingStandardsUpdate201409Member 2021-04-01 2021-06-30 0001674930 flgt:ClinicalInstitutionalContractsMember us-gaap:AccountingStandardsUpdate201409Member 2020-04-01 2020-06-30 0001674930 flgt:ClinicalInstitutionalContractsMember us-gaap:AccountingStandardsUpdate201409Member 2021-01-01 2021-06-30 0001674930 flgt:ClinicalInstitutionalContractsMember us-gaap:AccountingStandardsUpdate201409Member 2020-01-01 2020-06-30 0001674930 flgt:ClinicalInsuranceContractsMember us-gaap:AccountingStandardsUpdate201409Member 2021-04-01 2021-06-30 0001674930 flgt:ClinicalInsuranceContractsMember us-gaap:AccountingStandardsUpdate201409Member 2020-04-01 2020-06-30 0001674930 flgt:ClinicalInsuranceContractsMember us-gaap:AccountingStandardsUpdate201409Member 2021-01-01 2021-06-30 0001674930 flgt:ClinicalInsuranceContractsMember us-gaap:AccountingStandardsUpdate201409Member 2020-01-01 2020-06-30 0001674930 flgt:ClinicalPatientContractsMember us-gaap:AccountingStandardsUpdate201409Member 2021-04-01 2021-06-30 0001674930 flgt:ClinicalPatientContractsMember us-gaap:AccountingStandardsUpdate201409Member 2020-04-01 2020-06-30 0001674930 flgt:ClinicalPatientContractsMember us-gaap:AccountingStandardsUpdate201409Member 2021-01-01 2021-06-30 0001674930 flgt:ClinicalPatientContractsMember us-gaap:AccountingStandardsUpdate201409Member 2020-01-01 2020-06-30 0001674930 us-gaap:OtherCurrentAssetsMember 2021-06-30 0001674930 us-gaap:OtherCurrentAssetsMember 2020-12-31 0001674930 srt:CumulativeEffectPeriodOfAdoptionAdjustmentMember us-gaap:AccountingStandardsUpdate201613Member us-gaap:RetainedEarningsMember 2021-06-30 0001674930 srt:CumulativeEffectPeriodOfAdoptionAdjustmentMember us-gaap:AccountingStandardsUpdate201613Member us-gaap:RetainedEarningsMember us-gaap:OtherNoncurrentAssetsMember 2021-01-01 2021-06-30 0001674930 us-gaap:AccountingStandardsUpdate201912Member 2021-06-30 0001674930 flgt:ShortTermMarketableSecuritesMember us-gaap:CorporateDebtSecuritiesMember 2021-06-30 0001674930 flgt:ShortTermMarketableSecuritesMember us-gaap:MunicipalBondsMember 2021-06-30 0001674930 flgt:MarketableSecuritiesDueAfterOneYearThroughFiveYearsMember us-gaap:CorporateDebtSecuritiesMember 2021-06-30 0001674930 flgt:MarketableSecuritiesDueAfterOneYearThroughFiveYearsMember us-gaap:MunicipalBondsMember 2021-06-30 0001674930 flgt:MarketableSecuritiesDueAfterOneYearThroughFiveYearsMember flgt:YankeeDebtSecuritiesMember 2021-06-30 0001674930 flgt:MarketableSecuritiesDueAfterOneYearThroughFiveYearsMember us-gaap:USGovernmentAgenciesDebtSecuritiesMember 2021-06-30 0001674930 flgt:MarketableSecuritiesDueAfterFiveYearsThroughTenYearsMember us-gaap:MunicipalBondsMember 2021-06-30 0001674930 flgt:ShortTermMarketableSecuritesMember us-gaap:MoneyMarketFundsMember 2021-06-30 0001674930 flgt:ShortTermMarketableSecuritesMember us-gaap:BondsMember 2021-06-30 0001674930 flgt:ShortTermMarketableSecuritesMember us-gaap:ExchangeTradedFundsMember 2021-06-30 0001674930 flgt:ShortTermMarketableSecuritesMember 2021-06-30 0001674930 flgt:MarketableSecuritiesDueAfterOneYearThroughFiveYearsMember 2021-06-30 0001674930 flgt:MarketableSecuritiesDueAfterFiveYearsThroughTenYearsMember 2021-06-30 0001674930 flgt:ShortTermMarketableSecuritesMember us-gaap:CorporateDebtSecuritiesMember 2020-12-31 0001674930 flgt:MarketableSecuritiesDueAfterOneYearThroughFiveYearsMember us-gaap:CorporateDebtSecuritiesMember 2020-12-31 0001674930 flgt:MarketableSecuritiesDueAfterOneYearThroughFiveYearsMember us-gaap:USGovernmentAgenciesDebtSecuritiesMember 2020-12-31 0001674930 flgt:MarketableSecuritiesDueAfterOneYearThroughFiveYearsMember flgt:YankeeDebtSecuritiesMember 2020-12-31 0001674930 flgt:ShortTermMarketableSecuritesMember us-gaap:MoneyMarketFundsMember 2020-12-31 0001674930 flgt:ShortTermMarketableSecuritesMember us-gaap:BondsMember 2020-12-31 0001674930 flgt:ShortTermMarketableSecuritesMember us-gaap:ExchangeTradedFundsMember 2020-12-31 0001674930 flgt:ShortTermMarketableSecuritesMember 2020-12-31 0001674930 flgt:MarketableSecuritiesDueAfterOneYearThroughFiveYearsMember 2020-12-31 0001674930 2020-01-01 2020-12-31 0001674930 flgt:MarginAccountBorrowingMember 2021-06-30 0001674930 us-gaap:FairValueMeasurementsRecurringMember us-gaap:BondsMember 2021-06-30 0001674930 us-gaap:FairValueMeasurementsRecurringMember us-gaap:FairValueInputsLevel1Member us-gaap:BondsMember 2021-06-30 0001674930 us-gaap:FairValueMeasurementsRecurringMember us-gaap:FairValueInputsLevel2Member us-gaap:BondsMember 2021-06-30 0001674930 us-gaap:FairValueMeasurementsRecurringMember us-gaap:FairValueInputsLevel3Member us-gaap:BondsMember 2021-06-30 0001674930 us-gaap:FairValueMeasurementsRecurringMember us-gaap:ExchangeTradedFundsMember 2021-06-30 0001674930 us-gaap:FairValueMeasurementsRecurringMember us-gaap:FairValueInputsLevel1Member us-gaap:ExchangeTradedFundsMember 2021-06-30 0001674930 us-gaap:FairValueMeasurementsRecurringMember us-gaap:FairValueInputsLevel2Member us-gaap:ExchangeTradedFundsMember 2021-06-30 0001674930 us-gaap:FairValueMeasurementsRecurringMember us-gaap:FairValueInputsLevel3Member us-gaap:ExchangeTradedFundsMember 2021-06-30 0001674930 us-gaap:CorporateDebtSecuritiesMember us-gaap:FairValueMeasurementsRecurringMember 2021-06-30 0001674930 us-gaap:CorporateDebtSecuritiesMember us-gaap:FairValueMeasurementsRecurringMember us-gaap:FairValueInputsLevel1Member 2021-06-30 0001674930 us-gaap:CorporateDebtSecuritiesMember us-gaap:FairValueMeasurementsRecurringMember us-gaap:FairValueInputsLevel2Member 2021-06-30 0001674930 us-gaap:CorporateDebtSecuritiesMember us-gaap:FairValueMeasurementsRecurringMember us-gaap:FairValueInputsLevel3Member 2021-06-30 0001674930 us-gaap:MunicipalBondsMember us-gaap:FairValueMeasurementsRecurringMember 2021-06-30 0001674930 us-gaap:MunicipalBondsMember us-gaap:FairValueMeasurementsRecurringMember us-gaap:FairValueInputsLevel1Member 2021-06-30 0001674930 us-gaap:MunicipalBondsMember us-gaap:FairValueMeasurementsRecurringMember us-gaap:FairValueInputsLevel2Member 2021-06-30 0001674930 us-gaap:MunicipalBondsMember us-gaap:FairValueMeasurementsRecurringMember us-gaap:FairValueInputsLevel3Member 2021-06-30 0001674930 flgt:YankeeDebtSecuritiesMember us-gaap:FairValueMeasurementsRecurringMember 2021-06-30 0001674930 flgt:YankeeDebtSecuritiesMember us-gaap:FairValueMeasurementsRecurringMember us-gaap:FairValueInputsLevel1Member 2021-06-30 0001674930 flgt:YankeeDebtSecuritiesMember us-gaap:FairValueMeasurementsRecurringMember us-gaap:FairValueInputsLevel2Member 2021-06-30 0001674930 flgt:YankeeDebtSecuritiesMember us-gaap:FairValueMeasurementsRecurringMember us-gaap:FairValueInputsLevel3Member 2021-06-30 0001674930 us-gaap:USGovernmentAgenciesDebtSecuritiesMember us-gaap:FairValueMeasurementsRecurringMember 2021-06-30 0001674930 us-gaap:USGovernmentAgenciesDebtSecuritiesMember us-gaap:FairValueMeasurementsRecurringMember us-gaap:FairValueInputsLevel1Member 2021-06-30 0001674930 us-gaap:USGovernmentAgenciesDebtSecuritiesMember us-gaap:FairValueMeasurementsRecurringMember us-gaap:FairValueInputsLevel2Member 2021-06-30 0001674930 us-gaap:USGovernmentAgenciesDebtSecuritiesMember us-gaap:FairValueMeasurementsRecurringMember us-gaap:FairValueInputsLevel3Member 2021-06-30 0001674930 us-gaap:MoneyMarketFundsMember us-gaap:FairValueMeasurementsRecurringMember 2021-06-30 0001674930 us-gaap:MoneyMarketFundsMember us-gaap:FairValueMeasurementsRecurringMember us-gaap:FairValueInputsLevel1Member 2021-06-30 0001674930 us-gaap:MoneyMarketFundsMember us-gaap:FairValueMeasurementsRecurringMember us-gaap:FairValueInputsLevel2Member 2021-06-30 0001674930 us-gaap:MoneyMarketFundsMember us-gaap:FairValueMeasurementsRecurringMember us-gaap:FairValueInputsLevel3Member 2021-06-30 0001674930 us-gaap:FairValueMeasurementsRecurringMember 2021-06-30 0001674930 us-gaap:FairValueMeasurementsRecurringMember us-gaap:FairValueInputsLevel1Member 2021-06-30 0001674930 us-gaap:FairValueMeasurementsRecurringMember us-gaap:FairValueInputsLevel2Member 2021-06-30 0001674930 us-gaap:FairValueMeasurementsRecurringMember us-gaap:FairValueInputsLevel3Member 2021-06-30 0001674930 us-gaap:FairValueMeasurementsRecurringMember us-gaap:BondsMember 2020-12-31 0001674930 us-gaap:FairValueMeasurementsRecurringMember us-gaap:FairValueInputsLevel1Member us-gaap:BondsMember 2020-12-31 0001674930 us-gaap:FairValueMeasurementsRecurringMember us-gaap:FairValueInputsLevel2Member us-gaap:BondsMember 2020-12-31 0001674930 us-gaap:FairValueMeasurementsRecurringMember us-gaap:FairValueInputsLevel3Member us-gaap:BondsMember 2020-12-31 0001674930 us-gaap:FairValueMeasurementsRecurringMember us-gaap:ExchangeTradedFundsMember 2020-12-31 0001674930 us-gaap:FairValueMeasurementsRecurringMember us-gaap:FairValueInputsLevel1Member us-gaap:ExchangeTradedFundsMember 2020-12-31 0001674930 us-gaap:FairValueMeasurementsRecurringMember us-gaap:FairValueInputsLevel2Member us-gaap:ExchangeTradedFundsMember 2020-12-31 0001674930 us-gaap:FairValueMeasurementsRecurringMember us-gaap:FairValueInputsLevel3Member us-gaap:ExchangeTradedFundsMember 2020-12-31 0001674930 us-gaap:CorporateDebtSecuritiesMember us-gaap:FairValueMeasurementsRecurringMember 2020-12-31 0001674930 us-gaap:CorporateDebtSecuritiesMember us-gaap:FairValueMeasurementsRecurringMember us-gaap:FairValueInputsLevel1Member 2020-12-31 0001674930 us-gaap:CorporateDebtSecuritiesMember us-gaap:FairValueMeasurementsRecurringMember us-gaap:FairValueInputsLevel2Member 2020-12-31 0001674930 us-gaap:CorporateDebtSecuritiesMember us-gaap:FairValueMeasurementsRecurringMember us-gaap:FairValueInputsLevel3Member 2020-12-31 0001674930 us-gaap:USGovernmentAgenciesDebtSecuritiesMember us-gaap:FairValueMeasurementsRecurringMember 2020-12-31 0001674930 us-gaap:USGovernmentAgenciesDebtSecuritiesMember us-gaap:FairValueMeasurementsRecurringMember us-gaap:FairValueInputsLevel1Member 2020-12-31 0001674930 us-gaap:USGovernmentAgenciesDebtSecuritiesMember us-gaap:FairValueMeasurementsRecurringMember us-gaap:FairValueInputsLevel2Member 2020-12-31 0001674930 us-gaap:USGovernmentAgenciesDebtSecuritiesMember us-gaap:FairValueMeasurementsRecurringMember us-gaap:FairValueInputsLevel3Member 2020-12-31 0001674930 flgt:YankeeDebtSecuritiesMember us-gaap:FairValueMeasurementsRecurringMember 2020-12-31 0001674930 flgt:YankeeDebtSecuritiesMember us-gaap:FairValueMeasurementsRecurringMember us-gaap:FairValueInputsLevel1Member 2020-12-31 0001674930 flgt:YankeeDebtSecuritiesMember us-gaap:FairValueMeasurementsRecurringMember us-gaap:FairValueInputsLevel2Member 2020-12-31 0001674930 flgt:YankeeDebtSecuritiesMember us-gaap:FairValueMeasurementsRecurringMember us-gaap:FairValueInputsLevel3Member 2020-12-31 0001674930 us-gaap:MoneyMarketFundsMember us-gaap:FairValueMeasurementsRecurringMember 2020-12-31 0001674930 us-gaap:MoneyMarketFundsMember us-gaap:FairValueMeasurementsRecurringMember us-gaap:FairValueInputsLevel1Member 2020-12-31 0001674930 us-gaap:MoneyMarketFundsMember us-gaap:FairValueMeasurementsRecurringMember us-gaap:FairValueInputsLevel2Member 2020-12-31 0001674930 us-gaap:MoneyMarketFundsMember us-gaap:FairValueMeasurementsRecurringMember us-gaap:FairValueInputsLevel3Member 2020-12-31 0001674930 us-gaap:FairValueMeasurementsRecurringMember 2020-12-31 0001674930 us-gaap:FairValueMeasurementsRecurringMember us-gaap:FairValueInputsLevel1Member 2020-12-31 0001674930 us-gaap:FairValueMeasurementsRecurringMember us-gaap:FairValueInputsLevel2Member 2020-12-31 0001674930 us-gaap:FairValueMeasurementsRecurringMember us-gaap:FairValueInputsLevel3Member 2020-12-31 0001674930 flgt:MedicalLabEquipmentMember 2021-06-30 0001674930 flgt:MedicalLabEquipmentMember 2020-12-31 0001674930 us-gaap:BuildingMember 2021-06-30 0001674930 us-gaap:BuildingMember 2020-12-31 0001674930 flgt:AircraftMember 2021-06-30 0001674930 flgt:AircraftMember 2020-12-31 0001674930 us-gaap:ComputerEquipmentMember 2021-06-30 0001674930 us-gaap:ComputerEquipmentMember 2020-12-31 0001674930 us-gaap:LeaseholdImprovementsMember 2021-06-30 0001674930 us-gaap:LeaseholdImprovementsMember 2020-12-31 0001674930 us-gaap:FurnitureAndFixturesMember 2021-06-30 0001674930 us-gaap:FurnitureAndFixturesMember 2020-12-31 0001674930 flgt:AutomobileMember 2021-06-30 0001674930 flgt:AutomobileMember 2020-12-31 0001674930 us-gaap:BuildingImprovementsMember 2021-06-30 0001674930 us-gaap:BuildingImprovementsMember 2020-12-31 0001674930 us-gaap:SoftwareDevelopmentMember 2021-06-30 0001674930 us-gaap:SoftwareDevelopmentMember 2020-12-31 0001674930 us-gaap:LandImprovementsMember 2021-06-30 0001674930 us-gaap:LandImprovementsMember 2020-12-31 0001674930 flgt:GeneralEquipmentMember 2021-06-30 0001674930 flgt:GeneralEquipmentMember 2020-12-31 0001674930 us-gaap:LandMember 2021-06-30 0001674930 us-gaap:LandMember 2020-12-31 0001674930 flgt:AssetsNotYetPlacedInServiceMember 2021-06-30 0001674930 flgt:AssetsNotYetPlacedInServiceMember 2020-12-31 0001674930 flgt:MedicalLabEquipmentMember srt:MinimumMember 2021-01-01 2021-06-30 0001674930 flgt:MedicalLabEquipmentMember srt:MaximumMember 2021-01-01 2021-06-30 0001674930 us-gaap:BuildingMember 2021-01-01 2021-06-30 0001674930 flgt:AircraftMember 2021-01-01 2021-06-30 0001674930 us-gaap:ComputerEquipmentMember 2021-01-01 2021-06-30 0001674930 us-gaap:LeaseholdImprovementsMember 2021-01-01 2021-06-30 0001674930 us-gaap:FurnitureAndFixturesMember srt:MinimumMember 2021-01-01 2021-06-30 0001674930 us-gaap:FurnitureAndFixturesMember srt:MaximumMember 2021-01-01 2021-06-30 0001674930 flgt:AutomobileMember srt:MinimumMember 2021-01-01 2021-06-30 0001674930 flgt:AutomobileMember srt:MaximumMember 2021-01-01 2021-06-30 0001674930 us-gaap:BuildingImprovementsMember srt:MinimumMember 2021-01-01 2021-06-30 0001674930 us-gaap:BuildingImprovementsMember srt:MaximumMember 2021-01-01 2021-06-30 0001674930 us-gaap:SoftwareDevelopmentMember srt:MinimumMember 2021-01-01 2021-06-30 0001674930 us-gaap:SoftwareDevelopmentMember srt:MaximumMember 2021-01-01 2021-06-30 0001674930 us-gaap:LandImprovementsMember srt:MinimumMember 2021-01-01 2021-06-30 0001674930 us-gaap:LandImprovementsMember srt:MaximumMember 2021-01-01 2021-06-30 0001674930 flgt:GeneralEquipmentMember srt:MinimumMember 2021-01-01 2021-06-30 0001674930 flgt:GeneralEquipmentMember srt:MaximumMember 2021-01-01 2021-06-30 flgt:Segment 0001674930 country:US 2021-04-01 2021-06-30 0001674930 country:US 2020-04-01 2020-06-30 0001674930 country:US 2021-01-01 2021-06-30 0001674930 country:US 2020-01-01 2020-06-30 0001674930 us-gaap:NonUsMember 2021-04-01 2021-06-30 0001674930 us-gaap:NonUsMember 2020-04-01 2020-06-30 0001674930 us-gaap:NonUsMember 2021-01-01 2021-06-30 0001674930 us-gaap:NonUsMember 2020-01-01 2020-06-30 0001674930 srt:MaximumMember 2021-01-01 2021-06-30 0001674930 flgt:XilongScientificMember flgt:FFGeneBiotechMember 2021-06-30 0001674930 flgt:XilongScientificMember flgt:FFGeneBiotechMember 2021-01-01 2021-06-30 0001674930 flgt:ReagentsAndOtherSuppliesMember 2021-06-30 0001674930 flgt:MedicalLabEquipmentMember 2021-06-30 0001674930 flgt:MedicalLabFurnitureMember 2021-06-30 0001674930 2021-02-01 2021-02-28 utr:sqft 0001674930 stpr:TX 2021-03-31 0001674930 stpr:TX 2021-03-01 2021-03-31 0001674930 us-gaap:BuildingMember srt:MinimumMember 2021-01-01 2021-06-30 0001674930 us-gaap:BuildingMember srt:MaximumMember 2021-01-01 2021-06-30 0001674930 us-gaap:CostOfSalesMember 2021-04-01 2021-06-30 0001674930 us-gaap:CostOfSalesMember 2020-04-01 2020-06-30 0001674930 us-gaap:CostOfSalesMember 2021-01-01 2021-06-30 0001674930 us-gaap:CostOfSalesMember 2020-01-01 2020-06-30 0001674930 us-gaap:ResearchAndDevelopmentExpenseMember 2021-04-01 2021-06-30 0001674930 us-gaap:ResearchAndDevelopmentExpenseMember 2020-04-01 2020-06-30 0001674930 us-gaap:ResearchAndDevelopmentExpenseMember 2021-01-01 2021-06-30 0001674930 us-gaap:ResearchAndDevelopmentExpenseMember 2020-01-01 2020-06-30 0001674930 us-gaap:SellingAndMarketingExpenseMember 2021-04-01 2021-06-30 0001674930 us-gaap:SellingAndMarketingExpenseMember 2020-04-01 2020-06-30 0001674930 us-gaap:SellingAndMarketingExpenseMember 2021-01-01 2021-06-30 0001674930 us-gaap:SellingAndMarketingExpenseMember 2020-01-01 2020-06-30 0001674930 us-gaap:GeneralAndAdministrativeExpenseMember 2021-04-01 2021-06-30 0001674930 us-gaap:GeneralAndAdministrativeExpenseMember 2020-04-01 2020-06-30 0001674930 us-gaap:GeneralAndAdministrativeExpenseMember 2021-01-01 2021-06-30 0001674930 us-gaap:GeneralAndAdministrativeExpenseMember 2020-01-01 2020-06-30 0001674930 us-gaap:EmployeeStockOptionMember 2021-04-01 2021-06-30 0001674930 us-gaap:RestrictedStockUnitsRSUMember 2021-04-01 2021-06-30 0001674930 us-gaap:EmployeeStockOptionMember 2020-04-01 2020-06-30 0001674930 us-gaap:RestrictedStockUnitsRSUMember 2020-04-01 2020-06-30 0001674930 us-gaap:EmployeeStockOptionMember 2021-01-01 2021-06-30 0001674930 us-gaap:RestrictedStockUnitsRSUMember 2021-01-01 2021-06-30 0001674930 us-gaap:EmployeeStockOptionMember 2020-01-01 2020-06-30 0001674930 us-gaap:RestrictedStockUnitsRSUMember 2020-01-01 2020-06-30 0001674930 flgt:AHMCHealthcareIncMember flgt:GeneticSequencingServiceMember 2021-04-01 2021-06-30 0001674930 flgt:AHMCHealthcareIncMember flgt:GeneticSequencingServiceMember 2021-01-01 2021-06-30 0001674930 flgt:AHMCHealthcareIncMember flgt:GeneticSequencingServiceMember 2020-04-01 2020-06-30 0001674930 flgt:AHMCHealthcareIncMember flgt:GeneticSequencingServiceMember 2020-01-01 2020-06-30 0001674930 flgt:AHMCHealthcareIncMember flgt:GeneticSequencingServiceMember 2021-06-30 0001674930 flgt:AHMCHealthcareIncMember flgt:GeneticSequencingServiceMember 2020-12-31 0001674930 flgt:FulgentPharmaLimitedLiabilityCompanyMember flgt:ResearchDevelopmentServiceMember 2021-04-01 2021-06-30 0001674930 flgt:FulgentPharmaLimitedLiabilityCompanyMember flgt:ResearchDevelopmentServiceMember 2021-01-01 2021-06-30 0001674930 flgt:FulgentPharmaLimitedLiabilityCompanyMember flgt:ResearchDevelopmentServiceMember 2020-04-01 2020-06-30 0001674930 flgt:FulgentPharmaLimitedLiabilityCompanyMember flgt:ResearchDevelopmentServiceMember 2020-01-01 2020-06-30 0001674930 flgt:FulgentPharmaLimitedLiabilityCompanyMember 2021-04-01 2021-06-30 0001674930 flgt:FulgentPharmaLimitedLiabilityCompanyMember 2021-01-01 2021-06-30 0001674930 flgt:FulgentPharmaLimitedLiabilityCompanyMember 2020-04-01 2020-06-30 0001674930 flgt:FulgentPharmaLimitedLiabilityCompanyMember 2020-01-01 2020-06-30 0001674930 flgt:FulgentPharmaLimitedLiabilityCompanyMember 2021-06-30 0001674930 flgt:FulgentPharmaLimitedLiabilityCompanyMember 2020-12-31 0001674930 flgt:FFGeneBiotechMember 2017-04-30 0001674930 flgt:XilongScientificMember 2021-05-31 0001674930 flgt:FFGeneBiotechMember 2017-04-30 0001674930 flgt:FFGeneBiotechMember 2017-04-01 2017-04-30 0001674930 us-gaap:GeneralAndAdministrativeExpenseMember 2017-04-01 2017-04-30 0001674930 flgt:FFGeneBiotechMember 2017-04-30 0001674930 us-gaap:MeasurementInputDiscountForLackOfMarketabilityMember flgt:FFGeneBiotechMember 2017-04-30 0001674930 us-gaap:MeasurementInputDiscountRateMember flgt:FFGeneBiotechMember 2017-04-30 0001674930 flgt:MeasurementInputDiscountOwedToMarketParticipantAcquisitionPremiumMember flgt:FFGeneBiotechMember 2017-04-30 0001674930 flgt:FFGeneBiotechMember 2021-06-30 0001674930 flgt:FFGeneBiotechMember 2021-04-01 2021-06-30 0001674930 flgt:FFGeneBiotechMember 2021-01-01 2021-06-30 0001674930 flgt:FFGeneBiotechMember us-gaap:TechnologyBasedIntangibleAssetsMember 2017-04-30 0001674930 flgt:FFGeneBiotechMember us-gaap:TechnologyBasedIntangibleAssetsMember 2017-04-01 2017-04-30 0001674930 flgt:FFGeneBiotechMember us-gaap:CustomerRelationshipsMember 2017-04-30 0001674930 flgt:FFGeneBiotechMember us-gaap:CustomerRelationshipsMember 2017-04-01 2017-04-30 0001674930 flgt:NovemberTwoThousandTwentyEquityDistributionAgreementMember us-gaap:CommonStockMember srt:MaximumMember 2020-11-01 2020-11-30 0001674930 flgt:NovemberTwoThousandTwentyEquityDistributionAgreementMember us-gaap:CommonStockMember 2021-04-01 2021-06-30 0001674930 flgt:NovemberTwoThousandTwentyEquityDistributionAgreementMember us-gaap:CommonStockMember 2021-01-01 2021-06-30 0001674930 flgt:FFGeneBiotechMember 2021-06-30 0001674930 flgt:RoyaltyFreeTechnologyMember flgt:FFGeneBiotechMember 2021-06-30 0001674930 us-gaap:CustomerRelationshipsMember flgt:FFGeneBiotechMember 2021-06-30 0001674930 flgt:RoyaltyFreeTechnologyMember flgt:FFGeneBiotechMember 2021-01-01 2021-06-30 0001674930 us-gaap:CustomerRelationshipsMember flgt:FFGeneBiotechMember 2021-01-01 2021-06-30 0001674930 us-gaap:SubsequentEventMember 2021-07-31 0001674930 flgt:CytometrySpecialistsIncMember us-gaap:SubsequentEventMember 2021-08-06 2021-08-06 0001674930 flgt:CytometrySpecialistsIncMember us-gaap:SubsequentEventMember srt:MaximumMember 2021-08-06 2021-08-06

f

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, DC 20549

 

FORM 10-Q

 

(Mark One)

☒

QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the quarterly period ended June 30, 2021

or

☐

TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the transition period from                              to                             

Commission File Number: 001-37894

 

FULGENT GENETICS, INC.

(exact name of registrant as specified in its charter)

 

 

Delaware

81-2621304

(State or other jurisdiction of

incorporation or organization)

(I.R.S. Employer

Identification No.)

 

 

4978 Santa Anita Avenue

Temple City, CA

91780

(Address of principal executive offices)

(Zip Code)

 

(626) 350-0537

(Registrant’s telephone number, including area code)

 

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class

 

Trading Symbol(s)

 

Name of each exchange on which registered

Common Stock, par value $0.0001 per share

 

FLGT

 

The Nasdaq Stock Market 
(Nasdaq Global Market)

 

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.    Yes  ☒    No ☐

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§ 232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).    Yes  ☒    No  ☐

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

 

Large accelerated filer

 

☐

  

Accelerated filer

 

☐

 

 

 

 

Non-accelerated filer

 

☒

  

Smaller reporting company

 

☒

 

 

 

 

 

 

 

 

 

 

 

Emerging growth company

 

☒

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.    ☒

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).    Yes  ☐    No  ☒

As of August 1, 2021, there were 29,521,259 outstanding shares of the registrant’s common stock.

 

 

 

 

Table of Contents

 

 

Page

PART I—FINANCIAL INFORMATION

1

Item 1. Financial Statements (Unaudited)

1

Condensed Consolidated Balance Sheets

1

Condensed Consolidated Statements of Operations

2

Condensed Consolidated Statements of Comprehensive Income (Loss)

3

Condensed Consolidated Statements of Stockholders’ Equity

4

Condensed Consolidated Statements of Cash Flows

6

Notes to the Condensed Consolidated Financial Statements

7

Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations

23

Item 3. Quantitative and Qualitative Disclosures About Market Risk

32

Item 4. Controls and Procedures

32

PART II—OTHER INFORMATION

33

Item 1. Legal Proceedings

33

Item 1A. Risk Factors

33

Item 2. Unregistered Sales of Equity Securities and Use of Proceeds

63

Item 6. Exhibits

64

Exhibit Index

65

Signatures

66

 

 

 

 

 

i

 

PART I—FINANCIAL INFORMATION

Item 1. Financial Statements.

FULGENT GENETICS, INC.

Condensed Consolidated Balance Sheets

(in thousands, except par value data)

(unaudited)

 

 

June 30,

 

 

December 31,

 

 

2021

 

 

2020

 

Assets

 

 

 

 

 

 

 

Current assets

 

 

 

 

 

 

 

Cash and cash equivalents

$

100,461

 

 

$

87,426

 

Marketable securities

 

283,328

 

 

 

211,941

 

Trade accounts receivable, net of allowance for credit losses of $6,044 and $1,898

   as of June 30, 2021 and December 31, 2020, respectively

 

148,576

 

 

 

183,857

 

Other current assets

 

34,321

 

 

 

40,392

 

Total current assets

 

566,686

 

 

 

523,616

 

Marketable securities, long-term

 

393,250

 

 

 

132,502

 

Fixed assets, net

 

51,086

 

 

 

40,199

 

Acquisition-related intangible assets, net

 

6,829

 

 

 

—

 

Goodwill

 

23,107

 

 

 

—

 

Other long-term assets

 

8,897

 

 

 

4,144

 

Total assets

$

1,049,855

 

 

$

700,461

 

Liabilities and Stockholders’ Equity

 

 

 

 

 

 

 

Current liabilities

 

 

 

 

 

 

 

Accounts payable

$

14,743

 

 

$

26,488

 

Income tax payable

 

26,399

 

 

 

53,319

 

Contract liabilities

 

6,915

 

 

 

26,576

 

Customer deposit

 

45,327

 

 

 

185

 

Investment margin loan

 

15,077

 

 

 

15,019

 

Other current liabilities

 

13,063

 

 

 

8,528

 

Total current liabilities

 

121,524

 

 

 

130,115

 

Notes payable

 

5,899

 

 

 

—

 

Unrecognized tax benefits

 

505

 

 

 

377

 

Other long-term liabilities

 

1,202

 

 

 

582

 

Total liabilities

 

129,130

 

 

 

131,074

 

Commitments and contingencies (Note 8)

 

 

 

 

 

 

 

Stockholders’ equity

 

 

 

 

 

 

 

Common stock, $0.0001 par value per share, 50,000 shares authorized, 29,513 and

   28,178 shares issued and outstanding at June 30, 2021 and December 31, 2020,

   respectively

 

3

 

 

 

3

 

Preferred stock, $0.0001 par value per share, 1,000 shares authorized, no shares issued

   or outstanding at June 30, 2021 and December 31, 2020

 

—

 

 

 

—

 

Additional paid-in capital

 

482,255

 

 

 

418,065

 

Accumulated other comprehensive income (loss)

 

(265

)

 

 

438

 

Retained earnings

 

430,736

 

 

 

150,881

 

Total Fulgent stockholders' equity

 

912,729

 

 

 

569,387

 

Noncontrolling interest

 

7,996

 

 

 

—

 

Total stockholders’ equity

 

920,725

 

 

 

569,387

 

Total liabilities and stockholders’ equity

$

1,049,855

 

 

$

700,461

 

 

The accompanying notes are an integral part of these condensed consolidated financial statements.

1

FULGENT GENETICS, INC.

Condensed Consolidated Statements of Operations

(in thousands, except per share data)

(unaudited)

 

 

Three Months Ended June 30,

 

 

Six Months Ended June 30,

 

 

2021

 

 

2020

 

 

2021

 

 

2020

 

Revenue

$

153,616

 

 

$

17,265

 

 

$

513,045

 

 

$

25,018

 

Cost of revenue

 

35,858

 

 

 

7,717

 

 

 

109,933

 

 

 

11,774

 

Gross profit

 

117,758

 

 

 

9,548

 

 

 

403,112

 

 

 

13,244

 

Operating expenses:

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Research and development

 

5,312

 

 

 

1,849

 

 

 

10,734

 

 

 

3,827

 

Selling and marketing

 

5,219

 

 

 

3,260

 

 

 

10,227

 

 

 

4,857

 

General and administrative

 

8,329

 

 

 

1,799

 

 

 

16,331

 

 

 

3,834

 

Total operating expenses

 

18,860

 

 

 

6,908

 

 

 

37,292

 

 

 

12,518

 

Operating income

 

98,898

 

 

 

2,640

 

 

 

365,820

 

 

 

726

 

Interest and other income, net

 

604

 

 

 

275

 

 

 

886

 

 

 

516

 

Income before income taxes, gain on

   equity method investment and equity loss in investee

 

99,502

 

 

 

2,915

 

 

 

366,706

 

 

 

1,242

 

Provision for (benefit from) income taxes

 

23,589

 

 

 

(599

)

 

 

90,102

 

 

 

(565

)

Income before gain on equity method investment

     and equity loss in investee

 

75,913

 

 

 

3,514

 

 

 

276,604

 

 

 

1,807

 

Gain on equity method investment

 

3,734

 

 

 

—

 

 

 

3,734

 

 

 

—

 

Equity loss in investee

 

—

 

 

 

(193

)

 

 

—

 

 

 

(442

)

Net income from consolidated

     operations

 

79,647

 

 

 

3,321

 

 

 

280,338

 

 

 

1,365

 

Net loss attributable to noncontrolling

     interests

 

165

 

 

 

—

 

 

 

165

 

 

 

—

 

Net income attributable to Fulgent

$

79,812

 

 

$

3,321

 

 

$

280,503

 

 

$

1,365

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Net income per common share attributable to Fulgent:

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Basic

$

2.74

 

 

$

0.15

 

 

$

9.68

 

 

$

0.06

 

Diluted

$

2.59

 

 

$

0.14

 

 

$

9.10

 

 

$

0.06

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Weighted-average common shares:

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Basic

 

29,150

 

 

 

21,747

 

 

 

28,991

 

 

 

21,656

 

Diluted

 

30,830

 

 

 

22,920

 

 

 

30,809

 

 

 

22,824

 

 

The accompanying notes are an integral part of these condensed consolidated financial statements.

 

 

2

 

FULGENT GENETICS, INC.

Condensed Consolidated Statements of Comprehensive Income (Loss)

(in thousands)

(unaudited)

 

 

Three Months Ended June 30,

 

 

Six Months Ended June 30,

 

 

2021

 

 

2020

 

 

2021

 

 

2020

 

Net income from consolidated operations

$

79,647

 

 

$

3,321

 

 

$

280,338

 

 

$

1,365

 

Other comprehensive income (loss):

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Foreign currency translation gain (loss)

 

36

 

 

 

2

 

 

 

36

 

 

 

(1

)

Net unrealized gain (loss) on marketable securities, net of tax

 

(75

)

 

 

1,240

 

 

 

(729

)

 

 

904

 

Comprehensive income from consolidated operations

 

79,608

 

 

 

4,563

 

 

 

279,645

 

 

 

2,268

 

Net loss attributable to noncontrolling interest

 

165

 

 

 

—

 

 

 

165

 

 

 

—

 

Foreign currency translation gain attributable

   to noncontrolling interest

 

(10

)

 

 

—

 

 

 

(10

)

 

 

—

 

Comprehensive loss attributable to noncontrolling interest

 

155

 

 

 

—

 

 

 

155

 

 

 

—

 

Comprehensive income attributable to Fulgent

$

79,763

 

 

$

4,563

 

 

$

279,800

 

 

$

2,268

 

 

 

The accompanying notes are an integral part of these condensed consolidated financial statements.

3

FULGENT GENETICS, INC.

Condensed Consolidated Statements of Stockholders’ Equity

(in thousands)

(unaudited)

 

 

 

Fulgent Stockholders' Equity

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Shares

 

 

Amount

 

 

Additional

Paid-In Capital

 

 

Accumulated

Other Comprehensive

Income (Loss)

 

 

Retained Earnings

 

 

Fulgent Stockholders' Equity

 

 

Noncontrolling Interest

 

 

Total

Equity

 

Balance at December 31, 2020

 

 

28,178

 

 

$

3

 

 

$

418,065

 

 

$

438

 

 

$

150,881

 

 

$

569,387

 

 

$

—

 

 

$

569,387

 

Equity-based compensation

 

 

—

 

 

 

—

 

 

 

2,962

 

 

 

—

 

 

 

—

 

 

 

2,962

 

 

 

—

 

 

 

2,962

 

Exercise of common stock

   options

 

 

45

 

 

 

—

 

 

 

44

 

 

 

—

 

 

 

—

 

 

 

44

 

 

 

—

 

 

 

44

 

Restricted stock awards

 

 

187

 

 

 

—

 

 

 

—

 

 

 

—

 

 

 

—

 

 

 

—

 

 

 

—

 

 

 

—

 

Common stock withholding

   for employee tax

   obligations

 

 

(4

)

 

 

—

 

 

 

(513

)

 

 

—

 

 

 

—

 

 

 

(513

)

 

 

—

 

 

 

(513

)

Issuance of common stock

   at an average of $52.00 per

   share, net

 

 

583

 

 

 

—

 

 

 

30,297

 

 

 

—

 

 

 

—

 

 

 

30,297

 

 

 

—

 

 

 

30,297

 

Other comprehensive loss

 

 

—

 

 

 

—

 

 

 

—

 

 

 

(654

)

 

 

—

 

 

 

(654

)

 

 

—

 

 

 

(654

)

Cumulative effect of

   accounting change

 

 

—

 

 

 

—

 

 

 

—

 

 

 

—

 

 

 

(887

)

 

 

(887

)

 

 

—

 

 

 

(887

)

Cumulative tax effect of

   accounting change

 

 

—

 

 

 

—

 

 

 

—

 

 

 

—

 

 

 

239

 

 

 

239

 

 

 

—

 

 

 

239

 

Net income

 

 

—

 

 

 

—

 

 

 

—

 

 

 

—

 

 

 

200,691

 

 

 

200,691

 

 

 

—

 

 

 

200,691

 

Balance at March 31, 2021

 

 

28,989

 

 

 

3

 

 

 

450,855

 

 

 

(216

)

 

 

350,924

 

 

 

801,566

 

 

 

—

 

 

 

801,566

 

Equity-based compensation

 

 

—

 

 

 

—

 

 

 

3,526

 

 

 

—

 

 

 

—

 

 

 

3,526

 

 

 

—

 

 

 

3,526

 

Exercise of common stock

   options

 

 

4

 

 

 

—

 

 

 

24

 

 

 

—

 

 

 

—

 

 

 

24

 

 

 

—

 

 

 

24

 

Restricted stock awards

 

 

143

 

 

 

—

 

 

 

—

 

 

 

—

 

 

 

—

 

 

 

—

 

 

 

—

 

 

 

—

 

Common stock withholding

   for employee tax

   obligations

 

 

(1

)

 

 

—

 

 

 

(39

)

 

 

—

 

 

 

—

 

 

 

(39

)

 

 

—

 

 

 

(39

)

Issuance of common stock

   at an average of $73.75 per

   share, net

 

 

378

 

 

 

—

 

 

 

27,889

 

 

 

—

 

 

 

—

 

 

 

27,889

 

 

 

—

 

 

 

27,889

 

Noncontrolling interest

   assumed related to

   acquisitions

 

 

—

 

 

 

—

 

 

 

—

 

 

 

—

 

 

 

—

 

 

 

—

 

 

 

8,151

 

 

 

8,151

 

Other comprehensive

   gain (loss)

 

 

—

 

 

 

—

 

 

 

—

 

 

 

(49

)

 

 

 

 

 

 

(49

)

 

 

10

 

 

 

(39

)

Net income (loss)

 

 

—

 

 

 

—

 

 

 

—

 

 

 

—

 

 

 

79,812

 

 

 

79,812

 

 

 

(165

)

 

 

79,647

 

Balance at June 30, 2021

 

 

29,513

 

 

$

3

 

 

$

482,255

 

 

$

(265

)

 

$

430,736

 

 

$

912,729

 

 

$

7,996

 

 

$

920,725

 

 

The accompanying notes are an integral part of these condensed consolidated financial statements.

 

4

 

FULGENT GENETICS, INC.

Condensed Consolidated Statements of Stockholders’ Equity

(in thousands)

(unaudited)

 

 

 

Fulgent Stockholders' Equity

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Shares

 

 

Amount

 

 

Additional

Paid-In Capital

 

 

Accumulated

Other Comprehensive

Income (Loss)

 

 

Accumulated

Deficit

 

 

Total

Equity

 

Balance at December 31, 2019

 

 

21,483

 

 

$

2

 

 

$

146,058

 

 

$

146

 

 

$

(63,429

)

 

$

82,777

 

Equity-based compensation

 

 

—

 

 

 

—

 

 

 

924

 

 

 

—

 

 

 

—

 

 

 

924

 

Exercise of common stock options

 

 

33

 

 

 

—

 

 

 

12

 

 

 

—

 

 

 

—

 

 

 

12

 

Restricted stock awards

 

 

159

 

 

 

—

 

 

 

—

 

 

 

—

 

 

 

—

 

 

 

—

 

Common stock withholding

   for employee tax

   obligations

 

 

(3

)

 

 

—

 

 

 

(46

)

 

 

—

 

 

 

—

 

 

 

(46

)

Other comprehensive loss

 

 

—

 

 

 

—

 

 

 

—

 

 

 

(339

)

 

 

—

 

 

 

(339

)

Net loss

 

 

—

 

 

 

—

 

 

 

—

 

 

 

—

 

 

 

(1,956

)

 

 

(1,956

)

Balance at March 31, 2020

 

 

21,672

 

 

 

2

 

 

 

146,948

 

 

 

(193

)

 

 

(65,385

)

 

 

81,372

 

Equity-based compensation

 

 

—

 

 

 

—

 

 

 

1,080

 

 

 

—

 

 

 

—

 

 

 

1,080

 

Exercise of common stock options

 

 

11

 

 

 

—

 

 

 

28

 

 

 

—

 

 

 

—

 

 

 

28

 

Restricted stock awards

 

 

127

 

 

 

—

 

 

 

—

 

 

 

—

 

 

 

—

 

 

 

—

 

Other comprehensive gain

 

 

—

 

 

 

—

 

 

 

—

 

 

 

1,242

 

 

 

—

 

 

 

1,242

 

Net income

 

 

—

 

 

 

—

 

 

 

—

 

 

 

—

 

 

 

3,321

 

 

 

3,321

 

Balance at June 30, 2020

 

 

21,810

 

 

$

2

 

 

$

148,056

 

 

$

1,049

 

 

$

(62,064

)

 

$

87,043

 

 

The accompanying notes are an integral part of these condensed consolidated financial statements.

5

FULGENT GENETICS, INC.

Condensed Consolidated Statements of Cash Flows

(in thousands)

(unaudited)

 

 

Six Months Ended June 30,

 

 

 

2021

 

 

2020

 

Cash flow from operating activities:

 

 

 

 

 

 

 

 

Net income from consolidated

     operations

 

$

280,338

 

 

$

1,365

 

Adjustments to reconcile net income to net cash provided (used in) by operating activities:

 

 

 

 

 

 

 

 

Equity-based compensation

 

 

6,488

 

 

 

2,004

 

Depreciation and amortization

 

 

4,340

 

 

 

1,118

 

Noncash lease expense

 

 

298

 

 

 

220

 

Loss on disposal of fixed asset

 

 

598

 

 

 

—

 

Amortization of premium of marketable securities

 

 

3,171

 

 

 

218

 

Provision for credit losses

 

 

3,259

 

 

 

135

 

Deferred taxes

 

 

(3,055

)

 

 

—

 

Unrecognized tax benefits

 

 

128

 

 

 

—

 

Holding loss on equity securities

 

 

360

 

 

 

—

 

Equity loss in investee

 

 

—

 

 

 

442

 

Gain on equity method investment

 

 

(3,734

)

 

 

—

 

Other

 

 

(8

)

 

 

(6

)

Changes in operating assets and liabilities:

 

 

 

 

 

 

 

 

Trade accounts receivable

 

 

32,460

 

 

 

(7,437

)

Other current and long-term assets

 

 

(6,025

)

 

 

(3,827

)

Accounts payable

 

 

(10,256

)

 

 

2,284

 

Accrued liabilities and other liabilities

 

 

3,084

 

 

 

670

 

Income tax payable

 

 

(26,920

)

 

 

(24

)

Contract liabilities

 

 

(19,662

)

 

 

—

 

Customer deposit

 

 

44,719

 

 

 

—

 

Operating lease liabilities

 

 

(293

)

 

 

(205

)

Net cash provided by (used in) operating activities

 

 

309,290

 

 

 

(3,043

)

Cash flow from investing activities:

 

 

 

 

 

 

 

 

Purchases of fixed assets

 

 

(14,427

)

 

 

(1,207

)

Proceeds from sale of fixed assets

 

 

13

 

 

 

—

 

Purchase of marketable securities

 

 

(424,807

)

 

 

(12,387

)

Proceeds from sale of marketable securities

 

 

51,696

 

 

 

—

 

Maturities of marketable securities

 

 

34,538

 

 

 

7,327

 

Acquisition of businesses, net of cash acquired

 

 

(18,509

)

 

 

—

 

Net cash used in investing activities

 

 

(371,496

)

 

 

(6,267

)

Cash flow from financing activities:

 

 

 

 

 

 

 

 

Proceeds from (payment for) public offerings of common stock, net of issuance costs

 

 

75,656

 

 

 

(217

)

Proceeds from noncontrolling interest

 

 

10

 

 

 

—

 

Proceeds from exercise of stock options

 

 

68

 

 

 

40

 

Common stock withholding for employee tax obligations

 

 

(552

)

 

 

(46

)

Borrowing under margin account

 

 

58

 

 

 

—

 

Net cash provided by (used in) financing activities

 

 

75,240

 

 

 

(223

)

Effect of exchange rate changes on cash and cash equivalents

 

 

1

 

 

 

(1

)

Net increase (decrease) in cash and cash equivalents

 

 

13,035

 

 

 

(9,534

)

Cash and cash equivalents at beginning of period

 

 

87,426

 

 

 

11,965

 

Cash and cash equivalents at end of period

 

$

100,461

 

 

$

2,431

 

Supplemental disclosures of cash flow information:

 

 

 

 

 

 

 

 

Income taxes paid

 

$

119,980

 

 

$

28

 

Supplemental disclosures of non-cash investing and financing activities:

 

 

 

 

 

 

 

 

Purchases of fixed assets in accounts payable

 

$

742

 

 

$

497

 

Operating lease right-of-use assets obtained in exchange for lease liabilities

 

$

765

 

 

$

393

 

Operating lease right-of-use assets reduced due to lease modification

 

$

185

 

 

$

—

 

Public offerings costs included in accounts payable

 

$

30

 

 

$

2

 

The accompanying notes are an integral part of these condensed consolidated financial statements.

6

FULGENT GENETICS, INC.

Notes to the Condensed Consolidated Financial Statements

(unaudited)

 

Note 1. Overview and Basis of Presentation

The accompanying condensed consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America, or U.S. GAAP. These financial statements include the assets, liabilities, revenues and expenses of all subsidiaries and entities in which the Company has a controlling financial interest or is deemed to be the primary beneficiary. In determining whether the Company is the primary beneficiary of an entity, the Company applies a qualitative approach that determines whether it has both (i) the power to direct the economically significant activities of the entity and (ii) the obligation to absorb losses of, or the right to receive benefits from, the entity that could potentially be significant to that entity. The Company uses the equity method to account for its investments in entities that it does not control, but in which it has the ability to exercise significant influence over operating and financial policies. All significant intercompany accounts and transactions are eliminated from the accompanying condensed consolidated financial statements.

Nature of the Business

Fulgent Genetics, Inc., together with its subsidiaries, collectively referred to as the Company, unless otherwise noted or the context otherwise requires, is a technology company offering comprehensive genetic testing providing physicians with clinically actionable diagnostic information they can use to improve the quality of patient care. The Company has developed a proprietary technology platform that allows it to offer a broad and flexible test menu and continually expand and improve its proprietary genetic reference library, while maintaining accessible pricing, high accuracy and competitive turnaround times. Combining next generation sequencing, or NGS, with its technology platform, the Company performs full-gene sequencing with deletion/duplication analysis in single-gene tests; pre-established, multi-gene, disease-specific panels; and customized panels that can be tailored to meet specific customer needs. In 2019, the Company launched its first patient-initiated product, Picture Genetics, a new line of at-home screening tests that combines the Company’s advanced NGS solutions with actionable results and genetic counseling options for individuals. Since March 2020, the Company has commercially launched several tests for the detection of SARS-CoV-2, the virus that causes the novel coronavirus, or COVID-19, including NGS and reverse transcription polymerase chain reaction – based, or RT-PCR-based, tests. The Company has received an Emergency Use Authorization, or EUA, from the United States, or U.S., Food and Drug Administration, or the FDA, for the RT-PCR-based tests for the detection of SARS-CoV-2 using upper respiratory specimens (nasal, nasopharyngeal, and oropharyngeal swabs) and for the at-home testing service through Picture Genetics. The Company’s at-home testing service for COVID-19 and RT-PCR-based test have been granted an EUA by the FDA only for the detection of nucleic acid from SARS-CoV-2, not for any other viruses or pathogens. The Company believes its test menu offers more genes for testing than its competitors in today’s market, which enables it to provide expansive options for test customization and clinically actionable results. A cornerstone of the Company’s business is its ability to provide expansive options and flexibility for all clients’ unique testing needs.

Unaudited Interim Financial Information

The accompanying unaudited interim condensed consolidated financial statements have been prepared on the same basis as the Company’s audited consolidated financial statements as of and for the fiscal year ended December 31, 2020, which are included in the Company’s annual report on Form 10-K filed with the Securities and Exchange Commission, or SEC, on March 8, 2021, or 2020 Annual Report, and, in the opinion of management, include all adjustments, which are normal and recurring in nature, necessary for a fair presentation of the Company’s financial position and results of operations. Operating results for interim periods are not necessarily indicative of the results that may be expected for a full fiscal year or any other period. The accompanying Condensed Consolidated Balance Sheet as of December 31, 2020 has been derived from the Company’s audited consolidated financial statements at that date but does not include all of the disclosures required by U.S. GAAP. As such, the information included in this quarterly report on Form 10-Q should be read in conjunction with the Company’s audited consolidated financial statements included in the 2020 Annual Report, including the notes thereto.

 

 

 

7

 

Note 2. Summary of Significant Accounting Policies

See the summary of the Company’s significant accounting policies set forth in the notes to its consolidated financial statements included in the 2020 Annual Report.

Use of Estimates

The preparation of condensed consolidated financial statements in conformity with U.S. GAAP requires management to make certain estimates, judgments and assumptions that affect the reported amounts of assets and liabilities at the date of the financial statements, as well as the reported amounts of revenue and expenses during the reporting periods. These estimates, judgments and assumptions are based on historical data and experience available at the date of the accompanying condensed consolidated financial statements, as well as various other factors management believes to be reasonable under the circumstances, including but not limited to the potential impacts arising from the recent global pandemic related to COVID-19. As the extent and duration of the impacts from COVID-19 remain unclear, the Company’s estimates and assumptions may evolve as conditions change. Actual results could differ significantly from these estimates.

On an on-going basis, management evaluates its estimates, primarily those related to: (i) revenue recognition criteria, (ii) trade accounts receivable and allowances for credit losses, (iii) the useful lives of fixed assets, (iv) estimates of tax liabilities, (v) the valuation of equity method investments, (vi) valuation of acquisition-related intangibles and goodwill, and (vii) useful lives of intangible assets and fixed assets.

Foreign Currency Translation and Foreign Currency Transactions

The Company translates the assets and liabilities of its non-U.S. dollar functional currency subsidiaries into U.S. dollars using exchange rates in effect at the end of each period. Expenses for these subsidiaries are translated using rates that approximate those in effect during the period. Gains and losses from these translations are recognized in foreign currency translation included in accumulated other comprehensive income (loss) in the accompanying Condensed Consolidated Statements of Stockholders’ Equity. Gains from these translations were not significant in the three and six months ended June 30, 2021 and three months ended June 30, 2020, and loss from these translations for the six months ended June 30, 2020 was not significant. The Company and its subsidiaries that use the U.S. dollar as their functional currency remeasure monetary assets and liabilities at exchange rates in effect at the end of each period, and inventories, property and nonmonetary assets and liabilities at historical rates. Losses from these remeasurements in the three and six months ended June 30, 2021 and in the six months ended June 30, 2020 were not significant. Gains from these remeasurements were not significant in the three months ended June 30, 2020.

Leases

The Company determines if an arrangement is a lease at inception by evaluating whether the arrangement conveys the right to use an identified asset and whether the Company obtains substantially all of the economic benefits from and has the ability to direct the use of the asset. Operating lease right-of-use, or ROU, asset, short-term lease liabilities, and long-term lease liabilities were included in other long-term assets, other current liabilities, and other long-term liabilities, respectively, in the accompanying Condensed Consolidated Balance Sheets.

Lease ROU assets represent the Company’s right to use an underlying asset for the lease term and lease liabilities represent the Company’s obligation to make lease payments arising from the lease. Operating lease ROU assets and liabilities are recognized at the commencement date based on the present value of lease payments over the lease term, including options to extend the lease when it is reasonably certain that the Company will exercise that option. The Company uses its incremental borrowing rate based on the information available at the commencement date, including inquiries with its bank, in determining the present value of lease payments since its leases do not provide an implicit rate. The lease ROU asset includes any base rent payments made and excludes lease incentives and variable operating expenses. Lease expense for lease payments is recognized on a straight-line basis over the lease term.

The Company leases out space in buildings it owns in El Monte, California, to third-party tenants under noncancelable operating leases and has leased out such space since the Company purchased such buildings. The Company recognizes lease payments as income over the lease terms on a straight-line basis and recognizes variable lease payments as income in the period in which the changes in facts and circumstances on which the variable lease payments are based occur. The net rental income is included in the interest and other income, net, in the accompanying Condensed Consolidated Statement of Operations.

8

Concentration of Customers

In certain periods, a small number of customers has accounted for a significant portion of the Company’s revenue. After aggregating customers that are under common control or are affiliates, two customers contributed 20% and 16% of the Company’s revenue for the three months ended June 30, 2021, respectively, and two customers contributed 24% and 11% of the Company’s revenue for the six months ended June 30, 2021, respectively.  One customer contributed 45% of the Company’s revenue for the three months ended June 30, 2020, and one customer contributed 31% of the Company’s revenue for the six months ended June 30, 2020. One customer comprised 13% of total accounts receivable as of June 30, 2021. No customer comprised 10% or more of total accounts receivable as of December 31, 2020. Revenue from the U.S. government was less than 10% of total revenue for the three and six months ended June 30, 2021 and 2020.

Revenue from Contracts with Customers

Disaggregation of Revenue

The Company classifies its customers into three payor types: (i) Insurance, (ii) Institutional, including hospitals, medical institutions, other laboratories, governmental bodies, municipalities and large corporations, or (iii) Patients who pay directly, as the Company believes this best depicts how the nature, amount, timing, and uncertainty of its revenue and cash flows are affected by economic factors. The following table summarizes revenue from contracts with customers by payor type for the three and six months ended June 30, 2021 and 2020.

 

 

Three Months Ended June 30,

 

 

Six Months Ended June 30,

 

 

2021

 

 

2020

 

 

2021

 

 

2020

 

 

(in thousands)

 

Testing Services by payor

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Institutional

$

103,602

 

 

$

16,454

 

 

$

255,171

 

 

$

23,932

 

Insurance

 

49,520

 

 

 

691

 

 

 

257,078

 

 

 

825

 

Patient

 

494

 

 

 

120

 

 

 

796

 

 

 

261

 

Total Revenue

$

153,616

 

 

$

17,265

 

 

$

513,045

 

 

$

25,018

 

 

Contract Balances

Receivables from contracts with customers—As of June 30, 2021 and December 31, 2020, receivables from contracts with customers were approximately $148.6 million and $183.9 million, respectively, and are included within trade accounts receivable on the Condensed Consolidated Balance Sheets.

Contracts assets and liabilities —As of June 30, 2021 and December 31, 2020, contract assets from contracts with customers were $324,000 and $1.4 million, respectively, associated with contract execution and certain costs to fulfill a contract, and included in other current assets in the accompanying Condensed Consolidated Balance Sheets. Contract liabilities are recorded when the Company receives payment or bills prior to completing its obligation to transfer goods or services to a customer. The Company had $6.9 million and $26.6 million of contract liabilities as of June 30, 2021 and December 31, 2020, respectively. Revenues of $1.7 million and $196,000 for the three months and $25.5 million and $246,000 for the six months were recognized for the periods ended June 30, 2021 and 2020, respectively, related to contract liabilities at the beginning of the respective periods.

Transaction Price Allocated to Future Performance Obligations

The Company does not have material future obligations associated with testing services that extend beyond one year.

Reagents and Supplies

The Company maintains reagents and other consumables primarily used in sample collections and testing which are valued at the lower of cost or net realizable value. Cost is determined using actual costs on a first-in, first-out basis. The reagents and supplies were $25.4 million and $16.5 million as of June 30, 2021 and December 31, 2020, respectively, and was included in other current assets in the accompanying Condensed Consolidated Balance Sheets.

9

Customer Deposit

Customer deposit in the accompanying Condensed Consolidated Balance Sheets consists primarily of payments received from customers in excess of their outstanding trade accounts receivable balances, and the excess payments will be refunded to the customers or offset against future testing receivables.

Trade Accounts Receivable and Allowance for Credit Losses

Trade accounts receivable are stated at the amount the Company expects to collect. The Company maintains an allowance for credit losses for expected uncollectible trade accounts receivable, which is recorded as an offset to trade accounts receivable and changes in allowance for credit losses are classified as a general and administrative expense in the accompanying Condensed Consolidated Statements of Operations. The Company assesses collectability by reviewing trade accounts receivable on a collective basis where similar risk characteristics exist and on an individual basis when it identifies specific customers that have deterioration in credit quality such that they may no longer share similar risk characteristics with the other receivables. In determining the amount of the allowance for credit losses, the Company uses a probability-of-default and loss given default model, which allows the ability to define a point of default and measure credit losses for receivables that have reached the point of default for purposes of calculating the allowance for credit losses. Loss given default represents the likelihood that a receivable that has reached the point of default will not be collected in full. The Company will update its probability-of-default and loss given default factors annually to incorporate the most recent historical data and adjusts the quantitative portion of the reserve through its qualitative reserve overlay. The Company looks at qualitative factors such as general economic conditions in determining expected credit losses. During the three and six months ended June 30, 2021, the Company recorded $2.2 million and $3.3 million of provision for credit losses for trade accounts receivable, respectively. The provision was not significant for the three and six months ended June 30, 2020.

Marketable Securities

All marketable debt securities, which consist of corporate debt securities, municipal bonds, U.S. government agency debt securities, and Yankee debt securities issued by foreign governments or entities and denominated in U.S. dollars, have been classified as “available for sale”, and are carried at fair value. Unrealized gains and losses, net of any related tax effects, are excluded from earnings and are included in other comprehensive income (loss) and reported as a separate component of stockholders’ equity until realized. Realized gains and losses on marketable debt securities are included in interest and other income, net, in the accompanying Condensed Consolidated Statements of Operations. The cost of any marketable debt securities sold is based on the specific-identification method. The amortized cost of marketable debt securities is adjusted for amortization of premiums and accretion of discounts to maturity. Interest on marketable debt securities is included in interest and other income, net. In accordance with the Company’s investment policy, management invests to diversify credit risk and only invests in securities with high credit quality, including U.S. government securities, and the final maturity is tailored to the Company’s current liquidity needs with a maximum final maturity from the date of purchase of three years.

The Company’s investments in marketable equity securities are measured at fair value with the related gains and losses, realized and unrealized, recognized in interest and other income, net, in the accompanying Condensed Consolidated Statements of Operations. The cost of any marketable equity securities sold is based on the specific-identification method.

For available for sale debt securities, in an unrealized loss, the company determines whether a credit loss exists. The credit loss is estimated by considering available information relevant to the collectability of the security and information about past events, current conditions, and reasonable and supportable forecasts. Any credit loss is recorded as a charge to interest and other income, net, not to exceed the amount of the unrealized loss. If the Company has an intent to sell, or if it is more likely than not that the Company will be required to sell a debt security in an unrealized loss position before recovery of its amortized cost basis, the Company will write down the security to its fair value and record the corresponding charge as a component of interest and other income, net.

Business Combination

The Company uses the acquisition method of accounting and allocates the fair value of purchase consideration to the assets acquired and liabilities assumed from an acquiree based on their respective fair values as of the acquisition date. The excess of the fair value of purchase consideration over the fair value of these assets acquired and liabilities assumed is recorded as goodwill. When determining the fair values of assets acquired and liabilities assumed, management makes significant estimates and assumptions, especially with respect to intangible assets. Critical estimates in valuing intangible assets include, but are not limited to, expected future cash flows, which includes consideration of future growth and margins, future changes in technology, expected cost and time to develop in-process research and development, brand awareness and discount rates. Fair value estimates are based on the assumptions that management believes a market participant would use in pricing the asset or liability.

10

Goodwill

Goodwill is not amortized but is subject to impairment tests on an annual basis, or more frequently if indicators of potential impairment exist, and goodwill is written down when it is determined to be impaired. The Company will perform an annual impairment review in the fourth quarter of each fiscal year and compare the fair value of the reporting unit in which the goodwill resides to its carrying value.

Recent Accounting Pronouncements

The Company evaluates all Accounting Standards Updates, or ASUs, issued by the Financial Accounting Standards Board, or FASB, for consideration of their applicability. ASUs not included in the Company’s disclosures were assessed and determined to be either not applicable or are not expected to have a material impact on the Company’s condensed consolidated financial statements.

Recently Adopted Accounting Pronouncements

ASU 2016-13

In June 2016, the FASB issued ASU No. 2016-13, Financial Instruments-Credit Losses: Measurement of Credit Losses on Financial Instruments, or ASU 2016-13. ASU 2016-13 replaces the incurred loss impairment methodology in current U.S. GAAP with a methodology that reflects expected credit losses. The update is intended to provide financial statement users with more decision-useful information about the expected credit losses on financial instruments and other commitments to extend credit held by a reporting entity at each reporting date. Entities will apply the standard’s provisions as a cumulative-effect adjustment to retained earnings as of the beginning of the first reporting period in which the guidance is effective. The standard will be effective for annual reporting periods beginning after December 15, 2019, including interim periods within those reporting periods for public business entities that meet the definition of an SEC filer, excluding entities eligible to be smaller reporting companies as defined by the SEC. For all other entities, the amendments in this update are effective for fiscal years beginning after December 15, 2022, including interim periods within those fiscal years. Early application of the amendments is permitted. The Company adopted ASU 2016-13 using the modified retrospective approach as of January 1, 2021. The cumulative effect upon adoption was $887,000 to the retained earnings in the accompanying Condensed Consolidated Statements of Stockholders’ Equity and trade accounts receivable, net, in the accompanying Condensed Consolidated Balance Sheets. The cumulative tax effective was $239,000 to retained earnings and deferred tax assets included in other long-term assets in the accompanying Condensed Consolidated Balance Sheets. There was no impact related to available-for-sale debt securities.

ASU 2019-12

In December 2019, the FASB issued ASU No. 2019-12, Simplifying the Accounting for Income Taxes (Topic 740), or ASU 2019-12, which is intended to reduce the complexity of accounting standards while maintaining or enhancing the helpfulness of information provided to financial statement users.  The amendment in this ASU simplifies the accounting for income taxes by removing some exceptions including the incremental approach for intraperiod tax allocation, the requirement to recognize a deferred tax liability for equity method investments, the ability not to recognize a deferred tax liability for a foreign subsidiary, and the general methodology for calculating income taxes in an interim period. Other changes include requiring entities to recognize franchise tax that is partially based on income as an income-based tax and account for any incremental amount incurred as a non-income-based tax, evaluate tax basis step-up in goodwill obtained in a transaction that is not a business combination, and reflect the effect of an enacted change in tax laws or rates in the annual effective tax rate computation in the interim period that includes the enactment date, making minor codification improvements for income taxes related to employee stock ownership plans and investments in qualified affordable housing projects accounted for using the equity method, and specifying that an entity is not required to allocate the consolidated current and deferred tax expense to a legal entity that is not subject to tax in its separate financial statements. For public business entities, this amendment is effective for fiscal years, and interim periods within those fiscal years, beginning after December 15, 2020 with early adoption permitted. The Company adopted ASU 2019-12 in the first quarter of 2021, and the adoption had no material impact to the Company’s condensed consolidated financial statements.

 

11

 

Note 3. Marketable Securities

The Company’s marketable securities consisted of the following:

 

 

June 30, 2021

 

 

Amortized

Cost Basis

 

 

Unrealized

Gains

 

 

Unrealized

Losses

 

 

Aggregate

Fair Value

 

 

(in thousands)

 

Marketable securities:

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Short-term

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Equity securities

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Bond fund

$

169,366

 

 

$

10

 

 

$

(451

)

 

$

168,925

 

Exchange traded funds

 

35,042

 

 

 

—

 

 

 

(8

)

 

 

35,034

 

Available-for-sale debt securities

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Corporate debt securities

 

77,664

 

 

 

199

 

 

 

(9

)

 

 

77,854

 

Money market accounts

 

5,501

 

 

 

—

 

 

 

—

 

 

 

5,501

 

Municipal bonds

 

1,517

 

 

 

—

 

 

 

(1

)

 

 

1,516

 

Less: Cash equivalents

 

(5,501

)

 

 

—

 

 

 

—

 

 

 

(5,501

)

Total short-term marketable securities

 

283,589

 

 

 

209

 

 

 

(469

)

 

 

283,329

 

After 1 year through 5 years

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Corporate debt securities

 

354,979

 

 

 

188

 

 

 

(678

)

 

 

354,489

 

Municipal bonds

 

13,376

 

 

 

15

 

 

 

(19

)

 

 

13,372

 

Yankee debt securities

 

14,856

 

 

 

3

 

 

 

(109

)

 

 

14,750

 

U.S. government agency debt securities

 

1,500

 

 

 

—

 

 

 

(4

)

 

 

1,496

 

Total marketable securities due after 1 year through 5 years

 

384,711

 

 

 

206

 

 

 

(810

)

 

 

384,107

 

After 5 years through 10 years

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Municipal bonds

 

9,182

 

 

 

3

 

 

 

(43

)

 

 

9,142

 

Total marketable securities due after 5 years through 10 years

 

9,182

 

 

 

3

 

 

 

(43

)

 

 

9,142

 

Total marketable securities

$

677,482

 

 

$

418

 

 

$

(1,322

)

 

$

676,578

 

 

 

December 31, 2020

 

 

Amortized

Cost Basis

 

 

Unrealized

Gains

 

 

Unrealized

Losses

 

 

Aggregate

Fair Value

 

 

(in thousands)

 

Marketable securities:

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Short-term

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Equity securities

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Bond fund

$

153,269

 

 

$

67

 

 

$

(151

)

 

$

153,185

 

Exchange traded funds

 

17,614

 

 

 

—

 

 

 

(5

)

 

 

17,609

 

Available-for-sale debt securities

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Money market accounts

 

47,461

 

 

 

—

 

 

 

—

 

 

 

47,461

 

Corporate debt securities

 

41,061

 

 

 

101

 

 

 

(15

)

 

 

41,147

 

Less: Cash equivalents

 

(47,461

)

 

 

—

 

 

 

—

 

 

 

(47,461

)

Total short-term marketable securities

 

211,944

 

 

 

168

 

 

 

(171

)

 

 

211,941

 

After 1 year through 5 years

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Corporate debt securities

 

124,989

 

 

 

580

 

 

 

(117

)

 

 

125,452

 

U.S. government agency debt securities

 

1,000

 

 

 

2

 

 

 

—

 

 

 

1,002

 

Yankee debt securities

 

6,054

 

 

 

4

 

 

 

(10

)

 

 

6,048

 

Total marketable securities due after 1 year through 5 years

 

132,043

 

 

 

586

 

 

 

(127

)

 

 

132,502

 

Total marketable securities

$

343,987

 

 

$

754

 

 

$

(298

)

 

$

344,443

 

 

12

 

Gross unrealized losses on the Company’s marketable securities were $1.3 million as of June 30, 2021. Gross unrealized losses on the Company’s marketable securities were $298,000 as of December 31, 2020. The Company currently does not intend to sell these securities prior to maturity. During the three and six months ended June 30, 2021, the Company did not recognize credit losses.

The Company’s securities of $420.4 million are used as collateral for an outstanding margin account borrowing. As of June 30, 2021, the Company had an outstanding borrowing of $15.1 million under its margin account. Margin account borrowings were used for the purchase of real property located in El Monte, California in 2020.

 

Note 4. Fair Value Measurements

The authoritative guidance on fair value measurements establishes a framework with respect to measuring assets and liabilities at fair value on a recurring basis and non-recurring basis. Under the framework, fair value is defined as the exit price, or the amount that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants, as of the measurement date. The framework also establishes a three-tier hierarchy for inputs used in measuring fair value that maximizes the use of observable inputs and minimizes the use of unobservable inputs by requiring that the most observable inputs be used when available. Observable inputs are inputs market participants would use in valuing the asset or liability and are developed based on market data obtained from sources independent of the Company. Unobservable inputs are inputs that reflect the Company’s assumptions about the factors market participants would use in valuing the asset or liability and are developed based on the best information available in the circumstances. The hierarchy consists of the following three levels:

Level 1:

Inputs are quoted prices (unadjusted) in active markets for identical assets or liabilities that the reporting entity can access at the measurement date.

Level 2:

Inputs are inputs other than quoted prices included within Level 1 that are observable for the asset or liability, either directly or indirectly.

Level 3:

Inputs are unobservable inputs for the asset or liability.

 

The following tables present information about the Company’s financial assets measured at fair value on a recurring basis, based on the three-tier fair value hierarchy:

 

 

June 30, 2021

 

 

Total

 

 

Level 1

 

 

Level 2

 

 

Level 3

 

 

(in thousands)

 

Marketable securities and cash equivalents:

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Bond Fund

$

168,925

 

 

$

168,925

 

 

$

—

 

 

$

—

 

Exchange traded funds

 

35,034

 

 

 

35,034

 

 

 

—

 

 

 

—

 

Corporate debt securities

 

432,343

 

 

 

—

 

 

 

432,343

 

 

 

—

 

Municipal bonds

 

24,030

 

 

 

—

 

 

 

24,030

 

 

 

—

 

Yankee debt securities

 

14,750

 

 

 

—

 

 

 

14,750

 

 

 

—

 

U.S. government agency debt securities

 

1,496

 

 

 

—

 

 

 

1,496

 

 

 

—

 

Money market accounts

 

5,501

 

 

 

5,501

 

 

 

—

 

 

 

—

 

Total marketable securities and cash equivalents

$

682,079

 

 

$

209,460

 

 

$

472,619

 

 

$

—

 

 

 

December 31, 2020

 

 

Total

 

 

Level 1

 

 

Level 2

 

 

Level 3

 

 

(in thousands)

 

Marketable securities and cash equivalents:

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Bond Fund

$

153,185

 

 

$

153,185

 

 

$

—

 

 

$

—

 

Exchange traded funds

 

17,609

 

 

 

17,609

 

 

 

—

 

 

 

—

 

Corporate debt securities

 

166,599

 

 

 

—

 

 

 

166,599

 

 

 

—

 

U.S. government agency debt securities

 

1,002

 

 

 

—

 

 

 

1,002

 

 

 

—

 

Yankee debt securities

 

6,048

 

 

 

—

 

 

 

6,048

 

 

 

—

 

Money market accounts

 

47,461

 

 

 

47,461

 

 

 

—

 

 

 

—

 

Total marketable securities and cash equivalents

$

391,904

 

 

$

218,255

 

 

$

173,649

 

 

$

—

 

 

The Company’s Level 1 assets include marketable equity securities and money market instruments and are valued based upon observable market prices. Level 2 assets consist of U.S. government agency debt securities, municipal bonds, corporate debt securities and Yankee debt securities. Level 2 securities are valued based upon observable inputs that include reported trades, broker/dealer

13

quotes, bids and offers. As of June 30, 2021, the Company had no investments that were measured using unobservable (Level 3) inputs.

There were no transfers between fair value measurement levels during the three and six months ended June 30, 2021.

 

Note 5. Fixed Assets

Major classes of fixed assets consisted of the following:

 

 

 

June 30,

 

 

December 31,

 

 

Useful Lives

2021

 

 

2020

 

 

 

(in thousands)

 

Medical lab equipment

3 to 5 Years

$

30,108

 

 

$

20,849

 

Building

39 Years

 

6,731

 

 

 

6,731

 

Aircraft

7 Years

 

6,503

 

 

 

6,503

 

Computer hardware

3 Years

 

4,580

 

 

 

3,699

 

Leasehold improvements

Shorter of lease term or estimated useful life

 

1,941

 

 

 

1,580

 

Furniture and fixtures

2 to 5 Years

 

1,056

 

 

 

454

 

Automobile

2 to 5 Years

 

716

 

 

 

53

 

Building improvements

6 months to 5 Years

 

707

 

 

 

707

 

Computer software

3 to 5 Years

 

754

 

 

 

541

 

Land improvements

5 to 15 Years

 

403

 

 

 

403

 

General equipment

3 to 5 Years

 

44

 

 

 

44

 

Land

 

 

7,500

 

 

 

7,500

 

Assets not yet placed in service

 

 

4,783

 

 

 

2,055

 

Total

 

 

65,826

 

 

 

51,119

 

Less: Accumulated depreciation

 

 

(14,740

)

 

 

(10,920

)

Fixed assets, net

 

$

51,086

 

 

$

40,199

 

 

Depreciation expense on fixed assets totaled $2.3 million and $549,000 for the three months and $4.2 million and $1.1 million for the six months ended June 30, 2021 and 2020, respectively.

 

Note 6. Other Significant Balance Sheet Accounts

Other current assets consisted of the following:

 

 

June 30,

 

 

December 31,

 

 

2021

 

 

2020

 

 

(in thousands)

 

Reagents and supplies

$

25,373

 

 

$

16,491

 

Prepaid expenses

 

4,311

 

 

 

3,682

 

Marketable securities interest receivable

 

2,898

 

 

 

1,016

 

Other receivable

 

1,415

 

 

 

17,810

 

Contract assets

 

324

 

 

 

1,379

 

Prepaid income taxes

 

—

 

 

 

14

 

Total

$

34,321

 

 

$

40,392

 

 

Reagents and supplies include reagents and consumables used for COVID-19 testing and genetics testing and collection kits for COVID-19 testing. Other receivable as of December 31, 2020 primarily consists of proceeds to be received from public offerings of the Company’s common stock, which were all collected during the six months ended June 30, 2021.

 

14

 

Other current liabilities consisted of the following:

 

 

June 30,

 

 

December 31,

 

 

2021

 

 

2020

 

 

(in thousands)

 

Payroll liabilities

$

6,687

 

 

$

5,314

 

Sales tax payable and other

 

4,801

 

 

 

2,538

 

Operating lease liabilities

 

1,001

 

 

 

267

 

Due to related parties

 

574

 

 

 

409

 

Total

$

13,063

 

 

$

8,528

 

 

 

Note 7. Reporting Segment and Geographic Information

The Company views its operations and manages its business in one reporting segment. Long-lived assets were primarily located in the United States as of June 30, 2021 and December 31, 2020 with an insignificant amount located in China and Canada. Revenue by region during the three and six months ended June 30, 2021 and 2020 were as follows:

 

 

Three Months Ended June 30,

 

 

Six Months Ended June 30,

 

 

2021

 

 

2020

 

 

2021

 

 

2020

 

 

(in thousands)

 

Revenue:

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

United States

$

149,862

 

 

$

16,138

 

 

$

507,399

 

 

$

21,777

 

Foreign

 

3,754

 

 

 

1,127

 

 

 

5,646

 

 

 

3,241

 

Total

$

153,616

 

 

$

17,265

 

 

$

513,045

 

 

$

25,018

 

 

 

Note 8. Debt, Commitments and Contingencies

 

Debt

As of June 30, 2021, the Company had an outstanding borrowing of $15.1 million under its margin account with the custodian of the Company’s marketable debt security investment account, Pershing Advisor Solutions, LLC, a BNY Mellon Company. Margin account borrowings were used for the purchase of real property located in El Monte, California in 2020. The securities in the brokerage account were used as collateral for the margin loan. The custodian can issue a margin call at any time. The interest rate on the margin loan was the effective federal funds rate, or EFFR, plus a spread, and the EFFR and/or the spread can be changed by BNY Mellon at any time. The interest was 1% at the time of withdrawal of $15.0 million from the margin account, and the interest rate at June 30, 2021 was less than 1.0%. The Company did not make any other withdrawals from the margin account, and the outstanding balance of $15.1 million is included in the accompanying Condensed Consolidated Balance Sheets. The related interest expenses for the three and six months ended June 30, 2021 were $29,000 and $58,000, respectively. The related interest expenses were none for the three and six months ended June 30, 2020.

Notes payable as of June 30, 2021 consisted of $5.9 million of notes payable to Xilong Scientific Co., Ltd., or Xilong Scientific, by Fujian Fujun Gene Biotech Co., Ltd., or FF Gene Biotech, as defined in Note 14, Business Combination. The loan is payable on December 31, 2022 and interest rate on the loan is 4.97%.

Operating Leases

See Note 9, Leases, for further information.

Purchase Obligations

As of June 30, 2021, the Company had non-cancelable purchase obligations of $7.6 million, of which, $4.9 million for reagents and other supplies, $2.3 million for medical lab equipment, and $372,000 for medical lab furniture are payable within twelve months.

15

Contingencies

From time to time, the Company may be subject to legal proceedings and claims arising in the ordinary course of business. In the opinion of management, the outcome of these matters would not have a material effect on the Company’s condensed consolidated financial position, results of operations or cash flows.

 

Note 9. Leases

 

Lessee

The Company is party as a lessee to various non-cancelable operating leases with varying terms through February 2026 primarily for laboratory and office space and equipment. The Company has an option to renew one of these leases for one year after its expiration. On a lease-by-lease basis, the Company considers such options, which may be elected at the Company’s sole discretion, in determining the lease term. The Company does not have any finance leases or leases with variable lease payments. The Company’s lease agreements do not contain any residual value guarantees, material restrictive covenants, bargain purchase options or asset retirement obligations.

The Company’s headquarters are located in Temple City, California, which is comprised of various corporate offices and a laboratory certified under the Clinical Laboratory Improvement Amendments of 1988, or CLIA, accredited by the College of American Pathologists, or CAP, and licensed by the State of California Department of Public Health. Another CLIA-certified laboratory is located in Houston, Texas. Additional offices are located in Atlanta, Georgia and are used for certain report generation functions.

In February 2021, the Company extended the lease for its headquarters located in Temple City, California, to January 31, 2023. In March 2021, the Company entered into a new lease for its 12,000 square foot CLIA-certified laboratory in Houston, Texas, and the lease will expire in November 2023.

The operating lease right-of-use asset, short-term lease liabilities, and long-term lease liabilities as of June 30, 2021 and December 31, 2020 were as follows:

 

June 30,

 

 

December 31,

 

 

2021

 

 

2020

 

 

(in thousands)

 

Operating lease right-of-use asset

$

2,176

 

 

$

828

 

Operating lease liabilities, short term

$

1,001

 

 

$

267

 

Operating lease liabilities, long term

$

1,188

 

 

$

568

 

The following was operating lease expense:

 

 

Three months ended June 30,

 

 

Six months ended June 30,

 

 

2021

 

 

2020

 

 

2021

 

 

2020

 

 

(in thousands)

 

Operating lease cost

$

232

 

 

$

152

 

 

$

301

 

 

$

301

 

Short-term lease cost

 

61

 

 

 

3

 

 

 

192

 

 

 

3

 

Total lease cost

$

293

 

 

$

155

 

 

$

493

 

 

$

304

 

 

 

 

Supplemental information related to leases was the following:

 

 

June 30, 2021

 

Weighted average remaining lease term - operating leases

2.9 years

 

Weighted average discount rate - operating leases

 

3.26

%

 

16

 

The following is a maturity analysis of operating lease liabilities using undiscounted cash flows on an annual basis with renewal periods included:

 

 

Operating Leases

 

 

(in thousands)

 

Year Ending December 31,

 

 

 

2021 (remaining 6 months)

$

538

 

2022

 

881

 

2023

 

412

 

2024

 

216

 

2025

 

215

 

2026

 

37

 

Thereafter

 

—

 

Total lease payments

 

2,299

 

Less imputed interest

 

(110

)

Total

$

2,189

 

 

 

Lessor

The Company leases out space in buildings it owns to third-party tenants under noncancelable operating leases and has leased out such space since the Company purchased such buildings in October 2020. As of June 30, 2021, the remaining lease terms left range from 17 months to 42 months including renewal options and may include rent escalation clauses. Lease income primarily represents fixed lease payments from tenants recognized on a straight-line basis over the application lease term. Variable lease income represents tenant payments for real estate taxes, insurance and maintenance.

The lease income was $85,000 and $242,000 for the three and six months ended June 30, 2021, respectively, which was included in interest and other income, net, in the accompanying Condensed Consolidated Statements of Operations. Total lease income was as follows:

 

 

Three months ended June 30,

 

 

Six months ended June 30,

 

 

2021

 

 

2020

 

 

2021

 

 

2020

 

 

(in thousands)

 

Lease income

$

81

 

 

$

—

 

 

$

237

 

 

$

—

 

Variable lease income

 

4

 

 

 

—

 

 

 

5

 

 

 

—

 

Total lease income

$

85

 

 

$

—

 

 

$

242

 

 

$

—

 

 

Future fixed lease payments from tenants for all noncancelable operating leases as of June 30, 2021 are as follows:

 

 

Lease Payments

 

 

from Tenants

 

 

(in thousands)

 

Year Ending December 31,

 

 

 

2021 (remaining 6 months)

$

94

 

2022

 

190

 

2023

 

95

 

2024

 

61

 

Total

$

440

 

 

17

 

Note 10. Equity-Based Compensation

The Company has included equity-based compensation expense as part of cost of revenue and operating expenses in the accompanying Condensed Consolidated Statements of Operations as follows:

 

 

Three Months Ended June 30,

 

 

Six Months Ended June 30,

 

 

2021

 

 

2020

 

 

2021

 

 

2020

 

 

(in thousands)

 

Cost of revenue

$

692

 

 

$

270

 

 

$

1,366

 

 

$

501

 

Research and development

 

1,481

 

 

 

364

 

 

 

2,704

 

 

 

676

 

Selling and marketing

 

620

 

 

 

222

 

 

 

1,046

 

 

 

393

 

General and administrative

 

733

 

 

 

224

 

 

 

1,372

 

 

 

434

 

Total

$

3,526

 

 

$

1,080

 

 

$

6,488

 

 

$

2,004

 

 

Note 11. Provision for (Benefit from) Income Taxes

The effective tax rate used for interim periods is the estimated annual effective consolidated tax rate, based on the current estimate of full year results, except that taxes related to specific events, if any, are recorded in the interim period in which they occur. The annual effective tax rate is based upon several significant estimates and judgments, including the estimated annual pre-tax income of the Company in each tax jurisdiction in which it operates, and the development of tax planning strategies during the year. In addition, the Company’s tax expense can be impacted by changes in tax rates or laws and other factors that cannot be predicted with certainty. As such, there can be significant volatility in interim tax provisions.

The Company recorded consolidated provision for (benefit from) income taxes of $23.6 million and $90.1 million for the three and six months ended June 30, 2021, respectively, compared with $(599,000) and $(565,000) for the three and six months ended June 30, 2020, respectively. The Company’s effective tax rates were 24% and 25% for the three and six months ended June 30, 2021, respectively, compared with -21% and -45% or the three and six months ended June 30, 2020, respectively. The change in the effective tax rate for the three-month and six-month periods of 2021, relative to 2020, was primarily attributable to a significant increase in income for the first quarter of 2021, and, to a lesser extent, an increase in income for the second quarter of 2021, partially offset by increased windfall tax deductions related to stock-based compensation.

The Company is not currently under examination by any major income tax jurisdiction. During 2021, the statutes of limitations will lapse on the Company's 2017 federal tax year and certain 2016 and 2017 state tax years. The Company does not believe the federal or state statute lapses or any other event will significantly impact the balance of unrecognized tax benefits in the next twelve months. The net balance of unrecognized tax benefits was not material to the interim financial statements for the three and six months ended June 30, 2021 and 2020.

Note 12. Income per Share

The following table presents the calculation of basic and diluted income per share for the three and six months ended June 30, 2021 and 2020:

 

 

Three Months Ended June 30,

 

 

Six Months Ended June 30,

 

 

2021

 

 

2020

 

 

2021

 

 

2020

 

 

(in thousands, except per share data)

 

Net income attributable to Fulgent

$

79,812

 

 

$

3,321

 

 

$

280,503

 

 

$

1,365

 

Weighted-average common shares—outstanding, basic

 

29,150

 

 

 

21,747

 

 

 

28,991

 

 

 

21,656

 

Weighted-average common shares—outstanding, diluted

 

30,830

 

 

 

22,920

 

 

 

30,809

 

 

 

22,824

 

Net income per common share, basic

$

2.74

 

 

$

0.15

 

 

$

9.68

 

 

$

0.06

 

Net income per common share, diluted

$

2.59

 

 

$

0.14

 

 

$

9.10

 

 

$

0.06

 

18

 

The following securities have been excluded from the calculation of diluted income per share because their effect would have been anti-dilutive:

 

 

Three Months Ended June 30,

 

 

Six Months Ended June 30,

 

 

2021

 

 

2020

 

 

2021

 

 

2020

 

 

(in thousands)

 

Options

 

2

 

 

 

4

 

 

 

5

 

 

 

10

 

Restricted Stock Units

 

107

 

 

 

42

 

 

 

71

 

 

 

21

 

 

The anti-dilutive shares described above were calculated using the treasury stock method.

 

Note 13. Related Parties

Linda Marsh, who is a member of the Company’s board of directors, is currently the Senior Executive Vice President of AHMC Healthcare Inc., or AHMC. The Company performs genetic testing and other testing services, on an arms-length basis, for AHMC, and the Company recognized $738,000 and $1.9 million in revenue in the three and six months ended June 30, 2021, respectively. The Company did not perform any services for AHMC and did not recognize any revenue in the three and six months ended June 30, 2020. As of June 30, 2021 and December 31, 2020, $793,000 and $1.8 million was owed to the Company by AHMC, which is included in trade accounts receivable, net, in the accompanying Condensed Consolidated Balance Sheets, in connection with this relationship.

The Company and Fulgent Pharma LLC, the Company’s former subsidiary, are party to shared services arrangements where research and development and administrative services and office space and equipment are provided between the companies, on an arms-length basis. Ming Hsieh is the Manager and a member of Fulgent Pharma LLC. During the three and six months ended June 30, 2021, the cost of research development services rendered by Fulgent Pharma LLC for the Company was $97,000 and $205,000, respectively. The cost of research development services rendered by Fulgent Pharma LLC for the Company was not significant during the three and six months ended June 30, 2020. Amounts for services performed by the Company for Fulgent Pharma LLC were not significant during the three and six months ended June 31, 2021 and 2020. As of June 30, 2021, and December 31, 2020, $574,000 and $409,000, respectively, were owed to Fulgent Pharma LLC by the Company, which are included in due to related parties as a component in other current liabilities in the accompanying Condensed Consolidated Balance Sheets, in connection with these relationships.

 

Note 14. Business Combination

FF Gene Biotech

In April 2017, the Company acquired a 30% equity interest in FF Gene Biotech, a newly formed a joint venture with Xilong Scientific, and Fuzhou Jinqiang Investment Partnership (LP), or FJIP. The joint venture was formed under the laws of China to offer genetic testing services to customers in China.

In May 2021, the Company entered into a restructuring agreement with Xilong Scientific and FJIP, resulting in the Company indirectly acquiring a 72% controlling financial interest in FF Gene Biotech. As a result of the acquisition of FF Gene Biotech, or the FF Gene Biotech Acquisition, the Company will be more strategically aligned with it geographic expansion strategy. It also expects to reduce costs through economies of scale.

The goodwill of $23.1 million arising from the FF Gene Biotech Acquisition is attributed to the expected synergies and other benefits that will be potentially generated from the combination of the Company and FF Gene Biotech. The goodwill recognized is not deductible for tax purposes.

The Company allocated the purchase price to tangible and identified intangible assets acquired and liabilities assumed based on estimated fair values. As additional information becomes available, such as the finalization of the estimated fair value of tax-related items, the Company may further update the preliminary purchase price allocation during the remainder of the measurement period (up to one year from the FF Gene Biotech Acquisition date). The following table summarizes the consideration paid and the amounts of the assets acquired and liabilities assumed recognized at the FF Gene Biotech Acquisition date, as well as the fair value of the noncontrolling interest at the FF Gene Biotech Acquisition date.

 

19

 

 

Amounts

 

 

(in thousands)

 

Considerations

 

 

 

Cash

$

18,974

 

Fair value of the Company’s 30% equity interest held before the business combination

 

3,734

 

 

$

22,708

 

Recognized amounts of identifiable assets acquired and liabilities assumed

 

 

 

Financial assets

$

3,181

 

Reagents and supplies

 

1,288

 

Fixed assets

 

3,874

 

Other tangible assets

 

944

 

Identifiable intangible assets

 

6,958

 

Other current liabilities

 

(2,585

)

Notes payable

 

(5,893

)

Recognized amounts of identifiable assets acquired and liabilities assumed, net

 

7,767

 

Noncontrolling interest

 

(8,141

)

Goodwill

 

23,082

 

Total

$

22,708

 

The Company incurred $329,000 acquisition related costs, which was recorded as general and administrative expenses in its condensed consolidated statements of operations.

The fair value of the noncontrolling interest, or NCI, in FF Gene Biotech, a private entity, $8.1 million, was estimated by applying the income approach and market approach. The fair value measurement was based on significant inputs that are not observable in the market and thus represents a fair value categorized within Level 3 of the three-tier fair value hierarchy. The NCI represents a minority interest of 28% in the post-restructuring FF Gene Biotech. Since the NCI is the result of the restructuring, the implied value was utilized to value the NCI based on the 42% effective investment. After determining the implied value, a discount for lack of marketability was applied to the 28% interest representing lack of marketability related to the holding period to monetize the NCI in a future initial public offering, or IPO, or sale, and marketability related to market participant acquisition premiums implied in the value of the $19.0 million purchase price for a 42% interest. The resultant total discount applied was 35%, which is supported both by the put option analyses related to the potential holding period, and a 10% discount owed to a market participant acquisition premium.

The Company recognized a gain of $3.7 million as a result of remeasuring to fair value its 30% equity interest held before the FF Gene Biotech Acquisition. The fair value of the preexisting equity interest was determined based on the characteristics before consummating the FF Gene Biotech Acquisition and estimated by applying income approach and utilized the discounted cash flow method. The Company did not apply the market approach based on its characteristics before consummating the restructuring. The gain on the equity method investment is included in the Company’s Condensed Consolidated Statements of Operations for the three and six months ended June 30, 2021.

The amounts of FF Gene Biotech’s revenue and net losses included in the Company’s Condensed Consolidated Statements of Operations for the periods ended June 30, 2021 and the revenue and net losses of the combined entity had the acquisition date been January 1, 2021 are not material to the Company.

The identified intangible assets acquired in the FF Gene Biotech Acquisition consisted of a $5.7 million royalty-free technology with an estimated amortization life of 10 years and a $1.2 million customer relationships with an estimated amortization life of 5 years. The value of these assets were based upon the preliminary fair values as of the closing date of the FF Gene Biotech Acquisition.

The Company concluded FF Gene Biotech is a variable interest entity as FF Gene Biotech lacks sufficient capital to operate independently. The Company concluded that it alone has the power to direct the most significant activities of FF Gene Biotech and therefore is the primary beneficiary of the entity post the FF Gene Biotech Acquisition. Judgment regarding the level of influence over FF Gene Biotech includes consideration of key factors such as the Company's ownership interest, representation on the board of directors or other management body and participation in policy-making decisions. Post the FF Gene Biotech Acquisition, the financial results for FF Gene Biotech are included in the Company’s condensed financial statements. Prior to the FF Gene Biotech Acquisition, the financial results for FF Gene Biotech were not significant for pro forma financial information.

20

Note 15. Equity Distribution Agreement

In November 2020, the Company entered into an Equity Distribution Agreement, or the November 2020 Equity Distribution Agreement, with Piper Sandler & Co. (f/k/a Piper Jaffray & Co.), Oppenheimer & Co. Inc., and BTIG LLC, as sales agents, pursuant to which the Company may offer and sell, from time to time through Piper, shares of its common stock having an aggregate offering price of up to $175.0 million. Piper may receive a commission of up to 3% of the gross proceeds received by the Company for sales pursuant to the November 2020 Equity Distribution Agreement. During the three months ended June 30, 2021, the Company sold approximately 378,000 shares of its common stock pursuant to the November 2020 Equity Distribution Agreement at a weighted-average net selling price of $73.75. During the six months ended June 30, 2021, the Company sold approximately 961,000 shares of its common stock pursuant to the November 2020 Equity Distribution Agreement at a weighted-average net selling price of $60.56.

Note 16. Goodwill and Acquisition-Related Intangibles

Summaries of goodwill and acquisitions-related intangibles balances as of June 30, 2021 and December 30, 2020 were as follows:

 

 

 

June 30,

 

 

December 31,

 

 

Weighted-Average Amortization Period

2021

 

 

2020

 

 

 

(in thousands)

 

Goodwill

 

$

23,107

 

 

$

—

 

 

 

 

 

 

 

 

 

 

Royalty-free technology

10 Years

$

5,727

 

 

$

—

 

Less: accumulated amortization

 

 

(95

)

 

 

—

 

Royalty-free technology, net

 

 

5,632

 

 

 

—

 

 

 

 

 

 

 

 

 

 

Customer relationships

5 Years

 

1,238

 

 

 

—

 

Less: accumulated amortization

 

 

(41

)

 

 

—

 

Customer relationships, net

 

 

1,197

 

 

 

—

 

Total acquisition-related intangibles, net

 

$

6,829

 

 

$

—

 

 

During the three months ended June 30, 2021, the Company recorded $23.1 million of goodwill and $7.0 million of intangibles attributable to the FF Gene Biotech Acquisition. See Note 14, Business Combination, to the Company's condensed consolidated financial statements.

Based on the carrying value of acquisition-related intangibles recorded as of June 30, 2021, and assuming no subsequent impairment of the underlying assets, the annual amortization expense for acquisition-related intangibles is expected to be as follows:

 

 

Amounts

 

 

(in thousands)

 

2021 (remaining 6 months)

$

410

 

2022

 

821

 

2023

 

821

 

2024

 

821

 

2025

 

821

 

2026

 

656

 

Thereafter

 

2,479

 

Total

$

6,829

 

 

21

 

Note 17. Subsequent Events

In July 2021, the Company invested $20.0 million in Laboratory for Advanced Medicine, Inc., or Helio Health, incorporated in Cayman Islands, and, in connection with the investment in Helio Health, the Company obtained a minority shareholder interest. Helio Heath is an AI-driven healthcare company developing early testing capabilities for cancer. Through this partnership, the Company seeks to have access to an emerging liquid biopsy testing technology in the U.S. and China and exclusive commercial rights to Helio Health’s liquid biopsy tests in the U.S. and Canada.

In August 2021, the Company completed an acquisition of Cytometry Specialists, Inc., or CSI, a Georgia corporation, through the acquisition of all of the issued and outstanding common stock of CSI in exchange for $50.0 million in cash and up to $10.0 million in potential future milestone payments. Through the acquisition of CSI, the Company seeks to expand the Company’s presence and capabilities in somatic molecular diagnostics and cancer testing. The Company plans to leverage its established technology platform, NGS expertise, lab operations, and sales infrastructure in conjunction with CSI’s extensive cancer testing menu to establish a differentiated foothold in oncologic testing in the United States.

 

22

 

Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations.

The following discussion and analysis of our financial condition and results of operations should be read together with our condensed consolidated financial statements and related notes included in this report. Additionally, pursuant to Instruction 2 to paragraph (b) of Item 303 of Regulation S-K promulgated by the Securities and Exchange Commission in preparing this discussion and analysis, we presume that readers have access to and have read the discussion and analysis of our financial condition and results of operations included in our annual report on Form 10-K for our fiscal year ended December 31, 2020 filed with the SEC on March 8, 2021, or the 2020 Annual Report. As used in this discussion and analysis and elsewhere in this report, unless the context otherwise requires, the terms “Fulgent,” the “Company,” “we,” “us” and “our” refer to Fulgent Genetics, Inc. and its consolidated subsidiaries.

Forward-Looking Statements

The following discussion and analysis contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, or the Securities Act, and Section 21E of the Securities Exchange Act of 1934, as amended, or the Exchange Act. Forward-looking statements are statements other than historical facts and relate to future events or circumstances or our future performance, and they are based on our current assumptions, expectations and beliefs concerning future developments and their potential effect on our business. The forward-looking statements in this discussion and analysis include statements about, among other things, our future financial and operating performance, our future cash flows and liquidity and our growth strategies, as well as anticipated trends in our business and industry. These forward-looking statements are subject to a number of risks and uncertainties, including, among others, those described under “Item 1A. Risk Factors” in Part II of this report. Moreover, we operate in a competitive and rapidly evolving industry and new risks emerge from time to time. It is not possible for us to predict all of the risks we may face, nor can we assess the impact of all factors on our business or the extent to which any factor or combination of factors could cause actual results to differ from our expectations. In light of these risks and uncertainties, the forward-looking events and circumstances described in this discussion and analysis may not occur, and actual results could differ materially and adversely from those described in or implied by any forward-looking statements we make. Although we have based our forward-looking statements on assumptions and expectations we believe are reasonable, we cannot guarantee future results, levels of activity, performance or achievements or other future events. As a result, forward-looking statements should not be relied on or viewed as predictions of future events, and this discussion and analysis should be read with the understanding that actual future results, levels of activity, performance and achievements may be materially different than our current expectations. The forward-looking statements in this discussion and analysis speak only as of the date of this report, and except as required by law, we undertake no obligation to update publicly any forward-looking statements for any reason after the date of this report to conform these statements to actual results or to changes in our expectations.

Overview

We are a technology company offering large-scale COVID-19 testing services and comprehensive genetic testing to provide physicians with clinically actionable diagnostic information they can use to improve the quality of patient care. We have developed a proprietary technology platform that allows us to offer a broad and flexible test menu and continually expand and improve our proprietary genetic reference library, while maintaining accessible pricing, high accuracy and competitive turnaround times. Combining NGS with our technology platform, we perform full-gene sequencing with deletion/duplication analysis in single-gene tests; pre-established, multi-gene, disease-specific panels; and customized panels that can be tailored to meet specific customer needs. We believe our test menu offers more genes for testing than our competitors in today’s market, which enables us to provide expansive options for test customization and clinically actionable results.

Our technology platform, which integrates sophisticated data comparison and suppression algorithms, adaptive learning software, in comparison to our competitors advanced genetic diagnostics tools and integrated laboratory processes, allows us to offer a test menu with expansive genetic coverage. We believe the comprehensive data output and high detection rates of our tests, both made possible by this expansive genetic coverage, provide physicians with information they can readily incorporate into treatment decisions for their patients, which we refer to as clinical actionability. In addition, our technology platform facilitates our ability to perform customized genetic tests using our expansive library of genes, and we believe this flexibility increases the utility of the genetic data we produce. Further, our technology platform provides us with operating efficiencies that help lower our internal costs, which allows us to offer our tests at accessible price points. As a result, our efforts to build and continually enhance our technology platform allow us to deliver comprehensive, adaptable, clinically actionable and affordable genetic analysis while maintaining a low cost per billable test, enabling us to efficiently meet the needs of our growing base of customers.

23

Since March 2020, we have offered several tests for the detection of SARS-CoV-2, the virus that causes COVID-19, including NGS and RT-PCR-based tests. To date, we have processed orders for our COVID-19 tests from a variety of customers, including governmental bodies, municipalities, and large corporations. In 2020, we established and operated COVID-19 testing sites for certain municipal customers, including the County of Los Angeles and the New York City public school system. We also offer at-home COVID-19 testing services through our Picture Genetics platform that is used by many customers, including individuals and large organizations, such as the New York City Test and Trace program.

We offer tests at competitive prices, averaging approximately $96 per billable test delivered in the six months ended June 30, 2021, and at a lower cost to us than many of our competitors, averaging approximately $21 per billable test delivered in the six months ended June 30, 2021. Our volume has grown rapidly since our commercial launch, with 1.6 million and 5.3 million billable tests delivered in the three and six months ended June 30, 2021, compared to 181,000 and 194,000 billable tests delivered in the three and six months ended June 30, 2020, respectively. As of June 30, 2021, an aggregate of approximately 9.9 million billable tests have been delivered to over 1,500 customers since launching our first commercial genetic tests in 2013. We have experienced compound quarterly growth of 85% in the number of billable tests delivered in our last eight completed fiscal quarters. We recorded revenue and net income of $153.6 million and $79.8 million, respectively, in the three months ended June 30, 2021, compared to revenue and net income of $17.3 million and $3.3 million, respectively, in the three months ended June 30, 2020. We recorded revenue and net income of $513.0 million and $280.5 million, respectively, in the six months ended June 30, 2021, compared to revenue and net income of $25.0 million and $1.4 million, respectively, in the six months ended June 30, 2020. We achieved profitability in the first half of 2017, the second and third quarters of 2019, the second, third and fourth quarters of 2020, and the first and second quarter of 2021, but we have recorded losses in all other periods since our inception.

COVID-19 Considerations

The current COVID-19 pandemic has presented a substantial public health and economic challenge around the world and is affecting our employees, patients, communities and business operations, as well as the U.S. economy and financial markets. We are closely monitoring the impact of COVID-19 on all aspects of our business, including its impact on our customers, suppliers, third-party service providers, and our employees. The full extent to which the COVID-19 pandemic will directly or indirectly impact our business, results of operations and financial condition will depend on future developments that are highly uncertain and cannot be accurately predicted, including new information that may emerge concerning COVID-19, circumstances regarding the emergence and prevalence of COVID-19 variants, the success of vaccination campaigns (both in the United States and internationally), the actions taken to contain COVID-19 or treat it and related impacts on local, regional, national and international markets and supply chains.

In the first half of 2021 and for the entirety of the COVID-19 pandemic to this point, we continued to operate as an essential business in response to COVID-19. During the first half of 2021 and to date, the COVID-19 pandemic has not had a negative impact on our consolidated operating results. Rather, we have recognized significant revenue growth in connection with sales of our COVID-19 tests. Our ability to continue to operate as currently planned, including our ability to continue to offer our COVID‑19 tests with competitive results and turn-around times without any significant negative operational impact from the COVID-19 pandemic will depend in part on our, and any of our third‑party service providers’ and suppliers’ ability to protect our respective employees and supply chains. We have endeavored to follow the recommended actions of government and health authorities to protect our employees. We intend to continue to adhere to our employee safety measures to ensure that any disruptions to our operations remain minimal during the pandemic. However, the uncertainty resulting from the pandemic could result in an unforeseen disruption to our, or our third-party service providers’ and suppliers’, workforce and/or supply chain.

The COVID-19 pandemic has not negatively impacted the Company’s liquidity position as of June 30, 2021. We have not incurred any material impairments of our assets or a significant change in the fair value of our assets due to the COVID-19 pandemic as of June 30, 2021.

For additional information on risk factors related to the COVID-19 pandemic or other risks that could impact our results, please refer to “Item 1A. Risk Factors” in Part II of this Form 10-Q.

Business Risks and Uncertainties and Other Factors Affecting Our Performance

Our business and prospects are exposed to numerous risks and uncertainties. For more information, see “Item 1A. Risk Factors” in Part II of this report. In addition, our performance in any period is affected by a number of other factors. See the description of some of the material factors affecting our performance in “Item 7. Management’s Discussion and Analysis of Financial Condition and Results of Operations” of the 2020 Annual Report.

 

 

24

 

Results of Operations

The table below summarizes our results of operations for the periods indicated. For a financial overview relating to our results of operations, including general descriptions of the make-up of material line items of our statement of operations data, see “Item 7. Management’s Discussion and Analysis of Financial Condition and Results of Operations” of the 2020 Annual Report.

 

 

Three Months Ended

 

 

 

 

 

 

 

 

 

 

Six Months Ended

 

 

 

 

 

 

 

 

 

 

June 30,

 

 

$

 

 

%

 

 

June 30,

 

 

$

 

 

%

 

 

2021

 

 

2020

 

 

Change

 

 

Change

 

 

2021

 

 

2020

 

 

Change

 

 

Change

 

Statement of Operations Data:

(dollars and billable tests in thousands, except per billable test data)

 

Revenue

$

153,616

 

 

$

17,265

 

 

$

136,351

 

 

 

790

%

 

$

513,045

 

 

$

25,018

 

 

$

488,027

 

 

 

1,951

%

Cost of revenue

 

35,858

 

 

 

7,717

 

 

 

28,141

 

 

 

365

%

 

 

109,933

 

 

 

11,774

 

 

 

98,159

 

 

 

834

%

Gross profit

 

117,758

 

 

 

9,548

 

 

 

108,210

 

 

 

1,133

%

 

 

403,112

 

 

 

13,244

 

 

 

389,868

 

 

 

2,944

%

Operating expenses:

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Research and development

 

5,312

 

 

 

1,849

 

 

 

3,463

 

 

 

187

%

 

 

10,734

 

 

 

3,827

 

 

 

6,907

 

 

 

180

%

Selling and marketing

 

5,219

 

 

 

3,260

 

 

 

1,959

 

 

 

60

%

 

 

10,227

 

 

 

4,857

 

 

 

5,370

 

 

 

111

%

General and administrative

 

8,329

 

 

 

1,799

 

 

 

6,530

 

 

 

363

%

 

 

16,331

 

 

 

3,834

 

 

 

12,497

 

 

 

326

%

Total operating expenses

 

18,860

 

 

 

6,908

 

 

 

11,952

 

 

 

173

%

 

 

37,292

 

 

 

12,518

 

 

 

24,774

 

 

 

198

%

Operating income

 

98,898

 

 

 

2,640

 

 

 

96,258

 

 

 

3,646

%

 

 

365,820

 

 

 

726

 

 

 

365,094

 

 

 

50,288

%

Interest and other income, net

 

604

 

 

 

275

 

 

 

329

 

 

 

120

%

 

 

886

 

 

 

516

 

 

 

370

 

 

 

72

%

Income before income taxes, gain on

   equity method investment and

   equity loss in investee

 

99,502

 

 

 

2,915

 

 

 

96,587

 

 

 

3,313

%

 

 

366,706

 

 

 

1,242

 

 

 

365,464

 

 

 

29,425

%

Provision for (benefit from) income

      taxes

 

23,589

 

 

 

(599

)

 

 

24,188

 

 

 

4,038

%

 

 

90,102

 

 

 

(565

)

 

 

90,667

 

 

 

16,047

%

Income before gain on equity method

      and equity loss in investee

 

75,913

 

 

 

3,514

 

 

 

72,399

 

 

 

2,060

%

 

 

276,604

 

 

 

1,807

 

 

 

274,797

 

 

 

15,207

%

Gain on equity method investment

 

3,734

 

 

 

—

 

 

 

3,734

 

 

*

 

 

 

3,734

 

 

 

—

 

 

 

3,734

 

 

*

 

Equity loss in investee

 

—

 

 

 

(193

)

 

 

193

 

 

 

100

%

 

 

—

 

 

 

(442

)

 

 

442

 

 

 

100

%

Net income from consolidated

      operations

 

79,647

 

 

 

3,321

 

 

 

76,326

 

 

 

2,298

%

 

 

280,338

 

 

 

1,365

 

 

 

278,973

 

 

 

20,438

%

Net loss attributable to noncontrolling

      interests

 

165

 

 

 

—

 

 

 

165

 

 

*

 

 

 

165

 

 

 

—

 

 

 

165

 

 

*

 

Net income attributable to Fulgent

$

79,812

 

 

$

3,321

 

 

$

76,491

 

 

 

2,303

%

 

$

280,503

 

 

$

1,365

 

 

$

279,138

 

 

 

20,450

%

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Other Operating Data:

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Billable tests delivered(1)

 

1,559

 

 

 

181

 

 

 

1,378

 

 

 

761

%

 

 

5,333

 

 

 

194

 

 

 

5,139

 

 

 

2,649

%

Average price per billable test

      delivered(2)

$

99

 

 

$

96

 

 

$

3

 

 

 

3

%

 

$

96

 

 

$

129

 

 

$

(33

)

 

 

(26

%)

Cost per billable test delivered(3)

$

23

 

 

$

43

 

 

$

(20

)

 

 

(47

%)

 

$

21

 

 

$

61

 

 

$

(40

)

 

 

(66

%)

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

* Percentage not meaningful.

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

(1)

We determine the number of billable tests delivered in a period by counting the number of tests which are delivered to our customers and for which we bill our customers and recognize some amount of revenue in the period.

(2)

We calculate the average price per billable test delivered by dividing the amount of revenue we recognized from the billable tests delivered in a period by the number of billable tests delivered in the same period.

(3)

We calculate cost per billable test delivered by dividing our cost of revenue in a period by the number of billable tests delivered in the same period.

25

Revenue

Revenue increased $136.4 million, or 790%, from $17.3 million in the three months ended June 30, 2020 to $153.6 million in the three months ended June 30, 2021, and increased $488.0 million, or 1951%, from $25.0 million in the six months ended June 30, 2020 to $513.0 million in the six months ended June 30, 2021. The increase in revenue between periods was primarily due to increase in the number of billable tests delivered, primarily related to the increased orders for our COVID-19 tests, offset by a substantial decline in the average selling price per test.

The average price of the billable tests we delivered increased from $96 in the three months ended June 30, 2020 to $99 in the three months ended June 30, 2021, and decreased from $129 in the six months ended June 30, 2020 to $96 in the six months ended June 30, 2021. The decreases in the six months period were due to (i) lower price-points for the mix of tests we delivered, including COVID-19 tests launched in 2020, (ii) the mix of customers ordering tests in these periods, who may order tests at different rates depending on the arrangements we have negotiated with them, and (iii) our reduction of prices for certain of our tests due to general price degradation for genetic tests and other competitive factors during the three and six months ended June 30, 2021.

Revenue from non-U.S. sources increased $2.6 million, or 233%, from $1.1 million in the three months ended June 30, 2020 to $3.8 million in the three months ended June 30, 2021, and increased $2.4 million, or 74%, from $3.2 million in the six months ended June 30, 2020 to $5.6 million in the six months ended June 30, 2021. The increases in revenue from non-U.S. sources between periods were primarily due to increased sales of our traditional genetic testing services to customers in foreign countries.

The number of billable tests we delivered increased 1.4 million, from 181,000 in the three months ended June 30, 2020 to 1.6 million in the three months ended June 30, 2021, and increased 5.1 million, from 194,000 in the six months ended June 30, 2020 to 5.3 million in the six months ended June 30, 2021. The increases were primarily attributable to the expansion of our test menu, including our COVID-19 tests launched in 2020, and increases in sales to certain of our existing and new customers.

After aggregating customers that are under common control or are affiliates, two customers contributed 20% and 16% of the Company’s revenue for the three months ended June 30, 2021, respectively. Two customers contributed 24% and 11% of the Company’s revenue for the six months ended June 30, 2021, respectively.  

Cost of Revenue

Cost of revenue increased $28.1 million, or 365%, from $7.7 million in the three months ended June 30, 2020 to $35.9 million in the three months ended June 30, 2021. The increase was primarily due to increases of $10.4 million in consulting and outside labor expense related to increased outside labor for production in the current period, $8.8 million in reagent and supply expenses related to increased billable tests delivered, $4.1 million in personnel costs including equity-based compensation expense related to increased headcount and market price of the Company’s stock, $2.2 million in software expense related to usage of COVID-19 testing software, and $1.6 million in depreciation expenses related to medical lab equipment purchased for our COVID-19 tests.

Cost of revenue increased $98.2 million, or 834%, from $11.8 million in the six months ended June 30, 2020 to $109.9 million in the six months ended June 30, 2021. The increase was primarily due to increases of $51.7 million in reagent and supply expenses related to increased billable tests delivered, $24.7 million in consulting and outside labor expense related to increased outside labor for production in the current period, $9.1 million in personnel costs including equity-based compensation expense related to increased headcount and market price of the Company’s stock, $6.2 million in software expense related to usage of COVID-19 testing software, $2.9 million in depreciation expenses related to medical lab equipment purchased for our COVID-19 tests, and $1.6 million in facilities primarily related to certain modifications made to our mini vans used for our COVID-19 business.

Cost per billable test delivered decreased $20, or 47%, from $43 in the three months ended June 30, 2020 to $23 in the three months ended June 30, 2021 as the increase in the number of billable tests we delivered was greater than the increase in our cost of revenue due to economies of scale related to the increased number of billable tests for the period. Cost per billable test delivered decreased $40, or 66%, from $61 in the six months ended June 30, 2020 to $21 in the six months ended June 30, 2021 as the increase in the number of billable tests we delivered was greater than the increase in our cost of revenue. The greater increase in the number of billable tests we delivered was primarily attributable to new customers and our expanded test menu, including COVID-19 tests in 2020 which have a lower cost than our genetics tests. Our cost per billable test decreased in part due to our efforts to leverage our technology, such as engineered chemistry and competitive analytics powered by artificial intelligence and machine learning.

26

Our gross profit increased $108.2 million, from $9.5 million in the three months ended June 30, 2020 to $117.8 million in the three months ended June 30, 2021, and increased $389.9 million, from $13.2 million in the six months ended June 30, 2020 to $403.1 million in the six months ended June 30, 2021. Our gross profit as a percentage of revenue, or gross margin, increased from 55.3% to 76.7% between three months ended June 30, 2020 and 2021, and increased from 52.9% to 78.6% between six months ended June 30, 2020 and 2021, due in part to the increase in revenue and decreases in our cost per billable test and cost of revenue described above.

Research and Development

Research and development expenses increased $3.5 million, or 187%, from $1.8 million in the three months ended June 30, 2020 to $5.3 million in the three months ended June 30, 2021. The increase was primarily due to increases of $2.6 million in personnel costs including equity-based compensation expense related to increased headcount and market price of the Company’s stock and $750,000 in donation to COVID-19 research fund and colorectal cancer research.

Research and development expenses increased $6.9 million, or 180%, from $3.8 million in the six months ended June 30, 2020 to $10.7 million in the six months ended June 30, 2021. The increase was primarily due to increases of $4.2 million in personnel costs including equity-based compensation expense related to increased headcount and market price of the Company’s stock, $1.5 million in reagent and supply expenses related to increased reagent usage for COVID-19 research, and $750,000 in donation to a COVID-19 research fund and colorectal cancer research.

Selling and Marketing

Selling and marketing expenses increased $2.0 million, or 60% from $3.3 million in the three months ended June 30, 2020 to $5.2 million in the three months ended June 30, 2021. The increase was primarily due to increases of $2.4 million in personnel costs including equity-based compensation expense related to increased commission expense and market price of the Company’s stock, and $818,000 in consulting and outside labor expense related to COVID-19 marketing projects in the current period, partially offset by $1.5 million in marketing supplies, including kits to potential customers in the prior period.

Selling and marketing expenses increased $5.4 million, or 111% from $4.9 million in the six months ended June 30, 2020 to $10.2 million in the six months ended June 30, 2021. The increase was primarily due to increases of $4.7 million in personnel costs including equity-based compensation expense related to increased commission expense and market price of the Company’s stock, and $1.7 million in consulting and outside labor expense and $472,000 in marketing expense related to COVID-19 testing related marketing projects in the current period, partially offset by $1.7 million in marketing supplies, including kits to potential customers in the prior period.

General and Administrative

General and administrative expenses increased $6.5 million, or 363% from $1.8 million in the three months ended June 30, 2020 to $8.3 million in the three months ended June 30, 2021. The increase was primarily due to increases of $2.2 million in bad debt expense related to additional provision for credit losses in the current period, $1.5 million in personnel costs including equity-based compensation expense related to increased headcount and market price of the Company’s stock, $515,000 in legal and professional fees related to professional services obtained in the current period, $438,000 in accounting fees related to accounting services for public offering and internal control, $340,000 on loss in disposal of fixed assets, $225,000 in insurance related to the increase cost of liabilities and director and officers insurance, and $206,000 in consulting and outside labor expense related to the increased insurance billing.

General and administrative expenses increased $12.5 million, or 326% from $3.8 million in the six months ended June 30, 2020 to $16.3 million in the six months ended June 30, 2021. The increase was primarily due to increases of $3.1 million in bad debt expense related to additional provision for credit losses in the current period, $2.7 million in personnel costs including equity-based compensation related to increased headcount and market price of the Company’s stock, $2.6 million in software and licensing related to the increased number of COVID-19 tests, $878,000 in legal and professional fees related to professional services obtained in the current period, $358,000 in accounting fees related to accounting services for public offering and internal control, $353,000 in loss on disposal of fixed assets, $347,000 in other state tax related to the increase in revenue, $345,000 in insurance related to the increase cost of liabilities and director and officers insurance, and $345,000 in consulting and outside labor expense related to the increased insurance billing.

27

Interest Income and Other Income (Losses)

Interest income was $566,000 and $249,000 in the three months ended June 30, 2021 and 2020, respectively, and $796,000 and $575,000 in the six months ended June 30, 2021 and 2020, respectively. This income related to interest earned on various investments in marketable securities including holding gain or loss on marketable equity securities.

Other income (expense) was not significant in the three or six months ended June 30, 2021 and 2020, respectively. The primary components of other losses were rental income net of rental expenses and foreign currency exchange gain (loss).

Provision for (Benefit from) Income Taxes

Provision for (benefit from) income taxes were $23.6 million and $90.1 million for the three and six months ended June 30, 2021, respectively, and $(599,000) and $(565,000) for the three and six months ended June 30, 2020, respectively. The effective tax rate was 24% for the three months ended June 30, 2021 compared with -21% for the three months ended June 30, 2020. The effective tax rate was 25% for the six months ended June 30, 2021 compared with -45% for the six months ended June 30, 2020. The increase in effective tax rates for the three and six months ended June 30, 2021, relative to the comparative 2020 periods, was primarily attributable to a significant increase in income for the three and six months ended June 30, 2021, partially offset by increased windfall tax deductions related to stock-based compensation.

Gain on Equity Method Investment

The Company recognized a gain of $3.7 million in the three and six months ended June 30, 2021 related to the preexisting equity interest at FF Gene Biotech as a result of remeasuring to fair value its 30% equity interest held before the FF Gene Biotech Acquisition. The fair value of the preexisting equity interest was determined based on the characteristics before consummating the FF Gene Biotech Acquisition and estimated by applying income approach and utilized the discounted cash flow method. There was no such gain on equity method investment in the three and six months ended June 30, 2020.

Equity Loss in Investee

Equity loss in investee was $193,000 and $422,000 in the three and six months ended June 30, 2020, respectively. Equity loss in investee in 2020 relates to our 30% ownership interest in FF Gene Biotech.

Net Loss Attributable to Noncontrolling Interest

Net loss attributable to noncontrolling interest represents net loss of FF Gene Biotech attributable to the minority shareholders, Xilong Scientific and FJIP, which was not significant in the three and six months ended June 30, 2021.

Liquidity and Capital Resources

Liquidity and Sources of Cash

We had $100.5 million in cash and cash equivalents and $676.6 million in marketable securities, consisting of equity securities, corporate bonds, municipal bonds, and U.S. government agency securities, as of June 30, 2021. We had $87.4 million in cash and cash equivalents and $344.4 million in marketable securities, consisting of corporate bonds, as of December 31, 2020.

Initially after commencing operations in May 2012, our operations were financed primarily by our founder, Chief Executive Officer and Chairman of our board of directors, Ming Hsieh, and in more recent periods, by cash from our operations and equity financings.

Our primary uses of cash are to fund our operations as we continue to invest in and seek to grow our business. Cash used to fund operating expenses is impacted by the timing of our expense payments, as reflected in the changes in our outstanding accounts payable and accrued expenses.

On August 30, 2019, we entered into an Equity Distribution Agreement, or the 2019 Equity Distribution Agreement, with Piper, as sales agent, which was subsequently amended on August 4, 2020. Pursuant to the 2019 Equity Distribution Agreement, we offered and sold an aggregate of 104,000 shares of our common stock at a weighted-average net selling price of $9.37 per share, which resulted in $979,000 of net proceeds to the Company during the year ended December 31, 2019, and we sold an aggregate of 1.1 million shares of our common stock at a weighted-average net selling price of $38.50 per share, which resulted in $42.7 million of net proceeds to the Company during the year ended December 31, 2020. Shares sold under the 2019 Equity Distribution Agreement are offered and sold pursuant to the Company’s registration statement on Form S-3 (File No. 333-233227) filed with the SEC on August 12, 2019 and declared effective on August 23, 2019, and prospectus supplements and accompanying base prospectus filed with the SEC on August 30, 2019, May 6, 2020 and August 5, 2020.

28

On November 13, 2019, we entered into a Purchase Agreement with Piper, as representative of the several underwriters, pursuant to which we sold 2,673,750 shares of our common stock at a price of $10.52 per share, with a public offering price of $11.25 per share. We received net proceeds of approximately $27.6 million, after deducting underwriting discounts and commissions and offering expenses paid or payable by us of approximately $2.4 million. The shares issued and sold in the underwritten offering were sold pursuant to the Company’s registration statement on Form S-3 (File No. 333-233227), and a prospectus supplement and accompanying base prospectus filed with the SEC on November 13, 2019.

On September 25, 2020, we entered into the September 2020 Equity Distribution Agreement, with Piper as sales agent, pursuant to which we offered and sold an aggregate of 2.8 million shares of our common stock at a weighted-average net selling price of $42.90 per share, which resulted in $122.1 million of net proceeds to the Company. Shares sold under the September 2020 Equity Distribution Agreement were offered and sold pursuant to the Company’s registration statement on Form S-3 (File No. 333-239964) filed with the SEC on July 21, 2020, as amended on August 5, 2020, and declared effective on August 12, 2020, and a prospectus supplement and accompanying base prospectus filed with the SEC on September 25, 2020.

On November 20, 2020, we entered into the November 2020 Equity Distribution Agreement, with Piper, Oppenheimer & Co. Inc., and BTIG LLC, as sales agents, pursuant to which we may offer and sell, from time to time through Piper, shares of our common stock having an aggregate offering price of up to $175.0 million. Piper may receive a commission of up to 3% of the gross proceeds received by the Company for sales pursuant to the November 2020 Equity Distribution Agreement. During the year ended December 31, 2020, we sold an aggregate of 2.0 million shares of our common stock pursuant to the November 2020 Equity Distribution Agreement at a weighted-average net selling price of $48.70 per share, which resulted in $99.1 million of net proceeds to the Company. During the three months ended June 30, 2021, the Company sold approximately 378,000 shares of its common stock pursuant to the November 2020 Equity Distribution Agreement at a weighted-average net selling price of $73.75, which resulted in $27.9 million of net proceeds to the Company. During the six months ended June 30, 2021, the Company sold approximately 961,000 shares of its common stock pursuant to the November 2020 Equity Distribution Agreement at a weighted-average net selling price of $60.56, which resulted in $58.2 million of net proceeds to the Company. Shares sold under the November 2020 Equity Distribution Agreement were offered and sold pursuant to the Company’s registration statement on Form S-3 (File No. 333-239964) filed with the SEC on July 21, 2020, as amended on August 5, 2020, and declared effective on August 12, 2020, and a prospectus supplement and accompanying base prospectus filed with the SEC on November 20, 2020.

We believe our existing cash, cash equivalent, short-term marketable securities, along with cash from operations and proceeds from our equity financings, will be sufficient to meet our anticipated cash requirements for at least the next 12 months. Much of the losses we have incurred in certain prior periods were attributable to a variety of non-cash charges, including equity-based compensation expenses. As a result, in spite of the losses we recorded during these periods, cash provided by continuing operations has been mostly positive since 2015 and has significantly contributed to our ability to meet our liquidity needs, including paying for capital expenditures. Additionally, if our business continues to grow and we are able to achieve increased efficiencies and economies of scale in line with this growth, we expect increased revenue levels would increase our ability to rely on cash from our operations to support our business in future periods, even if our expenses also increase as a result of the growth of our business. Based on these factors, we anticipate that cash from our operations will continue to play a meaningful role in our ability to meet our liquidity requirements and pursue our business plans and strategies during the next 12 months and in the longer term.

However, our expectations regarding the cash that may be provided by our operations and our cash needs in future periods could turn out to be wrong, in which case we may require additional financing to support our operations, as we do not presently have any commitments for future capital. For instance, cash provided by our operations has in the past experienced fluctuations from period to period, which we expect may continue in the future. These fluctuations can occur because of a variety of factors, including, among others, factors relating to the ongoing COVID-19 pandemic, the amount and timing of sales of billable tests, the prices we charge for our tests due to changes in product mix, customer mix, general price degradation for tests or other factors, the rate and timing of our billing and collections cycles and the timing and amount of our commitments and other payments. Moreover, even if our liquidity expectations are correct, we may still seek to raise additional capital through securities offerings, credit facilities or other debt financings, asset sales or collaborations or licensing arrangements.

If we raise additional funds by issuing equity securities, our existing stockholders could experience substantial dilution. Additionally, any preferred stock we issue could provide for rights, preferences or privileges senior to those of our common stock, and our issuance of any additional equity securities, or the possibility of such an issuance, could cause the market price of our common stock to decline. The terms of any debt securities we issue or borrowings we incur, if available, could impose significant restrictions on our operations, such as limitations on our ability to incur additional debt or issue additional equity or other restrictions that could adversely affect our ability to conduct our business, and would result in increased fixed payment obligations. If we seek to sell assets or enter into collaborations or licensing arrangements to raise capital, we may be required to accept unfavorable terms or relinquish or license to a third party our rights to important or valuable technologies or tests we may otherwise seek to develop ourselves. Moreover, we may incur substantial costs in pursuing future capital, including investment banking, legal and accounting fees, printing and distribution expenses and other similar costs. Additional funding may not be available to us when needed, on acceptable terms or

29

at all. For example, the COVID-19 pandemic has caused disruption and volatility in the global capital markets, which could reduce our ability to access capital. If we are not able to secure funding if and when needed and on reasonable terms, we may be forced to delay, reduce the scope of or eliminate one or more sales and marketing initiatives, research and development programs or other growth plans or strategies. In addition, we may be forced to work with a partner on one or more aspects of our tests or market development programs or initiatives, which could lower the economic value to us of these tests, programs or initiatives. Any such outcome could significantly harm our business, performance and prospects.

Cash Flows

The following table summarizes our cash flows for each of the periods indicated:

 

 

Six Months Ended June 30,

 

 

2021

 

 

2020

 

 

(in thousands)

 

Net cash provided by (used in) operating activities

$

309,290

 

 

$

(3,043

)

Net cash used in investing activities

$

(371,496

)

 

$

(6,267

)

Net cash provided by (used in) financing activities

$

75,240

 

 

$

(223

)

 

Operating Activities

Cash provided by operating activities in the six months ended June 30, 2021 was $309.3 million. The difference between net income and cash provided by operating activities for the period was primarily due to the effects of $6.5 million in equity-based compensation expenses and $4.3 million in the depreciation and amortization. Cash provided by operating activities increased between periods primarily due to an increase of $44.7 million in customer deposit due to payments received from customer in excess of their outstanding trade accounts receivable balances, and a decrease of $32.5 million in trade receivable due to timing of payments, and partially offset by negative impact of decreases of $26.9 million in income tax payable due to the estimated tax payments made during the current period, $19.7 million in contract liabilities due to timing of payments, $10.3 million in accounts payable due to the timing of payments, and an increase of $6.0 million in other current and long-term assets related to additions in reagents and supplies.

Cash used in operating activities in the six months ended June 30, 2020 was $3.0 million. The difference between net income and cash used in operating activities for the period was primarily due to increases of $7.4 million in accounts receivable mainly due to timing of collections from customers and increased revenue and $3.8 million in other current assets related to purchases of an increased amount of reagents and supplies and equipment purchased that will be contributed to FF Gene Biotech, partially offset by the effects of $2.0 million in equity-based compensation expenses, $1.1 million in the depreciation of assets and $442,000 in equity loss in investee.

Investing Activities

Cash used in investing activities in the six months ended June 30, 2021 was $371.5 million, which primarily related to purchases of $424.8 million of marketable securities, $18.5 million related to a business acquisition, and purchase of $14.4 million of fixed assets consisting mainly of medical laboratory equipment and building construction, partially offset by $51.7 million related to sales of marketable securities and proceeds of $34.5 million related to maturities of marketable securities.

Cash used in investing activities in the six months ended June 30, 2020 was $6.3 million, which primarily related to purchases of $12.4 million of marketable securities and purchases of $1.2 million of fixed assets consisting mainly of medical laboratory equipment, leasehold improvements, and computer hardware, partially offset by proceeds of $7.3 million related to maturities of marketable securities.

Financing Activities

Cash provided by financing activities in the six months ended June 30, 2021 was $75.2 million, which primarily represents net proceeds from 2020 Equity Distribution Agreement. Cash used in financing activities in the six months ended June 30, 2020 was $223,000, which primarily represents payment for costs related to our underwritten offering in November 2019.

30

Critical Accounting Policies and Use of Estimates

This discussion and analysis is based on our condensed consolidated financial statements included in this report, which have been prepared in accordance with U.S. GAAP. The preparation of consolidated financial statements in accordance with U.S. GAAP requires management to make certain estimates, judgments and assumptions and decisions that affect the reported amounts and related disclosures, including the selection of appropriate accounting principles and the assumptions on which to base accounting estimates. In making these estimates and assumptions and reaching these decisions, we apply judgment based on our understanding and analysis of the relevant circumstances, including historical data and experience available at the date of the consolidated financial statements, as well as various other factors management believes to be reasonable under the circumstances, including but not limited to the potential impacts arising from the recent global pandemic related to COVID-19. As the extent and duration of the impacts from COVID-19 remain unclear, our estimates and assumptions may evolve as conditions change. Actual results could differ from our estimates. We are committed to incorporating accounting principles, assumptions and estimates that promote the representational faithfulness, verifiability, neutrality and transparency of the accounting information included in our consolidated financial statements.

Except as set forth in Note 2 (Summary of Significant Accounting Policies) to our condensed consolidated financial statements included in this report, there have been no significant changes to our critical accounting policies and estimates as described in the 2020 Annual Report.

The JOBS Act

We qualify as an “emerging growth company” as defined in the Jumpstart Our Business Startups Act of 2012, as amended, or JOBS Act. As an emerging growth company, we may take advantage of specified reduced disclosure and other requirements that are otherwise applicable to public companies that are not emerging growth companies, including an extended transition period to comply with new or revised accounting standards applicable to public companies. We have chosen to “opt out” of this extended transition period and, as a result, we will comply with new or revised accounting standards as required when they are adopted. This decision to opt out of the extended transition period under the JOBS Act is irrevocable. We expect to remain an emerging growth company until December 31, 2021, unless we issue more than $1.0 billion of non-convertible debt in any three-year period before that date.

Off-Balance Sheet Arrangements

We did not have during the periods presented, and we do not currently have, any off-balance sheet arrangements, as defined in the rules and regulations of the SEC, that have or are reasonably likely to have a current or future effect on our financial condition, changes in financial condition, revenue or expenses, results of operations, liquidity, capital expenditures or capital resources that is material to investors.

31

Item 3. Quantitative and Qualitative Disclosures About Market Risk.

Not applicable.

Item 4. Controls and Procedures.

Evaluation of Disclosure Controls and Procedures

Disclosure controls and procedures are controls and other procedures of a company that are designed to ensure that information required to be disclosed by the company in the reports that it files or submits under the Exchange Act is recorded, processed, summarized and reported within the time periods specified in the SEC’s rules and forms. Disclosure controls and procedures include, without limitation, controls and procedures designed to ensure that information required to be disclosed by a company in the reports that it files or submits under the Exchange Act is accumulated and communicated to the company’s management, including its principal executive and principal financial officers, or persons performing similar functions, as appropriate to allow timely decisions regarding required disclosure. As required by Rule 13a-15(b) under the Exchange Act, our management, with the participation of our Chief Executive Officer and Chief Financial Officer, conducted an evaluation of the effectiveness of our disclosure controls and procedures as of June 30, 2021. Based on this evaluation, our Chief Executive Officer and Chief Financial Officer concluded that our disclosure controls and procedures were effective as of June 30, 2021.

Changes in Internal Control over Financial Reporting

There have not been any changes in our internal control (as required by Rule 13a-15(b) under the Exchange Act) over the financial reporting during the three and six months ended June 30, 2021 that have materially affected or are reasonably likely to materially affect our internal control over financial reporting.

Inherent Limitations on Disclosure Controls and Procedures and Internal Control over Financial Reporting

Management recognizes that any controls and procedures, no matter how well-designed and operated, can provide only reasonable assurance of achieving their objectives, and management necessarily applies its judgment in evaluating the benefits of possible controls and procedures relative to their costs. Because of these inherent limitations, our disclosure and internal controls may not prevent or detect all instances of fraud, misstatements or other control issues. In addition, projections of any evaluation of the effectiveness of disclosure or internal controls to future periods are subject to risks, including, among others, that controls may become inadequate because of changes in conditions or that the degree of compliance with policies or procedures may deteriorate.

 

 

32

 

PART II—OTHER INFORMATION

From time to time, we may be involved in legal proceedings arising in the ordinary course of our business. We are not presently a party, and our properties are not presently subject, to any legal proceedings that, in the opinion of management, would have a material effect on our business. Regardless of outcome, litigation can have an adverse impact on us due to defense and settlement costs, diversion of management resources, negative publicity and reputational harm, among other factors.

Item 1A. Risk Factors.

Summary Risk Factors

The risk factors described below are a summary of the principal risk factors associated with an investment in us. These are not the only risks we face. You should carefully consider these risk factors, together with the risk factors set forth in “Item 1A. Risk Factors” of this report and the other reports and documents filed by us with the SEC.

 

•

Our results of operations may fluctuate significantly from period to period and can be difficult to predict.

 

•

The expansion of our COVID-19 testing business has resulted in a substantial change in our business that presents important challenges to our ability to manage our rapidly expanding business, and there can be no assurance that our recent growth due to demand for our COVID-19 tests, or that any revenue growth we may experience will continue.

 

•

We have a history of losses, and we may not be able to achieve or sustain profitability.

 

•

Our industry is subject to rapidly changing technology and new and increasing amounts of scientific data, and if we fail to keep pace with these technological advances, we may be unable to compete effectively and our business and prospects could suffer.

 

•

If we are not able to grow and diversify our customer base and increase demand for our tests from existing and new customers, our potential for growth could be limited.

 

•

Failure to comply with government laws and regulations related to submission of claims for our services could result in significant monetary damages and penalties and exclusion from the Medicare and Medicaid programs and corresponding foreign reimbursement programs.

 

•

We rely on a limited number of suppliers and, in some cases, a sole supplier, for certain of our laboratory substances, equipment and other materials, and any delays or difficulties securing these materials could disrupt our laboratory operations and materially harm our business.

 

•

Billing and collections processing for our tests is complex and time-consuming, and any delay in transmitting and collecting claims could have an adverse effect on our revenue.

 

•

We rely on highly skilled personnel in a broad array of disciplines, and if we are unable to hire, retain or motivate these individuals, we may not be able to maintain the quality of our tests or grow our business.

 

•

We may acquire businesses or assets, form joint ventures, make investments in other companies or technologies or establish other strategic relationships, any of which could harm our operating results, dilute our stockholders’ ownership or cause us to incur debt or significant expense.

 

•

Any changes in laws, regulations or the enforcement discretion of the FDA with respect to the marketing of diagnostic products, or violations of laws or regulations by us, could adversely affect our business, prospects, results of operations or financial condition.

 

•

If we fail to comply with applicable federal, state, local and foreign laboratory licensing requirements, we could lose the ability to perform our tests or experience disruptions to our business.

 

•

We conduct business in a heavily regulated industry. Complying with the numerous statutes and regulations pertaining to our business is expensive and time-consuming, and any failure by us, our consultants or commercial partners to comply could result in substantial penalties.

 

•

Changes in laws and regulations, or in their application, may adversely affect our business, financial condition and results of operations.

 

•

Marketing of our COVID-19 tests under the EUA from the FDA is subject to certain limitations and we are required to maintain compliance with the terms of the EUA, among other things, and the continuance of our EUA is subject to government discretion.

 

•

We primarily rely on trade secret protection, non-disclosure agreements and invention assignment agreements to protect our proprietary information, which may not be effective.

 

•

Litigation or other proceedings or third-party claims of intellectual property infringement or misappropriation could require us to spend significant time and money and prevent us from selling our tests.

 

•

An active, liquid trading market for our common stock may not be sustained, which could make it difficult for stockholders to sell their shares of our common stock.

33

 

•

The price of our common stock may be volatile and you could lose all or part of your investment.

 

•

Our principal stockholders and management own a significant percentage of our capital stock and are able to exert significant control over matters subject to stockholder approval.

Investing in our common stock involves a high degree of risk. Before making any investment decision with respect to our common stock, you should carefully consider the risks described below and all of the other information included in this report and the other filings we make with the SEC. We believe the risks and uncertainties described below are the most significant we face; and the occurrence of any of these risks could harm our business, financial condition, results of operations, prospects and reputation and could cause the trading price of our common stock to decline. Additional risks and uncertainties not presently known to us or that we currently deem immaterial may also impair our business.

Business and Strategy Risks

Our results of operations may fluctuate significantly from period to period and can be difficult to predict.

Our results of operations have experienced fluctuations from period to period, which we expect may continue in the future. These fluctuations can occur because of a variety of factors, including, among others, the amount and timing of sales of billable tests; the prices we charge for our tests due to changes in product, customer or payor mix, general price degradation for genetic tests or other competitive factors, global health crises and pandemics which may generate demand for our tests, such as the ongoing pandemic related to COVID-19, the disease caused by the novel coronavirus since named SARS-CoV-2, the rate and timing of our billings and collections and the timing and amount of our commitments and other payments, as well as the other risk factors discussed in this report. Our results have been, and may in the future be, impacted by events that may not recur regularly, in the same amounts or at all in the future. In 2020, we developed and began offering a series of COVID-19 tests, but the pricing and margins from these tests continue to evolve. For the year ended December 31, 2020, we experienced substantial revenue growth due primarily to recent sales of, and growing demand, for these COVID-19 tests. While we believe there will be a continued demand for our COVID-19 tests in the near term, the future outcome and circumstances of the COVID-19 pandemic continue to rapidly evolve and remain uncertain. There can be no assurance our COVID-19 related growth or other growth we may experience will continue. This recent growth and other fluctuations in our operating results may render period-to-period comparisons less meaningful, and investors should not rely on the results of any one period as an indicator of future performance. These fluctuations in our operating results could cause our performance in any particular period to fall below the expectations of securities analysts or investors or guidance we have provided to the public, which could negatively affect the price of our common stock. Moreover, our limited operating history may make it difficult to determine if fluctuations in our performance reflect seasonality, pandemic-related demand or other trends or if these fluctuations are the result of other factors or events.

The expansion of our COVID-19 testing business has resulted in a substantial change in our business that presents important challenges to our ability to manage our rapidly expanding business, and we anticipate that this business will eventually decrease as and if the prevalence of COVID-19 eventually decreases.

Since March 2020, we have commercially launched several COVID-19 tests for the detection of SARS-CoV-2, the virus that causes COVID-19, including NGS and RT-PCR-based tests. We have received an EUA from the FDA for RT-PCR-based tests for the detection of SARS-CoV-2 using upper respiratory specimens (nasal, nasopharyngeal, and oropharyngeal swabs) and for our at-home COVID-19 testing service through Picture Genetics. The FDA granted an EUA for our at-home testing service for COVID-19 and RT-PCR-based tests only for the detection of nucleic acid from SARS-CoV-2, not for any other viruses or pathogens. We are currently accepting patient samples directly to our Biosafety Level 2, certified laboratories in Temple City, California and Houston, Texas where we have the capacity to accept and process thousands of samples per day with a typical turn-around time of 24-48 hours from the time the sample is received and accepted. To date, we have processed orders for our COVID-19 tests from a variety of customers, including governmental bodies, municipalities, and large corporations. Due to the significant demand for COVID-19 testing services, our business has expanded rapidly since March 2020. This expansion has necessitated a very significant increase in our total headcount from 154 in March 2020 to 626 in June 2021, and the volume of tests we perform on a daily basis has increased by more than 2900% in that time.

In addition, while most of our genetics testing business relied upon direct payments from hospitals, medical institutions and other laboratories, the majority of our revenues from our COVID-19 testing business result from reimbursements from third party payors, including private insurance and Medicare. To meet the demand for COVID-19 testing, we have increased the number of shifts at our main laboratory in Temple City, California and established a new laboratory in Houston, Texas. This substantial increase in all of our activities has caused significant changes in our business and a dramatic increase in our revenues and operating results. Each of these developments presents new challenges for our company and management team, and we cannot provide assurance that we will continue to be able to manage those challenges effectively. Our management team has not previously managed a business through such a dramatic acceleration, and the impacts of any failures, mistakes or missed opportunities could be magnified by our current rate of growth. The continued success of this business will depend upon our ability to rapidly deliver accurate results, and any failure, or

34

perceived failure, in meeting these objectives could cause our COVID-19 testing business to decline rapidly. In addition, there are many new entrants to this market, and these competitors may cause price declines or reduced market share for us. The increase of our business with third party payors increases the regulatory scrutiny and risks that we face. While we anticipate that demand for our COVID-19 tests will eventually decrease, we are continuing to invest in expanding our capacity to meet the increasing demand that we anticipate over the next several years. There can be no assurance that our increased investments in our COVID-19 testing capacity and capabilities will result in desirable returns, and if our operating results decline as a result of decreased demand, whether as the result of a decline in the prevalence of COVID-19 or otherwise, our stock price could decline.

We have a history of losses, and we may not be able to achieve or sustain profitability.

We have a history of losses. Although we achieved profitability in the first half of 2017, the second and third quarters of 2019, the second, third and fourth quarters of 2020, and the first quarter and second quarter of 2021, we recorded losses in all other periods since our inception. We may not be able to maintain profitability in future periods. Further, our revenue levels may not grow at historical rates or at all, and we may not be able to achieve additional profitability or sustain profitability. We may incur additional losses in the future, particularly as we focus on investing in and growing our business and operations in response to recent demand for our COVID-19 tests. Our prior losses have had and any future losses may also have an adverse effect on our stockholders’ equity and working capital, which could negatively impact our operations and your investment in our company. Any failure to sustain or grow our revenue levels and achieve or maintain profitability would negatively affect our business, financial condition, results of operations and cash flows, and could cause the market price of our common stock to decline.

We are an early-stage company with a limited operating history, which could expose us to enhanced risks and increase the difficulty of evaluating our business and prospects.

We began operations in May 2012 and commercially launched our first genetic tests in 2013. As a result, we have only a limited operating history upon which you can evaluate our business and prospects. Our limited operating history makes it difficult to evaluate our current business and hinders our ability to reliably forecast our future operating results, including revenue, cash flows and movement toward sustained profitability. Our revenue levels may not continue to grow at historical rates or at all, and we may not be able to achieve or sustain profitability. We have encountered and will continue to encounter risks and uncertainties frequently experienced by growing companies in the life sciences and technology industries, such as risks related to an evolving and unpredictable industry and business model, management of growth and the other uncertainties described in this report. If our assumptions regarding these risks and uncertainties are incorrect or these risks and uncertainties change due to fluctuations in our markets, or if we do not address these risks successfully, our operating and financial results could differ materially from our expectations and our business could suffer.

Our industry is subject to rapidly changing technology and new and increasing amounts of scientific data, and if we fail to keep pace with these technological advances, we may be unable to compete effectively and our business and prospects could suffer.

In recent years, there have been numerous advances in the ability to analyze large amounts of genomic information and the role of genetics and gene variants in disease diagnosis and treatment. Our industry has been, and we believe will continue to be, characterized by rapid technological change, increasing amounts of data, frequent introductions of new genetic tests and evolving industry standards, all of which could make our tests obsolete if we are not able to enhance our tests more quickly and more effectively than our competitors. We believe our future success will depend in part on our ability to keep pace with the evolving needs of our customers in a timely and cost-effective manner and to pursue new market opportunities that develop as a result of technological and scientific advances. If we are not able to keep pace with these advances and increased customer expectations that develop as a result of these advances, we may be unable to sustain or grow our business and our future operations and prospects could suffer.

Our mix of customers can fluctuate from period to period and our revenue may be concentrated among only a small number of customers, and the loss of or a reduction in sales to any of our customers could materially harm our business.

The composition and concentration of our customer base can fluctuate from period to period, and in certain prior periods, a small number of customers accounted for a significant portion of our revenue. When customers who, to our knowledge, are under common control or otherwise affiliated with each other are aggregated, two customers contributed 20% and 16% of the Company’s revenue for the three months ended June 30, 2021, respectively. Two customers contributed 24% and 11% of the Company’s revenue for the six months ended June 30, 2021, respectively. For these customers and for customers generally, tests are purchased on a test-by-test basis and not pursuant to any long-term purchasing arrangements. As a result, any or all of our customers, including affiliated customers or customers under common control who purchase large quantities of billable tests, could decide at any time to decrease, delay or discontinue their orders from us which could adversely affect our revenue. Although we believe some of these fluctuations in customer demand may be attributable, in part, to the nature of our business, in which our customers can experience significant

35

volatility in their genetic testing demand from period to period in the ordinary course of their operations, these demand fluctuations, particularly for any key customers, can have a significant impact on our period-to-period performance regardless of their cause. In addition, the failure of any one of our customers or their payors to pay on a timely basis would negatively impact our results and cash flows. Our ability to maintain or increase sales to our existing customers depends on a variety of factors, including the other risk factors discussed in this report, many of which are beyond our control. Because of these and other factors, sales to any of our customers, including any key, affiliated or commonly controlled customers, may not continue in the amounts or at the rates as they have in the past, and such sales may never reach or exceed historical levels in any future period. The loss of any of our customers, or a reduction in orders or difficulties collecting payments for tests ordered by any of them, could significantly reduce our revenue and adversely affect our operating results.

If we are not able to grow and diversify our customer base and increase demand for our tests from existing and new customers, our potential for growth could be limited. We may incur cost overruns as a result of fixed price contracts which could limit profits or otherwise adversely affect our business results of operations and financial condition.

To achieve our desired revenue growth, we must increase test volume by further penetrating our existing hospital and medical institution customers and by expanding sales of our COVID-19 tests to additional governmental bodies, municipalities and large corporations in need of regular COVID-19 testing for large populations. In addition, we must grow our customer base beyond hospitals, medical institutions and other laboratories and into additional customer groups, such as individual physicians, other practitioners and research institutions. To this end, we are making efforts to diversify our customer market, including building relationships with research institutions and other similar institutional customers, national clinical laboratories, governmental bodies, municipalities and large corporations in need of regular COVID-19 testing for large populations and various other organizations to facilitate access to physicians, practitioners and other new customer groups, including certain U.S. government agencies. These efforts could fail. Even if we successfully develop relationships with new customers in these or any other new customers groups, these relationships may not lead to improve our ability to achieve or sustain profitability.

Generally, when we establish these new customer relationships, we agree with the applicable payor, laboratory or other customer to provide certain of our tests at negotiated rates, but, subject to limited exceptions, most of these relationships do not obligate any party to order our tests at any agreed volume or frequency or at all. Further, any relationships we may develop with any government agencies are subject to unique risks associated with government contracts, including cancellation if adequate appropriations for subsequent performance periods are not made and modification or termination at the government’s convenience and without prior notice. In particular, certain of government contracts are multi-award, indefinite-delivery and indefinite-quantity, or IDIQ, task order-based contracts, which generally provide for fixed price schedules for products and services, have no pre-set delivery schedules, have very low minimum purchase requirements, are typically competed among multiple awardees and force us to carry the burden of any cost overruns. Due to their nature, fixed-priced contracts inherently have more risk than cost reimbursable contracts. If we are unable to control costs or if our initial cost estimates are incorrect, we can lose money on these contracts. In addition, some of our contracts may have provisions relating to cost controls and audit rights, and if we fail to meet the terms specified in those contracts, we may not realize their full benefits. Low earnings caused by cost overruns and cost controls would have a negative impact on our results of operations. Since the price competition to win both IDIQ and fixed-priced contracts is intense and costs of further contracts performance cannot be predicted with certainty, there can be no assurance as to the profits, if any, that the Company will realize over the term of such contracts.

We may fail to obtain the customer growth needed to grow volumes and revenue levels as desired or anticipated or at all, which could occur for a variety of reasons, including, among others:

 

•

the genetic testing market generally, and particularly the market for NGS genetic tests and our COVID-19 tests, is relatively new and may not grow as predicted or may decline;

 

•

our efforts to improve our existing tests and develop and launch new tests may be unsuccessful;

 

•

we may not be able to convince additional hospitals, medical institutions and other laboratories or additional customer groups of the utility of our tests and their potential advantages over existing and new alternatives;

 

•

our investments in our sales and marketing functions, including our efforts to increase and restructure our sales force and re-focus and expand our marketing initiatives and strategies, may fail;

 

•

we may be unsuccessful in convincing customers of the benefits of our broad and customizable test menu;

 

•

genetic testing is expensive and many existing and potential new customers may be sensitive to pricing, particularly if we are not able to maintain low prices relative to our competitors;

 

•

potential new customers, particularly individual physicians and other practitioners, may not adopt our tests if coverage and adequate reimbursement are not available;

 

•

negative publicity or regulatory investigations into the actions of companies in our industry could raise doubts about the legitimacy of diagnostic technologies generally, and could result in scrutiny of diagnostic activities by the FDA, or other applicable government agencies; and

 

•

our competitors could introduce new tests that cover more genes or that provide more accurate, reliable or rapid results.

36

 

If we are unable to address these and other risks associated with growing our customer base and deepening our relationships with existing customers, we may not achieve our desired growth in billable tests and revenue, and our results of operations could be adversely impacted.

 

We face intense competition, which could intensify further in the future, and we may fail to maintain or increase our revenue levels, maintain the current prices and margins for our billable tests, or achieve or sustain profitability if we cannot compete successfully.

With the development of NGS, the clinical genetic testing market has become increasingly competitive, and as the COVID-19 pandemic continues, potentially competitive COVID-19 tests have entered and may continue to enter the market. This competition may intensify in the future. We face competition from a variety of sources, including, among others, an increasing number of companies seeking to develop and commercialize, or who have developed and commercialized, COVID-19 tests, dozens of companies focused on molecular genetic testing services, such as specialty and reference laboratories that offer traditional single-gene and multi-gene tests, and established and emerging healthcare, information technology and service companies that may develop and sell competitive products or services, which may include informatics, analysis, integrated genetic tools and services for health and wellness.

Additionally, participants in closely related markets, such as prenatal testing and clinical trial or companion diagnostic testing, could converge on offerings that are competitive with the type of tests we perform. Instances where potential competitors are aligned with key suppliers or are themselves suppliers could provide these potential competitors with significant advantages. Further, hospitals, research institutions, individual physicians and other practitioners, governmental bodies, municipalities and corporations may also seek to perform testing, including rapid COVID-19 testing, at their own facilities rather than use our services. In this regard, access to these on site or point-of-care testing solutions and the continued development of, and associated decreases in the cost of, equipment, reagents and other materials and databases and genetic data interpretation services may enable broader direct participation in genetic testing and analysis and drive down the use of third-party testing companies such as ours. Moreover, the biotechnology and genetic testing fields continue to undergo significant consolidation, permitting larger clinical laboratory service providers to increase cost efficiencies and service levels, resulting in more intense competition.

Many of our existing and potential future competitors have longer operating histories, larger customer bases, more expansive brand recognition and deeper market penetration, substantially greater financial, technological and research and development resources and selling and marketing capabilities, and considerably more experience dealing with third-party payors. As a result, they may be able to respond more quickly to changes in customer requirements or preferences, develop faster, better and more expansive advancements for their technologies and tests, create and implement more successful strategies for the promotion and sale of their tests, obtain more favorable results from third-party payors regarding coverage and reimbursement for their offerings, adopt more aggressive pricing and/or price reduction policies for their tests, secure supplies from vendors on more favorable terms or devote substantially more resources to infrastructure and systems development. We may not be able to compete effectively against these organizations.

Additionally, increased competition and cost-saving initiatives on the part of government entities and other third-party payors could result in downward pressure on the price for our testing services and genetic analysis and interpretation generally, which could harm our revenue levels and sales volume and our ability to gain market share. This downward pricing pressure could intensify in future periods, and we may not be able to maintain acceptable margins on our sales if we are forced to reduce prices for our tests to try to remain competitive, especially if we are also experiencing increasing expenses as we make efforts to grow our business or otherwise meet customer demands. The occurrence of these risks could materially harm our ability to achieve or sustain profitability. In addition, competitors may be acquired by, receive investments from or enter into other commercial relationships with larger, well-established and well-financed companies. Further, companies or governments that effectively control access to testing through umbrella contracts or regional preferences could promote our competitors or prevent us from performing certain tests in certain territories. If we are unable to compete successfully against current and future competitors for these or any other reasons, we may be unable to increase market acceptance and sales volume of our tests, which could prevent us from maintaining or increasing our revenue levels or achieving or sustaining profitability or could otherwise negatively affect our performance.

37

Our level of commercial success depends in part on our ability to generate and grow sales with our sales and marketing team, strategies and partnerships, and we may be unsuccessful in these efforts.

We may not be able to market or sell our existing tests or any tests we may develop in the future in order to drive demand sufficiently to support our desired growth. We currently sell our tests through a small internal sales force and a number of contractors who serve as independent sales representatives. Although we have made efforts to enhance and improve our internal sales department, it remains significantly smaller than many of our competitors’ sales teams. We have historically relied significantly on organic growth and word-of-mouth among our customers to generate interest in our tests, but our ability to rely on this type of interest in future periods is uncertain.

We believe our ability to maintain and grow sales volume in the future will depend in large part on our ability to further develop our sales team and create and implement effective sales and marketing strategies. We have been focused on these objectives and have taken steps to pursue them in recent periods, including hiring new key members and restructuring the organization of our sales and marketing team, re-focusing our sales and marketing initiatives and strategies and increasing the overall scope of our marketing activities. These efforts have required and will continue to involve significant time and expense. Moreover, these efforts may be unsuccessful. For instance, we may not be able to attract and hire the qualified personnel we need to grow or otherwise improve our sales and marketing team as quickly or as successfully as we would like for various reasons, including intense competition in our industry for qualified personnel and our relative lack of experience selling and marketing our tests. Even if we are able to further develop our sales and marketing team and strategy, we may not be successful in growing our customer base or increasing order volumes from our existing customers. Further, our reliance on independent sales representatives subjects us to risks, as we have very little control over their activities and they are generally free to market and sell other, potentially competing, products. As a result, these independent sales representatives could devote insufficient time or resources to marketing and selling our tests, could market them in an ineffective manner or could otherwise be unsuccessful in selling adequate or expected quantities of our tests.

In addition, our future sales levels will depend in large part on the effectiveness of our sales and marketing strategies, including our ability to expand our brand awareness by providing education about the benefits and full scale of our offering to the medical community in general and to our targeted geographic and customer markets. We also intend to continue to pursue targeted marketing initiatives, including working with medical professional societies to promote awareness of the benefits of our tests and genetic testing in general, pursuing or supporting scientific studies of our tests and publication of results in medical or scientific journals and making presentations at medical, scientific or industry conferences and trade shows. We may not be successful in implementing these initiatives or other marketing strategies we may develop and pursue. If we are not able to drive sufficient revenue using our sales and marketing strategies to support our planned growth, our business and results of operations would be negatively affected.

Our sales and marketing strategies also include a continued focus on growing our international sales and customer base, which we plan to pursue through our direct sales team, a number of independent contractor sales representatives, and, if opportunities arise, by engaging distributors or establishing other types of arrangements, such as joint ventures or other relationships, to manage or assist with sales, logistics, education or customer support in certain territories. To this end, we worked with Xi Long USA, Inc. to form a joint venture in the second quarter of 2017, which we refer to as FF Gene Biotech, to offer genetic testing to customers in China. We acquired additional ownership in FF Gene Biotech in May 2021 to obtain a controlling interest. Although FF Gene Biotech has enabled us to have an operational presence on the ground in China to capitalize on the large and growing genetic testing opportunity in the country and we believe FF Gene Biotech could result in expanded long-term opportunities to address the genetic testing market in Asia, these expectations could turn out to be wrong and we may never realize the benefits we anticipate from FF Gene Biotech. While it may become necessary to identify, qualify and engage other commercial partners or distributors with local industry experience and knowledge in order to effectively market and sell our tests outside the United States, we have established some relationships to cover any non-U.S. territories including FF Gene Biotech in China and other distribution relationships. As a result, we may not be successful in finding, attracting and retaining qualified distributors or other commercial partners or we may not be able to enter into arrangements covering desired territories on favorable terms. In addition, sales practices utilized by distributors or other commercial partners that are locally acceptable may not comply with sales practices or standards required under U.S. laws that apply to us, which could subject us to additional compliance risks. If our sales and marketing efforts outside the United States are not successful, we may not achieve significant acceptance for our tests in international markets, which could materially and adversely impact our business operations.

We will need to invest in and expand our infrastructure and hire additional skilled personnel in order to support our desired growth, and our failure to effectively manage any future growth could jeopardize our business.

To continue to increase the volume of tests we offer and deliver, we must make substantial investments in our infrastructure, including our testing capacity, laboratory capacity, information systems, enterprise software systems, customer service, billing and collections systems and processes and internal quality assurance programs. We will also need to invest in our workforce by hiring additional skilled personnel, including biostatisticians, geneticists, software engineers, laboratory directors and specialists, sales and marketing experts and other scientific, technical and managerial personnel to market, process, interpret and validate the quality of

38

results of our genetic tests and otherwise manage our operations. For example, before we deliver a report for any of our tests, including our COVID-19 tests, the results summarized in the report must be reviewed and approved by a licensed and qualified laboratory director. We currently have six laboratory directors, of which, five lab directors have all of the required licenses, including Dr. Han Lin Gao. We may need to hire additional licensed laboratory directors in the future to further scale our business. If we fail to hire additional qualified personnel when needed or otherwise develop our infrastructure sufficiently in advance of demand or if we fail to generate demand commensurate with our level of investment in our infrastructure, our business, prospects, financial condition and results of operations could be adversely affected. We are expanding our existing laboratory space and we may acquire new laboratory space, which would involve significant costs and attention from our management.

The time and resources required to implement new systems, to add and train new skilled personnel and to expand or acquire new laboratory space as needed are uncertain. Any future growth we may experience could create a strain on our organizational, administrative and operational infrastructure, including laboratory operations, quality control, customer service, sales and marketing and management. We may not be able to maintain the quality of or expected turnaround times for our tests or satisfy customer demand if and when it grows. Our ability to effectively manage any growth we experience will also require us to continue to improve our laboratory and other operational, financial and management systems and controls and our reporting processes and procedures, which may involve significant time and costs and which we may not be able to do successfully.

Our ability to achieve or sustain profitability depends on our collection of payment for the tests we deliver, which we may not be able to do successfully.

Since starting our genetic testing business, we have historically focused primarily on providing our tests to hospitals, medical institutions and other laboratories, our traditional genetic testing customer base. Our customer base for our COVID-19 tests is principally comprised of governmental bodies, municipalities, and large corporations who pay us directly or through third-party payors for our COVID-19 tests. In March 2020, the Coronavirus Aid, Relief, and Economic Security Act, or CARES Act, was enacted, and it provides for reimbursement to healthcare providers for COVID-19 tests provided to uninsured individuals, subject to continued available funding. In recent months, this reimbursement has accounted for a significant portion of our revenue. Should reimbursement under the CARES Act for COVID-19 testing cease to be available for any reason, our ability to collect payment would be adversely affected. Further, healthcare policy changes that influence the way healthcare is financed or other changes in the market that impact payment rates by institutional or non-institutional customers could also affect our collection rates. If we are unable to convince hospitals, medical institutions and other laboratories of the value and benefit provided by our tests, these customers may slow, or stop altogether, their purchases of our tests. Moreover, our ability to collect payment for our tests in a timely manner or at all from our healthcare provider customers may decline to the extent we expand our business into new healthcare provider customer groups, including individual physicians and other practitioners, from which collection rates are often significantly lower than hospitals, medical institutions and other laboratories and which involve substantial additional risks that are discussed in these risk factors below. Our collection risks also include the potential for default or bankruptcy by the party responsible for payment and other risks associated with payment collection generally. Any inability to maintain our past payment collection levels could cause our revenue and ability to achieve profitability to decline and adversely affect our business, prospects and financial condition.

If third-party payors do not provide coverage and adequate reimbursement for our tests, our potential for growth could be limited.

Coverage and reimbursement by third-party payors, including managed care organizations, private health insurers and government healthcare programs, such as Medicare and Medicaid, for the types of genetic tests we perform can be limited and uncertain. Although our existing customer base consists primarily of hospitals, medical institutions, municipalities, governmental bodies, large corporations and other laboratories from which we typically receive direct payment for ordered tests, including our COVID-19 tests, we believe our potential for future growth is dependent on our ability to attract new customer groups, including individual physicians and other practitioners. Our healthcare provider customers, including laboratories may not order our tests unless third-party payors cover and provide adequate reimbursement for a substantial portion of the price of the tests. If we are not able to obtain coverage and an acceptable level of reimbursement for our tests from third-party payors, there would typically be a greater co-insurance, deductible or co-payment requirement from the patient for whom the test is ordered or the patient may be forced to pay the entire cost of the test out-of-pocket, which could dissuade practitioners from ordering our tests and, if ordered, could result in a delay in or decreased likelihood of collecting payment, whether from patients or from third-party payors. We believe our ability to increase the number of tests we sell to our healthcare provider customers and any corresponding revenue will depend in part on our ability to achieve and maintain broad coverage and reimbursement for our tests from third-party payors.

39

Coverage and reimbursement by a third-party payor may depend on a number of factors, including a payor’s determination that a test is appropriate, medically necessary and cost-effective. Each payor makes its own decision as to whether to establish a policy or enter into a contract to cover our tests and the amount it will reimburse for each test, and any determination by a payor regarding coverage and amount of reimbursement for our tests would likely be made on an indication-by-indication basis. Even if a test has been approved for reimbursement for any particular indication or in any particular jurisdiction, there is no guarantee this test will remain approved for reimbursement or that any similar or additional tests will be approved for reimbursement in the future. Moreover, there can be no assurance that any new tests we launch will be reimbursed at all or at rates comparable to the rates of any previously reimbursed tests. In addition, the coding procedure used by all third-party payors with respect to establishing payment rates for various procedures, including our tests, is complex, does not currently adapt well to the genetic tests we perform and may not enable coverage and adequate reimbursement rates for our tests. If physicians fail to provide appropriate diagnosis codes for tests that they order, we may not be reimbursed for our tests. Additionally, if we are not able to obtain sufficient clinical information in support of our tests, third-party payors could designate our tests as experimental or investigational and decline to cover and reimburse our tests because of this designation. As a result of these factors, obtaining approvals from third-party payors to cover our tests and establishing adequate reimbursement levels is an unpredictable, challenging, time-consuming and costly process, and we may never be successful.

To date, we have contracted directly with national health insurance companies to become an in-network provider and enrolled as a supplier in the Medicare program and some state Medicaid programs, and we have also received payment for our tests from other third-party payors as an out-of-network provider. Although becoming an in-network provider or enrolling as a supplier means that we have agreed with these payors to provide certain of our tests at negotiated or set fee schedule rates, it does not obligate any physicians or other practitioners to order our tests or guarantee that we will receive reimbursement for our tests from these or any other payors at adequate levels. As a result, these payor relationships, any other similar relationships we may establish in the future, or any additional payments we may receive from other payors as an out-of-network provider, may not amount to acceptable levels of reimbursement for our tests or meaningful or any increases in our physician customer base or the number of billable tests we sell to physicians. We expect to focus on increasing coverage and reimbursement for our current tests and any future tests we may develop, but we cannot predict whether, under what circumstances, or at what payment levels payors will cover and reimburse us for our tests. Further, even if we are successful, we believe it could take several years to achieve coverage and adequate contracted reimbursement with third-party payors. If we fail to establish and maintain broad coverage and reimbursement for our tests, our ability to maintain or grow our test volume, customer base, collectability rates and revenue levels could be limited and our future prospects and our business could suffer.

Failure to comply with government laws and regulations related to submission of claims for our services could result in significant monetary damages and penalties and exclusion from the Medicare and Medicaid programs and corresponding foreign reimbursement programs.

We are subject to laws and regulations governing the submission of claims for payment for our services, such as those relating to: coverage of our services under Medicare, Medicaid and other state, federal and foreign health care programs; the amounts that we may bill for our services; and the party to which we must submit claims. Our failure to comply with applicable laws and regulations could result in our inability to receive payment for our services or in attempts by state and federal health care programs, such as Medicare and Medicaid, to recover payments already made. Submission of claims in violation of these laws and regulations can result in recoupment of payments already received, substantial civil monetary penalties, and exclusion from state and federal health care programs, and can subject us to liability under the federal False Claims Act and similar laws. The failure to report and return an overpayment to the Medicare or Medicaid program within 60 days of identifying its existence can give rise to liability under the False Claims Act. Further, a government agency could attempt to hold us liable for causing the improper submission of claims by another entity for services that we performed if we were found to have knowingly participated in the arrangement at issue.

We may not be successful in developing and marketing new tests, which could negatively impact our performance and prospects.

We believe our future success will depend in part on our ability to continue to expand our test offerings and develop and sell new tests. We may not be successful in launching or marketing any new tests we may develop, and, even if we are successful, the demand for our other tests could decrease or may not continue to increase at historical rates due to sales of the new tests. Our pipeline of new tests is in various stages of development and will be time-consuming and costly to fully develop and introduce, as development and marketing of new tests requires us to conduct research and development activities regarding the new tests and to further scale our laboratory processes and infrastructure to be able to analyze increasing amounts of more diverse data. Further, we may be unable to discover or develop and launch new tests for a variety of reasons, including failure of any proposed test to perform as expected, lack of validation or reference data for the test or failure to demonstrate the utility of the test. Further, any new test we are able to discover and develop may not be launched in a timely manner, meet applicable regulatory standards, successfully compete with other technologies and available tests, avoid infringing the proprietary rights of others, achieve coverage and adequate reimbursement from third-party payors, be capable of performance at commercial levels and at reasonable costs, be successfully marketed or achieve sufficient market acceptance for us to recoup our time and capital investment in the development of the test. Any failure to

40

successfully develop, market and sell new tests could negatively impact our ability to attract and retain customers and our revenue and prospects.

We are exposed to additional business, regulatory, political, operational, financial and economic risks related to our international operations.

Our existing customer base includes international customers from a variety of geographic markets. In addition, we have established FF Gene Biotech to offer genetic testing to customers in China. As part of our strategy, we aim to increase our volume of direct sales to international customers in a variety of markets by conducting targeted marketing outreach activities and, if opportunities arise, engaging distributors or establishing other types of arrangements, such as joint ventures or other relationships. However, we may never be successful in achieving these objectives, and even if we are successful, these strategies may not result in meaningful or any increases in our customer base, test volumes or revenue.

Doing business internationally involves a number of risks, including, among others:

 

 

•

compliance with the laws and regulations of multiple jurisdictions, which may be conflicting or subject to increasing stringency or other changes, including privacy regulations, tax laws, employment laws, healthcare regulatory requirements and other related approvals, including permitting and licensing requirements;

 

•

logistics associated with the shipment of blood or other tissue specimens, including infrastructure conditions, transportation delays and the impact of U.S. and local laws and regulations, such as export and import restrictions, tariffs or other charges and other trade barriers, all of which involve increased risk related to the trade policies of the current administration, which may threaten existing and proposed trade agreements and impose more restrictive U.S. export-import regulations that impact our business;

 

•

limits on our ability to penetrate international markets, including legal and regulatory requirements that would force us to conduct our tests locally by building additional laboratories or engaging in joint ventures or other relationships in order to offer our tests in certain countries, which relationships could involve significant time and resources to establish, deny us control over certain aspects of the foreign operations or reduce the economic value to us of these operations;

 

•

failure by us, any joint ventures or other arrangements we may establish or any distributors or other commercial partners we may engage to obtain any regulatory approvals required to market, sell and use our tests in various countries;

 

•

challenges predicting the market for genetic testing generally and tailoring our test menu to meet varying customer expectations in different countries and territories;

 

•

difficulties gaining market share in territories in which we do not have a strong physical presence or brand awareness;

 

•

complexities and difficulties obtaining protection for and enforcing our intellectual property rights;

 

•

difficulties in staffing and managing foreign operations;

 

•

complexities associated with managing multiple payor coverage and reimbursement regimes, government payors or patient self-pay systems;

 

•

financial risks, such as longer payment cycles, difficulty collecting trade accounts receivable and the impact of local and regional financial conditions on demand and payment for our tests;

 

•

exposure to foreign currency exchange rate fluctuations, including increased risk with respect to the Canadian dollar after we recently started billing certain of our Canadian hospital customers in their local currency and with respect to the RMB related to revenue received under our agreements with FF Gene Biotech;

 

•

risks relating to conversion and repatriation of certain foreign currencies, particularly the RMB, which is subject to legal procedures and restrictions on currency conversion and movement outside China and which could impact our ability to receive the anticipated financial benefits of our controlling interest in FF Gene Biotech;

 

•

natural disasters, political and economic instability, including wars, terrorism and political unrest, outbreak of disease (e.g. the COVID-19 pandemic), boycotts and other business restrictions; and

 

•

regulatory and compliance risks related to applicable anti-bribery laws, including requirements to maintain accurate information and control over activities that may fall within the purview of these laws.

Any of these factors could significantly harm our existing relationships with international customers or derail our international expansion plans, which would cause our revenue and results of operations to suffer.

In addition, we are exposed to a number of additional risks and challenges related to our efforts to access customers in China through FF Gene Biotech. These risks include, among others, difficulties predicting the market for genetic testing in Asia; competitive factors in this market, including challenges securing market share; local differences in customer demands and preferences and regulatory requirements; and many of the other risks of doing business internationally that are discussed above. Further, we could experience declines in our direct sales to, and revenue from, customers in Asia if any of these customers choose to order genetic tests from FF Gene Biotech instead of directly from us. As a result of these risks, although we believe FF Gene Biotech could result in expanded long-term opportunities to address the genetic testing market in Asia, this belief could turn out to be wrong and we may

41

never realize these or any other benefits we anticipate from FF Gene Biotech. Moreover, FF Gene Biotech or any joint venture we may seek to establish may never produce sufficient revenue to us to recover our capital and other investments in the joint venture, and we could become subject to liabilities based on our involvement in the joint venture’s operations. The materialization of any of these risks related to FF Gene Biotech could materially harm our performance and prospects.

If we are sued for product or professional liability, we could face substantial liabilities that exceed our resources.

Our business depends on our ability to provide reliable and accurate test results that incorporate rapidly evolving information about the role of genes and gene variants in disease and clinically relevant outcomes associated with these variants. Hundreds of genes can be implicated in some disorders and overlapping networks of genes and symptoms can be implicated in multiple conditions. As a result, substantial judgment is required in order to interpret the results of each test we perform and produce a report summarizing these results. Errors, such as failures to detect genomic variants with high accuracy, or mistakes, such as failures to completely and correctly identify the significance of gene variants, could subject us to product liability or professional liability claims. Any such claim against us could result in substantial damages and be costly and time-consuming to defend. Although we maintain liability insurance, including for errors and omissions, our insurance may not fully protect us from the financial impact of defending against these types of claims or any judgments, fines or settlement costs arising out of any such claims. Additionally, any liability claim brought against us, with or without merit, could increase our insurance rates or prevent us from securing adequate insurance coverage in the future. Moreover, any liability lawsuit could damage our reputation or force us to suspend sales of our tests. The occurrence of any of these events could have a material adverse effect on our business, reputation and results of operations.

If our laboratory facilities become inoperable, if we are forced to vacate a facility or if we are unable to obtain additional laboratory space as and when needed, we would be unable to perform our tests and our business would be harmed.

We perform all of our tests at our CLIA-certified laboratories in Temple City, California and Houston, Texas. Our laboratories and the equipment we use to perform our tests would be costly to replace and could require substantial lead time to replace and qualify for use. This and any other laboratory facilities and equipment we may use could be damaged or rendered inoperable by natural or man-made disasters, including earthquakes, floods, fires and power outages, which could render it difficult or impossible for us to perform our tests for some period of time. The inability to perform our tests or the backlog that could develop if a laboratory becomes inoperable for even a short time could result in the loss of customers or harm to our reputation. Although we maintain insurance for damage to our property and disruption of our business, this insurance may not be sufficient to cover all of our potential losses and may not continue to be available to us on acceptable terms, if at all.

Further, if we need to relocate from one laboratory facility to another laboratory facility or obtain additional laboratory space, we may have difficulty locating suitable space in a timely manner, on reasonable terms or at all, and even if acceptable space was available, it would be challenging, time-consuming and expensive to obtain or transfer the licensure and accreditation required for a commercial laboratory like ours and the equipment we use to perform our tests. These challenges could be amplified if we or our joint ventures or other commercial partners seek to procure and maintain laboratory space outside the United States as we pursue international expansion. If we are unable to obtain or are delayed in obtaining new laboratory space as needed, we may not be able to provide our existing tests or develop and launch new tests, which could result in harm to our business, reputation, financial condition and results of operations.

We face risks related to the impact of the COVID-19 pandemic and the related protective public health measures.

Despite our recent revenue growth and recent demand for our COVID-19 tests, our business could be materially and adversely affected by the effects of the global pandemic of COVID-19 and the related protective public health measures. Our business depends upon the continuous testing services that we provide at our laboratory facilities, and our business faces the same risks as are currently prevalent in most of the United States, including the risks that employees could contract COVID-19 which could result in a disruption in our ability to continue to provide testing services. Although we take what we believe are reasonable precautions to prevent the spread of COVID-19 within our facilities and among our employees, we cannot provide assurance that we will not suffer from an exposure to the SARS-CoV-2 virus that would require a temporary closure of our laboratory facilities, which would materially adversely affect our operations and financial results. Other adverse effects of the pandemic on our business could include disruptions or restrictions on our employees’ ability to travel, as well as temporary closures of the facilities of our suppliers, third party service providers or customers, which could impact our test volume and results of operations. In addition, a significant outbreak of contagious disease in the human population could result in a widespread health crisis that could adversely affect the economies and financial markets of many countries, resulting in an economic downturn that could affect demand for our tests and impact our results of operations.

42

We rely on a limited number of suppliers and, in some cases, a sole supplier, for certain of our laboratory substances, equipment and other materials, and any delays or difficulties securing these materials could disrupt our laboratory operations and materially harm our business.

We rely on a limited number of suppliers for certain of our laboratory substances, including reagents, as well as for the sequencers and various other equipment and materials we use in our laboratory operations. In particular, we rely on Illumina, Inc. as the sole supplier of the next generation sequencers and associated reagents we use to perform our genetic tests and as the sole provider of maintenance and repair services for these sequencers. We do not have long-term agreements with most of our suppliers and, as a result, they could cease supplying these materials and equipment to us at any time due to an inability to reach agreement with us on supply terms, disruptions in their operations, a determination to pursue other activities or lines of business or for other reasons, or they could fail to provide us with sufficient quantities of materials that meet our specifications. These suppliers may also be affected by the ongoing COVID-19 pandemic or its related effects on the global supply chain. Transitioning to a new supplier or locating a temporary substitute, if any are available, would be time-consuming and expensive, could result in interruptions in or otherwise affect the performance specifications of our laboratory operations or could require that we revalidate our tests. In addition, the use of equipment or materials provided by a replacement supplier could require us to alter our laboratory operations and procedures. Moreover, we believe there are currently only a few manufacturers that are capable of supplying and servicing some of the equipment and other materials necessary for our laboratory operations, including sequencers and various associated reagents. As a result, replacement equipment and materials that meet our quality control and performance requirements may not be available on reasonable terms, in a timely manner or at all. If we encounter delays or difficulties securing, reconfiguring or revalidating the equipment, reagents and other materials we require for our tests, including as a result of the COVID-19 pandemic, our operations could be materially disrupted and our business, financial condition, results of operations and reputation could be adversely affected.

Billing and collections processing for our tests is complex and time-consuming, and any delay in transmitting and collecting claims could have an adverse effect on our revenue.

Billing for our tests is complex, time-consuming and expensive. Depending on the billing arrangement and applicable law, we may bill various different parties for our tests, including customers directly in the case of our hospital and medical institution customers, as well as Medicare, Medicaid, insurance companies and patients, all of which may have different billing requirements. We may face increased risk in our collection efforts due to the complexities of these billing requirements, including long collection cycles and lower collection rates, which could adversely affect our business, results of operations and financial condition.

Several factors make this billing process complex, including:

 

•

differences between the list price for our tests and the reimbursement rates of payors;

 

•

compliance with complex federal and state regulations related to billing government healthcare programs, including Medicare and Medicaid;

 

•

disputes among payors as to which party is responsible for payment;

 

•

differences in coverage among payors and the effect of patient co-payments or co-insurance;

 

•

differences in information and billing requirements among payors;

 

•

incorrect or missing billing information; and

 

•

the resources required to manage the billing and claims appeals process.

We have developed internal systems and procedures to handle these billing and collections functions, but we will need to make significant efforts and expend substantial resources to further develop our systems and procedures to handle these aspects of our business, which could become increasingly important as we focus on increasing test volumes from non-hospital and medical institution customer groups and establishing coverage and reimbursement policies with third-party payors. As a result, these billing complexities, along with the related uncertainty in obtaining payment for our tests, could negatively affect our revenue and cash flow, our ability to achieve or sustain profitability and the consistency and comparability of our results of operations. In addition, if claims for our tests are not submitted to payors on a timely basis, or if we are required to switch to a different provider to handle our processing and collections functions, our revenue and our business could be adversely affected.

43

Ethical, legal and social concerns related to the use of genetic information could reduce demand for our tests.

Genetic testing has raised ethical, legal and social issues regarding privacy and the appropriate uses of the resulting information. Government authorities could, for social or other purposes, limit or regulate the use of genetic information or genetic testing or prohibit testing for genetic predisposition to certain conditions, particularly for those that have no known cure. Similarly, these concerns may cause patients to refuse to use, or physicians to be reluctant to order, genetic tests such as ours, even if permissible. These and other ethical, legal and social concerns may limit market acceptance and adoption of our tests or reduce the potential markets for our tests, any of which could have an adverse effect on our business, financial condition and results of operations.

Actual or attempted security breaches, loss of data or other disruptions could compromise sensitive information related to our business or to patients or prevent us from accessing critical information, any of which could expose us to liability and adversely affect our business and our reputation.

In the ordinary course of our business, we generate, collect and store sensitive data, including protected health information, or PHI, personally identifiable information, intellectual property and proprietary and other business-critical information, such as research and development data, commercial data and other business and financial information. We manage and maintain the data we generate, collect and store utilizing a combination of on-site systems and managed data center systems. We also communicate sensitive patient data when we deliver reports summarizing test results to our customers, which we deliver via our online encrypted web portal, encrypted email or fax or overnight courier. We face a number of risks related to protecting this information, including loss of access, unauthorized modification or inappropriate disclosure.

The secure processing, storage, maintenance and transmission of this information is vital to our operations and business strategy, and we devote significant resources to protecting the confidentiality and integrity of this information. Although we have implemented security measures and other controls designed to protect sensitive information from unauthorized access, use or disclosure, our information technology and infrastructure could fail, be inadequate or vulnerable to attacks by hackers or viruses or be breached due to employee error, malfeasance or other disruptions. A breach or interruption could compromise our information systems and the information we store could be accessed by unauthorized parties, manipulated, publicly disclosed, lost, or stolen. Any such unauthorized access, manipulation, disclosure or other loss of information could result in legal claims or proceedings and could result in liability or penalties under federal, state or foreign laws that protect the privacy of personal information, discussed below under “—We are subject to broad legal requirements regarding the information we test and analyze, and any failure to comply with these requirements could result in harsh penalties, damage our reputation and materially harm our business.” Additionally, unauthorized access, manipulation, loss, or dissemination could significantly damage our reputation and disrupt our operations, including our ability to perform our tests, analyze and provide test results, bill customers or other payors, process claims for reimbursement, provide customer service, conduct research and development activities, collect, process, and prepare company financial information, conduct education and outreach activities and manage the administrative aspects of our operations, as described further below under “—We depend on our information technology systems and any failure of these systems, due to hardware or software malfunctions, delays in operation, failures to implement new or enhanced systems or cybersecurity breaches, could harm our business.” The occurrence of any of these risks could materially adversely affect our business.

The loss of any member of our senior management team could adversely affect our business.

Our success depends in large part on the skills, experience and performance of our executive management team and others in key leadership positions, especially Ming Hsieh, our founder, Chief Executive Officer and Chairman of our board of directors, Paul Kim, our Chief Financial Officer, Dr. Han Lin Gao, our Chief Scientific Officer and Laboratory Director, and Jian Xie, our Chief Operating Officer. The continued efforts of these persons will be critical to us as we continue to develop our technologies and test processes and focus on growing our business. If we lose one or more key executives, we could experience difficulties maintaining our operations, including the ability to deliver reports to customers after review and approval by a licensed and qualified laboratory director, competing effectively, advancing our technologies, developing new tests and implementing our business strategies. All of our executives and employees, including Messrs. Hsieh, Kim and Xie, and Dr. Gao, are at-will, which means either we or the executive or employee may terminate their employment at any time. We do not carry key man insurance for any of our executives or other employees. In addition, we do not have long-term retention agreements in place with any of our executives or key employees.

44

We rely on highly skilled personnel in a broad array of disciplines, and if we are unable to hire, retain or motivate these individuals, we may not be able to maintain the quality of our tests or grow our business.

Our business, including our research and development programs, laboratory operations and administrative functions, largely depends on our continued ability to identify, hire, train, motivate and retain highly skilled personnel for all areas of our organization, including biostatisticians, geneticists, software engineers, laboratory directors and specialists, sales and marketing experts and other scientific, technical and managerial personnel. Competition in our industry for qualified executives and other employees is intense, and we may not be able to attract or retain the qualified personnel we need to execute our business plans due to high levels of competition for these personnel among our competitors, other life science businesses, universities and public and private research institutions. In addition, our compensation arrangements may not be successful in attracting new employees and retaining and motivating our existing employees. If we are not able to attract and retain the necessary personnel to accomplish our business objectives, we may experience constraints that could adversely affect our ability to expand our business and support our clinical laboratory operations and our sales and marketing and research and development efforts, which would negatively affect our prospects for future growth and success.

Any inability to obtain additional capital when needed and on acceptable terms may limit our ability to execute our business plans, and our liquidity needs could be materially affected by market fluctuations and general economic conditions.

We expect our capital expenditures and operating expenses to increase over the next several years as we seek to expand our infrastructure, sales and marketing and other commercial operations and research and development activities. As of June 30, 2021, we had cash and cash equivalents of approximately $100.5 million. We maintain our cash, cash equivalents and short-term marketable securities with high quality, accredited financial institutions. However, these accounts may exceed federally insured limits, and, while we believe the Company is not exposed to significant credit risk due to the financial strength of these depository institutions or investments, the failure or collapse of one or more of these depository institutions or default on these investments could materially adversely affect our ability to recover these assets and/or materially harm our financial condition. We may seek to fund future cash needs through securities offerings, credit facilities or other debt financings, asset sales or collaborations or licensing arrangements. Additional funding may not be available to us when needed, on acceptable terms or at all. For example, the COVID-19 pandemic has recently caused extreme disruption and volatility in the global capital markets, which could reduce our ability to access capital and/or adversely affect the stability of the depository institutions maintaining our assets.

If we raise additional funds by issuing equity securities, our existing stockholders could experience substantial dilution. Additionally, any preferred stock we issue could provide for rights, preferences or privileges senior to those of our common stock, and our issuance of any additional equity securities, or the possibility of such an issuance, could cause the market price of our common stock to decline. The terms of any debt securities we issue or borrowings we incur, if available, could impose significant restrictions on our operations, such as limitations on our ability to incur additional debt or issue additional equity or other restrictions that could adversely affect our ability to conduct our business, and would result in increased fixed payment obligations. If we seek to sell assets or enter into collaborations or licensing arrangements to raise capital, we may be required to accept unfavorable terms or relinquish or license to a third party our rights to important or valuable technologies or tests we may otherwise seek to develop ourselves. Moreover, we may incur substantial costs in pursuing future capital, including investment banking, legal and accounting fees, printing and distribution expenses and other similar costs. If we are not able to secure funding if and when needed and on reasonable terms, we may be forced to delay, reduce the scope of or eliminate one or more sales and marketing initiatives, research and development programs or other growth plans or strategies. In addition, we may be forced to work with a partner on one or more aspects of our tests or market development programs or initiatives, which could lower the economic value to us of these tests, programs or initiatives. Any such outcome could significantly harm our business, performance and prospects.

U.S. federal income tax reform could adversely affect us.

New legislation or regulation which could affect our tax burden could be enacted by a governmental authority. We cannot predict the timing or extent of such tax-related developments which could have a negative impact on our financial results. U.S. federal legislation affecting the tax laws was enacted in December, 2017 in the Tax Cuts and Jobs Act (“TCJA”); twice in March, 2020, first in the Families First Coronavirus Response Act and again in the Coronavirus Aid, Relief, and Economic Security Act (the “CARES Act”); in December, 2020 in the Consolidated Appropriates Act, 2021; and in March, 2021 in the American Rescue Plan Act of 2021. We cannot estimate how the changes in tax law from this legislation will affect our tax liability in future years.

Additionally, we use our best judgment in attempting to quantify and reserve for these tax obligations. However, a challenge by a taxing authority, our ability to utilize tax benefits such as carryforwards or tax credits, or a deviation from other tax-related assumptions may cause actual financial results to deviate from previous estimates.

45

We have previously and may again in the future acquire businesses or assets, form joint ventures, make investments in other companies or technologies or establish other strategic relationships, any of which could harm our operating results, dilute our stockholders’ ownership or cause us to incur debt or significant expense.

As part of our business strategy, we have previously and may again in the future pursue acquisitions of complementary businesses or assets, investments in other companies, such as our recent acquisition of CSI and our investment in Helio Health, technology licensing arrangements, joint ventures or other strategic relationships. As an organization, we have limited experience with respect to acquisitions, investments or the formation of strategic relationships or joint ventures. If we make acquisitions in the future, we may not be able to successfully integrate the acquired businesses or technologies into our existing operations, we could assume unknown or contingent liabilities and we could be forced to record significant write-offs or incur debt as a result of the acquisitions, any of which could harm our operating results. If we pursue relationships with pharmaceutical companies or other strategic relationships, our ability to establish and maintain these relationships could be challenging due to several factors, including competition with other genetic testing companies and internal and external constraints placed on pharmaceutical and other organizations that limit the number and type of relationships they can establish with companies like ours. Moreover, we may not be able to identify or complete any acquisition, investment, technology license, joint venture or other strategic relationship in a timely manner, on a cost-effective basis or at all, and we may not realize the anticipated benefits of any such transaction sufficiently to recoup our costs.

To finance any acquisitions, investments, joint ventures or other strategic relationships, we may seek to raise additional funds through securities offerings, credit facilities, asset sales or collaborations or licensing arrangements. Each of these methods of fundraising is subject to a variety of risks, including those discussed above under “—Any inability to obtain additional capital when needed and on acceptable terms may limit our ability to execute our business plans.” Further, additional funds from capital-raising transactions may not be available when needed, on acceptable terms or at all. Any inability to fund any acquisitions, investments or strategic relationships we pursue could cause us to forfeit opportunities we believe are promising or valuable, which could harm our prospects.

We may not be successful in our efforts to integrate any acquired businesses and technologies, and this may adversely affect our business and results of operations. We may incur unexpected liabilities as a result of our acquisitions.

Our ability to integrate any organizations or technology that we may acquire, including our recent acquisition of CSI, is subject to a number of risks including the following:

 

•

failure to integrate successfully the personnel, information systems, technology and operations of the acquired business;

 

•

failure to maximize the potential financial and strategic benefits of the acquisition;

 

•

failure to realize the expected synergies of the acquired business;

 

•

possible impairment of relationships with employees and clients as a result of any integration of new businesses and management personnel;

 

•

impairment of goodwill;

 

•

increased demand on human resources and operating systems, procedures and controls; and

 

•

reductions in future operating results as a result of the amortization of intangible assets.

 

Acquisitions are also accompanied by the risk that obligations and liabilities of an acquired business may not be adequately reflected in the historical financial statements of that business and the risk that historical financial statements may be based on assumptions, which are incorrect or inconsistent with our assumptions or approach to accounting policies. The acquisition and integration of businesses may not be managed effectively and any failure to manage the integration process could lead to disruptions in the overall activities of the Company, a loss of clients and revenue and increased expenses. Further, integration of an acquired business or technology could involve significant difficulties, and could require management and capital resources that otherwise would be available for ongoing development of our existing business or pursuit of other opportunities. We may also acquire contingent liabilities in connection with the acquisitions of business, which maybe material. Any estimates we might make regarding any acquired contingent liabilities and the likelihood that these liabilities will materialize could differ materially from the liabilities actually incurred. These circumstances could materially harm our business, results of operations and prospects.

We depend on our information technology systems and any failure of these systems, due to hardware or software malfunctions, delays in operation, and/or failures to implement new or enhanced systems or cybersecurity breaches, could harm our business.

We depend on information technology and telecommunications systems for significant elements of our operations, such as our laboratory information management systems, including test validation, specimen tracking and quality control; our bioinformatics analytical software systems; our reference library of information relating to genetic variants and their role in disease; personal information storage, maintenance and transmission; our customer-facing web-based software and customer service functions; our report production systems; our billing and reimbursement procedures; our scientific and medical data analysis and other research and

46

development activities and programs; and our general and administrative activities, including disclosure controls, internal control over financial reporting and other public reporting functions. In addition, our third-party service providers depend on technology and telecommunications systems in order to provide contracted services for us. We expect we will need to continue to expand and strengthen a number of enterprise software systems that affect a broad range of business processes and functions, particularly if and as our operations grow, including, for example, systems handling human resources, financial and other disclosure controls and reporting, customer relationship management, regulatory compliance, security controls and other infrastructure functions.

Information technology and telecommunications systems are vulnerable to disruption and damage from a variety of sources, including power outages and other telecommunications or network failures, natural disasters, and the outbreak of war or acts of terrorism. Breaches resulting in the compromise, disruption, degradation, manipulation, loss, theft, destruction, or unauthorized disclosure of sensitive information, can occur in a variety of ways, including but not limited to, negligent or wrongful conduct by employees or former employees or others with permitted access to our information technology systems and information, or wrongful conduct by hackers, competitors, or certain governments. Our third-party vendors and business partners face similar risks. Moreover, despite network security and back-up measures, our servers and other electronic systems are potentially vulnerable to cybersecurity breaches, such as physical or electronic break-ins, computer viruses, ransomware attacks, phishing schemes, and similar disruptive events. Despite the precautionary measures we have taken to detect and prevent or solve problems that could affect our information technology and telecommunications systems, there may be significant downtime or failures of these systems or those used by our third-party service providers. There can be no assurance that we will promptly detect and/or intercept any such disruption or security breach, if at all. Any such downtime or failure could prevent us from conducting tests, preparing and providing reports to customers, billing payors, responding to customer inquiries, conducting research and development activities, maintaining our financial and disclosure controls and other reporting functions and managing the administrative aspects of our business. Moreover, any such downtime or failure could force us to transfer data collection operations to an alternate provider of server-hosting services, which could involve significant costs and result in further delays in our ability to conduct tests, deliver reports to our customers and otherwise manage our operations. Further, although we carry property, business interruption and cyber lability insurance, the coverage may not be adequate to compensate for all losses that may occur in the event of system downtime or failure. Any such disruption or loss of information technology or telecommunications systems on which critical aspects of our operations depend could have a material adverse effect on our business and our reputation.

Additionally, if and as our business grows, we will need to continually improve and expand the scope of our technology systems in order to maintain their adequacy for the scale of our operations. Any failure to make such improvements or any significant delay in the planned implementation of new or enhanced systems could render our systems obsolete or inadequate, in which case our service to our customers and our other business activities could suffer and we could be more vulnerable to electronic breaches from outside sources.

We rely on commercial courier delivery services to transport specimens to our laboratory facilities in a timely and cost-efficient manner, and if these delivery services are disrupted, our business would be harmed.

Our business depends on our ability to quickly and reliably deliver test results to our customers. We typically receive specimens from customers within days of shipment, or in some cases overnight, for analysis at our laboratory facilities. Disruptions in delivery service, whether due to labor disruptions, bad weather, natural disasters, pandemics or epidemics, terrorist acts or threats or for other reasons, could adversely affect specimen integrity and our ability to process specimens in a timely manner and otherwise service our customers, and ultimately our reputation and our business. In addition, if we are unable to continue to obtain expedited delivery services on commercially reasonable terms, our operating results may be adversely affected.

If we are unable to maintain effective internal control over financial reporting, investors could lose confidence in the accuracy and completeness of our reported financial information and the market price of our common stock could decline.

We are required to maintain internal control over financial reporting and report any material weaknesses in these internal controls. Section 404 of the Sarbanes-Oxley Act requires that we evaluate and determine the effectiveness of our internal control over financial reporting and annually provide a management report on these internal controls. Although we have implemented systems, processes and controls and performed this evaluation as of the end of 2020, we will need to maintain and enhance these controls if and as we grow, and we may need to hire additional personnel and devote more resources to our financial reporting function in order to do so.

If we identify one or more material weaknesses during the process of annually evaluating our internal controls, we may not detect errors on a timely basis and our financial statements may be materially misstated. In addition, in that event, our management would be unable to conclude that our internal control over financial reporting is effective. Further, when we are no longer an emerging growth company or when and if we become a large accelerated filer or accelerated filer, our independent registered public accounting firm will be required to issue an attestation report on the effectiveness of our internal control over financial reporting. When that occurs, our independent registered public accounting firm may conclude that there are material weaknesses in our internal controls or

47

the level at which our internal controls are documented, designed, implemented or reviewed even if our management concludes that our internal control over financial reporting is effective.

If we or our auditors were to conclude that our internal control over financial reporting was not effective because one or more material weaknesses had been identified or if internal control deficiencies result in the restatement of our financial results, investors could lose confidence in the accuracy and completeness of our financial disclosures and the price of our common stock could decline.

Our disclosure controls and procedures may not prevent or detect all errors or acts of fraud.

We are subject to the periodic reporting and other requirements of the Exchange Act. We have implemented disclosure controls and procedures designed to provide reasonable assurance that information we must disclose in reports we file or submit under the Exchange Act is accumulated and communicated to management and recorded, processed, summarized and reported within the time periods specified in the rules and forms of the SEC. However, any disclosure controls and procedures, no matter how well-conceived and operated, can provide only reasonable, not absolute, assurance that the objectives of the control system are met. These inherent limitations include the realities that judgments in decision-making can be faulty and that breakdowns can occur because of simple errors or mistakes. Additionally, controls can be circumvented by the individual acts of some persons, by collusion of two or more people or by an unauthorized override of the controls. As a result, because of these inherent limitations in our control system, misstatements or omissions due to error or fraud may occur and may not be detected, which could result in failures to file required reports in a timely manner and filing reports containing incorrect information. Any of these outcomes could result in SEC enforcement actions, monetary fines or other penalties, damage to our reputation and harm to our financial condition and stock price.

We may elect to comply with reduced public company reporting requirements available to us because we are an emerging growth company and a smaller reporting company, which could make our common stock less attractive to investors.

We are an emerging growth company, as defined in the JOBS Act, and a smaller reporting company, as defined in applicable SEC rules, and we expect to remain as such until December 31, 2021 and January 1, 2022, respectively. As an emerging growth company and smaller reporting company, we are eligible for exemptions from certain reporting requirements applicable to other public companies, including, reduced financial statement and other financial disclosure requirements in registration statements and periodic reports we file, reduced disclosure obligations regarding executive compensation and, so long as we remain an emerging growth company, an exemption from the auditor attestation requirements of Section 404 of the Sarbanes-Oxley Act, exemption from the requirements to hold non-binding advisory votes on executive compensation and exemption from the requirements to obtain stockholder approval for any golden parachute payments not previously approved. We have relied on many of these exemptions in periodic reports to date, and investors may find our common stock less attractive if we choose to continue to rely on these exemptions, in which case there may be a less active trading market for our common stock and our stock price may be more volatile.

Under the Securities Act, emerging growth companies can elect to delay adoption of new or revised accounting standards until those standards apply to private companies. We have irrevocably elected not to avail ourselves of this exemption and, as a result, we are subject to the same new or revised accounting standards at the same time as other public companies that are not emerging growth companies.

The auditor for FF Gene Biotech, like other independent registered public accounting firms operating in China, is not permitted to be subject to inspection by the Public Company Accounting Oversight Board, and as such, investors may be deprived of the benefits of this inspection.

The independent registered public accounting firm that issues the audit reports for FF Gene Biotech, included in our reports filed with the SEC, as an auditor of companies that are traded publicly in the United States and a firm registered with the Public Company Accounting Oversight Board (United States), or PCAOB, is required by the laws of the United States to undergo regular inspections by PCAOB to assess its compliance with the laws of the United States and professional standards. On May 24, 2013, the PCAOB announced that it had signed a Memorandum of Understanding, or MOU, with Chinese securities regulators that would enable the PCAOB under certain circumstances to obtain audit work papers of China-based audit firms. The MOU establishes a framework under which the PCAOB can request and obtain audit papers and permits the PCAOB to share the work papers it obtains with the SEC, subject to certain requirements. But the MOU, which is non-binding, is also limited by its own terms. For instance, Chinese regulators may refuse to produce documents in specified circumstances, including where production would violate Chinese law or run contrary to the public interest. Moreover, the MOU does not provide the PCAOB with the ability to conduct on-the-ground inspections of auditors in China, an important part of the PCAOB’s oversight function. As a result, our auditor, like other independent registered public accounting firms operating in China, is currently not inspected by PCAOB in the same way that PCAOB inspects independent registered public accounting firms operating outside China. Inspections of other firms that PCAOB has conducted outside of China have identified deficiencies in those firms’ audit procedures and quality control procedures, which may be addressed as part of the inspection process to improve future audit quality. The inability of PCAOB to conduct regular inspections of independent registered

48

public accounting firms operating in China makes it more difficult to evaluate the effectiveness of our auditor’s audit procedures or quality control procedures. As a result, investors may be deprived of the benefits of PCAOB regular inspections.

 

Regulatory Risks

Any changes in laws, regulations or the enforcement discretion of the FDA with respect to the marketing of diagnostic products, or violations of laws or regulations by us, could adversely affect our business, prospects, results of operations or financial condition.

The laws and regulations governing the marketing of diagnostic products are evolving, extremely complex and in many instances, there are no significant regulatory or judicial interpretations of these laws and regulations. Pursuant to its authority under the federal Food, Drug, and Cosmetic Act, or FDC Act, the FDA has jurisdiction over medical devices, including in vitro diagnostics and, therefore, potentially our clinical laboratory tests. Among other things, pursuant to the FDC Act and its implementing regulations, the FDA regulates the research, testing, manufacturing, safety, labeling, storage, recordkeeping, premarket clearance or approval, marketing and promotion, and sales and distribution of medical devices in the United States to ensure that medical products distributed domestically are safe and effective for their intended uses. In addition, the FDA regulates the import and export of medical devices.

Although the FDA has statutory authority to assure that medical devices and in vitro diagnostics, including potentially our tests, are safe and effective for their intended uses, the FDA has historically exercised its enforcement discretion and not enforced applicable provisions of the FDC Act and regulations with respect to laboratory developed tests, or LDTs, which are a particular type of medical device. We believe our tests are LDTs. As a result, we believe our tests are not currently subject to the FDA’s enforcement of its medical device regulations and the applicable FDC Act provisions.

Even though we commercialize our tests as LDTs, our tests may in the future become subject to more onerous regulation by the FDA. For example, the FDA may disagree with our assessment that our tests fall within the definition of an LDT and seek to regulate our tests as medical devices. Moreover, the FDA issued draft guidance and a 2017 Discussion Paper to allow for further public discussion about an appropriate LDT oversight approach and to give congressional committees the opportunity to develop a legislative solution. The FDA also solicited public input and published two final guidance documents in April 2018 relating to FDA oversight of NGS-based tests. These two guidance documents describe the FDA’s thinking and recommendations regarding test developer’s use of FDA-recognized standards to support analytical validity, and public human genetic variant databases to support clinical validity, of these tests.

On August 19, 2020, the U.S. Department of Health and Human Services, or HHS, published a policy announcement that the FDA must go through the formal notice-and-comment rulemaking process before requiring pre-market review of LDTs rather than making such changes through guidance documents, compliance manuals, or other informal policy statements. However, laboratories may still voluntarily submit LDTs to the FDA for pre-market review. Although the ultimate impact of HHS’s policy statement on the FDA’s plans for regulating LDTs and its current thinking relating to such testing products is unclear, the announcement appears to confirm that laboratories may commercialize LDTs for clinical use without submitting such tests for FDA review and marketing authorization, including EUA. HHS’s policy statement does not affect proposed legislation for the regulation of LDTs, which is discussed below. It also continues to be unclear whether the Biden Administration, which assumed control of the executive branch on January 20, 2021, would take the same position as the former administration or seek to revoke or revise the HHS policy announcement from August 2020.

In December 2018, members of Congress released a discussion draft of a possible bill to regulate in vitro clinical tests including LDTs, and provided opportunities for additional stakeholders to also provide input on the proposed reform legislation. On March 5, 2020, U.S. Representatives Diana DeGette (D-CO) and Dr. Larry Bucshon (R-IN) formally introduced the long-awaited legislation, called the Verifying Accurate, Leading-edge IVCT Development Act, or VALID Act. An identical version of the bill was also introduced in the Senate and is sponsored by U.S. Senators Michael Bennet (D-CO) and Richard Burr (R-NC), demonstrating both bicameral and bipartisan support for the effort to overhaul how the FDA reviews and approves diagnostic tests going forward. The VALID Act would codify into law the term “in vitro clinical test” to create a new medical product category separate from medical devices that includes products currently regulated as in vitro diagnostics, or IVDs, as well as LDTs. The VALID Act would also create a new system for labs and hospitals to use to submit their tests electronically to the FDA for approval, which is aimed at reducing the amount of time it takes for the agency to approve such tests, and establish a new program to expedite the development of diagnostic tests that can be used to address a current unmet need for patients. A substantively unchanged version of the VALID Act was re-introduced in both houses of Congress on June 24, 2021.

49

It is unclear whether the VALID Act would be passed by Congress in its current form or signed into law by President Biden. Until the FDA promulgates binding regulations through notice-and-comment rulemaking regarding LDTs, or the VALID Act or other legislation is passed reforming the federal government’s regulation of LDTs, it is unknown how the FDA may regulate our tests in the future and what testing and data may be required to support any required clearance or approval.

If the FDA creates a new regulation to enforce its medical device requirements for LDTs or if the FDA disagrees with our assessment that our tests are LDTs, we could for the first time be subject to enforcement of a variety of regulatory requirements, including registration and listing, medical device reporting and quality control, and we could be required to obtain premarket clearance or approval for our existing tests and any new tests we may develop, which may force us to cease marketing our tests until we obtain the required clearance or approval. The premarket review process can be lengthy, expensive, time-consuming and unpredictable. Further, obtaining pre-market clearance may involve, among other things, successfully completing clinical trials. Clinical trials require significant time and cash resources and are subject to a high degree of risk, including risks of experiencing delays, failing to complete the trial or obtaining unexpected or negative results. If we are required to obtain premarket clearance or approval and/or conduct premarket clinical trials, our development costs could significantly increase, our introduction of any new tests we may develop may be delayed and sales of our existing tests could be interrupted or stopped. Any of these outcomes could reduce our revenue or increase our costs and materially adversely affect our business, prospects, results of operations or financial condition. Moreover, any cleared or approved labeling claims may not be consistent with our current claims or adequate to support continued adoption of and reimbursement for our tests. For instance, if we are required by the FDA to label our tests as investigational, or if labeling claims the FDA allows us to make are limited, order levels may decline and reimbursement may be adversely affected. As a result, we could experience significantly increased development costs and a delay in generating additional revenue from our existing tests or from tests we may develop.

In addition, while we qualify all materials used in our products in accordance with the regulations and guidelines of CLIA, the FDA could promulgate regulations or guidance documents impacting our ability to purchase materials necessary for the performance of our tests. If any of the reagents we obtain from suppliers and use in our tests are affected by future regulatory actions, our business could be adversely affected, including by increasing the cost of testing or delaying, limiting or prohibiting the purchase of reagents necessary to perform testing with our products.

Failure to comply with any applicable FDA requirements could trigger a range of enforcement actions by the FDA, including warning letters, civil monetary penalties, injunctions, criminal prosecution, recall or seizure, operating restrictions, partial suspension or total shutdown of operations and denial of or challenges to applications for clearance or approval, as well as significant adverse publicity.

If we fail to comply with applicable federal, state, local and foreign laboratory licensing requirements, we could lose the ability to perform our tests or experience disruptions to our business.

We are subject to CLIA, a federal law that establishes quality standards for all laboratory testing and is intended to ensure the accuracy, reliability and timeliness of patient results. CLIA requires that we hold a certificate specific to the laboratory examinations we perform and that we comply with various standards with respect to personnel qualifications, facility administration, proficiency testing, quality control, quality assurance and inspections. CLIA certification is required in order for us to be eligible to bill federal and state health care programs, as well as many private third-party payors, for our tests. We have obtained CLIA certification to conduct our tests at our laboratories in Temple City, California and in Houston, Texas.

In addition to CLIA requirements, we elect to participate in the accreditation program of CAP. The Centers for Medicare & Medicaid Services, or CMS, has deemed CAP standards to be equally or more stringent than CLIA regulations and has approved CAP as a recognized accrediting organization. Inspection by CAP is performed in lieu of inspection by CMS for CAP-accredited laboratories. Because we are accredited by the CAP Laboratory Accreditation Program, we are deemed to also comply with CLIA. In addition, some countries outside the United States require CAP accreditation as a condition to permitting clinical laboratories to test samples taken from their citizens. Failure to maintain CAP accreditation could have a material adverse effect on the sales of our tests and the results of our operations.

We are also required to maintain a license to conduct testing in the State of California. California laws establish standards for day-to-day operation of our clinical reference laboratory in Temple City, including with respect to the training and skills required of personnel, quality control and proficiency testing requirements. In addition, because we receive test specimens originating from New York, we have obtained a state laboratory permit for our Temple City laboratory from the New York Department of Health, or DOH. The New York state laboratory laws, regulations and rules are equal to or more stringent than the CLIA regulations. The laboratory director must maintain a Certificate of Qualification issued by New York’s DOH in permitted categories. We are subject to on-site routine and complaint-driven inspections under both California and New York state laboratory laws and regulations. If we are found to be out of compliance with either California or New York requirements, the CA Department of Public Health or New York’s DOH may suspend, restrict or revoke our license or laboratory permit, respectively (and, with respect to California, may exclude persons or

50

entities from owning, operating or directing a laboratory for two years following such license revocation), assess civil monetary penalties, or impose specific corrective action plans, among other sanctions. Any such actions could materially and adversely affect our business by prohibiting or limiting our ability to offer testing.

Moreover, certain other states require us to maintain out-of-state laboratory licenses or obtain approval on a test-specific basis to perform testing on specimens from these states. Additional states could adopt similar licensure requirements in the future, which could require us to modify, delay or discontinue our operations in such jurisdictions. We are also subject to regulation in foreign jurisdictions, which we expect will increase as we seek to expand international utilization of our tests or if jurisdictions in which we pursue operations adopt new or modified licensure requirements. Foreign licensure requirements could require review and modification of our tests in order to offer them in certain jurisdictions or could impose other limitations, such as restrictions on the transport of human blood or other tissue necessary for us to perform our tests that may limit our ability to make our tests available outside the United States. Additionally, complying with licensure requirements in new jurisdictions may be expensive, time-consuming and subject us to significant and unanticipated delays.

Failure to comply with applicable clinical laboratory licensure requirements could result in a range of enforcement actions, including license suspension, limitation or revocation, directed plan of correction, onsite monitoring, civil monetary penalties, civil injunctive suits, criminal sanctions and exclusion from the Medicare and Medicaid programs, as well as significant adverse publicity. Any sanction imposed under CLIA, its implementing regulations or state or foreign laws or regulations governing clinical laboratory licensure, or our failure to renew our CLIA certificate or any other required local, state or foreign license or accreditation, could have a material adverse effect on our business, financial condition and results of operations. In such case, even if we were able to bring our laboratory back into compliance, we could incur significant expenses and lose revenue while doing so.

We are subject to broad legal requirements regarding the information we test and analyze, and any failure to comply with these requirements could result in harsh penalties, damage our reputation and materially harm our business.

Our business is subject to federal and state laws that protect the privacy and security of personal information, including the Health Insurance Portability and Accountability Act of 1996, or HIPAA, the Health Information Technology for Economic and Clinical Health Act, or HITECH, and similar state laws, as well as numerous other federal, state and foreign laws, including consumer protection laws and regulations, that govern the collection, dissemination, use, access to, confidentiality and security of patient health information. In addition, new laws and regulations that further protect the privacy and security of medical records or medical information are regularly considered by federal and state governments. Further, with the recent increase in publicity regarding data breaches resulting in improper dissemination of consumer information, federal and state governments have passed or are considering laws regulating the actions that a business must take if it experiences a data breach, such as prompt disclosure to affected customers. The Federal Trade Commission, or FTC, and states’ Attorneys General have also brought enforcement actions and prosecuted some data breach cases as unfair and/or deceptive acts or practices under the Federal Trade Commission Act, or the FTC Act, and comparable state laws. In addition to data breach notification laws, some states have enacted statutes and rules requiring businesses to reasonably protect certain types of personal information they hold or to otherwise comply with certain specified data security requirements for personal information. We intend to continue to comprehensively protect all personal information and to comply with all applicable laws regarding the protection of such information.

Any failure to implement appropriate security measures to protect the confidentiality and integrity of personal information or any breach or other failure of these systems resulting in the unauthorized access, manipulation, disclosure or loss of this information could result in our noncompliance with these laws. Penalties for failure to comply with a requirement of HIPAA and HITECH vary significantly depending on the failure and could include civil monetary or criminal penalties.

The European Union formally adopted the General Data Protection Regulation, or GDPR, in 2016, which applies to all European Union member states from May 25, 2018 and replaced the European Data Protection Directive. The GDPR introduced stringent new data protection and operational requirements in the European Union for companies that receive or process personal data of European residents, as well as substantial fines for breaches of the data protection rules. It has increased our responsibility and liability in relation to personal data that we process and we are required to maintain additional mechanisms ensuring compliance with the GDPR. The GDPR is a complex law and the regulatory guidance is still evolving, including with respect to how the GDPR should be applied in the context of clinical studies and the collection, processing, and storage of sensitive personal data, including genetic information and testing. Furthermore, many of the countries within the European Union are still in the process of drafting supplementary data protection legislation in key fields where the GDPR allows for national variation, including the fields of clinical study and other health-related information. These variations in the law may raise our costs of compliance and result in greater legal risks. On July 16, 2020, the Court of Justice of the European Union or the CJEU, issued a landmark opinion in the case Maximilian Schrems vs. Facebook (Case C-311/18), or Schrems II. This decision calls into question certain data transfer mechanisms as between the European Union member states and the US. The CJEU is the highest court in Europe and the Schrems II decision heightens the burden on data importers to assess U.S. national security laws on their business, and future actions of European Union data protection authorities are difficult to predict at this early date. Consequently, there is some risk of any such data transfers from the European

51

Union being halted by one or more European Union member states. Any contractual arrangements requiring the transfer of personal data from the European Union to us in the United States will require greater scrutiny and assessments as required under Schrems II and may have an adverse impact on cross-border transfers of personal data, or increase costs of compliance.

In addition, many states, such as California (where one of our clinical laboratories is located), have implemented similar privacy laws and regulations, such as the California Confidentiality of Medical Information Act, that impose restrictive requirements regulating the use and disclosure of patient health information and other personal information. In addition to fines and penalties imposed upon violators, some of these state laws also afford private rights of action to individuals who believe their personal information has been misused. California’s patient privacy laws, for example, provide for penalties of up to $250,000 and permit injured parties to sue for damages. In addition to the California Confidentiality of Medical Information Act, California also recently enacted the California Consumer Privacy Act of 2018, or CCPA, which became effective on January 1, 2020. The CCPA has been characterized as the first “GDPR-like” privacy statute to be enacted in the United States because it mirrors a number of the key provisions of the GDPR. The CCPA establishes a new privacy framework for covered businesses in the State of California by creating an expanded definition of personal information, establishing new data privacy rights for California residents, imposing special rules on the collection of personal data from minors, and creating a new and potentially severe statutory damages framework for violations of the CCPA and for businesses that fail to implement reasonable security procedures and practices to prevent data breaches. On November 3, 2020, California voters passed the California Privacy Rights Act, or CPRA, which expands the CCPA. The CPRA will be fully effective in January of 2023 and, among other things, establishes the California Privacy Protection Agency, or CPPA, a new regulatory authority charged with administering and enforcing the CRPA and privacy rights in California. The CPPA will have the power to levy fines and bring other enforcement actions. The CPRA could impact our operations or that of our collaborators and business partners and impose new regulatory requirements and increase costs of compliance. Other states are considering expanded privacy legislation similar to the GDPR and CPRA, with Virginia recently enacting its own statute called the Consumer Data Protection Act, and several federal privacy proposals are under consideration in Congress.

The interplay of federal and state laws may be subject to varying interpretations by courts and government agencies, creating complex compliance issues for us and potentially exposing us to additional expense, adverse publicity and liability. Further, as regulatory focus on privacy issues continues to increase and laws and regulations concerning the protection of personal information expand and become more complex, these potential risks to our business could intensify. Additionally, the interpretation, application and interplay of consumer and health-related data protection laws in the United States, Europe and elsewhere are often uncertain, contradictory and in flux. As a result, it is possible that laws may be interpreted and applied in a manner that is inconsistent with our current practices. Moreover, these laws and their interpretations are constantly evolving and they may become more stringent over time. Complying with these laws or any new laws or interpretations of their application could involve significant time and substantial costs or require us to change our business practices and compliance procedures in a manner adverse to our business. We may not be able to obtain or maintain compliance with the diverse privacy and security requirements in all of the jurisdictions in which we currently or plan to do business, and failure to comply with any of these requirements could result in civil or criminal penalties, harm our reputation and materially adversely affect our business.

We conduct business in a heavily regulated industry. Complying with the numerous statutes and regulations pertaining to our business is expensive and time-consuming, and any failure by us, our consultants or commercial partners to comply could result in substantial penalties.

Our industry and our operations are heavily regulated by various federal, state, local and foreign laws and regulations, and the regulatory environment in which we operate could change significantly and adversely in the future. These laws and regulations currently include, among others:

 

•

the HHS policy decision from August 2020 establishing that the FDA does not presently have authority to oversee LDTs;

 

•

CLIA’s and CAP’s regulation of our laboratory activities;

 

•

federal and state laws and standards affecting reimbursement by government payors, including certain coding requirements to obtain reimbursement and certain changes to the payment mechanism for clinical laboratory services resulting from the Protecting Access to Medicare Act of 2014, or PAMA;

 

•

HIPAA and HITECH, which establish comprehensive federal standards with respect to the privacy and security of PHI, and requirements for the use of certain standardized electronic transactions with respect to transmission of such information, as well as similar laws protecting other types of personal information;

 

•

state laws governing the maintenance of personally identifiable information of state residents, including medical information, and which impose varying breach notification requirements, some of which allow private rights of action by individuals for violations and also impose penalties for such violations;

 

•

the federal Anti-Kickback Statute, which generally prohibits knowingly and willfully offering, paying, soliciting or receiving remuneration, directly or indirectly, in return for or to induce a person to refer to an individual any good, facility, item or service that is reimbursable under a federal health care program;

52

 

•

the federal Stark Law, which generally prohibits a physician from making a referral for certain designated health services covered by the Medicare program, including laboratory and pathology services, if the physician or an immediate family member has a financial relationship with the entity providing the designated health services;

 

•

the federal False Claims Act, which imposes civil penalties, and provides for civil whistleblower or qui tam actions, against individuals or entities for knowingly presenting, or causing to be presented, to the federal government, claims for payment that are false or fraudulent or making a false statement to avoid, decrease or conceal an obligation to pay money to the federal government;

 

•

the federal Civil Monetary Penalties Law, which generally prohibits, among other things, the offering or transfer of remuneration to a Medicare or Medicaid beneficiary if it is likely to influence the beneficiary’s selection of a particular provider, practitioner or supplier of services reimbursable by Medicare or Medicaid;

 

•

the Eliminating Kickbacks in Recovery Act of 2018, or EKRA, which imposes criminal penalties for knowing or willful payment or offer, or solicitation or receipt, of any remuneration, whether directly or indirectly, overtly or covertly, in cash or in kind, in exchange for the referral or inducement of laboratory testing (among other health care services) covered by health care benefit programs (including commercial insurers) unless a specific exception applies;

 

•

the Affordable Care Act, or ACA, which, among other things, establishes a requirement for providers and suppliers to report and return any overpayments received from the Medicare and Medicaid programs;

 

•

other federal and state fraud and abuse laws, such as anti-kickback laws, prohibitions on self-referral, fee-splitting restrictions, insurance fraud laws, anti-markup laws, prohibitions on the provision of tests at no or discounted cost to induce physician or patient adoption and false claims acts, some of which may extend to services reimbursable by any third-party payor, including private payors;

 

•

the federal Physician Sunshine Payment Act and various state laws on reporting relationships with health care providers and customers, which could be determined to apply to our LDTs;

 

•

the prohibition on reassignment of Medicare claims;

 

•

state laws that prohibit other specified healthcare practices, such as billing physicians for tests that they order, waiving coinsurance, copayments, deductibles and other amounts owed by patients, business corporations practicing medicine or employing or engaging physicians to practice medicine and billing a state Medicaid program at a price that is higher than what is charged to one or more other payors;

 

•

the U.S. Foreign Corrupt Practices Act, or FCPA, and applicable foreign anti-bribery laws;

 

•

federal, state and local regulations relating to the handling and disposal of regulated medical waste, hazardous waste and biohazardous waste and workplace safety for healthcare employees;

 

•

laws and regulations relating to health and safety, labor and employment, public reporting, taxation and other areas applicable to businesses generally, all of which are subject to change, including, for example, the significant changes to the taxation of business entities were enacted in December 2017; and

 

•

similar foreign laws and regulations that apply to us in the countries in which we operate or may operate in the future.

The genetic testing industry is currently under a high degree of government scrutiny. The Office of Inspector General for the Department of Health and Human Services and a variety of states’ Attorneys General have issued fraud alerts regarding a variety of cancer genetic testing fraud schemes, and the Department of Justice has announced indictments and guilty pleas in such fraud schemes involving a variety of individuals and entities, including genetic testing and other laboratories, physicians who order genetic testing for a large volume of patients without treating them, and third parties who arranged for the genetic testing by approaching patients through telemarketing calls, booths at public events, health fairs, and door-to-door visits. These individuals then shared the proceeds received from Medicare, TRICARE, and other third-party payors. This increased regulatory scrutiny could decrease demand for our testing services or increase our costs of regulatory compliance, either of which could have a material adverse effect on our business.

Any future growth of our business, including, in particular, growth of our international business and continued reliance on consultants, commercial partners and other third parties, may increase the potential for violating these laws. In some cases, our risk of violating these or other laws and regulations is further increased because of the lack of their complete interpretation by applicable regulatory authorities or courts, and their provisions are thus open to a variety of interpretations. Our Picture Genetics line of at-home genetic test offerings are patient-initiated screening tests, which may receive greater scrutiny from regulatory authorities than our traditional testing services that are offered directly to health care providers.

We have adopted policies and procedures designed to comply with these laws and regulations and, in the ordinary course of our business, we conduct internal reviews of our compliance with these laws. Our compliance is also subject to review by applicable government agencies. It is not always possible to identify and deter misconduct by employees, distributors, consultants and commercial partners, and the precautions we take to detect and prevent this activity may not be effective in controlling unknown or unmanaged risks or losses or in protecting us from government investigations or other actions or lawsuits stemming from a failure to comply with applicable laws or regulations. Additionally, we are subject to the risk that a person or government could allege such fraud or other misconduct, even if none occurred. Any action brought against us for violation of these or other laws or regulations, even if we successfully defend against it, could cause us to incur significant legal expenses, divert our management’s attention from

53

the operation of our business and harm our reputation. If our operations, including the conduct of our employees, consultants and commercial partners, are found to be in violation of any of these laws and regulations, we may be subject to applicable penalties associated with the violation, including administrative, civil and criminal penalties, damages, fines, individual imprisonment, exclusion from participation in federal healthcare programs, refunding of payments received by us and curtailment or cessation of our operations. Any of these consequences could seriously harm our business and our financial results.

Healthcare policy changes, including recently enacted and proposed new legislation reforming the U.S. healthcare system, could cause significant harm to our business, operations and financial condition.

The ACA made a number of substantial changes to the way healthcare is financed both by governmental and private payors. The ACA also introduced mechanisms to reduce the per capita rate of growth in Medicare spending if expenditures exceed certain targets. Any such reductions could affect reimbursement payments for our tests. The ACA also contains a number of other provisions, including provisions governing enrollment in federal and state healthcare programs, reimbursement matters and fraud and abuse, which we expect will impact our industry and our operations in ways that we cannot currently predict.

In April 2014, Congress passed PAMA, which included substantial changes to the way in which clinical laboratory services will be paid under Medicare. Under PAMA, certain clinical laboratories are required to periodically report to CMS private payor payment rates and volumes for their tests. Laboratories that fail to report the required payment information may be subject to substantial civil monetary penalties. Further, effective January 1, 2018, under PAMA, Medicare reimbursement for diagnostic tests will be based on the weighted-median of the payments made by private payors for these tests, rendering private payor payment levels even more significant. As a result, future Medicare payments may fluctuate more often and become subject to the willingness of private payors to recognize the value of diagnostic tests generally and any given test individually. The impact of this new payment system on rates for our tests, including any current or future tests we may develop, is uncertain.

On December 20, 2019, President Trump signed the Further Consolidated Appropriations Act, which included the Laboratory Access for Beneficiaries Act, or LAB Act. The LAB Act delayed by one year the reporting of payment data under PAMA for clinical diagnostic laboratory tests that are not advanced diagnostic laboratory tests until the first quarter of 2021. The CARES Act, which was signed into law on March 27, 2020, delayed the reporting period by an additional year, until the first quarter of 2022.

In addition, under PAMA, as amended by the LAB Act, any reduction to a particular payment rate resulting from the new methodology is limited to 10% per test per year in 2020 and to 15% per test per year in each of the years 2021 through 2023. The CARES Act delayed the 15% cut scheduled to take effect on January 1, 2021, for one year.

We cannot predict whether or when these or other recently enacted healthcare initiatives will be implemented at the federal or state level or how any such legislation or regulation may affect us. For instance, the payment reductions imposed by the ACA and the changes to reimbursement amounts paid by Medicare for tests such as ours based on the procedure set forth in PAMA, could limit the prices we will be able to charge or the amount of available reimbursement for our tests, which would reduce our revenue. Additionally, these healthcare policy changes could be amended or additional healthcare initiatives could be implemented in the future. For instance, the new Democrat-led presidential administration has been taking steps to strengthen the ACA and, following several years of litigation in the federal courts, in June 2021, the U.S. Supreme Court upheld the ACA when it dismissed a legal challenge to the ACA’s constitutionality. Legislation related to precision medicine is also being considered in Congress and, if passed and signed into law, such legislation may affect genetic or genomic testing and related clinical laboratory offerings.

Further, the impact on our business of the expansion of the federal and state governments’ role in the U.S. healthcare industry generally, including the social, governmental and other pressures to reduce healthcare costs while expanding individual benefits, is uncertain. Any future changes or initiatives could have a materially adverse effect on our business, financial condition, results of operations and cash flows.

Changes in laws and regulations, or in their application, may adversely affect our business, financial condition and results of operations.

The clinical laboratory testing industry is highly regulated, and failure to comply with applicable regulatory, supervisory, accreditation, registration or licensing requirements may adversely affect our business, financial condition and results of operations. In particular, the laws and regulations governing the marketing and research of clinical diagnostic testing are extremely complex, and in many instances there are no clear regulatory or judicial interpretations of these laws and regulations, increasing the risk that we may be found to be in violation of these laws.

Furthermore, the genetic testing industry as a whole is a growing industry and regulatory agencies such as HHS or the FDA may apply heightened scrutiny to new developments in the field, or the U.S. Congress may do so. Since 2017, Congress has been working

54

on legislation to create an LDT and IVD regulatory framework that would be separate and distinct from the existing medical device regulatory framework. On March 5, 2020, U.S. Representatives Diana DeGette (D-CO) and Dr. Larry Bucshon (R-IN) formally introduced the VALID Act in the House and an identical version of the bill was introduced in the U.S. Senate by Senators Michael Bennet (D-CO) and Richard Burr (R-NC). As anticipated from a discussion draft of the legislation released for stakeholder comment in December 2018, the VALID Act would codify into law the term “in vitro clinical test” to create a new medical product category separate from medical devices, and bring all such products within the scope of the FDA’s oversight. A substantively unchanged version of the VALID Act was re-introduced in both houses of Congress on June 24, 2021. It is unclear whether the VALID Act would be passed by Congress in its current form or signed into law by President Biden.

In addition, there has been a recent trend of increased U.S. federal and state regulation, scrutiny and enforcement relating to payments made to referral sources, which are governed by laws and regulations including the Stark law, the federal Anti-Kickback Statute, the federal False Claims Act, as well as state equivalents of such laws. For example, the Eliminating Kickbacks in Recovery Act of 2018, or EKRA, was passed in October 2018 as part of the Substance Use-Disorder Prevention that Promotes Opioid Recovery and Treatment for Patients and Communities Act. Similar to the federal Anti-Kickback Statute, EKRA imposes criminal penalties for knowing or willful payment or offer, or solicitation or receipt, of any remuneration, whether directly or indirectly, overtly or covertly, in cash or in kind, in exchange for the referral or inducement of laboratory testing (among other health care services) unless a specific exception applies. However, unlike the federal Anti-Kickback Statute, EKRA is not limited to services covered by federal or state health care programs but applies more broadly to services covered by “health care benefit programs,” including commercial insurers. Additionally, because EKRA’s exceptions are not identical to the federal Anti-Kickback Statute’s safe harbors, compliance with a federal Anti-Kickback Statute safe harbor does not guarantee protection under EKRA. As currently drafted, EKRA potentially expands the universe of arrangements that could be subject to government enforcement under federal fraud and abuse laws, and there is no agency guidance or court precedent to indicate how and to what extent it will be applied and enforced. We cannot assure you that our relationships with physicians, sales representatives, hospitals, customers, or any other party will not be subject to scrutiny or will survive regulatory challenge under such laws. If imposed for any reason, sanctions under the EKRA could have a negative effect on our business.

Marketing of our COVID-19 tests under the EUA from FDA is subject to certain limitations and we are required to maintain compliance with the terms of the EUA, among other things, and the continuance of our EUA is subject to government discretion.

Since March 2020, we have commercially launched several molecular tests for the detection of SARS-CoV-2, the virus that causes COVID-19, including NGS and RT-PCR-based tests as well as related antibody testing options. In May 2020, we were granted an EUA for our RT-PCR-based test for the detection of SARS-CoV-2 using upper and lower respiratory specimens (nasal, nasopharyngeal, and oropharyngeal swabs). In June 2020, we received an amendment to the EUA to add our at-home testing solution for COVID-19 through Picture Genetics. Since that time, the FDA has granted authorizations to revise the authorized labeling for the RT-PCR test and to allow for the use of an additional at-home specimen collection kit in conjunction with our test.

Although there are certain regulatory requirements the FDA has waived for the duration of the EUA, we remain subject to specific conditions of the authorizations. As with other FDA-regulated tests, issues could emerge during the course of the marketing and use of our test under an EUA that could impact our ability to continue the sale and distribution of the authorized test or home collection kit. Factors that may be out of the Company’s control, such as the availability of supplies and key personnel, may impact the Company’s ability to maintain testing capacity and test result delivery, and its other responses to the COVID-19 pandemic, and may have an adverse impact on the Company’s operations. Our EUA remains effective only until the HHS declaration is terminated or revoked, and FDA also may revoke an EUA if it determines the criteria for issuance are no longer met or other circumstances make such revocation appropriate to protect the public health or safety.

However, on August 19, 2020, HHS published a policy announcement that the FDA must go through the formal notice-and-comment rulemaking process before requiring pre-market review (including emergency use authorization) of LDTs rather than making such changes through guidance documents, compliance manuals, or other informal policy statements. Based on the HHS’s policy announcement, which specifically states that LDT developers are not required to obtain an EUA or other marketing authorization from FDA prior to commercialization, we believe we may continue to market our COVID-19 tests even if our EUA is terminated or revoked. The FDA may seek to establish a new regulation through notice-and-comment rulemaking requiring pre-market review and authorization of LDTs, and if that were to occur and if our EUA is either terminated or revoked, then in order to continue marketing our COVID-19 tests, we could be required to obtain the necessary regulatory clearances or approvals and be subject to the full and usual regulatory obligations. It continues to be unclear whether the Biden Administration, which assumed control of the executive branch on January 20, 2021, would take the same position as the former administration or seek to revoke or revise the HHS policy announcement from August 2020.

55

If the hazardous materials we use in our operations cause contamination or injury, we could be liable for resulting damages.

Our operations require the use of regulated medical waste, hazardous waste and biohazardous waste, including chemicals, biological agents and compounds and blood and other tissue specimens. We are subject on an ongoing basis to federal, state and local laws and regulations governing the use, storage, handling and disposal of these hazardous materials and other specified waste products. Although we typically use licensed or otherwise qualified outside vendors to dispose of this waste, applicable laws and regulations could hold us liable for damages and fines if our, or others’, business operations or other actions result in contamination to the environment or personal injury due to exposure to hazardous materials. We cannot eliminate the risk of contamination or injury, and any liability imposed on us for any resulting damages or injury could exceed our resources or any applicable insurance coverage. The cost to secure such insurance coverage and to comply with these laws and regulations could become more significant in the future, and any failure to comply could result in substantial costs and other business and reputational consequences, any of which could negatively affect our operating results.

If we were deemed to be an investment company under the Investment Company Act of 1940, as amended, applicable restrictions could make it impractical for us to continue our business as currently conducted and could have a material adverse effect on our business, financial condition and results of operations.

Under the Investment Company Act of 1940, or 1940 Act, a company generally will be deemed to be an “investment company” for purposes of the 1940 Act if (1) it is, or holds itself out as being, engaged primarily, or proposes to engage primarily, in the business of investing, reinvesting or trading in securities or (2) it engages, or proposes to engage, in the business of investing, reinvesting, owning, holding or trading in securities and it owns or proposes to acquire investment securities having a value exceeding 40% of the value of its total assets (exclusive of U.S. government securities and cash items) on an unconsolidated basis. We do not believe that we are an “investment company,” as such term is defined in either of those sections of the 1940 Act, and we intend to conduct our operations so that we will not be deemed an investment company. However, if we were to be deemed an investment company, restrictions imposed by the 1940 Act, including limitations on our capital structure and our ability to transact with affiliates, could make it impractical for us to continue our business as it is currently being conducted and could have a material adverse effect on our business, financial condition and results of operations.

Our partnerships and activities in China subject us to risks and uncertainties relating to the laws and regulations of China and the changes in relations between the United States and China.

Under its current leadership, the government of China has been pursuing economic reform policies, including by encouraging foreign trade and investment. However, there is no assurance that the Chinese government will continue to pursue such policies, that such policies will be successfully implemented, that such policies will not be significantly altered, or that such policies will be beneficial to our partnerships or activities in China. China’s system of laws can be unpredictable, especially with respect to foreign investment and foreign trade. The United States government has called for substantial changes to foreign trade policy with China and has raised, and has proposed to further raise in the future, tariffs on several Chinese goods. China has retaliated with increased tariffs on United States goods. Moreover, China’s legislature has recently adopted a national security law to substantially change the way Hong Kong has been governed since the territory was handed over by the United Kingdom to China in 1997. This law increases the power of the central government in Beijing over Hong Kong, limits the civil liberties of residents of Hong Kong and could restrict the ability of businesses in Hong Kong to continue to conduct business or to continue to with business as previously conducted. The U.S. State Department has indicated that the United States no longer considers Hong Kong to have significant autonomy from China. The U.S. State Department has recently enacted sanctions related to China’s governing of Hong Kong. Any further changes in United States trade policy could trigger retaliatory actions by affected countries, including China, resulting in trade wars. Any regulatory changes and changes in United States and China relations may have a material adverse effect on our partnerships or activities in China which could materially harm our business and financial condition.

We could be adversely affected by violations of the FCPA and other anti-bribery laws.

Our international operations are subject to various anti-bribery laws, including the FCPA and similar anti-bribery laws in the non-U.S. jurisdictions in which we operate. The FCPA prohibits companies and their intermediaries from offering, making, or authorizing improper payments to non-U.S. or foreign officials for the purpose of obtaining or retaining business or securing any other improper advantage. These laws are complex and far-reaching in nature, and we may be required in the future to alter one or more of our practices to be in compliance with these laws or any changes to these laws or their interpretation.

We currently engage in significant business outside the United States, and we plan to increase our international operations in the future. These operations could involve dealings with governments, foreign officials and state-owned entities, such as government hospitals, outside the United States. In addition, we may engage distributors, other commercial partners or third-party intermediaries,

56

such as representatives or contractors, or establish joint ventures or other arrangements to manage or assist with promotion and sale of our tests abroad and obtaining necessary permits, licenses and other regulatory approvals. Any such third parties could be deemed to be our agents and we could be held responsible for any corrupt or other illegal activities of our employees or these third parties, even if we do not explicitly authorize or have actual knowledge of such activities. We have instituted policies, procedures, and internal controls reasonably designed to promote compliance with the FCPA and other anti-corruption laws and we exercise a high degree of vigilance in maintaining, implementing and enforcing these policies and controls. However, these policies and controls could be circumvented or ignored and they cannot guarantee compliance with these laws and regulations. Any violations of these laws or allegations of such violations could disrupt our operations, involve significant management distraction, involve significant costs and expenses, including legal fees, and harm our reputation. Additionally, other U.S. companies in the medical device and pharmaceutical fields have faced substantial fines and criminal penalties in the recent past for violating the FCPA, and we could also incur these types of penalties, including criminal and civil penalties, disgorgement, and other remedial measures, if we violate the FCPA or other applicable anti-bribery laws. Any of these outcomes could result in a material adverse effect on our business, prospects, financial condition, or results of operations.

Our services present the potential for embezzlement, identity theft or other similar illegal behavior by our employees, consultants, service providers or commercial partners.

Our operations involve the use and disclosure of personal and business information that could be used to impersonate third parties or otherwise gain access to their data or funds. If any of our employees, consultants, service providers or commercial partners takes, converts or misuses these funds or data, we could be liable for any resulting damages, which could harm our financial condition and damage our business reputation.

We could be adversely affected by alleged violations of the FTC Act or other truth-in-advertising and consumer protection laws.

Our advertising for laboratory services and tests is subject to federal truth-in-advertising laws enforced by the FTC, as well as comparable state consumer protection laws. Under the FTC Act, the FTC is empowered, among other things, to (a) prevent unfair methods of competition and unfair or deceptive acts or practices in or affecting commerce; (b) seek monetary redress and other relief for conduct injurious to consumers; and (c) gather and compile information and conduct investigations relating to the organization, business, practices, and management of entities engaged in commerce. The FTC has very broad enforcement authority, and failure to abide by the substantive requirements of the FTC Act and other consumer protection laws can result in administrative or judicial penalties, including civil penalties, injunctions affecting the manner in which we would be able to market services or products in the future, or criminal prosecution. In conjunction with the launch of our Picture Genetics line of at-home genetic test offerings that are initiated by consumers, we plan to increase our advertising activities that would be subject to these federal and state truth-in-advertising laws. Any actual or perceived non-compliance with those laws could lead to an investigation by the FTC or a comparable state agency, or could lead to allegations of misleading advertising by private plaintiffs. Any such action against us would disrupt our business operations, cause damage to our reputation, and result in a material adverse effect on our business.

Intellectual Property Risks

We primarily rely on trade secret protection, non-disclosure agreements and invention assignment agreements to protect our proprietary information, which may not be effective.

We currently rely on trade secret protection, non-disclosure agreements and invention assignment agreements with our employees, consultants and third-parties to protect our confidential and proprietary information. Although our competitors have utilized and are expected to continue to utilize technologies and methods similar to ours and have aggregated and are expected to continue to aggregate libraries of genetic information similar to ours, we believe our success will depend in part on our ability to develop proprietary methods and libraries and to defend any advantages afforded to us by these methods and libraries relative to our competitors. If we do not protect our intellectual property and other confidential information adequately, competitors may be able to use our proprietary technologies and information and thereby erode any competitive advantages they provide us.

We will be able to protect our proprietary rights from unauthorized use by third parties only to the extent these rights are effectively maintained as confidential. We expect to rely primarily on trade secret and contractual protections for our confidential and proprietary information and we have taken security measures we believe are appropriate to protect this information. These measures, however, may not provide adequate protection for our trade secrets, know-how or other confidential information. We seek to protect our proprietary information by, among other things, entering into confidentiality agreements with employees, consultants and other third parties. These confidentiality agreements may not sufficiently safeguard our trade secrets and other confidential information and may not provide adequate remedies in the event of unauthorized use or disclosure of this information. Enforcing a claim that a party illegally disclosed or misappropriated a trade secret or other proprietary information could be difficult, expensive and time-consuming

57

and the outcome could be unpredictable. In addition, trade secrets or other confidential information could otherwise become known or be independently developed by others in a manner that could prevent legal recourse by us. If any of our trade secrets or other confidential or proprietary information were disclosed or misappropriated or if any such information was independently developed by a competitor, our competitive position could be harmed and our business could suffer.

Litigation or other proceedings or third-party claims of intellectual property infringement or misappropriation could require us to spend significant time and money and prevent us from selling our tests.

We believe our ability to succeed will depend in part on our avoidance of infringement of patents and other proprietary rights owned by third parties, including the intellectual property rights of competitors. There are numerous third-party-owned U.S. and foreign patents, pending patent applications and other intellectual property rights that cover technologies relevant to genetic testing. We may be unaware of patents or other intellectual property rights that a third-party might assert are infringed by our business, and there may be pending patent applications that, if issued, could be asserted against us. As a result, our existing or future operations may be alleged or found to infringe existing or future patents or other intellectual property rights of others. Moreover, as we continue to sell our existing tests and if we launch new tests and enter new markets, competitors may claim that our tests infringe or misappropriate their intellectual property rights as part of strategies designed to impede our existing operations or our entry into new markets.

If a patent infringement or misappropriation of intellectual property lawsuit was brought against us, we could be forced to discontinue or delay our development or sales of any tests or other activities that are the subject of the lawsuit while it is pending, even if it is not ultimately successful. In the event of a successful claim of infringement against us, we could be forced to pay substantial damages, including treble damages and attorneys’ fees if we were found to have willfully infringed patents; obtain one or more licenses, which may not be available on commercially reasonable terms when needed or at all; pay royalties, which may be substantial; or redesign any infringing tests or other activities, which may be impossible or require substantial time and expense. In addition, third parties making claims against us for infringement or misappropriation of their patents or other intellectual property rights could seek and obtain injunctive or other equitable relief, which, if granted, could prohibit us from performing some or all of our tests. Further, defense against these claims, regardless of their merit or success, could cause us to incur substantial expenses, be a substantial diversion to our management and other employee resources and significantly harm our reputation. Any of these outcomes could delay our introduction of new tests, significantly increase our costs or prevent us from conducting certain of our essential activities, which could materially adversely affect our ability to operate and grow our business.

Developments in patent law could have a negative impact on our business.

From time to time, the Supreme Court, other federal courts, the U.S. Congress or the U.S. Patent and Trademark Office, or USPTO, may change the standards of patentability, and any such changes could have a negative impact on our business.

Three cases involving diagnostic method claims and “gene patents” have been decided by the Supreme Court in recent years. In March 2012, the Supreme Court issued a decision in Mayo Collaborative v. Prometheus Laboratories, or Prometheus, a case involving patent claims directed to optimizing the amount of drug administered to a specific patient, holding that the applicable patents’ claims failed to incorporate sufficient inventive content above and beyond mere underlying natural correlations to allow the claimed processes to qualify as patent-eligible processes that apply natural laws. In June 2013, the Supreme Court decided Association for Molecular Pathology v. Myriad Genetics, or Myriad, a case challenging the validity of patent claims relating to the breast cancer susceptibility genes BRCA1 and BRCA2, holding that isolated genomic DNA that exists in nature, such as the DNA constituting the BRCA1 and BRCA2 genes, is not patentable subject matter, but that cDNA, which is an artificial construct created from RNA transcripts of genes, may be patent eligible. In June 2014, the Supreme Court decided Alice Corporation Pty. Ltd. v. CLS Bank International, or Alice, which affirmed the Prometheus and Myriad decisions and provided additional interpretation.

If we make efforts to seek patent protection for our technologies and tests, these efforts may be negatively impacted by the Prometheus, Myriad and Alice decisions, rulings in other cases or guidance or procedures issued by the USPTO. However, we cannot fully predict the impact of the Prometheus, Myriad and Alice decisions on the ability of genetic testing, biopharmaceutical or other companies to obtain or enforce patents relating to DNA, genes or genomic-related discoveries in the future, as the contours of when claims reciting laws of nature, natural phenomena or abstract ideas may meet patent eligibility requirements are not clear and may take years to develop via interpretation at the USPTO and in the courts. There are many previously issued patents claiming nucleic acids and diagnostic methods based on natural correlations that issued before these recent Supreme Court decisions and, although many of these patents may be invalid under the standards set forth in these decisions, they are presumed valid and enforceable until they are successfully challenged, and third parties holding these patents could allege that we infringe or request that we obtain a license under such patents. Whether based on patents issued before or after these Supreme Court decisions, we could be forced to defend against claims of patent infringement or obtain license rights, if available, under these patents. In particular, although the Supreme Court has held in Myriad that isolated genomic DNA is not patent-eligible subject matter, third parties could allege that our activities infringe other classes of gene-related patent claims. There are numerous risks associated with any patent infringement claim that may be

58

brought against us, as discussed above under “—Litigation or other proceedings or third-party claims of intellectual property infringement or misappropriation could require us to spend significant time and money and prevent us from selling our tests.”

In addition, the Leahy-Smith America Invents Act, or America Invents Act, which was signed into law in 2011, includes a number of significant changes to U.S. patent law. These changes include a transition from a “first-to-invent” system to a “first-to-file” system, changes to the way issued patents are challenged and changes to the way patent applications are disputed during the examination process. These changes may favor larger and more established companies that have greater resources to devote to patent application filing and prosecution. The USPTO has developed new regulations and procedures to govern the full implementation of the America Invents Act, but the impact of the America Invents Act on the cost of prosecuting any patent applications we may file, our ability to obtain patents based on our discoveries if we pursue them and our ability to enforce or defend any patents that may issue remains uncertain.

These and other substantive changes to U.S. patent law could affect our susceptibility to patent infringement claims and our ability to obtain any patents we may pursue and, if obtained, to enforce or defend them, any of which could have a material adverse effect on our business.

We may not be able to enforce our intellectual property rights outside the United States.

The laws of some foreign countries do not protect proprietary rights to the same extent as the laws of the United States, and many companies have encountered significant challenges in establishing and enforcing their proprietary rights outside the United States. These challenges can be caused by the absence of rules and methods for the establishment and enforcement of intellectual property rights in certain jurisdictions. In addition, the legal systems of some countries, particularly developing countries, do not favor the enforcement of certain intellectual property protection, especially relating to healthcare. These aspects of many foreign legal systems could make it difficult for us to prevent or stop the misappropriation of our intellectual property rights in these jurisdictions. Moreover, changes in the law and legal decisions by courts in foreign countries could affect our ability to obtain adequate protection for our technologies and enforce our intellectual property rights. As a result, our efforts to protect and enforce our intellectual property rights outside the United States may prove inadequate, in which case our ability to remain competitive and grow our business and revenue could be materially harmed.

Third parties may assert that our employees or consultants have wrongfully used or disclosed confidential information or misappropriated trade secrets.

We employ individuals who were previously employed at universities and biometric solution, genetic testing, diagnostic or other healthcare companies, including our competitors or potential competitors. Further, we may become subject to ownership disputes in the future arising from, for example, conflicting obligations of consultants or others who are involved in developing our and other parties’ technologies and intellectual property rights. Although we try to ensure that our employees and consultants do not use the proprietary information or know-how of others in their work for us, we may be subject to claims that we or our employees or consultants have inadvertently or otherwise used or disclosed intellectual property rights, including trade secrets or other proprietary information, of a former employer or other third-party. Litigation may be necessary to defend against these claims, should they arise. If we fail in defending against any such claims, we could be subject to monetary damages and the loss of valuable intellectual property rights or personnel. Even if we are successful in defending against any such claims, litigation could result in substantial costs, distract management and other employees and damage our reputation.

Common Stock Risks

An active, liquid trading market for our common stock may not be sustained, which could make it difficult for stockholders to sell their shares of our common stock.

An active trading market for our common stock may not be sustained. Further, Mr. Hsieh, our founder, Chief Executive Officer and Chairman of our board of directors, beneficially owns approximately 27% of our outstanding voting equity as of June 30, 2021. As a result, fewer shares are actively traded in the public market, which reduces the liquidity of our common stock. The lack of an active trading market could impair our stockholders’ ability to sell their shares at the desired time or at a price considered reasonable. Further, an inactive trading market may impair our ability to raise capital by selling shares of our common stock in the future, and may impair our ability to enter into strategic relationships or acquire companies or technologies using shares of our common stock as consideration.

Our common stock is listed on the Nasdaq Global Market, or Nasdaq, under the symbol “FLGT.” If we fail to satisfy the continued listing standards of Nasdaq, however, we could be de-listed, which would negatively impact the price and liquidity of our common stock.

59

The price of our common stock may be volatile and you could lose all or part of your investment.

The trading price of our common stock has experienced, and may continue to experience, wide fluctuations and significant volatility. This volatility may be exacerbated by the relatively small and illiquid market for our common stock. Other factors that may contribute to this volatility include, among others:

 

•

actual or anticipated fluctuations in our operating results;

 

•

competition from existing tests or new tests that may emerge, particularly if competitive factors in our industry, including prices for genetic or other testing, become more acute;

 

•

failures to meet or exceed financial estimates and projections of the investment community or guidance we have provided to the public;

 

•

issuance of new or updated research or reports by securities analysts or changed recommendations for our common stock;

 

•

announcements by us or our competitors of significant acquisitions, investments, strategic relationships, joint ventures, collaborations or capital commitments;

 

•

the timing and amount of our investments in our business and the market’s perception of these investments and their impact on our prospects;

 

•

actual or anticipated changes in laws or regulations applicable to our business or our tests;

 

•

additions or departures of key management or other personnel;

 

•

changes in coverage and reimbursement by current or potential payors;

 

•

inability to obtain additional funding as and when needed on reasonable terms;

 

•

disputes or other developments with respect to our or others’ intellectual property rights;

 

•

product liability claims or other litigation;

 

•

sales of our common stock by us or our stockholders;

 

•

general economic, political, industry and market conditions, including factors not directly related to our operating performance or the operating performance of our competitors, such as increased uncertainty in the U.S. regulatory environment for healthcare, trade and tax-related matters;

 

•

events that affect, or have the potential to affect, general economic conditions, including but not limited to political unrest, global trade wars, natural disasters, act of war, terrorism, or disease outbreaks (such as the global pandemic related to COVID-19);

 

•

and the other risk factors discussed in this report.

In addition, the stock market in general, and the market for the stock of companies in the life sciences and technology industries in particular, has experienced extreme price and volume fluctuations in recent years that have at times been unrelated or disproportionate to the operating performance of specific companies. These broad market and industry factors may negatively affect the market price of our common stock, regardless of our actual operating performance. In addition, in the past, following periods of volatility in the overall market and the market price of a particular company’s securities, securities class action litigation has often been instituted against such company. This type of litigation, if instituted against us, could result in substantial costs, a diversion of our management’s attention and resources and could damage our reputation.

Our principal stockholders and management own a significant percentage of our capital stock and are able to exert significant control over matters subject to stockholder approval.

Our executive officers, directors, beneficial owners of 5% or more of our outstanding voting equity and their respective affiliates collectively beneficially owns approximately 40% of our outstanding voting equity as of June 30, 2021, and of this, Mr. Hsieh, our founder, Chief Executive Officer and Chairman of our board of directors, by himself beneficially owns 27% of our outstanding voting equity as of June 30, 2021. As a result, these stockholders have the ability to control matters submitted to our stockholders for approval, including elections of directors, amendments to our organizational documents or approval of any merger, sale of assets or other major corporate transaction. This concentration of ownership may prevent or discourage unsolicited acquisition proposals or offers to acquire our common stock that some of our stockholders feel are in their best interests, as the interests of these stockholders may not coincide with the interests of our other stockholders and they may act in a manner that advances their best interests and not necessarily those of all of our stockholders. Further, this concentration of ownership could adversely affect the prevailing market price for our common stock.

Sales of a substantial number of shares of our common stock in the public market, or the perception that such sales could occur, could cause the price of our common stock to fall.

Sales of a substantial number of shares of our common stock in the public market could occur at any time. Any such sales, or the perception in the market that sales are pending or could occur, could reduce the market price of our common stock. All of the outstanding shares of our common stock are freely tradable without restriction in the public market, subject to certain volume and

60

manner of sale limitations applicable to shares held by our affiliates, as that term is defined in the Securities Act. In addition, subject to similar limitations and any other applicable legal and contractual limitations, all of the shares of our common stock subject to outstanding equity-based awards or reserved for issuance pursuant to such awards we may grant in the future are registered under the Securities Act or are otherwise eligible under applicable securities laws for free trading in the public market upon their issuance.

Future issuances of our common stock or rights to purchase our common stock, including pursuant to our equity incentive plan, could result in additional dilution to the percentage ownership of our stockholders and could cause the price of our common stock to fall.

To raise capital or for other strategic purposes, we may sell common stock, convertible securities or other equity securities in one or more transactions at prices and in a manner we determine from time to time. In addition, in November 2020 we entered into the November 2020 Equity Distribution Agreement, with Piper, Oppenheimer & Co. Inc., and BTIG LLC, as sales agents, pursuant to which we may, from time to time, sell through Piper as our sales agent shares of our common stock with an aggregate purchase price of up to $175.0 million. During the year ended December 31, 2020, we sold an aggregate of 2.0 million shares of our common stock pursuant to the November 2020 Equity Distribution Agreement at a weighted-average net selling price of $48.70 per share. During the three months ended June 30, 2021, the Company sold approximately 378,000 shares of its common stock pursuant to the November 2020 Equity Distribution Agreement at a weighted-average net selling price of $73.75. During the six months ended June 30, 2021, the Company sold approximately 961,000 shares of its common stock pursuant to the November 2020 Equity Distribution Agreement at a weighted-average net selling price of $60.56. We also may issue common stock or grant other equity awards for compensatory purposes under our equity incentive plan. If we issue common stock, convertible securities or other equity securities, including shares pursuant to the November 2020 Equity Distribution Agreement or equity awards under our equity incentive plan, our then-existing stockholders could be materially diluted by such issuances and, if we otherwise issue preferred stock, new investors could gain rights, preferences and privileges senior to the holders of our common stock, any of which could cause the price of our common stock to decline.

We do not intend to pay dividends on our common stock, so any returns will be limited to the value of our common stock.

We currently anticipate that we will retain any future earnings to finance the continued development, operation and expansion of our business. As a result, we do not anticipate declaring or paying any cash dividends or other distributions in the foreseeable future. Further, if we were to enter into a credit facility or issue debt securities or preferred stock in the future, we may become contractually restricted from paying dividends. If we do not pay dividends, our common stock may be less valuable because stockholders must rely on sales of their common stock after price appreciation, which may never occur, to realize any gains on their investment.

If securities or industry analysts do not publish research or reports about our business or if they issue an adverse or misleading opinion regarding our common stock, our stock price and trading volume could decline.

The trading market for our common stock is influenced by the research and reports that industry or securities analysts publish about us or our business. If one or more of these analysts ceases coverage of us or fails to publish reports on us regularly, we could lose visibility in the financial markets, which could cause the price and trading volume of our common stock to decline. Further, if any of these analysts issues an adverse or misleading opinion regarding us, our business model, our industry or our stock performance or if our operating results fail to meet analyst expectations, the price of our common stock could also decline.

Provisions in our charter documents and Delaware law could discourage, delay or prevent a change in control of our company or changes in our management and depress the market price of our common stock.

Our certificate of incorporation and bylaws contain provisions that could depress the market price of our common stock by acting to discourage, delay or prevent a change in control of our company or changes in our management that our stockholders may deem advantageous. These provisions, among other things:

 

•

authorize our board of directors to issue, without further action by our stockholders, up to 1.0 million shares of undesignated or “blank check” preferred stock;

 

•

prohibit stockholder action by written consent, thus requiring all stockholder actions to be taken at a duly noticed and held meeting of our stockholders;

 

•

specify that special meetings of our stockholders can be called only by our board of directors, the Chairman of our board of directors or our President, thereby eliminating the ability of our stockholders to call special meetings;

 

•

permit only our board of directors to establish the number of directors and fill vacancies on the board of directors, except as may be required by law;

 

•

permit our board of directors to amend our bylaws, subject to the power of our stockholders to repeal any such amendment;

 

•

do not permit cumulative voting by our stockholders on the election of directors; and

61

 

 

•

establish advance notice requirements for stockholders to propose nominees for election as directors or matters to be acted upon at annual meetings of stockholders.

In addition, we are subject to Section 203 of the Delaware General Corporation Law, or DGCL, which imposes certain restrictions on mergers, business combinations and other transactions between us and holders of 15% or more of our common stock. Section 203 may have the effect of discouraging, delaying or preventing a change in control of our company.

Holders of our common stock could be adversely affected if we issue preferred stock.

Pursuant to our certificate of incorporation, our board of directors is authorized to issue up to 1.0 million shares of preferred stock without any action by our stockholders. Our board of directors also has the power, without stockholder approval, to set the terms of any series of preferred stock that may be issued, among others, including voting rights, dividend rights and preferences over our common stock with respect to dividends or in the event of a dissolution, liquidation or winding up. If we issue preferred stock in the future that has preferences over our common stock with respect to payment of dividends or upon a liquidation, dissolution or winding up, or if we issue preferred stock that is convertible into our common stock at greater than a one-to-one ratio, the voting and other rights of the holders of our common stock and the market price of our common stock could be adversely affected.

Our certificate of incorporation designates the Court of Chancery of the State of Delaware as the sole and exclusive forum for certain types of actions and proceedings that may be initiated by our stockholders, which could limit our stockholders’ ability to obtain a judicial forum they consider favorable for disputes with us or our directors, officers or other employees.

Our certificate of incorporation and bylaws provide that, unless we consent in writing to the selection of an alternative forum, the Court of Chancery of the State of Delaware shall be the sole and exclusive forum for:

 

•

any derivative action brought on our behalf;

 

•

any direct action brought by a stockholder against us or any of our directors, officers or other employees, alleging a breach of a fiduciary duty;

 

•

any action brought by a stockholder against us or any of our directors, officers or other employees, alleging a violation of the DGCL, our certificate of incorporation or our bylaws; and

 

•

any action brought by a stockholder against us or any of our directors, officers or other employees, asserting a claim against us governed by the internal affairs doctrine.

We refer to the forgoing limitations as the Exclusive Forum Provisions. The Exclusive Forum Provisions do not apply to (i) actions in which the Court of Chancery in the State of Delaware concludes that an indispensable party is not subject to the jurisdiction of the Delaware courts, and (ii) actions in which a federal court has assumed exclusive jurisdiction of a proceeding.

Accordingly, the Exclusive Forum Provisions do not apply to actions brought to enforce a duty or liability created by the Exchange Act or the rules and regulations thereunder, or Exchange Act Claims. Further, the clause in our certificate of incorporation excepting “actions in which a federal court has assumed exclusive jurisdiction of a proceeding” from the Exclusive Forum Provisions is not intended to mean that a federal court must take any actual or affirmative action to assume jurisdiction over an Exchange Act Claim, as Section 27 of the Exchange Act creates exclusive federal jurisdiction over all Exchange Act Claims, regardless of whether a federal court takes any action. The Exclusive Forum Provisions also do not apply to federal and state suits brought to enforce any duty or liability created by the Securities Act or the rules and regulations thereunder, or Securities Act Claims. To the extent applicable or enforceable, the Exclusive Forum Provisions may limit a stockholder’s ability to bring a claim in a judicial forum it finds favorable for disputes with us or our directors, officers or other employees, which may discourage these lawsuits. Alternatively, for Securities Act Claims, Exchange Act Claims or claims for which a court were to find these Exclusive Forum Provisions inapplicable or unenforceable for one or more of the specified types of actions or proceedings, we may incur additional costs associated with resolving these matters in other jurisdictions, which could adversely affect our business, financial condition or results of operations.

62

Item 2. Unregistered Sales of Equity Securities and Use of Proceeds.

Use of Proceeds from Registered Securities

On October 4, 2016, we completed the IPO of our common stock, in which we issued and sold an aggregate of 4,830,000 shares of common stock (including 630,000 shares issued and sold on October 7, 2016 pursuant to the underwriters’ exercise in full of their option to purchase additional shares) at a public offering price of $9.00 per share. We received net proceeds from the IPO of approximately $36.0 million, after deducting underwriting discounts and commissions and offering expenses paid or payable by us of approximately $4.4 million. The shares issued and sold in the IPO were registered under the Securities Act on a registration statement on Form S-1 (File No. 333-213469), as amended, and the final prospectus dated September 28, 2016 included in such registration statement, or the Prospectus.

To date, we have used $28.8 million of the net proceeds from the IPO, of which, $4.5 million was used for contributions to our joint venture, FF Gene Biotech, in partial satisfaction of our contribution obligations under the cooperation agreement for the joint venture and $24.3 million was used to fund the Company’s operations. All other net proceeds from the IPO are invested in investment-grade and interest-bearing securities, such as money market accounts, certificates of deposit, commercial paper and guaranteed obligations of the U.S. government. There has been no material change in the planned use of proceeds from the IPO from that described in the Prospectus.

On August 30, 2019, we entered into the 2019 Equity Distribution Agreement with Piper as sales agent, which was amended on August 4, 2020. During the year ended December 31, 2019, we sold an aggregate of 104,000 shares of our common stock pursuant to the 2019 Equity Distribution Agreement at a weighted-average net selling price of $9.37 per share, which resulted in $979,000 of net proceeds to the Company. During the year ended December 31, 2020, we sold an aggregate of 1.1 million shares of our common stock pursuant to the 2019 Equity Distribution Agreement at a weighted-average net selling price of $38.50 per share, which resulted in $42.7 million of net proceeds to the Company. Shares sold under the Equity Distribution Agreement were offered and sold pursuant to our shelf registration statement on Form S-3 (File No. 333-233227) filed with the SEC on August 12, 2019 and declared effective on August 23, 2019, and prospectus supplements and accompanying base prospectus filed with the SEC on August 30, 2019, May 6, 2020 and August 5, 2020. There has been no material change in the planned use of proceeds as described in the prospectus supplements and accompanying base prospectus.

On November 13, 2019, we entered into a purchase agreement with Piper, as representative of the several underwriters, pursuant to which we sold 2,673,750 shares of our common stock at a price of $10.52 per share, with a public offering price of $11.25 per share. We received net proceeds of approximately $27.6 million, after deducting underwriting discounts and commissions and offering expenses paid or payable by us of approximately $2.4 million. The shares issued and sold in the underwritten offering were registered under the Securities Act and sold pursuant to our shelf registration statement on Form S-3 (File No. 333-233227), and a prospectus supplement and accompanying base prospectus filed with the SEC on November 13, 2019. There has been no material change in the planned use of proceeds as described in the prospectus supplement and accompanying base prospectus.

On September 25, 2020, we entered into an Equity Distribution Agreement, or the September 2020 Equity Distribution Agreement, with Piper as sales agent, pursuant to which we sold 2.8 million shares of our common stock pursuant to the September 2020 Equity Distribution Agreement at a weighted-average net selling price of $42.90 per share during the year ended December 31, 2020, which resulted in $122.1 million of net proceeds to the Company. Piper may receive a commission of up to 3% of the gross proceeds received by the Company for sales pursuant to the September 2020 Equity Distribution Agreement. Shares sold under the September 2020 Equity Distribution Agreement were offered and sold pursuant to our registration statement on Form S-3 (File No. 333-239964) filed with the SEC on July 21, 2020, as amended on August 5, 2020, and declared effective on August 12, 2020, and a prospectus supplement and accompanying base prospectus filed with the SEC on September 25, 2020. There has been no material change in the planned use of proceeds as described in the prospectus supplement and accompanying base prospectus.

63

On November 20, 2020, we entered into the November 2020 Equity Distribution Agreement, with Piper, Oppenheimer & Co. Inc., and BTIG LLC, as sales agents, pursuant to which we may offer and sell, from time to time through Piper, shares of our common stock having an aggregate offering price of up to $175.0 million. Piper may receive a commission of up to 3% of the gross proceeds received by the Company for sales pursuant to the November 2020 Equity Distribution Agreement. During the year ended December 31, 2020, we sold an aggregate of 2.0 million shares of our common stock pursuant to the November 2020 Equity Distribution Agreement at a weighted-average net selling price of $48.70 per share, which resulted in $99.1 million of net proceeds to the Company. During the six months ended June 30, 2021, we sold approximately 961,000 shares of our common stock pursuant to the November 2020 Equity Distribution Agreement at a weighted-average net selling price of $60.56, which resulted in $58.2 million of net proceeds to the Company. Shares sold under the November 2020 Equity Distribution Agreement were offered and sold pursuant to our registration statement on Form S-3 (File No. 333-239964) filed with the SEC on July 21, 2020, as amended on August 5, 2020, and declared effective on August 12, 2020, and a prospectus supplement and accompanying base prospectus filed with the SEC on November 20, 2020. There has been no material change in the planned use of proceeds as described in the prospectus supplement and accompanying base prospectus.

Item 6. Exhibits.

The information required by this Item 6 is set forth on the Exhibit Index that immediately precedes the signature page to this report and is incorporated herein by reference.

 

64

 

EXHIBIT INDEX

 

Exhibit

No.

Exhibit Title

Filed

with this

Form 10-Q

Incorporated by Reference

Form

 

Form No.

 

Date filed

 

 

 

 

 

 

 

 

  10.1§

Restructuring Agreement of Fujian Fujun Gene Biotech Co., Ltd.

X

 

 

 

 

 

 

 

 

 

 

 

 

 

  31.1

Certification of Principal Executive Officer pursuant to Rules 13a-14(a) and 15d-14(a) under the Securities Exchange Act of 1934, as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.

X

 

 

 

 

 

 

 

 

 

 

 

 

 

  31.2

Certification of Principal Financial Officer pursuant to Rules 13a-14(a) and 15d-14(a) under the Securities Exchange Act of 1934, as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.

X

 

 

 

 

 

 

 

 

 

 

 

 

 

  32.1*

Certification of Principal Executive Officer and Principal Financial Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.

X

 

 

 

 

 

 

 

 

 

 

 

 

 

101.INS

Inline XBRL Instance Document – the instance document does not appear in the Interactive Data File because XBRL tags are embedded within the Inline XBRL document.

X

 

 

 

 

 

 

 

 

 

 

 

 

 

101.SCH

Inline XBRL Taxonomy Extension Schema Document

X

 

 

 

 

 

 

 

 

 

 

 

 

 

101.CAL

Inline XBRL Taxonomy Extension Calculation Linkbase Document

X

 

 

 

 

 

 

 

 

 

 

 

 

 

101.DEF

Inline XBRL Taxonomy Extension Definition Linkbase Document

X

 

 

 

 

 

 

 

 

 

 

 

 

 

101.LAB

Inline XBRL Taxonomy Extension Label Linkbase Document

X

 

 

 

 

 

 

 

 

 

 

 

 

 

101.PRE

Inline XBRL Taxonomy Extension Presentation Linkbase Document

X

 

 

 

 

 

 

 

 

 

 

 

 

 

104

Cover Page Interactive Data File (embedded within the Inline XBRL document)

X

 

 

 

 

 

 

 

 

 

 

 

 

 

 

*

Furnished herewith.

^

Certain exhibits and schedules have been omitted pursuant to Item 601(a)(5) of Regulation S-K. The Company hereby undertakes to furnish supplementally a copy of any omitted exhibit or schedule upon request by the SEC.

§

Confidential treatment has been granted with respect to portions of this exhibit pursuant to Rule 24b-2 under the Exchange Act, and these confidential portions have been redacted from the version of this agreement that is incorporated by reference in this report. A complete copy of this exhibit, including the redacted portions, has been separately furnished to the SEC.

65

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

 

 

 

FULGENT GENETICS, INC.

 

 

 

 

Date: August 9, 2021

 

By:

/s/ Ming Hsieh

 

 

 

Ming Hsieh

 

 

 

President, Chief Executive Officer

(principal executive officer)

 

 

 

 

Date: August 9, 2021

 

By:

/s/ Paul Kim

 

 

 

Paul Kim

 

 

 

Chief Financial Officer

(principal financial and accounting officer)

 

 

 

66

 EX-10.1 2 flgt-ex101_40.htm EX-10.1 flgt-ex101_40.htm

Exhibit 10.1

 

Pursuant to Item 601(b)(10) of Regulation S-K, certain confidential portions of this exhibit have been omitted by means of marking such portions with asterisks as the identified confidential portions (i) are not material and (ii) would be competitively harmful if publicly disclosed.

 

Restructuring Agreement

of

Fujian Fujun Gene Biotech Co., Ltd

 

This Restructuring Agreement of Fujian Fujun Gene Biotech Co., Ltd (this “Agreement”) is made and entered into by and among the following parties on May 7, 2021 (the “Date of Signing”):

 

1.

Fujian Fujun Gene Biotech Co., Ltd, a limited liability company validly organized and legally existing under the laws of the People’s Republic of China (“China”, which, for the sole purpose of this Agreement, excludes Hong Kong, Macao and Taiwan) (“Fujian Fulgent”);

 

2.

Fulgent Investment Development Limited (Hong Kong), a limited liability company validly organized and legally existing under the laws of Hong Kong (“Fulgent”);

 

3.

Shenzhen Mingrui Consulting Co., Ltd, a limited liability company validly organized and legally existing under the Laws of China (“Shenzhen Mingrui”);

 

4.

Shenzhen Fujin Gene Technology Co., Ltd, a limited liability company validly organized and legally existing under the Laws of China (“Shenzhen Fujin”);

 

5.

Xilong Scientific Co., Ltd, a joint stock company validly organized and legally existing under the Laws of China (“Xilong Scientific”);

 

6.

Fuzhou Jinqiang Investment Partnership(Limited Partnership), a limited partnership validly organized and legally existing under the Laws of China (“Fuzhou Jinqiang”);

 

 

 

7.

Hanlin GAO, ID Card No.: ***, a natural person of Chinese nationality (together with “Fulgent”, “Shenzhen Mingrui” and “Shenzhen Fujin”, the “Fulgent Entities”);

 

8.

Shaoyi CHEN, ID Card No.: ***, a natural person of Chinese nationality.

 

Each of the said parties are hereinafter individually referred to as a “Party” and collectively as the “Parties”. For the purpose of this Agreement, “Laws of China” shall mean all laws, administrative regulations, rules, regulations, policy documents, regulations, decisions and policy documents of the local government or local government departments then in force of China.

 

WHEREAS:

 

1.

As of the Date of Signing, the registered capital of Fujian Fulgent is CNY 100 million and its shareholding structure is set forth in Annex 1 hereto.

 

2.

Shenzhen Fujin, Xilong Scientific and Fuzhou Jinqiang entered into a Cooperation Agreement on the Joint Investment to Establish Fujian Fujun Gene Biotech Co., Ltd. and the Supplementary Agreement to the Cooperation Agreement on the Joint Investment to Establish Fujian Fujun Gene Biotech Co., Ltd. on April 1st, 2016 (the “Cooperation Agreement”);

 

3

The Parties agree to restructure the shareholding structure of Fujian Fulgent and to construct a VIE structure in accordance with the terms and conditions of this Agreement (the “Restructuring”).

 

THEREFORE, the Parties hereto, based on the principle of equality and mutual benefit, enter into the following agreement with respect to the Restructuring.

 

 

2

 

 

Article 1          Restructuring Arrangement

The Parties agree to complete the Restructuring in accordance with the steps set out below in this Article:

 

1.1

Domestic shareholding structure adjustment

 

 

1.1.1

Equity Transfer by Existing Shareholders

 

 

(i)

Xilong Scientific agrees to transfer the registered capital of CNY 40,500,000 held by it in Fujian Fulgent (corresponding to 40.50% equity of Fujian Fulgent) to Shenzhen Fujin (“Xilong Equity Transfer”) at the price of CNY 1 (“Xilong Equity Transfer Price”). Fuzhou Jinqiang shall then agree to Xilong Equity Transfer and waive the right of first refusal. Xilong Scientific acknowledges that Shenzhen Fujin does not need to actually pay Xilong Equity Transfer Price, and Xilong Scientific shall issue a confirmation letter to Shenzhen Fujin for receipt of all Xilong Equity Transfer Price upon the execution of the equity transfer agreement on Xilong Equity Transfer. Shenzhen Fujin, Xilong Scientific and Fuzhou Jinqiang agree that, upon the completion of the Xilong Equity Transfer, they shall sign an articles of association of Fujian Fulgent, which shall include (but not be limited to) the following contents: (1) the board of directors of Fujian Fulgent shall consist of 3 directors, 2 of which shall be appointed by Shenzhen Fujin, 1 of which shall be the management of Fujian Fulgent nominated by Xilong Scientific, and the chairman shall be a director appointed by Shenzhen Fujin; (2) the chairman shall be the legal representative of the company.

 

 

(ii)

Fuzhou Jinqiang agrees to transfer its equity of 4.5% (corresponding to registered capital of CNY 4,500,000 in Fujian Fulgent) to Shenzhen Fujin (“Jinqiang Equity Transfer”, together with “Xilong Equity Transfer”, the “Equity Transfer of Existing Shareholders”) at the price of CNY 1 (“Jinqiang Equity Transfer Price”). Xilong Scientific shall then agree to Jinqiang Equity Transfer and waive the right of first refusal. Fuzhou Jinqiang

 

3

 

 

acknowledges Shenzhen Fujin does not need to actually pay the Jinqiang Equity Transfer Price, and Fuzhou Jinqiang shall issue a confirmation letter to Shenzhen Fujin for receipt of all Jinqiang Equity Transfer Price upon the execution of the equity transfer agreement on Jinqiang Equity Transfer.

 

 

(iii)

Xilong Scientific and Fuzhou Jinqiang shall respectively sign with Shenzhen Fujin the equity transfer agreement, the resolution of the board of shareholders, the articles of association (or amendment to the articles of association) of Fujian Fulgent and other necessary documents related to the Equity Transfer of Existing Shareholders. Fujian Fulgent shall be responsible for completing the industrial and commercial registration of changes related to the Equity Transfer of Existing Shareholders and bear the corresponding expenses. The Parties further agree that, the condition for completing the equity transfer by existing shareholders (including relevant industrial and commercial registration of change) is that they have executed the Cayman Shares Transfer Agreement (as defined in Article 1.2.2(i) hereof) and that, with respect to the Xilong Equity Transfer, the board of shareholders (or any other competent authority) of Xilong Scientific has duly approved the Xilong Equity Transfer.

 

 

(iv)

Upon the completion of the Equity Transfer of Existing Shareholders, the subscribed registered capital and shareholding ratio of each shareholder of Fujian Fulgent are as follows:

 

Shareholder

Registered Capital (CNY)

Shareholding Ratio

Shenzhen Fujin

75,000,000

75.00%

Xilong Scientific

10,500,000

10.5%

Fuzhou Jinqiang

14,500,000

14.5%

Total

100,000,000

100%

 

 

4

 

 

 

1.1.2

Employee Shareholding Platform

 

 

(i)

The Parties agree that, Hanlin GAO, as the general partner, and the entity designated by Fulgent, as the limited partners, will establish a limited partnership, which will serve as a shareholding platform for employee stock ownership incentive (the “Employee Shareholding Platform”).

 

 

(ii)

Shenzhen Fujin agrees to transfer the registered capital of CNY 10,500,000 held by it in Fujian Fulgent (corresponding to 10.50% of equity of Fujian Fulgent) to the Employee Shareholding Platform (“Fujin Equity Transfer”) at the price of CNY 1 (“Fujin Equity Transfer Price”). Xilong Scientific and Fuzhou Jinqiang shall then agree to Fujin Equity Transfer and waive the right of first refusal. Shenzhen Fujin acknowledges that the Employee Shareholding Platform does not need to actually pay Fujin Equity Transfer Price, and Shenzhen Fujin shall issue a confirmation letter to the Employee Shareholding Platform for receipt of all Fujin Equity Transfer Price upon the execution of the equity transfer agreement on Fujin Equity Transfer.

 

 

(iii)

Shenzhen Fujin, Xilong Scientific and Fuzhou Jinqiang shall cooperate in signing the resolution of the board of shareholders, the articles of association of Fujian Fulgent and other necessary documents related to the Fujin Equity Transfer. Fujian Fulgent shall be responsible for completing the industrial and commercial registration of changes related to the Fujin Equity Transfer and bear the corresponding expenses. The Parties further agree that, the condition for the commercial and industrial registration of change with respect to the Fujin Equity Transfer is that the Parties have executed the Cayman Shares Transfer Agreement (as defined in Article 1.2.2(i) hereof) and Fulgent VIE Agreements (as defined in Article 1.2.2 (iii)), and the Parties have executed relevant Equity Transfer Agreement relating to the equity transfer by existing shareholders.

 

 

5

 

 

 

(iv)

Upon the completion of Fujin Equity Transfer, the subscribed registered capital and shareholding ratio of each shareholder of Fujian Fulgent are as follows:

 

Shareholder

Registered Capital (CNY)

Shareholding Ratio

Shenzhen Fujin

64,500,000

64.50%

Xilong Scientific

10,500,000

10.50%

Fuzhou Jinqiang

14,500,000

14.50%

Employee Shareholding Platform

10,500,000

10.50%

Total

100,000,000

100%

 

 

1.1.3

Paid-in capital contribution and shareholder loan

 

 

(i)

Xilong Scientific, Shenzhen Fujin and Fuzhou Jinqiang acknowledge that, as of the Date of Signing, they have paid CNY 60,500,000, CNY 30,113,690 and CNY 0 to Fujian Fulgent respectively. Fujian Fulgent, Xilong Scientific, Shenzhen Fujin and Fuzhou Jinqiang agree that Xilong Scientific and Shenzhen Fujin shall no longer make the remaining payment (if any) to Fujian Fulgent and that Fujian Fulgent shall convert the corresponding amount of capital reserve into paid-in capital contributions of relevant shareholders.

 

 

(ii)

Xilong Scientific agrees to enter into a written loan agreement (“Loan Agreement”) with Fujian Fulgent and its subsidiaries, Fuzhou Furui Medical Laboratory Co., Ltd and Shanghai Fulgent Biotechnology Co., Ltd, agreeing that the loans of CNY 38,108,504.69 previously lent by Xilong Scientific to the related parties shall be repaid on December 31, 2022. The interest will be calculated from June 1, 2021 at a rate of 4.97% per annum (calculated on actual days if it is less than one year), and Shenzhen Fujin will provide a guarantee for the said loan.

 

6

 

 

1.2

Construction of VIE structure

 

Fulgent, Xilong Scientific and Fuzhou Jinqiang agree to construct the VIE structure for Fujian Fulgent as agreed in Article 1.2.

 

 

1.2.1

Establishment of entities

 

 

(i)

Xilong Scientific shall, as soon as possible after the signing of this Agreement, complete the filing and registration procedures with the competent department of development and reform, the ministry of commerce, and the administration of foreign exchange in the place where it is located (“ODI Filing”) with respect to Xilong Scientific and Fuzhou Jinqiang’s overseas investment.

 

 

7

 

 

 

(ii)

Fulgent shall be responsible for establishing a limited liability company in the Cayman Islands (the “Cayman Company”). The authorized share capital of the Cayman Company shall be USD 50,000, with a par price of USD 0.0001 per share, for a total of 500,000,000 authorized shares. The Cayman Company shall issue 69,000,000 ordinary shares to Fulgent (or its designated entity, as applicable). Xilong Scientific and Fuzhou Jinqiang acknowledge that, in order to avoid violation of relevant requirements of ODI Filing, Xilong Scientific and Fuzhou Jinqiang shall not hold any shares of the Cayman Company prior to the completion of ODI Filing. Upon completion of the ODI Filing, Fulgent shall cause the Cayman Company to issue 102,000,000 ordinary shares to Xilong Scientific and 29,000,000 ordinary shares to Fuzhou Jinqiang. After the issuance of the aforesaid shares, the Cayman Company’s equity structure shall be as follows:

 

Shareholder

Number of Shares

Type of Shares

Shareholding Ratio

Fulgent

69,000,000

Ordinary share

34.50%

Xilong Scientific

102,000,000

Ordinary share

51.00%

Fuzhou Jinqiang

29,000,000

Ordinary share

14.50%

Total

200,000,000

/

100%

 

 

 

(iii)

Fulgent, Xilong Scientific and Fuzhou Jinqiang agree that after the establishment of the Cayman Company, Cayman Company shall establish a limited liability company wholly owned by the Cayman Company in Hong Kong (the “Hong Kong Company”) and Hong Kong Company shall establish a wholly foreign-owned enterprise (the “WFOE”) in Shenzhen. The Parties agree that the Hong Kong Company shall have one director and the WFOE shall have an executive director, and the director of the Hong

 

8

 

 

Kong Company, the executive director and the legal representative of the WFOE shall be those persons designated by Fulgent.

 

 

1.2.2

Shares Transfer by the Cayman Company

 

 

(i)

Xilong Scientific, after acquiring the appropriate shares in Cayman Company in accordance with Article 1.2.1(ii) above, shall enter into an agreement for transfer of shares in Cayman Company (the “Cayman Shares Transfer Agreement”) with Fulgent (or its designated entity, as applicable) to transfer 81,000,000 ordinary shares in Cayman Company to Fulgent (or its designated entity, as applicable) (the “Cayman Shares Transfer”) at a price of CNY 122 million (or equivalent in USD) (the “Cayman Shares Transfer Price”). Upon execution of the Cayman Shares Transfer Agreement, Xilong Scientific shall cooperate with Fulgent and the Cayman Company to update the register of shareholders of the Cayman Company as soon as possible and register the aforesaid shares of the Cayman Company in the name of Fulgent (or its designated entity, as applicable). Upon the completion of the Cayman Shares Transfer, Cayman Company’s shareholding structure shall be as follows:

 

Shareholder

Number of Shares

Type of Shares

Shareholding Ratio

Fulgent

150,000,000

Ordinary share

75.00%

Xilong Scientific

21,000,000

Ordinary share

10.50%

Fuzhou Jinqiang

29,000,000

Ordinary share

14.50%

Total

200,000,000

/

100%

 

 

(ii)

Fulgent agrees that the Cayman Company shall repurchase at par 21,000,000 ordinary shares held by Fulgent in the Cayman Company upon the completion of the Cayman Shares Transfer (the “Cayman Shares Repurchase”), and reserve such 21,000,000 ordinary shares (the “Option Pool”) for the purpose of an employee stock ownership plan (“ESOP”) to be

 

9

 

 

established in the future. Upon the completion of the Cayman Shares Repurchase, the Cayman Company’s shareholding structure (at the fully diluted basis) shall be as follows:

 

Shareholder

Number of Shares

Type of Shares

Shareholding Ratio

Fulgent

129,000,000

Ordinary share

64.50%

Xilong Scientific

21,000,000

Ordinary share

10.50%

Fuzhou Jinqiang

29,000,000

Ordinary share

14.50%

Option Pool (reserved)

21,000,000

Ordinary share

10.50%

Total

200,000,000

/

100%

 

 

(iii)

The Cayman Shares Transfer Agreement shall stipulate that the conditions for Fulgent (or its designated entity, as applicable) to pay the Cayman Shares Transfer Price in full are at least the following (the “Conditions of Payment”): (1) all matters set forth in Article 1.1 hereof have been completed to the satisfaction of Fulgent, and the Parties concerned shall have paid to the relevant tax authorities all taxes and fees due to all matters set forth in Article 1.1 and Article 1.2 hereof in accordance with applicable laws; (2) Shenzhen Fujin, Xilong Scientific, Fuzhou Jinqiang, the Employee Shareholding Platform, Fujian Fulgent and WFOE have entered into the VIE control agreements in a form and content satisfactory to Fulgent (“Fulgent VIE Agreements”), and Shenzhen Fujin, Xilong Scientific, Fuzhou Jinqiang and the Employee Shareholding Platform have pledged all the equity held by them in Fujian Fulgent to WFOE in accordance with the Fulgent VIE Agreements and completed the registration of equity pledge; (3) the register of shareholders of the Cayman Company has been updated in accordance with Article 1.2.2 (i) and 1.2.2 (ii) hereof; (4) the Cayman Company has made an effective resolution to reserve the Cayman Company’s 21,000,000 ordinary shares as an Option Pool; (5) the articles of association of the Cayman Company have been amended to state that the board of directors of

 

10

 

 

Cayman Company shall consist of [3] directors, [2] of which shall be appointed by Fulgent (or its designated entity, as applicable) and [1] of which shall be the management of Fujian Fulgent nominated by Xilong Scientific; (6) the register of directors of the Cayman Company has recorded that the board of directors of the Cayman Company has been constituted in accordance with item (5) above; (7) the register of shareholders, articles of association, register of directors and relevant resolutions of the Cayman Company as mentioned in items (3) - (6) above have been filed with the registry of Cayman Company; (8) the Parties have executed the loan agreement to the satisfactory of Fulgent (9) there is no material breach of this Agreement by any Party hereto other than the Fulgent Entities (including but not limited to no Party’s breach of any undertaking under Article 1.4 hereof). Xilong Scientific shall cooperate with other relevant Parties to satisfy all the Conditions of Payment as soon as possible after the execution of the Cayman Shares Transfer Agreement. Fulgent (or its designated entity, as applicable) shall pay the Cayman Share Transfer Price to Xilong Scientific in a lump sum within 5 business days after the payment Conditions are fully met. If Fulgent (or its designated entity, as applicable) fails to make the payment in accordance with the said provisions, Shenzhen Fujin shall transfer the equity of Fujian Fulgent acquired in accordance with Article1.1.1 (i) hereof to Xilong Scientific free of charge.

 

 

(iv)

Shenzhen Fujin, Xilong Scientific and Fujian Fulgent shall, and each Party shall cause the Employee Shareholding Platform and WFOE to, sign the Fulgent VIE Agreements as soon as possible after the establishment of the WFOE. Shenzhen Fujin and Xilong Scientific shall, and Hanlin GAO shall cause the Employee Shareholding Platform to, as soon as possible complete the registration of equity pledge for pledge of all their equity of Fujian Fulgent to WFOE in accordance with the Fulgent VIE Agreements. The Parties further acknowledge that the conditions for Shenzhen Fujin to sign the Fulgent VIE Agreements and complete the registration of equity pledge

 

11

 

 

is that those specified in items (3) - (6) of Article 1.2.2 (iii) hereof have been completed.

 

 

(v)

Fulgent, Xilong Scientific and Fujian Jinqiang respectively acknowledge that their respective investments in Fujian Fulgent prior to the Restructuring shall not be invested abroad in the Cayman Company and then into the registered capital of the WFOE, the tax base loss arising from their future transfer of shares in Cayman Company due to which shall be borne by themselves.

 

1.3

ESOP

 

 

1.3.1

Fulgent, Shenzhen Fujin, Xilong Scientific and Fuzhou Jinqiang agree to establish ESOP by Fulgent upon completion of the VIE structure construction described in Article 1.2 hereof. Relevant incentive recipient shall actually contribute to the Employee Shareholding Platform and receive options of the Cayman Company in accordance with the specific requirements of ESOP. The first batch of options shall be exercised at the time of grant, upon confirmation of achievement of the performance indicators of 2021 at the end of 2021, upon confirmation of achievement of the performance indicators of 2022 at the end of 2022 and upon confirmation of achievement of the performance indicators of 2023 at the end of 2023, respectively. At such time, relevant persons shall pay to the Employee Shareholding Platform the exercise price in accordance with ESOP, which shall be calculated in accordance with the valuation of Fujian Fulgent at the time of execution of this Agreement in the amount of CNY 200 million. Fulgent shall decide on whom to distribute and how many to distribute in accordance with the ESOP. Fulgent and Hanlin GAO agree to cause the Employee Shareholding Platform to use all the capital contributions received from the partners for the actual capital contribution to Fujian Fulgent, and the part beyond the registered capital of Fujian Fulgent subscribed by the Employee Shareholding Platform to be included in Fujian Fulgent's capital reserve fund.

 

 

12

 

 

 

1.3.2

Xilong Scientific further agrees that the total voting rights of Fulgent (or its designated entity, as applicable) in the Cayman Company shall be increased by a certain amount in addition to the voting rights represented by the 129,000,000 ordinary shares of the Cayman Company that it actually holds. The number of such voting rights shall be equal to the number of voting rights of the ordinary shares (i.e., 21,000,000 ordinary shares) corresponding to Cayman Company’s reserved 10.5% Option Pool.

 

1.4

Commitment with respect to the Transitional Period

 

 

1.4.1

From the Date of Signing to the date of completion of the Restructuring (the “Transitional Period”), Fujian Fulgent shall, and Xilong Scientific and Fujian Fulgent shall cause all subsidiaries of Fujian Fulgent (which, together with Fujian Fulgent, as the “Group Companies”) to, carry on their business in the ordinary course of business, use their best efforts to maintain the integrity of business organization, maintain relations with third parties and retain existing managers and employees, and maintain the status quo (other than normal wear and tear) of all assets and property owned or used by the Group Companies.

 

 

1.4.2

During the Transitional Period and during normal working hours, Xilong Scientific and Fujian Fulgent shall provide to Fulgent and its representatives such information as they may reasonably request concerning the Group Companies, including but not limited to providing Fulgent’s appointed lawyers, accountants and other representatives with full access to all accounts, records, contracts, technical information, personnel information, management information and other documents of the Group Companies. Xilong Scientific and Fujian Fulgent agree that Fulgent shall have the right to conduct a prudent review of the Group Companies’ finances, assets and operations at any time during the Transitional Period. In addition, Xilong Scientific, Fuzhou Jinqiang or Fujian Fulgent shall immediately notify Fulgent in writing of any breach or threatened breach of this Agreement by Xilong Scientific, Fuzhou Jinqiang or Fujian Fulgent.

 

 

13

 

 

 

1.4.3

During the Transitional Period, Xilong Scientific and Fujian Fulgent shall promptly notify Fulgent in writing of the following matters and discuss with Fulgent the impact of such matters on the Group Companies to ensure that the Group Companies will operate stably in a reasonable manner:

 

 

(i)

any change in the share capital structure, financial position, assets, liabilities, business, prospects or operations of any Group Company which has or is likely to have any material adverse effect on such Group Company;

 

 

(ii)

signing by any Group Company of any agreement containing abnormal terms (including but not limited to long-term and harsh terms) or outside the normal course of business and any agreement or proposal or intention relating to the foregoing; and

 

 

(iii)

progress of approval/registration by government departments (as applicable).

 

 

1.4.4

From the Date of Signing to the date of completion of the Restructuring (the “Exclusive Period”), unless Fulgent agrees in writing in advance, Xilong Scientific, Fuzhou Jinqiang and Fujian Fulgent shall and shall cause their affiliates and advisors and their respective directors, executives and representatives (i) to work together with Fulgent and its affiliates on an exclusive basis in connection with the Restructuring; (ii) not to enter into any other transaction similar to the Restructuring or in conflict with the transaction contemplated by this Agreement (any such transaction is a “Third-party Transaction”); (iii) to immediately terminate any discussion or negotiation with any person with respect to a Third-party Transaction, and thereafter refrain from conducting or undertaking any discussion or negotiation with any person with respect to a Third-party Transaction, and refrain from providing any information to any person with respect to a Third-party Transaction; and (iv) not to encourage or do any other act to facilitate any inquiries or recommendations with respect to a possible Third-party Transaction. If Xilong Scientific, Fuzhou Jinqiang or Fujian Fulgent receives any inquiries from any other Party in connection with a possible Third-party Transaction, Fulgent shall be promptly notified.

 

14

 

 

 

1.4.5

Unless otherwise agreed by Fulgent in writing, Fujian Fulgent shall not, and Xilong Scientific and Fujian Fulgent shall cause the Group Companies not to, do any of the following during the Transitional Period (except for those related to the Restructuring):

 

 

(i)

to increase, decrease, distribute, issue, acquire, repay, transfer, pledge or redeem any registered capital or equity;

 

 

(ii)

to take any action that may result in dilution of Fulgent’s interest in the Cayman Company or Fujian Fulgent after the completion of the Restructuring by amending its articles of association or by reorganization, merger, sale of share capital, merger, disposal of assets or otherwise;

 

 

(iii)

to sell, lease, transfer, license or assign any assets, except in the ordinary course of business in a manner consistent with past operations;

 

 

(iv)

to assume or incur debts, liabilities, obligations or expenses in excess of CNY 200,000 (or its equivalent in another currency), other than those arising in the ordinary course of business;

 

 

(v)

to make any capital expenditure in excess of CNY 200,000 (or its equivalent in another currency), except for those made in the ordinary course of business;

 

 

(vi)

to create any security interest or encumbrance in any asset;

 

 

(vii)

to declare, pay and undertake the distribution of any dividend;

 

 

(viii)

to enter into any transaction with affiliates;

 

 

(ix)

to make or be a party to any acquisition;

 

 

15

 

 

 

(x)

to establish any subsidiary or acquire any equity or other interest in any other entity;

 

 

(xi)

except as expressly provided herein, to create or pass any employee equity incentive plan of the company, or grant or promise to grant options to employees;

 

 

(xii)

agree or undertake to do any of the said actions, including but not limited to the execution of term sheets, commitment letters and consent letters.

 

 

1.4.6

The Parties other than the Fulgent Entities undertake that, without prior written consent of Fulgent, they will not license or authorize (whether paid or free) to any third party Fulgent's trade secrets, know-how and patents obtained by them for any reason, or use such trade secrets, know-how and patents in any form of cooperation with any third party (whether paid or free) during the Transitional Period.

 

1.5

Taxes and fees

 

Each Party shall bear their respective taxes and fees incurred in connection with the Restructuring. Among them, Xilong Scientific shall, within 7 days upon receipt of the full amount of Cayman Share Transfer Price, declare and pay the taxes ("Taxes under Document No.7") to the competent tax authority, and provide the tax payment voucher to Fulgent within 3 business days after the relevant tax payment is settled. If Xilong Scientific fails to pay the Taxes under Document No.7 on schedule and in full and causes losses to the Fulgent entities, Xilong Scientific promises to compensate the relevant Fulgent entities for all losses. Notwithstanding the foregoing, if the transaction is not fully completed due to no fault of the Fulgent Entities, Xilong Scientific shall bear 50% of all taxes and fees incurred by Fulgent in connection with the transaction. Such taxes and fees include professional service fees incurred by Fulgent Entities and its advisers (including but not limited to legal counsel, financial adviser and other advisory bodies) in drafting this Agreement, other relevant agreements referred to herein and other documents related to the Restructuring, participation in negotiations, and establishment of the VIE structure.

 

16

 

 

Article 2          Representations and Warranties

 

2.1

Each Party hereby make the representations and warranties as follows:

 

 

2.1.1

in case it is a natural person, it has full capacity for civil conduct to sign and perform this Agreement and to assume legal obligations hereunder; in case it is an entity, it is an entity legally registered and validly existing under the laws of the place where it is registered.

 

2.1.2

in case it is a natural person, it has the right to enter into and perform this Agreement without any approval or authorization; in case it is an entity, it performs this Agreement within its power and scope of business, and it has obtained the necessary internal authorization and the consent and approval of any third party and government department, and does not violate any legal or contractual restrictions that are binding or have an impact on it.

 

2.1.3

This Agreement, once executed, shall constitute a legal and valid legal document binding upon it and enforceable against it.

 

Article 3          Effectiveness, Supplement, Modification, Amendment and Termination

 

3.1

The annexes hereto shall form an integral part of this Agreement and shall be supplementary to and have the same legal effect as the body text of this Agreement.

 

3.2

This Agreement shall come into force upon being signed by all Parties hereto.

 

3.3

This Agreement may be modified or altered upon consensus of the Parties hereto through consultation. Any modification or alternation shall be made in writing and shall become effective after being signed by all Parties hereto.

 

3.4

This Agreement may be terminated if the Parties hereto agree to do so in writing.

 

 

17

 

 

3.5

Effect of Termination

 

 

3.5.1

After the termination of this Agreement in accordance with Article 3.4, unless otherwise agreed by the Parties, the Parties hereto shall cooperate to restore to the state at the time of signing this Agreement or other state confirmed by the Parties through negotiation. Any tax and cost incurred in the process of restoring the status shall be borne by the Parties concerned.

 

 

3.5.2

Upon termination of this Agreement, all rights and obligations of the Parties hereunder shall come to an end. Any party shall not have any other claim against other party under or for the termination of this Agreement, except for the liability under Article 4 hereof.

 

Article 4          Liabilities for Breach

 

4.1

If any Party breaches the provisions hereof and fails to perform the Agreement in whole or in part, it shall be liable for breach of contract and indemnify the other Party for losses resulting therefrom (including legal costs and attorney's fees arising therefrom). In case of breach by more than one Party, each Party shall bear the corresponding liability based on the actual situation.

 

Article 5          Force Majeure

 

5.1

In the event of an earthquake, typhoon, flood, fire, military action, strike, riot, war, or other unforeseeable events of force majeure beyond the reasonable control of any Party hereto (each “Force Majeure Event”), which prevents the performance of this Agreement, such Party shall immediately notify the other Parties without delay and shall, within fifteen (15) days after such notice is given, provide detailed information and supporting documents of such event, explaining the reason for the failure or delay in performing all or part of its obligations hereunder. The Parties shall, through consultation, seek to find and implement a solution acceptable to all Parties.

 

 

18

 

 

5.2

In case of any Force Majeure Event, the Party affected shall not be liable for any damage, cost increase or loss suffered by any other Party as a result of failure or delay in performance of its obligations hereunder due to the Force Majeure Event, and such failure or delay in performance hereof shall not be deemed to be a breach of this Agreement. The Party claiming a Force Majeure Event shall take appropriate measures to reduce or eliminate the impact of the Force Majeure Event and attempt to resume performance of the obligations delayed or hindered by the Force Majeure Event as soon as possible.

 

5.3

If a Force Majeure Event or its effect prevents one or both Parties from performing all or part of their obligations hereunder for a period of more than one (1) month, the Parties not affected by the force majeure shall have the right to terminate this Agreement and release part of their obligations hereunder or delay the performance hereof.

 

Article 6Information Disclosure

 

6.1

The terms and rules relating to this Agreement and its annexes (including all terms and the existence of this Agreement and any related documents) are confidential information. Except as otherwise stipulated, the Parties hereto shall not disclose such confidential information to any third party, provided, however, that Xilong Scientific, as an listed company in the A-share market, may disclose relevant information about this Transaction.

 

6.2

Each Party shall keep confidential all proprietary or confidential data and information related to the Group Companies or their business, or belonging to other Parties, or disclosed by any Party at any time for the negotiation of this Agreement, or for establishing or operating the Group Company, or relevant contents of this Agreement (“Confidential Information”), and shall not disclose such information to any third party or person other than the Parties hereto, the Group Company, the professional consultants and the relevant government departments.

 

6.3

Each Party agrees and undertakes to procure its appointed directors not to use any Confidential Information for the purpose of exercising their functions as directors or for any purpose other than the purpose of carrying out the business of the Group Companies,

 

19

 

provided that such directors may use the same when they report to their appointing Parties, but such appointing Parties shall fulfill the confidentiality obligations hereunder.

 

6.4

Notwithstanding the foregoing, the Parties shall have the right to reveal the Restructuring to its own investors, partners, fund management companies, investment banks, accountants, legal counsel, potential investors in good faith, employees, lenders and business partners, provided that the individual or organization receiving the information has agreed to keep the information confidential.

 

6.5

The restrictions set forth in Article 6 shall not apply to information disclosed in the following circumstances:

 

 

(i)

any information required to be disclosed or used by the Laws or any regulatory authority of China;

 

 

(ii)

any information required to be disclosed or used in any judicial proceedings arising out of this Agreement or any other agreement entered into pursuant to this Agreement or reasonably disclosed to the tax authorities;

 

 

(iii)

any information disclosed to the professional counsel of each Party, provided that each Party shall require such professional consultant to comply with the provisions of Article 6 with respect to such Confidential Information as if it were a Party hereto;

 

 

(iv)

any information that has entered the public domain for any reason not attributable to the Parties hereto; and

 

 

(v)

any information disclosed or used by all other Parties with prior written approval.

 

If the Confidential Information is disclosed for any of the said reasons set forth in (i) or (ii), the Party disclosing the information shall discuss the disclosure and submission of the information with the other Parties at a reasonable time before the disclosure or submission of the information, and shall, as far as possible, make the receiving Party keep

 

20

 

the part of the information disclosed or submitted confidential if the other Parties requires the disclosure or submission of the information.

 

Article 7          Governing Law and Disputes Settlement

 

7.1

The execution, effectiveness, interpretation, performance and dispute resolution of this Agreement shall be governed by, and construed in accordance with, the Laws of China. However, in case any matter related to this Agreement are not provided for in the published Laws of China, general international business practices shall apply, mutatis mutandis, to the extent permitted by the Laws of China.

 

7.2

Any and all disputes arising out of or in connection with the performance of this Agreement shall be settled by the Parties through friendly negotiation. If any dispute cannot be settled through negotiation within fifteen (15) days after the occurrence of such dispute, any Party shall have the right to submit such dispute to the Shenzhen International Arbitration Court for arbitration in accordance with the arbitration rules of such court in effect at that time. The arbitration shall be conducted in accordance with the ordinary arbitration procedures. The language of arbitration shall be Chinese. The place of arbitration is Shenzhen. The arbitral award shall be final and binding upon both Parties.

 

7.3

During the settlement of the dispute, each Party shall continue to have its other rights hereunder and shall continue to perform its corresponding obligations under this Agreement.

 

Article 8          Supplementary Provisions

 

8.1

Headings used herein are for reference only and shall not affect the meaning or interpretation of any provision hereof.

 

8.2

Except as amended, supplemented or modified in writing after execution hereof, this Agreement and its annexes constitute the entire agreement between the Parties with respect to the Restructuring and supersede any prior agreements (including but not limited to the

 

21

 

Equity Transfer Agreement of Fujian Fujun Gene Biotech Co., Ltd signed by the Parties hereto on May 6, 2021, the “Prior Agreements”), term sheets, memoranda of understanding, representations or other obligations (whether written or oral, including any form of communication) between the Parties with respect to the Restructuring. In case of any inconsistency between such agreements (including but not limited to the Prior Agreements), term sheets, memoranda of understanding, representations or other obligations (whether written or oral, including any form of communication) and this Agreement, this Agreement shall prevail.

 

8.3

If any provision of this Agreement is invalid or unenforceable under any applicable Laws of China, such provision shall be deemed to be non-existent from the beginning without affecting the validity of the other provisions of this Agreement. The Parties hereto shall, to the extent permitted by law, negotiate and determine new terms to ensure that the intention of the original terms is fully realized.

 

8.4

This Agreement shall be binding upon the successors and assignees of each Party. The said successors and assignees shall have the rights and interests hereunder.

 

8.5

Except as otherwise provided herein, any Party’s failure or delay in exercising any right, power or privilege hereunder shall not constitute its waiver of such right, power or privilege, nor any single or partial exercise of such right, power or privilege shall preclude the exercise of any other right, power or privilege.

 

8.6

This Parties agree that, the Cooperation Agreement shall be terminated upon the Date of Signing of this Agreement.

 

8.7

This Agreement is made in eight copies, with each Party holding one of them which shall have the same legal effect. A photocopy or scanned copy of the signed page sent by the Parties by fax or e-mail shall be deemed to be a signed original and shall have the same legal effect as the original.

 

[End of the body text]

 

 

22

 

 

[No body text below. This is the signature page of the Restructuring Agreement of Fujian Fujun Gene Biotech Co., Ltd.]

 

 

Fujian Fujun Gene Biotech Co., Ltd. (seal)

 

 

 

/s/ Shaoqun Huang

Name: Shaoqun HUANG

Title: Legal Representative

 

 


 

Signature page of the Restructuring Agreement of Fujian Fulgent Biotechnology Co., Ltd.

 

 

[No body text below. This is the signature page of the Restructuring Agreement of Fujian Fujun Gene Biotech Co., Ltd.]

 

 

Fulgent Investment Development Limited (seal)

 

 

 

/s/ Ming Hsieh

Name: MING HSIEH

Title: Director

 


 

Signature page of the Restructuring Agreement of Fujian Fulgent Biotechnology Co., Ltd.

 

 

[No body text below. This is the signature page of the Restructuring Agreement of Fujian Fujun Gene Biotech Co., Ltd.]

 

 

 

Shenzhen Mingrui Consulting Co., Ltd. (seal)

 

 

 

/s/ Xiaoyong Yang

Name: Xiaoyong YANG

Title: Legal Representative

 

 


 

Signature page of the Restructuring Agreement of Fujian Fulgent Biotechnology Co., Ltd.

 

 

[No body text below. This is the signature page of the Restructuring Agreement of Fujian Fujun Gene Biotech Co., Ltd.]

 

 

 

Shenzhen Fujin Gene Technology Co., Ltd. (seal)

 

 

 

/s/ Hanlin Gao

Name: Hanlin GAO

Title: Legal Representative

 

 

 


 

Signature page of the Restructuring Agreement of Fujian Fulgent Biotechnology Co., Ltd.

 

 

[No body text below. This is the signature page of the Restructuring Agreement of Fujian Fujun Gene Biotech Co., Ltd.]

 

 

 

Xilong Scientific Co., Ltd. (seal)

 

 

 

/s/ Weipeng Huang

Name: Weipeng HUANG

Title: Legal Representative

 

 

 


 

Signature page of the Restructuring Agreement of Fujian Fulgent Biotechnology Co., Ltd.

 

 

[No body text below. This is the signature page of the Restructuring Agreement of Fujian Fujun Gene Biotech Co., Ltd.]

 

 

 

Fuzhou Jinqiang Investment Partnership (Limited Partnership) (seal)

 

 

 

/s/ Shaoyi Chen

Name: Shaoyi CHEN

Title: Executive Partner

 

 

 

 


 

Signature page of the Restructuring Agreement of Fujian Fulgent Biotechnology Co., Ltd.

 

 

[No body text below. This is the signature page of the Restructuring Agreement of Fujian Fujun Gene Biotech Co., Ltd.]

 

 

 

Hanlin GAO

 

 

 

/s/ Hanlin Gao

 

 

 

 

 

Signature page of the Restructuring Agreement of Fujian Fulgent Biotechnology Co., Ltd.

 

 

[No body text below. This is the signature page of the Restructuring Agreement of Fujian Fujun Gene Biotech Co., Ltd.]

 

 

 

Shaoyi CHEN

 

 

 

/s/ Shaoyi Chen

 

 

 

 


 

 

 

Annex 1          Shareholding Structure of Fujian Fulgent

 

Name

Subscribed Capital Contribution (CNY)

Paid-in Capital Contribution (CNY)

Shareholding Ratio

Shenzhen Fujin Gene Technology Co., Ltd.

30,000,000

30,113,690

30%

Xilong Scientific Co., Ltd.

51,000,000

60,500,000

51%

Fuzhou Jinqiang Investment Partnership(Limited Partnership)

19,000,000

0

19%

 

 

 

 EX-31.1 3 flgt-ex311_9.htm EX-31.1 flgt-ex311_9.htm

 

Exhibit 31.1

CERTIFICATION PURSUANT TO

RULES 13a-14(a) AND 15d-14(a) UNDER THE SECURITIES EXCHANGE ACT OF 1934,

AS ADOPTED PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002

I, Ming Hsieh, certify that:

1.

I have reviewed this Quarterly Report on Form 10-Q for the quarterly period ended June 30, 2021 of Fulgent Genetics, Inc.;

2.

Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

3.

Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

4.

The registrant’s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

 

(a)

Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiary, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

 

(b)

Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

 

(c)

Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

 

(d)

Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting

5.

The registrant’s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):

 

(a)

All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and

 

(b)

Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

 

Date: August 9, 2021

By:

/s/ Ming Hsieh

 

 

Ming Hsieh

 

 

President, Chief Executive Officer

 

 

(principal executive officer)

 

 

 EX-31.2 4 flgt-ex312_7.htm EX-31.2 flgt-ex312_7.htm

 

Exhibit 31.2

CERTIFICATION PURSUANT TO

RULES 13a-14(a) AND 15d-14(a) UNDER THE SECURITIES EXCHANGE ACT OF 1934,

AS ADOPTED PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002

I, Paul Kim, certify that:

1.

I have reviewed this Quarterly Report on Form 10-Q for the quarterly period ended June 30, 2021 of Fulgent Genetics, Inc.;

2.

Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

3.

Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

4.

The registrant’s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

 

(a)

Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiary, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

 

(b)

Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

 

(c)

Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

 

(d)

Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting

5.

The registrant’s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):

 

(a)

All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and

 

(b)

Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

 

Date: August 9, 2021

By:

/s/ Paul Kim

 

 

Paul Kim

 

 

Chief Financial Officer

 

 

(principal financial and accounting officer)

 

 

 EX-32.1 5 flgt-ex321_8.htm EX-32.1 flgt-ex321_8.htm

 

Exhibit 32.1

CERTIFICATION PURSUANT TO

18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO

SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

In connection with the Quarterly Report on Form 10-Q for the quarterly period ended June 30, 2021 of Fulgent Genetics, Inc. (the “Company”), as filed with the Securities and Exchange Commission on the date hereof (the “Report”), each of the undersigned hereby certifies in his capacity as the specified officer of the Company, pursuant to 18 U.S.C. § 1350, as adopted pursuant to § 906 of the Sarbanes-Oxley Act of 2002, that, to the best of his knowledge:

 

(1)

The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

 

(2)

The information contained in the Report fairly presents, in all material respects, the financial condition and result of operations of the Company.

 

Date: August 9, 2021

 

By:

/s/ Ming Hsieh

 

 

 

Ming Hsieh

 

 

 

President, Chief Executive Officer

 

 

 

(principal executive officer)

 

 

 

 

Date: August 9, 2021

 

By:

/s/ Paul Kim

 

 

 

Paul Kim

 

 

 

Chief Financial Officer

 

 

 

(principal financial and accounting officer)

 

This certification accompanies the Quarterly Report on Form 10-Q to which it relates and shall not be deemed filed with the Securities and Exchange Commission or incorporated by reference into any filing of the Company under the Securities Act of 1933, as amended, or the Securities Exchange Act of 1934, as amended (whether made before or after the date of the Form 10-Q), irrespective of any general incorporation language contained in such filing.

 

 

 EX-101.SCH 6 flgt-20210630.xsd XBRL TAXONOMY EXTENSION SCHEMA 00000 - Document - Template Link link:presentationLink link:calculationLink link:definitionLink 100000 - Document - Document and Entity Information link:calculationLink link:presentationLink link:definitionLink 100010 - Statement - Condensed Consolidated Balance Sheets link:calculationLink link:presentationLink link:definitionLink 100020 - Statement - Condensed Consolidated Balance Sheets (Parenthetical) link:calculationLink link:presentationLink link:definitionLink 100030 - Statement - Condensed Consolidated Statements of Operations (unaudited) link:calculationLink link:presentationLink link:definitionLink 100040 - Statement - Condensed Consolidated Statements of Comprehensive Income (Loss) (unaudited) link:calculationLink link:presentationLink link:definitionLink 100050 - Statement - Condensed Consolidated Statements of Stockholders' Equity (unaudited) link:calculationLink link:presentationLink link:definitionLink 100060 - Statement - Condensed Consolidated Statements of Stockholders' Equity (unaudited) (Parenthetical) link:calculationLink link:presentationLink link:definitionLink 100070 - Statement - Condensed Consolidated Statements of Cash Flows (unaudited) link:calculationLink link:presentationLink link:definitionLink 100080 - Disclosure - Overview and Basis of Presentation link:calculationLink link:presentationLink link:definitionLink 100090 - Disclosure - Summary of Significant Accounting Policies link:calculationLink link:presentationLink link:definitionLink 100100 - Disclosure - Marketable Securities link:calculationLink link:presentationLink link:definitionLink 100110 - Disclosure - Fair Value Measurements link:calculationLink link:presentationLink link:definitionLink 100120 - Disclosure - Fixed Assets link:calculationLink link:presentationLink link:definitionLink 100130 - Disclosure - Other Significant Balance Sheet Accounts link:calculationLink link:presentationLink link:definitionLink 100140 - Disclosure - Reporting Segment and Geographic Information link:calculationLink link:presentationLink link:definitionLink 100150 - Disclosure - Debt, Commitments and Contingencies link:calculationLink link:presentationLink link:definitionLink 100160 - Disclosure - Leases link:calculationLink link:presentationLink link:definitionLink 100170 - Disclosure - Equity-Based Compensation link:calculationLink link:presentationLink link:definitionLink 100180 - Disclosure - Provision for (Benefit from) Income Taxes link:calculationLink link:presentationLink link:definitionLink 100190 - Disclosure - Income per Share link:calculationLink link:presentationLink link:definitionLink 100200 - Disclosure - Related Parties link:calculationLink link:presentationLink link:definitionLink 100210 - Disclosure - Business Combination link:calculationLink link:presentationLink link:definitionLink 100220 - Disclosure - Equity Distribution Agreement link:calculationLink link:presentationLink link:definitionLink 100230 - Disclosure - Goodwill and Acquisition-Related Intangibles link:calculationLink link:presentationLink link:definitionLink 100240 - Disclosure - Subsequent Events link:calculationLink link:presentationLink link:definitionLink 100250 - Disclosure - Summary of Significant Accounting Policies (Policies) link:calculationLink link:presentationLink link:definitionLink 100260 - Disclosure - Summary of Significant Accounting Policies (Tables) link:calculationLink link:presentationLink link:definitionLink 100270 - Disclosure - Marketable Securities (Tables) link:calculationLink link:presentationLink link:definitionLink 100280 - Disclosure - Fair Value Measurements (Tables) link:calculationLink link:presentationLink link:definitionLink 100290 - Disclosure - Fixed Assets (Tables) link:calculationLink link:presentationLink link:definitionLink 100300 - Disclosure - Other Significant Balance Sheet Accounts (Tables) link:calculationLink link:presentationLink link:definitionLink 100310 - Disclosure - Reporting Segment and Geographic Information (Tables) link:calculationLink link:presentationLink link:definitionLink 100320 - Disclosure - Leases (Tables) link:calculationLink link:presentationLink link:definitionLink 100330 - Disclosure - Equity-Based Compensation (Tables) link:calculationLink link:presentationLink link:definitionLink 100340 - Disclosure - Income per Share (Tables) link:calculationLink link:presentationLink link:definitionLink 100350 - Disclosure - Business Combination (Tables) link:calculationLink link:presentationLink link:definitionLink 100360 - Disclosure - Goodwill and Acquisition-Related Intangibles (Tables) link:calculationLink link:presentationLink link:definitionLink 100370 - Disclosure - Summary of Significant Accounting Policies - Additional Information (Details) link:calculationLink link:presentationLink link:definitionLink 100380 - Disclosure - Summary of Significant Accounting Policies - Summary of Revenue from Contracts with Customers by Payor Type (Details) link:calculationLink link:presentationLink link:definitionLink 100390 - Disclosure - Marketable Securities - Summary of Marketable Securities (Details) link:calculationLink link:presentationLink link:definitionLink 100400 - Disclosure - Marketable Securities - Additional Information (Details) link:calculationLink link:presentationLink link:definitionLink 100410 - Disclosure - Fair Value Measurements - Information about Financial Assets Measured at Fair Value on Recurring Basis Based on Three-Tier Fair Value Hierarchy (Details) link:calculationLink link:presentationLink link:definitionLink 100420 - Disclosure - Fair Value Measurements - Additional Information (Details) link:calculationLink link:presentationLink link:definitionLink 100430 - Disclosure - Fixed Assets - Major Classes of Fixed Assets (Details) link:calculationLink link:presentationLink link:definitionLink 100440 - Disclosure - Fixed Assets - Additional Information (Details) link:calculationLink link:presentationLink link:definitionLink 100450 - Disclosure - Other Significant Balance Sheet Accounts - Schedule of Other Current Assets (Details) link:calculationLink link:presentationLink link:definitionLink 100460 - Disclosure - Other Significant Balance Sheet Accounts - Schedule of Other Current Liabilities (Details) link:calculationLink link:presentationLink link:definitionLink 100470 - Disclosure - Reporting Segment and Geographical Information - Additional Information (Details) link:calculationLink link:presentationLink link:definitionLink 100480 - Disclosure - Reporting Segment and Geographical Information - Summary of Revenue by Geographic Region (Details) link:calculationLink link:presentationLink link:definitionLink 100490 - Disclosure - Debt, Commitments and Contingencies - Additional Information (Details) link:calculationLink link:presentationLink link:definitionLink 100500 - Disclosure - Leases - Additional Information (Details) link:calculationLink link:presentationLink link:definitionLink 100510 - Disclosure - Leases - Schedule of Lease Right-of-Use Asset, Short-term Lease Liabilities, and Long-term Lease Liabilities (Details) link:calculationLink link:presentationLink link:definitionLink 100520 - Disclosure - Leases - Schedule of Operating Lease Expense (Details) link:calculationLink link:presentationLink link:definitionLink 100530 - Disclosure - Leases - Schedule of Supplemental Information Related to Leases (Details) link:calculationLink link:presentationLink link:definitionLink 100540 - Disclosure - Leases - Schedule of Maturity Analysis of Operating Lease Liabilities using Undiscounted Cash Flows on an Annual Basis (Details) link:calculationLink link:presentationLink link:definitionLink 100550 - Disclosure - Leases - Schedule of Maturity Analysis of Operating Lease Liabilities using Undiscounted Cash Flows on an Annual Basis (Details)2 link:calculationLink link:presentationLink link:definitionLink 100560 - Disclosure - Leases - Schedule of Lease Income (Details) link:calculationLink link:presentationLink link:definitionLink 100570 - Disclosure - Leases - Schedule of Future Fixed Lease Payments from Tenants for All Noncancelable Operating Leases (Details) link:calculationLink link:presentationLink link:definitionLink 100580 - Disclosure - Equity-Based Compensation - Summary of Equity-Based Compensation Expenses as Part of Cost of Revenue and Operating Expenses (Details) link:calculationLink link:presentationLink link:definitionLink 100590 - Disclosure - Provision for (Benefit from) Income Taxes - Additional Information (Details) link:calculationLink link:presentationLink link:definitionLink 100600 - Disclosure - Income per Share - Reconciliation of Basic and Diluted Income Per Share Computations (Details) link:calculationLink link:presentationLink link:definitionLink 100610 - Disclosure - Income per Share - Anti-dilutive Securities Excluded from Calculation of Diluted Income Per Share (Details) link:calculationLink link:presentationLink link:definitionLink 100620 - Disclosure - Related Parties - Additional Information (Details) link:calculationLink link:presentationLink link:definitionLink 100630 - Disclosure - Business Combination - Additional Information (Details) link:calculationLink link:presentationLink link:definitionLink 100640 - Disclosure - Business Combination - Summary of Consideration Paid and Amount of Assets Acquired and Liabilities Assumed (Details) link:calculationLink link:presentationLink link:definitionLink 100650 - Disclosure - Equity Distribution Agreement - Additional Information (Details) link:calculationLink link:presentationLink link:definitionLink 100660 - Disclosure - Goodwill and Acquisition-Related Intangibles - Summaries of Goodwill and Acquisitions-Related Intangibles Balances (Details) link:calculationLink link:presentationLink link:definitionLink 100670 - Disclosure - Goodwill and Acquisition-Related Intangibles - Additional Information (Details) link:calculationLink link:presentationLink link:definitionLink 100680 - Disclosure - Goodwill and Acquisition-Related Intangibles - Summary of Annual Amortization Expense For Acquisition-Related Intangibles (Details) link:calculationLink link:presentationLink link:definitionLink 100690 - Disclosure - Subsequent Events - Additional Information (Details) link:calculationLink link:presentationLink link:definitionLink EX-101.CAL 7 flgt-20210630_cal.xml XBRL TAXONOMY EXTENSION CALCULATION LINKBASE EX-101.DEF 8 flgt-20210630_def.xml XBRL TAXONOMY EXTENSION DEFINITION LINKBASE EX-101.LAB 9 flgt-20210630_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE Entity Central Index Key Available for sale debt trading securities accumulated gross unrealized gain before tax. Available for sale debt trading securities accumulated gross unrealized gain before tax. Available for sale securities and trading securities. Equity Securities Fv Ni Accumulated Gross Unrealized Gain Before Tax. Equity securities fv ni accumulated gross unrealized loss before tax. Available for sale securities debt, equity securities and trading securities unrealized gain before tax. Available for sale securities debt, equity securities and trading securities unrealized loss before tax. Available for sale securities debt equity securities and trading securities. Cover [Abstract] Document Type Document Type Amendment Flag Amendment Flag Document Period End Date Document Period End Date Document Fiscal Year Focus Document Fiscal Year Focus Document Fiscal Period Focus Document Fiscal Period Focus Trading Symbol Trading Symbol Entity Registrant Name Entity Registrant Name Entity Central Index Key Entity Current Reporting Status Entity Current Reporting Status Current Fiscal Year End Date Current Fiscal Year End Date Entity Filer Category Entity Filer Category Entity Small Business Entity Small Business Entity Emerging Growth Company Entity Emerging Growth Company Entity Ex Transition Period Entity Ex Transition Period Entity Shell Company Entity Shell Company Entity Common Stock, Shares Outstanding Entity Common Stock Shares Outstanding Entity File Number Entity File Number Entity Tax Identification Number Entity Tax Identification Number Entity Address, Address Line One Entity Address Address Line1 Entity Address, City or Town Entity Address City Or Town Entity Address, State or Province Entity Address State Or Province Entity Address, Postal Zip Code Entity Address Postal Zip Code City Area Code City Area Code Local Phone Number Local Phone Number Title of 12(b) Security Security12b Title Security Exchange Name Security Exchange Name Entity Interactive Data Current Entity Interactive Data Current Document Quarterly Report Document Quarterly Report Document Transition Report Document Transition Report Entity Incorporation, State or Country Code Entity Incorporation State Country Code Available for sale securities debt equity securities and trading securities current. Customer deposit. Investment margin liabilities current. Statement Of Financial Position [Abstract] Assets Assets [Abstract] Current assets Assets Current [Abstract] Cash and cash equivalents Cash And Cash Equivalents At Carrying Value Marketable securities Available For Sale Securities Debt Equity Securities And Trading Securities Current Trade accounts receivable, net of allowance for credit losses of $6,044 and $1,898 as of June 30, 2021 and December 31, 2020, respectively Accounts Receivable Net Current Other current assets Other Assets Current Total current assets Assets Current Marketable securities, long-term Available For Sale Securities Debt Securities Noncurrent Fixed assets, net Property Plant And Equipment Net Acquisition-related intangible assets, net Finite Lived Intangible Assets Net Goodwill Goodwill Other long-term assets Other Assets Noncurrent Total assets Assets Liabilities and Stockholders’ Equity Liabilities And Stockholders Equity [Abstract] Current liabilities Liabilities Current [Abstract] Accounts payable Accounts Payable Current Income tax payable Taxes Payable Current Contract liabilities Contract With Customer Liability Current Customer deposit Customer Deposit Investment margin loan Investment Margin Liabilities Current Other current liabilities Other Liabilities Current Total current liabilities Liabilities Current Notes payable Long Term Notes Payable Unrecognized tax benefits Unrecognized Tax Benefits Other long-term liabilities Other Liabilities Noncurrent Total liabilities Liabilities Commitments and contingencies (Note 8) Commitments And Contingencies Stockholders’ equity Stockholders Equity Including Portion Attributable To Noncontrolling Interest [Abstract] Common stock, $0.0001 par value per share, 50,000 shares authorized, 29,513 and 28,178 shares issued and outstanding at June 30, 2021 and December 31, 2020, respectively Common Stock Value Preferred stock, $0.0001 par value per share, 1,000 shares authorized, no shares issued or outstanding at June 30, 2021 and December 31, 2020 Preferred Stock Value Additional paid-in capital Additional Paid In Capital Common Stock Accumulated other comprehensive income (loss) Accumulated Other Comprehensive Income Loss Net Of Tax Retained earnings Retained Earnings Accumulated Deficit Total Fulgent stockholders' equity Stockholders Equity Noncontrolling interest Minority Interest Total stockholders’ equity Stockholders Equity Including Portion Attributable To Noncontrolling Interest Total liabilities and stockholders’ equity Liabilities And Stockholders Equity Allowance for credit losses Allowance For Doubtful Accounts Receivable Common stock, par value Common Stock Par Or Stated Value Per Share Common stock, shares authorized Common Stock Shares Authorized Common stock, shares issued Common Stock Shares Issued Common stock, shares outstanding Common Stock Shares Outstanding Preferred stock, par value Preferred Stock Par Or Stated Value Per Share Preferred stock, shares authorized Preferred Stock Shares Authorized Preferred stock, shares issued Preferred Stock Shares Issued Preferred stock, shares outstanding Preferred Stock Shares Outstanding Income before gain on equity method investment and equity loss in investee. Gain on equity method investment. Income Statement [Abstract] Revenue Revenue From Contract With Customer Excluding Assessed Tax Cost of revenue Cost Of Revenue Gross profit Gross Profit Operating expenses: Operating Expenses [Abstract] Research and development Research And Development Expense Selling and marketing Selling And Marketing Expense General and administrative General And Administrative Expense Total operating expenses Operating Expenses Operating income Operating Income Loss Interest and other income, net Interest And Other Income Income before income taxes, gain on equity method investment and equity loss in investee Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments Provision for (benefit from) income taxes Income Tax Expense Benefit Income before gain on equity method investment and equity loss in investee Income Before Gain On Equity Method Investment And Equity Loss In Investee Gain on equity method investment Gain On Equity Method Investment Equity loss in investee Income Loss From Equity Method Investments Net income from consolidated operations Profit Loss Net loss attributable to noncontrolling interests Net Income Loss Attributable To Noncontrolling Interest Net income attributable to Fulgent Net Income Loss Net income per common share attributable to Fulgent: Earnings Per Share Basic And Diluted [Abstract] Basic Income Loss From Continuing Operations Per Basic Share Diluted Income Loss From Continuing Operations Per Diluted Share Weighted-average common shares: Earnings Per Share Basic And Diluted Other Disclosures [Abstract] Basic Weighted Average Number Of Shares Outstanding Basic Diluted Weighted Average Number Of Diluted Shares Outstanding Statement Of Income And Comprehensive Income [Abstract] Net income from consolidated operations Other comprehensive income (loss): Other Comprehensive Income Loss Net Of Tax Period Increase Decrease [Abstract] Foreign currency translation gain (loss) Other Comprehensive Income Foreign Currency Transaction And Translation Gain Loss Arising During Period Net Of Tax Net unrealized gain (loss) on marketable securities, net of tax Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax Comprehensive income from consolidated operations Comprehensive Income Net Of Tax Including Portion Attributable To Noncontrolling Interest Foreign currency translation gain attributable to noncontrolling interest Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Noncontrolling Interest Comprehensive loss attributable to noncontrolling interest Comprehensive Income Net Of Tax Attributable To Noncontrolling Interest Comprehensive income attributable to Fulgent Comprehensive Income Net Of Tax Statement Of Stockholders Equity [Abstract] Statement [Table] Statement [Table] Equity Components Statement Equity Components [Axis] Equity Component Equity Component [Domain] Stockholders' Equity Common Stock [Member] Additional Paid-In Capital Additional Paid In Capital [Member] Accumulated Other Comprehensive Income (Loss) Accumulated Other Comprehensive Income [Member] Retained Earnings (Accumulated Deficit) Retained Earnings [Member] Fulgent Stockholders' Equity Parent [Member] Noncontrolling Interest Noncontrolling Interest [Member] Cumulative Effect, Period of Adoption Cumulative Effect Period Of Adoption [Axis] Cumulative Effect, Period of Adoption Cumulative Effect Period Of Adoption [Domain] Cumulative Effect, Period of Adoption, Adjustment Cumulative Effect Period Of Adoption Adjustment [Member] Statement [Line Items] Statement [Line Items] Beginning Balance Beginning Balance, Shares Equity-based compensation Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value Exercise of common stock options Stock Issued During Period Value Stock Options Exercised Exercise of common stock options, Shares Stock Issued During Period Shares Stock Options Exercised Restricted stock awards Stock Issued During Period Value Restricted Stock Award Net Of Forfeitures Restricted stock awards, Shares Stock Issued During Period Shares Restricted Stock Award Net Of Forfeitures Common stock withholding for employee tax obligations Adjustments Related To Tax Withholding For Share Based Compensation Common stock withholding for employee tax obligations, Shares Shares Paid For Tax Withholding For Share Based Compensation Repurchases of capital stock Stock Repurchased During Period Value Repurchases of capital stock, Shares Stock Repurchased During Period Shares Issuance of common stock Stock Issued During Period Value New Issues Issuance of common stock, Shares Stock Issued During Period Shares New Issues Noncontrolling interest assumed related to acquisitions Noncontrolling Interest Increase From Business Combination Other comprehensive gain (loss) Other Comprehensive Income Loss Net Of Tax Cumulative tax effect of accounting change Income Tax Effects Allocated Directly To Equity Cumulative Effect Of Change In Accounting Principle Net income (loss) Ending Balance Ending Balance, Shares Collaborative Arrangement and Arrangement Other than Collaborative Type Of Arrangement [Axis] Collaborative Arrangement and Arrangement Other than Collaborative Arrangements And Nonarrangement Transactions [Member] November two thousand twenty equity distribution agreement. November 2020 Equity Distribution Agreement November Two Thousand Twenty Equity Distribution Agreement [Member] Selling price per share Sale Of Stock Price Per Share Noncash lease expense. Unrecognized tax benefits operating activities. Holding income loss on equity securities. Increase (decrease) in customer deposit. Increase (decrease) in operating lease liabilities. Proceeds from maturity of marketable securities. Operating lease right-of-use assets reduced due to lease modification. Noncash or part noncash public offering costs included in accounts payable. Statement Of Cash Flows [Abstract] Cash flow from operating activities: Net Cash Provided By Used In Operating Activities [Abstract] Adjustments to reconcile net income to net cash provided (used in) by operating activities: Adjustments To Reconcile Net Income Loss To Cash Provided By Used In Operating Activities [Abstract] Equity-based compensation Share Based Compensation Depreciation and amortization Depreciation Depletion And Amortization Noncash lease expense Noncash Lease Expense Loss on disposal of fixed asset Gain Loss On Disposition Of Assets Amortization of premium of marketable securities Investment Income Amortization Of Premium Provision for credit losses Provision For Doubtful Accounts Deferred taxes Deferred Income Tax Expense Benefit Unrecognized tax benefits Unrecognized Tax Benefits Operating Activities Holding loss on equity securities Holding Income Loss On Equity Securities Equity loss in investee Gain on equity method investment Other Other Noncash Income Expense Changes in operating assets and liabilities: Increase Decrease In Operating Capital [Abstract] Trade accounts receivable Increase Decrease In Accounts Receivable Other current and long-term assets Increase Decrease In Other Operating Assets Accounts payable Increase Decrease In Accounts Payable Accrued liabilities and other liabilities Increase Decrease In Accrued Liabilities And Other Operating Liabilities Income tax payable Increase Decrease In Income Taxes Payable Net Of Income Taxes Receivable Contract liabilities Increase Decrease In Contract With Customer Liability Customer deposit Increase Decrease In Customer Deposit Operating lease liabilities Increase Decrease In Operating Lease Liabilities Net cash provided by (used in) operating activities Net Cash Provided By Used In Operating Activities Cash flow from investing activities: Net Cash Provided By Used In Investing Activities [Abstract] Purchases of fixed assets Payments To Acquire Property Plant And Equipment Proceeds from sale of fixed assets Proceeds From Sale Of Property Plant And Equipment Purchase of marketable securities Payments To Acquire Marketable Securities Proceeds from sale of marketable securities Proceeds From Sale Of Marketable Securities Maturities of marketable securities Proceeds From Sale And Maturity Of Marketable Securities Acquisition of businesses, net of cash acquired Payments To Acquire Businesses Net Of Cash Acquired Net cash used in investing activities Net Cash Provided By Used In Investing Activities Cash flow from financing activities: Net Cash Provided By Used In Financing Activities [Abstract] Proceeds from (payment for) public offerings of common stock, net of issuance costs Proceeds From Issuance Of Common Stock Proceeds from noncontrolling interest Proceeds From Minority Shareholders Proceeds from exercise of stock options Proceeds From Stock Options Exercised Common stock withholding for employee tax obligations Payments Related To Tax Withholding For Share Based Compensation Borrowing under margin account Proceeds From Issuance Of Debt Net cash provided by (used in) financing activities Net Cash Provided By Used In Financing Activities Effect of exchange rate changes on cash and cash equivalents Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Net increase (decrease) in cash and cash equivalents Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect Cash and cash equivalents at beginning of period Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Cash and cash equivalents at end of period Supplemental disclosures of cash flow information: Supplemental Cash Flow Information [Abstract] Income taxes paid Income Taxes Paid Supplemental disclosures of non-cash investing and financing activities: Noncash Investing And Financing Items [Abstract] Purchases of fixed assets in accounts payable Noncash Or Part Noncash Acquisition Fixed Assets Acquired1 Operating lease right-of-use assets obtained in exchange for lease liabilities Right Of Use Asset Obtained In Exchange For Operating Lease Liability Operating lease right-of-use assets reduced due to lease modification Operating Lease Right Of Use Assets Reduced Due To Lease Modification Public offerings costs included in accounts payable Noncash Or Part Noncash Public Offering Costs Included In Accounts Payable Organization Consolidation And Presentation Of Financial Statements [Abstract] Overview and Basis of Presentation Business Description And Basis Of Presentation [Text Block] Accounting Policies [Abstract] Summary of Significant Accounting Policies Significant Accounting Policies [Text Block] Investments Debt And Equity Securities [Abstract] Marketable Securities Investments In Debt And Equity Instruments Cash And Cash Equivalents Unrealized And Realized Gains Losses [Text Block] Fair Value Disclosures [Abstract] Fair Value Measurements Fair Value Measurement Inputs Disclosure [Text Block] Property Plant And Equipment [Abstract] Fixed Assets Property Plant And Equipment Disclosure [Text Block] Balance Sheet Related Disclosures [Abstract] Significant Balance Sheet Accounts Supplemental Balance Sheet Disclosures [Text Block] Segment Reporting [Abstract] Reporting Segment and Geographic Information Segment Reporting Disclosure [Text Block] Debt, commitments and contingencies disclosure. Debt, commitments and contingencies disclosure. Debt Commitments And Contingencies Disclosure [Abstract] Debt, Commitments and Contingencies Debt Commitments And Contingencies Disclosure [Text Block] Lessor and lessee. operating leases. Leases [Abstract] Leases Lessor And Lessee Operating Leases [Text Block] Disclosure Of Compensation Related Costs Sharebased Payments [Abstract] Equity-Based Compensation Disclosure Of Compensation Related Costs Share Based Payments [Text Block] Income Tax Disclosure [Abstract] Provision for (Benefit from) Income Taxes Income Tax Disclosure [Text Block] Earnings Per Share [Abstract] Income per Share Earnings Per Share [Text Block] Related Party Transactions [Abstract] Related Parties Related Party Transactions Disclosure [Text Block] Business Combinations [Abstract] Business Combination Business Combination Disclosure [Text Block] Equity distribution agreements disclosure. Equity [Abstract] Equity Distribution Agreement Equity Distribution Agreements Disclosure [Text Block] Goodwill And Intangible Assets Disclosure [Abstract] Goodwill and Acquisition-Related Intangibles Goodwill And Intangible Assets Disclosure [Text Block] Subsequent Events [Abstract] Subsequent Events Subsequent Events [Text Block] Use of Estimates Use Of Estimates Foreign Currency Translation and Foreign Currency Transactions Foreign Currency Transactions And Translations Policy [Text Block] Leases Lessee Leases Policy [Text Block] Concentration of Customers Concentration Risk Credit Risk Revenue from Contracts with Customers Revenue From Contract With Customer Policy [Text Block] Reagents and supplies. Reagents and Supplies Reagents And Supplies Policy [Text Block] Customer deposit. Customer Deposit Customer Deposit Policy [Text Block] Trade accounts receivable and allowance for credit losses. Trade Accounts Receivable And Allowance For Credit Losses Trade Accounts Receivable And Allowance For Credit Losses Policy [Text Block] Marketable Securities Marketable Securities Policy Business Combination Business Combinations Policy Goodwill Goodwill And Intangible Assets Goodwill Policy Recent Accounting and Recently Adopted Accounting Pronouncements New Accounting Pronouncements Policy Policy [Text Block] Accounting Standards Update Adjustments For New Accounting Pronouncements [Axis] Accounting Standards Update Type Of Adoption [Member] Accounting Standards Update 2014-09 Accounting Standards Update201409 [Member] Summary of Revenue from Contracts with Customers by Payor Type Disaggregation Of Revenue Table [Text Block] Schedule of available for sale debt securities and equity/trading securities reconciliation. Summary of Marketable Securities Schedule Of Available For Sale Debt Securities And Equity Trading Securities Reconciliation Table [Text Block] Information about Financial Assets Measured at Fair Value on Recurring Basis Based on Three-Tier Fair Value Hierarchy Fair Value Assets Measured On Recurring Basis [Text Block] Major Classes of Fixed Assets Property Plant And Equipment [Text Block] Schedule of Other Current Assets Schedule Of Other Current Assets Table [Text Block] Schedule of Other Current Liabilities Other Current Liabilities Table [Text Block] Summary of Revenue by Geographic Region Revenue From External Customers By Geographic Areas Table [Text Block] Schedule of lease right-of-use asset, short-term lease liabilities, and long-term lease liabilities. Schedule of Lease Right-of-Use Asset, Short-term Lease Liabilities, and Long-term Lease Liabilities Schedule Of Lease Right Of Use Asset Short Term Lease Liabilities And Long Term Lease Liabilities Table [Text Block] Schedule of Operating Lease Expense Lease Cost Table [Text Block] Schedule of supplemental information related to leases. Schedule of Supplemental Information Related to Leases Schedule Of Supplemental Information Related To Leases Table [Text Block] Schedule of Maturity Analysis of Operating Lease Liabilities using Undiscounted Cash Flows on an Annual Basis Lessee Operating Lease Liability Maturity Table [Text Block] Schedule of Lease Income Operating Lease Lease Income Table [Text Block] Schedule of Future Fixed Lease Payments from Tenants for All Noncancelable Operating Leases Lessor Operating Lease Payments To Be Received Maturity Table [Text Block] Summary of Equity-Based Compensation Schedule Of Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Text Block] Reconciliation of the Basic and Diluted Income Per Share Computations Schedule Of Earnings Per Share Basic And Diluted Table [Text Block] Anti-dilutive Securities Excluded from Calculation of Diluted Income Per Share Schedule Of Antidilutive Securities Excluded From Computation Of Earnings Per Share [Text Block] Schedule Of Business Acquisitions By Acquisition [Table] Schedule Of Business Acquisitions By Acquisition [Table] Business Acquisition Business Acquisition [Axis] Business Acquisition, Acquiree Business Acquisition Acquiree [Domain] FF Gene Biotech Member. FF Gene Biotech F F Gene Biotech [Member] Business Acquisition [Line Items] Business Acquisition [Line Items] Summary of Consideration Paid and Amount of Assets Acquired and Liabilities Assumed Schedule Of Business Acquisitions By Acquisition [Text Block] Summaries of Goodwill and Acquisitions-Related Intangibles Balances Schedule Of Intangible Assets And Goodwill Table [Text Block] Summary of Annual Amortization Expense For Acquisition-Related Intangibles Finite Lived Intangible Assets Amortization Expense Table [Text Block] Number of customers. Summary of Significant Accounting Policies [Line Items] Summary Of Significant Accounting Policies [Table] Summary Of Significant Accounting Policies [Table] Summary Of Significant Accounting Policies [Table] Concentration Risk Type Concentration Risk By Type [Axis] Concentration Risk Type Concentration Risk Type [Domain] Customer Concentration Risk Customer Concentration Risk [Member] Concentration Risk Benchmark Concentration Risk By Benchmark [Axis] Concentration Risk Benchmark Concentration Risk Benchmark [Domain] Revenue Sales Revenue Net [Member] Accounts Receivable Accounts Receivable [Member] Customer Major Customers [Axis] Customer Name Of Major Customer [Domain] Customer one. Customer One Customer One [Member] Customer two. Customer Two Customer Two [Member] Statistical Measurement Range [Axis] Statistical Measurement Range [Member] Minimum Minimum [Member] Maximum Maximum [Member] Balance Sheet Location Balance Sheet Location [Axis] Balance Sheet Location Balance Sheet Location [Domain] Other Current Assets Other Current Assets [Member] ASU 2016-13 Accounting Standards Update201613 [Member] Other Long-Term Assets Other Noncurrent Assets [Member] 2019-12 Accounting Standards Update201912 [Member] Summary Of Significant Accounting Policies [Line Items] Summary Of Significant Accounting Policies [Line Items] Number of customers Number Of Customers Concentration risk, percentage Concentration Risk Percentage1 Disaggregation Of Revenue [Table] Disaggregation Of Revenue [Table] Clinical institutional contracts. Clinical Institutional Contracts Clinical Institutional Contracts [Member] Clinical patients contracts. Clinical Patient Contracts Clinical Patient Contracts [Member] Clinical insurance contracts. Clinical Insurance Contracts Clinical Insurance Contracts [Member] Disaggregation Of Revenue [Line Items] Disaggregation Of Revenue [Line Items] Type of Revenue [Extensible List] Type Of Revenue Extensible List Revenue from contracts with customers by payor type Receivables from contract with customers Contract assets from contract with customers Contract With Customer Asset Net Contract liability Contract with customer liability, revenue recognized Contract With Customer Liability Revenue Recognized Practical expedient not to disclose amount of transaction price allocated to unsatisfied performance obligations Revenue Practical Expedient Remaining Performance Obligation Reagents and supplies current. Reagents and supplies Reagents And Supplies Current Provision for credit losses for accounts receivable Securities maturity period. Securities maturity period from date of purchase Securities Maturity Period Stockholders' equity Cumulative tax effect Accounting Standards Update [Extensible List] Accounting Standards Update Extensible List Accounting standards update, adopted Change In Accounting Principle Accounting Standards Update Adopted Accounting standards update, immaterial effect Change In Accounting Principle Accounting Standards Update Immaterial Effect Available for sale securities and trading securities cost. Available for sale securities debt, equity securities and trading securities amortized cost basis. Schedule Of Trading Securities And Other Trading Assets [Table] Schedule Of Trading Securities And Other Trading Assets [Table] Investment Secondary Categorization Investment Secondary Categorization [Axis] Investments by Secondary Categorization Investments By Secondary Categorization [Domain] Short-term marketable securites. Short-Term Marketable Securities Short Term Marketable Securites [Member] Marketable securities due after one year through five years. Marketable Securities due After 1 Year through 5 Years Marketable Securities Due After One Year Through Five Years [Member] Marketable securities due after five years through ten years. Marketable Securities due After 5 Year through 10 Years Marketable Securities Due After Five Years Through Ten Years [Member] Investment Type Investment Type [Axis] Investments Investment Type Categorization [Member] Bond Fund Bonds [Member] Exchange Traded Funds Exchange Traded Funds [Member] Money Market Accounts Money Market Funds [Member] Corporate Debt Securities Corporate Debt Securities [Member] Municipal Bonds Municipal Bonds [Member] Cash Equivalents Cash Equivalents [Member] Yankee debt securities. Yankee Debt Securities Yankee Debt Securities [Member] U.S. Government Agency Debt Securities U S Government Agencies Debt Securities [Member] Long-term marketable securities. Long-Term Marketable Securities Long Term Marketable Securities [Member] Schedule Of Trading Securities And Other Trading Assets [Line Items] Schedule Of Trading Securities And Other Trading Assets [Line Items] Marketable securities, Amortized Cost Basis Available For Sale Securities And Trading Securities Cost Marketable securities, Unrealized Gains Available For Sale Debt Trading Securities Accumulated Gross Unrealized Gain Before Tax Marketable securities, Unrealized Losses Available For Sale Debt Trading Securities Accumulated Gross Unrealized Loss Before Tax Marketable securities, Aggregate Fair Value Available For Sale Securities And Trading Securities Less: Cash equivalents Cash Equivalents At Carrying Value Cash and cash equivalents fair value disclosure Cash And Cash Equivalents Fair Value Disclosure Marketable securities, Amortized Cost Basis Equity Securities Fv Ni Cost Marketable securities, Unrealized Gains Equity Securities Fv Ni Accumulated Gross Unrealized Gain Before Tax Marketable securities, Unrealized Losses Equity Securities Fv Ni Accumulated Gross Unrealized Loss Before Tax Marketable securities, Aggregate Fair Value Equity Securities Fv Ni Marketable securities, Amortized Cost Basis Available For Sale Securities Debt Equity Securities And Trading Securities Amortized Cost Basis Marketable securities, Unrealized Gains Available For Sale Securities Debt Equity Securities And Trading Securities Unrealized Gain Before Tax Marketable securities, Unrealized Losses Available For Sale Securities Debt Equity Securities And Trading Securities Unrealized Loss Before Tax Marketable securities, Aggregate Fair Value Available For Sale Securities Debt Equity Securities And Trading Securities Available for sale debt securities and equity/trading securities gross unrealized loss. Cash equivalents and available for sale debt and securities. Schedule of available-for-sale and trading securities. Schedule of available-for-sale and trading securities. Schedule Of Available For Sale And Trading Securities [Table] Schedule Of Available For Sale And Trading Securities [Table] Credit Facility Credit Facility [Axis] Credit Facility Credit Facility [Domain] Margin account borrowing. Margin Account Borrowing Margin Account Borrowing [Member] Schedule Of Available For Sale And Trading Securities [Line Items] Schedule Of Available For Sale And Trading Securities [Line Items] Gross unrealized loss Available For Sale Debt Securities And Equity Trading Securities Gross Unrealized Loss Cash equivalent and available for sale debt securities Cash Equivalents And Available For Sale And Debt Securities Outstanding borrowing amount Credit losses Debt Securities Available For Sale Allowance For Credit Loss Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Table] Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Table] Measurement Frequency Fair Value By Measurement Frequency [Axis] Measurement Frequency Fair Value Measurement Frequency [Domain] Fair Value Measurements Recurring Fair Value Measurements Recurring [Member] Asset Class Fair Value By Asset Class [Axis] Asset Class Fair Value Assets Measured On Recurring Basis Unobservable Input Reconciliation By Asset Class [Domain] Fair Value Hierarchy and NAV Fair Value By Fair Value Hierarchy Level [Axis] Fair Value Hierarchy and NAV Fair Value Measurements Fair Value Hierarchy [Domain] Level 1 Fair Value Inputs Level1 [Member] Level 2 Fair Value Inputs Level2 [Member] Level 3 Fair Value Inputs Level3 [Member] Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items] Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items] Total equity trading securities Total marketable securities Available For Sale Securities Debt Securities Cash and cash equivalents fair value disclosure Total marketable securities and cash equivalents Assets Fair Value Disclosure Fair value assets, transfers between levels, amount. Fair value asset, investments measured using unobservable inputs Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Asset Value Fair value assets, transfers between levels, amount Fair Value Assets Transfers Between Levels Amount Schedule Of Property Plant And Equipment [Table] Schedule Of Property Plant And Equipment [Table] Long-Lived Tangible Asset Property Plant And Equipment By Type [Axis] Long-Lived Tangible Asset Property Plant And Equipment Type [Domain] Medical lab equipment. Medical Lab Equipment Medical Lab Equipment [Member] Building Building [Member] Computer Hardware Computer Equipment [Member] Aircraft. Aircraft Aircraft [Member] Furniture and Fixtures Furniture And Fixtures [Member] Computer Software Software Development [Member] General equipment. General Equipment General Equipment [Member] Automobile. Automobile Automobile [Member] Leasehold Improvements Leasehold Improvements [Member] Building Improvements Building Improvements [Member] Assets not yet placed in service. Assets Not Yet Placed in Service Assets Not Yet Placed In Service [Member] Land Improvements Land Improvements [Member] Land Land [Member] Minimum Property Plant And Equipment [Line Items] Property Plant And Equipment [Line Items] Fixed assets, gross Property Plant And Equipment Gross Less: Accumulated depreciation Accumulated Depreciation Depletion And Amortization Property Plant And Equipment Fixed assets, net Useful life in years Property Plant And Equipment Useful Life Useful life in years Property Plant And Equipment Estimated Useful Lives Depreciation expense on fixed assets Depreciation Marketable securities interest receivable current. Prepaid expenses Prepaid Expense Current Marketable securities interest receivable Marketable Securities Interest Receivable Current Other receivable Other Receivables Net Current Contract assets Contract With Customer Asset Net Current Prepaid income taxes Prepaid Taxes Total Payroll liabilities current. Sales tax payable and other current Payroll liabilities Payroll Liabilities Current Sales tax payable and other Sales Tax Payable And Other Current Operating lease liabilities Operating Lease Liability Current Due to related parties Due To Related Parties Current Total Number of reporting segments Number Of Reportable Segments Schedule Of Segment Reporting Information By Segment [Table] Schedule Of Segment Reporting Information By Segment [Table] Geographical Statement Geographical [Axis] Geographical Segment Geographical [Domain] United States UNITED STATES Foreign Non Us [Member] Segment Reporting Information [Line Items] Segment Reporting Information [Line Items] Debt security investment outstanding borrowing amount. Debt Instrument Interest Rate at Beginning of Period. Payments for closing of escrow, financed under margin loan. Debt instrument interest rate at end of period. Debt, commitments and contingencies. Debt, commitments and contingencies. Debt Commitments And Contingencies [Table] Debt Commitments And Contingencies [Table] Debt Instrument Debt Instrument [Axis] Debt Instrument, Name Debt Instrument Name [Domain] Xilong Scientific Member. Xilong Scientific Xilong Scientific [Member] Related Party Related Party Transactions By Related Party [Axis] Related Party Related Party [Domain] Recorded Unconditional Purchase Obligation by Category of Item Purchased Recorded Unconditional Purchase Obligation By Category Of Item Purchased [Axis] Unconditional Purchase Obligation, Category of Goods or Services Acquired Unconditional Purchase Obligation Category Of Goods Or Services Acquired [Domain] Reagents and other supplies. Reagents and Other Supplies Reagents And Other Supplies [Member] Medical lab furniture. Medical Lab Furniture Medical Lab Furniture [Member] Debt, Commitments and Contingencies [Line Items] Debt Commitments And Contingencies [Line Items] Debt security investment outstanding borrowing amount Debt Security Investment Outstanding Borrowing Amount Interest on loan withdrawn from margin account Debt Instrument Interest Rate At Beginning Of Period Payments for closing of escrow, financed under margin loan Payments For Closing Of Escrow Financed Under Margin Loan Interest rate Debt Instrument Interest Rate At End Of Period Interest expense Interest Expense Notes payable Notes Payable Debt instrument, interest rate terms Debt Instrument Description Debt instrument, interest rate Debt Instrument Interest Rate Effective Percentage Non-cancelable purchase obligations Purchase Obligation Non-cancelable purchase obligations, payable within twelve months Recorded Unconditional Purchase Obligation Due In Next Rolling Twelve Months Operating leases term of expiration. Lessee Lease Description [Table] Lessee Lease Description [Table] Houston, Texas TEXAS Lessee Lease Description [Line Items] Lessee Lease Description [Line Items] Operating leases term of expiration Operating Leases Term Of Expiration Operating leases, renewal term Lessee Operating Lease Renewal Term Lessee operating lease extended lease term expiration date. Lease, expiration month and year. Lessee operating lease extended lease term expiration date Lessee Operating Lease Extended Lease Term Expiration Date Area of lease Area Of Land Lease, expiration month and year Lease Expiration Month And Year Operating lease right-of-use asset Operating Lease Right Of Use Asset Operating lease, right-of-use asset, statement of financial position [Extensible List] Operating Lease Right Of Use Asset Statement Of Financial Position Extensible List Operating lease, liability, current, statement of financial position [Extensible List] Operating Lease Liability Current Statement Of Financial Position Extensible List Operating lease liabilities, long term Operating Lease Liability Noncurrent Operating lease, liability, noncurrent, statement of financial position [Extensible List] Operating Lease Liability Noncurrent Statement Of Financial Position Extensible List Operating lease cost Operating Lease Cost Short-term lease cost Short Term Lease Cost Total lease cost Lease Cost Weighted average remaining lease term - operating leases Operating Lease Weighted Average Remaining Lease Term1 Weighted average discount rate - operating leases Operating Lease Weighted Average Discount Rate Percent 2021 (remaining 6 months) Lessee Operating Lease Liability Payments Remainder Of Fiscal Year 2022 Lessee Operating Lease Liability Payments Due Next Twelve Months 2023 Lessee Operating Lease Liability Payments Due Year Two 2024 Lessee Operating Lease Liability Payments Due Year Three 2025 Lessee Operating Lease Liability Payments Due Year Four 2026 Lessee Operating Lease Liability Payments Due Year Five Thereafter Lessee Operating Lease Liability Payments Due After Year Five Total lease payments Lessee Operating Lease Liability Payments Due Less imputed interest Lessee Operating Lease Liability Undiscounted Excess Amount Total Operating Lease Liability Lessor, operating lease, remaining term of contract including renewal options. Remaining terms including renewal options Lessor Operating Lease Remaining Term Of Contract Including Renewal Options Lease income Operating Lease Lease Income Lease income Operating Lease Lease Income Lease Payments Variable lease income Operating Lease Variable Lease Income Total lease income 2021 (remaining 6 months) Lessor Operating Lease Payments To Be Received Remainder Of Fiscal Year 2022 Lessor Operating Lease Payments To Be Received Next Twelve Months 2023 Lessor Operating Lease Payments To Be Received Two Years 2024 Lessor Operating Lease Payments To Be Received Three Years Total Lessor Operating Lease Payments To Be Received Share Based Compensation [Abstract] Share based compensation allocation of recognized period costs. Share based compensation allocation of recognized period costs. Share Based Compensation Allocation Of Recognized Period Costs [Table] Share Based Compensation Allocation Of Recognized Period Costs [Table] Income Statement Location Income Statement Location [Axis] Income Statement Location Income Statement Location [Domain] Cost of Revenue Cost Of Sales [Member] Research and Development Research And Development Expense [Member] Selling and Marketing Selling And Marketing Expense [Member] General and Administrative General And Administrative Expense [Member] Share Based Compensation Allocation Of Recognized Period Costs [Line Items] Share Based Compensation Allocation Of Recognized Period Costs [Line Items] Equity-based compensation expense Allocated Share Based Compensation Expense Effective income tax rate Effective Income Tax Rate Continuing Operations Net income attributable to Fulgent Weighted-average common shares—outstanding, basic Weighted-average common shares—outstanding, diluted Net income per common share, basic Net income per common share, diluted Schedule Of Antidilutive Securities Excluded From Computation Of Earnings Per Share [Table] Schedule Of Antidilutive Securities Excluded From Computation Of Earnings Per Share [Table] Award Type Award Type [Axis] Award Type Share Based Compensation Arrangements By Share Based Payment Award Award Type And Plan Name [Domain] Options Employee Stock Option [Member] Restricted Stock Units Restricted Stock Units R S U [Member] Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items] Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items] Anti-dilutive securities excluded from calculation of diluted income per share Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount Schedule Of Related Party Transactions By Related Party [Table] Schedule Of Related Party Transactions By Related Party [Table] AHMC healthcare Inc. AHMC Healthcare Inc. A H M C Healthcare Inc [Member] Related Party Transaction Related Party Transaction [Axis] Related Party Transaction Related Party Transaction [Domain] Genetic sequencing service. Genetic Sequencing Services Genetic Sequencing Service [Member] Fulgent Pharma Limited Liability Company. Fulgent Pharma LLC Fulgent Pharma Limited Liability Company [Member] Research development service. Research Development Service Research Development Service [Member] Related Party Transaction [Line Items] Related Party Transaction [Line Items] Revenue from related parties Revenue From Related Parties Trade accounts receivable, net from related parties Accounts Receivable Related Parties Expenses to transport employees and supplies Related Party Transaction Expenses From Transactions With Related Party Related party costs Related Party Costs Investment, Name Schedule Of Equity Method Investment Equity Method Investee Name [Axis] Investment, Name Equity Method Investee Name [Domain] Legal Entity Legal Entity [Axis] Entity Entity [Domain] Measurement Input Type Measurement Input Type [Axis] Measurement Input Type Measurement Input Type [Domain] Discount for Lack of Marketability Measurement Input Discount For Lack Of Marketability [Member] Discount Measurement Input Discount Rate [Member] Measurement input discount owed to market participant acquisition premium. Discount Owed to Market Participant Acquisition Premium Measurement Input Discount Owed To Market Participant Acquisition Premium [Member] Ownership Ownership [Axis] Ownership Ownership [Domain] Finite-Lived Intangible Assets by Major Class Finite Lived Intangible Assets By Major Class [Axis] Finite-Lived Intangible Assets, Major Class Name Finite Lived Intangible Assets Major Class Name [Domain] Royalty-Free Technology Technology Based Intangible Assets [Member] Customer Relationships Customer Relationships [Member] Equity interest to be made in joint venture Equity Method Investment Ownership Percentage Business combination, recognized identifiable assets acquired and liabilities assumed, current assets, reagents and supplies. Business combination, recognized identifiable assets acquired and liabilities assumed, other tangible assets. Considerations Business Combination Consideration Transferred Including Equity Interest In Acquiree Held Prior To Combination [Abstract] Cash Payments To Acquire Businesses Gross Fair value of the Company’s 30% equity interest held before the business combination Business Combination Step Acquisition Equity Interest In Acquiree Fair Value1 Total Consideration and fair value of equity interest held before business combination Business Combination Consideration Transferred Including Equity Interest In Acquiree Held Prior To Combination1 Recognized amounts of identifiable assets acquired and liabilities assumed Business Combination Recognized Identifiable Assets Acquired Goodwill And Liabilities Assumed Less Noncontrolling Interest [Abstract] Financial assets Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Financial Assets Reagents and supplies Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Current Assets Reagents And Supplies Fixed assets Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Property Plant And Equipment Other tangible assets Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Other Tangible Assets Identifiable intangible assets Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Intangibles Other current liabilities Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Current Liabilities Other Notes payable Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Noncurrent Liabilities Long Term Debt Recognized amounts of identifiable assets acquired and liabilities assumed, net Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Net Noncontrolling interest Business Combination Acquisition Of Less Than100 Percent Noncontrolling Interest Fair Value Total Business Combination Recognized Identifiable Assets Acquired Goodwill And Liabilities Assumed Less Noncontrolling Interest Business Combination, Acquisition Related Costs Business Combination Acquisition Related Costs Increase in equity method investment ownership percentage. Business Combination,Fair value of noncontrolling interest Minority interest ownership percentage Minority Interest Ownership Percentage By Parent Percentage of effective investment Increase In Equity Method Investment Ownership Percentage Business combination, contingent consideration, liability, measurement input Business Combination Contingent Consideration Liability Measurement Input Purchase price for effective investment Business Combination Contingent Consideration Liability Percentage of preexisting equity interest Business Combination Step Acquisition Equity Interest In Acquiree Percentage Gain recognized on preexisting investment Business Combination Step Acquisition Equity Interest In Acquiree Remeasurement Gain Identified intangible assets assumed Estimated amortization life of identified intangible assets assumed Acquired Finite Lived Intangible Assets Weighted Average Useful Life Equity offering price. Percentage of commission to be paid from gross proceeds. Sale of stock, weighted average net selling price per share. Equity distribution agreements. Equity distribution agreements. Equity Distribution Agreements [Table] Equity Distribution Agreements [Table] Equity Distribution Agreements [Line Items] Equity Distribution Agreements [Line Items] Aggregate offering price Equity Offering Price Percentage of commission to be paid from gross proceeds Percentage Of Commission To Be Paid From Gross Proceeds Number of shares purchased Sale Of Stock Number Of Shares Issued In Transaction Sale of stock, weighted average net selling price per share Sale Of Stock Weighted Average Net Selling Price Per Share Goodwill and intangible assets. Goodwill and intangible assets. Goodwill And Intangible Assets [Table] Goodwill And Intangible Assets [Table] Royalty-free technology. Royalty-Free Technology Royalty Free Technology [Member] Goodwill And Intangible Assets [Line Items] Goodwill And Intangible Assets [Line Items] Acquisitions-related intangibles, gross Finite Lived Intangible Assets Gross Less: accumulated amortization Finite Lived Intangible Assets Accumulated Amortization Acquisitions-related intangibles, net Weighted-Average Amortization Period Intangibles Schedule Of Finite Lived Intangible Assets [Table] Schedule Of Finite Lived Intangible Assets [Table] Finite Lived Intangible Assets [Line Items] Finite Lived Intangible Assets [Line Items] 2021 (remaining 6 months) Finite Lived Intangible Assets Amortization Expense Remainder Of Fiscal Year 2022 Finite Lived Intangible Assets Amortization Expense Next Twelve Months 2023 Finite Lived Intangible Assets Amortization Expense Year Two 2024 Finite Lived Intangible Assets Amortization Expense Year Three 2025 Finite Lived Intangible Assets Amortization Expense Year Four 2026 Finite Lived Intangible Assets Amortization Expense Year Five Thereafter Finite Lived Intangible Assets Amortization Expense After Year Five Subsequent Event [Table] Subsequent Event [Table] Subsequent Event Type Subsequent Event Type [Axis] Subsequent Event Type Subsequent Event Type [Domain] Subsequent Events [Member] Subsequent Event [Member] Cytometry Specialists, Inc. Cytometry Specialists, Inc Cytometry Specialists Inc [Member] Subsequent Event [Line Items] Subsequent Event [Line Items] Investment Long Term Investments Potential future milestone payments. Acquisition of issued and outstanding common stock value Stock Issued During Period Value Acquisitions Potential future milestone payments Potential Future Milestone Payments EX-101.PRE 10 flgt-20210630_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE XML 11 flgt-10q_20210630_htm.xml IDEA: XBRL DOCUMENT 0001674930 2021-01-01 2021-06-30 0001674930 2021-08-01 0001674930 2021-06-30 0001674930 2020-12-31 0001674930 2021-04-01 2021-06-30 0001674930 2020-04-01 2020-06-30 0001674930 2020-01-01 2020-06-30 0001674930 us-gaap:CommonStockMember 2020-12-31 0001674930 us-gaap:AdditionalPaidInCapitalMember 2020-12-31 0001674930 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2020-12-31 0001674930 us-gaap:RetainedEarningsMember 2020-12-31 0001674930 us-gaap:ParentMember 2020-12-31 0001674930 us-gaap:AdditionalPaidInCapitalMember 2021-01-01 2021-03-31 0001674930 us-gaap:ParentMember 2021-01-01 2021-03-31 0001674930 2021-01-01 2021-03-31 0001674930 us-gaap:CommonStockMember 2021-01-01 2021-03-31 0001674930 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2021-01-01 2021-03-31 0001674930 srt:CumulativeEffectPeriodOfAdoptionAdjustmentMember us-gaap:RetainedEarningsMember 2020-12-31 0001674930 srt:CumulativeEffectPeriodOfAdoptionAdjustmentMember us-gaap:ParentMember 2020-12-31 0001674930 srt:CumulativeEffectPeriodOfAdoptionAdjustmentMember 2020-12-31 0001674930 us-gaap:RetainedEarningsMember 2021-01-01 2021-03-31 0001674930 us-gaap:CommonStockMember 2021-03-31 0001674930 us-gaap:AdditionalPaidInCapitalMember 2021-03-31 0001674930 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2021-03-31 0001674930 us-gaap:RetainedEarningsMember 2021-03-31 0001674930 us-gaap:ParentMember 2021-03-31 0001674930 2021-03-31 0001674930 us-gaap:AdditionalPaidInCapitalMember 2021-04-01 2021-06-30 0001674930 us-gaap:ParentMember 2021-04-01 2021-06-30 0001674930 us-gaap:CommonStockMember 2021-04-01 2021-06-30 0001674930 us-gaap:NoncontrollingInterestMember 2021-04-01 2021-06-30 0001674930 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2021-04-01 2021-06-30 0001674930 us-gaap:RetainedEarningsMember 2021-04-01 2021-06-30 0001674930 us-gaap:CommonStockMember 2021-06-30 0001674930 us-gaap:AdditionalPaidInCapitalMember 2021-06-30 0001674930 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2021-06-30 0001674930 us-gaap:RetainedEarningsMember 2021-06-30 0001674930 us-gaap:ParentMember 2021-06-30 0001674930 us-gaap:NoncontrollingInterestMember 2021-06-30 0001674930 flgt:NovemberTwoThousandTwentyEquityDistributionAgreementMember 2021-03-31 0001674930 flgt:NovemberTwoThousandTwentyEquityDistributionAgreementMember 2021-06-30 0001674930 us-gaap:CommonStockMember 2019-12-31 0001674930 us-gaap:AdditionalPaidInCapitalMember 2019-12-31 0001674930 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2019-12-31 0001674930 us-gaap:RetainedEarningsMember 2019-12-31 0001674930 2019-12-31 0001674930 us-gaap:AdditionalPaidInCapitalMember 2020-01-01 2020-03-31 0001674930 2020-01-01 2020-03-31 0001674930 us-gaap:CommonStockMember 2020-01-01 2020-03-31 0001674930 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2020-01-01 2020-03-31 0001674930 us-gaap:RetainedEarningsMember 2020-01-01 2020-03-31 0001674930 us-gaap:CommonStockMember 2020-03-31 0001674930 us-gaap:AdditionalPaidInCapitalMember 2020-03-31 0001674930 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2020-03-31 0001674930 us-gaap:RetainedEarningsMember 2020-03-31 0001674930 2020-03-31 0001674930 us-gaap:AdditionalPaidInCapitalMember 2020-04-01 2020-06-30 0001674930 us-gaap:CommonStockMember 2020-04-01 2020-06-30 0001674930 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2020-04-01 2020-06-30 0001674930 us-gaap:RetainedEarningsMember 2020-04-01 2020-06-30 0001674930 us-gaap:CommonStockMember 2020-06-30 0001674930 us-gaap:AdditionalPaidInCapitalMember 2020-06-30 0001674930 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2020-06-30 0001674930 us-gaap:RetainedEarningsMember 2020-06-30 0001674930 2020-06-30 0001674930 us-gaap:AccountingStandardsUpdate201409Member 2021-01-01 2021-06-30 0001674930 flgt:FFGeneBiotechMember 2021-01-01 2021-06-30 0001674930 us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember 2021-04-01 2021-06-30 0001674930 us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember 2021-01-01 2021-06-30 0001674930 flgt:CustomerOneMember us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember 2021-04-01 2021-06-30 0001674930 flgt:CustomerOneMember us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember 2021-01-01 2021-06-30 0001674930 flgt:CustomerTwoMember us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember 2021-04-01 2021-06-30 0001674930 flgt:CustomerTwoMember us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember 2021-01-01 2021-06-30 0001674930 us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember 2020-04-01 2020-06-30 0001674930 us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember 2020-01-01 2020-06-30 0001674930 flgt:CustomerOneMember us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember 2020-04-01 2020-06-30 0001674930 flgt:CustomerOneMember us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember 2020-01-01 2020-06-30 0001674930 us-gaap:AccountsReceivableMember us-gaap:CustomerConcentrationRiskMember 2020-01-01 2020-12-31 0001674930 us-gaap:AccountsReceivableMember us-gaap:CustomerConcentrationRiskMember 2021-01-01 2021-06-30 0001674930 srt:MinimumMember us-gaap:AccountsReceivableMember us-gaap:CustomerConcentrationRiskMember 2020-01-01 2020-12-31 0001674930 us-gaap:AccountingStandardsUpdate201409Member 2021-04-01 2021-06-30 0001674930 us-gaap:AccountingStandardsUpdate201409Member 2020-04-01 2020-06-30 0001674930 us-gaap:AccountingStandardsUpdate201409Member 2020-01-01 2020-06-30 0001674930 flgt:ClinicalInstitutionalContractsMember us-gaap:AccountingStandardsUpdate201409Member 2021-04-01 2021-06-30 0001674930 flgt:ClinicalInstitutionalContractsMember us-gaap:AccountingStandardsUpdate201409Member 2020-04-01 2020-06-30 0001674930 flgt:ClinicalInstitutionalContractsMember us-gaap:AccountingStandardsUpdate201409Member 2021-01-01 2021-06-30 0001674930 flgt:ClinicalInstitutionalContractsMember us-gaap:AccountingStandardsUpdate201409Member 2020-01-01 2020-06-30 0001674930 flgt:ClinicalInsuranceContractsMember us-gaap:AccountingStandardsUpdate201409Member 2021-04-01 2021-06-30 0001674930 flgt:ClinicalInsuranceContractsMember us-gaap:AccountingStandardsUpdate201409Member 2020-04-01 2020-06-30 0001674930 flgt:ClinicalInsuranceContractsMember us-gaap:AccountingStandardsUpdate201409Member 2021-01-01 2021-06-30 0001674930 flgt:ClinicalInsuranceContractsMember us-gaap:AccountingStandardsUpdate201409Member 2020-01-01 2020-06-30 0001674930 flgt:ClinicalPatientContractsMember us-gaap:AccountingStandardsUpdate201409Member 2021-04-01 2021-06-30 0001674930 flgt:ClinicalPatientContractsMember us-gaap:AccountingStandardsUpdate201409Member 2020-04-01 2020-06-30 0001674930 flgt:ClinicalPatientContractsMember us-gaap:AccountingStandardsUpdate201409Member 2021-01-01 2021-06-30 0001674930 flgt:ClinicalPatientContractsMember us-gaap:AccountingStandardsUpdate201409Member 2020-01-01 2020-06-30 0001674930 us-gaap:OtherCurrentAssetsMember 2021-06-30 0001674930 us-gaap:OtherCurrentAssetsMember 2020-12-31 0001674930 srt:CumulativeEffectPeriodOfAdoptionAdjustmentMember us-gaap:AccountingStandardsUpdate201613Member us-gaap:RetainedEarningsMember 2021-06-30 0001674930 srt:CumulativeEffectPeriodOfAdoptionAdjustmentMember us-gaap:AccountingStandardsUpdate201613Member us-gaap:OtherNoncurrentAssetsMember us-gaap:RetainedEarningsMember 2021-01-01 2021-06-30 0001674930 us-gaap:AccountingStandardsUpdate201912Member 2021-06-30 0001674930 flgt:ShortTermMarketableSecuritesMember us-gaap:CorporateDebtSecuritiesMember 2021-06-30 0001674930 flgt:ShortTermMarketableSecuritesMember us-gaap:MunicipalBondsMember 2021-06-30 0001674930 flgt:MarketableSecuritiesDueAfterOneYearThroughFiveYearsMember us-gaap:CorporateDebtSecuritiesMember 2021-06-30 0001674930 flgt:MarketableSecuritiesDueAfterOneYearThroughFiveYearsMember us-gaap:MunicipalBondsMember 2021-06-30 0001674930 flgt:MarketableSecuritiesDueAfterOneYearThroughFiveYearsMember flgt:YankeeDebtSecuritiesMember 2021-06-30 0001674930 flgt:MarketableSecuritiesDueAfterOneYearThroughFiveYearsMember us-gaap:USGovernmentAgenciesDebtSecuritiesMember 2021-06-30 0001674930 flgt:MarketableSecuritiesDueAfterFiveYearsThroughTenYearsMember us-gaap:MunicipalBondsMember 2021-06-30 0001674930 flgt:ShortTermMarketableSecuritesMember us-gaap:MoneyMarketFundsMember 2021-06-30 0001674930 flgt:ShortTermMarketableSecuritesMember us-gaap:BondsMember 2021-06-30 0001674930 flgt:ShortTermMarketableSecuritesMember us-gaap:ExchangeTradedFundsMember 2021-06-30 0001674930 flgt:ShortTermMarketableSecuritesMember 2021-06-30 0001674930 flgt:MarketableSecuritiesDueAfterOneYearThroughFiveYearsMember 2021-06-30 0001674930 flgt:MarketableSecuritiesDueAfterFiveYearsThroughTenYearsMember 2021-06-30 0001674930 flgt:ShortTermMarketableSecuritesMember us-gaap:CorporateDebtSecuritiesMember 2020-12-31 0001674930 flgt:MarketableSecuritiesDueAfterOneYearThroughFiveYearsMember us-gaap:CorporateDebtSecuritiesMember 2020-12-31 0001674930 flgt:MarketableSecuritiesDueAfterOneYearThroughFiveYearsMember us-gaap:USGovernmentAgenciesDebtSecuritiesMember 2020-12-31 0001674930 flgt:MarketableSecuritiesDueAfterOneYearThroughFiveYearsMember flgt:YankeeDebtSecuritiesMember 2020-12-31 0001674930 flgt:ShortTermMarketableSecuritesMember us-gaap:MoneyMarketFundsMember 2020-12-31 0001674930 flgt:ShortTermMarketableSecuritesMember us-gaap:BondsMember 2020-12-31 0001674930 flgt:ShortTermMarketableSecuritesMember us-gaap:ExchangeTradedFundsMember 2020-12-31 0001674930 flgt:ShortTermMarketableSecuritesMember 2020-12-31 0001674930 flgt:MarketableSecuritiesDueAfterOneYearThroughFiveYearsMember 2020-12-31 0001674930 2020-01-01 2020-12-31 0001674930 flgt:MarginAccountBorrowingMember 2021-06-30 0001674930 us-gaap:FairValueMeasurementsRecurringMember us-gaap:BondsMember 2021-06-30 0001674930 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:BondsMember 2021-06-30 0001674930 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:BondsMember 2021-06-30 0001674930 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:BondsMember 2021-06-30 0001674930 us-gaap:FairValueMeasurementsRecurringMember us-gaap:ExchangeTradedFundsMember 2021-06-30 0001674930 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:ExchangeTradedFundsMember 2021-06-30 0001674930 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:ExchangeTradedFundsMember 2021-06-30 0001674930 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:ExchangeTradedFundsMember 2021-06-30 0001674930 us-gaap:CorporateDebtSecuritiesMember us-gaap:FairValueMeasurementsRecurringMember 2021-06-30 0001674930 us-gaap:CorporateDebtSecuritiesMember us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2021-06-30 0001674930 us-gaap:CorporateDebtSecuritiesMember us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2021-06-30 0001674930 us-gaap:CorporateDebtSecuritiesMember us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember 2021-06-30 0001674930 us-gaap:MunicipalBondsMember us-gaap:FairValueMeasurementsRecurringMember 2021-06-30 0001674930 us-gaap:MunicipalBondsMember us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2021-06-30 0001674930 us-gaap:MunicipalBondsMember us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2021-06-30 0001674930 us-gaap:MunicipalBondsMember us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember 2021-06-30 0001674930 flgt:YankeeDebtSecuritiesMember us-gaap:FairValueMeasurementsRecurringMember 2021-06-30 0001674930 flgt:YankeeDebtSecuritiesMember us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2021-06-30 0001674930 flgt:YankeeDebtSecuritiesMember us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2021-06-30 0001674930 flgt:YankeeDebtSecuritiesMember us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember 2021-06-30 0001674930 us-gaap:USGovernmentAgenciesDebtSecuritiesMember us-gaap:FairValueMeasurementsRecurringMember 2021-06-30 0001674930 us-gaap:USGovernmentAgenciesDebtSecuritiesMember us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2021-06-30 0001674930 us-gaap:USGovernmentAgenciesDebtSecuritiesMember us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2021-06-30 0001674930 us-gaap:USGovernmentAgenciesDebtSecuritiesMember us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember 2021-06-30 0001674930 us-gaap:MoneyMarketFundsMember us-gaap:FairValueMeasurementsRecurringMember 2021-06-30 0001674930 us-gaap:MoneyMarketFundsMember us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2021-06-30 0001674930 us-gaap:MoneyMarketFundsMember us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2021-06-30 0001674930 us-gaap:MoneyMarketFundsMember us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember 2021-06-30 0001674930 us-gaap:FairValueMeasurementsRecurringMember 2021-06-30 0001674930 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2021-06-30 0001674930 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2021-06-30 0001674930 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember 2021-06-30 0001674930 us-gaap:FairValueMeasurementsRecurringMember us-gaap:BondsMember 2020-12-31 0001674930 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:BondsMember 2020-12-31 0001674930 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:BondsMember 2020-12-31 0001674930 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:BondsMember 2020-12-31 0001674930 us-gaap:FairValueMeasurementsRecurringMember us-gaap:ExchangeTradedFundsMember 2020-12-31 0001674930 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:ExchangeTradedFundsMember 2020-12-31 0001674930 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:ExchangeTradedFundsMember 2020-12-31 0001674930 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:ExchangeTradedFundsMember 2020-12-31 0001674930 us-gaap:CorporateDebtSecuritiesMember us-gaap:FairValueMeasurementsRecurringMember 2020-12-31 0001674930 us-gaap:CorporateDebtSecuritiesMember us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2020-12-31 0001674930 us-gaap:CorporateDebtSecuritiesMember us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2020-12-31 0001674930 us-gaap:CorporateDebtSecuritiesMember us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember 2020-12-31 0001674930 us-gaap:USGovernmentAgenciesDebtSecuritiesMember us-gaap:FairValueMeasurementsRecurringMember 2020-12-31 0001674930 us-gaap:USGovernmentAgenciesDebtSecuritiesMember us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2020-12-31 0001674930 us-gaap:USGovernmentAgenciesDebtSecuritiesMember us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2020-12-31 0001674930 us-gaap:USGovernmentAgenciesDebtSecuritiesMember us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember 2020-12-31 0001674930 flgt:YankeeDebtSecuritiesMember us-gaap:FairValueMeasurementsRecurringMember 2020-12-31 0001674930 flgt:YankeeDebtSecuritiesMember us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2020-12-31 0001674930 flgt:YankeeDebtSecuritiesMember us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2020-12-31 0001674930 flgt:YankeeDebtSecuritiesMember us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember 2020-12-31 0001674930 us-gaap:MoneyMarketFundsMember us-gaap:FairValueMeasurementsRecurringMember 2020-12-31 0001674930 us-gaap:MoneyMarketFundsMember us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2020-12-31 0001674930 us-gaap:MoneyMarketFundsMember us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2020-12-31 0001674930 us-gaap:MoneyMarketFundsMember us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember 2020-12-31 0001674930 us-gaap:FairValueMeasurementsRecurringMember 2020-12-31 0001674930 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2020-12-31 0001674930 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2020-12-31 0001674930 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember 2020-12-31 0001674930 flgt:MedicalLabEquipmentMember 2021-06-30 0001674930 flgt:MedicalLabEquipmentMember 2020-12-31 0001674930 us-gaap:BuildingMember 2021-06-30 0001674930 us-gaap:BuildingMember 2020-12-31 0001674930 flgt:AircraftMember 2021-06-30 0001674930 flgt:AircraftMember 2020-12-31 0001674930 us-gaap:ComputerEquipmentMember 2021-06-30 0001674930 us-gaap:ComputerEquipmentMember 2020-12-31 0001674930 us-gaap:LeaseholdImprovementsMember 2021-06-30 0001674930 us-gaap:LeaseholdImprovementsMember 2020-12-31 0001674930 us-gaap:FurnitureAndFixturesMember 2021-06-30 0001674930 us-gaap:FurnitureAndFixturesMember 2020-12-31 0001674930 flgt:AutomobileMember 2021-06-30 0001674930 flgt:AutomobileMember 2020-12-31 0001674930 us-gaap:BuildingImprovementsMember 2021-06-30 0001674930 us-gaap:BuildingImprovementsMember 2020-12-31 0001674930 us-gaap:SoftwareDevelopmentMember 2021-06-30 0001674930 us-gaap:SoftwareDevelopmentMember 2020-12-31 0001674930 us-gaap:LandImprovementsMember 2021-06-30 0001674930 us-gaap:LandImprovementsMember 2020-12-31 0001674930 flgt:GeneralEquipmentMember 2021-06-30 0001674930 flgt:GeneralEquipmentMember 2020-12-31 0001674930 us-gaap:LandMember 2021-06-30 0001674930 us-gaap:LandMember 2020-12-31 0001674930 flgt:AssetsNotYetPlacedInServiceMember 2021-06-30 0001674930 flgt:AssetsNotYetPlacedInServiceMember 2020-12-31 0001674930 srt:MinimumMember flgt:MedicalLabEquipmentMember 2021-01-01 2021-06-30 0001674930 srt:MaximumMember flgt:MedicalLabEquipmentMember 2021-01-01 2021-06-30 0001674930 us-gaap:BuildingMember 2021-01-01 2021-06-30 0001674930 flgt:AircraftMember 2021-01-01 2021-06-30 0001674930 us-gaap:ComputerEquipmentMember 2021-01-01 2021-06-30 0001674930 us-gaap:LeaseholdImprovementsMember 2021-01-01 2021-06-30 0001674930 srt:MinimumMember us-gaap:FurnitureAndFixturesMember 2021-01-01 2021-06-30 0001674930 srt:MaximumMember us-gaap:FurnitureAndFixturesMember 2021-01-01 2021-06-30 0001674930 srt:MinimumMember flgt:AutomobileMember 2021-01-01 2021-06-30 0001674930 srt:MaximumMember flgt:AutomobileMember 2021-01-01 2021-06-30 0001674930 srt:MinimumMember us-gaap:BuildingImprovementsMember 2021-01-01 2021-06-30 0001674930 srt:MaximumMember us-gaap:BuildingImprovementsMember 2021-01-01 2021-06-30 0001674930 srt:MinimumMember us-gaap:SoftwareDevelopmentMember 2021-01-01 2021-06-30 0001674930 srt:MaximumMember us-gaap:SoftwareDevelopmentMember 2021-01-01 2021-06-30 0001674930 srt:MinimumMember us-gaap:LandImprovementsMember 2021-01-01 2021-06-30 0001674930 srt:MaximumMember us-gaap:LandImprovementsMember 2021-01-01 2021-06-30 0001674930 srt:MinimumMember flgt:GeneralEquipmentMember 2021-01-01 2021-06-30 0001674930 srt:MaximumMember flgt:GeneralEquipmentMember 2021-01-01 2021-06-30 0001674930 country:US 2021-04-01 2021-06-30 0001674930 country:US 2020-04-01 2020-06-30 0001674930 country:US 2021-01-01 2021-06-30 0001674930 country:US 2020-01-01 2020-06-30 0001674930 us-gaap:NonUsMember 2021-04-01 2021-06-30 0001674930 us-gaap:NonUsMember 2020-04-01 2020-06-30 0001674930 us-gaap:NonUsMember 2021-01-01 2021-06-30 0001674930 us-gaap:NonUsMember 2020-01-01 2020-06-30 0001674930 srt:MaximumMember 2021-01-01 2021-06-30 0001674930 flgt:XilongScientificMember flgt:FFGeneBiotechMember 2021-06-30 0001674930 flgt:XilongScientificMember flgt:FFGeneBiotechMember 2021-01-01 2021-06-30 0001674930 flgt:ReagentsAndOtherSuppliesMember 2021-06-30 0001674930 flgt:MedicalLabEquipmentMember 2021-06-30 0001674930 flgt:MedicalLabFurnitureMember 2021-06-30 0001674930 2021-02-01 2021-02-28 0001674930 stpr:TX 2021-03-31 0001674930 stpr:TX 2021-03-01 2021-03-31 0001674930 srt:MinimumMember us-gaap:BuildingMember 2021-01-01 2021-06-30 0001674930 srt:MaximumMember us-gaap:BuildingMember 2021-01-01 2021-06-30 0001674930 us-gaap:CostOfSalesMember 2021-04-01 2021-06-30 0001674930 us-gaap:CostOfSalesMember 2020-04-01 2020-06-30 0001674930 us-gaap:CostOfSalesMember 2021-01-01 2021-06-30 0001674930 us-gaap:CostOfSalesMember 2020-01-01 2020-06-30 0001674930 us-gaap:ResearchAndDevelopmentExpenseMember 2021-04-01 2021-06-30 0001674930 us-gaap:ResearchAndDevelopmentExpenseMember 2020-04-01 2020-06-30 0001674930 us-gaap:ResearchAndDevelopmentExpenseMember 2021-01-01 2021-06-30 0001674930 us-gaap:ResearchAndDevelopmentExpenseMember 2020-01-01 2020-06-30 0001674930 us-gaap:SellingAndMarketingExpenseMember 2021-04-01 2021-06-30 0001674930 us-gaap:SellingAndMarketingExpenseMember 2020-04-01 2020-06-30 0001674930 us-gaap:SellingAndMarketingExpenseMember 2021-01-01 2021-06-30 0001674930 us-gaap:SellingAndMarketingExpenseMember 2020-01-01 2020-06-30 0001674930 us-gaap:GeneralAndAdministrativeExpenseMember 2021-04-01 2021-06-30 0001674930 us-gaap:GeneralAndAdministrativeExpenseMember 2020-04-01 2020-06-30 0001674930 us-gaap:GeneralAndAdministrativeExpenseMember 2021-01-01 2021-06-30 0001674930 us-gaap:GeneralAndAdministrativeExpenseMember 2020-01-01 2020-06-30 0001674930 us-gaap:EmployeeStockOptionMember 2021-04-01 2021-06-30 0001674930 us-gaap:RestrictedStockUnitsRSUMember 2021-04-01 2021-06-30 0001674930 us-gaap:EmployeeStockOptionMember 2020-04-01 2020-06-30 0001674930 us-gaap:RestrictedStockUnitsRSUMember 2020-04-01 2020-06-30 0001674930 us-gaap:EmployeeStockOptionMember 2021-01-01 2021-06-30 0001674930 us-gaap:RestrictedStockUnitsRSUMember 2021-01-01 2021-06-30 0001674930 us-gaap:EmployeeStockOptionMember 2020-01-01 2020-06-30 0001674930 us-gaap:RestrictedStockUnitsRSUMember 2020-01-01 2020-06-30 0001674930 flgt:GeneticSequencingServiceMember flgt:AHMCHealthcareIncMember 2021-04-01 2021-06-30 0001674930 flgt:GeneticSequencingServiceMember flgt:AHMCHealthcareIncMember 2021-01-01 2021-06-30 0001674930 flgt:GeneticSequencingServiceMember flgt:AHMCHealthcareIncMember 2020-04-01 2020-06-30 0001674930 flgt:GeneticSequencingServiceMember flgt:AHMCHealthcareIncMember 2020-01-01 2020-06-30 0001674930 flgt:GeneticSequencingServiceMember flgt:AHMCHealthcareIncMember 2021-06-30 0001674930 flgt:GeneticSequencingServiceMember flgt:AHMCHealthcareIncMember 2020-12-31 0001674930 flgt:ResearchDevelopmentServiceMember flgt:FulgentPharmaLimitedLiabilityCompanyMember 2021-04-01 2021-06-30 0001674930 flgt:ResearchDevelopmentServiceMember flgt:FulgentPharmaLimitedLiabilityCompanyMember 2021-01-01 2021-06-30 0001674930 flgt:ResearchDevelopmentServiceMember flgt:FulgentPharmaLimitedLiabilityCompanyMember 2020-04-01 2020-06-30 0001674930 flgt:ResearchDevelopmentServiceMember flgt:FulgentPharmaLimitedLiabilityCompanyMember 2020-01-01 2020-06-30 0001674930 flgt:FulgentPharmaLimitedLiabilityCompanyMember 2021-04-01 2021-06-30 0001674930 flgt:FulgentPharmaLimitedLiabilityCompanyMember 2021-01-01 2021-06-30 0001674930 flgt:FulgentPharmaLimitedLiabilityCompanyMember 2020-04-01 2020-06-30 0001674930 flgt:FulgentPharmaLimitedLiabilityCompanyMember 2020-01-01 2020-06-30 0001674930 flgt:FulgentPharmaLimitedLiabilityCompanyMember 2021-06-30 0001674930 flgt:FulgentPharmaLimitedLiabilityCompanyMember 2020-12-31 0001674930 flgt:FFGeneBiotechMember 2017-04-30 0001674930 flgt:XilongScientificMember 2021-05-31 0001674930 flgt:FFGeneBiotechMember 2017-04-30 0001674930 flgt:FFGeneBiotechMember 2017-04-01 2017-04-30 0001674930 us-gaap:GeneralAndAdministrativeExpenseMember 2017-04-01 2017-04-30 0001674930 flgt:FFGeneBiotechMember 2017-04-30 0001674930 flgt:FFGeneBiotechMember us-gaap:MeasurementInputDiscountForLackOfMarketabilityMember 2017-04-30 0001674930 flgt:FFGeneBiotechMember us-gaap:MeasurementInputDiscountRateMember 2017-04-30 0001674930 flgt:FFGeneBiotechMember flgt:MeasurementInputDiscountOwedToMarketParticipantAcquisitionPremiumMember 2017-04-30 0001674930 flgt:FFGeneBiotechMember 2021-06-30 0001674930 flgt:FFGeneBiotechMember 2021-04-01 2021-06-30 0001674930 flgt:FFGeneBiotechMember 2021-01-01 2021-06-30 0001674930 flgt:FFGeneBiotechMember us-gaap:TechnologyBasedIntangibleAssetsMember 2017-04-30 0001674930 flgt:FFGeneBiotechMember us-gaap:TechnologyBasedIntangibleAssetsMember 2017-04-01 2017-04-30 0001674930 flgt:FFGeneBiotechMember us-gaap:CustomerRelationshipsMember 2017-04-30 0001674930 flgt:FFGeneBiotechMember us-gaap:CustomerRelationshipsMember 2017-04-01 2017-04-30 0001674930 srt:MaximumMember us-gaap:CommonStockMember flgt:NovemberTwoThousandTwentyEquityDistributionAgreementMember 2020-11-01 2020-11-30 0001674930 us-gaap:CommonStockMember flgt:NovemberTwoThousandTwentyEquityDistributionAgreementMember 2021-04-01 2021-06-30 0001674930 us-gaap:CommonStockMember flgt:NovemberTwoThousandTwentyEquityDistributionAgreementMember 2021-01-01 2021-06-30 0001674930 flgt:FFGeneBiotechMember 2021-06-30 0001674930 flgt:FFGeneBiotechMember flgt:RoyaltyFreeTechnologyMember 2021-06-30 0001674930 flgt:FFGeneBiotechMember us-gaap:CustomerRelationshipsMember 2021-06-30 0001674930 flgt:FFGeneBiotechMember flgt:RoyaltyFreeTechnologyMember 2021-01-01 2021-06-30 0001674930 flgt:FFGeneBiotechMember us-gaap:CustomerRelationshipsMember 2021-01-01 2021-06-30 0001674930 us-gaap:SubsequentEventMember 2021-07-31 0001674930 flgt:CytometrySpecialistsIncMember us-gaap:SubsequentEventMember 2021-08-06 2021-08-06 0001674930 srt:MaximumMember flgt:CytometrySpecialistsIncMember us-gaap:SubsequentEventMember 2021-08-06 2021-08-06 shares iso4217:USD iso4217:USD shares flgt:Customer pure flgt:Segment utr:sqft false Q2 0001674930 --12-31 0.20 0.24 0.16 0.11 true us-gaap:AccountingStandardsUpdate201613Member true true true true 0.20 0.24 flgt:TestingServicesMember flgt:TestingServicesMember flgt:TestingServicesMember flgt:TestingServicesMember us-gaap:OtherAssetsNoncurrent us-gaap:OtherAssetsNoncurrent us-gaap:OtherLiabilitiesCurrent us-gaap:OtherLiabilitiesCurrent us-gaap:OtherLiabilitiesNoncurrent us-gaap:OtherLiabilitiesNoncurrent 10-Q true 2021-06-30 2021 false 001-37894 FULGENT GENETICS, INC. DE 81-2621304 4978 Santa Anita Avenue Temple City CA 91780 626 350-0537 Common Stock, par value $0.0001 per share FLGT NASDAQ Yes Yes Non-accelerated Filer true true true false 29521259 100461000 87426000 283328000 211941000 6044000 1898000 148576000 183857000 34321000 40392000 566686000 523616000 393250000 132502000 51086000 40199000 6829000 23107000 8897000 4144000 1049855000 700461000 14743000 26488000 26399000 53319000 6915000 26576000 45327000 185000 15077000 15019000 13063000 8528000 121524000 130115000 5899000 505000 377000 1202000 582000 129130000 131074000 0.0001 0.0001 50000000 50000000 29513000 29513000 28178000 28178000 3000 3000 0.0001 0.0001 1000000 1000000 0 0 0 0 482255000 418065000 -265000 438000 430736000 150881000 912729000 569387000 7996000 920725000 569387000 1049855000 700461000 153616000 17265000 513045000 25018000 35858000 7717000 109933000 11774000 117758000 9548000 403112000 13244000 5312000 1849000 10734000 3827000 5219000 3260000 10227000 4857000 8329000 1799000 16331000 3834000 18860000 6908000 37292000 12518000 98898000 2640000 365820000 726000 604000 275000 886000 516000 99502000 2915000 366706000 1242000 23589000 -599000 90102000 -565000 75913000 3514000 276604000 1807000 3734000 3734000 -193000 -442000 79647000 3321000 280338000 1365000 -165000 -165000 79812000 3321000 280503000 1365000 2.74 0.15 9.68 0.06 2.59 0.14 9.10 0.06 29150000 21747000 28991000 21656000 30830000 22920000 30809000 22824000 79647000 3321000 280338000 1365000 36000 2000 36000 -1000 -75000 1240000 -729000 904000 79608000 4563000 279645000 2268000 -165000 -165000 10000 10000 -155000 -155000 79763000 4563000 279800000 2268000 28178000 3000 418065000 438000 150881000 569387000 569387000 2962000 2962000 2962000 45000 44000 44000 44000 187000 4000 513000 513000 513000 52.00 583000 30297000 30297000 30297000 -654000 -654000 -654000 -887000 -887000 -887000 239000 239000 239000 200691000 200691000 200691000 28989000 3000 450855000 -216000 350924000 801566000 801566000 3526000 3526000 3526000 4000 24000 24000 24000 143000 1000 39000 39000 39000 73.75 378000 27889000 27889000 27889000 8151000 8151000 -49000 -49000 10000 -39000 79812000 79812000 -165000 79647000 29513000 3000 482255000 -265000 430736000 912729000 7996000 920725000 21483000 2000 146058000 146000 -63429000 82777000 924000 924000 33000 12000 12000 159000 3000 46000 46000 -339000 -339000 -1956000 -1956000 21672000 2000 146948000 -193000 -65385000 81372000 1080000 1080000 11000 28000 28000 127000 1242000 1242000 3321000 3321000 21810000 2000 148056000 1049000 -62064000 87043000 280338000 1365000 6488000 2004000 4340000 1118000 298000 220000 -598000 3171000 218000 3259000 135000 -3055000 -128000 -360000 -442000 3734000 8000 6000 -32460000 7437000 6025000 3827000 -10256000 2284000 3084000 670000 -26920000 -24000 -19662000 44719000 -293000 -205000 309290000 -3043000 14427000 1207000 13000 424807000 12387000 51696000 34538000 7327000 18509000 -371496000 -6267000 75656000 -217000 10000 68000 40000 552000 46000 58000 75240000 -223000 1000 -1000 13035000 -9534000 87426000 11965000 100461000 2431000 119980000 28000 742000 497000 765000 393000 185000 30000 2000 <p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Note 1. Overview and Basis of Presentation</p> <p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;color:#auto;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="text-decoration:none;">The accompanying condensed consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America, or U.S. GAAP. These financial statements include the assets, liabilities, revenues and expenses of all subsidiaries and entities in which the Company has a controlling financial interest or is deemed to be the primary beneficiary. In determining whether the Company is the primary beneficiary of an entity, the Company applies a qualitative approach that determines whether it has both (i) the power to direct the economically significant activities of the entity and (ii) the obligation to absorb losses of, or the right to receive benefits from, the entity that could potentially be significant to that entity. The Company uses the equity method to account for its investments in entities that it does not control, but in which it has the ability to exercise significant influence over operating and financial policies. All significant intercompany accounts and transactions are eliminated from the accompanying condensed consolidated financial statements.</span></p> <p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Nature of the Business</p> <p style="Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Fulgent Genetics, Inc., together with its subsidiaries, collectively referred to as the Company, unless otherwise noted or the context otherwise requires, is a technology company offering comprehensive genetic testing providing physicians with clinically actionable diagnostic information they can use to improve the quality of patient care. The Company has developed a proprietary technology platform that allows it to offer a broad and flexible test menu and continually expand and improve its proprietary genetic reference library, while maintaining accessible pricing, high accuracy and competitive turnaround times. Combining next generation sequencing, or NGS, with its technology platform, the Company performs full-gene sequencing with deletion/duplication analysis in single-gene tests; pre-established, multi-gene, disease-specific panels; and customized panels that can be tailored to meet specific customer needs. In 2019, the Company launched its first patient-initiated product, Picture Genetics, a new line of at-home screening tests that combines the Company’s advanced NGS solutions with actionable results and genetic counseling options for individuals. Since March 2020, the Company has commercially launched several tests for the detection of SARS-CoV-2, the virus that causes the novel coronavirus, or COVID-19, including NGS and reverse transcription polymerase chain reaction – based, or RT-PCR-based, tests. The Company has received an Emergency Use Authorization, or EUA, from the United States, or U.S., Food and Drug Administration, or the FDA, for the RT-PCR-based tests for the detection of SARS-CoV-2 using upper respiratory specimens (nasal, nasopharyngeal, and oropharyngeal swabs) and for the at-home testing service through Picture Genetics. The Company’s at-home testing service for COVID-19 and RT-PCR-based test have been granted an EUA by the FDA only for the detection of nucleic acid from SARS-CoV-2, not for any other viruses or pathogens. The Company believes its test menu offers more genes for testing than its competitors in today’s market, which enables it to provide expansive options for test customization and clinically actionable results. A cornerstone of the Company’s business is its ability to provide expansive options and flexibility for all clients’ unique testing needs.</p> <p style="Background-color:#FFFFFF;margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Unaudited Interim Financial Information </p> <p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.13%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The accompanying unaudited interim condensed consolidated financial statements have been prepared on the same basis as the Company’s audited consolidated financial statements as of and for the fiscal year ended December 31, 2020, which are included in the Company’s annual report on Form 10-K filed with the Securities and Exchange Commission, or SEC, on March 8, 2021, or 2020 Annual Report, and, in the opinion of management, include all adjustments, which are normal and recurring in nature, necessary for a fair presentation of the Company’s financial position and results of operations. Operating results for interim periods are not necessarily indicative of the results that may be expected for a full fiscal year or any other period. The accompanying Condensed Consolidated Balance Sheet as of December 31, 2020 has been derived from the Company’s audited consolidated financial statements at that date but does not include all of the disclosures required by U.S. GAAP. As such, the information included in this quarterly report on Form 10-Q should be read in conjunction with the Company’s audited consolidated financial statements included in the 2020 Annual Report, including the notes thereto.</p> <p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Note 2. Summary of Significant Accounting Policies</p> <p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="Background-color:#FFFFFF;">See the summary</span> of the <span style="Background-color:#FFFFFF;">Company’s significant accounting policies set forth in the notes to its consolidated </span>financial statements <span style="Background-color:#FFFFFF;">included in the 2020 Annual Report.</span></p> <p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Use of Estimates</p> <p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The preparation of condensed consolidated financial statements in conformity with U.S. GAAP requires management to make certain estimates, judgments and assumptions that affect the reported amounts of assets and liabilities at the date of the financial statements, as well as the reported amounts of revenue and expenses during the reporting periods. These estimates, judgments and assumptions are based on historical data and experience available at the date of the accompanying condensed consolidated financial statements, as well as various other factors management believes to be reasonable under the circumstances, including but not limited to the potential impacts arising from the recent global pandemic related to COVID-19. As the extent and duration of the impacts from COVID-19 remain unclear, the Company’s estimates and assumptions may evolve as conditions change. Actual results could differ significantly from these estimates.</p> <p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">On an on-going basis, management evaluates its estimates, primarily those related to: (i) revenue recognition criteria, (ii) trade accounts receivable and allowances for credit losses, (iii) the useful lives of fixed assets, (iv) estimates of tax liabilities, (v) the valuation of equity method investments, (vi) valuation of acquisition-related intangibles and goodwill, and (vii) useful lives of intangible assets and fixed assets.</p> <p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Foreign Currency Translation and Foreign Currency Transactions</p> <p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company translates the assets and liabilities of its non-U.S. dollar functional currency subsidiaries into U.S. dollars using exchange rates in effect at the end of each period. Expenses for these subsidiaries are translated using rates that approximate those in effect during the period. Gains and losses from these translations are recognized in foreign currency translation included in accumulated other comprehensive income (loss) in the accompanying Condensed Consolidated Statements of Stockholders’ Equity. Gains from these translations were not significant in the three and six months ended June 30, 2021 and three months ended June 30, 2020, and loss from these translations for the six months ended June 30, 2020 was not significant. The Company and its subsidiaries that use the U.S. dollar as their functional currency remeasure monetary assets and liabilities at exchange rates in effect at the end of each period, and inventories, property and nonmonetary assets and liabilities at historical rates. Losses from these remeasurements in the three and six months ended June 30, 2021 and in the six months ended June 30, 2020 were not significant. Gains from these remeasurements were not significant in the three months ended June 30, 2020.</p> <p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Leases</p> <p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company determines if an arrangement is a lease at inception by evaluating whether the arrangement conveys the right to use an identified asset and whether the Company obtains substantially all of the economic benefits from and has the ability to direct the use of the asset. Operating lease right-of-use, or ROU, asset, short-term lease liabilities, and long-term lease liabilities were included in other long-term assets, other current liabilities, and other long-term liabilities, respectively, in the accompanying Condensed Consolidated Balance Sheets.</p> <p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Lease ROU assets represent the Company’s right to use an underlying asset for the lease term and lease liabilities represent the Company’s obligation to make lease payments arising from the lease. Operating lease ROU assets and liabilities are recognized at the commencement date based on the present value of lease payments over the lease term, including options to extend the lease when it is reasonably certain that the Company will exercise that option. The Company uses its incremental borrowing rate based on the information available at the commencement date, including inquiries with its bank, in determining the present value of lease payments since its leases do not provide an implicit rate. The lease ROU asset includes any base rent payments made and excludes lease incentives and variable operating expenses. Lease expense for lease payments is recognized on a straight-line basis over the lease term.</p> <p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company leases out space in buildings it owns in El Monte, California, to third-party tenants under noncancelable operating leases and has leased out such space since the Company purchased such buildings. The Company recognizes lease payments as income over the lease terms on a straight-line basis and recognizes variable lease payments as income in the period in which the changes in facts and circumstances on which the variable lease payments are based occur. The net rental income is included in the interest and other income, net, in the accompanying Condensed Consolidated Statement of Operations.</p> <p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Concentration of Customers</p> <p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In certain periods, a small number of customers has accounted for a significant portion of the Company’s revenue. After aggregating customers that are under common control or are affiliates, two customers contributed <span style="-sec-ix-hidden:F_000455">20% and 16%</span> of the Company’s revenue for the three months ended June 30, 2021, respectively, and two customers contributed <span style="-sec-ix-hidden:F_000456_2">24% and 11%</span> of the Company’s revenue for the six months ended June 30, 2021, respectively.<span style="Background-color:#FFFFFF;color:#000000;">  One customer contributed 45% of the Company’s revenue for the three months ended June 30, 2020, and one customer contributed 31% of the Company’s revenue for the six months ended June 30, 2020.</span> One customer comprised 13% of total accounts receivable as of June 30, 2021. No customer comprised 10% or more of total accounts receivable as of December<span style="color:#000000;"> 31, 2020. </span>Revenue from the U.S. government was less than 10% of total revenue for the three and six months ended June 30, 2021 and 2020.</p> <p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Revenue from Contracts with Customers</p> <p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Disaggregation of Revenue</p> <p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company classifies its customers into three payor types: (i) Insurance, (ii) Institutional, including hospitals, medical institutions, other laboratories, governmental bodies, municipalities and large corporations, or (iii) Patients who pay directly, as the Company believes this best depicts how the nature, amount, timing, and uncertainty of its revenue and cash flows are affected by economic factors. The following table summarizes revenue from contracts with customers by payor type for the <span style="color:#000000;">three and six months ended June 30, 2021 and 2020</span>.</p> <p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;"> </p> <div> <table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;"> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:42.7%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:26.9%; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Three Months Ended June 30,</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.44%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:26.9%; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Six Months Ended June 30,</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:42.7%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.22%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2021</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.44%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.22%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.44%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.22%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2021</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.44%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.22%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:42.7%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="14" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:56.28%;" valign="top"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(in thousands)</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:42.7%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Testing Services by payor</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><span style="-sec-ix-hidden:F_000467"> </span></p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.22%;white-space:nowrap;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><span style="-sec-ix-hidden:F_000468"> </span></p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><span style="-sec-ix-hidden:F_000469"> </span></p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.44%;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><span style="-sec-ix-hidden:F_000470"> </span></p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.22%;white-space:nowrap;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.44%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.22%;white-space:nowrap;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.44%;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.22%;white-space:nowrap;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:42.7%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Institutional</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.22%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">103,602</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.44%;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.22%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">16,454</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.44%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.22%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">255,171</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.44%;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.22%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">23,932</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:42.7%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Insurance</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.22%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">49,520</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.44%;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.22%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">691</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.44%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.22%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">257,078</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.44%;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.22%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">825</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:42.7%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Patient</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.22%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">494</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.44%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.22%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">120</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.44%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.22%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">796</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.44%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.22%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">261</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:42.7%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Total Revenue</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.22%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">153,616</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.44%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.22%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">17,265</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.44%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.22%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">513,045</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.44%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.22%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">25,018</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> </table></div> <p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;"> </p> <p style="margin-top:8pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Contract Balances</p> <p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-style:italic;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Receivables from contracts with customers<span style="font-style:normal;">—As of June 30, 2021 and December 31, 2020, receivables from contracts with customers were approximately $148.6 million and $183.9 million, respectively, and are included within trade accounts receivable on the Condensed Consolidated Balance Sheets.</span></p> <p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-style:italic;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Contracts assets and liabilities<span style="font-style:normal;"> —As of June 30, 2021 and December 31, 2020, contract assets from contracts with customers were $324,000 and $1.4 million, respectively, associated with contract execution and certain costs to fulfill a contract, and included in other current assets in the accompanying Condensed Consolidated Balance Sheets. Contract liabilities are recorded when the Company receives payment or bills prior to completing its obligation to transfer goods or services to a customer. The Company had $6.9 million and $26.6 million of contract liabilities as of June 30, 2021 and December 31, 2020, respectively. Revenues of $1.7 million and $196,000 for the three months and $25.5 million and $246,000 for the six months were recognized for the periods ended June 30, 2021 and 2020, respectively, related to contract liabilities at the beginning of the respective periods.</span></p> <p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Transaction Price Allocated to Future Performance Obligations</p> <p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company does not have material future obligations associated with testing services that extend beyond one year.</p> <p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Reagents and Supplies</p> <p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.17%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company maintains reagents and other consumables primarily used in sample collections and testing which are valued at the lower of cost or net realizable value. Cost is determined using actual costs on a first-in, first-out basis. The reagents and supplies were $25.4 million and $16.5 million as of June 30, 2021 and December 31, 2020, respectively, and was included in other current assets in the accompanying Condensed Consolidated Balance Sheets.</p> <p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Customer Deposit</p> <p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.17%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Customer deposit in the accompanying Condensed Consolidated Balance Sheets consists primarily of payments received from customers in excess of their outstanding trade accounts receivable balances, and the excess payments will be refunded to the customers or offset against future testing receivables.</p> <p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Trade Accounts Receivable and Allowance for Credit Losses</p> <p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.13%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Trade accounts receivable are stated at the amount the Company expects to collect. The Company maintains an allowance for credit losses for expected uncollectible trade accounts receivable, which is recorded as an offset to trade accounts receivable and changes in allowance for credit losses are classified as a general and administrative expense in the accompanying Condensed Consolidated Statements of Operations. The Company assesses collectability by reviewing trade accounts receivable on a collective basis where similar risk characteristics exist and on an individual basis when it identifies specific customers that have deterioration in credit quality such that they may no longer share similar risk characteristics with the other receivables. In determining the amount of the allowance for credit losses, the Company uses a probability-of-default and loss given default model, which allows the ability to define a point of default and measure credit losses for receivables that have reached the point of default for purposes of calculating the allowance for credit losses. Loss given default represents the likelihood that a receivable that has reached the point of default will not be collected in full. The Company will update its probability-of-default and loss given default factors annually to incorporate the most recent historical data and adjusts the quantitative portion of the reserve through its qualitative reserve overlay. The Company looks at qualitative factors such as general economic conditions in determining expected credit losses. During the three and six months ended June 30, 2021, the Company recorded $2.2 million and $3.3 million of provision for credit losses for trade accounts receivable, respectively. The provision was not significant for the three and six months ended June 30, 2020.</p> <p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Marketable Securities</p> <p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.17%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">All marketable debt securities, which consist of corporate debt securities, municipal bonds, U.S. government agency debt securities, and Yankee debt securities issued by foreign governments or entities and denominated in U.S. dollars, have been classified as “available for sale”, and are carried at fair value. Unrealized gains and losses, net of any related tax effects, are excluded from earnings and are included in other comprehensive income (loss) and reported as a separate component of stockholders’ equity until realized. Realized gains and losses on marketable debt securities are included in interest and other income, net, in the accompanying Condensed Consolidated Statements of Operations. The cost of any marketable debt securities sold is based on the specific-identification method. The amortized cost of marketable debt securities is adjusted for amortization of premiums and accretion of discounts to maturity. Interest on marketable debt securities is included in interest and other income, net. In accordance with the Company’s investment policy, management invests to diversify credit risk and only invests in securities with high credit quality, including U.S. government securities, and the final maturity is tailored to the Company’s current liquidity needs with a maximum final maturity from the date of purchase of three years.</p> <p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.13%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company’s investments in marketable equity securities are measured at fair value with the related gains and losses, realized and unrealized, recognized in interest and other income, net, in the accompanying Condensed Consolidated Statements of Operations. The cost of any marketable equity securities sold is based on the specific-identification method.</p> <p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.13%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">For available for sale debt securities, in an unrealized loss, the company determines whether a credit loss exists. The credit loss is estimated by considering available information relevant to the collectability of the security and information about past events, current conditions, and reasonable and supportable forecasts. Any credit loss is recorded as a charge to interest and other income, net, not to exceed the amount of the unrealized loss. If the Company has an intent to sell, or if it is more likely than not that the Company will be required to sell a debt security in an unrealized loss position before recovery of its amortized cost basis, the Company will write down the security to its fair value and record the corresponding charge as a component of interest and other income, net.</p> <p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Business Combination</p> <p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.17%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company uses the acquisition method of accounting and allocates the fair value of purchase consideration to the assets acquired and liabilities assumed from an acquiree based on their respective fair values as of the acquisition date. The excess of the fair value of purchase consideration over the fair value of these assets acquired and liabilities assumed is recorded as goodwill. When determining the fair values of assets acquired and liabilities assumed, management makes significant estimates and assumptions, especially with respect to intangible assets. Critical estimates in valuing intangible assets include, but are not limited to, expected future cash flows, which includes consideration of future growth and margins, future changes in technology, expected cost and time to develop in-process research and development, brand awareness and discount rates. Fair value estimates are based on the assumptions that management believes a market participant would use in pricing the asset or liability.</p> <p style="text-align:justify;margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Goodwill</p> <p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.13%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Goodwill is not amortized but is subject to impairment tests on an annual basis, or more frequently if indicators of potential impairment exist, and goodwill is written down when it is determined to be impaired. The Company will perform an annual impairment review in the fourth quarter of each fiscal year and compare the fair value of the reporting unit in which the goodwill resides to its carrying value. </p> <p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Recent Accounting Pronouncements</p> <p style="margin-bottom:0pt;margin-top:6pt;text-indent:5.15%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company evaluates all Accounting Standards Updates, or ASUs, issued by the Financial Accounting Standards Board, or FASB, for consideration of their applicability. ASUs not included in the Company’s disclosures were assessed and determined to be either not applicable or are not expected to have a material impact on the Company’s condensed consolidated financial statements.</p> <p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Recently Adopted Accounting Pronouncements</p> <p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-style:italic;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">ASU 2016-13</p> <p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.17%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In June 2016, the FASB issued ASU No. 2016-13, Financial Instruments-Credit Losses: Measurement of Credit Losses on Financial Instruments, or ASU 2016-13. ASU 2016-13 replaces the incurred loss impairment methodology in current U.S. GAAP with a methodology that reflects expected credit losses. The update is intended to provide financial statement users with more decision-useful information about the expected credit losses on financial instruments and other commitments to extend credit held by a reporting entity at each reporting date. Entities will apply the standard’s provisions as a cumulative-effect adjustment to retained earnings as of the beginning of the first reporting period in which the guidance is effective. The standard will be effective for annual reporting periods beginning after December 15, 2019, including interim periods within those reporting periods for public business entities that meet the definition of an SEC filer, excluding entities eligible to be smaller reporting companies as defined by the SEC. For all other entities, the amendments in this update are effective for fiscal years beginning after December 15, 2022, including interim periods within those fiscal years. Early application of the amendments is permitted. The Company adopted ASU 2016-13 using the modified retrospective approach as of January 1, 2021. The cumulative effect upon adoption was $887,000 to the retained earnings in the accompanying Condensed Consolidated Statements of Stockholders’ Equity and trade accounts receivable, net, in the accompanying Condensed Consolidated Balance Sheets. The cumulative tax effective was $239,000 to retained earnings and deferred tax assets included in other long-term assets in the accompanying Condensed Consolidated Balance Sheets. There was no impact related to available-for-sale debt securities.</p> <p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-style:italic;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">ASU 2019-12</p> <p style="margin-top:6pt;margin-bottom:0pt;text-indent:5%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In December 2019, the FASB issued ASU No. 2019-12, Simplifying the Accounting for Income Taxes (Topic 740), or ASU 2019-12, which is intended to reduce the complexity of accounting standards while maintaining or enhancing the helpfulness of information provided to financial statement users.  The amendment in this ASU simplifies the accounting for income taxes by removing some exceptions including the incremental approach for intraperiod tax allocation, the requirement to recognize a deferred tax liability for equity method investments, the ability not to recognize a deferred tax liability for a foreign subsidiary, and the general methodology for calculating income taxes in an interim period. Other changes include requiring entities to recognize franchise tax that is partially based on income as an income-based tax and account for any incremental amount incurred as a non-income-based tax, evaluate tax basis step-up in goodwill obtained in a transaction that is not a business combination, and reflect the effect of an enacted change in tax laws or rates in the annual effective tax rate computation in the interim period that includes the enactment date, making minor codification improvements for income taxes related to employee stock ownership plans and investments in qualified affordable housing projects accounted for using the equity method, and specifying that an entity is not required to allocate the consolidated current and deferred tax expense to a legal entity that is not subject to tax in its separate financial statements. For public business entities, this amendment is effective for fiscal years, and interim periods within those fiscal years, beginning after December 15, 2020 with early adoption permitted. The Company adopted ASU 2019-12 in the first quarter of 2021, and the adoption had no material impact to the Company’s condensed consolidated financial statements.</p> <p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Use of Estimates</p> <p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The preparation of condensed consolidated financial statements in conformity with U.S. GAAP requires management to make certain estimates, judgments and assumptions that affect the reported amounts of assets and liabilities at the date of the financial statements, as well as the reported amounts of revenue and expenses during the reporting periods. These estimates, judgments and assumptions are based on historical data and experience available at the date of the accompanying condensed consolidated financial statements, as well as various other factors management believes to be reasonable under the circumstances, including but not limited to the potential impacts arising from the recent global pandemic related to COVID-19. As the extent and duration of the impacts from COVID-19 remain unclear, the Company’s estimates and assumptions may evolve as conditions change. Actual results could differ significantly from these estimates.</p> <p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">On an on-going basis, management evaluates its estimates, primarily those related to: (i) revenue recognition criteria, (ii) trade accounts receivable and allowances for credit losses, (iii) the useful lives of fixed assets, (iv) estimates of tax liabilities, (v) the valuation of equity method investments, (vi) valuation of acquisition-related intangibles and goodwill, and (vii) useful lives of intangible assets and fixed assets.</p> <p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Foreign Currency Translation and Foreign Currency Transactions</p> <p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company translates the assets and liabilities of its non-U.S. dollar functional currency subsidiaries into U.S. dollars using exchange rates in effect at the end of each period. Expenses for these subsidiaries are translated using rates that approximate those in effect during the period. Gains and losses from these translations are recognized in foreign currency translation included in accumulated other comprehensive income (loss) in the accompanying Condensed Consolidated Statements of Stockholders’ Equity. Gains from these translations were not significant in the three and six months ended June 30, 2021 and three months ended June 30, 2020, and loss from these translations for the six months ended June 30, 2020 was not significant. The Company and its subsidiaries that use the U.S. dollar as their functional currency remeasure monetary assets and liabilities at exchange rates in effect at the end of each period, and inventories, property and nonmonetary assets and liabilities at historical rates. Losses from these remeasurements in the three and six months ended June 30, 2021 and in the six months ended June 30, 2020 were not significant. Gains from these remeasurements were not significant in the three months ended June 30, 2020.</p> <p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Leases</p> <p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company determines if an arrangement is a lease at inception by evaluating whether the arrangement conveys the right to use an identified asset and whether the Company obtains substantially all of the economic benefits from and has the ability to direct the use of the asset. Operating lease right-of-use, or ROU, asset, short-term lease liabilities, and long-term lease liabilities were included in other long-term assets, other current liabilities, and other long-term liabilities, respectively, in the accompanying Condensed Consolidated Balance Sheets.</p> <p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Lease ROU assets represent the Company’s right to use an underlying asset for the lease term and lease liabilities represent the Company’s obligation to make lease payments arising from the lease. Operating lease ROU assets and liabilities are recognized at the commencement date based on the present value of lease payments over the lease term, including options to extend the lease when it is reasonably certain that the Company will exercise that option. The Company uses its incremental borrowing rate based on the information available at the commencement date, including inquiries with its bank, in determining the present value of lease payments since its leases do not provide an implicit rate. The lease ROU asset includes any base rent payments made and excludes lease incentives and variable operating expenses. Lease expense for lease payments is recognized on a straight-line basis over the lease term.</p> <p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company leases out space in buildings it owns in El Monte, California, to third-party tenants under noncancelable operating leases and has leased out such space since the Company purchased such buildings. The Company recognizes lease payments as income over the lease terms on a straight-line basis and recognizes variable lease payments as income in the period in which the changes in facts and circumstances on which the variable lease payments are based occur. The net rental income is included in the interest and other income, net, in the accompanying Condensed Consolidated Statement of Operations.</p> <p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Concentration of Customers</p> <p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In certain periods, a small number of customers has accounted for a significant portion of the Company’s revenue. After aggregating customers that are under common control or are affiliates, two customers contributed <span style="-sec-ix-hidden:F_000455">20% and 16%</span> of the Company’s revenue for the three months ended June 30, 2021, respectively, and two customers contributed <span style="-sec-ix-hidden:F_000456_2">24% and 11%</span> of the Company’s revenue for the six months ended June 30, 2021, respectively.<span style="Background-color:#FFFFFF;color:#000000;">  One customer contributed 45% of the Company’s revenue for the three months ended June 30, 2020, and one customer contributed 31% of the Company’s revenue for the six months ended June 30, 2020.</span> One customer comprised 13% of total accounts receivable as of June 30, 2021. No customer comprised 10% or more of total accounts receivable as of December<span style="color:#000000;"> 31, 2020. </span>Revenue from the U.S. government was less than 10% of total revenue for the three and six months ended June 30, 2021 and 2020.</p> 2 2 1 0.45 1 0.31 1 0.13 0 0.10 <p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Revenue from Contracts with Customers</p> <p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Disaggregation of Revenue</p> <p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company classifies its customers into three payor types: (i) Insurance, (ii) Institutional, including hospitals, medical institutions, other laboratories, governmental bodies, municipalities and large corporations, or (iii) Patients who pay directly, as the Company believes this best depicts how the nature, amount, timing, and uncertainty of its revenue and cash flows are affected by economic factors. The following table summarizes revenue from contracts with customers by payor type for the <span style="color:#000000;">three and six months ended June 30, 2021 and 2020</span>.</p> <p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;"> </p> <div> <table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;"> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:42.7%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:26.9%; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Three Months Ended June 30,</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.44%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:26.9%; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Six Months Ended June 30,</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:42.7%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.22%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2021</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.44%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.22%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.44%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.22%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2021</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.44%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.22%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:42.7%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="14" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:56.28%;" valign="top"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(in thousands)</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:42.7%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Testing Services by payor</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><span style="-sec-ix-hidden:F_000467"> </span></p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.22%;white-space:nowrap;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><span style="-sec-ix-hidden:F_000468"> </span></p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><span style="-sec-ix-hidden:F_000469"> </span></p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.44%;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><span style="-sec-ix-hidden:F_000470"> </span></p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.22%;white-space:nowrap;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.44%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.22%;white-space:nowrap;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.44%;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.22%;white-space:nowrap;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:42.7%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Institutional</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.22%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">103,602</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.44%;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.22%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">16,454</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.44%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.22%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">255,171</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.44%;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.22%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">23,932</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:42.7%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Insurance</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.22%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">49,520</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.44%;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.22%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">691</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.44%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.22%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">257,078</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.44%;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.22%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">825</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:42.7%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Patient</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.22%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">494</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.44%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.22%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">120</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.44%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.22%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">796</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.44%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.22%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">261</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:42.7%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Total Revenue</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.22%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">153,616</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.44%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.22%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">17,265</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.44%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.22%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">513,045</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.44%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.22%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">25,018</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> </table></div> <p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;"> </p> <p style="margin-top:8pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Contract Balances</p> <p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-style:italic;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Receivables from contracts with customers<span style="font-style:normal;">—As of June 30, 2021 and December 31, 2020, receivables from contracts with customers were approximately $148.6 million and $183.9 million, respectively, and are included within trade accounts receivable on the Condensed Consolidated Balance Sheets.</span></p> <p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-style:italic;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Contracts assets and liabilities<span style="font-style:normal;"> —As of June 30, 2021 and December 31, 2020, contract assets from contracts with customers were $324,000 and $1.4 million, respectively, associated with contract execution and certain costs to fulfill a contract, and included in other current assets in the accompanying Condensed Consolidated Balance Sheets. Contract liabilities are recorded when the Company receives payment or bills prior to completing its obligation to transfer goods or services to a customer. The Company had $6.9 million and $26.6 million of contract liabilities as of June 30, 2021 and December 31, 2020, respectively. Revenues of $1.7 million and $196,000 for the three months and $25.5 million and $246,000 for the six months were recognized for the periods ended June 30, 2021 and 2020, respectively, related to contract liabilities at the beginning of the respective periods.</span></p> <p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Transaction Price Allocated to Future Performance Obligations</p> <p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company does not have material future obligations associated with testing services that extend beyond one year.</p> The following table summarizes revenue from contracts with customers by payor type for the <span style="color:#000000;">three and six months ended June 30, 2021 and 2020</span>. <p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;"> </p> <div> <table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;"> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:42.7%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:26.9%; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Three Months Ended June 30,</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.44%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:26.9%; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Six Months Ended June 30,</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:42.7%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.22%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2021</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.44%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.22%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.44%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.22%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2021</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.44%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.22%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:42.7%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="14" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:56.28%;" valign="top"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(in thousands)</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:42.7%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Testing Services by payor</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><span style="-sec-ix-hidden:F_000467"> </span></p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.22%;white-space:nowrap;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><span style="-sec-ix-hidden:F_000468"> </span></p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><span style="-sec-ix-hidden:F_000469"> </span></p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.44%;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><span style="-sec-ix-hidden:F_000470"> </span></p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.22%;white-space:nowrap;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.44%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.22%;white-space:nowrap;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.44%;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.22%;white-space:nowrap;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:42.7%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Institutional</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.22%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">103,602</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.44%;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.22%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">16,454</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.44%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.22%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">255,171</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.44%;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.22%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">23,932</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:42.7%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Insurance</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.22%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">49,520</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.44%;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.22%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">691</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.44%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.22%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">257,078</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.44%;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.22%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">825</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:42.7%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Patient</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.22%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">494</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.44%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.22%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">120</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.44%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.22%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">796</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.44%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.22%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">261</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:42.7%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Total Revenue</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.22%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">153,616</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.44%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.22%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">17,265</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.44%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.22%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">513,045</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.44%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.22%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">25,018</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> </table></div> <p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;"> </p> 103602000 16454000 255171000 23932000 49520000 691000 257078000 825000 494000 120000 796000 261000 153616000 17265000 513045000 25018000 148600000 183900000 324000 1400000 6900000 26600000 1700000 196000 25500000 246000 <p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Reagents and Supplies</p> <p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.17%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company maintains reagents and other consumables primarily used in sample collections and testing which are valued at the lower of cost or net realizable value. Cost is determined using actual costs on a first-in, first-out basis. The reagents and supplies were $25.4 million and $16.5 million as of June 30, 2021 and December 31, 2020, respectively, and was included in other current assets in the accompanying Condensed Consolidated Balance Sheets.</p> 25400000 16500000 <p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Customer Deposit</p> <p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.17%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Customer deposit in the accompanying Condensed Consolidated Balance Sheets consists primarily of payments received from customers in excess of their outstanding trade accounts receivable balances, and the excess payments will be refunded to the customers or offset against future testing receivables.</p> <p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Trade Accounts Receivable and Allowance for Credit Losses</p> <p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.13%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Trade accounts receivable are stated at the amount the Company expects to collect. The Company maintains an allowance for credit losses for expected uncollectible trade accounts receivable, which is recorded as an offset to trade accounts receivable and changes in allowance for credit losses are classified as a general and administrative expense in the accompanying Condensed Consolidated Statements of Operations. The Company assesses collectability by reviewing trade accounts receivable on a collective basis where similar risk characteristics exist and on an individual basis when it identifies specific customers that have deterioration in credit quality such that they may no longer share similar risk characteristics with the other receivables. In determining the amount of the allowance for credit losses, the Company uses a probability-of-default and loss given default model, which allows the ability to define a point of default and measure credit losses for receivables that have reached the point of default for purposes of calculating the allowance for credit losses. Loss given default represents the likelihood that a receivable that has reached the point of default will not be collected in full. The Company will update its probability-of-default and loss given default factors annually to incorporate the most recent historical data and adjusts the quantitative portion of the reserve through its qualitative reserve overlay. The Company looks at qualitative factors such as general economic conditions in determining expected credit losses. During the three and six months ended June 30, 2021, the Company recorded $2.2 million and $3.3 million of provision for credit losses for trade accounts receivable, respectively. The provision was not significant for the three and six months ended June 30, 2020.</p> 2200000 3300000 <p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Marketable Securities</p> <p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.17%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">All marketable debt securities, which consist of corporate debt securities, municipal bonds, U.S. government agency debt securities, and Yankee debt securities issued by foreign governments or entities and denominated in U.S. dollars, have been classified as “available for sale”, and are carried at fair value. Unrealized gains and losses, net of any related tax effects, are excluded from earnings and are included in other comprehensive income (loss) and reported as a separate component of stockholders’ equity until realized. Realized gains and losses on marketable debt securities are included in interest and other income, net, in the accompanying Condensed Consolidated Statements of Operations. The cost of any marketable debt securities sold is based on the specific-identification method. The amortized cost of marketable debt securities is adjusted for amortization of premiums and accretion of discounts to maturity. Interest on marketable debt securities is included in interest and other income, net. In accordance with the Company’s investment policy, management invests to diversify credit risk and only invests in securities with high credit quality, including U.S. government securities, and the final maturity is tailored to the Company’s current liquidity needs with a maximum final maturity from the date of purchase of three years.</p> <p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.13%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company’s investments in marketable equity securities are measured at fair value with the related gains and losses, realized and unrealized, recognized in interest and other income, net, in the accompanying Condensed Consolidated Statements of Operations. The cost of any marketable equity securities sold is based on the specific-identification method.</p> <p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.13%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">For available for sale debt securities, in an unrealized loss, the company determines whether a credit loss exists. The credit loss is estimated by considering available information relevant to the collectability of the security and information about past events, current conditions, and reasonable and supportable forecasts. Any credit loss is recorded as a charge to interest and other income, net, not to exceed the amount of the unrealized loss. If the Company has an intent to sell, or if it is more likely than not that the Company will be required to sell a debt security in an unrealized loss position before recovery of its amortized cost basis, the Company will write down the security to its fair value and record the corresponding charge as a component of interest and other income, net.</p> P3Y <p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Business Combination</p> <p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.17%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company uses the acquisition method of accounting and allocates the fair value of purchase consideration to the assets acquired and liabilities assumed from an acquiree based on their respective fair values as of the acquisition date. The excess of the fair value of purchase consideration over the fair value of these assets acquired and liabilities assumed is recorded as goodwill. When determining the fair values of assets acquired and liabilities assumed, management makes significant estimates and assumptions, especially with respect to intangible assets. Critical estimates in valuing intangible assets include, but are not limited to, expected future cash flows, which includes consideration of future growth and margins, future changes in technology, expected cost and time to develop in-process research and development, brand awareness and discount rates. Fair value estimates are based on the assumptions that management believes a market participant would use in pricing the asset or liability.</p> <p style="text-align:justify;margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Goodwill</p> <p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.13%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Goodwill is not amortized but is subject to impairment tests on an annual basis, or more frequently if indicators of potential impairment exist, and goodwill is written down when it is determined to be impaired. The Company will perform an annual impairment review in the fourth quarter of each fiscal year and compare the fair value of the reporting unit in which the goodwill resides to its carrying value. </p> <p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Recent Accounting Pronouncements</p> <p style="margin-bottom:0pt;margin-top:6pt;text-indent:5.15%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company evaluates all Accounting Standards Updates, or ASUs, issued by the Financial Accounting Standards Board, or FASB, for consideration of their applicability. ASUs not included in the Company’s disclosures were assessed and determined to be either not applicable or are not expected to have a material impact on the Company’s condensed consolidated financial statements.</p> <p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Recently Adopted Accounting Pronouncements</p> <p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-style:italic;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">ASU 2016-13</p> <p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.17%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In June 2016, the FASB issued ASU No. 2016-13, Financial Instruments-Credit Losses: Measurement of Credit Losses on Financial Instruments, or ASU 2016-13. ASU 2016-13 replaces the incurred loss impairment methodology in current U.S. GAAP with a methodology that reflects expected credit losses. The update is intended to provide financial statement users with more decision-useful information about the expected credit losses on financial instruments and other commitments to extend credit held by a reporting entity at each reporting date. Entities will apply the standard’s provisions as a cumulative-effect adjustment to retained earnings as of the beginning of the first reporting period in which the guidance is effective. The standard will be effective for annual reporting periods beginning after December 15, 2019, including interim periods within those reporting periods for public business entities that meet the definition of an SEC filer, excluding entities eligible to be smaller reporting companies as defined by the SEC. For all other entities, the amendments in this update are effective for fiscal years beginning after December 15, 2022, including interim periods within those fiscal years. Early application of the amendments is permitted. The Company adopted ASU 2016-13 using the modified retrospective approach as of January 1, 2021. The cumulative effect upon adoption was $887,000 to the retained earnings in the accompanying Condensed Consolidated Statements of Stockholders’ Equity and trade accounts receivable, net, in the accompanying Condensed Consolidated Balance Sheets. The cumulative tax effective was $239,000 to retained earnings and deferred tax assets included in other long-term assets in the accompanying Condensed Consolidated Balance Sheets. There was no impact related to available-for-sale debt securities.</p> <p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-style:italic;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">ASU 2019-12</p> <p style="margin-top:6pt;margin-bottom:0pt;text-indent:5%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In December 2019, the FASB issued ASU No. 2019-12, Simplifying the Accounting for Income Taxes (Topic 740), or ASU 2019-12, which is intended to reduce the complexity of accounting standards while maintaining or enhancing the helpfulness of information provided to financial statement users.  The amendment in this ASU simplifies the accounting for income taxes by removing some exceptions including the incremental approach for intraperiod tax allocation, the requirement to recognize a deferred tax liability for equity method investments, the ability not to recognize a deferred tax liability for a foreign subsidiary, and the general methodology for calculating income taxes in an interim period. Other changes include requiring entities to recognize franchise tax that is partially based on income as an income-based tax and account for any incremental amount incurred as a non-income-based tax, evaluate tax basis step-up in goodwill obtained in a transaction that is not a business combination, and reflect the effect of an enacted change in tax laws or rates in the annual effective tax rate computation in the interim period that includes the enactment date, making minor codification improvements for income taxes related to employee stock ownership plans and investments in qualified affordable housing projects accounted for using the equity method, and specifying that an entity is not required to allocate the consolidated current and deferred tax expense to a legal entity that is not subject to tax in its separate financial statements. For public business entities, this amendment is effective for fiscal years, and interim periods within those fiscal years, beginning after December 15, 2020 with early adoption permitted. The Company adopted ASU 2019-12 in the first quarter of 2021, and the adoption had no material impact to the Company’s condensed consolidated financial statements.</p> 887000 239000 <p style="margin-top:9pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Note 3. Marketable Securities</p> <p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company’s marketable securities consisted of the following:</p> <p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;"> </p> <div> <table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;"> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:42.7%; border-bottom:solid 0.75pt transparent;" valign="middle"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="14" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:56.28%; border-bottom:solid 0.75pt #000000;" valign="middle"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">June 30, 2021</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="middle"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:42.7%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.22%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Amortized</p> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Cost Basis</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.44%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.22%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Unrealized</p> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Gains</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.44%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.22%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Unrealized</p> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Losses</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.44%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.22%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Aggregate</p> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Fair Value</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:42.7%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="14" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:56.28%;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(in thousands)</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:42.7%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Marketable securities:</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.22%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.44%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.22%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.44%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.22%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.44%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.22%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:42.7%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Short-term</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.22%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.44%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.22%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.44%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.22%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.44%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.22%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:42.7%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Equity securities</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.22%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.44%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.22%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.44%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.22%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.44%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.22%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:42.7%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Bond fund</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.22%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">169,366</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.44%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.22%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.44%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.22%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(451</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.44%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.22%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">168,925</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:42.7%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Exchange traded funds</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.22%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">35,042</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.44%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.22%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.44%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.22%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(8</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.44%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.22%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">35,034</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:42.7%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Available-for-sale debt securities</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.22%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.44%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.22%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.44%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.22%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.44%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.22%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:42.7%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Corporate debt securities</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.22%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">77,664</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.44%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.22%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">199</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.44%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.22%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(9</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.44%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.22%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">77,854</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:42.7%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Money market accounts</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.22%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5,501</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.44%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.22%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.44%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.22%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.44%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.22%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5,501</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:42.7%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Municipal bonds</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.22%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,517</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.44%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.22%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.44%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.22%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(1</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.44%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.22%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,516</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:42.7%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Less: Cash equivalents</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.22%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(5,501</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.44%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.22%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.44%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.22%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.44%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.22%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(5,501</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:42.7%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total short-term marketable securities</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.22%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">283,589</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.44%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.22%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">209</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.44%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.22%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(469</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.44%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.22%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">283,329</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:42.7%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">After 1 year through 5 years</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.22%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.44%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.22%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.44%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.22%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.44%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.22%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:42.7%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Corporate debt securities</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.22%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">354,979</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.44%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.22%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">188</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.44%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.22%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(678</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.44%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.22%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">354,489</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:42.7%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Municipal bonds</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.22%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">13,376</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.44%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.22%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">15</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.44%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.22%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(19</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.44%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.22%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">13,372</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:42.7%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Yankee debt securities</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.22%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">14,856</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.44%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.22%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.44%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.22%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(109</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.44%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.22%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">14,750</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:42.7%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">U.S. government agency debt securities</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.22%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,500</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.44%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.22%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.44%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.22%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(4</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.44%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.22%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,496</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:42.7%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total marketable securities due after 1 year through 5 years</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.22%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">384,711</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.44%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.22%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">206</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.44%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.22%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(810</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.44%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.22%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">384,107</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:42.7%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">After 5 years through 10 years</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.22%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.44%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.22%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.44%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.22%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.44%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.22%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:42.7%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Municipal bonds</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.22%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">9,182</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.44%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.22%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.44%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.22%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(43</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.44%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.22%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">9,142</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:42.7%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total marketable securities due after 5 years through 10 years</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.22%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">9,182</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.44%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.22%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.44%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.22%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(43</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.44%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.22%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">9,142</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:42.7%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total marketable securities</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.22%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">677,482</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.44%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.22%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">418</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.44%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.22%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(1,322</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.44%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.22%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">676,578</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> </table></div> <p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;"> </p> <div> <table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;"> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:42.7%; border-bottom:solid 0.75pt transparent;" valign="middle"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="14" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:56.28%; border-bottom:solid 0.75pt #000000;" valign="middle"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December 31, 2020</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="middle"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:42.7%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.22%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Amortized</p> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Cost Basis</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.44%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.22%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Unrealized</p> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Gains</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.44%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.22%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Unrealized</p> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Losses</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.44%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.22%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Aggregate</p> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Fair Value</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:42.7%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="14" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:56.28%;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(in thousands)</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:42.7%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Marketable securities:</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.22%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.44%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.22%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.44%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.22%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.44%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.22%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:42.7%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Short-term</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.22%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.44%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.22%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.44%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.22%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.44%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.22%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:42.7%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Equity securities</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.22%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.44%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.22%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.44%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.22%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.44%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.22%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:42.7%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Bond fund</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.22%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">153,269</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.44%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.22%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">67</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.44%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.22%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(151</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.44%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.22%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">153,185</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:42.7%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Exchange traded funds</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.22%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">17,614</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.44%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.22%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.44%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.22%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(5</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.44%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.22%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">17,609</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:42.7%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Available-for-sale debt securities</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.22%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.44%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.22%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.44%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.22%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.44%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.22%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:42.7%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Money market accounts</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.22%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">47,461</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.44%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.22%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.44%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.22%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.44%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.22%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">47,461</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:42.7%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Corporate debt securities</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.22%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">41,061</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.44%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.22%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">101</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.44%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.22%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(15</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.44%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.22%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">41,147</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:42.7%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Less: Cash equivalents</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.22%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(47,461</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.44%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.22%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.44%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.22%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.44%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.22%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(47,461</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:42.7%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total short-term marketable securities</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.22%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">211,944</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.44%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.22%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">168</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.44%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.22%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(171</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.44%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.22%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">211,941</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:42.7%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">After 1 year through 5 years</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.22%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.44%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.22%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.44%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.22%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.44%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.22%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:42.7%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Corporate debt securities</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.22%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">124,989</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.44%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.22%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">580</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.44%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.22%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(117</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.44%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.22%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">125,452</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:42.7%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">U.S. government agency debt securities</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.22%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,000</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.44%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.22%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.44%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.22%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.44%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.22%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,002</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:42.7%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Yankee debt securities</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.22%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6,054</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.44%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.22%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.44%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.22%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(10</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.44%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.22%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6,048</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:42.7%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total marketable securities due after 1 year through 5 years</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.22%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">132,043</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.44%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.22%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">586</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.44%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.22%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(127</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.44%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.22%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">132,502</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:42.7%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total marketable securities</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.22%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">343,987</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.44%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.22%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">754</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.44%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.22%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(298</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.44%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.22%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">344,443</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> </table></div> <p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;"> </p> <p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"> </p> <p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Gross unrealized losses on the Company’s marketable securities were $1.3 million as of June 30, 2021. Gross unrealized losses on the Company’s marketable securities were $298,000 as of December 31, 2020. The Company currently does not intend to sell these securities prior to maturity. During the three and six months ended June 30, 2021, the Company did not recognize credit losses.</p> <p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company’s securities of $420.4 million are used as collateral for an outstanding margin account borrowing. As of June 30, 2021, the Company had an outstanding borrowing of $15.1 million under its margin account. Margin account borrowings were used for the purchase of real property located in El Monte, California in 2020.</p> <p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company’s marketable securities consisted of the following:</p> <p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;"> </p> <div> <table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;"> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:42.7%; border-bottom:solid 0.75pt transparent;" valign="middle"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="14" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:56.28%; border-bottom:solid 0.75pt #000000;" valign="middle"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">June 30, 2021</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="middle"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:42.7%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.22%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Amortized</p> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Cost Basis</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.44%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.22%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Unrealized</p> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Gains</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.44%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.22%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Unrealized</p> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Losses</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.44%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.22%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Aggregate</p> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Fair Value</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:42.7%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="14" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:56.28%;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(in thousands)</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:42.7%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Marketable securities:</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.22%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.44%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.22%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.44%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.22%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.44%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.22%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:42.7%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Short-term</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.22%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.44%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.22%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.44%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.22%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.44%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.22%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:42.7%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Equity securities</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.22%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.44%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.22%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.44%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.22%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.44%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.22%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:42.7%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Bond fund</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.22%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">169,366</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.44%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.22%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.44%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.22%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(451</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.44%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.22%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">168,925</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:42.7%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Exchange traded funds</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.22%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">35,042</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.44%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.22%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.44%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.22%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(8</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.44%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.22%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">35,034</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:42.7%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Available-for-sale debt securities</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.22%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.44%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.22%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.44%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.22%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.44%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.22%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:42.7%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Corporate debt securities</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.22%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">77,664</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.44%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.22%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">199</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.44%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.22%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(9</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.44%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.22%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">77,854</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:42.7%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Money market accounts</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.22%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5,501</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.44%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.22%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.44%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.22%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.44%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.22%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5,501</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:42.7%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Municipal bonds</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.22%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,517</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.44%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.22%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.44%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.22%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(1</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.44%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.22%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,516</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:42.7%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Less: Cash equivalents</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.22%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(5,501</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.44%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.22%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.44%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.22%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.44%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.22%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(5,501</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:42.7%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total short-term marketable securities</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.22%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">283,589</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.44%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.22%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">209</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.44%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.22%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(469</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.44%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.22%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">283,329</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:42.7%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">After 1 year through 5 years</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.22%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.44%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.22%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.44%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.22%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.44%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.22%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:42.7%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Corporate debt securities</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.22%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">354,979</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.44%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.22%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">188</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.44%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.22%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(678</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.44%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.22%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">354,489</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:42.7%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Municipal bonds</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.22%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">13,376</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.44%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.22%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">15</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.44%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.22%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(19</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.44%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.22%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">13,372</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:42.7%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Yankee debt securities</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.22%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">14,856</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.44%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.22%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.44%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.22%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(109</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.44%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.22%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">14,750</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:42.7%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">U.S. government agency debt securities</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.22%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,500</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.44%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.22%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.44%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.22%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(4</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.44%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.22%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,496</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:42.7%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total marketable securities due after 1 year through 5 years</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.22%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">384,711</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.44%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.22%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">206</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.44%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.22%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(810</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.44%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.22%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">384,107</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:42.7%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">After 5 years through 10 years</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.22%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.44%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.22%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.44%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.22%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.44%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.22%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:42.7%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Municipal bonds</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.22%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">9,182</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.44%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.22%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.44%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.22%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(43</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.44%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.22%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">9,142</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:42.7%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total marketable securities due after 5 years through 10 years</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.22%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">9,182</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.44%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.22%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.44%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.22%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(43</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.44%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.22%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">9,142</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:42.7%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total marketable securities</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.22%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">677,482</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.44%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.22%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">418</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.44%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.22%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(1,322</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.44%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.22%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">676,578</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> </table></div> <p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;"> </p> <div> <table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;"> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:42.7%; border-bottom:solid 0.75pt transparent;" valign="middle"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="14" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:56.28%; border-bottom:solid 0.75pt #000000;" valign="middle"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December 31, 2020</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="middle"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:42.7%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.22%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Amortized</p> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Cost Basis</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.44%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.22%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Unrealized</p> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Gains</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.44%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.22%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Unrealized</p> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Losses</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.44%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.22%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Aggregate</p> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Fair Value</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:42.7%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="14" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:56.28%;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(in thousands)</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:42.7%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Marketable securities:</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.22%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.44%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.22%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.44%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.22%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.44%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.22%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:42.7%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Short-term</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.22%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.44%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.22%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.44%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.22%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.44%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.22%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:42.7%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Equity securities</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.22%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.44%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.22%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.44%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.22%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.44%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.22%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:42.7%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Bond fund</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.22%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">153,269</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.44%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.22%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">67</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.44%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.22%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(151</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.44%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.22%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">153,185</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:42.7%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Exchange traded funds</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.22%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">17,614</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.44%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.22%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.44%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.22%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(5</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.44%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.22%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">17,609</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:42.7%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Available-for-sale debt securities</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.22%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.44%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.22%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.44%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.22%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.44%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.22%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:42.7%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Money market accounts</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.22%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">47,461</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.44%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.22%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.44%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.22%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.44%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.22%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">47,461</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:42.7%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Corporate debt securities</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.22%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">41,061</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.44%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.22%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">101</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.44%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.22%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(15</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.44%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.22%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">41,147</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:42.7%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Less: Cash equivalents</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.22%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(47,461</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.44%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.22%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.44%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.22%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.44%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.22%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(47,461</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:42.7%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total short-term marketable securities</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.22%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">211,944</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.44%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.22%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">168</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.44%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.22%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(171</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.44%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.22%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">211,941</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:42.7%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">After 1 year through 5 years</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.22%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.44%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.22%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.44%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.22%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.44%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.22%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:42.7%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Corporate debt securities</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.22%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">124,989</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.44%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.22%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">580</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.44%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.22%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(117</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.44%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.22%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">125,452</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:42.7%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">U.S. government agency debt securities</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.22%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,000</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.44%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.22%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.44%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.22%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.44%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.22%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,002</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:42.7%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Yankee debt securities</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.22%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6,054</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.44%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.22%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.44%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.22%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(10</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.44%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.22%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6,048</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:42.7%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total marketable securities due after 1 year through 5 years</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.22%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">132,043</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.44%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.22%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">586</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.44%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.22%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(127</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.44%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.22%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">132,502</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:42.7%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total marketable securities</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.22%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">343,987</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.44%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.22%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">754</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.44%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.22%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(298</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.44%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.22%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">344,443</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> </table></div> 169366000 10000 451000 168925000 35042000 8000 35034000 77664000 199000 9000 77854000 5501000 5501000 1517000 1000 1516000 5501000 5501000 283589000 209000 469000 283329000 354979000 188000 678000 354489000 13376000 15000 19000 13372000 14856000 3000 109000 14750000 1500000 4000 1496000 384711000 206000 810000 384107000 9182000 3000 43000 9142000 9182000 3000 43000 9142000 677482000 418000 1322000 676578000 153269000 67000 151000 153185000 17614000 5000 17609000 47461000 47461000 41061000 101000 15000 41147000 47461000 47461000 211944000 168000 171000 211941000 124989000 580000 117000 125452000 1000000 2000 1002000 6054000 4000 10000 6048000 132043000 586000 127000 132502000 343987000 754000 298000 344443000 1300000 298000 0 420400000 15100000 <p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Note 4. <span style="Background-color:#FFFFFF;color:#000000;">Fair Value Measurements</span></p> <p style="margin-bottom:6pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The authoritative guidance on fair value measurements establishes a framework with respect to measuring assets and liabilities at fair value on a recurring basis and non-recurring basis. Under the framework, fair value is defined as the exit price, or the amount that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants, as of the measurement date. The framework also establishes a three-tier hierarchy for inputs used in measuring fair value that maximizes the use of observable inputs and minimizes the use of unobservable inputs by requiring that the most observable inputs be used when available. Observable inputs are inputs market participants would use in valuing the asset or liability and are developed based on market data obtained from sources independent of the Company. Unobservable inputs are inputs that reflect the Company’s assumptions about the factors market participants would use in valuing the asset or liability and are developed based on the best information available in the circumstances. The hierarchy consists of the following three levels:</p> <div style="align:left;"> <table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse; margin-left:5%;width:89.98%;"> <tr style="height:30.65pt;"> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.7%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Level 1:</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:90.3%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Inputs are quoted prices (unadjusted) in active markets for identical assets or liabilities that the reporting entity can access at the measurement date.</p></td> </tr> <tr style="height:31.15pt;"> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.7%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Level 2:</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:90.3%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Inputs are inputs other than quoted prices included within Level 1 that are observable for the asset or liability, either directly or indirectly.</p></td> </tr> <tr style="height:15.05pt;"> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.7%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Level 3:</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:90.3%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Inputs are unobservable inputs for the asset or liability.</p></td> </tr> </table></div> <p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;"> </p> <p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.54%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The following tables present information about the Company’s financial assets measured at fair value on a recurring basis, based on the three-tier fair value hierarchy:</p> <p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;"> </p> <div> <table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;"> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:42.7%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="14" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:56.28%; border-bottom:solid 0.75pt #000000;" valign="top"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">June 30, 2021</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:42.7%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.22%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="top"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Total</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.44%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="top"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.22%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="top"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Level 1</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.44%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="top"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.22%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="top"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Level 2</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.44%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="top"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.22%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="top"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Level 3</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:42.7%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="14" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:56.28%;" valign="top"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(in thousands)</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:42.7%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Marketable securities and cash equivalents:</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.22%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.44%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.22%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.44%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.22%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.44%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.22%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:42.7%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Bond Fund</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.22%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">168,925</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.44%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.22%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">168,925</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.44%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.22%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.44%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.22%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:42.7%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Exchange traded funds</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.22%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">35,034</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.44%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.22%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">35,034</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.44%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.22%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.44%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.22%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:42.7%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Corporate debt securities</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.22%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">432,343</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.44%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.22%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.44%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.22%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">432,343</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.44%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.22%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:42.7%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Municipal bonds</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.22%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">24,030</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.44%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.22%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.44%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.22%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">24,030</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.44%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.22%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:42.7%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Yankee debt securities</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.22%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">14,750</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.44%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.22%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.44%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.22%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">14,750</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.44%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.22%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:42.7%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">U.S. government agency debt securities</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.22%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,496</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.44%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.22%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.44%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.22%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,496</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.44%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.22%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:42.7%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Money market accounts</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.22%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5,501</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.44%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.22%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5,501</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.44%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.22%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.44%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.22%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:42.7%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total marketable securities and cash equivalents</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.22%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">682,079</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.44%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.22%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">209,460</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.44%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.22%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">472,619</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.44%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.22%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> </table></div> <p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;"> </p> <div> <table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;"> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:42.7%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="14" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:56.28%; border-bottom:solid 0.75pt #000000;" valign="top"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December 31, 2020</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:42.7%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.22%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Total</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.44%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.22%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Level 1</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.44%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.22%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Level 2</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.44%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.22%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Level 3</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:42.7%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="14" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:56.28%;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(in thousands)</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:42.7%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Marketable securities and cash equivalents:</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.22%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.44%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.22%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.44%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.22%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.44%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.22%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:42.7%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Bond Fund</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.22%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">153,185</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.44%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.22%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">153,185</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.44%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.22%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.44%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.22%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:42.7%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Exchange traded funds</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.22%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">17,609</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.44%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.22%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">17,609</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.44%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.22%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.44%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.22%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:42.7%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Corporate debt securities</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.22%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">166,599</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.44%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.22%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.44%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.22%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">166,599</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.44%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.22%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:42.7%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">U.S. government agency debt securities</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.22%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,002</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.44%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.22%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.44%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.22%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,002</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.44%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.22%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:42.7%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Yankee debt securities</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.22%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6,048</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.44%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.22%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.44%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.22%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6,048</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.44%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.22%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:42.7%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Money market accounts</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.22%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">47,461</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.44%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.22%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">47,461</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.44%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.22%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.44%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.22%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:42.7%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total marketable securities and cash equivalents</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.22%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">391,904</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.44%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.22%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">218,255</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.44%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.22%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">173,649</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.44%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.22%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> </table></div> <p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;"> </p> <p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company’s Level 1 assets include marketable equity securities and money market instruments and are valued based upon observable market prices. Level 2 assets consist of U.S. government agency debt securities, municipal bonds, corporate debt securities and Yankee debt securities. Level 2 securities are valued based upon observable inputs that include reported trades, broker/dealer </p> <p style="margin-bottom:0pt;margin-top:0pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">quotes, bids and offers. </span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As of </span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">June</span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> 30</span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">, 202</span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1</span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">, the Company had </span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">no</span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> investments that were measured using unobservable (Level 3) inputs. </span></p> <p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">There were no transfers between fair value measurement levels during the three and six months ended June 30, 2021.</p> <p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.54%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The following tables present information about the Company’s financial assets measured at fair value on a recurring basis, based on the three-tier fair value hierarchy:</p> <p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;"> </p> <div> <table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;"> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:42.7%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="14" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:56.28%; border-bottom:solid 0.75pt #000000;" valign="top"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">June 30, 2021</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:42.7%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.22%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="top"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Total</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.44%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="top"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.22%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="top"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Level 1</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.44%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="top"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.22%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="top"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Level 2</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.44%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="top"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.22%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="top"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Level 3</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:42.7%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="14" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:56.28%;" valign="top"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(in thousands)</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:42.7%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Marketable securities and cash equivalents:</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.22%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.44%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.22%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.44%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.22%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.44%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.22%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:42.7%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Bond Fund</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.22%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">168,925</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.44%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.22%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">168,925</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.44%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.22%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.44%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.22%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:42.7%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Exchange traded funds</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.22%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">35,034</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.44%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.22%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">35,034</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.44%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.22%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.44%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.22%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:42.7%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Corporate debt securities</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.22%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">432,343</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.44%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.22%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.44%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.22%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">432,343</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.44%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.22%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:42.7%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Municipal bonds</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.22%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">24,030</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.44%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.22%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.44%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.22%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">24,030</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.44%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.22%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:42.7%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Yankee debt securities</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.22%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">14,750</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.44%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.22%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.44%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.22%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">14,750</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.44%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.22%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:42.7%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">U.S. government agency debt securities</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.22%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,496</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.44%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.22%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.44%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.22%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,496</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.44%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.22%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:42.7%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Money market accounts</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.22%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5,501</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.44%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.22%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5,501</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.44%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.22%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.44%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.22%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:42.7%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total marketable securities and cash equivalents</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.22%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">682,079</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.44%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.22%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">209,460</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.44%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.22%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">472,619</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.44%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.22%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> </table></div> <div> <table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;"> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:42.7%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="14" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:56.28%; border-bottom:solid 0.75pt #000000;" valign="top"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December 31, 2020</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:42.7%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.22%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Total</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.44%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.22%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Level 1</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.44%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.22%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Level 2</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.44%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.22%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Level 3</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:42.7%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="14" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:56.28%;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(in thousands)</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:42.7%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Marketable securities and cash equivalents:</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.22%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.44%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.22%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.44%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.22%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.44%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.22%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:42.7%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Bond Fund</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.22%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">153,185</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.44%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.22%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">153,185</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.44%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.22%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.44%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.22%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:42.7%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Exchange traded funds</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.22%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">17,609</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.44%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.22%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">17,609</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.44%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.22%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.44%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.22%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:42.7%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Corporate debt securities</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.22%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">166,599</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.44%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.22%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.44%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.22%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">166,599</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.44%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.22%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:42.7%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">U.S. government agency debt securities</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.22%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,002</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.44%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.22%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.44%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.22%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,002</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.44%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.22%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:42.7%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Yankee debt securities</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.22%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6,048</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.44%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.22%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.44%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.22%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6,048</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.44%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.22%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:42.7%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Money market accounts</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.22%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">47,461</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.44%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.22%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">47,461</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.44%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.22%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.44%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.22%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:42.7%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total marketable securities and cash equivalents</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.22%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">391,904</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.44%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.22%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">218,255</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.44%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.22%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">173,649</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.44%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.22%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> </table></div> 168925000 168925000 0 0 35034000 35034000 0 0 432343000 0 432343000 0 24030000 0 24030000 0 14750000 0 14750000 0 1496000 0 1496000 0 5501000 5501000 0 0 682079000 209460000 472619000 0 153185000 153185000 0 0 17609000 17609000 0 0 166599000 0 166599000 0 1002000 0 1002000 0 6048000 0 6048000 0 47461000 47461000 0 0 391904000 218255000 173649000 0 0 0 <p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Note 5. Fixed Assets</p> <p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Major classes of fixed assets consisted of the following:</p> <p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;"> </p> <div> <table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;"> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:38.28%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:38.28%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.96%; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">June 30,</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.18%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.24%; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December 31,</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:38.28%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:38.28%; border-bottom:solid 0.75pt #000000;" valign="top"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Useful Lives</p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.96%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2021</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.18%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.24%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:38.28%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:38.28%; border-top:solid 0.75pt #000000;" valign="top"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:22.4%;" valign="top"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(in thousands)</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:38.28%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Medical lab equipment</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:38.28%;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3 to 5 Years</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.96%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">30,108</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.18%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.24%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">20,849</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:38.28%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Building</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:38.28%;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">39 Years</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.96%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6,731</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.18%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.24%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6,731</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:38.28%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Aircraft</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:38.28%;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7 Years</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.96%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6,503</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.18%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.24%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6,503</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:38.28%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Computer hardware</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:38.28%;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3 Years</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.96%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,580</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.18%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.24%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,699</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:38.28%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Leasehold improvements</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:38.28%;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Shorter of lease term or estimated useful life</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.96%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,941</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.18%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.24%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,580</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:38.28%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Furniture and fixtures</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:38.28%;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2 to 5 Years</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.96%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,056</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.18%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.24%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">454</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:38.28%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Automobile</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:38.28%;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2 to 5 Years</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.96%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">716</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.18%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.24%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">53</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:38.28%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Building improvements</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:38.28%;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6 months to 5 Years</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.96%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">707</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.18%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.24%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">707</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:38.28%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Computer software</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:38.28%;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3 to 5 Years</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.96%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">754</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.18%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.24%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">541</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:38.28%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Land improvements</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:38.28%;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5 to 15 Years</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.96%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">403</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.18%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.24%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">403</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:38.28%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">General equipment</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:38.28%;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3 to 5 Years</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.96%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">44</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.18%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.24%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">44</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:38.28%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Land</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:38.28%;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.96%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7,500</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.18%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.24%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7,500</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:38.28%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Assets not yet placed in service</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:38.28%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.96%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,783</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.18%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.24%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,055</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:38.28%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:38.28%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.96%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">65,826</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.18%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.24%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">51,119</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:38.28%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Less: Accumulated depreciation</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:38.28%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.96%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(14,740</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.18%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.24%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(10,920</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:38.28%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Fixed assets, net</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:38.28%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.96%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">51,086</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.18%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.24%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">40,199</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> </table></div> <p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;"> </p> <p style="margin-top:2pt;margin-bottom:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Depreciation expense on fixed assets totaled $2.3 million and $549,000 for the three months and $4.2 million and $1.1 million for the six months ended June 30, 2021 and 2020, respectively.</p> <p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Major classes of fixed assets consisted of the following:</p> <p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;"> </p> <div> <table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;"> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:38.28%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:38.28%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.96%; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">June 30,</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.18%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.24%; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December 31,</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:38.28%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:38.28%; border-bottom:solid 0.75pt #000000;" valign="top"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Useful Lives</p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.96%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2021</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.18%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.24%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:38.28%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:38.28%; border-top:solid 0.75pt #000000;" valign="top"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:22.4%;" valign="top"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(in thousands)</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:38.28%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Medical lab equipment</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:38.28%;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3 to 5 Years</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.96%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">30,108</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.18%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.24%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">20,849</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:38.28%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Building</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:38.28%;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">39 Years</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.96%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6,731</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.18%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.24%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6,731</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:38.28%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Aircraft</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:38.28%;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7 Years</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.96%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6,503</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.18%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.24%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6,503</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:38.28%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Computer hardware</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:38.28%;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3 Years</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.96%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,580</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.18%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.24%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,699</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:38.28%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Leasehold improvements</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:38.28%;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Shorter of lease term or estimated useful life</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.96%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,941</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.18%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.24%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,580</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:38.28%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Furniture and fixtures</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:38.28%;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2 to 5 Years</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.96%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,056</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.18%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.24%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">454</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:38.28%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Automobile</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:38.28%;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2 to 5 Years</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.96%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">716</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.18%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.24%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">53</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:38.28%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Building improvements</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:38.28%;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6 months to 5 Years</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.96%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">707</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.18%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.24%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">707</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:38.28%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Computer software</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:38.28%;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3 to 5 Years</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.96%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">754</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.18%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.24%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">541</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:38.28%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Land improvements</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:38.28%;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5 to 15 Years</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.96%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">403</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.18%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.24%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">403</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:38.28%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">General equipment</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:38.28%;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3 to 5 Years</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.96%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">44</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.18%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.24%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">44</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:38.28%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Land</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:38.28%;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.96%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7,500</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.18%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.24%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7,500</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:38.28%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Assets not yet placed in service</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:38.28%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.96%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,783</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.18%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.24%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,055</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:38.28%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:38.28%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.96%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">65,826</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.18%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.24%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">51,119</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:38.28%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Less: Accumulated depreciation</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:38.28%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.96%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(14,740</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.18%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.24%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(10,920</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:38.28%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Fixed assets, net</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:38.28%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.96%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">51,086</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.18%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.24%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">40,199</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> </table></div> P3Y P5Y 30108000 20849000 P39Y 6731000 6731000 P7Y 6503000 6503000 P3Y 4580000 3699000 Shorter of lease term or estimated useful life 1941000 1580000 P2Y P5Y 1056000 454000 P2Y P5Y 716000 53000 P6M P5Y 707000 707000 P3Y P5Y 754000 541000 P5Y P15Y 403000 403000 P3Y P5Y 44000 44000 7500000 7500000 4783000 2055000 65826000 51119000 14740000 10920000 51086000 40199000 2300000 549000 4200000 1100000 <p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Note 6. Other Significant Balance Sheet Accounts</p> <p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Other current assets consisted of the following:</p> <p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;"> </p> <div> <table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;"> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:60.46%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.72%; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">June 30,</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.04%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.72%; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December 31,</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:60.46%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.72%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2021</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.04%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.72%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:60.46%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:38.52%;" valign="top"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(in thousands)</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:60.46%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Reagents and supplies</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.72%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">25,373</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.04%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.72%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">16,491</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:60.46%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Prepaid expenses</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.72%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,311</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.04%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.72%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,682</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:60.46%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Marketable securities interest receivable</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.72%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,898</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.04%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.72%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,016</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:60.46%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Other receivable</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.72%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,415</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.04%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.72%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">17,810</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:60.46%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Contract assets</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.72%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">324</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.04%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.72%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,379</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:60.46%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Prepaid income taxes</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.72%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.04%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.72%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">14</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:60.46%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.72%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">34,321</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.04%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.72%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">40,392</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> </table></div> <p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.54%;font-size:10pt;"> </p> <p style="margin-top:2pt;margin-bottom:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Reagents and supplies include reagents and consumables used for COVID-19 testing and genetics testing and collection kits for COVID-19 testing. Other receivable as of December 31, 2020 primarily consists of proceeds to be received from public offerings of the Company’s common stock, which were all collected during the six months ended June 30, 2021.</p> <p style="margin-top:2pt;margin-bottom:0pt;text-indent:4.54%;font-size:10pt;"> </p> <p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"> </p> <p style="margin-top:2pt;margin-bottom:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Other current liabilities consisted of the following:</p> <p style="margin-top:2pt;margin-bottom:0pt;text-indent:4.54%;font-size:10pt;"> </p> <div> <table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;"> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:60.46%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.72%; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">June 30,</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.04%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.72%; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December 31,</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:60.46%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.72%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2021</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.04%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.72%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:60.46%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:38.52%;" valign="top"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(in thousands)</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:60.46%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Payroll liabilities</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.72%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6,687</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.04%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.72%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5,314</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:60.46%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Sales tax payable and other</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.72%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,801</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.04%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.72%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,538</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:60.46%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Operating lease liabilities</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.72%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,001</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.04%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.72%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">267</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:60.46%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Due to related parties</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.72%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">574</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.04%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.72%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">409</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:60.46%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.72%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">13,063</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.04%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.72%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8,528</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> </table></div> <p style="margin-top:2pt;margin-bottom:0pt;text-indent:4.54%;font-size:10pt;"> </p> <p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Other current assets consisted of the following:</p> <p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;"> </p> <div> <table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;"> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:60.46%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.72%; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">June 30,</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.04%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.72%; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December 31,</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:60.46%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.72%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2021</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.04%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.72%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:60.46%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:38.52%;" valign="top"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(in thousands)</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:60.46%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Reagents and supplies</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.72%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">25,373</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.04%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.72%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">16,491</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:60.46%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Prepaid expenses</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.72%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,311</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.04%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.72%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,682</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:60.46%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Marketable securities interest receivable</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.72%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,898</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.04%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.72%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,016</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:60.46%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Other receivable</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.72%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,415</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.04%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.72%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">17,810</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:60.46%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Contract assets</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.72%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">324</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.04%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.72%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,379</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:60.46%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Prepaid income taxes</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.72%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.04%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.72%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">14</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:60.46%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.72%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">34,321</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.04%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.72%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">40,392</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> </table></div> 25373000 16491000 4311000 3682000 2898000 1016000 1415000 17810000 324000 1379000 14000 34321000 40392000 <p style="margin-top:2pt;margin-bottom:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Other current liabilities consisted of the following:</p> <p style="margin-top:2pt;margin-bottom:0pt;text-indent:4.54%;font-size:10pt;"> </p> <div> <table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;"> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:60.46%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.72%; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">June 30,</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.04%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.72%; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December 31,</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:60.46%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.72%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2021</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.04%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.72%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:60.46%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:38.52%;" valign="top"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(in thousands)</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:60.46%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Payroll liabilities</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.72%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6,687</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.04%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.72%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5,314</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:60.46%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Sales tax payable and other</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.72%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,801</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.04%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.72%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,538</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:60.46%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Operating lease liabilities</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.72%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,001</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.04%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.72%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">267</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:60.46%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Due to related parties</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.72%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">574</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.04%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.72%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">409</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:60.46%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.72%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">13,063</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.04%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.72%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8,528</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> </table></div> 6687000 5314000 4801000 2538000 1001000 267000 574000 409000 13063000 8528000 <p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><span style="Background-color:#FFFFFF;">Note </span><span style="color:#000000;">7. Reporting Segment and Geographic Information</span></p> <p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company views its operations and manages its business in one reporting segment. Long-lived assets were primarily located in the United States as of June 30, 2021 and December 31, 2020 with an insignificant amount located in China and Canada. Revenue by region during the three and six months ended June 30, 2021 and 2020 were as follows:</p> <p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;"> </p> <div> <table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;"> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:42.7%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:26.9%; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Three Months Ended June 30,</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.44%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:26.9%; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Six Months Ended June 30,</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:42.7%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.22%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2021</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.44%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.22%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.44%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.22%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2021</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.44%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.22%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:42.7%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="14" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:56.28%;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(in thousands)</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:42.7%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Revenue:</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.22%;white-space:nowrap;" valign="top"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.44%;" valign="top"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.22%;white-space:nowrap;" valign="top"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.44%;" valign="top"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.22%;white-space:nowrap;" valign="top"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.44%;" valign="top"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.22%;white-space:nowrap;" valign="top"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:42.7%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">United States</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.22%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">149,862</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.44%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.22%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">16,138</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.44%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.22%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">507,399</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.44%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.22%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">21,777</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:42.7%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Foreign</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.22%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,754</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.44%; border-bottom:solid 0.75pt transparent;" valign="top"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.22%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,127</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.44%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.22%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5,646</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.44%; border-bottom:solid 0.75pt transparent;" valign="top"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.22%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,241</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:42.7%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.22%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="top"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">153,616</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.44%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.22%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="top"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">17,265</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.44%; border-bottom:double 2.5pt transparent;" valign="top"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.22%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="top"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">513,045</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.44%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.22%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="top"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">25,018</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> </table></div> 1 Revenue by region during the three and six months ended June 30, 2021 and 2020 were as follows: <p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;"> </p> <div> <table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;"> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:42.7%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:26.9%; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Three Months Ended June 30,</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.44%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:26.9%; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Six Months Ended June 30,</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:42.7%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.22%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2021</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.44%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.22%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.44%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.22%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2021</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.44%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.22%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:42.7%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="14" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:56.28%;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(in thousands)</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:42.7%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Revenue:</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.22%;white-space:nowrap;" valign="top"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.44%;" valign="top"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.22%;white-space:nowrap;" valign="top"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.44%;" valign="top"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.22%;white-space:nowrap;" valign="top"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.44%;" valign="top"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.22%;white-space:nowrap;" valign="top"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:42.7%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">United States</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.22%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">149,862</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.44%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.22%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">16,138</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.44%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.22%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">507,399</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.44%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.22%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">21,777</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:42.7%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Foreign</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.22%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,754</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.44%; border-bottom:solid 0.75pt transparent;" valign="top"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.22%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,127</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.44%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.22%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5,646</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.44%; border-bottom:solid 0.75pt transparent;" valign="top"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.22%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,241</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:42.7%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.22%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="top"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">153,616</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.44%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.22%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="top"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">17,265</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.44%; border-bottom:double 2.5pt transparent;" valign="top"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.22%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="top"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">513,045</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.44%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.22%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="top"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">25,018</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> </table></div> 149862000 16138000 507399000 21777000 3754000 1127000 5646000 3241000 153616000 17265000 513045000 25018000 <p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><span style="Background-color:#FFFFFF;">Note </span><span style="color:#000000;">8. Debt, Commitments and Contingencies</span></p> <p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;;font-size:10pt;"> </p> <p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Debt</p> <p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.13%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As of June 30, 2021, the Company had an outstanding borrowing of $15.1 million under its margin account with the custodian of the Company’s marketable debt security investment account, Pershing Advisor Solutions, LLC, a BNY Mellon Company. Margin account borrowings were used for the purchase of real property located in El Monte, California in 2020. The securities in the brokerage account were used as collateral for the margin loan. The custodian can issue a margin call at any time. The interest rate on the margin loan was the effective federal funds rate, or EFFR, plus a spread, and the EFFR and/or the spread can be changed by BNY Mellon at any time. The interest was 1% at the time of withdrawal of $15.0 million from the margin account, and the interest rate at June 30, 2021 was less than 1.0%. The Company did not make any other withdrawals from the margin account, and the outstanding balance of $15.1 million is included in the accompanying Condensed Consolidated Balance Sheets. The related interest expenses for the three and six months ended June 30, 2021 were $29,000 and $58,000, respectively. The related interest expenses were none for the three and six months ended June 30, 2020.</p> <p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.13%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Notes payable as of June 30, 2021 consisted of $5.9 million of notes payable to <span style="Background-color:#FFFFFF;">Xilong Scientific Co., Ltd., or </span>Xilong Scientific, by <span style="Background-color:#FFFFFF;">Fujian Fujun Gene Biotech Co., Ltd., or </span>FF Gene Biotech, as defined in Note 14, Business Combination. The loan is payable on December 31, 2022 and interest rate on the loan is 4.97%.</p> <p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Operating Leases</p> <p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.17%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">See Note 9, Leases, for further information.<span style="color:#000000;"> </span></p> <p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Purchase Obligations</p> <p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As of June 30, 2021, the Company had non-cancelable purchase obligations of $7.6 million, of which, $4.9 million for reagents and other supplies, $2.3 million for medical lab equipment, and $372,000 for medical lab furniture are payable within twelve months.</p> <p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Contingencies</p> <p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">From time to time, the Company may be subject to legal proceedings and claims arising in the ordinary course of business. In the opinion of management, the outcome of these matters would not have a material effect on the Company’s condensed consolidated financial position, results of operations or cash flows.</p> 15100000 0.01 15000000.0 0.010 15100000 29000 58000 0 0 5900000 The loan is payable on December 31, 2022 and interest rate on the loan is 4.97%. 0.0497 7600000 4900000 2300000 372000 <p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Note 9. Leases</p> <p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;;font-size:10pt;"> </p> <p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Lessee</p> <p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company is party as a lessee to various non-cancelable operating leases with varying terms through February 2026 primarily for laboratory and office space and equipment.<span style="text-decoration:none;color:#auto;"> The Company has an option to renew one of these leases for one year after its expiration.</span> On a lease-by-lease basis, the Company considers such options, which may be elected at the Company’s sole discretion, in determining the lease term. The Company does not have any finance leases or leases with variable lease payments. The Company’s lease agreements do not contain any residual value guarantees, material restrictive covenants, bargain purchase options or asset retirement obligations.</p> <p style="Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company’s headquarters are located in Temple City, California, which is comprised of various corporate offices and a laboratory certified under the Clinical Laboratory Improvement Amendments of 1988, or CLIA, accredited by the College of American Pathologists, or CAP, and licensed by the State of California Department of Public Health. Another CLIA-certified laboratory is located in Houston, Texas. Additional offices are located in Atlanta, Georgia and are used for certain report generation functions.</p> <p style="Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In February 2021, the Company extended the lease for its headquarters located in Temple City, California, to January 31, 2023. In March 2021, the Company entered into a new lease for its 12,000 square foot CLIA-certified laboratory in Houston, Texas, and the lease will expire in November 2023<span style="color:#000000;">.</span></p> <p style="Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The operating lease right-of-use asset, short-term lease liabilities, and long-term lease liabilities as of June 30, 2021 and December 31, 2020 were as follows:</p> <div> <table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;"> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:60.46%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.72%; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">June 30,</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.04%;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.72%; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December 31,</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:60.46%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.72%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2021</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.04%; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.72%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:60.46%;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:38.52%; border-top:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(in thousands)</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:60.46%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Operating lease right-of-use asset</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.72%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,176</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.04%;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.72%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">828</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:60.46%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Operating lease liabilities, short term</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.72%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,001</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.04%;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.72%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">267</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:60.46%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Operating lease liabilities, long term</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.72%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,188</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.04%;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.72%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">568</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> </table></div> <p style="Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The following was operating lease expense:</p> <p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;"> </p> <div> <table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;"> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:42.7%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:26.9%; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Three months ended June 30,</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.44%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:26.9%; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Six months ended June 30,</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:42.7%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.22%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2021</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.44%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.22%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.44%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.22%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2021</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.44%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.22%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:42.7%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="14" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:56.28%;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(in thousands)</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:42.7%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Operating lease cost</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.22%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">232</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.44%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.22%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">152</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.44%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.22%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">301</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.44%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.22%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">301</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:42.7%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Short-term lease cost</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.22%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">61</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.44%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.22%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.44%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.22%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">192</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.44%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.22%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:42.7%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total lease cost</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.22%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">293</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.44%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.22%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">155</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.44%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.22%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">493</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.44%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.22%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">304</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> </table></div> <p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;"> </p> <p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;"> </p> <p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;"> </p> <p style="Background-color:#FFFFFF;margin-top:2pt;margin-bottom:0pt;text-indent:4.54%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Supplemental information related to leases was the following:</p> <p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;"> </p> <div> <table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;"> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:76.34%; border-bottom:solid 0.75pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:22.64%; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">June 30, 2021</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:76.34%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Weighted average remaining lease term - operating leases</p></td> <td colspan="2" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:22.64%; border-top:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2.9 years</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:76.34%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Weighted average discount rate - operating leases</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.64%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3.26</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td> </tr> </table></div> <p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;"> </p> <p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"> </p> <p style="Background-color:#FFFFFF;margin-top:2pt;margin-bottom:0pt;text-indent:4.54%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The following is a maturity analysis of operating lease liabilities using undiscounted cash flows on an annual basis with renewal periods included:</p> <p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;"> </p> <div> <table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;"> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:76.34%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:22.64%; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Operating Leases</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:76.34%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:22.64%; border-top:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(in thousands)</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:76.34%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Year Ending December 31,</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.64%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:76.34%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2021 (remaining 6 months)</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.64%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">538</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:76.34%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2022</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.64%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">881</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:76.34%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2023</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.64%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">412</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:76.34%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2024</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.64%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">216</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:76.34%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2025</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.64%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">215</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:76.34%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2026</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.64%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">37</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:76.34%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Thereafter</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.64%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:76.34%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total lease payments</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.64%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,299</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:76.34%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Less imputed interest</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.64%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(110</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:76.34%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.64%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,189</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> </table></div> <p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;"> </p> <p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;"> </p> <p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Lessor</p> <p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.13%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company leases out space in buildings it owns to third-party tenants under noncancelable operating leases and has leased out such space since the Company purchased such buildings in October 2020. As of June 30, 2021, the remaining lease terms left range from 17 months to 42 months including renewal options and may include rent escalation clauses. Lease income primarily represents fixed lease payments from tenants recognized on a straight-line basis over the application lease term. Variable lease income represents tenant payments for real estate taxes, insurance and maintenance.</p> <p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.13%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The lease income was $85,000 and $242,000 for the three and six months ended June 30, 2021, respectively, which was included in interest and other income, net, in the accompanying Condensed Consolidated Statements of Operations. Total lease income was as follows:</p> <p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;"> </p> <div> <table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;"> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:42.7%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:26.9%; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Three months ended June 30,</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.44%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:26.9%; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Six months ended June 30,</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:42.7%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.22%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2021</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.44%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.22%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.44%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.22%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2021</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.44%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.22%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:42.7%;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="14" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:56.28%;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(in thousands)</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:42.7%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Lease income</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.22%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">81</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.44%;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.22%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.44%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.22%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">237</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.44%;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.22%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:42.7%; border-bottom:solid 0.75pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Variable lease income</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.22%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.44%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.22%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.44%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.22%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.44%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.22%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:42.7%; border-bottom:double 2.5pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total lease income</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.22%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">85</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.44%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.22%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.44%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.22%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">242</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.44%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.22%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> </table></div> <p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;"> </p> <p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Future fixed lease payments from tenants for all noncancelable operating leases as of June 30, 2021 are as follows:</p> <p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;"> </p> <div> <table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;"> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:76.2%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:22.78%;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Lease Payments</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:76.2%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:22.78%; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">from Tenants</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:76.2%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:22.78%; border-top:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(in thousands)</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:76.2%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Year Ending December 31,</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.78%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:76.2%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2021 (remaining 6 months)</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.78%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">94</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:76.2%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2022</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.78%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">190</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:76.2%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2023</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.78%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">95</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:76.2%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2024</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.78%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">61</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:76.2%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.78%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">440</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> </table></div> <p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;"> </p> <p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"> </p> 2026-02 P1Y 2023-01-31 12000 2023-11 <p style="Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The operating lease right-of-use asset, short-term lease liabilities, and long-term lease liabilities as of June 30, 2021 and December 31, 2020 were as follows:</p> <div> <table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;"> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:60.46%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.72%; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">June 30,</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.04%;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.72%; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December 31,</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:60.46%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.72%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2021</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.04%; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.72%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:60.46%;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:38.52%; border-top:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(in thousands)</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:60.46%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Operating lease right-of-use asset</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.72%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,176</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.04%;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.72%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">828</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:60.46%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Operating lease liabilities, short term</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.72%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,001</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.04%;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.72%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">267</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:60.46%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Operating lease liabilities, long term</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.72%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,188</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.04%;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.72%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">568</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> </table></div> 2176000 828000 1001000 267000 1188000 568000 <p style="Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The following was operating lease expense:</p> <p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;"> </p> <div> <table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;"> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:42.7%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:26.9%; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Three months ended June 30,</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.44%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:26.9%; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Six months ended June 30,</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:42.7%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.22%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2021</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.44%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.22%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.44%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.22%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2021</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.44%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.22%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:42.7%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="14" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:56.28%;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(in thousands)</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:42.7%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Operating lease cost</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.22%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">232</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.44%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.22%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">152</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.44%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.22%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">301</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.44%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.22%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">301</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:42.7%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Short-term lease cost</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.22%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">61</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.44%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.22%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.44%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.22%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">192</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.44%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.22%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:42.7%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total lease cost</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.22%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">293</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.44%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.22%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">155</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.44%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.22%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">493</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.44%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.22%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">304</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> </table></div> 232000 152000 301000 301000 61000 3000 192000 3000 293000 155000 493000 304000 <p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;"> </p> <p style="Background-color:#FFFFFF;margin-top:2pt;margin-bottom:0pt;text-indent:4.54%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Supplemental information related to leases was the following:</p> <p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;"> </p> <div> <table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;"> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:76.34%; border-bottom:solid 0.75pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:22.64%; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">June 30, 2021</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:76.34%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Weighted average remaining lease term - operating leases</p></td> <td colspan="2" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:22.64%; border-top:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2.9 years</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:76.34%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Weighted average discount rate - operating leases</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.64%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3.26</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td> </tr> </table></div> P2Y10M24D 0.0326 The following is a maturity analysis of operating lease liabilities using undiscounted cash flows on an annual basis with renewal periods included: <div> <table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;"> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:76.34%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:22.64%; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Operating Leases</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:76.34%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:22.64%; border-top:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(in thousands)</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:76.34%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Year Ending December 31,</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.64%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:76.34%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2021 (remaining 6 months)</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.64%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">538</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:76.34%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2022</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.64%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">881</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:76.34%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2023</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.64%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">412</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:76.34%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2024</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.64%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">216</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:76.34%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2025</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.64%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">215</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:76.34%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2026</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.64%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">37</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:76.34%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Thereafter</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.64%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:76.34%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total lease payments</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.64%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,299</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:76.34%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Less imputed interest</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.64%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(110</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:76.34%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.64%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,189</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> </table></div> <p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;"> </p> 538000 881000 412000 216000 215000 37000 2299000 110000 2189000 P17M P42M 85000 242000 Total lease income was as follows: <div> <table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;"> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:42.7%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:26.9%; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Three months ended June 30,</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.44%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:26.9%; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Six months ended June 30,</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:42.7%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.22%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2021</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.44%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.22%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.44%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.22%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2021</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.44%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.22%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:42.7%;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="14" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:56.28%;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(in thousands)</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:42.7%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Lease income</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.22%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">81</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.44%;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.22%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.44%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.22%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">237</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.44%;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.22%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:42.7%; border-bottom:solid 0.75pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Variable lease income</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.22%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.44%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.22%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.44%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.22%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.44%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.22%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:42.7%; border-bottom:double 2.5pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total lease income</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.22%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">85</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.44%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.22%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.44%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.22%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">242</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.44%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.22%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> </table></div> <p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;"> </p> 81000 237000 4000 5000 85000 242000 <p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Future fixed lease payments from tenants for all noncancelable operating leases as of June 30, 2021 are as follows:</p> <p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;"> </p> <div> <table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;"> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:76.2%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:22.78%;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Lease Payments</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:76.2%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:22.78%; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">from Tenants</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:76.2%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:22.78%; border-top:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(in thousands)</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:76.2%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Year Ending December 31,</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.78%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:76.2%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2021 (remaining 6 months)</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.78%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">94</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:76.2%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2022</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.78%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">190</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:76.2%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2023</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.78%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">95</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:76.2%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2024</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.78%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">61</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:76.2%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.78%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">440</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> </table></div> <p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;"> </p> <p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"> </p> 94000 190000 95000 61000 440000 <p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Note 10. Equity-Based Compensation</p> <p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="Background-color:#FFFFFF;">The Company has included equity-based compensation expense as part of cost of revenue and operating expenses in the accompanying Condensed Consolidated Statements of Operations as follows:</span></p> <p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;"> </p> <div> <table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;"> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:42.7%; border-bottom:solid 0.75pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:26.9%; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Three Months Ended June 30,</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.44%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:26.9%; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Six Months Ended June 30,</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:42.7%; border-bottom:solid 0.75pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.22%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2021</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.44%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.22%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.44%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.22%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2021</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.44%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.22%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:42.7%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="14" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:56.28%;" valign="top"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(in thousands)</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:42.7%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Cost of revenue</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.22%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">692</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.44%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.22%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">270</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.44%;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.22%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,366</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.44%;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.22%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">501</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:42.7%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Research and development</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.22%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,481</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.44%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.22%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">364</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.44%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.22%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,704</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.44%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.22%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">676</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:42.7%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Selling and marketing</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.22%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">620</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.44%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.22%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">222</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.44%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.22%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,046</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.44%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.22%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">393</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:42.7%; border-bottom:solid 0.75pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">General and administrative</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.22%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">733</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.44%; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.22%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">224</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.44%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.22%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,372</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.44%; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.22%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">434</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:42.7%; border-bottom:double 2.5pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.22%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,526</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.44%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.22%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,080</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.44%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.22%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6,488</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.44%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.22%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,004</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> </table></div> <p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;"> </p> <p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="Background-color:#FFFFFF;">The Company has included equity-based compensation expense as part of cost of revenue and operating expenses in the accompanying Condensed Consolidated Statements of Operations as follows:</span></p> <p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;"> </p> <div> <table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;"> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:42.7%; border-bottom:solid 0.75pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:26.9%; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Three Months Ended June 30,</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.44%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:26.9%; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Six Months Ended June 30,</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:42.7%; border-bottom:solid 0.75pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.22%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2021</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.44%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.22%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.44%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.22%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2021</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.44%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.22%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:42.7%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="14" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:56.28%;" valign="top"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(in thousands)</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:42.7%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Cost of revenue</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.22%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">692</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.44%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.22%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">270</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.44%;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.22%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,366</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.44%;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.22%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">501</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:42.7%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Research and development</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.22%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,481</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.44%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.22%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">364</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.44%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.22%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,704</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.44%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.22%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">676</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:42.7%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Selling and marketing</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.22%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">620</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.44%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.22%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">222</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.44%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.22%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,046</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.44%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.22%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">393</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:42.7%; border-bottom:solid 0.75pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">General and administrative</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.22%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">733</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.44%; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.22%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">224</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.44%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.22%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,372</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.44%; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.22%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">434</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:42.7%; border-bottom:double 2.5pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.22%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,526</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.44%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.22%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,080</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.44%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.22%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6,488</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.44%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.22%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,004</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> </table></div> 692000 270000 1366000 501000 1481000 364000 2704000 676000 620000 222000 1046000 393000 733000 224000 1372000 434000 3526000 1080000 6488000 2004000 <p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Note 11. Provision for (Benefit from) Income Taxes</p> <p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The effective tax rate used for interim periods is the estimated annual effective consolidated tax rate, based on the current estimate of full year results, except that taxes related to specific events, if any, are recorded in the interim period in which they occur. The annual effective tax rate is based upon several significant estimates and judgments, including the estimated annual pre-tax income of the Company in each tax jurisdiction in which it operates, and the development of tax planning strategies during the year. In addition, the Company’s tax expense can be impacted by changes in tax rates or laws and other factors that cannot be predicted with certainty. As such, there can be significant volatility in interim tax provisions.</p> <p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company recorded consolidated provision for (benefit from) income taxes of $23.6 million and $90.1 million for the three and six months ended June 30, 2021, respectively, compared with $(599,000) and $(565,000) for the three and six months ended June 30, 2020, respectively. The Company’s effective tax rates were 24% and 25% for the three and six months ended June 30, 2021, respectively, compared with -21% and -45% or the three and six months ended June 30, 2020, respectively. The change in the effective tax rate for the three-month and six-month periods of 2021, relative to 2020, was primarily attributable to a significant increase in income for the first quarter of 2021, and, to a lesser extent, an increase in income for the second quarter of 2021, partially offset by increased windfall tax deductions related to stock-based compensation.</p> <p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company is not currently under examination by any major income tax jurisdiction. During 2021, the statutes of limitations will lapse on the Company's 2017 federal tax year and certain 2016 and 2017 state tax years. The Company does not believe the federal or state statute lapses or any other event will significantly impact the balance of unrecognized tax benefits in the next twelve months. The net balance of unrecognized tax benefits was not material to the interim financial statements for the three and six months ended June 30, 2021 and 2020.</p> 23600000 90100000 -599000 -565000 0.24 0.25 -0.21 -0.45 <p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Note 12. Income per Share</p> <p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The following table presents <span style="Background-color:#FFFFFF;color:#000000;">the calculation of basic and diluted income per share </span>for the three and six months ended June 30, 2021 and 2020:</p> <p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;"> </p> <div> <table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;"> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:42.7%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:26.9%; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Three Months Ended June 30,</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.44%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:26.9%; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Six Months Ended June 30,</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:42.7%; border-bottom:solid 0.75pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.22%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2021</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.44%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.22%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.44%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.22%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2021</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.44%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.22%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:42.7%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="14" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:56.28%;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(in thousands, except per share data)</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:42.7%; border-bottom:double 2.5pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net income attributable to Fulgent</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.22%; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">79,812</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.44%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.22%; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,321</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.44%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.22%; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">280,503</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.44%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.22%; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,365</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:42.7%; border-bottom:double 2.5pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Weighted-average common shares—outstanding, basic</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.22%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">29,150</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.44%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.22%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">21,747</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.44%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.22%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">28,991</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.44%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.22%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">21,656</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:42.7%; border-bottom:double 2.5pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Weighted-average common shares—outstanding, diluted</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.22%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">30,830</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.44%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.22%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">22,920</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.44%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.22%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">30,809</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.44%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.22%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">22,824</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:42.7%; border-bottom:double 2.5pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net income per common share, basic</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.22%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2.74</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.44%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.22%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">0.15</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.44%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.22%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">9.68</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.44%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.22%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">0.06</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:42.7%; border-bottom:double 2.5pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net income per common share, diluted</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.22%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2.59</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.44%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.22%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">0.14</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.44%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.22%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">9.10</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.44%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.22%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">0.06</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> </table></div> <p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"> </p> <p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The following securities have been excluded from the calculation of diluted income per share because their effect would have been anti-dilutive:</p> <p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;"> </p> <div> <table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;"> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:42.7%; border-bottom:solid 0.75pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:26.9%; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Three Months Ended June 30,</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.44%;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:26.9%; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Six Months Ended June 30,</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:42.7%; border-bottom:solid 0.75pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.22%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2021</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.44%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.22%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.44%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.22%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2021</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.44%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.22%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:42.7%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="14" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:56.28%;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(in thousands)</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:42.7%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Options</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.22%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.44%;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.22%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.44%;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.22%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.44%;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.22%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:42.7%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Restricted Stock Units</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.22%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">107</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.44%;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.22%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">42</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.44%;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.22%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">71</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.44%;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.22%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">21</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> </table></div> <p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;"> </p> <p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The anti-dilutive shares described above were calculated using the treasury stock method. </p> <p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The following table presents <span style="Background-color:#FFFFFF;color:#000000;">the calculation of basic and diluted income per share </span>for the three and six months ended June 30, 2021 and 2020:</p> <p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;"> </p> <div> <table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;"> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:42.7%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:26.9%; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Three Months Ended June 30,</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.44%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:26.9%; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Six Months Ended June 30,</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:42.7%; border-bottom:solid 0.75pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.22%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2021</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.44%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.22%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.44%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.22%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2021</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.44%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.22%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:42.7%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="14" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:56.28%;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(in thousands, except per share data)</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:42.7%; border-bottom:double 2.5pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net income attributable to Fulgent</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.22%; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">79,812</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.44%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.22%; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,321</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.44%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.22%; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">280,503</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.44%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.22%; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,365</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:42.7%; border-bottom:double 2.5pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Weighted-average common shares—outstanding, basic</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.22%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">29,150</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.44%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.22%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">21,747</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.44%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.22%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">28,991</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.44%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.22%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">21,656</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:42.7%; border-bottom:double 2.5pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Weighted-average common shares—outstanding, diluted</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.22%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">30,830</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.44%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.22%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">22,920</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.44%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.22%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">30,809</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.44%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.22%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">22,824</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:42.7%; border-bottom:double 2.5pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net income per common share, basic</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.22%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2.74</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.44%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.22%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">0.15</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.44%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.22%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">9.68</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.44%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.22%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">0.06</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:42.7%; border-bottom:double 2.5pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net income per common share, diluted</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.22%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2.59</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.44%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.22%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">0.14</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.44%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.22%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">9.10</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.44%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.22%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">0.06</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> </table></div> 79812000 3321000 280503000 1365000 29150000 21747000 28991000 21656000 30830000 22920000 30809000 22824000 2.74 0.15 9.68 0.06 2.59 0.14 9.10 0.06 <p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The following securities have been excluded from the calculation of diluted income per share because their effect would have been anti-dilutive:</p> <p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;"> </p> <div> <table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;"> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:42.7%; border-bottom:solid 0.75pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:26.9%; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Three Months Ended June 30,</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.44%;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:26.9%; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Six Months Ended June 30,</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:42.7%; border-bottom:solid 0.75pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.22%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2021</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.44%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.22%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.44%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.22%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2021</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.44%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.22%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:42.7%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="14" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:56.28%;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(in thousands)</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:42.7%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Options</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.22%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.44%;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.22%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.44%;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.22%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.44%;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.22%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:42.7%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Restricted Stock Units</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.22%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">107</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.44%;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.22%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">42</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.44%;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.22%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">71</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.44%;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.22%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">21</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> </table></div> 2000 4000 5000 10000 107000 42000 71000 21000 <p style="margin-top:9pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Note 13. Related Parties</p> <p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Linda Marsh, who is a member of the Company’s board of directors, is currently<span style="color:#000000;"> the Senior Executive Vice President of AHMC Healthcare Inc.</span>, or AHMC. The Company performs genetic testing and other testing services, on an arms-length basis, for AHMC, and the Company recognized $738,000 and $1.9 million in revenue in the three and six months ended June 30, 2021, respectively. The Company did not perform any services for AHMC and did not recognize any revenue in the three and six months ended June 30, 2020. As of June 30, 2021 and December 31, 2020, $793,000 and $1.8 million was owed to the Company by AHMC, which is included in trade accounts receivable, net, in the accompanying Condensed Consolidated Balance Sheets, in connection with this relationship.</p> <p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company and Fulgent Pharma LLC, the Company’s former subsidiary, are party to shared services arrangements where research and development and administrative services and office space and equipment are provided between the companies, on an arms-length basis. Ming Hsieh is the Manager and a member of Fulgent Pharma LLC. During the three and six months ended June 30, 2021, the cost of research development services rendered by Fulgent Pharma LLC for the Company was $97,000 and $205,000, respectively. The cost of research development services rendered by Fulgent Pharma LLC for the Company was not significant during the three and six months ended June 30, 2020. Amounts for services performed by the Company for Fulgent Pharma LLC were not significant during the three and six months ended June 31, 2021 and 2020. As of June 30, 2021, and December 31, 2020, $574,000 and $409,000, respectively, were owed to Fulgent Pharma LLC by the Company, which are included in due to related parties as a component in other current liabilities in the accompanying Condensed Consolidated Balance Sheets, in connection with these relationships.</p> 738000 1900000 0 0 793000 1800000 97000 205000 0 0 0 0 0 0 574000 409000 <p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Note 14. Business Combination</p> <p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">FF Gene Biotech</p> <p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="Background-color:#FFFFFF;">In April 2017, the Company acquired a 30% equity interest in </span><span style="color:#000000;">FF Gene Biotech</span><span style="Background-color:#FFFFFF;">, a newly formed a joint venture with Xilong Scientific, and</span><span style="Background-color:#FFFFFF;color:#000000;"> </span><span style="Background-color:#FFFFFF;">Fuzhou Jinqiang Investment Partnership (LP), or </span><span style="color:#000000;">FJIP. The joint venture was formed under the laws of </span><span style="Background-color:#FFFFFF;">China</span><span style="color:#000000;"> to offer</span><span style="Background-color:#FFFFFF;"> genetic testing services to customers in China.</span></p> <p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In May 2021, <span style="Background-color:#FFFFFF;">the Company entered into a restructuring agreement </span>with Xilong Scientific and FJIP, resulting in the Company indirectly acquiring a <span style="Background-color:#FFFFFF;">72</span>% controlling financial interest in FF Gene Biotech. As a result of the acquisition<span style="Background-color:#FFFFFF;"> of FF Gene Biotech, or the FF Gene Biotech Acquisition</span>, the Company will be more strategically aligned with it geographic expansion strategy. It also expects to reduce costs through economies of scale.</p> <p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The goodwill of $23.1 million arising from the FF Gene Biotech Acquisition is attributed to the expected synergies and other benefits that will be potentially generated from the combination of the Company and FF Gene Biotech. The goodwill recognized is not deductible for tax purposes<span style="Background-color:#FFFFFF;">. </span></p> <p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company allocated the purchase price to tangible and identified intangible assets acquired and liabilities assumed based on estimated fair values. As additional information becomes available, such as the finalization of the estimated fair value of tax-related items, the Company may further update the preliminary purchase price allocation during the remainder of the measurement period (up to one year from the <span style="color:#000000;">FF Gene Biotech Acquisition </span>date). <span style="color:#000000;">The following table summarizes the consideration paid and the amounts of the assets acquired and liabilities assumed recognized at the FF Gene Biotech Acquisition date, as well as the fair value of the noncontrolling interest at the FF Gene Biotech Acquisition date.</span></p> <p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;"> </p> <p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"> </p> <div> <table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;"> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:84.34%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.7%; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Amounts</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.98%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:84.34%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.7%; border-top:solid 0.75pt #000000;" valign="top"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(in thousands)</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.98%;white-space:nowrap;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:84.34%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Considerations</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.62%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.98%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:84.34%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Cash</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.62%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">18,974</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.98%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:84.34%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Fair value of the Company’s 30% equity interest held before the business combination</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.62%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,734</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.98%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:84.34%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.62%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">22,708</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.98%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:84.34%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Recognized amounts of identifiable assets acquired and liabilities assumed</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.62%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.98%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:84.34%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Financial assets</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.62%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,181</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.98%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:84.34%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Reagents and supplies</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.62%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,288</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.98%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:84.34%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Fixed assets</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.62%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,874</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.98%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:84.34%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Other tangible assets</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.62%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">944</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.98%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:84.34%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Identifiable intangible assets</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.62%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6,958</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.98%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:84.34%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Other current liabilities</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.62%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(2,585</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.98%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:84.34%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Notes payable</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.62%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(5,893</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.98%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:84.34%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Recognized amounts of identifiable assets acquired and liabilities assumed, net</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.62%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7,767</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.98%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:84.34%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Noncontrolling interest</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.62%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(8,141</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.98%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:84.34%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Goodwill</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.62%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">23,082</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.98%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:84.34%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.62%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">22,708</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.98%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> </table></div> <p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="Background-color:#FFFFFF;">The Company incurred $329,000 acquisition related costs, which was recorded as general and administrative expenses in its condensed consolidated statements of operations.</span></p> <p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="Background-color:#FFFFFF;">The fair value of the noncontrolling interest, or NCI, in FF Gene Biotech, a private entity, $8.1 million, was estimated by applying the income approach and market approach. The fair value measurement was based on significant inputs that are not observable in the market and thus represents a fair value categorized within Level 3 of the</span><span style="color:#000000;"> three-tier fair value hierarchy</span><span style="Background-color:#FFFFFF;">. The NCI represents a minority interest of 28% in the post-restructuring FF Gene Biotech. Since the NCI is the result of the restructuring, the implied value was utilized to value the NCI based on the 42% effective investment. After determining the implied value, a discount for lack of marketability was applied to the 28% interest representing lack of marketability related to the holding period to monetize the NCI in a future initial public offering, or IPO, or sale, and marketability related to market participant acquisition premiums implied in the value of the $19.0 million purchase price for a 42% interest. The resultant total discount applied was 35%, which is supported both by the put option analyses related to the potential holding period, and a 10% discount owed to a market participant acquisition premium.</span></p> <p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="Background-color:#FFFFFF;">The Company recognized a gain of $</span><span style="color:#000000;">3.7</span> million<span style="Background-color:#FFFFFF;"> as a result of remeasuring to fair value its </span><span style="color:#000000;">30</span><span style="Background-color:#FFFFFF;">% equity interest held before the </span><span style="color:#000000;">FF Gene Biotech Acquisition</span><span style="Background-color:#FFFFFF;">. The fair value of the preexisting equity interest was determined based on the characteristics before consummating the </span><span style="color:#000000;">FF Gene Biotech Acquisition</span><span style="Background-color:#FFFFFF;"> and estimated by applying income approach and utilized the discounted cash flow method. The Company did not apply the market approach based on its characteristics before consummating the restructuring. The gain on the equity method investment is included in the Company’s Condensed Consolidated Statements of Operations for the three and six months ended June 30, 2021.</span></p> <p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The amounts of FF Gene Biotech’s revenue and net losses included in the <span style="Background-color:#FFFFFF;">Company’s Condensed Consolidated Statements of Operations for the periods ended June 30, 2021 and the revenue and net losses of the combined entity had the acquisition date been January 1, 2021 are not material to the Company.</span></p> <p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="Background-color:#FFFFFF;">The </span><span style="color:#000000;">identified intangible assets acquired in the FF Gene Biotech Acquisition consisted of a $5.7 million royalty-free technology with an estimated amortization life of 10 years and a $1.2 million customer relationships with an estimated amortization life of 5 years. The value of these assets were based upon the preliminary fair values as of the closing date of the FF Gene Biotech Acquisition.</span></p> <p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company concluded <span style="Background-color:#FFFFFF;">FF Gene Biotech is a variable interest entity </span>as FF Gene Biotech lacks sufficient capital to operate independently. The Company concluded that it alone has<span style="Background-color:#FFFFFF;"> </span>the power to direct the most <span style="Background-color:#FFFFFF;">significant </span>activities of FF Gene Biotech<span style="Background-color:#FFFFFF;"> and </span>therefore is the primary beneficiary of the entity post the FF Gene Biotech Acquisition.<span style="Background-color:#FFFFFF;"> Judgment regarding the level of influence over FF Gene Biotech includes consideration of key factors such as the Company's ownership interest, representation on the board of directors or other management body and participation in policy-making decisions. Post the </span>FF Gene Biotech Acquisition<span style="Background-color:#FFFFFF;">, the financial results for FF Gene Biotech are included in the Company’s condensed financial statements. Prior to the </span>FF Gene Biotech Acquisition<span style="Background-color:#FFFFFF;">, the financial results for FF Gene Biotech were not significant for pro forma financial information.</span></p> 0.30 0.72 23100000 The following table summarizes the consideration paid and the amounts of the assets acquired and liabilities assumed recognized at the FF Gene Biotech Acquisition date, as well as the fair value of the noncontrolling interest at the FF Gene Biotech Acquisition date. <p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;"> </p> <p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"> </p> <div> <table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;"> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:84.34%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.7%; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Amounts</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.98%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:84.34%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.7%; border-top:solid 0.75pt #000000;" valign="top"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(in thousands)</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.98%;white-space:nowrap;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:84.34%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Considerations</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.62%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.98%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:84.34%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Cash</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.62%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">18,974</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.98%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:84.34%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Fair value of the Company’s 30% equity interest held before the business combination</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.62%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,734</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.98%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:84.34%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.62%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">22,708</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.98%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:84.34%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Recognized amounts of identifiable assets acquired and liabilities assumed</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.62%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.98%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:84.34%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Financial assets</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.62%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,181</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.98%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:84.34%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Reagents and supplies</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.62%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,288</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.98%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:84.34%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Fixed assets</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.62%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,874</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.98%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:84.34%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Other tangible assets</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.62%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">944</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.98%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:84.34%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Identifiable intangible assets</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.62%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6,958</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.98%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:84.34%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Other current liabilities</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.62%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(2,585</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.98%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:84.34%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Notes payable</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.62%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(5,893</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.98%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:84.34%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Recognized amounts of identifiable assets acquired and liabilities assumed, net</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.62%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7,767</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.98%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:84.34%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Noncontrolling interest</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.62%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(8,141</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.98%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:84.34%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Goodwill</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.62%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">23,082</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.98%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:84.34%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.62%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">22,708</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.98%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> </table></div> 18974000 3734000 22708000 3181000 1288000 3874000 944000 6958000 2585000 5893000 7767000 8141000 23082000 22708000 329000000 8100000 0.28 0.42 28 19000000.0 0.42 35 10 3700000 3700000 0.30 0.30 5700000 P10Y 1200000 P5Y <p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Note 15. Equity Distribution Agreement</p> <p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In November 2020, the Company entered into an Equity Distribution Agreement, or the November 2020 Equity Distribution Agreement, with Piper Sandler &amp; Co. (f/k/a Piper Jaffray &amp; Co.), Oppenheimer &amp; Co. Inc., and BTIG LLC, as sales agents, pursuant to which the Company may offer and sell, from time to time through Piper, shares of its common stock having an aggregate offering price of up to $175.0 million. Piper may receive a commission of up to 3% of the gross proceeds received by the Company for sales pursuant to the November 2020 Equity Distribution Agreement. During the three months ended June 30, 2021, the Company sold approximately 378,000 shares of its common stock pursuant to the November 2020 Equity Distribution Agreement at a weighted-average net selling price of $73.75. During the six months ended June 30, 2021, the Company sold approximately 961,000 shares of its common stock pursuant to the November 2020 Equity Distribution Agreement at a weighted-average net selling price of $60.56.</p> 175000000.0 0.03 378000 73.75 961000 60.56 <p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Note 16. Goodwill and Acquisition-Related Intangibles</p> <p style="margin-top:12pt;margin-bottom:0pt;text-indent:5%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Summaries of goodwill and acquisitions-related intangibles balances as of June 30, 2021 and December 30, 2020 were as follows:</p> <p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;"> </p> <div> <table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;"> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:33.76%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:33.92%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.5%; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">June 30,</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.12%; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December 31,</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:33.76%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:33.92%; border-bottom:solid 0.75pt #000000;" valign="top"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Weighted-Average Amortization Period</p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.5%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2021</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.12%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:33.76%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:33.92%; border-top:solid 0.75pt #000000;" valign="top"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:31.28%;" valign="top"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(in thousands)</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:33.76%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Goodwill</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:33.92%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.5%; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">23,107</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.12%; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:33.76%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:33.92%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.5%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.12%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:33.76%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Royalty-free technology</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:33.92%;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10 Years</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.5%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5,727</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.12%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:33.76%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Less: accumulated amortization</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:33.92%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.5%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(95</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.12%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:33.76%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Royalty-free technology, net</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:33.92%;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.5%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5,632</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.12%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:33.76%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:33.92%;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.5%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.12%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:33.76%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Customer relationships</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:33.92%;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5 Years</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.5%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,238</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.12%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:33.76%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Less: accumulated amortization</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:33.92%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.5%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(41</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.12%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:33.76%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Customer relationships, net</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:33.92%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.5%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,197</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.12%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:33.76%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total acquisition-related intangibles, net</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:33.92%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.5%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6,829</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.12%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> </table></div> <p style="margin-bottom:0pt;margin-top:0pt;text-indent:5%;font-family:Times New Roman;font-size:10pt;"> </p> <p style="margin-bottom:0pt;margin-top:0pt;text-indent:5%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">During the three months ended June 30, 2021, the Company recorded $23.1 million of goodwill and $7.0 million of intangibles attributable to the FF Gene Biotech Acquisition. See Note 14, Business Combination, to the Company's condensed consolidated financial statements.</p> <p style="margin-top:12pt;margin-bottom:0pt;text-indent:5%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Based on the carrying value of acquisition-related intangibles recorded as of June 30, 2021, and assuming no subsequent impairment of the underlying assets, the annual amortization expense for acquisition-related intangibles is expected to be as follows:</p> <p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;"> </p> <div> <table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;"> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.24%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:31.74%; border-bottom:solid 0.75pt #000000;" valign="top"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Amounts</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.24%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:31.74%; border-top:solid 0.75pt #000000;" valign="top"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(in thousands)</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.24%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2021 (remaining 6 months)</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.74%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">410</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.24%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2022</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.74%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">821</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.24%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2023</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.74%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">821</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.24%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2024</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.74%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">821</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.24%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2025</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.74%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">821</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.24%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2026</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.74%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">656</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.24%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Thereafter</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.74%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,479</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.24%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.74%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6,829</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> </table></div> <p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;"> </p> <p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"> </p> <p style="margin-top:12pt;margin-bottom:0pt;text-indent:5%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Summaries of goodwill and acquisitions-related intangibles balances as of June 30, 2021 and December 30, 2020 were as follows:</p> <p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;"> </p> <div> <table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;"> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:33.76%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:33.92%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.5%; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">June 30,</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.12%; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December 31,</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:33.76%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:33.92%; border-bottom:solid 0.75pt #000000;" valign="top"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Weighted-Average Amortization Period</p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.5%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2021</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.12%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:33.76%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:33.92%; border-top:solid 0.75pt #000000;" valign="top"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:31.28%;" valign="top"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(in thousands)</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:33.76%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Goodwill</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:33.92%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.5%; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">23,107</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.12%; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:33.76%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:33.92%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.5%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.12%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:33.76%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Royalty-free technology</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:33.92%;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10 Years</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.5%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5,727</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.12%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:33.76%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Less: accumulated amortization</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:33.92%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.5%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(95</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.12%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:33.76%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Royalty-free technology, net</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:33.92%;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.5%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5,632</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.12%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:33.76%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:33.92%;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.5%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.12%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:33.76%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Customer relationships</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:33.92%;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5 Years</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.5%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,238</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.12%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:33.76%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Less: accumulated amortization</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:33.92%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.5%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(41</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.12%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:33.76%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Customer relationships, net</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:33.92%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.5%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,197</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.12%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:33.76%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total acquisition-related intangibles, net</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:33.92%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.5%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6,829</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.12%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> </table></div> 23107000 P10Y 5727000 95000 5632000 P5Y 1238000 41000 1197000 6829000 23100000 7000000.0 <p style="margin-top:12pt;margin-bottom:0pt;text-indent:5%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Based on the carrying value of acquisition-related intangibles recorded as of June 30, 2021, and assuming no subsequent impairment of the underlying assets, the annual amortization expense for acquisition-related intangibles is expected to be as follows:</p> <p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;"> </p> <div> <table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;"> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.24%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:31.74%; border-bottom:solid 0.75pt #000000;" valign="top"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Amounts</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.24%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:31.74%; border-top:solid 0.75pt #000000;" valign="top"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(in thousands)</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.24%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2021 (remaining 6 months)</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.74%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">410</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.24%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2022</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.74%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">821</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.24%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2023</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.74%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">821</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.24%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2024</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.74%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">821</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.24%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2025</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.74%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">821</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.24%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2026</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.74%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">656</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.24%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Thereafter</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.74%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,479</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.24%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.74%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6,829</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> </table></div> 410000 821000 821000 821000 821000 656000 2479000 6829000 <p style="margin-top:9pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Note 17. Subsequent Events</p> <p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In July 2021, the Company invested $20.0 million in Laboratory for Advanced Medicine, Inc., or Helio Health, incorporated in Cayman Islands, and, in connection with the investment in Helio Health, the Company obtained a minority shareholder interest. Helio Heath is an AI-driven healthcare company developing early testing capabilities for cancer. <span style="color:#000000;">Through this partnership, the Company seeks to have access to an emerging liquid biopsy testing technology in the U.S. and China and exclusive commercial rights to Helio Health’s liquid biopsy tests in the U.S. and Canada.</span></p> <p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In August 2021, the Company completed an acquisition of Cytometry Specialists, Inc., or CSI, a Georgia corporation, through the acquisition of all of the issued and outstanding common stock of CSI in exchange for $50.0 million in cash and up to $10.0 million in potential future milestone payments. Through the acquisition of CSI, the Company seeks to <span style="color:#000000;">expand the Company’s presence and capabilities in somatic molecular diagnostics and cancer testing</span>. <span style="color:#000000;">The Company plans to leverage its established technology platform, NGS expertise, lab operations, and sales infrastructure in conjunction with CSI’s extensive cancer testing menu to establish a differentiated foothold in oncologic testing in the United States.</span></p> <p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.54%;font-size:10pt;"> </p> <p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"> </p> 20000000.0 50000000.0 10000000.0 XML 12 R1.htm IDEA: XBRL DOCUMENT v3.21.2
Document and Entity Information - shares
 6 Months Ended
Jun. 30, 2021
Aug. 01, 2021
Cover [Abstract]    
Document Type 10-Q  
Amendment Flag false  
Document Period End Date Jun. 30, 2021  
Document Fiscal Year Focus 2021  
Document Fiscal Period Focus Q2  
Trading Symbol FLGT  
Entity Registrant Name FULGENT GENETICS, INC.  
Entity Central Index Key 0001674930  
Entity Current Reporting Status Yes  
Current Fiscal Year End Date --12-31  
Entity Filer Category Non-accelerated Filer  
Entity Small Business true  
Entity Emerging Growth Company true  
Entity Ex Transition Period true  
Entity Shell Company false  
Entity Common Stock, Shares Outstanding   29,521,259
Entity File Number 001-37894  
Entity Tax Identification Number 81-2621304  
Entity Address, Address Line One 4978 Santa Anita Avenue  
Entity Address, City or Town Temple City  
Entity Address, State or Province CA  
Entity Address, Postal Zip Code 91780  
City Area Code 626  
Local Phone Number 350-0537  
Title of 12(b) Security Common Stock, par value $0.0001 per share  
Security Exchange Name NASDAQ  
Entity Interactive Data Current Yes  
Document Quarterly Report true  
Document Transition Report false  
Entity Incorporation, State or Country Code DE  
XML 13 R2.htm IDEA: XBRL DOCUMENT v3.21.2
Condensed Consolidated Balance Sheets - USD ($)
$ in Thousands
Jun. 30, 2021
Dec. 31, 2020
Current assets    
Cash and cash equivalents $ 100,461 $ 87,426
Marketable securities 283,328 211,941
Trade accounts receivable, net of allowance for credit losses of $6,044 and $1,898 as of June 30, 2021 and December 31, 2020, respectively 148,576 183,857
Other current assets 34,321 40,392
Total current assets 566,686 523,616
Marketable securities, long-term 393,250 132,502
Fixed assets, net 51,086 40,199
Acquisition-related intangible assets, net 6,829  
Goodwill 23,107  
Other long-term assets 8,897 4,144
Total assets 1,049,855 700,461
Current liabilities    
Accounts payable 14,743 26,488
Income tax payable 26,399 53,319
Contract liabilities 6,915 26,576
Customer deposit 45,327 185
Investment margin loan 15,077 15,019
Other current liabilities 13,063 8,528
Total current liabilities 121,524 130,115
Notes payable 5,899  
Unrecognized tax benefits 505 377
Other long-term liabilities 1,202 582
Total liabilities 129,130 131,074
Commitments and contingencies (Note 8)
Stockholders’ equity    
Common stock, $0.0001 par value per share, 50,000 shares authorized, 29,513 and 28,178 shares issued and outstanding at June 30, 2021 and December 31, 2020, respectively 3 3
Preferred stock, $0.0001 par value per share, 1,000 shares authorized, no shares issued or outstanding at June 30, 2021 and December 31, 2020
Additional paid-in capital 482,255 418,065
Accumulated other comprehensive income (loss) (265) 438
Retained earnings 430,736 150,881
Total Fulgent stockholders' equity 912,729 569,387
Noncontrolling interest 7,996  
Total stockholders’ equity 920,725 569,387
Total liabilities and stockholders’ equity $ 1,049,855 $ 700,461
XML 14 R3.htm IDEA: XBRL DOCUMENT v3.21.2
Condensed Consolidated Balance Sheets (Parenthetical) - USD ($)
$ in Thousands
Jun. 30, 2021
Dec. 31, 2020
Statement Of Financial Position [Abstract]    
Allowance for credit losses $ 6,044 $ 1,898
Common stock, par value $ 0.0001 $ 0.0001
Common stock, shares authorized 50,000,000 50,000,000
Common stock, shares issued 29,513,000 28,178,000
Common stock, shares outstanding 29,513,000 28,178,000
Preferred stock, par value $ 0.0001 $ 0.0001
Preferred stock, shares authorized 1,000,000 1,000,000
Preferred stock, shares issued 0 0
Preferred stock, shares outstanding 0 0
XML 15 R4.htm IDEA: XBRL DOCUMENT v3.21.2
Condensed Consolidated Statements of Operations (unaudited) - USD ($)
shares in Thousands
 3 Months Ended 6 Months Ended
Jun. 30, 2021
Jun. 30, 2020
Jun. 30, 2021
Jun. 30, 2020
Income Statement [Abstract]        
Revenue $ 153,616,000 $ 17,265,000 $ 513,045,000 $ 25,018,000
Cost of revenue 35,858,000 7,717,000 109,933,000 11,774,000
Gross profit 117,758,000 9,548,000 403,112,000 13,244,000
Operating expenses:        
Research and development 5,312,000 1,849,000 10,734,000 3,827,000
Selling and marketing 5,219,000 3,260,000 10,227,000 4,857,000
General and administrative 8,329,000 1,799,000 16,331,000 3,834,000
Total operating expenses 18,860,000 6,908,000 37,292,000 12,518,000
Operating income 98,898,000 2,640,000 365,820,000 726,000
Interest and other income, net 604,000 275,000 886,000 516,000
Income before income taxes, gain on equity method investment and equity loss in investee 99,502,000 2,915,000 366,706,000 1,242,000
Provision for (benefit from) income taxes 23,589,000 (599,000) 90,102,000 (565,000)
Income before gain on equity method investment and equity loss in investee 75,913,000 3,514,000 276,604,000 1,807,000
Gain on equity method investment 3,734,000   3,734,000  
Equity loss in investee   (193,000)   (442,000)
Net income from consolidated operations 79,647,000 3,321,000 280,338,000 1,365,000
Net loss attributable to noncontrolling interests 165,000   165,000  
Net income attributable to Fulgent $ 79,812,000 $ 3,321,000 $ 280,503,000 $ 1,365,000
Net income per common share attributable to Fulgent:        
Basic $ 2.74 $ 0.15 $ 9.68 $ 0.06
Diluted $ 2.59 $ 0.14 $ 9.10 $ 0.06
Weighted-average common shares:        
Basic 29,150 21,747 28,991 21,656
Diluted 30,830 22,920 30,809 22,824
XML 16 R5.htm IDEA: XBRL DOCUMENT v3.21.2
Condensed Consolidated Statements of Comprehensive Income (Loss) (unaudited) - USD ($)
$ in Thousands
 3 Months Ended 6 Months Ended
Jun. 30, 2021
Jun. 30, 2020
Jun. 30, 2021
Jun. 30, 2020
Statement Of Income And Comprehensive Income [Abstract]        
Net income from consolidated operations $ 79,647 $ 3,321 $ 280,338 $ 1,365
Other comprehensive income (loss):        
Foreign currency translation gain (loss) 36 2 36 (1)
Net unrealized gain (loss) on marketable securities, net of tax (75) 1,240 (729) 904
Comprehensive income from consolidated operations 79,608 4,563 279,645 2,268
Net loss attributable to noncontrolling interests 165   165  
Foreign currency translation gain attributable to noncontrolling interest (10)   (10)  
Comprehensive loss attributable to noncontrolling interest 155   155  
Comprehensive income attributable to Fulgent $ 79,763 $ 4,563 $ 279,800 $ 2,268
XML 17 R6.htm IDEA: XBRL DOCUMENT v3.21.2
Condensed Consolidated Statements of Stockholders' Equity (unaudited) - USD ($)
shares in Thousands, $ in Thousands
Total
Cumulative Effect, Period of Adoption, Adjustment
Stockholders' Equity
Additional Paid-In Capital
Accumulated Other Comprehensive Income (Loss)
Retained Earnings (Accumulated Deficit)
Retained Earnings (Accumulated Deficit)
Cumulative Effect, Period of Adoption, Adjustment
Fulgent Stockholders' Equity
Fulgent Stockholders' Equity
Cumulative Effect, Period of Adoption, Adjustment
Noncontrolling Interest
Beginning Balance at Dec. 31, 2019 $ 82,777   $ 2 $ 146,058 $ 146 $ (63,429)        
Beginning Balance, Shares at Dec. 31, 2019     21,483              
Equity-based compensation 924     924            
Exercise of common stock options 12     12            
Exercise of common stock options, Shares     33              
Restricted stock awards, Shares     159              
Common stock withholding for employee tax obligations (46)     (46)            
Common stock withholding for employee tax obligations, Shares     (3)              
Other comprehensive gain (loss) (339)       (339)          
Net income (loss) (1,956)         (1,956)        
Ending Balance at Mar. 31, 2020 81,372   $ 2 146,948 (193) (65,385)        
Ending Balance, Shares at Mar. 31, 2020     21,672              
Beginning Balance at Dec. 31, 2019 82,777   $ 2 146,058 146 (63,429)        
Beginning Balance, Shares at Dec. 31, 2019     21,483              
Net income (loss) 1,365                  
Ending Balance at Jun. 30, 2020 87,043   $ 2 148,056 1,049 (62,064)        
Ending Balance, Shares at Jun. 30, 2020     21,810              
Beginning Balance at Mar. 31, 2020 81,372   $ 2 146,948 (193) (65,385)        
Beginning Balance, Shares at Mar. 31, 2020     21,672              
Equity-based compensation 1,080     1,080            
Exercise of common stock options 28     28            
Exercise of common stock options, Shares     11              
Restricted stock awards, Shares     127              
Other comprehensive gain (loss) 1,242       1,242          
Net income (loss) 3,321         3,321        
Ending Balance at Jun. 30, 2020 87,043   $ 2 148,056 1,049 (62,064)        
Ending Balance, Shares at Jun. 30, 2020     21,810              
Beginning Balance at Dec. 31, 2020 $ 569,387 $ (887) $ 3 418,065 438 150,881 $ (887) $ 569,387 $ (887)  
Beginning Balance, Shares at Dec. 31, 2020 28,178   28,178              
Equity-based compensation $ 2,962     2,962       2,962    
Exercise of common stock options 44     44       44    
Exercise of common stock options, Shares     45              
Restricted stock awards, Shares     187              
Common stock withholding for employee tax obligations (513)     (513)       (513)    
Common stock withholding for employee tax obligations, Shares     (4)              
Issuance of common stock 30,297     30,297       30,297    
Issuance of common stock, Shares     583              
Other comprehensive gain (loss) (654)       (654)     (654)    
Cumulative tax effect of accounting change 239         239   239    
Net income (loss) 200,691         200,691   200,691    
Ending Balance at Mar. 31, 2021 801,566   $ 3 450,855 (216) 350,924   801,566    
Ending Balance, Shares at Mar. 31, 2021     28,989              
Beginning Balance at Dec. 31, 2020 $ 569,387 $ (887) $ 3 418,065 438 150,881 $ (887) 569,387 $ (887)  
Beginning Balance, Shares at Dec. 31, 2020 28,178   28,178              
Net income (loss) $ 280,338                  
Ending Balance at Jun. 30, 2021 $ 920,725   $ 3 482,255 (265) 430,736   912,729   $ 7,996
Ending Balance, Shares at Jun. 30, 2021 29,513   29,513              
Beginning Balance at Mar. 31, 2021 $ 801,566   $ 3 450,855 (216) 350,924   801,566    
Beginning Balance, Shares at Mar. 31, 2021     28,989              
Equity-based compensation 3,526     3,526       3,526    
Exercise of common stock options 24     24       24    
Exercise of common stock options, Shares     4              
Restricted stock awards, Shares     143              
Common stock withholding for employee tax obligations (39)     (39)       (39)    
Common stock withholding for employee tax obligations, Shares     (1)              
Issuance of common stock 27,889     27,889       27,889    
Issuance of common stock, Shares     378              
Noncontrolling interest assumed related to acquisitions 8,151                 8,151
Other comprehensive gain (loss) (39)       (49)     (49)   10
Net income (loss) 79,647         79,812   79,812   (165)
Ending Balance at Jun. 30, 2021 $ 920,725   $ 3 $ 482,255 $ (265) $ 430,736   $ 912,729   $ 7,996
Ending Balance, Shares at Jun. 30, 2021 29,513   29,513              
XML 18 R7.htm IDEA: XBRL DOCUMENT v3.21.2
Condensed Consolidated Statements of Stockholders' Equity (unaudited) (Parenthetical) - $ / shares
Jun. 30, 2021
Mar. 31, 2021
November 2020 Equity Distribution Agreement    
Selling price per share $ 73.75 $ 52.00
XML 19 R8.htm IDEA: XBRL DOCUMENT v3.21.2
Condensed Consolidated Statements of Cash Flows (unaudited) - USD ($)
$ in Thousands
 6 Months Ended
Jun. 30, 2021
Jun. 30, 2020
Cash flow from operating activities:    
Net income from consolidated operations $ 280,338 $ 1,365
Adjustments to reconcile net income to net cash provided (used in) by operating activities:    
Equity-based compensation 6,488 2,004
Depreciation and amortization 4,340 1,118
Noncash lease expense 298 220
Loss on disposal of fixed asset 598  
Amortization of premium of marketable securities 3,171 218
Provision for credit losses 3,259 135
Deferred taxes (3,055)  
Unrecognized tax benefits 128  
Holding loss on equity securities 360  
Equity loss in investee   442
Gain on equity method investment (3,734)  
Other (8) (6)
Changes in operating assets and liabilities:    
Trade accounts receivable 32,460 (7,437)
Other current and long-term assets (6,025) (3,827)
Accounts payable (10,256) 2,284
Accrued liabilities and other liabilities 3,084 670
Income tax payable (26,920) (24)
Contract liabilities (19,662)  
Customer deposit 44,719  
Operating lease liabilities (293) (205)
Net cash provided by (used in) operating activities 309,290 (3,043)
Cash flow from investing activities:    
Purchases of fixed assets (14,427) (1,207)
Proceeds from sale of fixed assets 13  
Purchase of marketable securities (424,807) (12,387)
Proceeds from sale of marketable securities 51,696  
Maturities of marketable securities 34,538 7,327
Acquisition of businesses, net of cash acquired (18,509)  
Net cash used in investing activities (371,496) (6,267)
Cash flow from financing activities:    
Proceeds from (payment for) public offerings of common stock, net of issuance costs 75,656 (217)
Proceeds from noncontrolling interest 10  
Proceeds from exercise of stock options 68 40
Common stock withholding for employee tax obligations (552) (46)
Borrowing under margin account 58  
Net cash provided by (used in) financing activities 75,240 (223)
Effect of exchange rate changes on cash and cash equivalents 1 (1)
Net increase (decrease) in cash and cash equivalents 13,035 (9,534)
Cash and cash equivalents at beginning of period 87,426 11,965
Cash and cash equivalents at end of period 100,461 2,431
Supplemental disclosures of cash flow information:    
Income taxes paid 119,980 28
Supplemental disclosures of non-cash investing and financing activities:    
Purchases of fixed assets in accounts payable 742 497
Operating lease right-of-use assets obtained in exchange for lease liabilities 765 393
Operating lease right-of-use assets reduced due to lease modification 185  
Public offerings costs included in accounts payable $ 30 $ 2
XML 20 R9.htm IDEA: XBRL DOCUMENT v3.21.2
Overview and Basis of Presentation
 6 Months Ended
Jun. 30, 2021
Organization Consolidation And Presentation Of Financial Statements [Abstract]  
Overview and Basis of Presentation

Note 1. Overview and Basis of Presentation

The accompanying condensed consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America, or U.S. GAAP. These financial statements include the assets, liabilities, revenues and expenses of all subsidiaries and entities in which the Company has a controlling financial interest or is deemed to be the primary beneficiary. In determining whether the Company is the primary beneficiary of an entity, the Company applies a qualitative approach that determines whether it has both (i) the power to direct the economically significant activities of the entity and (ii) the obligation to absorb losses of, or the right to receive benefits from, the entity that could potentially be significant to that entity. The Company uses the equity method to account for its investments in entities that it does not control, but in which it has the ability to exercise significant influence over operating and financial policies. All significant intercompany accounts and transactions are eliminated from the accompanying condensed consolidated financial statements.

Nature of the Business

Fulgent Genetics, Inc., together with its subsidiaries, collectively referred to as the Company, unless otherwise noted or the context otherwise requires, is a technology company offering comprehensive genetic testing providing physicians with clinically actionable diagnostic information they can use to improve the quality of patient care. The Company has developed a proprietary technology platform that allows it to offer a broad and flexible test menu and continually expand and improve its proprietary genetic reference library, while maintaining accessible pricing, high accuracy and competitive turnaround times. Combining next generation sequencing, or NGS, with its technology platform, the Company performs full-gene sequencing with deletion/duplication analysis in single-gene tests; pre-established, multi-gene, disease-specific panels; and customized panels that can be tailored to meet specific customer needs. In 2019, the Company launched its first patient-initiated product, Picture Genetics, a new line of at-home screening tests that combines the Company’s advanced NGS solutions with actionable results and genetic counseling options for individuals. Since March 2020, the Company has commercially launched several tests for the detection of SARS-CoV-2, the virus that causes the novel coronavirus, or COVID-19, including NGS and reverse transcription polymerase chain reaction – based, or RT-PCR-based, tests. The Company has received an Emergency Use Authorization, or EUA, from the United States, or U.S., Food and Drug Administration, or the FDA, for the RT-PCR-based tests for the detection of SARS-CoV-2 using upper respiratory specimens (nasal, nasopharyngeal, and oropharyngeal swabs) and for the at-home testing service through Picture Genetics. The Company’s at-home testing service for COVID-19 and RT-PCR-based test have been granted an EUA by the FDA only for the detection of nucleic acid from SARS-CoV-2, not for any other viruses or pathogens. The Company believes its test menu offers more genes for testing than its competitors in today’s market, which enables it to provide expansive options for test customization and clinically actionable results. A cornerstone of the Company’s business is its ability to provide expansive options and flexibility for all clients’ unique testing needs.

Unaudited Interim Financial Information

The accompanying unaudited interim condensed consolidated financial statements have been prepared on the same basis as the Company’s audited consolidated financial statements as of and for the fiscal year ended December 31, 2020, which are included in the Company’s annual report on Form 10-K filed with the Securities and Exchange Commission, or SEC, on March 8, 2021, or 2020 Annual Report, and, in the opinion of management, include all adjustments, which are normal and recurring in nature, necessary for a fair presentation of the Company’s financial position and results of operations. Operating results for interim periods are not necessarily indicative of the results that may be expected for a full fiscal year or any other period. The accompanying Condensed Consolidated Balance Sheet as of December 31, 2020 has been derived from the Company’s audited consolidated financial statements at that date but does not include all of the disclosures required by U.S. GAAP. As such, the information included in this quarterly report on Form 10-Q should be read in conjunction with the Company’s audited consolidated financial statements included in the 2020 Annual Report, including the notes thereto.
XML 21 R10.htm IDEA: XBRL DOCUMENT v3.21.2
Summary of Significant Accounting Policies
 6 Months Ended
Jun. 30, 2021
Accounting Policies [Abstract]  
Summary of Significant Accounting Policies

Note 2. Summary of Significant Accounting Policies

See the summary of the Company’s significant accounting policies set forth in the notes to its consolidated financial statements included in the 2020 Annual Report.

Use of Estimates

The preparation of condensed consolidated financial statements in conformity with U.S. GAAP requires management to make certain estimates, judgments and assumptions that affect the reported amounts of assets and liabilities at the date of the financial statements, as well as the reported amounts of revenue and expenses during the reporting periods. These estimates, judgments and assumptions are based on historical data and experience available at the date of the accompanying condensed consolidated financial statements, as well as various other factors management believes to be reasonable under the circumstances, including but not limited to the potential impacts arising from the recent global pandemic related to COVID-19. As the extent and duration of the impacts from COVID-19 remain unclear, the Company’s estimates and assumptions may evolve as conditions change. Actual results could differ significantly from these estimates.

On an on-going basis, management evaluates its estimates, primarily those related to: (i) revenue recognition criteria, (ii) trade accounts receivable and allowances for credit losses, (iii) the useful lives of fixed assets, (iv) estimates of tax liabilities, (v) the valuation of equity method investments, (vi) valuation of acquisition-related intangibles and goodwill, and (vii) useful lives of intangible assets and fixed assets.

Foreign Currency Translation and Foreign Currency Transactions

The Company translates the assets and liabilities of its non-U.S. dollar functional currency subsidiaries into U.S. dollars using exchange rates in effect at the end of each period. Expenses for these subsidiaries are translated using rates that approximate those in effect during the period. Gains and losses from these translations are recognized in foreign currency translation included in accumulated other comprehensive income (loss) in the accompanying Condensed Consolidated Statements of Stockholders’ Equity. Gains from these translations were not significant in the three and six months ended June 30, 2021 and three months ended June 30, 2020, and loss from these translations for the six months ended June 30, 2020 was not significant. The Company and its subsidiaries that use the U.S. dollar as their functional currency remeasure monetary assets and liabilities at exchange rates in effect at the end of each period, and inventories, property and nonmonetary assets and liabilities at historical rates. Losses from these remeasurements in the three and six months ended June 30, 2021 and in the six months ended June 30, 2020 were not significant. Gains from these remeasurements were not significant in the three months ended June 30, 2020.

Leases

The Company determines if an arrangement is a lease at inception by evaluating whether the arrangement conveys the right to use an identified asset and whether the Company obtains substantially all of the economic benefits from and has the ability to direct the use of the asset. Operating lease right-of-use, or ROU, asset, short-term lease liabilities, and long-term lease liabilities were included in other long-term assets, other current liabilities, and other long-term liabilities, respectively, in the accompanying Condensed Consolidated Balance Sheets.

Lease ROU assets represent the Company’s right to use an underlying asset for the lease term and lease liabilities represent the Company’s obligation to make lease payments arising from the lease. Operating lease ROU assets and liabilities are recognized at the commencement date based on the present value of lease payments over the lease term, including options to extend the lease when it is reasonably certain that the Company will exercise that option. The Company uses its incremental borrowing rate based on the information available at the commencement date, including inquiries with its bank, in determining the present value of lease payments since its leases do not provide an implicit rate. The lease ROU asset includes any base rent payments made and excludes lease incentives and variable operating expenses. Lease expense for lease payments is recognized on a straight-line basis over the lease term.

The Company leases out space in buildings it owns in El Monte, California, to third-party tenants under noncancelable operating leases and has leased out such space since the Company purchased such buildings. The Company recognizes lease payments as income over the lease terms on a straight-line basis and recognizes variable lease payments as income in the period in which the changes in facts and circumstances on which the variable lease payments are based occur. The net rental income is included in the interest and other income, net, in the accompanying Condensed Consolidated Statement of Operations.

Concentration of Customers

In certain periods, a small number of customers has accounted for a significant portion of the Company’s revenue. After aggregating customers that are under common control or are affiliates, two customers contributed 20% and 16% of the Company’s revenue for the three months ended June 30, 2021, respectively, and two customers contributed 24% and 11% of the Company’s revenue for the six months ended June 30, 2021, respectively.  One customer contributed 45% of the Company’s revenue for the three months ended June 30, 2020, and one customer contributed 31% of the Company’s revenue for the six months ended June 30, 2020. One customer comprised 13% of total accounts receivable as of June 30, 2021. No customer comprised 10% or more of total accounts receivable as of December 31, 2020. Revenue from the U.S. government was less than 10% of total revenue for the three and six months ended June 30, 2021 and 2020.

Revenue from Contracts with Customers

Disaggregation of Revenue

The Company classifies its customers into three payor types: (i) Insurance, (ii) Institutional, including hospitals, medical institutions, other laboratories, governmental bodies, municipalities and large corporations, or (iii) Patients who pay directly, as the Company believes this best depicts how the nature, amount, timing, and uncertainty of its revenue and cash flows are affected by economic factors. The following table summarizes revenue from contracts with customers by payor type for the three and six months ended June 30, 2021 and 2020.

 

 

Three Months Ended June 30,

 

 

Six Months Ended June 30,

 

 

2021

 

 

2020

 

 

2021

 

 

2020

 

 

(in thousands)

 

Testing Services by payor

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Institutional

$

103,602

 

 

$

16,454

 

 

$

255,171

 

 

$

23,932

 

Insurance

 

49,520

 

 

 

691

 

 

 

257,078

 

 

 

825

 

Patient

 

494

 

 

 

120

 

 

 

796

 

 

 

261

 

Total Revenue

$

153,616

 

 

$

17,265

 

 

$

513,045

 

 

$

25,018

 

 

Contract Balances

Receivables from contracts with customers—As of June 30, 2021 and December 31, 2020, receivables from contracts with customers were approximately $148.6 million and $183.9 million, respectively, and are included within trade accounts receivable on the Condensed Consolidated Balance Sheets.

Contracts assets and liabilities —As of June 30, 2021 and December 31, 2020, contract assets from contracts with customers were $324,000 and $1.4 million, respectively, associated with contract execution and certain costs to fulfill a contract, and included in other current assets in the accompanying Condensed Consolidated Balance Sheets. Contract liabilities are recorded when the Company receives payment or bills prior to completing its obligation to transfer goods or services to a customer. The Company had $6.9 million and $26.6 million of contract liabilities as of June 30, 2021 and December 31, 2020, respectively. Revenues of $1.7 million and $196,000 for the three months and $25.5 million and $246,000 for the six months were recognized for the periods ended June 30, 2021 and 2020, respectively, related to contract liabilities at the beginning of the respective periods.

Transaction Price Allocated to Future Performance Obligations

The Company does not have material future obligations associated with testing services that extend beyond one year.

Reagents and Supplies

The Company maintains reagents and other consumables primarily used in sample collections and testing which are valued at the lower of cost or net realizable value. Cost is determined using actual costs on a first-in, first-out basis. The reagents and supplies were $25.4 million and $16.5 million as of June 30, 2021 and December 31, 2020, respectively, and was included in other current assets in the accompanying Condensed Consolidated Balance Sheets.

Customer Deposit

Customer deposit in the accompanying Condensed Consolidated Balance Sheets consists primarily of payments received from customers in excess of their outstanding trade accounts receivable balances, and the excess payments will be refunded to the customers or offset against future testing receivables.

Trade Accounts Receivable and Allowance for Credit Losses

Trade accounts receivable are stated at the amount the Company expects to collect. The Company maintains an allowance for credit losses for expected uncollectible trade accounts receivable, which is recorded as an offset to trade accounts receivable and changes in allowance for credit losses are classified as a general and administrative expense in the accompanying Condensed Consolidated Statements of Operations. The Company assesses collectability by reviewing trade accounts receivable on a collective basis where similar risk characteristics exist and on an individual basis when it identifies specific customers that have deterioration in credit quality such that they may no longer share similar risk characteristics with the other receivables. In determining the amount of the allowance for credit losses, the Company uses a probability-of-default and loss given default model, which allows the ability to define a point of default and measure credit losses for receivables that have reached the point of default for purposes of calculating the allowance for credit losses. Loss given default represents the likelihood that a receivable that has reached the point of default will not be collected in full. The Company will update its probability-of-default and loss given default factors annually to incorporate the most recent historical data and adjusts the quantitative portion of the reserve through its qualitative reserve overlay. The Company looks at qualitative factors such as general economic conditions in determining expected credit losses. During the three and six months ended June 30, 2021, the Company recorded $2.2 million and $3.3 million of provision for credit losses for trade accounts receivable, respectively. The provision was not significant for the three and six months ended June 30, 2020.

Marketable Securities

All marketable debt securities, which consist of corporate debt securities, municipal bonds, U.S. government agency debt securities, and Yankee debt securities issued by foreign governments or entities and denominated in U.S. dollars, have been classified as “available for sale”, and are carried at fair value. Unrealized gains and losses, net of any related tax effects, are excluded from earnings and are included in other comprehensive income (loss) and reported as a separate component of stockholders’ equity until realized. Realized gains and losses on marketable debt securities are included in interest and other income, net, in the accompanying Condensed Consolidated Statements of Operations. The cost of any marketable debt securities sold is based on the specific-identification method. The amortized cost of marketable debt securities is adjusted for amortization of premiums and accretion of discounts to maturity. Interest on marketable debt securities is included in interest and other income, net. In accordance with the Company’s investment policy, management invests to diversify credit risk and only invests in securities with high credit quality, including U.S. government securities, and the final maturity is tailored to the Company’s current liquidity needs with a maximum final maturity from the date of purchase of three years.

The Company’s investments in marketable equity securities are measured at fair value with the related gains and losses, realized and unrealized, recognized in interest and other income, net, in the accompanying Condensed Consolidated Statements of Operations. The cost of any marketable equity securities sold is based on the specific-identification method.

For available for sale debt securities, in an unrealized loss, the company determines whether a credit loss exists. The credit loss is estimated by considering available information relevant to the collectability of the security and information about past events, current conditions, and reasonable and supportable forecasts. Any credit loss is recorded as a charge to interest and other income, net, not to exceed the amount of the unrealized loss. If the Company has an intent to sell, or if it is more likely than not that the Company will be required to sell a debt security in an unrealized loss position before recovery of its amortized cost basis, the Company will write down the security to its fair value and record the corresponding charge as a component of interest and other income, net.

Business Combination

The Company uses the acquisition method of accounting and allocates the fair value of purchase consideration to the assets acquired and liabilities assumed from an acquiree based on their respective fair values as of the acquisition date. The excess of the fair value of purchase consideration over the fair value of these assets acquired and liabilities assumed is recorded as goodwill. When determining the fair values of assets acquired and liabilities assumed, management makes significant estimates and assumptions, especially with respect to intangible assets. Critical estimates in valuing intangible assets include, but are not limited to, expected future cash flows, which includes consideration of future growth and margins, future changes in technology, expected cost and time to develop in-process research and development, brand awareness and discount rates. Fair value estimates are based on the assumptions that management believes a market participant would use in pricing the asset or liability.

Goodwill

Goodwill is not amortized but is subject to impairment tests on an annual basis, or more frequently if indicators of potential impairment exist, and goodwill is written down when it is determined to be impaired. The Company will perform an annual impairment review in the fourth quarter of each fiscal year and compare the fair value of the reporting unit in which the goodwill resides to its carrying value.

Recent Accounting Pronouncements

The Company evaluates all Accounting Standards Updates, or ASUs, issued by the Financial Accounting Standards Board, or FASB, for consideration of their applicability. ASUs not included in the Company’s disclosures were assessed and determined to be either not applicable or are not expected to have a material impact on the Company’s condensed consolidated financial statements.

Recently Adopted Accounting Pronouncements

ASU 2016-13

In June 2016, the FASB issued ASU No. 2016-13, Financial Instruments-Credit Losses: Measurement of Credit Losses on Financial Instruments, or ASU 2016-13. ASU 2016-13 replaces the incurred loss impairment methodology in current U.S. GAAP with a methodology that reflects expected credit losses. The update is intended to provide financial statement users with more decision-useful information about the expected credit losses on financial instruments and other commitments to extend credit held by a reporting entity at each reporting date. Entities will apply the standard’s provisions as a cumulative-effect adjustment to retained earnings as of the beginning of the first reporting period in which the guidance is effective. The standard will be effective for annual reporting periods beginning after December 15, 2019, including interim periods within those reporting periods for public business entities that meet the definition of an SEC filer, excluding entities eligible to be smaller reporting companies as defined by the SEC. For all other entities, the amendments in this update are effective for fiscal years beginning after December 15, 2022, including interim periods within those fiscal years. Early application of the amendments is permitted. The Company adopted ASU 2016-13 using the modified retrospective approach as of January 1, 2021. The cumulative effect upon adoption was $887,000 to the retained earnings in the accompanying Condensed Consolidated Statements of Stockholders’ Equity and trade accounts receivable, net, in the accompanying Condensed Consolidated Balance Sheets. The cumulative tax effective was $239,000 to retained earnings and deferred tax assets included in other long-term assets in the accompanying Condensed Consolidated Balance Sheets. There was no impact related to available-for-sale debt securities.

ASU 2019-12

In December 2019, the FASB issued ASU No. 2019-12, Simplifying the Accounting for Income Taxes (Topic 740), or ASU 2019-12, which is intended to reduce the complexity of accounting standards while maintaining or enhancing the helpfulness of information provided to financial statement users.  The amendment in this ASU simplifies the accounting for income taxes by removing some exceptions including the incremental approach for intraperiod tax allocation, the requirement to recognize a deferred tax liability for equity method investments, the ability not to recognize a deferred tax liability for a foreign subsidiary, and the general methodology for calculating income taxes in an interim period. Other changes include requiring entities to recognize franchise tax that is partially based on income as an income-based tax and account for any incremental amount incurred as a non-income-based tax, evaluate tax basis step-up in goodwill obtained in a transaction that is not a business combination, and reflect the effect of an enacted change in tax laws or rates in the annual effective tax rate computation in the interim period that includes the enactment date, making minor codification improvements for income taxes related to employee stock ownership plans and investments in qualified affordable housing projects accounted for using the equity method, and specifying that an entity is not required to allocate the consolidated current and deferred tax expense to a legal entity that is not subject to tax in its separate financial statements. For public business entities, this amendment is effective for fiscal years, and interim periods within those fiscal years, beginning after December 15, 2020 with early adoption permitted. The Company adopted ASU 2019-12 in the first quarter of 2021, and the adoption had no material impact to the Company’s condensed consolidated financial statements.
XML 22 R11.htm IDEA: XBRL DOCUMENT v3.21.2
Marketable Securities
 6 Months Ended
Jun. 30, 2021
Investments Debt And Equity Securities [Abstract]  
Marketable Securities

Note 3. Marketable Securities

The Company’s marketable securities consisted of the following:

 

 

June 30, 2021

 

 

Amortized

Cost Basis

 

 

Unrealized

Gains

 

 

Unrealized

Losses

 

 

Aggregate

Fair Value

 

 

(in thousands)

 

Marketable securities:

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Short-term

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Equity securities

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Bond fund

$

169,366

 

 

$

10

 

 

$

(451

)

 

$

168,925

 

Exchange traded funds

 

35,042

 

 

 

—

 

 

 

(8

)

 

 

35,034

 

Available-for-sale debt securities

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Corporate debt securities

 

77,664

 

 

 

199

 

 

 

(9

)

 

 

77,854

 

Money market accounts

 

5,501

 

 

 

—

 

 

 

—

 

 

 

5,501

 

Municipal bonds

 

1,517

 

 

 

—

 

 

 

(1

)

 

 

1,516

 

Less: Cash equivalents

 

(5,501

)

 

 

—

 

 

 

—

 

 

 

(5,501

)

Total short-term marketable securities

 

283,589

 

 

 

209

 

 

 

(469

)

 

 

283,329

 

After 1 year through 5 years

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Corporate debt securities

 

354,979

 

 

 

188

 

 

 

(678

)

 

 

354,489

 

Municipal bonds

 

13,376

 

 

 

15

 

 

 

(19

)

 

 

13,372

 

Yankee debt securities

 

14,856

 

 

 

3

 

 

 

(109

)

 

 

14,750

 

U.S. government agency debt securities

 

1,500

 

 

 

—

 

 

 

(4

)

 

 

1,496

 

Total marketable securities due after 1 year through 5 years

 

384,711

 

 

 

206

 

 

 

(810

)

 

 

384,107

 

After 5 years through 10 years

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Municipal bonds

 

9,182

 

 

 

3

 

 

 

(43

)

 

 

9,142

 

Total marketable securities due after 5 years through 10 years

 

9,182

 

 

 

3

 

 

 

(43

)

 

 

9,142

 

Total marketable securities

$

677,482

 

 

$

418

 

 

$

(1,322

)

 

$

676,578

 

 

 

December 31, 2020

 

 

Amortized

Cost Basis

 

 

Unrealized

Gains

 

 

Unrealized

Losses

 

 

Aggregate

Fair Value

 

 

(in thousands)

 

Marketable securities:

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Short-term

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Equity securities

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Bond fund

$

153,269

 

 

$

67

 

 

$

(151

)

 

$

153,185

 

Exchange traded funds

 

17,614

 

 

 

—

 

 

 

(5

)

 

 

17,609

 

Available-for-sale debt securities

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Money market accounts

 

47,461

 

 

 

—

 

 

 

—

 

 

 

47,461

 

Corporate debt securities

 

41,061

 

 

 

101

 

 

 

(15

)

 

 

41,147

 

Less: Cash equivalents

 

(47,461

)

 

 

—

 

 

 

—

 

 

 

(47,461

)

Total short-term marketable securities

 

211,944

 

 

 

168

 

 

 

(171

)

 

 

211,941

 

After 1 year through 5 years

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Corporate debt securities

 

124,989

 

 

 

580

 

 

 

(117

)

 

 

125,452

 

U.S. government agency debt securities

 

1,000

 

 

 

2

 

 

 

—

 

 

 

1,002

 

Yankee debt securities

 

6,054

 

 

 

4

 

 

 

(10

)

 

 

6,048

 

Total marketable securities due after 1 year through 5 years

 

132,043

 

 

 

586

 

 

 

(127

)

 

 

132,502

 

Total marketable securities

$

343,987

 

 

$

754

 

 

$

(298

)

 

$

344,443

 

 

 

Gross unrealized losses on the Company’s marketable securities were $1.3 million as of June 30, 2021. Gross unrealized losses on the Company’s marketable securities were $298,000 as of December 31, 2020. The Company currently does not intend to sell these securities prior to maturity. During the three and six months ended June 30, 2021, the Company did not recognize credit losses.

The Company’s securities of $420.4 million are used as collateral for an outstanding margin account borrowing. As of June 30, 2021, the Company had an outstanding borrowing of $15.1 million under its margin account. Margin account borrowings were used for the purchase of real property located in El Monte, California in 2020.
XML 23 R12.htm IDEA: XBRL DOCUMENT v3.21.2
Fair Value Measurements
 6 Months Ended
Jun. 30, 2021
Fair Value Disclosures [Abstract]  
Fair Value Measurements

Note 4. Fair Value Measurements

The authoritative guidance on fair value measurements establishes a framework with respect to measuring assets and liabilities at fair value on a recurring basis and non-recurring basis. Under the framework, fair value is defined as the exit price, or the amount that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants, as of the measurement date. The framework also establishes a three-tier hierarchy for inputs used in measuring fair value that maximizes the use of observable inputs and minimizes the use of unobservable inputs by requiring that the most observable inputs be used when available. Observable inputs are inputs market participants would use in valuing the asset or liability and are developed based on market data obtained from sources independent of the Company. Unobservable inputs are inputs that reflect the Company’s assumptions about the factors market participants would use in valuing the asset or liability and are developed based on the best information available in the circumstances. The hierarchy consists of the following three levels:

Level 1:

Inputs are quoted prices (unadjusted) in active markets for identical assets or liabilities that the reporting entity can access at the measurement date.

Level 2:

Inputs are inputs other than quoted prices included within Level 1 that are observable for the asset or liability, either directly or indirectly.

Level 3:

Inputs are unobservable inputs for the asset or liability.

 

The following tables present information about the Company’s financial assets measured at fair value on a recurring basis, based on the three-tier fair value hierarchy:

 

 

June 30, 2021

 

 

Total

 

 

Level 1

 

 

Level 2

 

 

Level 3

 

 

(in thousands)

 

Marketable securities and cash equivalents:

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Bond Fund

$

168,925

 

 

$

168,925

 

 

$

—

 

 

$

—

 

Exchange traded funds

 

35,034

 

 

 

35,034

 

 

 

—

 

 

 

—

 

Corporate debt securities

 

432,343

 

 

 

—

 

 

 

432,343

 

 

 

—

 

Municipal bonds

 

24,030

 

 

 

—

 

 

 

24,030

 

 

 

—

 

Yankee debt securities

 

14,750

 

 

 

—

 

 

 

14,750

 

 

 

—

 

U.S. government agency debt securities

 

1,496

 

 

 

—

 

 

 

1,496

 

 

 

—

 

Money market accounts

 

5,501

 

 

 

5,501

 

 

 

—

 

 

 

—

 

Total marketable securities and cash equivalents

$

682,079

 

 

$

209,460

 

 

$

472,619

 

 

$

—

 

 

 

December 31, 2020

 

 

Total

 

 

Level 1

 

 

Level 2

 

 

Level 3

 

 

(in thousands)

 

Marketable securities and cash equivalents:

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Bond Fund

$

153,185

 

 

$

153,185

 

 

$

—

 

 

$

—

 

Exchange traded funds

 

17,609

 

 

 

17,609

 

 

 

—

 

 

 

—

 

Corporate debt securities

 

166,599

 

 

 

—

 

 

 

166,599

 

 

 

—

 

U.S. government agency debt securities

 

1,002

 

 

 

—

 

 

 

1,002

 

 

 

—

 

Yankee debt securities

 

6,048

 

 

 

—

 

 

 

6,048

 

 

 

—

 

Money market accounts

 

47,461

 

 

 

47,461

 

 

 

—

 

 

 

—

 

Total marketable securities and cash equivalents

$

391,904

 

 

$

218,255

 

 

$

173,649

 

 

$

—

 

 

The Company’s Level 1 assets include marketable equity securities and money market instruments and are valued based upon observable market prices. Level 2 assets consist of U.S. government agency debt securities, municipal bonds, corporate debt securities and Yankee debt securities. Level 2 securities are valued based upon observable inputs that include reported trades, broker/dealer

quotes, bids and offers. As of June 30, 2021, the Company had no investments that were measured using unobservable (Level 3) inputs.

There were no transfers between fair value measurement levels during the three and six months ended June 30, 2021.
XML 24 R13.htm IDEA: XBRL DOCUMENT v3.21.2
Fixed Assets
 6 Months Ended
Jun. 30, 2021
Property Plant And Equipment [Abstract]  
Fixed Assets

Note 5. Fixed Assets

Major classes of fixed assets consisted of the following:

 

 

 

June 30,

 

 

December 31,

 

 

Useful Lives

2021

 

 

2020

 

 

 

(in thousands)

 

Medical lab equipment

3 to 5 Years

$

30,108

 

 

$

20,849

 

Building

39 Years

 

6,731

 

 

 

6,731

 

Aircraft

7 Years

 

6,503

 

 

 

6,503

 

Computer hardware

3 Years

 

4,580

 

 

 

3,699

 

Leasehold improvements

Shorter of lease term or estimated useful life

 

1,941

 

 

 

1,580

 

Furniture and fixtures

2 to 5 Years

 

1,056

 

 

 

454

 

Automobile

2 to 5 Years

 

716

 

 

 

53

 

Building improvements

6 months to 5 Years

 

707

 

 

 

707

 

Computer software

3 to 5 Years

 

754

 

 

 

541

 

Land improvements

5 to 15 Years

 

403

 

 

 

403

 

General equipment

3 to 5 Years

 

44

 

 

 

44

 

Land

 

 

7,500

 

 

 

7,500

 

Assets not yet placed in service

 

 

4,783

 

 

 

2,055

 

Total

 

 

65,826

 

 

 

51,119

 

Less: Accumulated depreciation

 

 

(14,740

)

 

 

(10,920

)

Fixed assets, net

 

$

51,086

 

 

$

40,199

 

 

Depreciation expense on fixed assets totaled $2.3 million and $549,000 for the three months and $4.2 million and $1.1 million for the six months ended June 30, 2021 and 2020, respectively.
XML 25 R14.htm IDEA: XBRL DOCUMENT v3.21.2
Other Significant Balance Sheet Accounts
 6 Months Ended
Jun. 30, 2021
Balance Sheet Related Disclosures [Abstract]  
Significant Balance Sheet Accounts

Note 6. Other Significant Balance Sheet Accounts

Other current assets consisted of the following:

 

 

June 30,

 

 

December 31,

 

 

2021

 

 

2020

 

 

(in thousands)

 

Reagents and supplies

$

25,373

 

 

$

16,491

 

Prepaid expenses

 

4,311

 

 

 

3,682

 

Marketable securities interest receivable

 

2,898

 

 

 

1,016

 

Other receivable

 

1,415

 

 

 

17,810

 

Contract assets

 

324

 

 

 

1,379

 

Prepaid income taxes

 

—

 

 

 

14

 

Total

$

34,321

 

 

$

40,392

 

 

Reagents and supplies include reagents and consumables used for COVID-19 testing and genetics testing and collection kits for COVID-19 testing. Other receivable as of December 31, 2020 primarily consists of proceeds to be received from public offerings of the Company’s common stock, which were all collected during the six months ended June 30, 2021.

 

 

Other current liabilities consisted of the following:

 

 

June 30,

 

 

December 31,

 

 

2021

 

 

2020

 

 

(in thousands)

 

Payroll liabilities

$

6,687

 

 

$

5,314

 

Sales tax payable and other

 

4,801

 

 

 

2,538

 

Operating lease liabilities

 

1,001

 

 

 

267

 

Due to related parties

 

574

 

 

 

409

 

Total

$

13,063

 

 

$

8,528

 

 
XML 26 R15.htm IDEA: XBRL DOCUMENT v3.21.2
Reporting Segment and Geographic Information
 6 Months Ended
Jun. 30, 2021
Segment Reporting [Abstract]  
Reporting Segment and Geographic Information

Note 7. Reporting Segment and Geographic Information

The Company views its operations and manages its business in one reporting segment. Long-lived assets were primarily located in the United States as of June 30, 2021 and December 31, 2020 with an insignificant amount located in China and Canada. Revenue by region during the three and six months ended June 30, 2021 and 2020 were as follows:

 

 

Three Months Ended June 30,

 

 

Six Months Ended June 30,

 

 

2021

 

 

2020

 

 

2021

 

 

2020

 

 

(in thousands)

 

Revenue:

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

United States

$

149,862

 

 

$

16,138

 

 

$

507,399

 

 

$

21,777

 

Foreign

 

3,754

 

 

 

1,127

 

 

 

5,646

 

 

 

3,241

 

Total

$

153,616

 

 

$

17,265

 

 

$

513,045

 

 

$

25,018

 
XML 27 R16.htm IDEA: XBRL DOCUMENT v3.21.2
Debt, Commitments and Contingencies
 6 Months Ended
Jun. 30, 2021
Debt Commitments And Contingencies Disclosure [Abstract]  
Debt, Commitments and Contingencies

Note 8. Debt, Commitments and Contingencies

 

Debt

As of June 30, 2021, the Company had an outstanding borrowing of $15.1 million under its margin account with the custodian of the Company’s marketable debt security investment account, Pershing Advisor Solutions, LLC, a BNY Mellon Company. Margin account borrowings were used for the purchase of real property located in El Monte, California in 2020. The securities in the brokerage account were used as collateral for the margin loan. The custodian can issue a margin call at any time. The interest rate on the margin loan was the effective federal funds rate, or EFFR, plus a spread, and the EFFR and/or the spread can be changed by BNY Mellon at any time. The interest was 1% at the time of withdrawal of $15.0 million from the margin account, and the interest rate at June 30, 2021 was less than 1.0%. The Company did not make any other withdrawals from the margin account, and the outstanding balance of $15.1 million is included in the accompanying Condensed Consolidated Balance Sheets. The related interest expenses for the three and six months ended June 30, 2021 were $29,000 and $58,000, respectively. The related interest expenses were none for the three and six months ended June 30, 2020.

Notes payable as of June 30, 2021 consisted of $5.9 million of notes payable to Xilong Scientific Co., Ltd., or Xilong Scientific, by Fujian Fujun Gene Biotech Co., Ltd., or FF Gene Biotech, as defined in Note 14, Business Combination. The loan is payable on December 31, 2022 and interest rate on the loan is 4.97%.

Operating Leases

See Note 9, Leases, for further information.

Purchase Obligations

As of June 30, 2021, the Company had non-cancelable purchase obligations of $7.6 million, of which, $4.9 million for reagents and other supplies, $2.3 million for medical lab equipment, and $372,000 for medical lab furniture are payable within twelve months.

Contingencies

From time to time, the Company may be subject to legal proceedings and claims arising in the ordinary course of business. In the opinion of management, the outcome of these matters would not have a material effect on the Company’s condensed consolidated financial position, results of operations or cash flows.
XML 28 R17.htm IDEA: XBRL DOCUMENT v3.21.2
Leases
 6 Months Ended
Jun. 30, 2021
Leases [Abstract]  
Leases

Note 9. Leases

 

Lessee

The Company is party as a lessee to various non-cancelable operating leases with varying terms through February 2026 primarily for laboratory and office space and equipment. The Company has an option to renew one of these leases for one year after its expiration. On a lease-by-lease basis, the Company considers such options, which may be elected at the Company’s sole discretion, in determining the lease term. The Company does not have any finance leases or leases with variable lease payments. The Company’s lease agreements do not contain any residual value guarantees, material restrictive covenants, bargain purchase options or asset retirement obligations.

The Company’s headquarters are located in Temple City, California, which is comprised of various corporate offices and a laboratory certified under the Clinical Laboratory Improvement Amendments of 1988, or CLIA, accredited by the College of American Pathologists, or CAP, and licensed by the State of California Department of Public Health. Another CLIA-certified laboratory is located in Houston, Texas. Additional offices are located in Atlanta, Georgia and are used for certain report generation functions.

In February 2021, the Company extended the lease for its headquarters located in Temple City, California, to January 31, 2023. In March 2021, the Company entered into a new lease for its 12,000 square foot CLIA-certified laboratory in Houston, Texas, and the lease will expire in November 2023.

The operating lease right-of-use asset, short-term lease liabilities, and long-term lease liabilities as of June 30, 2021 and December 31, 2020 were as follows:

 

June 30,

 

 

December 31,

 

 

2021

 

 

2020

 

 

(in thousands)

 

Operating lease right-of-use asset

$

2,176

 

 

$

828

 

Operating lease liabilities, short term

$

1,001

 

 

$

267

 

Operating lease liabilities, long term

$

1,188

 

 

$

568

 

The following was operating lease expense:

 

 

Three months ended June 30,

 

 

Six months ended June 30,

 

 

2021

 

 

2020

 

 

2021

 

 

2020

 

 

(in thousands)

 

Operating lease cost

$

232

 

 

$

152

 

 

$

301

 

 

$

301

 

Short-term lease cost

 

61

 

 

 

3

 

 

 

192

 

 

 

3

 

Total lease cost

$

293

 

 

$

155

 

 

$

493

 

 

$

304

 

 

 

 

Supplemental information related to leases was the following:

 

 

June 30, 2021

 

Weighted average remaining lease term - operating leases

2.9 years

 

Weighted average discount rate - operating leases

 

3.26

%

 

 

The following is a maturity analysis of operating lease liabilities using undiscounted cash flows on an annual basis with renewal periods included:

 

 

Operating Leases

 

 

(in thousands)

 

Year Ending December 31,

 

 

 

2021 (remaining 6 months)

$

538

 

2022

 

881

 

2023

 

412

 

2024

 

216

 

2025

 

215

 

2026

 

37

 

Thereafter

 

—

 

Total lease payments

 

2,299

 

Less imputed interest

 

(110

)

Total

$

2,189

 

 

 

Lessor

The Company leases out space in buildings it owns to third-party tenants under noncancelable operating leases and has leased out such space since the Company purchased such buildings in October 2020. As of June 30, 2021, the remaining lease terms left range from 17 months to 42 months including renewal options and may include rent escalation clauses. Lease income primarily represents fixed lease payments from tenants recognized on a straight-line basis over the application lease term. Variable lease income represents tenant payments for real estate taxes, insurance and maintenance.

The lease income was $85,000 and $242,000 for the three and six months ended June 30, 2021, respectively, which was included in interest and other income, net, in the accompanying Condensed Consolidated Statements of Operations. Total lease income was as follows:

 

 

Three months ended June 30,

 

 

Six months ended June 30,

 

 

2021

 

 

2020

 

 

2021

 

 

2020

 

 

(in thousands)

 

Lease income

$

81

 

 

$

—

 

 

$

237

 

 

$

—

 

Variable lease income

 

4

 

 

 

—

 

 

 

5

 

 

 

—

 

Total lease income

$

85

 

 

$

—

 

 

$

242

 

 

$

—

 

 

Future fixed lease payments from tenants for all noncancelable operating leases as of June 30, 2021 are as follows:

 

 

Lease Payments

 

 

from Tenants

 

 

(in thousands)

 

Year Ending December 31,

 

 

 

2021 (remaining 6 months)

$

94

 

2022

 

190

 

2023

 

95

 

2024

 

61

 

Total

$

440

 

 

 
XML 29 R18.htm IDEA: XBRL DOCUMENT v3.21.2
Equity-Based Compensation
 6 Months Ended
Jun. 30, 2021
Disclosure Of Compensation Related Costs Sharebased Payments [Abstract]  
Equity-Based Compensation

Note 10. Equity-Based Compensation

The Company has included equity-based compensation expense as part of cost of revenue and operating expenses in the accompanying Condensed Consolidated Statements of Operations as follows:

 

 

Three Months Ended June 30,

 

 

Six Months Ended June 30,

 

 

2021

 

 

2020

 

 

2021

 

 

2020

 

 

(in thousands)

 

Cost of revenue

$

692

 

 

$

270

 

 

$

1,366

 

 

$

501

 

Research and development

 

1,481

 

 

 

364

 

 

 

2,704

 

 

 

676

 

Selling and marketing

 

620

 

 

 

222

 

 

 

1,046

 

 

 

393

 

General and administrative

 

733

 

 

 

224

 

 

 

1,372

 

 

 

434

 

Total

$

3,526

 

 

$

1,080

 

 

$

6,488

 

 

$

2,004

 

 
XML 30 R19.htm IDEA: XBRL DOCUMENT v3.21.2
Provision for (Benefit from) Income Taxes
 6 Months Ended
Jun. 30, 2021
Income Tax Disclosure [Abstract]  
Provision for (Benefit from) Income Taxes

Note 11. Provision for (Benefit from) Income Taxes

The effective tax rate used for interim periods is the estimated annual effective consolidated tax rate, based on the current estimate of full year results, except that taxes related to specific events, if any, are recorded in the interim period in which they occur. The annual effective tax rate is based upon several significant estimates and judgments, including the estimated annual pre-tax income of the Company in each tax jurisdiction in which it operates, and the development of tax planning strategies during the year. In addition, the Company’s tax expense can be impacted by changes in tax rates or laws and other factors that cannot be predicted with certainty. As such, there can be significant volatility in interim tax provisions.

The Company recorded consolidated provision for (benefit from) income taxes of $23.6 million and $90.1 million for the three and six months ended June 30, 2021, respectively, compared with $(599,000) and $(565,000) for the three and six months ended June 30, 2020, respectively. The Company’s effective tax rates were 24% and 25% for the three and six months ended June 30, 2021, respectively, compared with -21% and -45% or the three and six months ended June 30, 2020, respectively. The change in the effective tax rate for the three-month and six-month periods of 2021, relative to 2020, was primarily attributable to a significant increase in income for the first quarter of 2021, and, to a lesser extent, an increase in income for the second quarter of 2021, partially offset by increased windfall tax deductions related to stock-based compensation.

The Company is not currently under examination by any major income tax jurisdiction. During 2021, the statutes of limitations will lapse on the Company's 2017 federal tax year and certain 2016 and 2017 state tax years. The Company does not believe the federal or state statute lapses or any other event will significantly impact the balance of unrecognized tax benefits in the next twelve months. The net balance of unrecognized tax benefits was not material to the interim financial statements for the three and six months ended June 30, 2021 and 2020.
XML 31 R20.htm IDEA: XBRL DOCUMENT v3.21.2
Income per Share
 6 Months Ended
Jun. 30, 2021
Earnings Per Share [Abstract]  
Income per Share

Note 12. Income per Share

The following table presents the calculation of basic and diluted income per share for the three and six months ended June 30, 2021 and 2020:

 

 

Three Months Ended June 30,

 

 

Six Months Ended June 30,

 

 

2021

 

 

2020

 

 

2021

 

 

2020

 

 

(in thousands, except per share data)

 

Net income attributable to Fulgent

$

79,812

 

 

$

3,321

 

 

$

280,503

 

 

$

1,365

 

Weighted-average common shares—outstanding, basic

 

29,150

 

 

 

21,747

 

 

 

28,991

 

 

 

21,656

 

Weighted-average common shares—outstanding, diluted

 

30,830

 

 

 

22,920

 

 

 

30,809

 

 

 

22,824

 

Net income per common share, basic

$

2.74

 

 

$

0.15

 

 

$

9.68

 

 

$

0.06

 

Net income per common share, diluted

$

2.59

 

 

$

0.14

 

 

$

9.10

 

 

$

0.06

 

 

The following securities have been excluded from the calculation of diluted income per share because their effect would have been anti-dilutive:

 

 

Three Months Ended June 30,

 

 

Six Months Ended June 30,

 

 

2021

 

 

2020

 

 

2021

 

 

2020

 

 

(in thousands)

 

Options

 

2

 

 

 

4

 

 

 

5

 

 

 

10

 

Restricted Stock Units

 

107

 

 

 

42

 

 

 

71

 

 

 

21

 

 

The anti-dilutive shares described above were calculated using the treasury stock method.

XML 32 R21.htm IDEA: XBRL DOCUMENT v3.21.2
Related Parties
 6 Months Ended
Jun. 30, 2021
Related Party Transactions [Abstract]  
Related Parties

Note 13. Related Parties

Linda Marsh, who is a member of the Company’s board of directors, is currently the Senior Executive Vice President of AHMC Healthcare Inc., or AHMC. The Company performs genetic testing and other testing services, on an arms-length basis, for AHMC, and the Company recognized $738,000 and $1.9 million in revenue in the three and six months ended June 30, 2021, respectively. The Company did not perform any services for AHMC and did not recognize any revenue in the three and six months ended June 30, 2020. As of June 30, 2021 and December 31, 2020, $793,000 and $1.8 million was owed to the Company by AHMC, which is included in trade accounts receivable, net, in the accompanying Condensed Consolidated Balance Sheets, in connection with this relationship.

The Company and Fulgent Pharma LLC, the Company’s former subsidiary, are party to shared services arrangements where research and development and administrative services and office space and equipment are provided between the companies, on an arms-length basis. Ming Hsieh is the Manager and a member of Fulgent Pharma LLC. During the three and six months ended June 30, 2021, the cost of research development services rendered by Fulgent Pharma LLC for the Company was $97,000 and $205,000, respectively. The cost of research development services rendered by Fulgent Pharma LLC for the Company was not significant during the three and six months ended June 30, 2020. Amounts for services performed by the Company for Fulgent Pharma LLC were not significant during the three and six months ended June 31, 2021 and 2020. As of June 30, 2021, and December 31, 2020, $574,000 and $409,000, respectively, were owed to Fulgent Pharma LLC by the Company, which are included in due to related parties as a component in other current liabilities in the accompanying Condensed Consolidated Balance Sheets, in connection with these relationships.
XML 33 R22.htm IDEA: XBRL DOCUMENT v3.21.2
Business Combination
 6 Months Ended
Jun. 30, 2021
Business Combinations [Abstract]  
Business Combination

Note 14. Business Combination

FF Gene Biotech

In April 2017, the Company acquired a 30% equity interest in FF Gene Biotech, a newly formed a joint venture with Xilong Scientific, and Fuzhou Jinqiang Investment Partnership (LP), or FJIP. The joint venture was formed under the laws of China to offer genetic testing services to customers in China.

In May 2021, the Company entered into a restructuring agreement with Xilong Scientific and FJIP, resulting in the Company indirectly acquiring a 72% controlling financial interest in FF Gene Biotech. As a result of the acquisition of FF Gene Biotech, or the FF Gene Biotech Acquisition, the Company will be more strategically aligned with it geographic expansion strategy. It also expects to reduce costs through economies of scale.

The goodwill of $23.1 million arising from the FF Gene Biotech Acquisition is attributed to the expected synergies and other benefits that will be potentially generated from the combination of the Company and FF Gene Biotech. The goodwill recognized is not deductible for tax purposes.

The Company allocated the purchase price to tangible and identified intangible assets acquired and liabilities assumed based on estimated fair values. As additional information becomes available, such as the finalization of the estimated fair value of tax-related items, the Company may further update the preliminary purchase price allocation during the remainder of the measurement period (up to one year from the FF Gene Biotech Acquisition date). The following table summarizes the consideration paid and the amounts of the assets acquired and liabilities assumed recognized at the FF Gene Biotech Acquisition date, as well as the fair value of the noncontrolling interest at the FF Gene Biotech Acquisition date.

 

 

 

Amounts

 

 

(in thousands)

 

Considerations

 

 

 

Cash

$

18,974

 

Fair value of the Company’s 30% equity interest held before the business combination

 

3,734

 

 

$

22,708

 

Recognized amounts of identifiable assets acquired and liabilities assumed

 

 

 

Financial assets

$

3,181

 

Reagents and supplies

 

1,288

 

Fixed assets

 

3,874

 

Other tangible assets

 

944

 

Identifiable intangible assets

 

6,958

 

Other current liabilities

 

(2,585

)

Notes payable

 

(5,893

)

Recognized amounts of identifiable assets acquired and liabilities assumed, net

 

7,767

 

Noncontrolling interest

 

(8,141

)

Goodwill

 

23,082

 

Total

$

22,708

 

The Company incurred $329,000 acquisition related costs, which was recorded as general and administrative expenses in its condensed consolidated statements of operations.

The fair value of the noncontrolling interest, or NCI, in FF Gene Biotech, a private entity, $8.1 million, was estimated by applying the income approach and market approach. The fair value measurement was based on significant inputs that are not observable in the market and thus represents a fair value categorized within Level 3 of the three-tier fair value hierarchy. The NCI represents a minority interest of 28% in the post-restructuring FF Gene Biotech. Since the NCI is the result of the restructuring, the implied value was utilized to value the NCI based on the 42% effective investment. After determining the implied value, a discount for lack of marketability was applied to the 28% interest representing lack of marketability related to the holding period to monetize the NCI in a future initial public offering, or IPO, or sale, and marketability related to market participant acquisition premiums implied in the value of the $19.0 million purchase price for a 42% interest. The resultant total discount applied was 35%, which is supported both by the put option analyses related to the potential holding period, and a 10% discount owed to a market participant acquisition premium.

The Company recognized a gain of $3.7 million as a result of remeasuring to fair value its 30% equity interest held before the FF Gene Biotech Acquisition. The fair value of the preexisting equity interest was determined based on the characteristics before consummating the FF Gene Biotech Acquisition and estimated by applying income approach and utilized the discounted cash flow method. The Company did not apply the market approach based on its characteristics before consummating the restructuring. The gain on the equity method investment is included in the Company’s Condensed Consolidated Statements of Operations for the three and six months ended June 30, 2021.

The amounts of FF Gene Biotech’s revenue and net losses included in the Company’s Condensed Consolidated Statements of Operations for the periods ended June 30, 2021 and the revenue and net losses of the combined entity had the acquisition date been January 1, 2021 are not material to the Company.

The identified intangible assets acquired in the FF Gene Biotech Acquisition consisted of a $5.7 million royalty-free technology with an estimated amortization life of 10 years and a $1.2 million customer relationships with an estimated amortization life of 5 years. The value of these assets were based upon the preliminary fair values as of the closing date of the FF Gene Biotech Acquisition.

The Company concluded FF Gene Biotech is a variable interest entity as FF Gene Biotech lacks sufficient capital to operate independently. The Company concluded that it alone has the power to direct the most significant activities of FF Gene Biotech and therefore is the primary beneficiary of the entity post the FF Gene Biotech Acquisition. Judgment regarding the level of influence over FF Gene Biotech includes consideration of key factors such as the Company's ownership interest, representation on the board of directors or other management body and participation in policy-making decisions. Post the FF Gene Biotech Acquisition, the financial results for FF Gene Biotech are included in the Company’s condensed financial statements. Prior to the FF Gene Biotech Acquisition, the financial results for FF Gene Biotech were not significant for pro forma financial information.
XML 34 R23.htm IDEA: XBRL DOCUMENT v3.21.2
Equity Distribution Agreement
 6 Months Ended
Jun. 30, 2021
Equity [Abstract]  
Equity Distribution Agreement

Note 15. Equity Distribution Agreement

In November 2020, the Company entered into an Equity Distribution Agreement, or the November 2020 Equity Distribution Agreement, with Piper Sandler & Co. (f/k/a Piper Jaffray & Co.), Oppenheimer & Co. Inc., and BTIG LLC, as sales agents, pursuant to which the Company may offer and sell, from time to time through Piper, shares of its common stock having an aggregate offering price of up to $175.0 million. Piper may receive a commission of up to 3% of the gross proceeds received by the Company for sales pursuant to the November 2020 Equity Distribution Agreement. During the three months ended June 30, 2021, the Company sold approximately 378,000 shares of its common stock pursuant to the November 2020 Equity Distribution Agreement at a weighted-average net selling price of $73.75. During the six months ended June 30, 2021, the Company sold approximately 961,000 shares of its common stock pursuant to the November 2020 Equity Distribution Agreement at a weighted-average net selling price of $60.56.
XML 35 R24.htm IDEA: XBRL DOCUMENT v3.21.2
Goodwill and Acquisition-Related Intangibles
 6 Months Ended
Jun. 30, 2021
Goodwill And Intangible Assets Disclosure [Abstract]  
Goodwill and Acquisition-Related Intangibles

Note 16. Goodwill and Acquisition-Related Intangibles

Summaries of goodwill and acquisitions-related intangibles balances as of June 30, 2021 and December 30, 2020 were as follows:

 

 

 

June 30,

 

 

December 31,

 

 

Weighted-Average Amortization Period

2021

 

 

2020

 

 

 

(in thousands)

 

Goodwill

 

$

23,107

 

 

$

—

 

 

 

 

 

 

 

 

 

 

Royalty-free technology

10 Years

$

5,727

 

 

$

—

 

Less: accumulated amortization

 

 

(95

)

 

 

—

 

Royalty-free technology, net

 

 

5,632

 

 

 

—

 

 

 

 

 

 

 

 

 

 

Customer relationships

5 Years

 

1,238

 

 

 

—

 

Less: accumulated amortization

 

 

(41

)

 

 

—

 

Customer relationships, net

 

 

1,197

 

 

 

—

 

Total acquisition-related intangibles, net

 

$

6,829

 

 

$

—

 

 

During the three months ended June 30, 2021, the Company recorded $23.1 million of goodwill and $7.0 million of intangibles attributable to the FF Gene Biotech Acquisition. See Note 14, Business Combination, to the Company's condensed consolidated financial statements.

Based on the carrying value of acquisition-related intangibles recorded as of June 30, 2021, and assuming no subsequent impairment of the underlying assets, the annual amortization expense for acquisition-related intangibles is expected to be as follows:

 

 

Amounts

 

 

(in thousands)

 

2021 (remaining 6 months)

$

410

 

2022

 

821

 

2023

 

821

 

2024

 

821

 

2025

 

821

 

2026

 

656

 

Thereafter

 

2,479

 

Total

$

6,829

 

 

 
XML 36 R25.htm IDEA: XBRL DOCUMENT v3.21.2
Subsequent Events
 6 Months Ended
Jun. 30, 2021
Subsequent Events [Abstract]  
Subsequent Events

Note 17. Subsequent Events

In July 2021, the Company invested $20.0 million in Laboratory for Advanced Medicine, Inc., or Helio Health, incorporated in Cayman Islands, and, in connection with the investment in Helio Health, the Company obtained a minority shareholder interest. Helio Heath is an AI-driven healthcare company developing early testing capabilities for cancer. Through this partnership, the Company seeks to have access to an emerging liquid biopsy testing technology in the U.S. and China and exclusive commercial rights to Helio Health’s liquid biopsy tests in the U.S. and Canada.

In August 2021, the Company completed an acquisition of Cytometry Specialists, Inc., or CSI, a Georgia corporation, through the acquisition of all of the issued and outstanding common stock of CSI in exchange for $50.0 million in cash and up to $10.0 million in potential future milestone payments. Through the acquisition of CSI, the Company seeks to expand the Company’s presence and capabilities in somatic molecular diagnostics and cancer testing. The Company plans to leverage its established technology platform, NGS expertise, lab operations, and sales infrastructure in conjunction with CSI’s extensive cancer testing menu to establish a differentiated foothold in oncologic testing in the United States.

 

 
XML 37 R26.htm IDEA: XBRL DOCUMENT v3.21.2
Summary of Significant Accounting Policies (Policies)
 6 Months Ended
Jun. 30, 2021
Accounting Policies [Abstract]  
Use of Estimates

Use of Estimates

The preparation of condensed consolidated financial statements in conformity with U.S. GAAP requires management to make certain estimates, judgments and assumptions that affect the reported amounts of assets and liabilities at the date of the financial statements, as well as the reported amounts of revenue and expenses during the reporting periods. These estimates, judgments and assumptions are based on historical data and experience available at the date of the accompanying condensed consolidated financial statements, as well as various other factors management believes to be reasonable under the circumstances, including but not limited to the potential impacts arising from the recent global pandemic related to COVID-19. As the extent and duration of the impacts from COVID-19 remain unclear, the Company’s estimates and assumptions may evolve as conditions change. Actual results could differ significantly from these estimates.

On an on-going basis, management evaluates its estimates, primarily those related to: (i) revenue recognition criteria, (ii) trade accounts receivable and allowances for credit losses, (iii) the useful lives of fixed assets, (iv) estimates of tax liabilities, (v) the valuation of equity method investments, (vi) valuation of acquisition-related intangibles and goodwill, and (vii) useful lives of intangible assets and fixed assets.
Foreign Currency Translation and Foreign Currency Transactions

Foreign Currency Translation and Foreign Currency Transactions

The Company translates the assets and liabilities of its non-U.S. dollar functional currency subsidiaries into U.S. dollars using exchange rates in effect at the end of each period. Expenses for these subsidiaries are translated using rates that approximate those in effect during the period. Gains and losses from these translations are recognized in foreign currency translation included in accumulated other comprehensive income (loss) in the accompanying Condensed Consolidated Statements of Stockholders’ Equity. Gains from these translations were not significant in the three and six months ended June 30, 2021 and three months ended June 30, 2020, and loss from these translations for the six months ended June 30, 2020 was not significant. The Company and its subsidiaries that use the U.S. dollar as their functional currency remeasure monetary assets and liabilities at exchange rates in effect at the end of each period, and inventories, property and nonmonetary assets and liabilities at historical rates. Losses from these remeasurements in the three and six months ended June 30, 2021 and in the six months ended June 30, 2020 were not significant. Gains from these remeasurements were not significant in the three months ended June 30, 2020.
Leases

Leases

The Company determines if an arrangement is a lease at inception by evaluating whether the arrangement conveys the right to use an identified asset and whether the Company obtains substantially all of the economic benefits from and has the ability to direct the use of the asset. Operating lease right-of-use, or ROU, asset, short-term lease liabilities, and long-term lease liabilities were included in other long-term assets, other current liabilities, and other long-term liabilities, respectively, in the accompanying Condensed Consolidated Balance Sheets.

Lease ROU assets represent the Company’s right to use an underlying asset for the lease term and lease liabilities represent the Company’s obligation to make lease payments arising from the lease. Operating lease ROU assets and liabilities are recognized at the commencement date based on the present value of lease payments over the lease term, including options to extend the lease when it is reasonably certain that the Company will exercise that option. The Company uses its incremental borrowing rate based on the information available at the commencement date, including inquiries with its bank, in determining the present value of lease payments since its leases do not provide an implicit rate. The lease ROU asset includes any base rent payments made and excludes lease incentives and variable operating expenses. Lease expense for lease payments is recognized on a straight-line basis over the lease term.

The Company leases out space in buildings it owns in El Monte, California, to third-party tenants under noncancelable operating leases and has leased out such space since the Company purchased such buildings. The Company recognizes lease payments as income over the lease terms on a straight-line basis and recognizes variable lease payments as income in the period in which the changes in facts and circumstances on which the variable lease payments are based occur. The net rental income is included in the interest and other income, net, in the accompanying Condensed Consolidated Statement of Operations.
Concentration of Customers

Concentration of Customers

In certain periods, a small number of customers has accounted for a significant portion of the Company’s revenue. After aggregating customers that are under common control or are affiliates, two customers contributed 20% and 16% of the Company’s revenue for the three months ended June 30, 2021, respectively, and two customers contributed 24% and 11% of the Company’s revenue for the six months ended June 30, 2021, respectively.  One customer contributed 45% of the Company’s revenue for the three months ended June 30, 2020, and one customer contributed 31% of the Company’s revenue for the six months ended June 30, 2020. One customer comprised 13% of total accounts receivable as of June 30, 2021. No customer comprised 10% or more of total accounts receivable as of December 31, 2020. Revenue from the U.S. government was less than 10% of total revenue for the three and six months ended June 30, 2021 and 2020.
Revenue from Contracts with Customers

Revenue from Contracts with Customers

Disaggregation of Revenue

The Company classifies its customers into three payor types: (i) Insurance, (ii) Institutional, including hospitals, medical institutions, other laboratories, governmental bodies, municipalities and large corporations, or (iii) Patients who pay directly, as the Company believes this best depicts how the nature, amount, timing, and uncertainty of its revenue and cash flows are affected by economic factors. The following table summarizes revenue from contracts with customers by payor type for the three and six months ended June 30, 2021 and 2020.

 

 

Three Months Ended June 30,

 

 

Six Months Ended June 30,

 

 

2021

 

 

2020

 

 

2021

 

 

2020

 

 

(in thousands)

 

Testing Services by payor

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Institutional

$

103,602

 

 

$

16,454

 

 

$

255,171

 

 

$

23,932

 

Insurance

 

49,520

 

 

 

691

 

 

 

257,078

 

 

 

825

 

Patient

 

494

 

 

 

120

 

 

 

796

 

 

 

261

 

Total Revenue

$

153,616

 

 

$

17,265

 

 

$

513,045

 

 

$

25,018

 

 

Contract Balances

Receivables from contracts with customers—As of June 30, 2021 and December 31, 2020, receivables from contracts with customers were approximately $148.6 million and $183.9 million, respectively, and are included within trade accounts receivable on the Condensed Consolidated Balance Sheets.

Contracts assets and liabilities —As of June 30, 2021 and December 31, 2020, contract assets from contracts with customers were $324,000 and $1.4 million, respectively, associated with contract execution and certain costs to fulfill a contract, and included in other current assets in the accompanying Condensed Consolidated Balance Sheets. Contract liabilities are recorded when the Company receives payment or bills prior to completing its obligation to transfer goods or services to a customer. The Company had $6.9 million and $26.6 million of contract liabilities as of June 30, 2021 and December 31, 2020, respectively. Revenues of $1.7 million and $196,000 for the three months and $25.5 million and $246,000 for the six months were recognized for the periods ended June 30, 2021 and 2020, respectively, related to contract liabilities at the beginning of the respective periods.

Transaction Price Allocated to Future Performance Obligations

The Company does not have material future obligations associated with testing services that extend beyond one year.
Reagents and Supplies

Reagents and Supplies

The Company maintains reagents and other consumables primarily used in sample collections and testing which are valued at the lower of cost or net realizable value. Cost is determined using actual costs on a first-in, first-out basis. The reagents and supplies were $25.4 million and $16.5 million as of June 30, 2021 and December 31, 2020, respectively, and was included in other current assets in the accompanying Condensed Consolidated Balance Sheets.
Customer Deposit

Customer Deposit

Customer deposit in the accompanying Condensed Consolidated Balance Sheets consists primarily of payments received from customers in excess of their outstanding trade accounts receivable balances, and the excess payments will be refunded to the customers or offset against future testing receivables.
Trade Accounts Receivable And Allowance For Credit Losses

Trade Accounts Receivable and Allowance for Credit Losses

Trade accounts receivable are stated at the amount the Company expects to collect. The Company maintains an allowance for credit losses for expected uncollectible trade accounts receivable, which is recorded as an offset to trade accounts receivable and changes in allowance for credit losses are classified as a general and administrative expense in the accompanying Condensed Consolidated Statements of Operations. The Company assesses collectability by reviewing trade accounts receivable on a collective basis where similar risk characteristics exist and on an individual basis when it identifies specific customers that have deterioration in credit quality such that they may no longer share similar risk characteristics with the other receivables. In determining the amount of the allowance for credit losses, the Company uses a probability-of-default and loss given default model, which allows the ability to define a point of default and measure credit losses for receivables that have reached the point of default for purposes of calculating the allowance for credit losses. Loss given default represents the likelihood that a receivable that has reached the point of default will not be collected in full. The Company will update its probability-of-default and loss given default factors annually to incorporate the most recent historical data and adjusts the quantitative portion of the reserve through its qualitative reserve overlay. The Company looks at qualitative factors such as general economic conditions in determining expected credit losses. During the three and six months ended June 30, 2021, the Company recorded $2.2 million and $3.3 million of provision for credit losses for trade accounts receivable, respectively. The provision was not significant for the three and six months ended June 30, 2020.
Marketable Securities

Marketable Securities

All marketable debt securities, which consist of corporate debt securities, municipal bonds, U.S. government agency debt securities, and Yankee debt securities issued by foreign governments or entities and denominated in U.S. dollars, have been classified as “available for sale”, and are carried at fair value. Unrealized gains and losses, net of any related tax effects, are excluded from earnings and are included in other comprehensive income (loss) and reported as a separate component of stockholders’ equity until realized. Realized gains and losses on marketable debt securities are included in interest and other income, net, in the accompanying Condensed Consolidated Statements of Operations. The cost of any marketable debt securities sold is based on the specific-identification method. The amortized cost of marketable debt securities is adjusted for amortization of premiums and accretion of discounts to maturity. Interest on marketable debt securities is included in interest and other income, net. In accordance with the Company’s investment policy, management invests to diversify credit risk and only invests in securities with high credit quality, including U.S. government securities, and the final maturity is tailored to the Company’s current liquidity needs with a maximum final maturity from the date of purchase of three years.

The Company’s investments in marketable equity securities are measured at fair value with the related gains and losses, realized and unrealized, recognized in interest and other income, net, in the accompanying Condensed Consolidated Statements of Operations. The cost of any marketable equity securities sold is based on the specific-identification method.

For available for sale debt securities, in an unrealized loss, the company determines whether a credit loss exists. The credit loss is estimated by considering available information relevant to the collectability of the security and information about past events, current conditions, and reasonable and supportable forecasts. Any credit loss is recorded as a charge to interest and other income, net, not to exceed the amount of the unrealized loss. If the Company has an intent to sell, or if it is more likely than not that the Company will be required to sell a debt security in an unrealized loss position before recovery of its amortized cost basis, the Company will write down the security to its fair value and record the corresponding charge as a component of interest and other income, net.
Business Combination

Business Combination

The Company uses the acquisition method of accounting and allocates the fair value of purchase consideration to the assets acquired and liabilities assumed from an acquiree based on their respective fair values as of the acquisition date. The excess of the fair value of purchase consideration over the fair value of these assets acquired and liabilities assumed is recorded as goodwill. When determining the fair values of assets acquired and liabilities assumed, management makes significant estimates and assumptions, especially with respect to intangible assets. Critical estimates in valuing intangible assets include, but are not limited to, expected future cash flows, which includes consideration of future growth and margins, future changes in technology, expected cost and time to develop in-process research and development, brand awareness and discount rates. Fair value estimates are based on the assumptions that management believes a market participant would use in pricing the asset or liability.
Goodwill

Goodwill

Goodwill is not amortized but is subject to impairment tests on an annual basis, or more frequently if indicators of potential impairment exist, and goodwill is written down when it is determined to be impaired. The Company will perform an annual impairment review in the fourth quarter of each fiscal year and compare the fair value of the reporting unit in which the goodwill resides to its carrying value.

Recent Accounting and Recently Adopted Accounting Pronouncements

Recent Accounting Pronouncements

The Company evaluates all Accounting Standards Updates, or ASUs, issued by the Financial Accounting Standards Board, or FASB, for consideration of their applicability. ASUs not included in the Company’s disclosures were assessed and determined to be either not applicable or are not expected to have a material impact on the Company’s condensed consolidated financial statements.

Recently Adopted Accounting Pronouncements

ASU 2016-13

In June 2016, the FASB issued ASU No. 2016-13, Financial Instruments-Credit Losses: Measurement of Credit Losses on Financial Instruments, or ASU 2016-13. ASU 2016-13 replaces the incurred loss impairment methodology in current U.S. GAAP with a methodology that reflects expected credit losses. The update is intended to provide financial statement users with more decision-useful information about the expected credit losses on financial instruments and other commitments to extend credit held by a reporting entity at each reporting date. Entities will apply the standard’s provisions as a cumulative-effect adjustment to retained earnings as of the beginning of the first reporting period in which the guidance is effective. The standard will be effective for annual reporting periods beginning after December 15, 2019, including interim periods within those reporting periods for public business entities that meet the definition of an SEC filer, excluding entities eligible to be smaller reporting companies as defined by the SEC. For all other entities, the amendments in this update are effective for fiscal years beginning after December 15, 2022, including interim periods within those fiscal years. Early application of the amendments is permitted. The Company adopted ASU 2016-13 using the modified retrospective approach as of January 1, 2021. The cumulative effect upon adoption was $887,000 to the retained earnings in the accompanying Condensed Consolidated Statements of Stockholders’ Equity and trade accounts receivable, net, in the accompanying Condensed Consolidated Balance Sheets. The cumulative tax effective was $239,000 to retained earnings and deferred tax assets included in other long-term assets in the accompanying Condensed Consolidated Balance Sheets. There was no impact related to available-for-sale debt securities.

ASU 2019-12

In December 2019, the FASB issued ASU No. 2019-12, Simplifying the Accounting for Income Taxes (Topic 740), or ASU 2019-12, which is intended to reduce the complexity of accounting standards while maintaining or enhancing the helpfulness of information provided to financial statement users.  The amendment in this ASU simplifies the accounting for income taxes by removing some exceptions including the incremental approach for intraperiod tax allocation, the requirement to recognize a deferred tax liability for equity method investments, the ability not to recognize a deferred tax liability for a foreign subsidiary, and the general methodology for calculating income taxes in an interim period. Other changes include requiring entities to recognize franchise tax that is partially based on income as an income-based tax and account for any incremental amount incurred as a non-income-based tax, evaluate tax basis step-up in goodwill obtained in a transaction that is not a business combination, and reflect the effect of an enacted change in tax laws or rates in the annual effective tax rate computation in the interim period that includes the enactment date, making minor codification improvements for income taxes related to employee stock ownership plans and investments in qualified affordable housing projects accounted for using the equity method, and specifying that an entity is not required to allocate the consolidated current and deferred tax expense to a legal entity that is not subject to tax in its separate financial statements. For public business entities, this amendment is effective for fiscal years, and interim periods within those fiscal years, beginning after December 15, 2020 with early adoption permitted. The Company adopted ASU 2019-12 in the first quarter of 2021, and the adoption had no material impact to the Company’s condensed consolidated financial statements.
XML 38 R27.htm IDEA: XBRL DOCUMENT v3.21.2
Summary of Significant Accounting Policies (Tables)
 6 Months Ended
Jun. 30, 2021
Accounting Standards Update 2014-09  
Summary of Revenue from Contracts with Customers by Payor Type The following table summarizes revenue from contracts with customers by payor type for the three and six months ended June 30, 2021 and 2020.

 

 

Three Months Ended June 30,

 

 

Six Months Ended June 30,

 

 

2021

 

 

2020

 

 

2021

 

 

2020

 

 

(in thousands)

 

Testing Services by payor

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Institutional

$

103,602

 

 

$

16,454

 

 

$

255,171

 

 

$

23,932

 

Insurance

 

49,520

 

 

 

691

 

 

 

257,078

 

 

 

825

 

Patient

 

494

 

 

 

120

 

 

 

796

 

 

 

261

 

Total Revenue

$

153,616

 

 

$

17,265

 

 

$

513,045

 

 

$

25,018

 

 
XML 39 R28.htm IDEA: XBRL DOCUMENT v3.21.2
Marketable Securities (Tables)
 6 Months Ended
Jun. 30, 2021
Investments Debt And Equity Securities [Abstract]  
Summary of Marketable Securities

The Company’s marketable securities consisted of the following:

 

 

June 30, 2021

 

 

Amortized

Cost Basis

 

 

Unrealized

Gains

 

 

Unrealized

Losses

 

 

Aggregate

Fair Value

 

 

(in thousands)

 

Marketable securities:

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Short-term

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Equity securities

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Bond fund

$

169,366

 

 

$

10

 

 

$

(451

)

 

$

168,925

 

Exchange traded funds

 

35,042

 

 

 

—

 

 

 

(8

)

 

 

35,034

 

Available-for-sale debt securities

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Corporate debt securities

 

77,664

 

 

 

199

 

 

 

(9

)

 

 

77,854

 

Money market accounts

 

5,501

 

 

 

—

 

 

 

—

 

 

 

5,501

 

Municipal bonds

 

1,517

 

 

 

—

 

 

 

(1

)

 

 

1,516

 

Less: Cash equivalents

 

(5,501

)

 

 

—

 

 

 

—

 

 

 

(5,501

)

Total short-term marketable securities

 

283,589

 

 

 

209

 

 

 

(469

)

 

 

283,329

 

After 1 year through 5 years

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Corporate debt securities

 

354,979

 

 

 

188

 

 

 

(678

)

 

 

354,489

 

Municipal bonds

 

13,376

 

 

 

15

 

 

 

(19

)

 

 

13,372

 

Yankee debt securities

 

14,856

 

 

 

3

 

 

 

(109

)

 

 

14,750

 

U.S. government agency debt securities

 

1,500

 

 

 

—

 

 

 

(4

)

 

 

1,496

 

Total marketable securities due after 1 year through 5 years

 

384,711

 

 

 

206

 

 

 

(810

)

 

 

384,107

 

After 5 years through 10 years

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Municipal bonds

 

9,182

 

 

 

3

 

 

 

(43

)

 

 

9,142

 

Total marketable securities due after 5 years through 10 years

 

9,182

 

 

 

3

 

 

 

(43

)

 

 

9,142

 

Total marketable securities

$

677,482

 

 

$

418

 

 

$

(1,322

)

 

$

676,578

 

 

 

December 31, 2020

 

 

Amortized

Cost Basis

 

 

Unrealized

Gains

 

 

Unrealized

Losses

 

 

Aggregate

Fair Value

 

 

(in thousands)

 

Marketable securities:

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Short-term

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Equity securities

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Bond fund

$

153,269

 

 

$

67

 

 

$

(151

)

 

$

153,185

 

Exchange traded funds

 

17,614

 

 

 

—

 

 

 

(5

)

 

 

17,609

 

Available-for-sale debt securities

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Money market accounts

 

47,461

 

 

 

—

 

 

 

—

 

 

 

47,461

 

Corporate debt securities

 

41,061

 

 

 

101

 

 

 

(15

)

 

 

41,147

 

Less: Cash equivalents

 

(47,461

)

 

 

—

 

 

 

—

 

 

 

(47,461

)

Total short-term marketable securities

 

211,944

 

 

 

168

 

 

 

(171

)

 

 

211,941

 

After 1 year through 5 years

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Corporate debt securities

 

124,989

 

 

 

580

 

 

 

(117

)

 

 

125,452

 

U.S. government agency debt securities

 

1,000

 

 

 

2

 

 

 

—

 

 

 

1,002

 

Yankee debt securities

 

6,054

 

 

 

4

 

 

 

(10

)

 

 

6,048

 

Total marketable securities due after 1 year through 5 years

 

132,043

 

 

 

586

 

 

 

(127

)

 

 

132,502

 

Total marketable securities

$

343,987

 

 

$

754

 

 

$

(298

)

 

$

344,443

 
XML 40 R29.htm IDEA: XBRL DOCUMENT v3.21.2
Fair Value Measurements (Tables)
 6 Months Ended
Jun. 30, 2021
Fair Value Disclosures [Abstract]  
Information about Financial Assets Measured at Fair Value on Recurring Basis Based on Three-Tier Fair Value Hierarchy

The following tables present information about the Company’s financial assets measured at fair value on a recurring basis, based on the three-tier fair value hierarchy:

 

 

June 30, 2021

 

 

Total

 

 

Level 1

 

 

Level 2

 

 

Level 3

 

 

(in thousands)

 

Marketable securities and cash equivalents:

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Bond Fund

$

168,925

 

 

$

168,925

 

 

$

—

 

 

$

—

 

Exchange traded funds

 

35,034

 

 

 

35,034

 

 

 

—

 

 

 

—

 

Corporate debt securities

 

432,343

 

 

 

—

 

 

 

432,343

 

 

 

—

 

Municipal bonds

 

24,030

 

 

 

—

 

 

 

24,030

 

 

 

—

 

Yankee debt securities

 

14,750

 

 

 

—

 

 

 

14,750

 

 

 

—

 

U.S. government agency debt securities

 

1,496

 

 

 

—

 

 

 

1,496

 

 

 

—

 

Money market accounts

 

5,501

 

 

 

5,501

 

 

 

—

 

 

 

—

 

Total marketable securities and cash equivalents

$

682,079

 

 

$

209,460

 

 

$

472,619

 

 

$

—

 

 

December 31, 2020

 

 

Total

 

 

Level 1

 

 

Level 2

 

 

Level 3

 

 

(in thousands)

 

Marketable securities and cash equivalents:

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Bond Fund

$

153,185

 

 

$

153,185

 

 

$

—

 

 

$

—

 

Exchange traded funds

 

17,609

 

 

 

17,609

 

 

 

—

 

 

 

—

 

Corporate debt securities

 

166,599

 

 

 

—

 

 

 

166,599

 

 

 

—

 

U.S. government agency debt securities

 

1,002

 

 

 

—

 

 

 

1,002

 

 

 

—

 

Yankee debt securities

 

6,048

 

 

 

—

 

 

 

6,048

 

 

 

—

 

Money market accounts

 

47,461

 

 

 

47,461

 

 

 

—

 

 

 

—

 

Total marketable securities and cash equivalents

$

391,904

 

 

$

218,255

 

 

$

173,649

 

 

$

—

 
XML 41 R30.htm IDEA: XBRL DOCUMENT v3.21.2
Fixed Assets (Tables)
 6 Months Ended
Jun. 30, 2021
Property Plant And Equipment [Abstract]  
Major Classes of Fixed Assets

Major classes of fixed assets consisted of the following:

 

 

 

June 30,

 

 

December 31,

 

 

Useful Lives

2021

 

 

2020

 

 

 

(in thousands)

 

Medical lab equipment

3 to 5 Years

$

30,108

 

 

$

20,849

 

Building

39 Years

 

6,731

 

 

 

6,731

 

Aircraft

7 Years

 

6,503

 

 

 

6,503

 

Computer hardware

3 Years

 

4,580

 

 

 

3,699

 

Leasehold improvements

Shorter of lease term or estimated useful life

 

1,941

 

 

 

1,580

 

Furniture and fixtures

2 to 5 Years

 

1,056

 

 

 

454

 

Automobile

2 to 5 Years

 

716

 

 

 

53

 

Building improvements

6 months to 5 Years

 

707

 

 

 

707

 

Computer software

3 to 5 Years

 

754

 

 

 

541

 

Land improvements

5 to 15 Years

 

403

 

 

 

403

 

General equipment

3 to 5 Years

 

44

 

 

 

44

 

Land

 

 

7,500

 

 

 

7,500

 

Assets not yet placed in service

 

 

4,783

 

 

 

2,055

 

Total

 

 

65,826

 

 

 

51,119

 

Less: Accumulated depreciation

 

 

(14,740

)

 

 

(10,920

)

Fixed assets, net

 

$

51,086

 

 

$

40,199

 
XML 42 R31.htm IDEA: XBRL DOCUMENT v3.21.2
Other Significant Balance Sheet Accounts (Tables)
 6 Months Ended
Jun. 30, 2021
Balance Sheet Related Disclosures [Abstract]  
Schedule of Other Current Assets

Other current assets consisted of the following:

 

 

June 30,

 

 

December 31,

 

 

2021

 

 

2020

 

 

(in thousands)

 

Reagents and supplies

$

25,373

 

 

$

16,491

 

Prepaid expenses

 

4,311

 

 

 

3,682

 

Marketable securities interest receivable

 

2,898

 

 

 

1,016

 

Other receivable

 

1,415

 

 

 

17,810

 

Contract assets

 

324

 

 

 

1,379

 

Prepaid income taxes

 

—

 

 

 

14

 

Total

$

34,321

 

 

$

40,392

 
Schedule of Other Current Liabilities

Other current liabilities consisted of the following:

 

 

June 30,

 

 

December 31,

 

 

2021

 

 

2020

 

 

(in thousands)

 

Payroll liabilities

$

6,687

 

 

$

5,314

 

Sales tax payable and other

 

4,801

 

 

 

2,538

 

Operating lease liabilities

 

1,001

 

 

 

267

 

Due to related parties

 

574

 

 

 

409

 

Total

$

13,063

 

 

$

8,528

 
XML 43 R32.htm IDEA: XBRL DOCUMENT v3.21.2
Reporting Segment and Geographic Information (Tables)
 6 Months Ended
Jun. 30, 2021
Segment Reporting [Abstract]  
Summary of Revenue by Geographic Region Revenue by region during the three and six months ended June 30, 2021 and 2020 were as follows:

 

 

Three Months Ended June 30,

 

 

Six Months Ended June 30,

 

 

2021

 

 

2020

 

 

2021

 

 

2020

 

 

(in thousands)

 

Revenue:

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

United States

$

149,862

 

 

$

16,138

 

 

$

507,399

 

 

$

21,777

 

Foreign

 

3,754

 

 

 

1,127

 

 

 

5,646

 

 

 

3,241

 

Total

$

153,616

 

 

$

17,265

 

 

$

513,045

 

 

$

25,018

 
XML 44 R33.htm IDEA: XBRL DOCUMENT v3.21.2
Leases (Tables)
 6 Months Ended
Jun. 30, 2021
Leases [Abstract]  
Schedule of Lease Right-of-Use Asset, Short-term Lease Liabilities, and Long-term Lease Liabilities

The operating lease right-of-use asset, short-term lease liabilities, and long-term lease liabilities as of June 30, 2021 and December 31, 2020 were as follows:

 

June 30,

 

 

December 31,

 

 

2021

 

 

2020

 

 

(in thousands)

 

Operating lease right-of-use asset

$

2,176

 

 

$

828

 

Operating lease liabilities, short term

$

1,001

 

 

$

267

 

Operating lease liabilities, long term

$

1,188

 

 

$

568

 
Schedule of Operating Lease Expense

The following was operating lease expense:

 

 

Three months ended June 30,

 

 

Six months ended June 30,

 

 

2021

 

 

2020

 

 

2021

 

 

2020

 

 

(in thousands)

 

Operating lease cost

$

232

 

 

$

152

 

 

$

301

 

 

$

301

 

Short-term lease cost

 

61

 

 

 

3

 

 

 

192

 

 

 

3

 

Total lease cost

$

293

 

 

$

155

 

 

$

493

 

 

$

304

 
Schedule of Supplemental Information Related to Leases

 

Supplemental information related to leases was the following:

 

 

June 30, 2021

 

Weighted average remaining lease term - operating leases

2.9 years

 

Weighted average discount rate - operating leases

 

3.26

%
Schedule of Maturity Analysis of Operating Lease Liabilities using Undiscounted Cash Flows on an Annual Basis The following is a maturity analysis of operating lease liabilities using undiscounted cash flows on an annual basis with renewal periods included:

 

Operating Leases

 

 

(in thousands)

 

Year Ending December 31,

 

 

 

2021 (remaining 6 months)

$

538

 

2022

 

881

 

2023

 

412

 

2024

 

216

 

2025

 

215

 

2026

 

37

 

Thereafter

 

—

 

Total lease payments

 

2,299

 

Less imputed interest

 

(110

)

Total

$

2,189

 

 
Schedule of Lease Income Total lease income was as follows:

 

Three months ended June 30,

 

 

Six months ended June 30,

 

 

2021

 

 

2020

 

 

2021

 

 

2020

 

 

(in thousands)

 

Lease income

$

81

 

 

$

—

 

 

$

237

 

 

$

—

 

Variable lease income

 

4

 

 

 

—

 

 

 

5

 

 

 

—

 

Total lease income

$

85

 

 

$

—

 

 

$

242

 

 

$

—

 

 
Schedule of Future Fixed Lease Payments from Tenants for All Noncancelable Operating Leases

Future fixed lease payments from tenants for all noncancelable operating leases as of June 30, 2021 are as follows:

 

 

Lease Payments

 

 

from Tenants

 

 

(in thousands)

 

Year Ending December 31,

 

 

 

2021 (remaining 6 months)

$

94

 

2022

 

190

 

2023

 

95

 

2024

 

61

 

Total

$

440

 

 

 
XML 45 R34.htm IDEA: XBRL DOCUMENT v3.21.2
Equity-Based Compensation (Tables)
 6 Months Ended
Jun. 30, 2021
Disclosure Of Compensation Related Costs Sharebased Payments [Abstract]  
Summary of Equity-Based Compensation

The Company has included equity-based compensation expense as part of cost of revenue and operating expenses in the accompanying Condensed Consolidated Statements of Operations as follows:

 

 

Three Months Ended June 30,

 

 

Six Months Ended June 30,

 

 

2021

 

 

2020

 

 

2021

 

 

2020

 

 

(in thousands)

 

Cost of revenue

$

692

 

 

$

270

 

 

$

1,366

 

 

$

501

 

Research and development

 

1,481

 

 

 

364

 

 

 

2,704

 

 

 

676

 

Selling and marketing

 

620

 

 

 

222

 

 

 

1,046

 

 

 

393

 

General and administrative

 

733

 

 

 

224

 

 

 

1,372

 

 

 

434

 

Total

$

3,526

 

 

$

1,080

 

 

$

6,488

 

 

$

2,004

 
XML 46 R35.htm IDEA: XBRL DOCUMENT v3.21.2
Income per Share (Tables)
 6 Months Ended
Jun. 30, 2021
Earnings Per Share [Abstract]  
Reconciliation of the Basic and Diluted Income Per Share Computations

The following table presents the calculation of basic and diluted income per share for the three and six months ended June 30, 2021 and 2020:

 

 

Three Months Ended June 30,

 

 

Six Months Ended June 30,

 

 

2021

 

 

2020

 

 

2021

 

 

2020

 

 

(in thousands, except per share data)

 

Net income attributable to Fulgent

$

79,812

 

 

$

3,321

 

 

$

280,503

 

 

$

1,365

 

Weighted-average common shares—outstanding, basic

 

29,150

 

 

 

21,747

 

 

 

28,991

 

 

 

21,656

 

Weighted-average common shares—outstanding, diluted

 

30,830

 

 

 

22,920

 

 

 

30,809

 

 

 

22,824

 

Net income per common share, basic

$

2.74

 

 

$

0.15

 

 

$

9.68

 

 

$

0.06

 

Net income per common share, diluted

$

2.59

 

 

$

0.14

 

 

$

9.10

 

 

$

0.06

 
Anti-dilutive Securities Excluded from Calculation of Diluted Income Per Share

The following securities have been excluded from the calculation of diluted income per share because their effect would have been anti-dilutive:

 

 

Three Months Ended June 30,

 

 

Six Months Ended June 30,

 

 

2021

 

 

2020

 

 

2021

 

 

2020

 

 

(in thousands)

 

Options

 

2

 

 

 

4

 

 

 

5

 

 

 

10

 

Restricted Stock Units

 

107

 

 

 

42

 

 

 

71

 

 

 

21

 
XML 47 R36.htm IDEA: XBRL DOCUMENT v3.21.2
Business Combination (Tables)
 6 Months Ended
Jun. 30, 2021
FF Gene Biotech  
Business Acquisition [Line Items]  
Summary of Consideration Paid and Amount of Assets Acquired and Liabilities Assumed The following table summarizes the consideration paid and the amounts of the assets acquired and liabilities assumed recognized at the FF Gene Biotech Acquisition date, as well as the fair value of the noncontrolling interest at the FF Gene Biotech Acquisition date.

 

 

 

Amounts

 

 

(in thousands)

 

Considerations

 

 

 

Cash

$

18,974

 

Fair value of the Company’s 30% equity interest held before the business combination

 

3,734

 

 

$

22,708

 

Recognized amounts of identifiable assets acquired and liabilities assumed

 

 

 

Financial assets

$

3,181

 

Reagents and supplies

 

1,288

 

Fixed assets

 

3,874

 

Other tangible assets

 

944

 

Identifiable intangible assets

 

6,958

 

Other current liabilities

 

(2,585

)

Notes payable

 

(5,893

)

Recognized amounts of identifiable assets acquired and liabilities assumed, net

 

7,767

 

Noncontrolling interest

 

(8,141

)

Goodwill

 

23,082

 

Total

$

22,708

 
XML 48 R37.htm IDEA: XBRL DOCUMENT v3.21.2
Goodwill and Acquisition-Related Intangibles (Tables)
 6 Months Ended
Jun. 30, 2021
Goodwill And Intangible Assets Disclosure [Abstract]  
Summaries of Goodwill and Acquisitions-Related Intangibles Balances

Summaries of goodwill and acquisitions-related intangibles balances as of June 30, 2021 and December 30, 2020 were as follows:

 

 

 

June 30,

 

 

December 31,

 

 

Weighted-Average Amortization Period

2021

 

 

2020

 

 

 

(in thousands)

 

Goodwill

 

$

23,107

 

 

$

—

 

 

 

 

 

 

 

 

 

 

Royalty-free technology

10 Years

$

5,727

 

 

$

—

 

Less: accumulated amortization

 

 

(95

)

 

 

—

 

Royalty-free technology, net

 

 

5,632

 

 

 

—

 

 

 

 

 

 

 

 

 

 

Customer relationships

5 Years

 

1,238

 

 

 

—

 

Less: accumulated amortization

 

 

(41

)

 

 

—

 

Customer relationships, net

 

 

1,197

 

 

 

—

 

Total acquisition-related intangibles, net

 

$

6,829

 

 

$

—

 
Summary of Annual Amortization Expense For Acquisition-Related Intangibles

Based on the carrying value of acquisition-related intangibles recorded as of June 30, 2021, and assuming no subsequent impairment of the underlying assets, the annual amortization expense for acquisition-related intangibles is expected to be as follows:

 

 

Amounts

 

 

(in thousands)

 

2021 (remaining 6 months)

$

410

 

2022

 

821

 

2023

 

821

 

2024

 

821

 

2025

 

821

 

2026

 

656

 

Thereafter

 

2,479

 

Total

$

6,829

 
XML 49 R38.htm IDEA: XBRL DOCUMENT v3.21.2
Summary of Significant Accounting Policies - Additional Information (Details)
 3 Months Ended 6 Months Ended 12 Months Ended
Jun. 30, 2021
USD ($)
Customer
Mar. 31, 2021
USD ($)
Jun. 30, 2020
USD ($)
Customer
Jun. 30, 2021
USD ($)
Customer
Jun. 30, 2020
USD ($)
Customer
Dec. 31, 2020
USD ($)
Customer
Summary Of Significant Accounting Policies [Line Items]            
Receivables from contract with customers $ 148,576,000     $ 148,576,000   $ 183,857,000
Contract liability 6,915,000     6,915,000   26,576,000
Contract with customer liability, revenue recognized 1,700,000   $ 196,000 $ 25,500,000 $ 246,000  
Practical expedient not to disclose amount of transaction price allocated to unsatisfied performance obligations       true    
Reagents and supplies 25,373,000     $ 25,373,000   16,491,000
Provision for credit losses for accounts receivable 2,200,000     $ 3,259,000 $ 135,000  
Securities maturity period from date of purchase       3 years    
Stockholders' equity $ 912,729,000     $ 912,729,000   569,387,000
Cumulative tax effect   $ 239,000        
Accounting Standards Update [Extensible List]       ASU 2016-13    
Accounting standards update, adopted true     true    
Accounting standards update, immaterial effect true     true    
Retained Earnings (Accumulated Deficit)            
Summary Of Significant Accounting Policies [Line Items]            
Cumulative tax effect   $ 239,000        
2019-12            
Summary Of Significant Accounting Policies [Line Items]            
Accounting standards update, adopted true     true    
Accounting standards update, immaterial effect true     true    
Cumulative Effect, Period of Adoption, Adjustment | ASU 2016-13 | Retained Earnings (Accumulated Deficit)            
Summary Of Significant Accounting Policies [Line Items]            
Stockholders' equity $ 887,000     $ 887,000    
Other Current Assets            
Summary Of Significant Accounting Policies [Line Items]            
Contract assets from contract with customers $ 324,000     324,000   $ 1,400,000
Other Long-Term Assets | Cumulative Effect, Period of Adoption, Adjustment | ASU 2016-13 | Retained Earnings (Accumulated Deficit)            
Summary Of Significant Accounting Policies [Line Items]            
Cumulative tax effect       $ 239,000    
Customer Concentration Risk | Revenue            
Summary Of Significant Accounting Policies [Line Items]            
Number of customers | Customer 2   1 2 1  
Customer Concentration Risk | Revenue | Customer One            
Summary Of Significant Accounting Policies [Line Items]            
Concentration risk, percentage 20.00%   45.00% 24.00% 31.00%  
Customer Concentration Risk | Revenue | Customer Two            
Summary Of Significant Accounting Policies [Line Items]            
Concentration risk, percentage 16.00%     11.00%    
Customer Concentration Risk | Accounts Receivable            
Summary Of Significant Accounting Policies [Line Items]            
Number of customers | Customer       1   0
Concentration risk, percentage       13.00%    
Customer Concentration Risk | Accounts Receivable | Minimum            
Summary Of Significant Accounting Policies [Line Items]            
Concentration risk, percentage           10.00%
XML 50 R39.htm IDEA: XBRL DOCUMENT v3.21.2
Summary of Significant Accounting Policies - Summary of Revenue from Contracts with Customers by Payor Type (Details) - USD ($)
$ in Thousands
 3 Months Ended 6 Months Ended
Jun. 30, 2021
Jun. 30, 2020
Jun. 30, 2021
Jun. 30, 2020
Disaggregation Of Revenue [Line Items]        
Revenue from contracts with customers by payor type $ 153,616 $ 17,265 $ 513,045 $ 25,018
Accounting Standards Update 2014-09        
Disaggregation Of Revenue [Line Items]        
Type of Revenue [Extensible List] flgt:TestingServicesMember flgt:TestingServicesMember flgt:TestingServicesMember flgt:TestingServicesMember
Revenue from contracts with customers by payor type $ 153,616 $ 17,265 $ 513,045 $ 25,018
Clinical Institutional Contracts | Accounting Standards Update 2014-09        
Disaggregation Of Revenue [Line Items]        
Revenue from contracts with customers by payor type 103,602 16,454 255,171 23,932
Clinical Patient Contracts | Accounting Standards Update 2014-09        
Disaggregation Of Revenue [Line Items]        
Revenue from contracts with customers by payor type 494 120 796 261
Clinical Insurance Contracts | Accounting Standards Update 2014-09        
Disaggregation Of Revenue [Line Items]        
Revenue from contracts with customers by payor type $ 49,520 $ 691 $ 257,078 $ 825
XML 51 R40.htm IDEA: XBRL DOCUMENT v3.21.2
Marketable Securities - Summary of Marketable Securities (Details) - USD ($)
$ in Thousands
Jun. 30, 2021
Dec. 31, 2020
Schedule Of Trading Securities And Other Trading Assets [Line Items]    
Cash and cash equivalents $ 100,461 $ 87,426
Less: Cash equivalents (5,501) (47,461)
Marketable securities, Amortized Cost Basis 677,482 343,987
Marketable securities, Unrealized Gains 418 754
Marketable securities, Unrealized Losses (1,322) (298)
Marketable securities, Aggregate Fair Value 676,578 344,443
Short-Term Marketable Securities    
Schedule Of Trading Securities And Other Trading Assets [Line Items]    
Marketable securities, Amortized Cost Basis 283,589 211,944
Marketable securities, Unrealized Gains 209 168
Marketable securities, Unrealized Losses (469) (171)
Marketable securities, Aggregate Fair Value 283,329 211,941
Short-Term Marketable Securities | Bond Fund    
Schedule Of Trading Securities And Other Trading Assets [Line Items]    
Marketable securities, Amortized Cost Basis 169,366 153,269
Marketable securities, Unrealized Gains 10 67
Marketable securities, Unrealized Losses (451) (151)
Marketable securities, Aggregate Fair Value 168,925 153,185
Short-Term Marketable Securities | Exchange Traded Funds    
Schedule Of Trading Securities And Other Trading Assets [Line Items]    
Marketable securities, Amortized Cost Basis 35,042 17,614
Marketable securities, Unrealized Losses (8) (5)
Marketable securities, Aggregate Fair Value 35,034 17,609
Short-Term Marketable Securities | Money Market Accounts    
Schedule Of Trading Securities And Other Trading Assets [Line Items]    
Cash and cash equivalents 5,501 47,461
Cash and cash equivalents fair value disclosure 5,501 47,461
Short-Term Marketable Securities | Corporate Debt Securities    
Schedule Of Trading Securities And Other Trading Assets [Line Items]    
Marketable securities, Amortized Cost Basis 77,664 41,061
Marketable securities, Unrealized Gains 199 101
Marketable securities, Unrealized Losses (9) (15)
Marketable securities, Aggregate Fair Value 77,854 41,147
Short-Term Marketable Securities | Municipal Bonds    
Schedule Of Trading Securities And Other Trading Assets [Line Items]    
Marketable securities, Amortized Cost Basis 1,517  
Marketable securities, Unrealized Losses (1)  
Marketable securities, Aggregate Fair Value 1,516  
Marketable Securities due After 1 Year through 5 Years    
Schedule Of Trading Securities And Other Trading Assets [Line Items]    
Marketable securities, Amortized Cost Basis 384,711 132,043
Marketable securities, Unrealized Gains 206 586
Marketable securities, Unrealized Losses (810) (127)
Marketable securities, Aggregate Fair Value 384,107 132,502
Marketable Securities due After 1 Year through 5 Years | Corporate Debt Securities    
Schedule Of Trading Securities And Other Trading Assets [Line Items]    
Marketable securities, Amortized Cost Basis 354,979 124,989
Marketable securities, Unrealized Gains 188 580
Marketable securities, Unrealized Losses (678) (117)
Marketable securities, Aggregate Fair Value 354,489 125,452
Marketable Securities due After 1 Year through 5 Years | Municipal Bonds    
Schedule Of Trading Securities And Other Trading Assets [Line Items]    
Marketable securities, Amortized Cost Basis 13,376  
Marketable securities, Unrealized Gains 15  
Marketable securities, Unrealized Losses (19)  
Marketable securities, Aggregate Fair Value 13,372  
Marketable Securities due After 1 Year through 5 Years | Yankee Debt Securities    
Schedule Of Trading Securities And Other Trading Assets [Line Items]    
Marketable securities, Amortized Cost Basis 14,856 6,054
Marketable securities, Unrealized Gains 3 4
Marketable securities, Unrealized Losses (109) (10)
Marketable securities, Aggregate Fair Value 14,750 6,048
Marketable Securities due After 1 Year through 5 Years | U.S. Government Agency Debt Securities    
Schedule Of Trading Securities And Other Trading Assets [Line Items]    
Marketable securities, Amortized Cost Basis 1,500 1,000
Marketable securities, Unrealized Gains   2
Marketable securities, Unrealized Losses (4)  
Marketable securities, Aggregate Fair Value 1,496 $ 1,002
Marketable Securities due After 5 Year through 10 Years    
Schedule Of Trading Securities And Other Trading Assets [Line Items]    
Marketable securities, Amortized Cost Basis 9,182  
Marketable securities, Unrealized Gains 3  
Marketable securities, Unrealized Losses (43)  
Marketable securities, Aggregate Fair Value 9,142  
Marketable Securities due After 5 Year through 10 Years | Municipal Bonds    
Schedule Of Trading Securities And Other Trading Assets [Line Items]    
Marketable securities, Amortized Cost Basis 9,182  
Marketable securities, Unrealized Gains 3  
Marketable securities, Unrealized Losses (43)  
Marketable securities, Aggregate Fair Value $ 9,142  
XML 52 R41.htm IDEA: XBRL DOCUMENT v3.21.2
Marketable Securities - Additional Information (Details) - USD ($)
 6 Months Ended 12 Months Ended
Jun. 30, 2021
Dec. 31, 2020
Schedule Of Available For Sale And Trading Securities [Line Items]    
Gross unrealized loss $ 1,300,000 $ 298,000
Outstanding borrowing amount 15,077,000 $ 15,019,000
Credit losses 0  
Margin Account Borrowing    
Schedule Of Available For Sale And Trading Securities [Line Items]    
Cash equivalent and available for sale debt securities $ 420,400,000  
XML 53 R42.htm IDEA: XBRL DOCUMENT v3.21.2
Fair Value Measurements - Information about Financial Assets Measured at Fair Value on Recurring Basis Based on Three-Tier Fair Value Hierarchy (Details) - Fair Value Measurements Recurring - USD ($)
$ in Thousands
Jun. 30, 2021
Dec. 31, 2020
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]    
Total marketable securities and cash equivalents $ 682,079 $ 391,904
Bond Fund    
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]    
Total equity trading securities 168,925 153,185
Exchange Traded Funds    
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]    
Total equity trading securities 35,034 17,609
Level 1    
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]    
Total marketable securities and cash equivalents 209,460 218,255
Level 1 | Bond Fund    
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]    
Total equity trading securities 168,925 153,185
Level 1 | Exchange Traded Funds    
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]    
Total equity trading securities 35,034 17,609
Level 2    
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]    
Total marketable securities and cash equivalents 472,619 173,649
Level 2 | Bond Fund    
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]    
Total equity trading securities 0 0
Level 2 | Exchange Traded Funds    
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]    
Total equity trading securities 0 0
Level 3    
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]    
Total marketable securities and cash equivalents 0 0
Level 3 | Bond Fund    
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]    
Total equity trading securities 0 0
Level 3 | Exchange Traded Funds    
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]    
Total equity trading securities 0 0
Corporate Debt Securities    
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]    
Total marketable securities 432,343 166,599
Corporate Debt Securities | Level 1    
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]    
Total marketable securities 0 0
Corporate Debt Securities | Level 2    
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]    
Total marketable securities 432,343 166,599
Corporate Debt Securities | Level 3    
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]    
Total marketable securities 0 0
Money Market Accounts    
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]    
Cash and cash equivalents fair value disclosure 5,501 47,461
Money Market Accounts | Level 1    
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]    
Cash and cash equivalents fair value disclosure 5,501 47,461
Money Market Accounts | Level 2    
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]    
Cash and cash equivalents fair value disclosure 0 0
Money Market Accounts | Level 3    
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]    
Cash and cash equivalents fair value disclosure 0 0
Municipal Bonds    
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]    
Total marketable securities 24,030  
Municipal Bonds | Level 1    
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]    
Total marketable securities 0  
Municipal Bonds | Level 2    
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]    
Total marketable securities 24,030  
Municipal Bonds | Level 3    
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]    
Total marketable securities 0  
Yankee Debt Securities    
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]    
Total marketable securities 14,750 6,048
Yankee Debt Securities | Level 1    
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]    
Total marketable securities 0 0
Yankee Debt Securities | Level 2    
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]    
Total marketable securities 14,750 6,048
Yankee Debt Securities | Level 3    
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]    
Total marketable securities 0 0
U.S. Government Agency Debt Securities    
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]    
Total marketable securities 1,496 1,002
U.S. Government Agency Debt Securities | Level 1    
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]    
Total marketable securities 0 0
U.S. Government Agency Debt Securities | Level 2    
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]    
Total marketable securities 1,496 1,002
U.S. Government Agency Debt Securities | Level 3    
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]    
Total marketable securities $ 0 $ 0
XML 54 R43.htm IDEA: XBRL DOCUMENT v3.21.2
Fair Value Measurements - Additional Information (Details)
Jun. 30, 2021
USD ($)
Fair Value Disclosures [Abstract]  
Fair value asset, investments measured using unobservable inputs $ 0
Fair value assets, transfers between levels, amount $ 0
XML 55 R44.htm IDEA: XBRL DOCUMENT v3.21.2
Fixed Assets - Major Classes of Fixed Assets (Details) - USD ($)
$ in Thousands
 6 Months Ended
Jun. 30, 2021
Dec. 31, 2020
Property Plant And Equipment [Line Items]    
Fixed assets, gross $ 65,826 $ 51,119
Less: Accumulated depreciation (14,740) (10,920)
Fixed assets, net 51,086 40,199
Medical Lab Equipment    
Property Plant And Equipment [Line Items]    
Fixed assets, gross $ 30,108 20,849
Medical Lab Equipment | Minimum    
Property Plant And Equipment [Line Items]    
Useful life in years 3 years  
Medical Lab Equipment | Maximum    
Property Plant And Equipment [Line Items]    
Useful life in years 5 years  
Building    
Property Plant And Equipment [Line Items]    
Fixed assets, gross $ 6,731 6,731
Useful life in years 39 years  
Computer Hardware    
Property Plant And Equipment [Line Items]    
Fixed assets, gross $ 4,580 3,699
Useful life in years 3 years  
Aircraft    
Property Plant And Equipment [Line Items]    
Fixed assets, gross $ 6,503 6,503
Useful life in years 7 years  
Furniture and Fixtures    
Property Plant And Equipment [Line Items]    
Fixed assets, gross $ 1,056 454
Furniture and Fixtures | Minimum    
Property Plant And Equipment [Line Items]    
Useful life in years 2 years  
Furniture and Fixtures | Maximum    
Property Plant And Equipment [Line Items]    
Useful life in years 5 years  
Computer Software    
Property Plant And Equipment [Line Items]    
Fixed assets, gross $ 754 541
Computer Software | Minimum    
Property Plant And Equipment [Line Items]    
Useful life in years 3 years  
Computer Software | Maximum    
Property Plant And Equipment [Line Items]    
Useful life in years 5 years  
General Equipment    
Property Plant And Equipment [Line Items]    
Fixed assets, gross $ 44 44
General Equipment | Minimum    
Property Plant And Equipment [Line Items]    
Useful life in years 3 years  
General Equipment | Maximum    
Property Plant And Equipment [Line Items]    
Useful life in years 5 years  
Automobile    
Property Plant And Equipment [Line Items]    
Fixed assets, gross $ 716 53
Automobile | Minimum    
Property Plant And Equipment [Line Items]    
Useful life in years 2 years  
Automobile | Maximum    
Property Plant And Equipment [Line Items]    
Useful life in years 5 years  
Leasehold Improvements    
Property Plant And Equipment [Line Items]    
Fixed assets, gross $ 1,941 1,580
Useful life in years Shorter of lease term or estimated useful life  
Building Improvements    
Property Plant And Equipment [Line Items]    
Fixed assets, gross $ 707 707
Building Improvements | Minimum    
Property Plant And Equipment [Line Items]    
Useful life in years 6 months  
Building Improvements | Maximum    
Property Plant And Equipment [Line Items]    
Useful life in years 5 years  
Assets Not Yet Placed in Service    
Property Plant And Equipment [Line Items]    
Fixed assets, gross $ 4,783 2,055
Land Improvements    
Property Plant And Equipment [Line Items]    
Fixed assets, gross $ 403 403
Land Improvements | Minimum    
Property Plant And Equipment [Line Items]    
Useful life in years 5 years  
Land Improvements | Maximum    
Property Plant And Equipment [Line Items]    
Useful life in years 15 years  
Land    
Property Plant And Equipment [Line Items]    
Fixed assets, gross $ 7,500 $ 7,500
XML 56 R45.htm IDEA: XBRL DOCUMENT v3.21.2
Fixed Assets - Additional Information (Details) - USD ($)
 3 Months Ended 6 Months Ended
Jun. 30, 2021
Jun. 30, 2020
Jun. 30, 2021
Jun. 30, 2020
Property Plant And Equipment [Abstract]        
Depreciation expense on fixed assets $ 2,300,000 $ 549,000 $ 4,200,000 $ 1,100,000
XML 57 R46.htm IDEA: XBRL DOCUMENT v3.21.2
Other Significant Balance Sheet Accounts - Schedule of Other Current Assets (Details) - USD ($)
$ in Thousands
Jun. 30, 2021
Dec. 31, 2020
Balance Sheet Related Disclosures [Abstract]    
Reagents and supplies $ 25,373 $ 16,491
Prepaid expenses 4,311 3,682
Marketable securities interest receivable 2,898 1,016
Other receivable 1,415 17,810
Contract assets 324 1,379
Prepaid income taxes   14
Total $ 34,321 $ 40,392
XML 58 R47.htm IDEA: XBRL DOCUMENT v3.21.2
Other Significant Balance Sheet Accounts - Schedule of Other Current Liabilities (Details) - USD ($)
$ in Thousands
Jun. 30, 2021
Dec. 31, 2020
Balance Sheet Related Disclosures [Abstract]    
Payroll liabilities $ 6,687 $ 5,314
Sales tax payable and other 4,801 2,538
Operating lease liabilities 1,001 267
Due to related parties 574 409
Total $ 13,063 $ 8,528
XML 59 R48.htm IDEA: XBRL DOCUMENT v3.21.2
Reporting Segment and Geographical Information - Additional Information (Details)
 6 Months Ended
Jun. 30, 2021
Segment
Segment Reporting [Abstract]  
Number of reporting segments 1
XML 60 R49.htm IDEA: XBRL DOCUMENT v3.21.2
Reporting Segment and Geographical Information - Summary of Revenue by Geographic Region (Details) - USD ($)
$ in Thousands
 3 Months Ended 6 Months Ended
Jun. 30, 2021
Jun. 30, 2020
Jun. 30, 2021
Jun. 30, 2020
Segment Reporting Information [Line Items]        
Revenue $ 153,616 $ 17,265 $ 513,045 $ 25,018
United States        
Segment Reporting Information [Line Items]        
Revenue 149,862 16,138 507,399 21,777
Foreign        
Segment Reporting Information [Line Items]        
Revenue $ 3,754 $ 1,127 $ 5,646 $ 3,241
XML 61 R50.htm IDEA: XBRL DOCUMENT v3.21.2
Debt, Commitments and Contingencies - Additional Information (Details) - USD ($)
 3 Months Ended 6 Months Ended
Jun. 30, 2021
Jun. 30, 2020
Jun. 30, 2021
Jun. 30, 2020
Dec. 31, 2020
Debt, Commitments and Contingencies [Line Items]          
Debt security investment outstanding borrowing amount     $ 15,100,000    
Interest on loan withdrawn from margin account     1.00%    
Payments for closing of escrow, financed under margin loan     $ 15,000,000.0    
Investment margin loan $ 15,077,000   15,077,000   $ 15,019,000
Interest expense 29,000 $ 0 58,000 $ 0  
Non-cancelable purchase obligations 7,600,000   7,600,000    
Reagents and Other Supplies          
Debt, Commitments and Contingencies [Line Items]          
Non-cancelable purchase obligations, payable within twelve months 4,900,000   4,900,000    
Medical Lab Equipment          
Debt, Commitments and Contingencies [Line Items]          
Non-cancelable purchase obligations, payable within twelve months 2,300,000   2,300,000    
Medical Lab Furniture          
Debt, Commitments and Contingencies [Line Items]          
Non-cancelable purchase obligations, payable within twelve months 372,000   372,000    
Xilong Scientific | FF Gene Biotech          
Debt, Commitments and Contingencies [Line Items]          
Notes payable $ 5,900,000   $ 5,900,000    
Debt instrument, interest rate terms     The loan is payable on December 31, 2022 and interest rate on the loan is 4.97%.    
Debt instrument, interest rate 4.97%   4.97%    
Maximum          
Debt, Commitments and Contingencies [Line Items]          
Interest rate     1.00%    
XML 62 R51.htm IDEA: XBRL DOCUMENT v3.21.2
Leases - Additional Information (Details)
 1 Months Ended 3 Months Ended 6 Months Ended
Mar. 31, 2021
ft²
Feb. 28, 2021
Jun. 30, 2021
USD ($)
Jun. 30, 2021
USD ($)
Lessee Lease Description [Line Items]        
Operating leases term of expiration       2026-02
Operating leases, renewal term     1 year 1 year
Lessee operating lease extended lease term expiration date   Jan. 31, 2023    
Lease income | $     $ 85,000 $ 242,000
Building | Minimum        
Lessee Lease Description [Line Items]        
Remaining terms including renewal options       17 months
Building | Maximum        
Lessee Lease Description [Line Items]        
Remaining terms including renewal options       42 months
Houston, Texas        
Lessee Lease Description [Line Items]        
Area of lease | ft² 12,000      
Lease, expiration month and year 2023-11      
XML 63 R52.htm IDEA: XBRL DOCUMENT v3.21.2
Leases - Schedule of Lease Right-of-Use Asset, Short-term Lease Liabilities, and Long-term Lease Liabilities (Details) - USD ($)
$ in Thousands
Jun. 30, 2021
Dec. 31, 2020
Leases [Abstract]    
Operating lease right-of-use asset $ 2,176 $ 828
Operating lease, right-of-use asset, statement of financial position [Extensible List] Other long-term assets Other long-term assets
Operating lease liabilities $ 1,001 $ 267
Operating lease, liability, current, statement of financial position [Extensible List] Other current liabilities Other current liabilities
Operating lease liabilities, long term $ 1,188 $ 568
Operating lease, liability, noncurrent, statement of financial position [Extensible List] Other long-term liabilities Other long-term liabilities
XML 64 R53.htm IDEA: XBRL DOCUMENT v3.21.2
Leases - Schedule of Operating Lease Expense (Details) - USD ($)
$ in Thousands
 3 Months Ended 6 Months Ended
Jun. 30, 2021
Jun. 30, 2020
Jun. 30, 2021
Jun. 30, 2020
Leases [Abstract]        
Operating lease cost $ 232 $ 152 $ 301 $ 301
Short-term lease cost 61 3 192 3
Total lease cost $ 293 $ 155 $ 493 $ 304
XML 65 R54.htm IDEA: XBRL DOCUMENT v3.21.2
Leases - Schedule of Supplemental Information Related to Leases (Details)
Jun. 30, 2021
Leases [Abstract]  
Weighted average remaining lease term - operating leases 2 years 10 months 24 days
Weighted average discount rate - operating leases 3.26%
XML 66 R55.htm IDEA: XBRL DOCUMENT v3.21.2
Leases - Schedule of Maturity Analysis of Operating Lease Liabilities using Undiscounted Cash Flows on an Annual Basis (Details)
$ in Thousands
Jun. 30, 2021
USD ($)
Leases [Abstract]  
2021 (remaining 6 months) $ 538
2022 881
2023 412
2024 216
2025 215
2026 37
Total lease payments 2,299
Less imputed interest (110)
Total $ 2,189
XML 67 R56.htm IDEA: XBRL DOCUMENT v3.21.2
Leases - Schedule of Lease Income (Details) - USD ($)
 3 Months Ended 6 Months Ended
Jun. 30, 2021
Jun. 30, 2021
Leases [Abstract]    
Lease income $ 81,000 $ 237,000
Variable lease income 4,000 5,000
Total lease income $ 85,000 $ 242,000
XML 68 R57.htm IDEA: XBRL DOCUMENT v3.21.2
Leases - Schedule of Future Fixed Lease Payments from Tenants for All Noncancelable Operating Leases (Details)
$ in Thousands
Jun. 30, 2021
USD ($)
Leases [Abstract]  
2021 (remaining 6 months) $ 94
2022 190
2023 95
2024 61
Total $ 440
XML 69 R58.htm IDEA: XBRL DOCUMENT v3.21.2
Equity-Based Compensation - Summary of Equity-Based Compensation Expenses as Part of Cost of Revenue and Operating Expenses (Details) - USD ($)
$ in Thousands
 3 Months Ended 6 Months Ended
Jun. 30, 2021
Jun. 30, 2020
Jun. 30, 2021
Jun. 30, 2020
Share Based Compensation Allocation Of Recognized Period Costs [Line Items]        
Equity-based compensation expense $ 3,526 $ 1,080 $ 6,488 $ 2,004
Cost of Revenue        
Share Based Compensation Allocation Of Recognized Period Costs [Line Items]        
Equity-based compensation expense 692 270 1,366 501
Research and Development        
Share Based Compensation Allocation Of Recognized Period Costs [Line Items]        
Equity-based compensation expense 1,481 364 2,704 676
Selling and Marketing        
Share Based Compensation Allocation Of Recognized Period Costs [Line Items]        
Equity-based compensation expense 620 222 1,046 393
General and Administrative        
Share Based Compensation Allocation Of Recognized Period Costs [Line Items]        
Equity-based compensation expense $ 733 $ 224 $ 1,372 $ 434
XML 70 R59.htm IDEA: XBRL DOCUMENT v3.21.2
Provision for (Benefit from) Income Taxes - Additional Information (Details) - USD ($)
 3 Months Ended 6 Months Ended
Jun. 30, 2021
Jun. 30, 2020
Jun. 30, 2021
Jun. 30, 2020
Income Tax Disclosure [Abstract]        
Effective income tax rate 24.00% (21.00%) 25.00% (45.00%)
Provision for (benefit from) income taxes $ 23,589,000 $ (599,000) $ 90,102,000 $ (565,000)
XML 71 R60.htm IDEA: XBRL DOCUMENT v3.21.2
Income per Share - Reconciliation of Basic and Diluted Income Per Share Computations (Details) - USD ($)
$ / shares in Units, shares in Thousands, $ in Thousands
 3 Months Ended 6 Months Ended
Jun. 30, 2021
Jun. 30, 2020
Jun. 30, 2021
Jun. 30, 2020
Earnings Per Share [Abstract]        
Net income attributable to Fulgent $ 79,812 $ 3,321 $ 280,503 $ 1,365
Weighted-average common shares—outstanding, basic 29,150 21,747 28,991 21,656
Weighted-average common shares—outstanding, diluted 30,830 22,920 30,809 22,824
Net income per common share, basic $ 2.74 $ 0.15 $ 9.68 $ 0.06
Net income per common share, diluted $ 2.59 $ 0.14 $ 9.10 $ 0.06
XML 72 R61.htm IDEA: XBRL DOCUMENT v3.21.2
Income per Share - Anti-dilutive Securities Excluded from Calculation of Diluted Income Per Share (Details) - shares
shares in Thousands
 3 Months Ended 6 Months Ended
Jun. 30, 2021
Jun. 30, 2020
Jun. 30, 2021
Jun. 30, 2020
Options        
Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]        
Anti-dilutive securities excluded from calculation of diluted income per share 2 4 5 10
Restricted Stock Units        
Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]        
Anti-dilutive securities excluded from calculation of diluted income per share 107 42 71 21
XML 73 R62.htm IDEA: XBRL DOCUMENT v3.21.2
Related Parties - Additional Information (Details) - USD ($)
 3 Months Ended 6 Months Ended
Jun. 30, 2021
Jun. 30, 2020
Jun. 30, 2021
Jun. 30, 2020
Dec. 31, 2020
Related Party Transaction [Line Items]          
Due to related parties $ 574,000   $ 574,000   $ 409,000
AHMC Healthcare Inc. | Genetic Sequencing Services          
Related Party Transaction [Line Items]          
Revenue from related parties 738,000 $ 0 1,900,000 $ 0  
Trade accounts receivable, net from related parties 793,000   793,000   1,800,000
Fulgent Pharma LLC          
Related Party Transaction [Line Items]          
Related party costs 0 0 0 0  
Due to related parties 574,000   574,000   $ 409,000
Fulgent Pharma LLC | Research Development Service          
Related Party Transaction [Line Items]          
Expenses to transport employees and supplies $ 97,000 $ 0 $ 205,000 $ 0  
XML 74 R63.htm IDEA: XBRL DOCUMENT v3.21.2
Business Combination - Additional Information (Details) - USD ($)
$ in Thousands
 1 Months Ended 3 Months Ended 6 Months Ended
Apr. 30, 2017
Jun. 30, 2021
Jun. 30, 2021
May 31, 2021
Business Acquisition [Line Items]        
Goodwill   $ 23,107 $ 23,107  
FF Gene Biotech        
Business Acquisition [Line Items]        
Minority interest ownership percentage 28.00%      
General and Administrative        
Business Acquisition [Line Items]        
Business Combination, Acquisition Related Costs $ 329,000      
FF Gene Biotech        
Business Acquisition [Line Items]        
Goodwill 23,082 $ 23,107 $ 23,107  
Business Combination,Fair value of noncontrolling interest $ 8,141      
Percentage of effective investment 42.00%      
Purchase price for effective investment $ 19,000      
Identified intangible assets assumed 6,958      
FF Gene Biotech | Royalty-Free Technology        
Business Acquisition [Line Items]        
Identified intangible assets assumed $ 5,700      
Estimated amortization life of identified intangible assets assumed 10 years      
FF Gene Biotech | Customer Relationships        
Business Acquisition [Line Items]        
Identified intangible assets assumed $ 1,200      
Estimated amortization life of identified intangible assets assumed 5 years   5 years  
FF Gene Biotech | Discount for Lack of Marketability        
Business Acquisition [Line Items]        
Business combination, contingent consideration, liability, measurement input 28      
FF Gene Biotech | Discount        
Business Acquisition [Line Items]        
Business combination, contingent consideration, liability, measurement input 35      
FF Gene Biotech | Discount Owed to Market Participant Acquisition Premium        
Business Acquisition [Line Items]        
Business combination, contingent consideration, liability, measurement input 10      
Xilong Scientific        
Business Acquisition [Line Items]        
Equity interest to be made in joint venture       72.00%
FF Gene Biotech        
Business Acquisition [Line Items]        
Equity interest to be made in joint venture 30.00%      
Percentage of preexisting equity interest   30.00% 30.00%  
Gain recognized on preexisting investment   $ 3,700 $ 3,700  
XML 75 R64.htm IDEA: XBRL DOCUMENT v3.21.2
Business Combination - Summary of Consideration Paid and Amount of Assets Acquired and Liabilities Assumed (Details) - USD ($)
$ in Thousands
 1 Months Ended
Apr. 30, 2017
Jun. 30, 2021
Recognized amounts of identifiable assets acquired and liabilities assumed    
Goodwill   $ 23,107
FF Gene Biotech    
Considerations    
Cash $ 18,974  
Fair value of the Company’s 30% equity interest held before the business combination 3,734  
Total Consideration and fair value of equity interest held before business combination 22,708  
Recognized amounts of identifiable assets acquired and liabilities assumed    
Financial assets 3,181  
Reagents and supplies 1,288  
Fixed assets 3,874  
Other tangible assets 944  
Identifiable intangible assets 6,958  
Other current liabilities (2,585)  
Notes payable (5,893)  
Recognized amounts of identifiable assets acquired and liabilities assumed, net 7,767  
Noncontrolling interest (8,141)  
Goodwill 23,082 $ 23,107
Total $ 22,708  
XML 76 R65.htm IDEA: XBRL DOCUMENT v3.21.2
Equity Distribution Agreement - Additional Information (Details) - November 2020 Equity Distribution Agreement - Stockholders' Equity - USD ($)
 1 Months Ended 3 Months Ended 6 Months Ended
Nov. 30, 2020
Jun. 30, 2021
Jun. 30, 2021
Equity Distribution Agreements [Line Items]      
Number of shares purchased   378,000 961,000
Sale of stock, weighted average net selling price per share   $ 73.75 $ 60.56
Maximum      
Equity Distribution Agreements [Line Items]      
Aggregate offering price $ 175,000,000.0    
Percentage of commission to be paid from gross proceeds 3.00%    
XML 77 R66.htm IDEA: XBRL DOCUMENT v3.21.2
Goodwill and Acquisition-Related Intangibles - Summaries of Goodwill and Acquisitions-Related Intangibles Balances (Details) - USD ($)
$ in Thousands
 1 Months Ended 6 Months Ended
Apr. 30, 2017
Jun. 30, 2021
Goodwill And Intangible Assets [Line Items]    
Goodwill   $ 23,107
Acquisitions-related intangibles, net   6,829
FF Gene Biotech    
Goodwill And Intangible Assets [Line Items]    
Goodwill $ 23,082 23,107
Acquisitions-related intangibles, gross   7,000
Acquisitions-related intangibles, net   6,829
FF Gene Biotech | Royalty-Free Technology    
Goodwill And Intangible Assets [Line Items]    
Acquisitions-related intangibles, gross   5,727
Less: accumulated amortization   (95)
Acquisitions-related intangibles, net   $ 5,632
Weighted-Average Amortization Period   10 years
FF Gene Biotech | Customer Relationships    
Goodwill And Intangible Assets [Line Items]    
Acquisitions-related intangibles, gross   $ 1,238
Less: accumulated amortization   (41)
Acquisitions-related intangibles, net   $ 1,197
Weighted-Average Amortization Period 5 years 5 years
XML 78 R67.htm IDEA: XBRL DOCUMENT v3.21.2
Goodwill and Acquisition-Related Intangibles - Additional Information (Details) - USD ($)
$ in Thousands
Jun. 30, 2021
Apr. 30, 2017
Goodwill And Intangible Assets [Line Items]    
Goodwill $ 23,107  
FF Gene Biotech    
Goodwill And Intangible Assets [Line Items]    
Goodwill 23,107 $ 23,082
Intangibles $ 7,000  
XML 79 R68.htm IDEA: XBRL DOCUMENT v3.21.2
Goodwill and Acquisition-Related Intangibles - Summary of Annual Amortization Expense For Acquisition-Related Intangibles (Details)
$ in Thousands
Jun. 30, 2021
USD ($)
Finite Lived Intangible Assets [Line Items]  
Acquisitions-related intangibles, net $ 6,829
FF Gene Biotech  
Finite Lived Intangible Assets [Line Items]  
2021 (remaining 6 months) 410
2022 821
2023 821
2024 821
2025 821
2026 656
Thereafter 2,479
Acquisitions-related intangibles, net $ 6,829
XML 80 R69.htm IDEA: XBRL DOCUMENT v3.21.2
Subsequent Events - Additional Information (Details) - Subsequent Events [Member] - USD ($)
Aug. 06, 2021
Jul. 31, 2021
Subsequent Event [Line Items]    
Investment   $ 20,000,000.0
Cytometry Specialists, Inc    
Subsequent Event [Line Items]    
Acquisition of issued and outstanding common stock value $ 50,000,000.0  
Cytometry Specialists, Inc | Maximum    
Subsequent Event [Line Items]    
Potential future milestone payments $ 10,000,000.0  
EXCEL 81 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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a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
  •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end

    •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end XML 82 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 83 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 84 FilingSummary.xml IDEA: XBRL DOCUMENT 3.21.2 html 314 399 1 false 86 0 false 7 false false R1.htm 100000 - Document - Document and Entity Information Sheet http://fulgentdiagnostics.com/20210630/taxonomy/role/DocumentDocumentAndEntityInformation Document and Entity Information Cover 1 false false R2.htm 100010 - Statement - Condensed Consolidated Balance Sheets Sheet http://fulgentdiagnostics.com/20210630/taxonomy/role/StatementCondensedConsolidatedBalanceSheets Condensed Consolidated Balance Sheets Statements 2 false false R3.htm 100020 - Statement - Condensed Consolidated Balance Sheets (Parenthetical) Sheet http://fulgentdiagnostics.com/20210630/taxonomy/role/StatementCondensedConsolidatedBalanceSheetsParenthetical Condensed Consolidated Balance Sheets (Parenthetical) Statements 3 false false R4.htm 100030 - Statement - Condensed Consolidated Statements of Operations (unaudited) Sheet http://fulgentdiagnostics.com/20210630/taxonomy/role/StatementCondensedConsolidatedStatementsOfOperationsUnaudited Condensed Consolidated Statements of Operations (unaudited) Statements 4 false false R5.htm 100040 - Statement - Condensed Consolidated Statements of Comprehensive Income (Loss) (unaudited) Sheet http://fulgentdiagnostics.com/20210630/taxonomy/role/StatementCondensedConsolidatedStatementsOfComprehensiveIncomeLossUnaudited Condensed Consolidated Statements of Comprehensive Income (Loss) (unaudited) Statements 5 false false R6.htm 100050 - Statement - Condensed Consolidated Statements of Stockholders' Equity (unaudited) Sheet http://fulgentdiagnostics.com/20210630/taxonomy/role/StatementCondensedConsolidatedStatementsOfStockholdersEquityUnaudited Condensed Consolidated Statements of Stockholders' Equity (unaudited) Statements 6 false false R7.htm 100060 - Statement - Condensed Consolidated Statements of Stockholders' Equity (unaudited) (Parenthetical) Sheet http://fulgentdiagnostics.com/20210630/taxonomy/role/StatementCondensedConsolidatedStatementsOfStockholdersEquityUnauditedParenthetical Condensed Consolidated Statements of Stockholders' Equity (unaudited) (Parenthetical) Statements 7 false false R8.htm 100070 - Statement - Condensed Consolidated Statements of Cash Flows (unaudited) Sheet http://fulgentdiagnostics.com/20210630/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited Condensed Consolidated Statements of Cash Flows (unaudited) Statements 8 false false R9.htm 100080 - Disclosure - Overview and Basis of Presentation Sheet http://fulgentdiagnostics.com/20210630/taxonomy/role/DisclosureOverviewAndBasisOfPresentation Overview and Basis of Presentation Notes 9 false false R10.htm 100090 - Disclosure - Summary of Significant Accounting Policies Sheet http://fulgentdiagnostics.com/20210630/taxonomy/role/DisclosureSummaryOfSignificantAccountingPolicies Summary of Significant Accounting Policies Notes 10 false false R11.htm 100100 - Disclosure - Marketable Securities Sheet http://fulgentdiagnostics.com/20210630/taxonomy/role/DisclosureMarketableSecurities Marketable Securities Notes 11 false false R12.htm 100110 - Disclosure - Fair Value Measurements Sheet http://fulgentdiagnostics.com/20210630/taxonomy/role/DisclosureFairValueMeasurements Fair Value Measurements Notes 12 false false R13.htm 100120 - Disclosure - Fixed Assets Sheet http://fulgentdiagnostics.com/20210630/taxonomy/role/DisclosureFixedAssets Fixed Assets Notes 13 false false R14.htm 100130 - Disclosure - Other Significant Balance Sheet Accounts Sheet http://fulgentdiagnostics.com/20210630/taxonomy/role/DisclosureOtherSignificantBalanceSheetAccounts Other Significant Balance Sheet Accounts Notes 14 false false R15.htm 100140 - Disclosure - Reporting Segment and Geographic Information Sheet http://fulgentdiagnostics.com/20210630/taxonomy/role/DisclosureReportingSegmentAndGeographicInformation Reporting Segment and Geographic Information Notes 15 false false R16.htm 100150 - Disclosure - Debt, Commitments and Contingencies Sheet http://fulgentdiagnostics.com/20210630/taxonomy/role/DisclosureDebtCommitmentsAndContingencies Debt, Commitments and Contingencies Notes 16 false false R17.htm 100160 - Disclosure - Leases Sheet http://fulgentdiagnostics.com/20210630/taxonomy/role/DisclosureLeases Leases Notes 17 false false R18.htm 100170 - Disclosure - Equity-Based Compensation Sheet http://fulgentdiagnostics.com/20210630/taxonomy/role/DisclosureEquityBasedCompensation Equity-Based Compensation Notes 18 false false R19.htm 100180 - Disclosure - Provision for (Benefit from) Income Taxes Sheet http://fulgentdiagnostics.com/20210630/taxonomy/role/DisclosureProvisionForBenefitFromIncomeTaxes Provision for (Benefit from) Income Taxes Notes 19 false false R20.htm 100190 - Disclosure - Income per Share Sheet http://fulgentdiagnostics.com/20210630/taxonomy/role/DisclosureIncomePerShare Income per Share Notes 20 false false R21.htm 100200 - Disclosure - Related Parties Sheet http://fulgentdiagnostics.com/20210630/taxonomy/role/DisclosureRelatedParties Related Parties Notes 21 false false R22.htm 100210 - Disclosure - Business Combination Sheet http://fulgentdiagnostics.com/20210630/taxonomy/role/DisclosureBusinessCombination Business Combination Notes 22 false false R23.htm 100220 - Disclosure - Equity Distribution Agreement Sheet http://fulgentdiagnostics.com/20210630/taxonomy/role/DisclosureEquityDistributionAgreement Equity Distribution Agreement Notes 23 false false R24.htm 100230 - Disclosure - Goodwill and Acquisition-Related Intangibles Sheet http://fulgentdiagnostics.com/20210630/taxonomy/role/DisclosureGoodwillAndAcquisitionRelatedIntangibles Goodwill and Acquisition-Related Intangibles Notes 24 false false R25.htm 100240 - Disclosure - Subsequent Events Sheet http://fulgentdiagnostics.com/20210630/taxonomy/role/DisclosureSubsequentEvents Subsequent Events Notes 25 false false R26.htm 100250 - Disclosure - Summary of Significant Accounting Policies (Policies) Sheet http://fulgentdiagnostics.com/20210630/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies Summary of Significant Accounting Policies (Policies) Policies http://fulgentdiagnostics.com/20210630/taxonomy/role/DisclosureSummaryOfSignificantAccountingPolicies 26 false false R27.htm 100260 - Disclosure - Summary of Significant Accounting Policies (Tables) Sheet http://fulgentdiagnostics.com/20210630/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesTables Summary of Significant Accounting Policies (Tables) Tables http://fulgentdiagnostics.com/20210630/taxonomy/role/DisclosureSummaryOfSignificantAccountingPolicies 27 false false R28.htm 100270 - Disclosure - Marketable Securities (Tables) Sheet http://fulgentdiagnostics.com/20210630/taxonomy/role/DisclosureMarketableSecuritiesTables Marketable Securities (Tables) Tables http://fulgentdiagnostics.com/20210630/taxonomy/role/DisclosureMarketableSecurities 28 false false R29.htm 100280 - Disclosure - Fair Value Measurements (Tables) Sheet http://fulgentdiagnostics.com/20210630/taxonomy/role/DisclosureFairValueMeasurementsTables Fair Value Measurements (Tables) Tables http://fulgentdiagnostics.com/20210630/taxonomy/role/DisclosureFairValueMeasurements 29 false false R30.htm 100290 - Disclosure - Fixed Assets (Tables) Sheet http://fulgentdiagnostics.com/20210630/taxonomy/role/DisclosureFixedAssetsTables Fixed Assets (Tables) Tables http://fulgentdiagnostics.com/20210630/taxonomy/role/DisclosureFixedAssets 30 false false R31.htm 100300 - Disclosure - Other Significant Balance Sheet Accounts (Tables) Sheet http://fulgentdiagnostics.com/20210630/taxonomy/role/DisclosureOtherSignificantBalanceSheetAccountsTables Other Significant Balance Sheet Accounts (Tables) Tables http://fulgentdiagnostics.com/20210630/taxonomy/role/DisclosureOtherSignificantBalanceSheetAccounts 31 false false R32.htm 100310 - Disclosure - Reporting Segment and Geographic Information (Tables) Sheet http://fulgentdiagnostics.com/20210630/taxonomy/role/DisclosureReportingSegmentAndGeographicInformationTables Reporting Segment and Geographic Information (Tables) Tables http://fulgentdiagnostics.com/20210630/taxonomy/role/DisclosureReportingSegmentAndGeographicInformation 32 false false R33.htm 100320 - Disclosure - Leases (Tables) Sheet http://fulgentdiagnostics.com/20210630/taxonomy/role/DisclosureLeasesTables Leases (Tables) Tables http://fulgentdiagnostics.com/20210630/taxonomy/role/DisclosureLeases 33 false false R34.htm 100330 - Disclosure - Equity-Based Compensation (Tables) Sheet http://fulgentdiagnostics.com/20210630/taxonomy/role/DisclosureEquityBasedCompensationTables Equity-Based Compensation (Tables) Tables http://fulgentdiagnostics.com/20210630/taxonomy/role/DisclosureEquityBasedCompensation 34 false false R35.htm 100340 - Disclosure - Income per Share (Tables) Sheet http://fulgentdiagnostics.com/20210630/taxonomy/role/DisclosureIncomePerShareTables Income per Share (Tables) Tables http://fulgentdiagnostics.com/20210630/taxonomy/role/DisclosureIncomePerShare 35 false false R36.htm 100350 - Disclosure - Business Combination (Tables) Sheet http://fulgentdiagnostics.com/20210630/taxonomy/role/DisclosureBusinessCombinationTables Business Combination (Tables) Tables http://fulgentdiagnostics.com/20210630/taxonomy/role/DisclosureBusinessCombination 36 false false R37.htm 100360 - Disclosure - Goodwill and Acquisition-Related Intangibles (Tables) Sheet http://fulgentdiagnostics.com/20210630/taxonomy/role/DisclosureGoodwillAndAcquisitionRelatedIntangiblesTables Goodwill and Acquisition-Related Intangibles (Tables) Tables http://fulgentdiagnostics.com/20210630/taxonomy/role/DisclosureGoodwillAndAcquisitionRelatedIntangibles 37 false false R38.htm 100370 - Disclosure - Summary of Significant Accounting Policies - Additional Information (Details) Sheet http://fulgentdiagnostics.com/20210630/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails Summary of Significant Accounting Policies - Additional Information (Details) Details 38 false false R39.htm 100380 - Disclosure - Summary of Significant Accounting Policies - Summary of Revenue from Contracts with Customers by Payor Type (Details) Sheet http://fulgentdiagnostics.com/20210630/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesSummaryOfRevenueFromContractsWithCustomersByPayorTypeDetails Summary of Significant Accounting Policies - Summary of Revenue from Contracts with Customers by Payor Type (Details) Details 39 false false R40.htm 100390 - Disclosure - Marketable Securities - Summary of Marketable Securities (Details) Sheet http://fulgentdiagnostics.com/20210630/taxonomy/role/DisclosureMarketableSecuritiesSummaryOfMarketableSecuritiesDetails Marketable Securities - Summary of Marketable Securities (Details) Details 40 false false R41.htm 100400 - Disclosure - Marketable Securities - Additional Information (Details) Sheet http://fulgentdiagnostics.com/20210630/taxonomy/role/DisclosureMarketableSecuritiesAdditionalInformationDetails Marketable Securities - Additional Information (Details) Details 41 false false R42.htm 100410 - Disclosure - Fair Value Measurements - Information about Financial Assets Measured at Fair Value on Recurring Basis Based on Three-Tier Fair Value Hierarchy (Details) Sheet http://fulgentdiagnostics.com/20210630/taxonomy/role/DisclosureFairValueMeasurementsInformationAboutFinancialAssetsMeasuredAtFairValueOnRecurringBasisBasedOnThreeTierFairValueHierarchyDetails Fair Value Measurements - Information about Financial Assets Measured at Fair Value on Recurring Basis Based on Three-Tier Fair Value Hierarchy (Details) Details 42 false false R43.htm 100420 - Disclosure - Fair Value Measurements - Additional Information (Details) Sheet http://fulgentdiagnostics.com/20210630/taxonomy/role/DisclosureFairValueMeasurementsAdditionalInformationDetails Fair Value Measurements - Additional Information (Details) Details 43 false false R44.htm 100430 - Disclosure - Fixed Assets - Major Classes of Fixed Assets (Details) Sheet http://fulgentdiagnostics.com/20210630/taxonomy/role/DisclosureFixedAssetsMajorClassesOfFixedAssetsDetails Fixed Assets - Major Classes of Fixed Assets (Details) Details 44 false false R45.htm 100440 - Disclosure - Fixed Assets - Additional Information (Details) Sheet http://fulgentdiagnostics.com/20210630/taxonomy/role/DisclosureFixedAssetsAdditionalInformationDetails Fixed Assets - Additional Information (Details) Details 45 false false R46.htm 100450 - Disclosure - Other Significant Balance Sheet Accounts - Schedule of Other Current Assets (Details) Sheet http://fulgentdiagnostics.com/20210630/taxonomy/role/DisclosureOtherSignificantBalanceSheetAccountsScheduleOfOtherCurrentAssetsDetails Other Significant Balance Sheet Accounts - Schedule of Other Current Assets (Details) Details 46 false false R47.htm 100460 - Disclosure - Other Significant Balance Sheet Accounts - Schedule of Other Current Liabilities (Details) Sheet http://fulgentdiagnostics.com/20210630/taxonomy/role/DisclosureOtherSignificantBalanceSheetAccountsScheduleOfOtherCurrentLiabilitiesDetails Other Significant Balance Sheet Accounts - Schedule of Other Current Liabilities (Details) Details 47 false false R48.htm 100470 - Disclosure - Reporting Segment and Geographical Information - Additional Information (Details) Sheet http://fulgentdiagnostics.com/20210630/taxonomy/role/DisclosureReportingSegmentAndGeographicalInformationAdditionalInformationDetails Reporting Segment and Geographical Information - Additional Information (Details) Details 48 false false R49.htm 100480 - Disclosure - Reporting Segment and Geographical Information - Summary of Revenue by Geographic Region (Details) Sheet http://fulgentdiagnostics.com/20210630/taxonomy/role/DisclosureReportingSegmentAndGeographicalInformationSummaryOfRevenueByGeographicRegionDetails Reporting Segment and Geographical Information - Summary of Revenue by Geographic Region (Details) Details 49 false false R50.htm 100490 - Disclosure - Debt, Commitments and Contingencies - Additional Information (Details) Sheet http://fulgentdiagnostics.com/20210630/taxonomy/role/DisclosureDebtCommitmentsAndContingenciesAdditionalInformationDetails Debt, Commitments and Contingencies - Additional Information (Details) Details 50 false false R51.htm 100500 - Disclosure - Leases - Additional Information (Details) Sheet http://fulgentdiagnostics.com/20210630/taxonomy/role/DisclosureLeasesAdditionalInformationDetails Leases - Additional Information (Details) Details 51 false false R52.htm 100510 - Disclosure - Leases - Schedule of Lease Right-of-Use Asset, Short-term Lease Liabilities, and Long-term Lease Liabilities (Details) Sheet http://fulgentdiagnostics.com/20210630/taxonomy/role/DisclosureLeasesScheduleOfLeaseRightOfUseAssetShortTermLeaseLiabilitiesAndLongTermLeaseLiabilitiesDetails Leases - Schedule of Lease Right-of-Use Asset, Short-term Lease Liabilities, and Long-term Lease Liabilities (Details) Details 52 false false R53.htm 100520 - Disclosure - Leases - Schedule of Operating Lease Expense (Details) Sheet http://fulgentdiagnostics.com/20210630/taxonomy/role/DisclosureLeasesScheduleOfOperatingLeaseExpenseDetails Leases - Schedule of Operating Lease Expense (Details) Details 53 false false R54.htm 100530 - Disclosure - Leases - Schedule of Supplemental Information Related to Leases (Details) Sheet http://fulgentdiagnostics.com/20210630/taxonomy/role/DisclosureLeasesScheduleOfSupplementalInformationRelatedToLeasesDetails Leases - Schedule of Supplemental Information Related to Leases (Details) Details 54 false false R55.htm 100540 - Disclosure - Leases - Schedule of Maturity Analysis of Operating Lease Liabilities using Undiscounted Cash Flows on an Annual Basis (Details) Sheet http://fulgentdiagnostics.com/20210630/taxonomy/role/DisclosureLeasesScheduleOfMaturityAnalysisOfOperatingLeaseLiabilitiesUsingUndiscountedCashFlowsOnAnnualBasisDetails Leases - Schedule of Maturity Analysis of Operating Lease Liabilities using Undiscounted Cash Flows on an Annual Basis (Details) Details 55 false false R56.htm 100560 - Disclosure - Leases - Schedule of Lease Income (Details) Sheet http://fulgentdiagnostics.com/20210630/taxonomy/role/DisclosureLeasesScheduleOfLeaseIncomeDetails Leases - Schedule of Lease Income (Details) Details 56 false false R57.htm 100570 - Disclosure - Leases - Schedule of Future Fixed Lease Payments from Tenants for All Noncancelable Operating Leases (Details) Sheet http://fulgentdiagnostics.com/20210630/taxonomy/role/DisclosureLeasesScheduleOfFutureFixedLeasePaymentsFromTenantsForAllNoncancelableOperatingLeasesDetails Leases - Schedule of Future Fixed Lease Payments from Tenants for All Noncancelable Operating Leases (Details) Details 57 false false R58.htm 100580 - Disclosure - Equity-Based Compensation - Summary of Equity-Based Compensation Expenses as Part of Cost of Revenue and Operating Expenses (Details) Sheet http://fulgentdiagnostics.com/20210630/taxonomy/role/DisclosureEquityBasedCompensationSummaryOfEquityBasedCompensationExpensesAsPartOfCostOfRevenueAndOperatingExpensesDetails Equity-Based Compensation - Summary of Equity-Based Compensation Expenses as Part of Cost of Revenue and Operating Expenses (Details) Details 58 false false R59.htm 100590 - Disclosure - Provision for (Benefit from) Income Taxes - Additional Information (Details) Sheet http://fulgentdiagnostics.com/20210630/taxonomy/role/DisclosureProvisionForBenefitFromIncomeTaxesAdditionalInformationDetails Provision for (Benefit from) Income Taxes - Additional Information (Details) Details http://fulgentdiagnostics.com/20210630/taxonomy/role/DisclosureProvisionForBenefitFromIncomeTaxes 59 false false R60.htm 100600 - Disclosure - Income per Share - Reconciliation of Basic and Diluted Income Per Share Computations (Details) Sheet http://fulgentdiagnostics.com/20210630/taxonomy/role/DisclosureIncomePerShareReconciliationOfBasicAndDilutedIncomePerShareComputationsDetails Income per Share - Reconciliation of Basic and Diluted Income Per Share Computations (Details) Details 60 false false R61.htm 100610 - Disclosure - Income per Share - Anti-dilutive Securities Excluded from Calculation of Diluted Income Per Share (Details) Sheet http://fulgentdiagnostics.com/20210630/taxonomy/role/DisclosureIncomePerShareAntiDilutiveSecuritiesExcludedFromCalculationOfDilutedIncomePerShareDetails Income per Share - Anti-dilutive Securities Excluded from Calculation of Diluted Income Per Share (Details) Details 61 false false R62.htm 100620 - Disclosure - Related Parties - Additional Information (Details) Sheet http://fulgentdiagnostics.com/20210630/taxonomy/role/DisclosureRelatedPartiesAdditionalInformationDetails Related Parties - Additional Information (Details) Details 62 false false R63.htm 100630 - Disclosure - Business Combination - Additional Information (Details) Sheet http://fulgentdiagnostics.com/20210630/taxonomy/role/DisclosureBusinessCombinationAdditionalInformationDetails Business Combination - Additional Information (Details) Details 63 false false R64.htm 100640 - Disclosure - Business Combination - Summary of Consideration Paid and Amount of Assets Acquired and Liabilities Assumed (Details) Sheet http://fulgentdiagnostics.com/20210630/taxonomy/role/DisclosureBusinessCombinationSummaryOfConsiderationPaidAndAmountOfAssetsAcquiredAndLiabilitiesAssumedDetails Business Combination - Summary of Consideration Paid and Amount of Assets Acquired and Liabilities Assumed (Details) Details 64 false false R65.htm 100650 - Disclosure - Equity Distribution Agreement - Additional Information (Details) Sheet http://fulgentdiagnostics.com/20210630/taxonomy/role/DisclosureEquityDistributionAgreementAdditionalInformationDetails Equity Distribution Agreement - Additional Information (Details) Details 65 false false R66.htm 100660 - Disclosure - Goodwill and Acquisition-Related Intangibles - Summaries of Goodwill and Acquisitions-Related Intangibles Balances (Details) Sheet http://fulgentdiagnostics.com/20210630/taxonomy/role/DisclosureGoodwillAndAcquisitionRelatedIntangiblesSummariesOfGoodwillAndAcquisitionsRelatedIntangiblesBalancesDetails Goodwill and Acquisition-Related Intangibles - Summaries of Goodwill and Acquisitions-Related Intangibles Balances (Details) Details 66 false false R67.htm 100670 - Disclosure - Goodwill and Acquisition-Related Intangibles - Additional Information (Details) Sheet http://fulgentdiagnostics.com/20210630/taxonomy/role/DisclosureGoodwillAndAcquisitionRelatedIntangiblesAdditionalInformationDetails Goodwill and Acquisition-Related Intangibles - Additional Information (Details) Details 67 false false R68.htm 100680 - Disclosure - Goodwill and Acquisition-Related Intangibles - Summary of Annual Amortization Expense For Acquisition-Related Intangibles (Details) Sheet http://fulgentdiagnostics.com/20210630/taxonomy/role/DisclosureGoodwillAndAcquisitionRelatedIntangiblesSummaryOfAnnualAmortizationExpenseForAcquisitionRelatedIntangiblesDetails Goodwill and Acquisition-Related Intangibles - Summary of Annual Amortization Expense For Acquisition-Related Intangibles (Details) Details 68 false false R69.htm 100690 - Disclosure - Subsequent Events - Additional Information (Details) Sheet http://fulgentdiagnostics.com/20210630/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails Subsequent Events - Additional Information (Details) Details 69 false false All Reports Book All Reports flgt-10q_20210630.htm flgt-20210630.xsd flgt-20210630_cal.xml flgt-20210630_def.xml flgt-20210630_lab.xml flgt-20210630_pre.xml flgt-ex101_40.htm flgt-ex311_9.htm flgt-ex312_7.htm flgt-ex321_8.htm http://xbrl.sec.gov/country/2020-01-31 http://xbrl.sec.gov/stpr/2018-01-31 http://fasb.org/us-gaap/2020-01-31 http://fasb.org/srt/2020-01-31 http://xbrl.sec.gov/dei/2020-01-31 true true JSON 87 MetaLinks.json IDEA: XBRL DOCUMENT { "instance": { "flgt-10q_20210630.htm": { "axisCustom": 0, "axisStandard": 30, "contextCount": 314, "dts": { "calculationLink": { "local": [ "flgt-20210630_cal.xml" ] }, "definitionLink": { "local": [ "flgt-20210630_def.xml" ], "remote": [ "http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-eedm-def-2020-01-31.xml", "http://xbrl.fasb.org/srt/2020/elts/srt-eedm1-def-2020-01-31.xml" ] }, "inline": { "local": [ "flgt-10q_20210630.htm" ] }, "labelLink": { "local": [ "flgt-20210630_lab.xml" ], "remote": [ "http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-doc-2020-01-31.xml", "https://xbrl.sec.gov/dei/2020/dei-doc-2020-01-31.xml" ] }, "presentationLink": { "local": [ "flgt-20210630_pre.xml" ] }, "referenceLink": { "remote": [ "https://xbrl.sec.gov/dei/2020/dei-ref-2020-01-31.xml", "http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-ref-2020-01-31.xml" ] }, "schema": { "local": [ "flgt-20210630.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "https://xbrl.sec.gov/country/2020/country-2020-01-31.xsd", "http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd", "https://xbrl.sec.gov/currency/2020/currency-2020-01-31.xsd", "https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd", "http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd", "https://xbrl.sec.gov/exch/2020/exch-2020-01-31.xsd", "http://www.xbrl.org/lrr/arcrole/factExplanatory-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "https://xbrl.sec.gov/naics/2017/naics-2017-01-31.xsd", "https://xbrl.sec.gov/sic/2020/sic-2020-01-31.xsd", "http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://xbrl.fasb.org/srt/2020/elts/srt-types-2020-01-31.xsd", "http://xbrl.fasb.org/srt/2020/elts/srt-roles-2020-01-31.xsd", "https://xbrl.sec.gov/stpr/2018/stpr-2018-01-31.xsd", "http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd", "http://xbrl.fasb.org/us-gaap/2020/elts/us-roles-2020-01-31.xsd", "http://xbrl.fasb.org/us-gaap/2020/elts/us-types-2020-01-31.xsd", "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd", "http://xbrl.fasb.org/us-gaap/2020/elts/us-parts-codification-2020-01-31.xsd", "http://www.xbrl.org/lrr/role/deprecated-2009-12-16.xsd" ] } }, "elementCount": 553, "entityCount": 1, "hidden": { "http://fasb.org/us-gaap/2020-01-31": 26, "http://xbrl.sec.gov/dei/2020-01-31": 4, "total": 30 }, "keyCustom": 56, "keyStandard": 343, "memberCustom": 27, "memberStandard": 49, "nsprefix": "flgt", "nsuri": "http://fulgentdiagnostics.com/20210630", "report": { "R1": { "firstAnchor": { "ancestors": [ "p", "body", "html" ], "baseRef": "flgt-10q_20210630.htm", "contextRef": "C_0001674930_20210101_20210630", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "document", "isDefault": "true", "longName": "100000 - Document - Document and Entity Information", "role": "http://fulgentdiagnostics.com/20210630/taxonomy/role/DocumentDocumentAndEntityInformation", "shortName": "Document and Entity Information", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "p", "body", "html" ], "baseRef": "flgt-10q_20210630.htm", "contextRef": "C_0001674930_20210101_20210630", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R10": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "flgt-10q_20210630.htm", "contextRef": "C_0001674930_20210101_20210630", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SignificantAccountingPoliciesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100090 - Disclosure - Summary of Significant Accounting Policies", "role": "http://fulgentdiagnostics.com/20210630/taxonomy/role/DisclosureSummaryOfSignificantAccountingPolicies", "shortName": "Summary of Significant Accounting Policies", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "flgt-10q_20210630.htm", "contextRef": "C_0001674930_20210101_20210630", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SignificantAccountingPoliciesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R11": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "flgt-10q_20210630.htm", "contextRef": "C_0001674930_20210101_20210630", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:InvestmentsInDebtAndEquityInstrumentsCashAndCashEquivalentsUnrealizedAndRealizedGainsLossesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100100 - Disclosure - Marketable Securities", "role": "http://fulgentdiagnostics.com/20210630/taxonomy/role/DisclosureMarketableSecurities", "shortName": "Marketable Securities", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "flgt-10q_20210630.htm", "contextRef": "C_0001674930_20210101_20210630", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:InvestmentsInDebtAndEquityInstrumentsCashAndCashEquivalentsUnrealizedAndRealizedGainsLossesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R12": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "flgt-10q_20210630.htm", "contextRef": "C_0001674930_20210101_20210630", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:FairValueMeasurementInputsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100110 - Disclosure - Fair Value Measurements", "role": "http://fulgentdiagnostics.com/20210630/taxonomy/role/DisclosureFairValueMeasurements", "shortName": "Fair Value Measurements", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "flgt-10q_20210630.htm", "contextRef": "C_0001674930_20210101_20210630", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:FairValueMeasurementInputsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R13": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "flgt-10q_20210630.htm", "contextRef": "C_0001674930_20210101_20210630", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100120 - Disclosure - Fixed Assets", "role": "http://fulgentdiagnostics.com/20210630/taxonomy/role/DisclosureFixedAssets", "shortName": "Fixed Assets", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "flgt-10q_20210630.htm", "contextRef": "C_0001674930_20210101_20210630", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R14": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "flgt-10q_20210630.htm", "contextRef": "C_0001674930_20210101_20210630", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SupplementalBalanceSheetDisclosuresTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100130 - Disclosure - Other Significant Balance Sheet Accounts", "role": "http://fulgentdiagnostics.com/20210630/taxonomy/role/DisclosureOtherSignificantBalanceSheetAccounts", "shortName": "Other Significant Balance Sheet Accounts", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "flgt-10q_20210630.htm", "contextRef": "C_0001674930_20210101_20210630", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SupplementalBalanceSheetDisclosuresTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R15": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "flgt-10q_20210630.htm", "contextRef": "C_0001674930_20210101_20210630", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SegmentReportingDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100140 - Disclosure - Reporting Segment and Geographic Information", "role": "http://fulgentdiagnostics.com/20210630/taxonomy/role/DisclosureReportingSegmentAndGeographicInformation", "shortName": "Reporting Segment and Geographic Information", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "flgt-10q_20210630.htm", "contextRef": "C_0001674930_20210101_20210630", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SegmentReportingDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R16": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "flgt-10q_20210630.htm", "contextRef": "C_0001674930_20210101_20210630", "decimals": null, "first": true, "lang": "en-US", "name": "flgt:DebtCommitmentsAndContingenciesDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100150 - Disclosure - Debt, Commitments and Contingencies", "role": "http://fulgentdiagnostics.com/20210630/taxonomy/role/DisclosureDebtCommitmentsAndContingencies", "shortName": "Debt, Commitments and Contingencies", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "flgt-10q_20210630.htm", "contextRef": "C_0001674930_20210101_20210630", "decimals": null, "first": true, "lang": "en-US", "name": "flgt:DebtCommitmentsAndContingenciesDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R17": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "flgt-10q_20210630.htm", "contextRef": "C_0001674930_20210101_20210630", "decimals": null, "first": true, "lang": "en-US", "name": "flgt:LessorAndLesseeOperatingLeasesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100160 - Disclosure - Leases", "role": "http://fulgentdiagnostics.com/20210630/taxonomy/role/DisclosureLeases", "shortName": "Leases", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "flgt-10q_20210630.htm", "contextRef": "C_0001674930_20210101_20210630", "decimals": null, "first": true, "lang": "en-US", "name": "flgt:LessorAndLesseeOperatingLeasesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R18": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "flgt-10q_20210630.htm", "contextRef": "C_0001674930_20210101_20210630", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100170 - Disclosure - Equity-Based Compensation", "role": "http://fulgentdiagnostics.com/20210630/taxonomy/role/DisclosureEquityBasedCompensation", "shortName": "Equity-Based Compensation", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "flgt-10q_20210630.htm", "contextRef": "C_0001674930_20210101_20210630", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R19": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "flgt-10q_20210630.htm", "contextRef": "C_0001674930_20210101_20210630", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:IncomeTaxDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100180 - Disclosure - Provision for (Benefit from) Income Taxes", "role": "http://fulgentdiagnostics.com/20210630/taxonomy/role/DisclosureProvisionForBenefitFromIncomeTaxes", "shortName": "Provision for (Benefit from) Income Taxes", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "flgt-10q_20210630.htm", "contextRef": "C_0001674930_20210101_20210630", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:IncomeTaxDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R2": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "body", "html" ], "baseRef": "flgt-10q_20210630.htm", "contextRef": "C_0001674930_20210630", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue", "reportCount": 1, "unitRef": "U_iso4217USD", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "100010 - Statement - Condensed Consolidated Balance Sheets", "role": "http://fulgentdiagnostics.com/20210630/taxonomy/role/StatementCondensedConsolidatedBalanceSheets", "shortName": "Condensed Consolidated Balance Sheets", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "body", "html" ], "baseRef": "flgt-10q_20210630.htm", "contextRef": "C_0001674930_20210630", "decimals": "-3", "lang": null, "name": "flgt:AvailableForSaleSecuritiesDebtEquitySecuritiesAndTradingSecuritiesCurrent", "reportCount": 1, "unique": true, "unitRef": "U_iso4217USD", "xsiNil": "false" } }, "R20": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "flgt-10q_20210630.htm", "contextRef": "C_0001674930_20210101_20210630", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:EarningsPerShareTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100190 - Disclosure - Income per Share", "role": "http://fulgentdiagnostics.com/20210630/taxonomy/role/DisclosureIncomePerShare", "shortName": "Income per Share", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "flgt-10q_20210630.htm", "contextRef": "C_0001674930_20210101_20210630", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:EarningsPerShareTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R21": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "flgt-10q_20210630.htm", "contextRef": "C_0001674930_20210101_20210630", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100200 - Disclosure - Related Parties", "role": "http://fulgentdiagnostics.com/20210630/taxonomy/role/DisclosureRelatedParties", "shortName": "Related Parties", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "flgt-10q_20210630.htm", "contextRef": "C_0001674930_20210101_20210630", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R22": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "flgt-10q_20210630.htm", "contextRef": "C_0001674930_20210101_20210630", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:BusinessCombinationDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100210 - Disclosure - Business Combination", "role": "http://fulgentdiagnostics.com/20210630/taxonomy/role/DisclosureBusinessCombination", "shortName": "Business Combination", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "flgt-10q_20210630.htm", "contextRef": "C_0001674930_20210101_20210630", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:BusinessCombinationDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R23": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "flgt-10q_20210630.htm", "contextRef": "C_0001674930_20210101_20210630", "decimals": null, "first": true, "lang": "en-US", "name": "flgt:EquityDistributionAgreementsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100220 - Disclosure - Equity Distribution Agreement", "role": "http://fulgentdiagnostics.com/20210630/taxonomy/role/DisclosureEquityDistributionAgreement", "shortName": "Equity Distribution Agreement", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "flgt-10q_20210630.htm", "contextRef": "C_0001674930_20210101_20210630", "decimals": null, "first": true, "lang": "en-US", "name": "flgt:EquityDistributionAgreementsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R24": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "flgt-10q_20210630.htm", "contextRef": "C_0001674930_20210101_20210630", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100230 - Disclosure - Goodwill and Acquisition-Related Intangibles", "role": "http://fulgentdiagnostics.com/20210630/taxonomy/role/DisclosureGoodwillAndAcquisitionRelatedIntangibles", "shortName": "Goodwill and Acquisition-Related Intangibles", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "flgt-10q_20210630.htm", "contextRef": "C_0001674930_20210101_20210630", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R25": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "flgt-10q_20210630.htm", "contextRef": "C_0001674930_20210101_20210630", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SubsequentEventsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100240 - Disclosure - Subsequent Events", "role": "http://fulgentdiagnostics.com/20210630/taxonomy/role/DisclosureSubsequentEvents", "shortName": "Subsequent Events", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "flgt-10q_20210630.htm", "contextRef": "C_0001674930_20210101_20210630", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SubsequentEventsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R26": { "firstAnchor": { "ancestors": [ "us-gaap:SignificantAccountingPoliciesTextBlock", "body", "html" ], "baseRef": "flgt-10q_20210630.htm", "contextRef": "C_0001674930_20210101_20210630", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:UseOfEstimates", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100250 - Disclosure - Summary of Significant Accounting Policies (Policies)", "role": "http://fulgentdiagnostics.com/20210630/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies", "shortName": "Summary of Significant Accounting Policies (Policies)", "subGroupType": "policies", "uniqueAnchor": { "ancestors": [ "us-gaap:SignificantAccountingPoliciesTextBlock", "body", "html" ], "baseRef": "flgt-10q_20210630.htm", "contextRef": "C_0001674930_20210101_20210630", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:UseOfEstimates", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R27": { "firstAnchor": { "ancestors": [ "p", "us-gaap:RevenueFromContractWithCustomerPolicyTextBlock", "ix:continuation", "body", "html" ], "baseRef": "flgt-10q_20210630.htm", "contextRef": "C_0001674930_us-gaapAdjustmentsForNewAccountingPronouncementsAxis_us-gaapAccountingStandardsUpdate201409Member_20210101_20210630", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DisaggregationOfRevenueTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100260 - Disclosure - Summary of Significant Accounting Policies (Tables)", "role": "http://fulgentdiagnostics.com/20210630/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesTables", "shortName": "Summary of Significant Accounting Policies (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "p", "us-gaap:RevenueFromContractWithCustomerPolicyTextBlock", "ix:continuation", "body", "html" ], "baseRef": "flgt-10q_20210630.htm", "contextRef": "C_0001674930_us-gaapAdjustmentsForNewAccountingPronouncementsAxis_us-gaapAccountingStandardsUpdate201409Member_20210101_20210630", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DisaggregationOfRevenueTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R28": { "firstAnchor": { "ancestors": [ "us-gaap:InvestmentsInDebtAndEquityInstrumentsCashAndCashEquivalentsUnrealizedAndRealizedGainsLossesTextBlock", "body", "html" ], "baseRef": "flgt-10q_20210630.htm", "contextRef": "C_0001674930_20210101_20210630", "decimals": null, "first": true, "lang": "en-US", "name": "flgt:ScheduleOfAvailableForSaleDebtSecuritiesAndEquityTradingSecuritiesReconciliationTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100270 - Disclosure - Marketable Securities (Tables)", "role": "http://fulgentdiagnostics.com/20210630/taxonomy/role/DisclosureMarketableSecuritiesTables", "shortName": "Marketable Securities (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "us-gaap:InvestmentsInDebtAndEquityInstrumentsCashAndCashEquivalentsUnrealizedAndRealizedGainsLossesTextBlock", "body", "html" ], "baseRef": "flgt-10q_20210630.htm", "contextRef": "C_0001674930_20210101_20210630", "decimals": null, "first": true, "lang": "en-US", "name": "flgt:ScheduleOfAvailableForSaleDebtSecuritiesAndEquityTradingSecuritiesReconciliationTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R29": { "firstAnchor": { "ancestors": [ "us-gaap:FairValueMeasurementInputsDisclosureTextBlock", "body", "html" ], "baseRef": "flgt-10q_20210630.htm", "contextRef": "C_0001674930_20210101_20210630", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100280 - Disclosure - Fair Value Measurements (Tables)", "role": "http://fulgentdiagnostics.com/20210630/taxonomy/role/DisclosureFairValueMeasurementsTables", "shortName": "Fair Value Measurements (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "us-gaap:FairValueMeasurementInputsDisclosureTextBlock", "body", "html" ], "baseRef": "flgt-10q_20210630.htm", "contextRef": "C_0001674930_20210101_20210630", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R3": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "body", "html" ], "baseRef": "flgt-10q_20210630.htm", "contextRef": "C_0001674930_20210630", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:AllowanceForDoubtfulAccountsReceivable", "reportCount": 1, "unique": true, "unitRef": "U_iso4217USD", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "100020 - Statement - Condensed Consolidated Balance Sheets (Parenthetical)", "role": "http://fulgentdiagnostics.com/20210630/taxonomy/role/StatementCondensedConsolidatedBalanceSheetsParenthetical", "shortName": "Condensed Consolidated Balance Sheets (Parenthetical)", "subGroupType": "parenthetical", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "body", "html" ], "baseRef": "flgt-10q_20210630.htm", "contextRef": "C_0001674930_20210630", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:AllowanceForDoubtfulAccountsReceivable", "reportCount": 1, "unique": true, "unitRef": "U_iso4217USD", "xsiNil": "false" } }, "R30": { "firstAnchor": { "ancestors": [ "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "body", "html" ], "baseRef": "flgt-10q_20210630.htm", "contextRef": "C_0001674930_20210101_20210630", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:PropertyPlantAndEquipmentTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100290 - Disclosure - Fixed Assets (Tables)", "role": "http://fulgentdiagnostics.com/20210630/taxonomy/role/DisclosureFixedAssetsTables", "shortName": "Fixed Assets (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "body", "html" ], "baseRef": "flgt-10q_20210630.htm", "contextRef": "C_0001674930_20210101_20210630", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:PropertyPlantAndEquipmentTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R31": { "firstAnchor": { "ancestors": [ "us-gaap:SupplementalBalanceSheetDisclosuresTextBlock", "body", "html" ], "baseRef": "flgt-10q_20210630.htm", "contextRef": "C_0001674930_20210101_20210630", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfOtherCurrentAssetsTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100300 - Disclosure - Other Significant Balance Sheet Accounts (Tables)", "role": "http://fulgentdiagnostics.com/20210630/taxonomy/role/DisclosureOtherSignificantBalanceSheetAccountsTables", "shortName": "Other Significant Balance Sheet Accounts (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "us-gaap:SupplementalBalanceSheetDisclosuresTextBlock", "body", "html" ], "baseRef": "flgt-10q_20210630.htm", "contextRef": "C_0001674930_20210101_20210630", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfOtherCurrentAssetsTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R32": { "firstAnchor": { "ancestors": [ "p", "us-gaap:SegmentReportingDisclosureTextBlock", "body", "html" ], "baseRef": "flgt-10q_20210630.htm", "contextRef": "C_0001674930_20210101_20210630", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:RevenueFromExternalCustomersByGeographicAreasTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100310 - Disclosure - Reporting Segment and Geographic Information (Tables)", "role": "http://fulgentdiagnostics.com/20210630/taxonomy/role/DisclosureReportingSegmentAndGeographicInformationTables", "shortName": "Reporting Segment and Geographic Information (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "p", "us-gaap:SegmentReportingDisclosureTextBlock", "body", "html" ], "baseRef": "flgt-10q_20210630.htm", "contextRef": "C_0001674930_20210101_20210630", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:RevenueFromExternalCustomersByGeographicAreasTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R33": { "firstAnchor": { "ancestors": [ "flgt:LessorAndLesseeOperatingLeasesTextBlock", "body", "html" ], "baseRef": "flgt-10q_20210630.htm", "contextRef": "C_0001674930_20210101_20210630", "decimals": null, "first": true, "lang": "en-US", "name": "flgt:ScheduleOfLeaseRightOfUseAssetShortTermLeaseLiabilitiesAndLongTermLeaseLiabilitiesTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100320 - Disclosure - Leases (Tables)", "role": "http://fulgentdiagnostics.com/20210630/taxonomy/role/DisclosureLeasesTables", "shortName": "Leases (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "flgt:LessorAndLesseeOperatingLeasesTextBlock", "body", "html" ], "baseRef": "flgt-10q_20210630.htm", "contextRef": "C_0001674930_20210101_20210630", "decimals": null, "first": true, "lang": "en-US", "name": "flgt:ScheduleOfLeaseRightOfUseAssetShortTermLeaseLiabilitiesAndLongTermLeaseLiabilitiesTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R34": { "firstAnchor": { "ancestors": [ "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "body", "html" ], "baseRef": "flgt-10q_20210630.htm", "contextRef": "C_0001674930_20210101_20210630", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100330 - Disclosure - Equity-Based Compensation (Tables)", "role": "http://fulgentdiagnostics.com/20210630/taxonomy/role/DisclosureEquityBasedCompensationTables", "shortName": "Equity-Based Compensation (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "body", "html" ], "baseRef": "flgt-10q_20210630.htm", "contextRef": "C_0001674930_20210101_20210630", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R35": { "firstAnchor": { "ancestors": [ "us-gaap:EarningsPerShareTextBlock", "body", "html" ], "baseRef": "flgt-10q_20210630.htm", "contextRef": "C_0001674930_20210101_20210630", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100340 - Disclosure - Income per Share (Tables)", "role": "http://fulgentdiagnostics.com/20210630/taxonomy/role/DisclosureIncomePerShareTables", "shortName": "Income per Share (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "us-gaap:EarningsPerShareTextBlock", "body", "html" ], "baseRef": "flgt-10q_20210630.htm", "contextRef": "C_0001674930_20210101_20210630", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R36": { "firstAnchor": { "ancestors": [ "span", "p", "us-gaap:BusinessCombinationDisclosureTextBlock", "body", "html" ], "baseRef": "flgt-10q_20210630.htm", "contextRef": "C_0001674930_us-gaapBusinessAcquisitionAxis_flgtFFGeneBiotechMember_20210101_20210630", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100350 - Disclosure - Business Combination (Tables)", "role": "http://fulgentdiagnostics.com/20210630/taxonomy/role/DisclosureBusinessCombinationTables", "shortName": "Business Combination (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "span", "p", "us-gaap:BusinessCombinationDisclosureTextBlock", "body", "html" ], "baseRef": "flgt-10q_20210630.htm", "contextRef": "C_0001674930_us-gaapBusinessAcquisitionAxis_flgtFFGeneBiotechMember_20210101_20210630", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R37": { "firstAnchor": { "ancestors": [ "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock", "body", "html" ], "baseRef": "flgt-10q_20210630.htm", "contextRef": "C_0001674930_20210101_20210630", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100360 - Disclosure - Goodwill and Acquisition-Related Intangibles (Tables)", "role": "http://fulgentdiagnostics.com/20210630/taxonomy/role/DisclosureGoodwillAndAcquisitionRelatedIntangiblesTables", "shortName": "Goodwill and Acquisition-Related Intangibles (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock", "body", "html" ], "baseRef": "flgt-10q_20210630.htm", "contextRef": "C_0001674930_20210101_20210630", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R38": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "body", "html" ], "baseRef": "flgt-10q_20210630.htm", "contextRef": "C_0001674930_20210630", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:AccountsReceivableNetCurrent", "reportCount": 1, "unitRef": "U_iso4217USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100370 - Disclosure - Summary of Significant Accounting Policies - Additional Information (Details)", "role": "http://fulgentdiagnostics.com/20210630/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails", "shortName": "Summary of Significant Accounting Policies - Additional Information (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "p", "us-gaap:RevenueFromContractWithCustomerPolicyTextBlock", "ix:continuation", "body", "html" ], "baseRef": "flgt-10q_20210630.htm", "contextRef": "C_0001674930_20210401_20210630", "decimals": "-5", "lang": null, "name": "us-gaap:ContractWithCustomerLiabilityRevenueRecognized", "reportCount": 1, "unique": true, "unitRef": "U_iso4217USD", "xsiNil": "false" } }, "R39": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "body", "html" ], "baseRef": "flgt-10q_20210630.htm", "contextRef": "C_0001674930_20210401_20210630", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax", "reportCount": 1, "unitRef": "U_iso4217USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100380 - Disclosure - Summary of Significant Accounting Policies - Summary of Revenue from Contracts with Customers by Payor Type (Details)", "role": "http://fulgentdiagnostics.com/20210630/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesSummaryOfRevenueFromContractsWithCustomersByPayorTypeDetails", "shortName": "Summary of Significant Accounting Policies - Summary of Revenue from Contracts with Customers by Payor Type (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "ix:continuation", "us-gaap:RevenueFromContractWithCustomerPolicyTextBlock", "ix:continuation", "body", "html" ], "baseRef": "flgt-10q_20210630.htm", "contextRef": "C_0001674930_us-gaapAdjustmentsForNewAccountingPronouncementsAxis_us-gaapAccountingStandardsUpdate201409Member_20210401_20210630", "decimals": "-3", "lang": null, "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax", "reportCount": 1, "unique": true, "unitRef": "U_iso4217USD", "xsiNil": "false" } }, "R4": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "body", "html" ], "baseRef": "flgt-10q_20210630.htm", "contextRef": "C_0001674930_20210401_20210630", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax", "reportCount": 1, "unitRef": "U_iso4217USD", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "100030 - Statement - Condensed Consolidated Statements of Operations (unaudited)", "role": "http://fulgentdiagnostics.com/20210630/taxonomy/role/StatementCondensedConsolidatedStatementsOfOperationsUnaudited", "shortName": "Condensed Consolidated Statements of Operations (unaudited)", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "body", "html" ], "baseRef": "flgt-10q_20210630.htm", "contextRef": "C_0001674930_20210401_20210630", "decimals": "-3", "lang": null, "name": "us-gaap:CostOfRevenue", "reportCount": 1, "unique": true, "unitRef": "U_iso4217USD", "xsiNil": "false" } }, "R40": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "body", "html" ], "baseRef": "flgt-10q_20210630.htm", "contextRef": "C_0001674930_20210630", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue", "reportCount": 1, "unitRef": "U_iso4217USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100390 - Disclosure - Marketable Securities - Summary of Marketable Securities (Details)", "role": "http://fulgentdiagnostics.com/20210630/taxonomy/role/DisclosureMarketableSecuritiesSummaryOfMarketableSecuritiesDetails", "shortName": "Marketable Securities - Summary of Marketable Securities (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "flgt:ScheduleOfAvailableForSaleDebtSecuritiesAndEquityTradingSecuritiesReconciliationTableTextBlock", "us-gaap:InvestmentsInDebtAndEquityInstrumentsCashAndCashEquivalentsUnrealizedAndRealizedGainsLossesTextBlock", "body", "html" ], "baseRef": "flgt-10q_20210630.htm", "contextRef": "C_0001674930_20210630", "decimals": "-3", "lang": null, "name": "us-gaap:CashEquivalentsAtCarryingValue", "reportCount": 1, "unique": true, "unitRef": "U_iso4217USD", "xsiNil": "false" } }, "R41": { "firstAnchor": { "ancestors": [ "p", "ix:continuation", "body", "html" ], "baseRef": "flgt-10q_20210630.htm", "contextRef": "C_0001674930_20210101_20210630", "decimals": "-5", "first": true, "lang": null, "name": "flgt:AvailableForSaleDebtSecuritiesAndEquityTradingSecuritiesGrossUnrealizedLoss", "reportCount": 1, "unique": true, "unitRef": "U_iso4217USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100400 - Disclosure - Marketable Securities - Additional Information (Details)", "role": "http://fulgentdiagnostics.com/20210630/taxonomy/role/DisclosureMarketableSecuritiesAdditionalInformationDetails", "shortName": "Marketable Securities - Additional Information (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "ix:continuation", "body", "html" ], "baseRef": "flgt-10q_20210630.htm", "contextRef": "C_0001674930_20210101_20210630", "decimals": "-5", "first": true, "lang": null, "name": "flgt:AvailableForSaleDebtSecuritiesAndEquityTradingSecuritiesGrossUnrealizedLoss", "reportCount": 1, "unique": true, "unitRef": "U_iso4217USD", "xsiNil": "false" } }, "R42": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock", "us-gaap:FairValueMeasurementInputsDisclosureTextBlock", "body", "html" ], "baseRef": "flgt-10q_20210630.htm", "contextRef": "C_0001674930_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_20210630", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:AssetsFairValueDisclosure", "reportCount": 1, "unique": true, "unitRef": "U_iso4217USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100410 - Disclosure - Fair Value Measurements - Information about Financial Assets Measured at Fair Value on Recurring Basis Based on Three-Tier Fair Value Hierarchy (Details)", "role": "http://fulgentdiagnostics.com/20210630/taxonomy/role/DisclosureFairValueMeasurementsInformationAboutFinancialAssetsMeasuredAtFairValueOnRecurringBasisBasedOnThreeTierFairValueHierarchyDetails", "shortName": "Fair Value Measurements - Information about Financial Assets Measured at Fair Value on Recurring Basis Based on Three-Tier Fair Value Hierarchy (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock", "us-gaap:FairValueMeasurementInputsDisclosureTextBlock", "body", "html" ], "baseRef": "flgt-10q_20210630.htm", "contextRef": "C_0001674930_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_20210630", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:AssetsFairValueDisclosure", "reportCount": 1, "unique": true, "unitRef": "U_iso4217USD", "xsiNil": "false" } }, "R43": { "firstAnchor": { "ancestors": [ "span", "p", "ix:continuation", "body", "html" ], "baseRef": "flgt-10q_20210630.htm", "contextRef": "C_0001674930_20210630", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue", "reportCount": 1, "unique": true, "unitRef": "U_iso4217USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100420 - Disclosure - Fair Value Measurements - Additional Information (Details)", "role": "http://fulgentdiagnostics.com/20210630/taxonomy/role/DisclosureFairValueMeasurementsAdditionalInformationDetails", "shortName": "Fair Value Measurements - Additional Information (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "p", "ix:continuation", "body", "html" ], "baseRef": "flgt-10q_20210630.htm", "contextRef": "C_0001674930_20210630", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue", "reportCount": 1, "unique": true, "unitRef": "U_iso4217USD", "xsiNil": "false" } }, "R44": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "us-gaap:PropertyPlantAndEquipmentTextBlock", "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "body", "html" ], "baseRef": "flgt-10q_20210630.htm", "contextRef": "C_0001674930_20210630", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:PropertyPlantAndEquipmentGross", "reportCount": 1, "unique": true, "unitRef": "U_iso4217USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100430 - Disclosure - Fixed Assets - Major Classes of Fixed Assets (Details)", "role": "http://fulgentdiagnostics.com/20210630/taxonomy/role/DisclosureFixedAssetsMajorClassesOfFixedAssetsDetails", "shortName": "Fixed Assets - Major Classes of Fixed Assets (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "us-gaap:PropertyPlantAndEquipmentTextBlock", "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "body", "html" ], "baseRef": "flgt-10q_20210630.htm", "contextRef": "C_0001674930_20210630", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:PropertyPlantAndEquipmentGross", "reportCount": 1, "unique": true, "unitRef": "U_iso4217USD", "xsiNil": "false" } }, "R45": { "firstAnchor": { "ancestors": [ "p", "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "body", "html" ], "baseRef": "flgt-10q_20210630.htm", "contextRef": "C_0001674930_20210401_20210630", "decimals": "-5", "first": true, "lang": null, "name": "us-gaap:Depreciation", "reportCount": 1, "unique": true, "unitRef": "U_iso4217USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100440 - Disclosure - Fixed Assets - Additional Information (Details)", "role": "http://fulgentdiagnostics.com/20210630/taxonomy/role/DisclosureFixedAssetsAdditionalInformationDetails", "shortName": "Fixed Assets - Additional Information (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "body", "html" ], "baseRef": "flgt-10q_20210630.htm", "contextRef": "C_0001674930_20210401_20210630", "decimals": "-5", "first": true, "lang": null, "name": "us-gaap:Depreciation", "reportCount": 1, "unique": true, "unitRef": "U_iso4217USD", "xsiNil": "false" } }, "R46": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "us-gaap:ScheduleOfOtherCurrentAssetsTableTextBlock", "us-gaap:SupplementalBalanceSheetDisclosuresTextBlock", "body", "html" ], "baseRef": "flgt-10q_20210630.htm", "contextRef": "C_0001674930_20210630", "decimals": "-3", "first": true, "lang": null, "name": "flgt:ReagentsAndSuppliesCurrent", "reportCount": 1, "unitRef": "U_iso4217USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100450 - Disclosure - Other Significant Balance Sheet Accounts - Schedule of Other Current Assets (Details)", "role": "http://fulgentdiagnostics.com/20210630/taxonomy/role/DisclosureOtherSignificantBalanceSheetAccountsScheduleOfOtherCurrentAssetsDetails", "shortName": "Other Significant Balance Sheet Accounts - Schedule of Other Current Assets (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "us-gaap:ScheduleOfOtherCurrentAssetsTableTextBlock", "us-gaap:SupplementalBalanceSheetDisclosuresTextBlock", "body", "html" ], "baseRef": "flgt-10q_20210630.htm", "contextRef": "C_0001674930_20210630", "decimals": "-3", "lang": null, "name": "us-gaap:PrepaidExpenseCurrent", "reportCount": 1, "unique": true, "unitRef": "U_iso4217USD", "xsiNil": "false" } }, "R47": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "us-gaap:OtherCurrentLiabilitiesTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "flgt-10q_20210630.htm", "contextRef": "C_0001674930_20210630", "decimals": "-3", "first": true, "lang": null, "name": "flgt:PayrollLiabilitiesCurrent", "reportCount": 1, "unique": true, "unitRef": "U_iso4217USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100460 - Disclosure - Other Significant Balance Sheet Accounts - Schedule of Other Current Liabilities (Details)", "role": "http://fulgentdiagnostics.com/20210630/taxonomy/role/DisclosureOtherSignificantBalanceSheetAccountsScheduleOfOtherCurrentLiabilitiesDetails", "shortName": "Other Significant Balance Sheet Accounts - Schedule of Other Current Liabilities (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "us-gaap:OtherCurrentLiabilitiesTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "flgt-10q_20210630.htm", "contextRef": "C_0001674930_20210630", "decimals": "-3", "first": true, "lang": null, "name": "flgt:PayrollLiabilitiesCurrent", "reportCount": 1, "unique": true, "unitRef": "U_iso4217USD", "xsiNil": "false" } }, "R48": { "firstAnchor": { "ancestors": [ "p", "us-gaap:SegmentReportingDisclosureTextBlock", "body", "html" ], "baseRef": "flgt-10q_20210630.htm", "contextRef": "C_0001674930_20210101_20210630", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:NumberOfReportableSegments", "reportCount": 1, "unique": true, "unitRef": "U_flgtSegment", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100470 - Disclosure - Reporting Segment and Geographical Information - Additional Information (Details)", "role": "http://fulgentdiagnostics.com/20210630/taxonomy/role/DisclosureReportingSegmentAndGeographicalInformationAdditionalInformationDetails", "shortName": "Reporting Segment and Geographical Information - Additional Information (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "us-gaap:SegmentReportingDisclosureTextBlock", "body", "html" ], "baseRef": "flgt-10q_20210630.htm", "contextRef": "C_0001674930_20210101_20210630", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:NumberOfReportableSegments", "reportCount": 1, "unique": true, "unitRef": "U_flgtSegment", "xsiNil": "false" } }, "R49": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "body", "html" ], "baseRef": "flgt-10q_20210630.htm", "contextRef": "C_0001674930_20210401_20210630", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax", "reportCount": 1, "unitRef": "U_iso4217USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100480 - Disclosure - Reporting Segment and Geographical Information - Summary of Revenue by Geographic Region (Details)", "role": "http://fulgentdiagnostics.com/20210630/taxonomy/role/DisclosureReportingSegmentAndGeographicalInformationSummaryOfRevenueByGeographicRegionDetails", "shortName": "Reporting Segment and Geographical Information - Summary of Revenue by Geographic Region (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "ix:continuation", "us-gaap:SegmentReportingDisclosureTextBlock", "body", "html" ], "baseRef": "flgt-10q_20210630.htm", "contextRef": "C_0001674930_srtStatementGeographicalAxis_countryUS_20210401_20210630", "decimals": "-3", "lang": null, "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax", "reportCount": 1, "unique": true, "unitRef": "U_iso4217USD", "xsiNil": "false" } }, "R5": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "body", "html" ], "baseRef": "flgt-10q_20210630.htm", "contextRef": "C_0001674930_20210401_20210630", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:ProfitLoss", "reportCount": 1, "unitRef": "U_iso4217USD", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "100040 - Statement - Condensed Consolidated Statements of Comprehensive Income (Loss) (unaudited)", "role": "http://fulgentdiagnostics.com/20210630/taxonomy/role/StatementCondensedConsolidatedStatementsOfComprehensiveIncomeLossUnaudited", "shortName": "Condensed Consolidated Statements of Comprehensive Income (Loss) (unaudited)", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "body", "html" ], "baseRef": "flgt-10q_20210630.htm", "contextRef": "C_0001674930_20210401_20210630", "decimals": "-3", "lang": null, "name": "us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax", "reportCount": 1, "unique": true, "unitRef": "U_iso4217USD", "xsiNil": "false" } }, "R50": { "firstAnchor": { "ancestors": [ "p", "flgt:DebtCommitmentsAndContingenciesDisclosureTextBlock", "body", "html" ], "baseRef": "flgt-10q_20210630.htm", "contextRef": "C_0001674930_20210101_20210630", "decimals": "-5", "first": true, "lang": null, "name": "flgt:DebtSecurityInvestmentOutstandingBorrowingAmount", "reportCount": 1, "unique": true, "unitRef": "U_iso4217USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100490 - Disclosure - Debt, Commitments and Contingencies - Additional Information (Details)", "role": "http://fulgentdiagnostics.com/20210630/taxonomy/role/DisclosureDebtCommitmentsAndContingenciesAdditionalInformationDetails", "shortName": "Debt, Commitments and Contingencies - Additional Information (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "flgt:DebtCommitmentsAndContingenciesDisclosureTextBlock", "body", "html" ], "baseRef": "flgt-10q_20210630.htm", "contextRef": "C_0001674930_20210101_20210630", "decimals": "-5", "first": true, "lang": null, "name": "flgt:DebtSecurityInvestmentOutstandingBorrowingAmount", "reportCount": 1, "unique": true, "unitRef": "U_iso4217USD", "xsiNil": "false" } }, "R51": { "firstAnchor": { "ancestors": [ "p", "flgt:LessorAndLesseeOperatingLeasesTextBlock", "body", "html" ], "baseRef": "flgt-10q_20210630.htm", "contextRef": "C_0001674930_20210101_20210630", "decimals": null, "first": true, "lang": "en-US", "name": "flgt:OperatingLeasesTermOfExpiration", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100500 - Disclosure - Leases - Additional Information (Details)", "role": "http://fulgentdiagnostics.com/20210630/taxonomy/role/DisclosureLeasesAdditionalInformationDetails", "shortName": "Leases - Additional Information (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "flgt:LessorAndLesseeOperatingLeasesTextBlock", "body", "html" ], "baseRef": "flgt-10q_20210630.htm", "contextRef": "C_0001674930_20210101_20210630", "decimals": null, "first": true, "lang": "en-US", "name": "flgt:OperatingLeasesTermOfExpiration", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R52": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "flgt:ScheduleOfLeaseRightOfUseAssetShortTermLeaseLiabilitiesAndLongTermLeaseLiabilitiesTableTextBlock", "flgt:LessorAndLesseeOperatingLeasesTextBlock", "body", "html" ], "baseRef": "flgt-10q_20210630.htm", "contextRef": "C_0001674930_20210630", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:OperatingLeaseRightOfUseAsset", "reportCount": 1, "unique": true, "unitRef": "U_iso4217USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100510 - Disclosure - Leases - Schedule of Lease Right-of-Use Asset, Short-term Lease Liabilities, and Long-term Lease Liabilities (Details)", "role": "http://fulgentdiagnostics.com/20210630/taxonomy/role/DisclosureLeasesScheduleOfLeaseRightOfUseAssetShortTermLeaseLiabilitiesAndLongTermLeaseLiabilitiesDetails", "shortName": "Leases - Schedule of Lease Right-of-Use Asset, Short-term Lease Liabilities, and Long-term Lease Liabilities (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "flgt:ScheduleOfLeaseRightOfUseAssetShortTermLeaseLiabilitiesAndLongTermLeaseLiabilitiesTableTextBlock", "flgt:LessorAndLesseeOperatingLeasesTextBlock", "body", "html" ], "baseRef": "flgt-10q_20210630.htm", "contextRef": "C_0001674930_20210630", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:OperatingLeaseRightOfUseAsset", "reportCount": 1, "unique": true, "unitRef": "U_iso4217USD", "xsiNil": "false" } }, "R53": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "us-gaap:LeaseCostTableTextBlock", "flgt:LessorAndLesseeOperatingLeasesTextBlock", "body", "html" ], "baseRef": "flgt-10q_20210630.htm", "contextRef": "C_0001674930_20210401_20210630", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:OperatingLeaseCost", "reportCount": 1, "unique": true, "unitRef": "U_iso4217USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100520 - Disclosure - Leases - Schedule of Operating Lease Expense (Details)", "role": "http://fulgentdiagnostics.com/20210630/taxonomy/role/DisclosureLeasesScheduleOfOperatingLeaseExpenseDetails", "shortName": "Leases - Schedule of Operating Lease Expense (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "us-gaap:LeaseCostTableTextBlock", "flgt:LessorAndLesseeOperatingLeasesTextBlock", "body", "html" ], "baseRef": "flgt-10q_20210630.htm", "contextRef": "C_0001674930_20210401_20210630", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:OperatingLeaseCost", "reportCount": 1, "unique": true, "unitRef": "U_iso4217USD", "xsiNil": "false" } }, "R54": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "flgt:ScheduleOfSupplementalInformationRelatedToLeasesTableTextBlock", "flgt:LessorAndLesseeOperatingLeasesTextBlock", "body", "html" ], "baseRef": "flgt-10q_20210630.htm", "contextRef": "C_0001674930_20210630", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100530 - Disclosure - Leases - Schedule of Supplemental Information Related to Leases (Details)", "role": "http://fulgentdiagnostics.com/20210630/taxonomy/role/DisclosureLeasesScheduleOfSupplementalInformationRelatedToLeasesDetails", "shortName": "Leases - Schedule of Supplemental Information Related to Leases (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "flgt:ScheduleOfSupplementalInformationRelatedToLeasesTableTextBlock", "flgt:LessorAndLesseeOperatingLeasesTextBlock", "body", "html" ], "baseRef": "flgt-10q_20210630.htm", "contextRef": "C_0001674930_20210630", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R55": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "ix:continuation", "ix:continuation", "body", "html" ], "baseRef": "flgt-10q_20210630.htm", "contextRef": "C_0001674930_20210630", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear", "reportCount": 1, "unique": true, "unitRef": "U_iso4217USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100540 - Disclosure - Leases - Schedule of Maturity Analysis of Operating Lease Liabilities using Undiscounted Cash Flows on an Annual Basis (Details)", "role": "http://fulgentdiagnostics.com/20210630/taxonomy/role/DisclosureLeasesScheduleOfMaturityAnalysisOfOperatingLeaseLiabilitiesUsingUndiscountedCashFlowsOnAnnualBasisDetails", "shortName": "Leases - Schedule of Maturity Analysis of Operating Lease Liabilities using Undiscounted Cash Flows on an Annual Basis (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "ix:continuation", "ix:continuation", "body", "html" ], "baseRef": "flgt-10q_20210630.htm", "contextRef": "C_0001674930_20210630", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear", "reportCount": 1, "unique": true, "unitRef": "U_iso4217USD", "xsiNil": "false" } }, "R56": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "ix:continuation", "ix:continuation", "body", "html" ], "baseRef": "flgt-10q_20210630.htm", "contextRef": "C_0001674930_20210401_20210630", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:OperatingLeaseLeaseIncomeLeasePayments", "reportCount": 1, "unique": true, "unitRef": "U_iso4217USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100560 - Disclosure - Leases - Schedule of Lease Income (Details)", "role": "http://fulgentdiagnostics.com/20210630/taxonomy/role/DisclosureLeasesScheduleOfLeaseIncomeDetails", "shortName": "Leases - Schedule of Lease Income (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "ix:continuation", "ix:continuation", "body", "html" ], "baseRef": "flgt-10q_20210630.htm", "contextRef": "C_0001674930_20210401_20210630", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:OperatingLeaseLeaseIncomeLeasePayments", "reportCount": 1, "unique": true, "unitRef": "U_iso4217USD", "xsiNil": "false" } }, "R57": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "us-gaap:LessorOperatingLeasePaymentsToBeReceivedMaturityTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "flgt-10q_20210630.htm", "contextRef": "C_0001674930_20210630", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:LessorOperatingLeasePaymentsToBeReceivedRemainderOfFiscalYear", "reportCount": 1, "unique": true, "unitRef": "U_iso4217USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100570 - Disclosure - Leases - Schedule of Future Fixed Lease Payments from Tenants for All Noncancelable Operating Leases (Details)", "role": "http://fulgentdiagnostics.com/20210630/taxonomy/role/DisclosureLeasesScheduleOfFutureFixedLeasePaymentsFromTenantsForAllNoncancelableOperatingLeasesDetails", "shortName": "Leases - Schedule of Future Fixed Lease Payments from Tenants for All Noncancelable Operating Leases (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "us-gaap:LessorOperatingLeasePaymentsToBeReceivedMaturityTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "flgt-10q_20210630.htm", "contextRef": "C_0001674930_20210630", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:LessorOperatingLeasePaymentsToBeReceivedRemainderOfFiscalYear", "reportCount": 1, "unique": true, "unitRef": "U_iso4217USD", "xsiNil": "false" } }, "R58": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock", "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "body", "html" ], "baseRef": "flgt-10q_20210630.htm", "contextRef": "C_0001674930_20210401_20210630", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:AllocatedShareBasedCompensationExpense", "reportCount": 1, "unique": true, "unitRef": "U_iso4217USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100580 - Disclosure - Equity-Based Compensation - Summary of Equity-Based Compensation Expenses as Part of Cost of Revenue and Operating Expenses (Details)", "role": "http://fulgentdiagnostics.com/20210630/taxonomy/role/DisclosureEquityBasedCompensationSummaryOfEquityBasedCompensationExpensesAsPartOfCostOfRevenueAndOperatingExpensesDetails", "shortName": "Equity-Based Compensation - Summary of Equity-Based Compensation Expenses as Part of Cost of Revenue and Operating Expenses (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock", "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "body", "html" ], "baseRef": "flgt-10q_20210630.htm", "contextRef": "C_0001674930_20210401_20210630", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:AllocatedShareBasedCompensationExpense", "reportCount": 1, "unique": true, "unitRef": "U_iso4217USD", "xsiNil": "false" } }, "R59": { "firstAnchor": { "ancestors": [ "p", "us-gaap:IncomeTaxDisclosureTextBlock", "body", "html" ], "baseRef": "flgt-10q_20210630.htm", "contextRef": "C_0001674930_20210401_20210630", "decimals": "2", "first": true, "lang": null, "name": "us-gaap:EffectiveIncomeTaxRateContinuingOperations", "reportCount": 1, "unique": true, "unitRef": "U_xbrlipure", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100590 - Disclosure - Provision for (Benefit from) Income Taxes - Additional Information (Details)", "role": "http://fulgentdiagnostics.com/20210630/taxonomy/role/DisclosureProvisionForBenefitFromIncomeTaxesAdditionalInformationDetails", "shortName": "Provision for (Benefit from) Income Taxes - Additional Information (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "us-gaap:IncomeTaxDisclosureTextBlock", "body", "html" ], "baseRef": "flgt-10q_20210630.htm", "contextRef": "C_0001674930_20210401_20210630", "decimals": "2", "first": true, "lang": null, "name": "us-gaap:EffectiveIncomeTaxRateContinuingOperations", "reportCount": 1, "unique": true, "unitRef": "U_xbrlipure", "xsiNil": "false" } }, "R6": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "body", "html" ], "baseRef": "flgt-10q_20210630.htm", "contextRef": "C_0001674930_20191231", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest", "reportCount": 1, "unitRef": "U_iso4217USD", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "100050 - Statement - Condensed Consolidated Statements of Stockholders' Equity (unaudited)", "role": "http://fulgentdiagnostics.com/20210630/taxonomy/role/StatementCondensedConsolidatedStatementsOfStockholdersEquityUnaudited", "shortName": "Condensed Consolidated Statements of Stockholders' Equity (unaudited)", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "body", "html" ], "baseRef": "flgt-10q_20210630.htm", "contextRef": "C_0001674930_20200101_20200331", "decimals": "-3", "lang": null, "name": "us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue", "reportCount": 1, "unique": true, "unitRef": "U_iso4217USD", "xsiNil": "false" } }, "R60": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "body", "html" ], "baseRef": "flgt-10q_20210630.htm", "contextRef": "C_0001674930_20210401_20210630", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:NetIncomeLoss", "reportCount": 1, "unitRef": "U_iso4217USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100600 - Disclosure - Income per Share - Reconciliation of Basic and Diluted Income Per Share Computations (Details)", "role": "http://fulgentdiagnostics.com/20210630/taxonomy/role/DisclosureIncomePerShareReconciliationOfBasicAndDilutedIncomePerShareComputationsDetails", "shortName": "Income per Share - Reconciliation of Basic and Diluted Income Per Share Computations (Details)", "subGroupType": "details", "uniqueAnchor": null }, "R61": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock", "ix:continuation", "body", "html" ], "baseRef": "flgt-10q_20210630.htm", "contextRef": "C_0001674930_us-gaapAwardTypeAxis_us-gaapEmployeeStockOptionMember_20210401_20210630", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "reportCount": 1, "unique": true, "unitRef": "U_xbrlishares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100610 - Disclosure - Income per Share - Anti-dilutive Securities Excluded from Calculation of Diluted Income Per Share (Details)", "role": "http://fulgentdiagnostics.com/20210630/taxonomy/role/DisclosureIncomePerShareAntiDilutiveSecuritiesExcludedFromCalculationOfDilutedIncomePerShareDetails", "shortName": "Income per Share - Anti-dilutive Securities Excluded from Calculation of Diluted Income Per Share (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock", "ix:continuation", "body", "html" ], "baseRef": "flgt-10q_20210630.htm", "contextRef": "C_0001674930_us-gaapAwardTypeAxis_us-gaapEmployeeStockOptionMember_20210401_20210630", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "reportCount": 1, "unique": true, "unitRef": "U_xbrlishares", "xsiNil": "false" } }, "R62": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "us-gaap:OtherCurrentLiabilitiesTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "flgt-10q_20210630.htm", "contextRef": "C_0001674930_20210630", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:DueToRelatedPartiesCurrent", "reportCount": 1, "unitRef": "U_iso4217USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100620 - Disclosure - Related Parties - Additional Information (Details)", "role": "http://fulgentdiagnostics.com/20210630/taxonomy/role/DisclosureRelatedPartiesAdditionalInformationDetails", "shortName": "Related Parties - Additional Information (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "us-gaap:RelatedPartyTransactionsDisclosureTextBlock", "body", "html" ], "baseRef": "flgt-10q_20210630.htm", "contextRef": "C_0001674930_us-gaapRelatedPartyTransactionAxis_flgtGeneticSequencingServiceMember_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_flgtAHMCHealthcareIncMember_20210401_20210630", "decimals": "0", "lang": null, "name": "us-gaap:RevenueFromRelatedParties", "reportCount": 1, "unique": true, "unitRef": "U_iso4217USD", "xsiNil": "false" } }, "R63": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "body", "html" ], "baseRef": "flgt-10q_20210630.htm", "contextRef": "C_0001674930_20210630", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:Goodwill", "reportCount": 1, "unitRef": "U_iso4217USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100630 - Disclosure - Business Combination - Additional Information (Details)", "role": "http://fulgentdiagnostics.com/20210630/taxonomy/role/DisclosureBusinessCombinationAdditionalInformationDetails", "shortName": "Business Combination - Additional Information (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "p", "ix:continuation", "body", "html" ], "baseRef": "flgt-10q_20210630.htm", "contextRef": "C_0001674930_srtOwnershipAxis_flgtFFGeneBiotechMember_20170430", "decimals": "INF", "lang": null, "name": "us-gaap:MinorityInterestOwnershipPercentageByParent", "reportCount": 1, "unique": true, "unitRef": "U_xbrlipure", "xsiNil": "false" } }, "R64": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "body", "html" ], "baseRef": "flgt-10q_20210630.htm", "contextRef": "C_0001674930_20210630", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:Goodwill", "reportCount": 1, "unitRef": "U_iso4217USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100640 - Disclosure - Business Combination - Summary of Consideration Paid and Amount of Assets Acquired and Liabilities Assumed (Details)", "role": "http://fulgentdiagnostics.com/20210630/taxonomy/role/DisclosureBusinessCombinationSummaryOfConsiderationPaidAndAmountOfAssetsAcquiredAndLiabilitiesAssumedDetails", "shortName": "Business Combination - Summary of Consideration Paid and Amount of Assets Acquired and Liabilities Assumed (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "ix:continuation", "ix:continuation", "body", "html" ], "baseRef": "flgt-10q_20210630.htm", "contextRef": "C_0001674930_us-gaapBusinessAcquisitionAxis_flgtFFGeneBiotechMember_20170401_20170430", "decimals": "-3", "lang": null, "name": "us-gaap:PaymentsToAcquireBusinessesGross", "reportCount": 1, "unique": true, "unitRef": "U_iso4217USD", "xsiNil": "false" } }, "R65": { "firstAnchor": { "ancestors": [ "p", "flgt:EquityDistributionAgreementsDisclosureTextBlock", "body", "html" ], "baseRef": "flgt-10q_20210630.htm", "contextRef": "C_0001674930_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_us-gaapTypeOfArrangementAxis_flgtNovemberTwoThousandTwentyEquityDistributionAgreementMember_20210401_20210630", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction", "reportCount": 1, "unique": true, "unitRef": "U_xbrlishares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100650 - Disclosure - Equity Distribution Agreement - Additional Information (Details)", "role": "http://fulgentdiagnostics.com/20210630/taxonomy/role/DisclosureEquityDistributionAgreementAdditionalInformationDetails", "shortName": "Equity Distribution Agreement - Additional Information (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "flgt:EquityDistributionAgreementsDisclosureTextBlock", "body", "html" ], "baseRef": "flgt-10q_20210630.htm", "contextRef": "C_0001674930_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_us-gaapTypeOfArrangementAxis_flgtNovemberTwoThousandTwentyEquityDistributionAgreementMember_20210401_20210630", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction", "reportCount": 1, "unique": true, "unitRef": "U_xbrlishares", "xsiNil": "false" } }, "R66": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "body", "html" ], "baseRef": "flgt-10q_20210630.htm", "contextRef": "C_0001674930_20210630", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:Goodwill", "reportCount": 1, "unitRef": "U_iso4217USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100660 - Disclosure - Goodwill and Acquisition-Related Intangibles - Summaries of Goodwill and Acquisitions-Related Intangibles Balances (Details)", "role": "http://fulgentdiagnostics.com/20210630/taxonomy/role/DisclosureGoodwillAndAcquisitionRelatedIntangiblesSummariesOfGoodwillAndAcquisitionsRelatedIntangiblesBalancesDetails", "shortName": "Goodwill and Acquisition-Related Intangibles - Summaries of Goodwill and Acquisitions-Related Intangibles Balances (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "us-gaap:ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock", "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock", "body", "html" ], "baseRef": "flgt-10q_20210630.htm", "contextRef": "C_0001674930_us-gaapBusinessAcquisitionAxis_flgtFFGeneBiotechMember_us-gaapFiniteLivedIntangibleAssetsByMajorClassAxis_flgtRoyaltyFreeTechnologyMember_20210630", "decimals": "-3", "lang": null, "name": "us-gaap:FiniteLivedIntangibleAssetsGross", "reportCount": 1, "unique": true, "unitRef": "U_iso4217USD", "xsiNil": "false" } }, "R67": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "body", "html" ], "baseRef": "flgt-10q_20210630.htm", "contextRef": "C_0001674930_20210630", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:Goodwill", "reportCount": 1, "unitRef": "U_iso4217USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100670 - Disclosure - Goodwill and Acquisition-Related Intangibles - Additional Information (Details)", "role": "http://fulgentdiagnostics.com/20210630/taxonomy/role/DisclosureGoodwillAndAcquisitionRelatedIntangiblesAdditionalInformationDetails", "shortName": "Goodwill and Acquisition-Related Intangibles - Additional Information (Details)", "subGroupType": "details", "uniqueAnchor": null }, "R68": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "body", "html" ], "baseRef": "flgt-10q_20210630.htm", "contextRef": "C_0001674930_20210630", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:FiniteLivedIntangibleAssetsNet", "reportCount": 1, "unitRef": "U_iso4217USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100680 - Disclosure - Goodwill and Acquisition-Related Intangibles - Summary of Annual Amortization Expense For Acquisition-Related Intangibles (Details)", "role": "http://fulgentdiagnostics.com/20210630/taxonomy/role/DisclosureGoodwillAndAcquisitionRelatedIntangiblesSummaryOfAnnualAmortizationExpenseForAcquisitionRelatedIntangiblesDetails", "shortName": "Goodwill and Acquisition-Related Intangibles - Summary of Annual Amortization Expense For Acquisition-Related Intangibles (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock", "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock", "body", "html" ], "baseRef": "flgt-10q_20210630.htm", "contextRef": "C_0001674930_us-gaapBusinessAcquisitionAxis_flgtFFGeneBiotechMember_20210630", "decimals": "-3", "lang": null, "name": "us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear", "reportCount": 1, "unique": true, "unitRef": "U_iso4217USD", "xsiNil": "false" } }, "R69": { "firstAnchor": { "ancestors": [ "p", "us-gaap:SubsequentEventsTextBlock", "body", "html" ], "baseRef": "flgt-10q_20210630.htm", "contextRef": "C_0001674930_us-gaapSubsequentEventTypeAxis_us-gaapSubsequentEventMember_20210731", "decimals": "-5", "first": true, "lang": null, "name": "us-gaap:LongTermInvestments", "reportCount": 1, "unique": true, "unitRef": "U_iso4217USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100690 - Disclosure - Subsequent Events - Additional Information (Details)", "role": "http://fulgentdiagnostics.com/20210630/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails", "shortName": "Subsequent Events - Additional Information (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "us-gaap:SubsequentEventsTextBlock", "body", "html" ], "baseRef": "flgt-10q_20210630.htm", "contextRef": "C_0001674930_us-gaapSubsequentEventTypeAxis_us-gaapSubsequentEventMember_20210731", "decimals": "-5", "first": true, "lang": null, "name": "us-gaap:LongTermInvestments", "reportCount": 1, "unique": true, "unitRef": "U_iso4217USD", "xsiNil": "false" } }, "R7": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "body", "html" ], "baseRef": "flgt-10q_20210630.htm", "contextRef": "C_0001674930_us-gaapTypeOfArrangementAxis_flgtNovemberTwoThousandTwentyEquityDistributionAgreementMember_20210630", "decimals": "2", "first": true, "lang": null, "name": "us-gaap:SaleOfStockPricePerShare", "reportCount": 1, "unique": true, "unitRef": "U_iso4217USD_xbrlishares", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "100060 - Statement - Condensed Consolidated Statements of Stockholders' Equity (unaudited) (Parenthetical)", "role": "http://fulgentdiagnostics.com/20210630/taxonomy/role/StatementCondensedConsolidatedStatementsOfStockholdersEquityUnauditedParenthetical", "shortName": "Condensed Consolidated Statements of Stockholders' Equity (unaudited) (Parenthetical)", "subGroupType": "parenthetical", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "body", "html" ], "baseRef": "flgt-10q_20210630.htm", "contextRef": "C_0001674930_us-gaapTypeOfArrangementAxis_flgtNovemberTwoThousandTwentyEquityDistributionAgreementMember_20210630", "decimals": "2", "first": true, "lang": null, "name": "us-gaap:SaleOfStockPricePerShare", "reportCount": 1, "unique": true, "unitRef": "U_iso4217USD_xbrlishares", "xsiNil": "false" } }, "R8": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "body", "html" ], "baseRef": "flgt-10q_20210630.htm", "contextRef": "C_0001674930_20210101_20210630", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:ProfitLoss", "reportCount": 1, "unitRef": "U_iso4217USD", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "100070 - Statement - Condensed Consolidated Statements of Cash Flows (unaudited)", "role": "http://fulgentdiagnostics.com/20210630/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited", "shortName": "Condensed Consolidated Statements of Cash Flows (unaudited)", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "body", "html" ], "baseRef": "flgt-10q_20210630.htm", "contextRef": "C_0001674930_20210101_20210630", "decimals": "-3", "lang": null, "name": "us-gaap:ShareBasedCompensation", "reportCount": 1, "unique": true, "unitRef": "U_iso4217USD", "xsiNil": "false" } }, "R9": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "flgt-10q_20210630.htm", "contextRef": "C_0001674930_20210101_20210630", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100080 - Disclosure - Overview and Basis of Presentation", "role": "http://fulgentdiagnostics.com/20210630/taxonomy/role/DisclosureOverviewAndBasisOfPresentation", "shortName": "Overview and Basis of Presentation", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "flgt-10q_20210630.htm", "contextRef": "C_0001674930_20210101_20210630", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } } }, "segmentCount": 86, "tag": { "country_US": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "UNITED STATES", "terseLabel": "United States" } } }, "localname": "US", "nsuri": "http://xbrl.sec.gov/country/2020-01-31", "presentation": [ "http://fulgentdiagnostics.com/20210630/taxonomy/role/DisclosureReportingSegmentAndGeographicalInformationSummaryOfRevenueByGeographicRegionDetails" ], "xbrltype": "domainItemType" }, "dei_AmendmentFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.", "label": "Amendment Flag", "terseLabel": "Amendment Flag" } } }, "localname": "AmendmentFlag", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://fulgentdiagnostics.com/20210630/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_CityAreaCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Area code of city", "label": "City Area Code", "terseLabel": "City Area Code" } } }, "localname": "CityAreaCode", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://fulgentdiagnostics.com/20210630/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_CoverAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Cover page.", "label": "Cover [Abstract]" } } }, "localname": "CoverAbstract", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "xbrltype": "stringItemType" }, "dei_CurrentFiscalYearEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "End date of current fiscal year in the format --MM-DD.", "label": "Current Fiscal Year End Date", "terseLabel": "Current Fiscal Year End Date" } } }, "localname": "CurrentFiscalYearEndDate", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://fulgentdiagnostics.com/20210630/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "gMonthDayItemType" }, "dei_DocumentFiscalPeriodFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.", "label": "Document Fiscal Period Focus", "terseLabel": "Document Fiscal Period Focus" } } }, "localname": "DocumentFiscalPeriodFocus", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://fulgentdiagnostics.com/20210630/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "fiscalPeriodItemType" }, "dei_DocumentFiscalYearFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.", "label": "Document Fiscal Year Focus", "terseLabel": "Document Fiscal Year Focus" } } }, "localname": "DocumentFiscalYearFocus", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://fulgentdiagnostics.com/20210630/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "gYearItemType" }, "dei_DocumentPeriodEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented. If there is no historical data in the report, use the filing date. The format of the date is YYYY-MM-DD.", "label": "Document Period End Date", "terseLabel": "Document Period End Date" } } }, "localname": "DocumentPeriodEndDate", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://fulgentdiagnostics.com/20210630/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "dateItemType" }, "dei_DocumentQuarterlyReport": { "auth_ref": [ "r560" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as an quarterly report.", "label": "Document Quarterly Report", "terseLabel": "Document Quarterly Report" } } }, "localname": "DocumentQuarterlyReport", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://fulgentdiagnostics.com/20210630/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_DocumentTransitionReport": { "auth_ref": [ "r561" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as a transition report.", "label": "Document Transition Report", "terseLabel": "Document Transition Report" } } }, "localname": "DocumentTransitionReport", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://fulgentdiagnostics.com/20210630/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_DocumentType": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.", "label": "Document Type", "terseLabel": "Document Type" } } }, "localname": "DocumentType", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://fulgentdiagnostics.com/20210630/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "submissionTypeItemType" }, "dei_EntityAddressAddressLine1": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 1 such as Attn, Building Name, Street Name", "label": "Entity Address Address Line1", "terseLabel": "Entity Address, Address Line One" } } }, "localname": "EntityAddressAddressLine1", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://fulgentdiagnostics.com/20210630/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCityOrTown": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the City or Town", "label": "Entity Address City Or Town", "terseLabel": "Entity Address, City or Town" } } }, "localname": "EntityAddressCityOrTown", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://fulgentdiagnostics.com/20210630/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressPostalZipCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Code for the postal or zip code", "label": "Entity Address Postal Zip Code", "terseLabel": "Entity Address, Postal Zip Code" } } }, "localname": "EntityAddressPostalZipCode", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://fulgentdiagnostics.com/20210630/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressStateOrProvince": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the state or province.", "label": "Entity Address State Or Province", "terseLabel": "Entity Address, State or Province" } } }, "localname": "EntityAddressStateOrProvince", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://fulgentdiagnostics.com/20210630/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "stateOrProvinceItemType" }, "dei_EntityCentralIndexKey": { "auth_ref": [ "r562" ], "lang": { "en-us": { "role": { "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.", "label": "Entity Central Index Key", "terseLabel": "Entity Central Index Key" } } }, "localname": "EntityCentralIndexKey", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://fulgentdiagnostics.com/20210630/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "centralIndexKeyItemType" }, "dei_EntityCommonStockSharesOutstanding": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.", "label": "Entity Common Stock Shares Outstanding", "verboseLabel": "Entity Common Stock, Shares Outstanding" } } }, "localname": "EntityCommonStockSharesOutstanding", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://fulgentdiagnostics.com/20210630/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "sharesItemType" }, "dei_EntityCurrentReportingStatus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Current Reporting Status", "terseLabel": "Entity Current Reporting Status" } } }, "localname": "EntityCurrentReportingStatus", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://fulgentdiagnostics.com/20210630/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "yesNoItemType" }, "dei_EntityDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "All the names of the entities being reported upon in a document. Any legal structure used to conduct activities or to hold assets. Some examples of such structures are corporations, partnerships, limited liability companies, grantor trusts, and other trusts. This item does not include business and geographical segments which are included in the geographical or business segments domains.", "label": "Entity [Domain]", "terseLabel": "Entity" } } }, "localname": "EntityDomain", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://fulgentdiagnostics.com/20210630/taxonomy/role/DisclosureBusinessCombinationAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "dei_EntityEmergingGrowthCompany": { "auth_ref": [ "r562" ], "lang": { "en-us": { "role": { "documentation": "Indicate if registrant meets the emerging growth company criteria.", "label": "Entity Emerging Growth Company", "terseLabel": "Entity Emerging Growth Company" } } }, "localname": "EntityEmergingGrowthCompany", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://fulgentdiagnostics.com/20210630/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_EntityExTransitionPeriod": { "auth_ref": [ "r564" ], "lang": { "en-us": { "role": { "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.", "label": "Entity Ex Transition Period", "terseLabel": "Entity Ex Transition Period" } } }, "localname": "EntityExTransitionPeriod", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://fulgentdiagnostics.com/20210630/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_EntityFileNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.", "label": "Entity File Number", "terseLabel": "Entity File Number" } } }, "localname": "EntityFileNumber", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://fulgentdiagnostics.com/20210630/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "fileNumberItemType" }, "dei_EntityFilerCategory": { "auth_ref": [ "r562" ], "lang": { "en-us": { "role": { "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Filer Category", "verboseLabel": "Entity Filer Category" } } }, "localname": "EntityFilerCategory", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://fulgentdiagnostics.com/20210630/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "filerCategoryItemType" }, "dei_EntityIncorporationStateCountryCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Two-character EDGAR code representing the state or country of incorporation.", "label": "Entity Incorporation State Country Code", "terseLabel": "Entity Incorporation, State or Country Code" } } }, "localname": "EntityIncorporationStateCountryCode", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://fulgentdiagnostics.com/20210630/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "edgarStateCountryItemType" }, "dei_EntityInteractiveDataCurrent": { "auth_ref": [ "r563" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).", "label": "Entity Interactive Data Current", "terseLabel": "Entity Interactive Data Current" } } }, "localname": "EntityInteractiveDataCurrent", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://fulgentdiagnostics.com/20210630/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "yesNoItemType" }, "dei_EntityRegistrantName": { "auth_ref": [ "r562" ], "lang": { "en-us": { "role": { "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.", "label": "Entity Registrant Name", "terseLabel": "Entity Registrant Name" } } }, "localname": "EntityRegistrantName", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://fulgentdiagnostics.com/20210630/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityShellCompany": { "auth_ref": [ "r562" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.", "label": "Entity Shell Company", "terseLabel": "Entity Shell Company" } } }, "localname": "EntityShellCompany", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://fulgentdiagnostics.com/20210630/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_EntitySmallBusiness": { "auth_ref": [ "r562" ], "lang": { "en-us": { "role": { "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).", "label": "Entity Small Business", "terseLabel": "Entity Small Business" } } }, "localname": "EntitySmallBusiness", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://fulgentdiagnostics.com/20210630/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_EntityTaxIdentificationNumber": { "auth_ref": [ "r562" ], "lang": { "en-us": { "role": { "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.", "label": "Entity Tax Identification Number", "terseLabel": "Entity Tax Identification Number" } } }, "localname": "EntityTaxIdentificationNumber", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://fulgentdiagnostics.com/20210630/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "employerIdItemType" }, "dei_LegalEntityAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The set of legal entities associated with a report.", "label": "Legal Entity [Axis]", "terseLabel": "Legal Entity" } } }, "localname": "LegalEntityAxis", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://fulgentdiagnostics.com/20210630/taxonomy/role/DisclosureBusinessCombinationAdditionalInformationDetails" ], "xbrltype": "stringItemType" }, "dei_LocalPhoneNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Local phone number for entity.", "label": "Local Phone Number", "terseLabel": "Local Phone Number" } } }, "localname": "LocalPhoneNumber", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://fulgentdiagnostics.com/20210630/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_Security12bTitle": { "auth_ref": [ "r558" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(b) registered security.", "label": "Security12b Title", "terseLabel": "Title of 12(b) Security" } } }, "localname": "Security12bTitle", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://fulgentdiagnostics.com/20210630/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "securityTitleItemType" }, "dei_SecurityExchangeName": { "auth_ref": [ "r559" ], "lang": { "en-us": { "role": { "documentation": "Name of the Exchange on which a security is registered.", "label": "Security Exchange Name", "terseLabel": "Security Exchange Name" } } }, "localname": "SecurityExchangeName", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://fulgentdiagnostics.com/20210630/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "edgarExchangeCodeItemType" }, "dei_TradingSymbol": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Trading symbol of an instrument as listed on an exchange.", "label": "Trading Symbol", "terseLabel": "Trading Symbol" } } }, "localname": "TradingSymbol", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://fulgentdiagnostics.com/20210630/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "tradingSymbolItemType" }, "flgt_AHMCHealthcareIncMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "AHMC healthcare Inc.", "label": "A H M C Healthcare Inc [Member]", "terseLabel": "AHMC Healthcare Inc." } } }, "localname": "AHMCHealthcareIncMember", "nsuri": "http://fulgentdiagnostics.com/20210630", "presentation": [ "http://fulgentdiagnostics.com/20210630/taxonomy/role/DisclosureRelatedPartiesAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "flgt_AircraftMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Aircraft.", "label": "Aircraft [Member]", "terseLabel": "Aircraft" } } }, "localname": "AircraftMember", "nsuri": "http://fulgentdiagnostics.com/20210630", "presentation": [ "http://fulgentdiagnostics.com/20210630/taxonomy/role/DisclosureFixedAssetsMajorClassesOfFixedAssetsDetails" ], "xbrltype": "domainItemType" }, "flgt_AssetsNotYetPlacedInServiceMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Assets not yet placed in service.", "label": "Assets Not Yet Placed In Service [Member]", "terseLabel": "Assets Not Yet Placed in Service" } } }, "localname": "AssetsNotYetPlacedInServiceMember", "nsuri": "http://fulgentdiagnostics.com/20210630", "presentation": [ "http://fulgentdiagnostics.com/20210630/taxonomy/role/DisclosureFixedAssetsMajorClassesOfFixedAssetsDetails" ], "xbrltype": "domainItemType" }, "flgt_AutomobileMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Automobile.", "label": "Automobile [Member]", "terseLabel": "Automobile" } } }, "localname": "AutomobileMember", "nsuri": "http://fulgentdiagnostics.com/20210630", "presentation": [ "http://fulgentdiagnostics.com/20210630/taxonomy/role/DisclosureFixedAssetsMajorClassesOfFixedAssetsDetails" ], "xbrltype": "domainItemType" }, "flgt_AvailableForSaleDebtSecuritiesAndEquityTradingSecuritiesGrossUnrealizedLoss": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Available for sale debt securities and equity/trading securities gross unrealized loss.", "label": "Available For Sale Debt Securities And Equity Trading Securities Gross Unrealized Loss", "terseLabel": "Gross unrealized loss" } } }, "localname": "AvailableForSaleDebtSecuritiesAndEquityTradingSecuritiesGrossUnrealizedLoss", "nsuri": "http://fulgentdiagnostics.com/20210630", "presentation": [ "http://fulgentdiagnostics.com/20210630/taxonomy/role/DisclosureMarketableSecuritiesAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "flgt_AvailableForSaleDebtTradingSecuritiesAccumulatedGrossUnrealizedGainBeforeTax": { "auth_ref": [], "calculation": { "http://fulgentdiagnostics.com/20210630/taxonomy/role/DisclosureMarketableSecuritiesSummaryOfMarketableSecuritiesDetails": { "order": 10070.0, "parentTag": "flgt_AvailableForSaleSecuritiesAndTradingSecuritiesCost", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Available for sale debt trading securities accumulated gross unrealized gain before tax.", "label": "Available For Sale Debt Trading Securities Accumulated Gross Unrealized Gain Before Tax", "terseLabel": "Marketable securities, Unrealized Gains" } } }, "localname": "AvailableForSaleDebtTradingSecuritiesAccumulatedGrossUnrealizedGainBeforeTax", "nsuri": "http://fulgentdiagnostics.com/20210630", "presentation": [ "http://fulgentdiagnostics.com/20210630/taxonomy/role/DisclosureMarketableSecuritiesSummaryOfMarketableSecuritiesDetails" ], "xbrltype": "monetaryItemType" }, "flgt_AvailableForSaleDebtTradingSecuritiesAccumulatedGrossUnrealizedLossBeforeTax": { "auth_ref": [], "calculation": { "http://fulgentdiagnostics.com/20210630/taxonomy/role/DisclosureMarketableSecuritiesSummaryOfMarketableSecuritiesDetails": { "order": 10080.0, "parentTag": "flgt_AvailableForSaleSecuritiesAndTradingSecuritiesCost", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Available for sale debt trading securities accumulated gross unrealized gain before tax.", "label": "Available For Sale Debt Trading Securities Accumulated Gross Unrealized Loss Before Tax", "negatedLabel": "Marketable securities, Unrealized Losses" } } }, "localname": "AvailableForSaleDebtTradingSecuritiesAccumulatedGrossUnrealizedLossBeforeTax", "nsuri": "http://fulgentdiagnostics.com/20210630", "presentation": [ "http://fulgentdiagnostics.com/20210630/taxonomy/role/DisclosureMarketableSecuritiesSummaryOfMarketableSecuritiesDetails" ], "xbrltype": "monetaryItemType" }, "flgt_AvailableForSaleSecuritiesAndTradingSecurities": { "auth_ref": [], "calculation": { "http://fulgentdiagnostics.com/20210630/taxonomy/role/DisclosureMarketableSecuritiesSummaryOfMarketableSecuritiesDetails": { "order": 10090.0, "parentTag": "flgt_AvailableForSaleSecuritiesAndTradingSecuritiesCost", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Available for sale securities and trading securities.", "label": "Available For Sale Securities And Trading Securities", "terseLabel": "Marketable securities, Aggregate Fair Value" } } }, "localname": "AvailableForSaleSecuritiesAndTradingSecurities", "nsuri": "http://fulgentdiagnostics.com/20210630", "presentation": [ "http://fulgentdiagnostics.com/20210630/taxonomy/role/DisclosureMarketableSecuritiesSummaryOfMarketableSecuritiesDetails" ], "xbrltype": "monetaryItemType" }, "flgt_AvailableForSaleSecuritiesAndTradingSecuritiesCost": { "auth_ref": [], "calculation": { "http://fulgentdiagnostics.com/20210630/taxonomy/role/DisclosureMarketableSecuritiesSummaryOfMarketableSecuritiesDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Available for sale securities and trading securities cost.", "label": "Available For Sale Securities And Trading Securities Cost", "totalLabel": "Marketable securities, Amortized Cost Basis" } } }, "localname": "AvailableForSaleSecuritiesAndTradingSecuritiesCost", "nsuri": "http://fulgentdiagnostics.com/20210630", "presentation": [ "http://fulgentdiagnostics.com/20210630/taxonomy/role/DisclosureMarketableSecuritiesSummaryOfMarketableSecuritiesDetails" ], "xbrltype": "monetaryItemType" }, "flgt_AvailableForSaleSecuritiesDebtEquitySecuritiesAndTradingSecurities": { "auth_ref": [], "calculation": { "http://fulgentdiagnostics.com/20210630/taxonomy/role/DisclosureMarketableSecuritiesSummaryOfMarketableSecuritiesDetails": { "order": 10030.0, "parentTag": "flgt_AvailableForSaleSecuritiesDebtEquitySecuritiesAndTradingSecuritiesAmortizedCostBasis", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Available for sale securities debt equity securities and trading securities.", "label": "Available For Sale Securities Debt Equity Securities And Trading Securities", "terseLabel": "Marketable securities, Aggregate Fair Value" } } }, "localname": "AvailableForSaleSecuritiesDebtEquitySecuritiesAndTradingSecurities", "nsuri": "http://fulgentdiagnostics.com/20210630", "presentation": [ "http://fulgentdiagnostics.com/20210630/taxonomy/role/DisclosureMarketableSecuritiesSummaryOfMarketableSecuritiesDetails" ], "xbrltype": "monetaryItemType" }, "flgt_AvailableForSaleSecuritiesDebtEquitySecuritiesAndTradingSecuritiesAmortizedCostBasis": { "auth_ref": [], "calculation": { "http://fulgentdiagnostics.com/20210630/taxonomy/role/DisclosureMarketableSecuritiesSummaryOfMarketableSecuritiesDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Available for sale securities debt, equity securities and trading securities amortized cost basis.", "label": "Available For Sale Securities Debt Equity Securities And Trading Securities Amortized Cost Basis", "totalLabel": "Marketable securities, Amortized Cost Basis" } } }, "localname": "AvailableForSaleSecuritiesDebtEquitySecuritiesAndTradingSecuritiesAmortizedCostBasis", "nsuri": "http://fulgentdiagnostics.com/20210630", "presentation": [ "http://fulgentdiagnostics.com/20210630/taxonomy/role/DisclosureMarketableSecuritiesSummaryOfMarketableSecuritiesDetails" ], "xbrltype": "monetaryItemType" }, "flgt_AvailableForSaleSecuritiesDebtEquitySecuritiesAndTradingSecuritiesCurrent": { "auth_ref": [], "calculation": { "http://fulgentdiagnostics.com/20210630/taxonomy/role/StatementCondensedConsolidatedBalanceSheets": { "order": 10280.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Available for sale securities debt equity securities and trading securities current.", "label": "Available For Sale Securities Debt Equity Securities And Trading Securities Current", "terseLabel": "Marketable securities" } } }, "localname": "AvailableForSaleSecuritiesDebtEquitySecuritiesAndTradingSecuritiesCurrent", "nsuri": "http://fulgentdiagnostics.com/20210630", "presentation": [ "http://fulgentdiagnostics.com/20210630/taxonomy/role/StatementCondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "flgt_AvailableForSaleSecuritiesDebtEquitySecuritiesAndTradingSecuritiesUnrealizedGainBeforeTax": { "auth_ref": [], "calculation": { "http://fulgentdiagnostics.com/20210630/taxonomy/role/DisclosureMarketableSecuritiesSummaryOfMarketableSecuritiesDetails": { "order": 10010.0, "parentTag": "flgt_AvailableForSaleSecuritiesDebtEquitySecuritiesAndTradingSecuritiesAmortizedCostBasis", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Available for sale securities debt, equity securities and trading securities unrealized gain before tax.", "label": "Available For Sale Securities Debt Equity Securities And Trading Securities Unrealized Gain Before Tax", "terseLabel": "Marketable securities, Unrealized Gains" } } }, "localname": "AvailableForSaleSecuritiesDebtEquitySecuritiesAndTradingSecuritiesUnrealizedGainBeforeTax", "nsuri": "http://fulgentdiagnostics.com/20210630", "presentation": [ "http://fulgentdiagnostics.com/20210630/taxonomy/role/DisclosureMarketableSecuritiesSummaryOfMarketableSecuritiesDetails" ], "xbrltype": "monetaryItemType" }, "flgt_AvailableForSaleSecuritiesDebtEquitySecuritiesAndTradingSecuritiesUnrealizedLossBeforeTax": { "auth_ref": [], "calculation": { "http://fulgentdiagnostics.com/20210630/taxonomy/role/DisclosureMarketableSecuritiesSummaryOfMarketableSecuritiesDetails": { "order": 10020.0, "parentTag": "flgt_AvailableForSaleSecuritiesDebtEquitySecuritiesAndTradingSecuritiesAmortizedCostBasis", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Available for sale securities debt, equity securities and trading securities unrealized loss before tax.", "label": "Available For Sale Securities Debt Equity Securities And Trading Securities Unrealized Loss Before Tax", "negatedLabel": "Marketable securities, Unrealized Losses" } } }, "localname": "AvailableForSaleSecuritiesDebtEquitySecuritiesAndTradingSecuritiesUnrealizedLossBeforeTax", "nsuri": "http://fulgentdiagnostics.com/20210630", "presentation": [ "http://fulgentdiagnostics.com/20210630/taxonomy/role/DisclosureMarketableSecuritiesSummaryOfMarketableSecuritiesDetails" ], "xbrltype": "monetaryItemType" }, "flgt_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReagentsAndSupplies": { "auth_ref": [], "calculation": { "http://fulgentdiagnostics.com/20210630/taxonomy/role/DisclosureBusinessCombinationSummaryOfConsiderationPaidAndAmountOfAssetsAcquiredAndLiabilitiesAssumedDetails": { "order": 10050.0, "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Business combination, recognized identifiable assets acquired and liabilities assumed, current assets, reagents and supplies.", "label": "Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Current Assets Reagents And Supplies", "terseLabel": "Reagents and supplies" } } }, "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReagentsAndSupplies", "nsuri": "http://fulgentdiagnostics.com/20210630", "presentation": [ "http://fulgentdiagnostics.com/20210630/taxonomy/role/DisclosureBusinessCombinationSummaryOfConsiderationPaidAndAmountOfAssetsAcquiredAndLiabilitiesAssumedDetails" ], "xbrltype": "monetaryItemType" }, "flgt_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherTangibleAssets": { "auth_ref": [], "calculation": { "http://fulgentdiagnostics.com/20210630/taxonomy/role/DisclosureBusinessCombinationSummaryOfConsiderationPaidAndAmountOfAssetsAcquiredAndLiabilitiesAssumedDetails": { "order": 10070.0, "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Business combination, recognized identifiable assets acquired and liabilities assumed, other tangible assets.", "label": "Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Other Tangible Assets", "terseLabel": "Other tangible assets" } } }, "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherTangibleAssets", "nsuri": "http://fulgentdiagnostics.com/20210630", "presentation": [ "http://fulgentdiagnostics.com/20210630/taxonomy/role/DisclosureBusinessCombinationSummaryOfConsiderationPaidAndAmountOfAssetsAcquiredAndLiabilitiesAssumedDetails" ], "xbrltype": "monetaryItemType" }, "flgt_CashEquivalentsAndAvailableForSaleAndDebtSecurities": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Cash equivalents and available for sale debt and securities.", "label": "Cash Equivalents And Available For Sale And Debt Securities", "terseLabel": "Cash equivalent and available for sale debt securities" } } }, "localname": "CashEquivalentsAndAvailableForSaleAndDebtSecurities", "nsuri": "http://fulgentdiagnostics.com/20210630", "presentation": [ "http://fulgentdiagnostics.com/20210630/taxonomy/role/DisclosureMarketableSecuritiesAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "flgt_ClinicalInstitutionalContractsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Clinical institutional contracts.", "label": "Clinical Institutional Contracts [Member]", "terseLabel": "Clinical Institutional Contracts" } } }, "localname": "ClinicalInstitutionalContractsMember", "nsuri": "http://fulgentdiagnostics.com/20210630", "presentation": [ "http://fulgentdiagnostics.com/20210630/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesSummaryOfRevenueFromContractsWithCustomersByPayorTypeDetails" ], "xbrltype": "domainItemType" }, "flgt_ClinicalInsuranceContractsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Clinical insurance contracts.", "label": "Clinical Insurance Contracts [Member]", "terseLabel": "Clinical Insurance Contracts" } } }, "localname": "ClinicalInsuranceContractsMember", "nsuri": "http://fulgentdiagnostics.com/20210630", "presentation": [ "http://fulgentdiagnostics.com/20210630/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesSummaryOfRevenueFromContractsWithCustomersByPayorTypeDetails" ], "xbrltype": "domainItemType" }, "flgt_ClinicalPatientContractsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Clinical patients contracts.", "label": "Clinical Patient Contracts [Member]", "terseLabel": "Clinical Patient Contracts" } } }, "localname": "ClinicalPatientContractsMember", "nsuri": "http://fulgentdiagnostics.com/20210630", "presentation": [ "http://fulgentdiagnostics.com/20210630/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesSummaryOfRevenueFromContractsWithCustomersByPayorTypeDetails" ], "xbrltype": "domainItemType" }, "flgt_CustomerDeposit": { "auth_ref": [], "calculation": { "http://fulgentdiagnostics.com/20210630/taxonomy/role/StatementCondensedConsolidatedBalanceSheets": { "order": 10180.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Customer deposit.", "label": "Customer Deposit", "terseLabel": "Customer deposit" } } }, "localname": "CustomerDeposit", "nsuri": "http://fulgentdiagnostics.com/20210630", "presentation": [ "http://fulgentdiagnostics.com/20210630/taxonomy/role/StatementCondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "flgt_CustomerDepositPolicyTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Customer deposit.", "label": "Customer Deposit Policy [Text Block]", "terseLabel": "Customer Deposit" } } }, "localname": "CustomerDepositPolicyTextBlock", "nsuri": "http://fulgentdiagnostics.com/20210630", "presentation": [ "http://fulgentdiagnostics.com/20210630/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "flgt_CustomerOneMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Customer one.", "label": "Customer One [Member]", "terseLabel": "Customer One" } } }, "localname": "CustomerOneMember", "nsuri": "http://fulgentdiagnostics.com/20210630", "presentation": [ "http://fulgentdiagnostics.com/20210630/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "flgt_CustomerTwoMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Customer two.", "label": "Customer Two [Member]", "terseLabel": "Customer Two" } } }, "localname": "CustomerTwoMember", "nsuri": "http://fulgentdiagnostics.com/20210630", "presentation": [ "http://fulgentdiagnostics.com/20210630/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "flgt_CytometrySpecialistsIncMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Cytometry Specialists, Inc.", "label": "Cytometry Specialists Inc [Member]", "terseLabel": "Cytometry Specialists, Inc" } } }, "localname": "CytometrySpecialistsIncMember", "nsuri": "http://fulgentdiagnostics.com/20210630", "presentation": [ "http://fulgentdiagnostics.com/20210630/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "flgt_DebtCommitmentsAndContingenciesDisclosureAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Debt, commitments and contingencies disclosure.", "label": "Debt Commitments And Contingencies Disclosure [Abstract]" } } }, "localname": "DebtCommitmentsAndContingenciesDisclosureAbstract", "nsuri": "http://fulgentdiagnostics.com/20210630", "xbrltype": "stringItemType" }, "flgt_DebtCommitmentsAndContingenciesDisclosureTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Debt, commitments and contingencies disclosure.", "label": "Debt Commitments And Contingencies Disclosure [Text Block]", "terseLabel": "Debt, Commitments and Contingencies" } } }, "localname": "DebtCommitmentsAndContingenciesDisclosureTextBlock", "nsuri": "http://fulgentdiagnostics.com/20210630", "presentation": [ "http://fulgentdiagnostics.com/20210630/taxonomy/role/DisclosureDebtCommitmentsAndContingencies" ], "xbrltype": "textBlockItemType" }, "flgt_DebtCommitmentsAndContingenciesLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Debt, commitments and contingencies.", "label": "Debt Commitments And Contingencies [Line Items]", "terseLabel": "Debt, Commitments and Contingencies [Line Items]" } } }, "localname": "DebtCommitmentsAndContingenciesLineItems", "nsuri": "http://fulgentdiagnostics.com/20210630", "presentation": [ "http://fulgentdiagnostics.com/20210630/taxonomy/role/DisclosureDebtCommitmentsAndContingenciesAdditionalInformationDetails" ], "xbrltype": "stringItemType" }, "flgt_DebtCommitmentsAndContingenciesTable": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Debt, commitments and contingencies.", "label": "Debt Commitments And Contingencies [Table]", "terseLabel": "Debt Commitments And Contingencies [Table]" } } }, "localname": "DebtCommitmentsAndContingenciesTable", "nsuri": "http://fulgentdiagnostics.com/20210630", "presentation": [ "http://fulgentdiagnostics.com/20210630/taxonomy/role/DisclosureDebtCommitmentsAndContingenciesAdditionalInformationDetails" ], "xbrltype": "stringItemType" }, "flgt_DebtInstrumentInterestRateAtBeginningOfPeriod": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Debt Instrument Interest Rate at Beginning of Period.", "label": "Debt Instrument Interest Rate At Beginning Of Period", "terseLabel": "Interest on loan withdrawn from margin account" } } }, "localname": "DebtInstrumentInterestRateAtBeginningOfPeriod", "nsuri": "http://fulgentdiagnostics.com/20210630", "presentation": [ "http://fulgentdiagnostics.com/20210630/taxonomy/role/DisclosureDebtCommitmentsAndContingenciesAdditionalInformationDetails" ], "xbrltype": "percentItemType" }, "flgt_DebtInstrumentInterestRateAtEndOfPeriod": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Debt instrument interest rate at end of period.", "label": "Debt Instrument Interest Rate At End Of Period", "terseLabel": "Interest rate" } } }, "localname": "DebtInstrumentInterestRateAtEndOfPeriod", "nsuri": "http://fulgentdiagnostics.com/20210630", "presentation": [ "http://fulgentdiagnostics.com/20210630/taxonomy/role/DisclosureDebtCommitmentsAndContingenciesAdditionalInformationDetails" ], "xbrltype": "percentItemType" }, "flgt_DebtSecurityInvestmentOutstandingBorrowingAmount": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Debt security investment outstanding borrowing amount.", "label": "Debt Security Investment Outstanding Borrowing Amount", "terseLabel": "Debt security investment outstanding borrowing amount" } } }, "localname": "DebtSecurityInvestmentOutstandingBorrowingAmount", "nsuri": "http://fulgentdiagnostics.com/20210630", "presentation": [ "http://fulgentdiagnostics.com/20210630/taxonomy/role/DisclosureDebtCommitmentsAndContingenciesAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "flgt_EquityDistributionAgreementsDisclosureTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Equity distribution agreements disclosure.", "label": "Equity Distribution Agreements Disclosure [Text Block]", "terseLabel": "Equity Distribution Agreement" } } }, "localname": "EquityDistributionAgreementsDisclosureTextBlock", "nsuri": "http://fulgentdiagnostics.com/20210630", "presentation": [ "http://fulgentdiagnostics.com/20210630/taxonomy/role/DisclosureEquityDistributionAgreement" ], "xbrltype": "textBlockItemType" }, "flgt_EquityDistributionAgreementsLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Equity distribution agreements.", "label": "Equity Distribution Agreements [Line Items]", "terseLabel": "Equity Distribution Agreements [Line Items]" } } }, "localname": "EquityDistributionAgreementsLineItems", "nsuri": "http://fulgentdiagnostics.com/20210630", "presentation": [ "http://fulgentdiagnostics.com/20210630/taxonomy/role/DisclosureEquityDistributionAgreementAdditionalInformationDetails" ], "xbrltype": "stringItemType" }, "flgt_EquityDistributionAgreementsTable": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Equity distribution agreements.", "label": "Equity Distribution Agreements [Table]", "terseLabel": "Equity Distribution Agreements [Table]" } } }, "localname": "EquityDistributionAgreementsTable", "nsuri": "http://fulgentdiagnostics.com/20210630", "presentation": [ "http://fulgentdiagnostics.com/20210630/taxonomy/role/DisclosureEquityDistributionAgreementAdditionalInformationDetails" ], "xbrltype": "stringItemType" }, "flgt_EquityOfferingPrice": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Equity offering price.", "label": "Equity Offering Price", "terseLabel": "Aggregate offering price" } } }, "localname": "EquityOfferingPrice", "nsuri": "http://fulgentdiagnostics.com/20210630", "presentation": [ "http://fulgentdiagnostics.com/20210630/taxonomy/role/DisclosureEquityDistributionAgreementAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "flgt_EquitySecuritiesFvNiAccumulatedGrossUnrealizedGainBeforeTax": { "auth_ref": [], "calculation": { "http://fulgentdiagnostics.com/20210630/taxonomy/role/DisclosureMarketableSecuritiesSummaryOfMarketableSecuritiesDetails": { "order": 10040.0, "parentTag": "us-gaap_EquitySecuritiesFvNiCost", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Equity Securities Fv Ni Accumulated Gross Unrealized Gain Before Tax.", "label": "Equity Securities Fv Ni Accumulated Gross Unrealized Gain Before Tax", "terseLabel": "Marketable securities, Unrealized Gains" } } }, "localname": "EquitySecuritiesFvNiAccumulatedGrossUnrealizedGainBeforeTax", "nsuri": "http://fulgentdiagnostics.com/20210630", "presentation": [ "http://fulgentdiagnostics.com/20210630/taxonomy/role/DisclosureMarketableSecuritiesSummaryOfMarketableSecuritiesDetails" ], "xbrltype": "monetaryItemType" }, "flgt_EquitySecuritiesFvNiAccumulatedGrossUnrealizedLossBeforeTax": { "auth_ref": [], "calculation": { "http://fulgentdiagnostics.com/20210630/taxonomy/role/DisclosureMarketableSecuritiesSummaryOfMarketableSecuritiesDetails": { "order": 10050.0, "parentTag": "us-gaap_EquitySecuritiesFvNiCost", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Equity securities fv ni accumulated gross unrealized loss before tax.", "label": "Equity Securities Fv Ni Accumulated Gross Unrealized Loss Before Tax", "negatedLabel": "Marketable securities, Unrealized Losses" } } }, "localname": "EquitySecuritiesFvNiAccumulatedGrossUnrealizedLossBeforeTax", "nsuri": "http://fulgentdiagnostics.com/20210630", "presentation": [ "http://fulgentdiagnostics.com/20210630/taxonomy/role/DisclosureMarketableSecuritiesSummaryOfMarketableSecuritiesDetails" ], "xbrltype": "monetaryItemType" }, "flgt_FFGeneBiotechMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "FF Gene Biotech Member.", "label": "F F Gene Biotech [Member]", "terseLabel": "FF Gene Biotech" } } }, "localname": "FFGeneBiotechMember", "nsuri": "http://fulgentdiagnostics.com/20210630", "presentation": [ "http://fulgentdiagnostics.com/20210630/taxonomy/role/DisclosureBusinessCombinationAdditionalInformationDetails", "http://fulgentdiagnostics.com/20210630/taxonomy/role/DisclosureBusinessCombinationSummaryOfConsiderationPaidAndAmountOfAssetsAcquiredAndLiabilitiesAssumedDetails", "http://fulgentdiagnostics.com/20210630/taxonomy/role/DisclosureBusinessCombinationTables", "http://fulgentdiagnostics.com/20210630/taxonomy/role/DisclosureDebtCommitmentsAndContingenciesAdditionalInformationDetails", "http://fulgentdiagnostics.com/20210630/taxonomy/role/DisclosureGoodwillAndAcquisitionRelatedIntangiblesAdditionalInformationDetails", "http://fulgentdiagnostics.com/20210630/taxonomy/role/DisclosureGoodwillAndAcquisitionRelatedIntangiblesSummariesOfGoodwillAndAcquisitionsRelatedIntangiblesBalancesDetails", "http://fulgentdiagnostics.com/20210630/taxonomy/role/DisclosureGoodwillAndAcquisitionRelatedIntangiblesSummaryOfAnnualAmortizationExpenseForAcquisitionRelatedIntangiblesDetails" ], "xbrltype": "domainItemType" }, "flgt_FairValueAssetsTransfersBetweenLevelsAmount": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Fair value assets, transfers between levels, amount.", "label": "Fair Value Assets Transfers Between Levels Amount", "terseLabel": "Fair value assets, transfers between levels, amount" } } }, "localname": "FairValueAssetsTransfersBetweenLevelsAmount", "nsuri": "http://fulgentdiagnostics.com/20210630", "presentation": [ "http://fulgentdiagnostics.com/20210630/taxonomy/role/DisclosureFairValueMeasurementsAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "flgt_FulgentPharmaLimitedLiabilityCompanyMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Fulgent Pharma Limited Liability Company.", "label": "Fulgent Pharma Limited Liability Company [Member]", "terseLabel": "Fulgent Pharma LLC" } } }, "localname": "FulgentPharmaLimitedLiabilityCompanyMember", "nsuri": "http://fulgentdiagnostics.com/20210630", "presentation": [ "http://fulgentdiagnostics.com/20210630/taxonomy/role/DisclosureRelatedPartiesAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "flgt_GainOnEquityMethodInvestment": { "auth_ref": [], "calculation": { "http://fulgentdiagnostics.com/20210630/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited": { "order": 10270.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 }, "http://fulgentdiagnostics.com/20210630/taxonomy/role/StatementCondensedConsolidatedStatementsOfOperationsUnaudited": { "order": 10040.0, "parentTag": "us-gaap_ProfitLoss", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Gain on equity method investment.", "label": "Gain On Equity Method Investment", "negatedLabel": "Gain on equity method investment", "terseLabel": "Gain on equity method investment" } } }, "localname": "GainOnEquityMethodInvestment", "nsuri": "http://fulgentdiagnostics.com/20210630", "presentation": [ "http://fulgentdiagnostics.com/20210630/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited", "http://fulgentdiagnostics.com/20210630/taxonomy/role/StatementCondensedConsolidatedStatementsOfOperationsUnaudited" ], "xbrltype": "monetaryItemType" }, "flgt_GeneralEquipmentMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "General equipment.", "label": "General Equipment [Member]", "terseLabel": "General Equipment" } } }, "localname": "GeneralEquipmentMember", "nsuri": "http://fulgentdiagnostics.com/20210630", "presentation": [ "http://fulgentdiagnostics.com/20210630/taxonomy/role/DisclosureFixedAssetsMajorClassesOfFixedAssetsDetails" ], "xbrltype": "domainItemType" }, "flgt_GeneticSequencingServiceMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Genetic sequencing service.", "label": "Genetic Sequencing Service [Member]", "terseLabel": "Genetic Sequencing Services" } } }, "localname": "GeneticSequencingServiceMember", "nsuri": "http://fulgentdiagnostics.com/20210630", "presentation": [ "http://fulgentdiagnostics.com/20210630/taxonomy/role/DisclosureRelatedPartiesAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "flgt_GoodwillAndIntangibleAssetsLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Goodwill and intangible assets.", "label": "Goodwill And Intangible Assets [Line Items]", "terseLabel": "Goodwill And Intangible Assets [Line Items]" } } }, "localname": "GoodwillAndIntangibleAssetsLineItems", "nsuri": "http://fulgentdiagnostics.com/20210630", "presentation": [ "http://fulgentdiagnostics.com/20210630/taxonomy/role/DisclosureGoodwillAndAcquisitionRelatedIntangiblesAdditionalInformationDetails", "http://fulgentdiagnostics.com/20210630/taxonomy/role/DisclosureGoodwillAndAcquisitionRelatedIntangiblesSummariesOfGoodwillAndAcquisitionsRelatedIntangiblesBalancesDetails" ], "xbrltype": "stringItemType" }, "flgt_GoodwillAndIntangibleAssetsTable": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Goodwill and intangible assets.", "label": "Goodwill And Intangible Assets [Table]", "terseLabel": "Goodwill And Intangible Assets [Table]" } } }, "localname": "GoodwillAndIntangibleAssetsTable", "nsuri": "http://fulgentdiagnostics.com/20210630", "presentation": [ "http://fulgentdiagnostics.com/20210630/taxonomy/role/DisclosureGoodwillAndAcquisitionRelatedIntangiblesAdditionalInformationDetails", "http://fulgentdiagnostics.com/20210630/taxonomy/role/DisclosureGoodwillAndAcquisitionRelatedIntangiblesSummariesOfGoodwillAndAcquisitionsRelatedIntangiblesBalancesDetails" ], "xbrltype": "stringItemType" }, "flgt_HoldingIncomeLossOnEquitySecurities": { "auth_ref": [], "calculation": { "http://fulgentdiagnostics.com/20210630/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited": { "order": 10250.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Holding income loss on equity securities.", "label": "Holding Income Loss On Equity Securities", "negatedLabel": "Holding loss on equity securities" } } }, "localname": "HoldingIncomeLossOnEquitySecurities", "nsuri": "http://fulgentdiagnostics.com/20210630", "presentation": [ "http://fulgentdiagnostics.com/20210630/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "flgt_IncomeBeforeGainOnEquityMethodInvestmentAndEquityLossInInvestee": { "auth_ref": [], "calculation": { "http://fulgentdiagnostics.com/20210630/taxonomy/role/StatementCondensedConsolidatedStatementsOfOperationsUnaudited": { "order": 10030.0, "parentTag": "us-gaap_ProfitLoss", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Income before gain on equity method investment and equity loss in investee.", "label": "Income Before Gain On Equity Method Investment And Equity Loss In Investee", "totalLabel": "Income before gain on equity method investment and equity loss in investee" } } }, "localname": "IncomeBeforeGainOnEquityMethodInvestmentAndEquityLossInInvestee", "nsuri": "http://fulgentdiagnostics.com/20210630", "presentation": [ "http://fulgentdiagnostics.com/20210630/taxonomy/role/StatementCondensedConsolidatedStatementsOfOperationsUnaudited" ], "xbrltype": "monetaryItemType" }, "flgt_IncreaseDecreaseInCustomerDeposit": { "auth_ref": [], "calculation": { "http://fulgentdiagnostics.com/20210630/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited": { "order": 10350.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Increase (decrease) in customer deposit.", "label": "Increase Decrease In Customer Deposit", "terseLabel": "Customer deposit" } } }, "localname": "IncreaseDecreaseInCustomerDeposit", "nsuri": "http://fulgentdiagnostics.com/20210630", "presentation": [ "http://fulgentdiagnostics.com/20210630/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "flgt_IncreaseDecreaseInOperatingLeaseLiabilities": { "auth_ref": [], "calculation": { "http://fulgentdiagnostics.com/20210630/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited": { "order": 10360.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Increase (decrease) in operating lease liabilities.", "label": "Increase Decrease In Operating Lease Liabilities", "terseLabel": "Operating lease liabilities" } } }, "localname": "IncreaseDecreaseInOperatingLeaseLiabilities", "nsuri": "http://fulgentdiagnostics.com/20210630", "presentation": [ "http://fulgentdiagnostics.com/20210630/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "flgt_IncreaseInEquityMethodInvestmentOwnershipPercentage": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Increase in equity method investment ownership percentage.", "label": "Increase In Equity Method Investment Ownership Percentage", "terseLabel": "Percentage of effective investment" } } }, "localname": "IncreaseInEquityMethodInvestmentOwnershipPercentage", "nsuri": "http://fulgentdiagnostics.com/20210630", "presentation": [ "http://fulgentdiagnostics.com/20210630/taxonomy/role/DisclosureBusinessCombinationAdditionalInformationDetails" ], "xbrltype": "percentItemType" }, "flgt_InvestmentMarginLiabilitiesCurrent": { "auth_ref": [], "calculation": { "http://fulgentdiagnostics.com/20210630/taxonomy/role/StatementCondensedConsolidatedBalanceSheets": { "order": 10190.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Investment margin liabilities current.", "label": "Investment Margin Liabilities Current", "terseLabel": "Investment margin loan", "verboseLabel": "Outstanding borrowing amount" } } }, "localname": "InvestmentMarginLiabilitiesCurrent", "nsuri": "http://fulgentdiagnostics.com/20210630", "presentation": [ "http://fulgentdiagnostics.com/20210630/taxonomy/role/DisclosureDebtCommitmentsAndContingenciesAdditionalInformationDetails", "http://fulgentdiagnostics.com/20210630/taxonomy/role/DisclosureMarketableSecuritiesAdditionalInformationDetails", "http://fulgentdiagnostics.com/20210630/taxonomy/role/StatementCondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "flgt_LeaseExpirationMonthAndYear": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Lease, expiration month and year.", "label": "Lease Expiration Month And Year", "terseLabel": "Lease, expiration month and year" } } }, "localname": "LeaseExpirationMonthAndYear", "nsuri": "http://fulgentdiagnostics.com/20210630", "presentation": [ "http://fulgentdiagnostics.com/20210630/taxonomy/role/DisclosureLeasesAdditionalInformationDetails" ], "xbrltype": "gYearMonthItemType" }, "flgt_LesseeOperatingLeaseExtendedLeaseTermExpirationDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Lessee operating lease extended lease term expiration date.", "label": "Lessee Operating Lease Extended Lease Term Expiration Date", "terseLabel": "Lessee operating lease extended lease term expiration date" } } }, "localname": "LesseeOperatingLeaseExtendedLeaseTermExpirationDate", "nsuri": "http://fulgentdiagnostics.com/20210630", "presentation": [ "http://fulgentdiagnostics.com/20210630/taxonomy/role/DisclosureLeasesAdditionalInformationDetails" ], "xbrltype": "dateItemType" }, "flgt_LessorAndLesseeOperatingLeasesTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Lessor and lessee. operating leases.", "label": "Lessor And Lessee Operating Leases [Text Block]", "terseLabel": "Leases" } } }, "localname": "LessorAndLesseeOperatingLeasesTextBlock", "nsuri": "http://fulgentdiagnostics.com/20210630", "presentation": [ "http://fulgentdiagnostics.com/20210630/taxonomy/role/DisclosureLeases" ], "xbrltype": "textBlockItemType" }, "flgt_LessorOperatingLeaseRemainingTermOfContractIncludingRenewalOptions": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Lessor, operating lease, remaining term of contract including renewal options.", "label": "Lessor Operating Lease Remaining Term Of Contract Including Renewal Options", "terseLabel": "Remaining terms including renewal options" } } }, "localname": "LessorOperatingLeaseRemainingTermOfContractIncludingRenewalOptions", "nsuri": "http://fulgentdiagnostics.com/20210630", "presentation": [ "http://fulgentdiagnostics.com/20210630/taxonomy/role/DisclosureLeasesAdditionalInformationDetails" ], "xbrltype": "durationItemType" }, "flgt_LongTermMarketableSecuritiesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Long-term marketable securities.", "label": "Long Term Marketable Securities [Member]", "terseLabel": "Long-Term Marketable Securities" } } }, "localname": "LongTermMarketableSecuritiesMember", "nsuri": "http://fulgentdiagnostics.com/20210630", "presentation": [ "http://fulgentdiagnostics.com/20210630/taxonomy/role/DisclosureMarketableSecuritiesSummaryOfMarketableSecuritiesDetails" ], "xbrltype": "domainItemType" }, "flgt_MarginAccountBorrowingMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Margin account borrowing.", "label": "Margin Account Borrowing [Member]", "terseLabel": "Margin Account Borrowing" } } }, "localname": "MarginAccountBorrowingMember", "nsuri": "http://fulgentdiagnostics.com/20210630", "presentation": [ "http://fulgentdiagnostics.com/20210630/taxonomy/role/DisclosureMarketableSecuritiesAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "flgt_MarketableSecuritiesDueAfterFiveYearsThroughTenYearsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Marketable securities due after five years through ten years.", "label": "Marketable Securities Due After Five Years Through Ten Years [Member]", "terseLabel": "Marketable Securities due After 5 Year through 10 Years" } } }, "localname": "MarketableSecuritiesDueAfterFiveYearsThroughTenYearsMember", "nsuri": "http://fulgentdiagnostics.com/20210630", "presentation": [ "http://fulgentdiagnostics.com/20210630/taxonomy/role/DisclosureMarketableSecuritiesSummaryOfMarketableSecuritiesDetails" ], "xbrltype": "domainItemType" }, "flgt_MarketableSecuritiesDueAfterOneYearThroughFiveYearsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Marketable securities due after one year through five years.", "label": "Marketable Securities Due After One Year Through Five Years [Member]", "terseLabel": "Marketable Securities due After 1 Year through 5 Years" } } }, "localname": "MarketableSecuritiesDueAfterOneYearThroughFiveYearsMember", "nsuri": "http://fulgentdiagnostics.com/20210630", "presentation": [ "http://fulgentdiagnostics.com/20210630/taxonomy/role/DisclosureMarketableSecuritiesSummaryOfMarketableSecuritiesDetails" ], "xbrltype": "domainItemType" }, "flgt_MarketableSecuritiesInterestReceivableCurrent": { "auth_ref": [], "calculation": { "http://fulgentdiagnostics.com/20210630/taxonomy/role/DisclosureOtherSignificantBalanceSheetAccountsScheduleOfOtherCurrentAssetsDetails": { "order": 10030.0, "parentTag": "us-gaap_OtherAssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Marketable securities interest receivable current.", "label": "Marketable Securities Interest Receivable Current", "terseLabel": "Marketable securities interest receivable" } } }, "localname": "MarketableSecuritiesInterestReceivableCurrent", "nsuri": "http://fulgentdiagnostics.com/20210630", "presentation": [ "http://fulgentdiagnostics.com/20210630/taxonomy/role/DisclosureOtherSignificantBalanceSheetAccountsScheduleOfOtherCurrentAssetsDetails" ], "xbrltype": "monetaryItemType" }, "flgt_MeasurementInputDiscountOwedToMarketParticipantAcquisitionPremiumMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Measurement input discount owed to market participant acquisition premium.", "label": "Measurement Input Discount Owed To Market Participant Acquisition Premium [Member]", "terseLabel": "Discount Owed to Market Participant Acquisition Premium" } } }, "localname": "MeasurementInputDiscountOwedToMarketParticipantAcquisitionPremiumMember", "nsuri": "http://fulgentdiagnostics.com/20210630", "presentation": [ "http://fulgentdiagnostics.com/20210630/taxonomy/role/DisclosureBusinessCombinationAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "flgt_MedicalLabEquipmentMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Medical lab equipment.", "label": "Medical Lab Equipment [Member]", "terseLabel": "Medical Lab Equipment" } } }, "localname": "MedicalLabEquipmentMember", "nsuri": "http://fulgentdiagnostics.com/20210630", "presentation": [ "http://fulgentdiagnostics.com/20210630/taxonomy/role/DisclosureDebtCommitmentsAndContingenciesAdditionalInformationDetails", "http://fulgentdiagnostics.com/20210630/taxonomy/role/DisclosureFixedAssetsMajorClassesOfFixedAssetsDetails" ], "xbrltype": "domainItemType" }, "flgt_MedicalLabFurnitureMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Medical lab furniture.", "label": "Medical Lab Furniture [Member]", "terseLabel": "Medical Lab Furniture" } } }, "localname": "MedicalLabFurnitureMember", "nsuri": "http://fulgentdiagnostics.com/20210630", "presentation": [ "http://fulgentdiagnostics.com/20210630/taxonomy/role/DisclosureDebtCommitmentsAndContingenciesAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "flgt_NoncashLeaseExpense": { "auth_ref": [], "calculation": { "http://fulgentdiagnostics.com/20210630/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited": { "order": 10190.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Noncash lease expense.", "label": "Noncash Lease Expense", "terseLabel": "Noncash lease expense" } } }, "localname": "NoncashLeaseExpense", "nsuri": "http://fulgentdiagnostics.com/20210630", "presentation": [ "http://fulgentdiagnostics.com/20210630/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "flgt_NoncashOrPartNoncashPublicOfferingCostsIncludedInAccountsPayable": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Noncash or part noncash public offering costs included in accounts payable.", "label": "Noncash Or Part Noncash Public Offering Costs Included In Accounts Payable", "terseLabel": "Public offerings costs included in accounts payable" } } }, "localname": "NoncashOrPartNoncashPublicOfferingCostsIncludedInAccountsPayable", "nsuri": "http://fulgentdiagnostics.com/20210630", "presentation": [ "http://fulgentdiagnostics.com/20210630/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "flgt_NovemberTwoThousandTwentyEquityDistributionAgreementMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "November two thousand twenty equity distribution agreement.", "label": "November Two Thousand Twenty Equity Distribution Agreement [Member]", "terseLabel": "November 2020 Equity Distribution Agreement" } } }, "localname": "NovemberTwoThousandTwentyEquityDistributionAgreementMember", "nsuri": "http://fulgentdiagnostics.com/20210630", "presentation": [ "http://fulgentdiagnostics.com/20210630/taxonomy/role/DisclosureEquityDistributionAgreementAdditionalInformationDetails", "http://fulgentdiagnostics.com/20210630/taxonomy/role/StatementCondensedConsolidatedStatementsOfStockholdersEquityUnauditedParenthetical" ], "xbrltype": "domainItemType" }, "flgt_NumberOfCustomers": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of customers.", "label": "Number Of Customers", "terseLabel": "Number of customers" } } }, "localname": "NumberOfCustomers", "nsuri": "http://fulgentdiagnostics.com/20210630", "presentation": [ "http://fulgentdiagnostics.com/20210630/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails" ], "xbrltype": "integerItemType" }, "flgt_OperatingLeaseRightOfUseAssetsReducedDueToLeaseModification": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Operating lease right-of-use assets reduced due to lease modification.", "label": "Operating Lease Right Of Use Assets Reduced Due To Lease Modification", "terseLabel": "Operating lease right-of-use assets reduced due to lease modification" } } }, "localname": "OperatingLeaseRightOfUseAssetsReducedDueToLeaseModification", "nsuri": "http://fulgentdiagnostics.com/20210630", "presentation": [ "http://fulgentdiagnostics.com/20210630/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "flgt_OperatingLeasesTermOfExpiration": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Operating leases term of expiration.", "label": "Operating Leases Term Of Expiration", "terseLabel": "Operating leases term of expiration" } } }, "localname": "OperatingLeasesTermOfExpiration", "nsuri": "http://fulgentdiagnostics.com/20210630", "presentation": [ "http://fulgentdiagnostics.com/20210630/taxonomy/role/DisclosureLeasesAdditionalInformationDetails" ], "xbrltype": "gYearMonthItemType" }, "flgt_PaymentsForClosingOfEscrowFinancedUnderMarginLoan": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Payments for closing of escrow, financed under margin loan.", "label": "Payments For Closing Of Escrow Financed Under Margin Loan", "terseLabel": "Payments for closing of escrow, financed under margin loan" } } }, "localname": "PaymentsForClosingOfEscrowFinancedUnderMarginLoan", "nsuri": "http://fulgentdiagnostics.com/20210630", "presentation": [ "http://fulgentdiagnostics.com/20210630/taxonomy/role/DisclosureDebtCommitmentsAndContingenciesAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "flgt_PayrollLiabilitiesCurrent": { "auth_ref": [], "calculation": { "http://fulgentdiagnostics.com/20210630/taxonomy/role/DisclosureOtherSignificantBalanceSheetAccountsScheduleOfOtherCurrentLiabilitiesDetails": { "order": 10010.0, "parentTag": "us-gaap_OtherLiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Payroll liabilities current.", "label": "Payroll Liabilities Current", "terseLabel": "Payroll liabilities" } } }, "localname": "PayrollLiabilitiesCurrent", "nsuri": "http://fulgentdiagnostics.com/20210630", "presentation": [ "http://fulgentdiagnostics.com/20210630/taxonomy/role/DisclosureOtherSignificantBalanceSheetAccountsScheduleOfOtherCurrentLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "flgt_PercentageOfCommissionToBePaidFromGrossProceeds": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Percentage of commission to be paid from gross proceeds.", "label": "Percentage Of Commission To Be Paid From Gross Proceeds", "terseLabel": "Percentage of commission to be paid from gross proceeds" } } }, "localname": "PercentageOfCommissionToBePaidFromGrossProceeds", "nsuri": "http://fulgentdiagnostics.com/20210630", "presentation": [ "http://fulgentdiagnostics.com/20210630/taxonomy/role/DisclosureEquityDistributionAgreementAdditionalInformationDetails" ], "xbrltype": "percentItemType" }, "flgt_PotentialFutureMilestonePayments": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Potential future milestone payments.", "label": "Potential Future Milestone Payments", "terseLabel": "Potential future milestone payments" } } }, "localname": "PotentialFutureMilestonePayments", "nsuri": "http://fulgentdiagnostics.com/20210630", "presentation": [ "http://fulgentdiagnostics.com/20210630/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "flgt_ProceedsFromSaleOfMarketableSecurities": { "auth_ref": [], "calculation": { "http://fulgentdiagnostics.com/20210630/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited": { "order": 10130.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Proceeds from maturity of marketable securities.", "label": "Proceeds From Sale Of Marketable Securities", "terseLabel": "Proceeds from sale of marketable securities" } } }, "localname": "ProceedsFromSaleOfMarketableSecurities", "nsuri": "http://fulgentdiagnostics.com/20210630", "presentation": [ "http://fulgentdiagnostics.com/20210630/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "flgt_ReagentsAndOtherSuppliesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Reagents and other supplies.", "label": "Reagents And Other Supplies [Member]", "terseLabel": "Reagents and Other Supplies" } } }, "localname": "ReagentsAndOtherSuppliesMember", "nsuri": "http://fulgentdiagnostics.com/20210630", "presentation": [ "http://fulgentdiagnostics.com/20210630/taxonomy/role/DisclosureDebtCommitmentsAndContingenciesAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "flgt_ReagentsAndSuppliesCurrent": { "auth_ref": [], "calculation": { "http://fulgentdiagnostics.com/20210630/taxonomy/role/DisclosureOtherSignificantBalanceSheetAccountsScheduleOfOtherCurrentAssetsDetails": { "order": 10010.0, "parentTag": "us-gaap_OtherAssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Reagents and supplies current.", "label": "Reagents And Supplies Current", "terseLabel": "Reagents and supplies" } } }, "localname": "ReagentsAndSuppliesCurrent", "nsuri": "http://fulgentdiagnostics.com/20210630", "presentation": [ "http://fulgentdiagnostics.com/20210630/taxonomy/role/DisclosureOtherSignificantBalanceSheetAccountsScheduleOfOtherCurrentAssetsDetails", "http://fulgentdiagnostics.com/20210630/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "flgt_ReagentsAndSuppliesPolicyTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Reagents and supplies.", "label": "Reagents And Supplies Policy [Text Block]", "terseLabel": "Reagents and Supplies" } } }, "localname": "ReagentsAndSuppliesPolicyTextBlock", "nsuri": "http://fulgentdiagnostics.com/20210630", "presentation": [ "http://fulgentdiagnostics.com/20210630/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "flgt_ResearchDevelopmentServiceMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Research development service.", "label": "Research Development Service [Member]", "terseLabel": "Research Development Service" } } }, "localname": "ResearchDevelopmentServiceMember", "nsuri": "http://fulgentdiagnostics.com/20210630", "presentation": [ "http://fulgentdiagnostics.com/20210630/taxonomy/role/DisclosureRelatedPartiesAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "flgt_RoyaltyFreeTechnologyMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Royalty-free technology.", "label": "Royalty Free Technology [Member]", "terseLabel": "Royalty-Free Technology" } } }, "localname": "RoyaltyFreeTechnologyMember", "nsuri": "http://fulgentdiagnostics.com/20210630", "presentation": [ "http://fulgentdiagnostics.com/20210630/taxonomy/role/DisclosureGoodwillAndAcquisitionRelatedIntangiblesSummariesOfGoodwillAndAcquisitionsRelatedIntangiblesBalancesDetails" ], "xbrltype": "domainItemType" }, "flgt_SaleOfStockWeightedAverageNetSellingPricePerShare": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Sale of stock, weighted average net selling price per share.", "label": "Sale Of Stock Weighted Average Net Selling Price Per Share", "terseLabel": "Sale of stock, weighted average net selling price per share" } } }, "localname": "SaleOfStockWeightedAverageNetSellingPricePerShare", "nsuri": "http://fulgentdiagnostics.com/20210630", "presentation": [ "http://fulgentdiagnostics.com/20210630/taxonomy/role/DisclosureEquityDistributionAgreementAdditionalInformationDetails" ], "xbrltype": "perShareItemType" }, "flgt_SalesTaxPayableAndOtherCurrent": { "auth_ref": [], "calculation": { "http://fulgentdiagnostics.com/20210630/taxonomy/role/DisclosureOtherSignificantBalanceSheetAccountsScheduleOfOtherCurrentLiabilitiesDetails": { "order": 10020.0, "parentTag": "us-gaap_OtherLiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Sales tax payable and other current", "label": "Sales Tax Payable And Other Current", "terseLabel": "Sales tax payable and other" } } }, "localname": "SalesTaxPayableAndOtherCurrent", "nsuri": "http://fulgentdiagnostics.com/20210630", "presentation": [ "http://fulgentdiagnostics.com/20210630/taxonomy/role/DisclosureOtherSignificantBalanceSheetAccountsScheduleOfOtherCurrentLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "flgt_ScheduleOfAvailableForSaleAndTradingSecuritiesLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Schedule of available-for-sale and trading securities.", "label": "Schedule Of Available For Sale And Trading Securities [Line Items]", "terseLabel": "Schedule Of Available For Sale And Trading Securities [Line Items]" } } }, "localname": "ScheduleOfAvailableForSaleAndTradingSecuritiesLineItems", "nsuri": "http://fulgentdiagnostics.com/20210630", "presentation": [ "http://fulgentdiagnostics.com/20210630/taxonomy/role/DisclosureMarketableSecuritiesAdditionalInformationDetails" ], "xbrltype": "stringItemType" }, "flgt_ScheduleOfAvailableForSaleAndTradingSecuritiesTable": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Schedule of available-for-sale and trading securities.", "label": "Schedule Of Available For Sale And Trading Securities [Table]", "terseLabel": "Schedule Of Available For Sale And Trading Securities [Table]" } } }, "localname": "ScheduleOfAvailableForSaleAndTradingSecuritiesTable", "nsuri": "http://fulgentdiagnostics.com/20210630", "presentation": [ "http://fulgentdiagnostics.com/20210630/taxonomy/role/DisclosureMarketableSecuritiesAdditionalInformationDetails" ], "xbrltype": "stringItemType" }, "flgt_ScheduleOfAvailableForSaleDebtSecuritiesAndEquityTradingSecuritiesReconciliationTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Schedule of available for sale debt securities and equity/trading securities reconciliation.", "label": "Schedule Of Available For Sale Debt Securities And Equity Trading Securities Reconciliation Table [Text Block]", "terseLabel": "Summary of Marketable Securities" } } }, "localname": "ScheduleOfAvailableForSaleDebtSecuritiesAndEquityTradingSecuritiesReconciliationTableTextBlock", "nsuri": "http://fulgentdiagnostics.com/20210630", "presentation": [ "http://fulgentdiagnostics.com/20210630/taxonomy/role/DisclosureMarketableSecuritiesTables" ], "xbrltype": "textBlockItemType" }, "flgt_ScheduleOfLeaseRightOfUseAssetShortTermLeaseLiabilitiesAndLongTermLeaseLiabilitiesTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Schedule of lease right-of-use asset, short-term lease liabilities, and long-term lease liabilities.", "label": "Schedule Of Lease Right Of Use Asset Short Term Lease Liabilities And Long Term Lease Liabilities Table [Text Block]", "terseLabel": "Schedule of Lease Right-of-Use Asset, Short-term Lease Liabilities, and Long-term Lease Liabilities" } } }, "localname": "ScheduleOfLeaseRightOfUseAssetShortTermLeaseLiabilitiesAndLongTermLeaseLiabilitiesTableTextBlock", "nsuri": "http://fulgentdiagnostics.com/20210630", "presentation": [ "http://fulgentdiagnostics.com/20210630/taxonomy/role/DisclosureLeasesTables" ], "xbrltype": "textBlockItemType" }, "flgt_ScheduleOfSupplementalInformationRelatedToLeasesTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Schedule of supplemental information related to leases.", "label": "Schedule Of Supplemental Information Related To Leases Table [Text Block]", "terseLabel": "Schedule of Supplemental Information Related to Leases" } } }, "localname": "ScheduleOfSupplementalInformationRelatedToLeasesTableTextBlock", "nsuri": "http://fulgentdiagnostics.com/20210630", "presentation": [ "http://fulgentdiagnostics.com/20210630/taxonomy/role/DisclosureLeasesTables" ], "xbrltype": "textBlockItemType" }, "flgt_SecuritiesMaturityPeriod": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Securities maturity period.", "label": "Securities Maturity Period", "terseLabel": "Securities maturity period from date of purchase" } } }, "localname": "SecuritiesMaturityPeriod", "nsuri": "http://fulgentdiagnostics.com/20210630", "presentation": [ "http://fulgentdiagnostics.com/20210630/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails" ], "xbrltype": "durationItemType" }, "flgt_ShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Share based compensation allocation of recognized period costs.", "label": "Share Based Compensation Allocation Of Recognized Period Costs [Line Items]", "terseLabel": "Share Based Compensation Allocation Of Recognized Period Costs [Line Items]" } } }, "localname": "ShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems", "nsuri": "http://fulgentdiagnostics.com/20210630", "presentation": [ "http://fulgentdiagnostics.com/20210630/taxonomy/role/DisclosureEquityBasedCompensationSummaryOfEquityBasedCompensationExpensesAsPartOfCostOfRevenueAndOperatingExpensesDetails" ], "xbrltype": "stringItemType" }, "flgt_ShareBasedCompensationAllocationOfRecognizedPeriodCostsTable": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Share based compensation allocation of recognized period costs.", "label": "Share Based Compensation Allocation Of Recognized Period Costs [Table]", "terseLabel": "Share Based Compensation Allocation Of Recognized Period Costs [Table]" } } }, "localname": "ShareBasedCompensationAllocationOfRecognizedPeriodCostsTable", "nsuri": "http://fulgentdiagnostics.com/20210630", "presentation": [ "http://fulgentdiagnostics.com/20210630/taxonomy/role/DisclosureEquityBasedCompensationSummaryOfEquityBasedCompensationExpensesAsPartOfCostOfRevenueAndOperatingExpensesDetails" ], "xbrltype": "stringItemType" }, "flgt_ShortTermMarketableSecuritesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Short-term marketable securites.", "label": "Short Term Marketable Securites [Member]", "terseLabel": "Short-Term Marketable Securities" } } }, "localname": "ShortTermMarketableSecuritesMember", "nsuri": "http://fulgentdiagnostics.com/20210630", "presentation": [ "http://fulgentdiagnostics.com/20210630/taxonomy/role/DisclosureMarketableSecuritiesSummaryOfMarketableSecuritiesDetails" ], "xbrltype": "domainItemType" }, "flgt_SummaryOfSignificantAccountingPoliciesLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Summary of Significant Accounting Policies [Line Items]", "label": "Summary Of Significant Accounting Policies [Line Items]", "terseLabel": "Summary Of Significant Accounting Policies [Line Items]" } } }, "localname": "SummaryOfSignificantAccountingPoliciesLineItems", "nsuri": "http://fulgentdiagnostics.com/20210630", "presentation": [ "http://fulgentdiagnostics.com/20210630/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails" ], "xbrltype": "stringItemType" }, "flgt_SummaryOfSignificantAccountingPoliciesTable": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Summary Of Significant Accounting Policies [Table]", "label": "Summary Of Significant Accounting Policies [Table]", "terseLabel": "Summary Of Significant Accounting Policies [Table]" } } }, "localname": "SummaryOfSignificantAccountingPoliciesTable", "nsuri": "http://fulgentdiagnostics.com/20210630", "presentation": [ "http://fulgentdiagnostics.com/20210630/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails" ], "xbrltype": "stringItemType" }, "flgt_TradeAccountsReceivableAndAllowanceForCreditLossesPolicyTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Trade accounts receivable and allowance for credit losses.", "label": "Trade Accounts Receivable And Allowance For Credit Losses Policy [Text Block]", "terseLabel": "Trade Accounts Receivable And Allowance For Credit Losses" } } }, "localname": "TradeAccountsReceivableAndAllowanceForCreditLossesPolicyTextBlock", "nsuri": "http://fulgentdiagnostics.com/20210630", "presentation": [ "http://fulgentdiagnostics.com/20210630/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "flgt_UnrecognizedTaxBenefitsOperatingActivities": { "auth_ref": [], "calculation": { "http://fulgentdiagnostics.com/20210630/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited": { "order": 10240.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Unrecognized tax benefits operating activities.", "label": "Unrecognized Tax Benefits Operating Activities", "negatedLabel": "Unrecognized tax benefits" } } }, "localname": "UnrecognizedTaxBenefitsOperatingActivities", "nsuri": "http://fulgentdiagnostics.com/20210630", "presentation": [ "http://fulgentdiagnostics.com/20210630/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "flgt_XilongScientificMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Xilong Scientific Member.", "label": "Xilong Scientific [Member]", "terseLabel": "Xilong Scientific" } } }, "localname": "XilongScientificMember", "nsuri": "http://fulgentdiagnostics.com/20210630", "presentation": [ "http://fulgentdiagnostics.com/20210630/taxonomy/role/DisclosureBusinessCombinationAdditionalInformationDetails", "http://fulgentdiagnostics.com/20210630/taxonomy/role/DisclosureDebtCommitmentsAndContingenciesAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "flgt_YankeeDebtSecuritiesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Yankee debt securities.", "label": "Yankee Debt Securities [Member]", "terseLabel": "Yankee Debt Securities" } } }, "localname": "YankeeDebtSecuritiesMember", "nsuri": "http://fulgentdiagnostics.com/20210630", "presentation": [ "http://fulgentdiagnostics.com/20210630/taxonomy/role/DisclosureFairValueMeasurementsInformationAboutFinancialAssetsMeasuredAtFairValueOnRecurringBasisBasedOnThreeTierFairValueHierarchyDetails", "http://fulgentdiagnostics.com/20210630/taxonomy/role/DisclosureMarketableSecuritiesSummaryOfMarketableSecuritiesDetails" ], "xbrltype": "domainItemType" }, "srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember": { "auth_ref": [ "r109", "r117", "r200", "r298", "r299", "r300", "r317", "r318" ], "lang": { "en-us": { "role": { "label": "Cumulative Effect Period Of Adoption Adjustment [Member]", "terseLabel": "Cumulative Effect, Period of Adoption, Adjustment" } } }, "localname": "CumulativeEffectPeriodOfAdoptionAdjustmentMember", "nsuri": "http://fasb.org/srt/2020-01-31", "presentation": [ "http://fulgentdiagnostics.com/20210630/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails", "http://fulgentdiagnostics.com/20210630/taxonomy/role/StatementCondensedConsolidatedStatementsOfStockholdersEquityUnaudited" ], "xbrltype": "domainItemType" }, "srt_CumulativeEffectPeriodOfAdoptionAxis": { "auth_ref": [ "r109", "r117", "r200", "r298", "r299", "r300", "r317", "r318" ], "lang": { "en-us": { "role": { "label": "Cumulative Effect Period Of Adoption [Axis]", "terseLabel": "Cumulative Effect, Period of Adoption" } } }, "localname": "CumulativeEffectPeriodOfAdoptionAxis", "nsuri": "http://fasb.org/srt/2020-01-31", "presentation": [ "http://fulgentdiagnostics.com/20210630/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails", "http://fulgentdiagnostics.com/20210630/taxonomy/role/StatementCondensedConsolidatedStatementsOfStockholdersEquityUnaudited" ], "xbrltype": "stringItemType" }, "srt_CumulativeEffectPeriodOfAdoptionDomain": { "auth_ref": [ "r109", "r117", "r200", "r298", "r299", "r300", "r317", "r318" ], "lang": { "en-us": { "role": { "label": "Cumulative Effect Period Of Adoption [Domain]", "terseLabel": "Cumulative Effect, Period of Adoption" } } }, "localname": "CumulativeEffectPeriodOfAdoptionDomain", "nsuri": "http://fasb.org/srt/2020-01-31", "presentation": [ "http://fulgentdiagnostics.com/20210630/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails", "http://fulgentdiagnostics.com/20210630/taxonomy/role/StatementCondensedConsolidatedStatementsOfStockholdersEquityUnaudited" ], "xbrltype": "domainItemType" }, "srt_EquityMethodInvesteeNameDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Equity Method Investee Name [Domain]", "terseLabel": "Investment, Name" } } }, "localname": "EquityMethodInvesteeNameDomain", "nsuri": "http://fasb.org/srt/2020-01-31", "presentation": [ "http://fulgentdiagnostics.com/20210630/taxonomy/role/DisclosureBusinessCombinationAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "srt_MajorCustomersAxis": { "auth_ref": [ "r179", "r257", "r262", "r508" ], "lang": { "en-us": { "role": { "label": "Major Customers [Axis]", "terseLabel": "Customer" } } }, "localname": "MajorCustomersAxis", "nsuri": "http://fasb.org/srt/2020-01-31", "presentation": [ "http://fulgentdiagnostics.com/20210630/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails", "http://fulgentdiagnostics.com/20210630/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesSummaryOfRevenueFromContractsWithCustomersByPayorTypeDetails" ], "xbrltype": "stringItemType" }, "srt_MaximumMember": { "auth_ref": [ "r280", "r282", "r439", "r440", "r441", "r442", "r443", "r444", "r445", "r506", "r509" ], "lang": { "en-us": { "role": { "label": "Maximum [Member]", "terseLabel": "Maximum" } } }, "localname": "MaximumMember", "nsuri": "http://fasb.org/srt/2020-01-31", "presentation": [ "http://fulgentdiagnostics.com/20210630/taxonomy/role/DisclosureDebtCommitmentsAndContingenciesAdditionalInformationDetails", "http://fulgentdiagnostics.com/20210630/taxonomy/role/DisclosureEquityDistributionAgreementAdditionalInformationDetails", "http://fulgentdiagnostics.com/20210630/taxonomy/role/DisclosureFixedAssetsMajorClassesOfFixedAssetsDetails", "http://fulgentdiagnostics.com/20210630/taxonomy/role/DisclosureLeasesAdditionalInformationDetails", "http://fulgentdiagnostics.com/20210630/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails", "http://fulgentdiagnostics.com/20210630/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "srt_MinimumMember": { "auth_ref": [ "r280", "r282", "r439", "r440", "r441", "r442", "r443", "r444", "r445", "r506", "r509" ], "lang": { "en-us": { "role": { "label": "Minimum [Member]", "terseLabel": "Minimum", "verboseLabel": "Minimum" } } }, "localname": "MinimumMember", "nsuri": "http://fasb.org/srt/2020-01-31", "presentation": [ "http://fulgentdiagnostics.com/20210630/taxonomy/role/DisclosureDebtCommitmentsAndContingenciesAdditionalInformationDetails", "http://fulgentdiagnostics.com/20210630/taxonomy/role/DisclosureEquityDistributionAgreementAdditionalInformationDetails", "http://fulgentdiagnostics.com/20210630/taxonomy/role/DisclosureFixedAssetsMajorClassesOfFixedAssetsDetails", "http://fulgentdiagnostics.com/20210630/taxonomy/role/DisclosureLeasesAdditionalInformationDetails", "http://fulgentdiagnostics.com/20210630/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails", "http://fulgentdiagnostics.com/20210630/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "srt_NameOfMajorCustomerDomain": { "auth_ref": [ "r179", "r257", "r262", "r508" ], "lang": { "en-us": { "role": { "label": "Name Of Major Customer [Domain]", "terseLabel": "Customer" } } }, "localname": "NameOfMajorCustomerDomain", "nsuri": "http://fasb.org/srt/2020-01-31", "presentation": [ "http://fulgentdiagnostics.com/20210630/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails", "http://fulgentdiagnostics.com/20210630/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesSummaryOfRevenueFromContractsWithCustomersByPayorTypeDetails" ], "xbrltype": "domainItemType" }, "srt_OwnershipAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Ownership [Axis]", "terseLabel": "Ownership" } } }, "localname": "OwnershipAxis", "nsuri": "http://fasb.org/srt/2020-01-31", "presentation": [ "http://fulgentdiagnostics.com/20210630/taxonomy/role/DisclosureBusinessCombinationAdditionalInformationDetails" ], "xbrltype": "stringItemType" }, "srt_OwnershipDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Ownership [Domain]", "terseLabel": "Ownership" } } }, "localname": "OwnershipDomain", "nsuri": "http://fasb.org/srt/2020-01-31", "presentation": [ "http://fulgentdiagnostics.com/20210630/taxonomy/role/DisclosureBusinessCombinationAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "srt_RangeAxis": { "auth_ref": [ "r269", "r280", "r282", "r439", "r440", "r441", "r442", "r443", "r444", "r445", "r506", "r509" ], "lang": { "en-us": { "role": { "label": "Range [Axis]", "terseLabel": "Statistical Measurement" } } }, "localname": "RangeAxis", "nsuri": "http://fasb.org/srt/2020-01-31", "presentation": [ "http://fulgentdiagnostics.com/20210630/taxonomy/role/DisclosureDebtCommitmentsAndContingenciesAdditionalInformationDetails", "http://fulgentdiagnostics.com/20210630/taxonomy/role/DisclosureEquityDistributionAgreementAdditionalInformationDetails", "http://fulgentdiagnostics.com/20210630/taxonomy/role/DisclosureFixedAssetsMajorClassesOfFixedAssetsDetails", "http://fulgentdiagnostics.com/20210630/taxonomy/role/DisclosureLeasesAdditionalInformationDetails", "http://fulgentdiagnostics.com/20210630/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails", "http://fulgentdiagnostics.com/20210630/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails" ], "xbrltype": "stringItemType" }, "srt_RangeMember": { "auth_ref": [ "r269", "r280", "r282", "r439", "r440", "r441", "r442", "r443", "r444", "r445", "r506", "r509" ], "lang": { "en-us": { "role": { "label": "Range [Member]", "terseLabel": "Statistical Measurement" } } }, "localname": "RangeMember", "nsuri": "http://fasb.org/srt/2020-01-31", "presentation": [ "http://fulgentdiagnostics.com/20210630/taxonomy/role/DisclosureDebtCommitmentsAndContingenciesAdditionalInformationDetails", "http://fulgentdiagnostics.com/20210630/taxonomy/role/DisclosureEquityDistributionAgreementAdditionalInformationDetails", "http://fulgentdiagnostics.com/20210630/taxonomy/role/DisclosureFixedAssetsMajorClassesOfFixedAssetsDetails", "http://fulgentdiagnostics.com/20210630/taxonomy/role/DisclosureLeasesAdditionalInformationDetails", "http://fulgentdiagnostics.com/20210630/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails", "http://fulgentdiagnostics.com/20210630/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis": { "auth_ref": [ "r191" ], "lang": { "en-us": { "role": { "label": "Schedule Of Equity Method Investment Equity Method Investee Name [Axis]", "terseLabel": "Investment, Name" } } }, "localname": "ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis", "nsuri": "http://fasb.org/srt/2020-01-31", "presentation": [ "http://fulgentdiagnostics.com/20210630/taxonomy/role/DisclosureBusinessCombinationAdditionalInformationDetails" ], "xbrltype": "stringItemType" }, "srt_SegmentGeographicalDomain": { "auth_ref": [ "r175", "r176", "r257", "r261", "r507", "r548", "r549", "r550", "r551", "r552", "r553", "r554", "r555" ], "lang": { "en-us": { "role": { "label": "Segment Geographical [Domain]", "terseLabel": "Geographical" } } }, "localname": "SegmentGeographicalDomain", "nsuri": "http://fasb.org/srt/2020-01-31", "presentation": [ "http://fulgentdiagnostics.com/20210630/taxonomy/role/DisclosureLeasesAdditionalInformationDetails", "http://fulgentdiagnostics.com/20210630/taxonomy/role/DisclosureReportingSegmentAndGeographicalInformationSummaryOfRevenueByGeographicRegionDetails" ], "xbrltype": "domainItemType" }, "srt_StatementGeographicalAxis": { "auth_ref": [ "r175", "r176", "r257", "r261", "r507", "r544", "r548", "r549", "r550", "r551", "r552", "r553", "r554", "r555", "r556" ], "lang": { "en-us": { "role": { "label": "Statement Geographical [Axis]", "terseLabel": "Geographical" } } }, "localname": "StatementGeographicalAxis", "nsuri": "http://fasb.org/srt/2020-01-31", "presentation": [ "http://fulgentdiagnostics.com/20210630/taxonomy/role/DisclosureLeasesAdditionalInformationDetails", "http://fulgentdiagnostics.com/20210630/taxonomy/role/DisclosureReportingSegmentAndGeographicalInformationSummaryOfRevenueByGeographicRegionDetails" ], "xbrltype": "stringItemType" }, "stpr_TX": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "TEXAS", "terseLabel": "Houston, Texas" } } }, "localname": "TX", "nsuri": "http://xbrl.sec.gov/stpr/2018-01-31", "presentation": [ "http://fulgentdiagnostics.com/20210630/taxonomy/role/DisclosureLeasesAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_AccountingPoliciesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Accounting Policies [Abstract]" } } }, "localname": "AccountingPoliciesAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "xbrltype": "stringItemType" }, "us-gaap_AccountingStandardsUpdate201409Member": { "auth_ref": [ "r267" ], "lang": { "en-us": { "role": { "documentation": "Accounting Standards Update 2014-09 Revenue from Contracts with Customers (Topic 606).", "label": "Accounting Standards Update201409 [Member]", "terseLabel": "Accounting Standards Update 2014-09" } } }, "localname": "AccountingStandardsUpdate201409Member", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://fulgentdiagnostics.com/20210630/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesSummaryOfRevenueFromContractsWithCustomersByPayorTypeDetails", "http://fulgentdiagnostics.com/20210630/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesTables" ], "xbrltype": "domainItemType" }, "us-gaap_AccountingStandardsUpdate201613Member": { "auth_ref": [ "r193" ], "lang": { "en-us": { "role": { "documentation": "Accounting Standards Update 2016-13 Financial Instruments-Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments.", "label": "Accounting Standards Update201613 [Member]", "terseLabel": "ASU 2016-13" } } }, "localname": "AccountingStandardsUpdate201613Member", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://fulgentdiagnostics.com/20210630/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_AccountingStandardsUpdate201912Member": { "auth_ref": [ "r315", "r316", "r317", "r318" ], "lang": { "en-us": { "role": { "documentation": "Accounting Standards Update 2019-12 Income Taxes (Topic 740): Simplifying the Accounting for Income Taxes.", "label": "Accounting Standards Update201912 [Member]", "terseLabel": "2019-12" } } }, "localname": "AccountingStandardsUpdate201912Member", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://fulgentdiagnostics.com/20210630/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_AccountingStandardsUpdateExtensibleList": { "auth_ref": [ "r111", "r112", "r113", "r114", "r197", "r198", "r199", "r200", "r202", "r203", "r294", "r295", "r296", "r297", "r298", "r299", "r300", "r301", "r317", "r318", "r510", "r511", "r512", "r513", "r514", "r515", "r516", "r517", "r518", "r519", "r520", "r521" ], "lang": { "en-us": { "role": { "documentation": "Indicates amendment to accounting standards.", "label": "Accounting Standards Update Extensible List", "terseLabel": "Accounting Standards Update [Extensible List]" } } }, "localname": "AccountingStandardsUpdateExtensibleList", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://fulgentdiagnostics.com/20210630/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails" ], "xbrltype": "extensibleListItemType" }, "us-gaap_AccountsPayableCurrent": { "auth_ref": [ "r33" ], "calculation": { "http://fulgentdiagnostics.com/20210630/taxonomy/role/StatementCondensedConsolidatedBalanceSheets": { "order": 10150.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "label": "Accounts Payable Current", "terseLabel": "Accounts payable" } } }, "localname": "AccountsPayableCurrent", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://fulgentdiagnostics.com/20210630/taxonomy/role/StatementCondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccountsReceivableMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Due from customers or clients for goods or services that have been delivered or sold.", "label": "Accounts Receivable [Member]", "terseLabel": "Accounts Receivable" } } }, "localname": "AccountsReceivableMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://fulgentdiagnostics.com/20210630/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_AccountsReceivableNetCurrent": { "auth_ref": [ "r3", "r21", "r181", "r182" ], "calculation": { "http://fulgentdiagnostics.com/20210630/taxonomy/role/StatementCondensedConsolidatedBalanceSheets": { "order": 10290.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.", "label": "Accounts Receivable Net Current", "terseLabel": "Trade accounts receivable, net of allowance for credit losses of $6,044 and $1,898 as of June 30, 2021 and December 31, 2020, respectively", "verboseLabel": "Receivables from contract with customers" } } }, "localname": "AccountsReceivableNetCurrent", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://fulgentdiagnostics.com/20210630/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails", "http://fulgentdiagnostics.com/20210630/taxonomy/role/StatementCondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccountsReceivableRelatedParties": { "auth_ref": [ "r20", "r101", "r428", "r430", "r494" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "For an unclassified balance sheet, amount of receivables arising from transactions with related parties.", "label": "Accounts Receivable Related Parties", "terseLabel": "Trade accounts receivable, net from related parties" } } }, "localname": "AccountsReceivableRelatedParties", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://fulgentdiagnostics.com/20210630/taxonomy/role/DisclosureRelatedPartiesAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment": { "auth_ref": [ "r31", "r229" ], "calculation": { "http://fulgentdiagnostics.com/20210630/taxonomy/role/DisclosureFixedAssetsMajorClassesOfFixedAssetsDetails": { "order": 10020.0, "parentTag": "us-gaap_PropertyPlantAndEquipmentNet", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.", "label": "Accumulated Depreciation Depletion And Amortization Property Plant And Equipment", "negatedLabel": "Less: Accumulated depreciation" } } }, "localname": "AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://fulgentdiagnostics.com/20210630/taxonomy/role/DisclosureFixedAssetsMajorClassesOfFixedAssetsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax": { "auth_ref": [ "r24", "r50", "r51", "r52", "r490", "r517", "r521" ], "calculation": { "http://fulgentdiagnostics.com/20210630/taxonomy/role/StatementCondensedConsolidatedBalanceSheets": { "order": 10090.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge.", "label": "Accumulated Other Comprehensive Income Loss Net Of Tax", "terseLabel": "Accumulated other comprehensive income (loss)" } } }, "localname": "AccumulatedOtherComprehensiveIncomeLossNetOfTax", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://fulgentdiagnostics.com/20210630/taxonomy/role/StatementCondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccumulatedOtherComprehensiveIncomeMember": { "auth_ref": [ "r49", "r52", "r53", "r106", "r107", "r108", "r362", "r512", "r513" ], "lang": { "en-us": { "role": { "documentation": "Accumulated increase (decrease) in equity from transactions and other events and circumstances from non-owner sources, attributable to the parent. Excludes net income (loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners.", "label": "Accumulated Other Comprehensive Income [Member]", "terseLabel": "Accumulated Other Comprehensive Income (Loss)" } } }, "localname": "AccumulatedOtherComprehensiveIncomeMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://fulgentdiagnostics.com/20210630/taxonomy/role/StatementCondensedConsolidatedStatementsOfStockholdersEquityUnaudited" ], "xbrltype": "domainItemType" }, "us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife": { "auth_ref": [ "r218" ], "lang": { "en-us": { "role": { "documentation": "Weighted average amortization period of finite-lived intangible assets acquired either individually or as part of a group of assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.", "label": "Acquired Finite Lived Intangible Assets Weighted Average Useful Life", "terseLabel": "Estimated amortization life of identified intangible assets assumed", "verboseLabel": "Weighted-Average Amortization Period" } } }, "localname": "AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://fulgentdiagnostics.com/20210630/taxonomy/role/DisclosureBusinessCombinationAdditionalInformationDetails", "http://fulgentdiagnostics.com/20210630/taxonomy/role/DisclosureGoodwillAndAcquisitionRelatedIntangiblesSummariesOfGoodwillAndAcquisitionsRelatedIntangiblesBalancesDetails" ], "xbrltype": "durationItemType" }, "us-gaap_AdditionalPaidInCapitalCommonStock": { "auth_ref": [ "r22" ], "calculation": { "http://fulgentdiagnostics.com/20210630/taxonomy/role/StatementCondensedConsolidatedBalanceSheets": { "order": 10080.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Value received from shareholders in common stock-related transactions that are in excess of par value or stated value and amounts received from other stock-related transactions. Includes only common stock transactions (excludes preferred stock transactions). May be called contributed capital, capital in excess of par, capital surplus, or paid-in capital.", "label": "Additional Paid In Capital Common Stock", "terseLabel": "Additional paid-in capital" } } }, "localname": "AdditionalPaidInCapitalCommonStock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://fulgentdiagnostics.com/20210630/taxonomy/role/StatementCondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AdditionalPaidInCapitalMember": { "auth_ref": [ "r106", "r107", "r108", "r298", "r299", "r300" ], "lang": { "en-us": { "role": { "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders.", "label": "Additional Paid In Capital [Member]", "terseLabel": "Additional Paid-In Capital" } } }, "localname": "AdditionalPaidInCapitalMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://fulgentdiagnostics.com/20210630/taxonomy/role/StatementCondensedConsolidatedStatementsOfStockholdersEquityUnaudited" ], "xbrltype": "domainItemType" }, "us-gaap_AdjustmentsForNewAccountingPronouncementsAxis": { "auth_ref": [ "r111", "r112", "r113", "r114", "r197", "r198", "r199", "r200", "r202", "r203", "r294", "r295", "r296", "r297", "r298", "r299", "r300", "r301", "r315", "r316", "r317", "r318", "r448", "r449", "r450", "r510", "r511", "r512", "r513", "r514", "r515", "r516", "r517", "r518", "r519", "r520", "r521" ], "lang": { "en-us": { "role": { "documentation": "Information by amendment to accounting standards.", "label": "Adjustments For New Accounting Pronouncements [Axis]", "terseLabel": "Accounting Standards Update" } } }, "localname": "AdjustmentsForNewAccountingPronouncementsAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://fulgentdiagnostics.com/20210630/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails", "http://fulgentdiagnostics.com/20210630/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesSummaryOfRevenueFromContractsWithCustomersByPayorTypeDetails", "http://fulgentdiagnostics.com/20210630/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesTables" ], "xbrltype": "stringItemType" }, "us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of decrease to equity for grantee's tax withholding obligation for award under share-based payment arrangement.", "label": "Adjustments Related To Tax Withholding For Share Based Compensation", "negatedLabel": "Common stock withholding for employee tax obligations" } } }, "localname": "AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://fulgentdiagnostics.com/20210630/taxonomy/role/StatementCondensedConsolidatedStatementsOfStockholdersEquityUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue": { "auth_ref": [ "r283", "r285", "r303", "r304" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.", "label": "Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value", "terseLabel": "Equity-based compensation" } } }, "localname": "AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://fulgentdiagnostics.com/20210630/taxonomy/role/StatementCondensedConsolidatedStatementsOfStockholdersEquityUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Adjustments To Reconcile Net Income Loss To Cash Provided By Used In Operating Activities [Abstract]", "terseLabel": "Adjustments to reconcile net income to net cash provided (used in) by operating activities:" } } }, "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://fulgentdiagnostics.com/20210630/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "xbrltype": "stringItemType" }, "us-gaap_AllocatedShareBasedCompensationExpense": { "auth_ref": [ "r285", "r291", "r302" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.", "label": "Allocated Share Based Compensation Expense", "terseLabel": "Equity-based compensation expense" } } }, "localname": "AllocatedShareBasedCompensationExpense", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://fulgentdiagnostics.com/20210630/taxonomy/role/DisclosureEquityBasedCompensationSummaryOfEquityBasedCompensationExpensesAsPartOfCostOfRevenueAndOperatingExpensesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AllowanceForDoubtfulAccountsReceivable": { "auth_ref": [ "r183", "r204", "r205", "r207" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of allowance for credit loss on accounts receivable.", "label": "Allowance For Doubtful Accounts Receivable", "terseLabel": "Allowance for credit losses" } } }, "localname": "AllowanceForDoubtfulAccountsReceivable", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://fulgentdiagnostics.com/20210630/taxonomy/role/StatementCondensedConsolidatedBalanceSheetsParenthetical" ], "xbrltype": "monetaryItemType" }, "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": { "auth_ref": [ "r130" ], "lang": { "en-us": { "role": { "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.", "label": "Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount", "terseLabel": "Anti-dilutive securities excluded from calculation of diluted income per share" } } }, "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://fulgentdiagnostics.com/20210630/taxonomy/role/DisclosureIncomePerShareAntiDilutiveSecuritiesExcludedFromCalculationOfDilutedIncomePerShareDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]", "terseLabel": "Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]" } } }, "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://fulgentdiagnostics.com/20210630/taxonomy/role/DisclosureIncomePerShareAntiDilutiveSecuritiesExcludedFromCalculationOfDilutedIncomePerShareDetails" ], "xbrltype": "stringItemType" }, "us-gaap_AreaOfLand": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Area of land held.", "label": "Area Of Land", "terseLabel": "Area of lease" } } }, "localname": "AreaOfLand", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://fulgentdiagnostics.com/20210630/taxonomy/role/DisclosureLeasesAdditionalInformationDetails" ], "xbrltype": "areaItemType" }, "us-gaap_ArrangementsAndNonarrangementTransactionsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.", "label": "Arrangements And Nonarrangement Transactions [Member]", "terseLabel": "Collaborative Arrangement and Arrangement Other than Collaborative" } } }, "localname": "ArrangementsAndNonarrangementTransactionsMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://fulgentdiagnostics.com/20210630/taxonomy/role/DisclosureEquityDistributionAgreementAdditionalInformationDetails", "http://fulgentdiagnostics.com/20210630/taxonomy/role/StatementCondensedConsolidatedStatementsOfStockholdersEquityUnauditedParenthetical" ], "xbrltype": "domainItemType" }, "us-gaap_Assets": { "auth_ref": [ "r99", "r158", "r163", "r170", "r192", "r355", "r363", "r386", "r465", "r488" ], "calculation": { "http://fulgentdiagnostics.com/20210630/taxonomy/role/StatementCondensedConsolidatedBalanceSheets": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.", "label": "Assets", "totalLabel": "Total assets" } } }, "localname": "Assets", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://fulgentdiagnostics.com/20210630/taxonomy/role/StatementCondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AssetsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Assets [Abstract]", "terseLabel": "Assets" } } }, "localname": "AssetsAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://fulgentdiagnostics.com/20210630/taxonomy/role/StatementCondensedConsolidatedBalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_AssetsCurrent": { "auth_ref": [ "r6", "r8", "r45", "r99", "r192", "r355", "r363", "r386" ], "calculation": { "http://fulgentdiagnostics.com/20210630/taxonomy/role/StatementCondensedConsolidatedBalanceSheets": { "order": 10210.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.", "label": "Assets Current", "totalLabel": "Total current assets" } } }, "localname": "AssetsCurrent", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://fulgentdiagnostics.com/20210630/taxonomy/role/StatementCondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AssetsCurrentAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Assets Current [Abstract]", "terseLabel": "Current assets" } } }, "localname": "AssetsCurrentAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://fulgentdiagnostics.com/20210630/taxonomy/role/StatementCondensedConsolidatedBalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_AssetsFairValueDisclosure": { "auth_ref": [ "r372" ], "calculation": { "http://fulgentdiagnostics.com/20210630/taxonomy/role/DisclosureFairValueMeasurementsInformationAboutFinancialAssetsMeasuredAtFairValueOnRecurringBasisBasedOnThreeTierFairValueHierarchyDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Fair value portion of probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.", "label": "Assets Fair Value Disclosure", "totalLabel": "Total marketable securities and cash equivalents" } } }, "localname": "AssetsFairValueDisclosure", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://fulgentdiagnostics.com/20210630/taxonomy/role/DisclosureFairValueMeasurementsInformationAboutFinancialAssetsMeasuredAtFairValueOnRecurringBasisBasedOnThreeTierFairValueHierarchyDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AvailableForSaleSecuritiesDebtSecurities": { "auth_ref": [ "r185", "r188", "r208", "r470" ], "calculation": { "http://fulgentdiagnostics.com/20210630/taxonomy/role/DisclosureFairValueMeasurementsInformationAboutFinancialAssetsMeasuredAtFairValueOnRecurringBasisBasedOnThreeTierFairValueHierarchyDetails": { "order": 10030.0, "parentTag": "us-gaap_AssetsFairValueDisclosure", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).", "label": "Available For Sale Securities Debt Securities", "verboseLabel": "Total marketable securities" } } }, "localname": "AvailableForSaleSecuritiesDebtSecurities", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://fulgentdiagnostics.com/20210630/taxonomy/role/DisclosureFairValueMeasurementsInformationAboutFinancialAssetsMeasuredAtFairValueOnRecurringBasisBasedOnThreeTierFairValueHierarchyDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent": { "auth_ref": [ "r187", "r208" ], "calculation": { "http://fulgentdiagnostics.com/20210630/taxonomy/role/StatementCondensedConsolidatedBalanceSheets": { "order": 10220.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), classified as noncurrent.", "label": "Available For Sale Securities Debt Securities Noncurrent", "terseLabel": "Marketable securities, long-term" } } }, "localname": "AvailableForSaleSecuritiesDebtSecuritiesNoncurrent", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://fulgentdiagnostics.com/20210630/taxonomy/role/StatementCondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AwardTypeAxis": { "auth_ref": [ "r286", "r292" ], "lang": { "en-us": { "role": { "documentation": "Information by type of award under share-based payment arrangement.", "label": "Award Type [Axis]", "terseLabel": "Award Type" } } }, "localname": "AwardTypeAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://fulgentdiagnostics.com/20210630/taxonomy/role/DisclosureIncomePerShareAntiDilutiveSecuritiesExcludedFromCalculationOfDilutedIncomePerShareDetails" ], "xbrltype": "stringItemType" }, "us-gaap_BalanceSheetLocationAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Information by location on balance sheet (statement of financial position).", "label": "Balance Sheet Location [Axis]", "terseLabel": "Balance Sheet Location" } } }, "localname": "BalanceSheetLocationAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://fulgentdiagnostics.com/20210630/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_BalanceSheetLocationDomain": { "auth_ref": [ "r368", "r369" ], "lang": { "en-us": { "role": { "documentation": "Location in the balance sheet (statement of financial position).", "label": "Balance Sheet Location [Domain]", "terseLabel": "Balance Sheet Location" } } }, "localname": "BalanceSheetLocationDomain", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://fulgentdiagnostics.com/20210630/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_BalanceSheetRelatedDisclosuresAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Balance Sheet Related Disclosures [Abstract]" } } }, "localname": "BalanceSheetRelatedDisclosuresAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "xbrltype": "stringItemType" }, "us-gaap_BondsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Debt security, in which the authorized issuer owes the holder a debt and is obliged to repay the principal and interest (the coupon).", "label": "Bonds [Member]", "terseLabel": "Bond Fund" } } }, "localname": "BondsMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://fulgentdiagnostics.com/20210630/taxonomy/role/DisclosureFairValueMeasurementsInformationAboutFinancialAssetsMeasuredAtFairValueOnRecurringBasisBasedOnThreeTierFairValueHierarchyDetails", "http://fulgentdiagnostics.com/20210630/taxonomy/role/DisclosureMarketableSecuritiesSummaryOfMarketableSecuritiesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_BuildingImprovementsMember": { "auth_ref": [ "r228" ], "lang": { "en-us": { "role": { "documentation": "Addition, improvement, or renovation to a facility held for productive use including, but not limited to, office, production, storage and distribution facilities.", "label": "Building Improvements [Member]", "terseLabel": "Building Improvements" } } }, "localname": "BuildingImprovementsMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://fulgentdiagnostics.com/20210630/taxonomy/role/DisclosureFixedAssetsMajorClassesOfFixedAssetsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_BuildingMember": { "auth_ref": [ "r228" ], "lang": { "en-us": { "role": { "documentation": "Facility held for productive use including, but not limited to, office, production, storage and distribution facilities.", "label": "Building [Member]", "terseLabel": "Building" } } }, "localname": "BuildingMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://fulgentdiagnostics.com/20210630/taxonomy/role/DisclosureFixedAssetsMajorClassesOfFixedAssetsDetails", "http://fulgentdiagnostics.com/20210630/taxonomy/role/DisclosureLeasesAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_BusinessAcquisitionAcquireeDomain": { "auth_ref": [ "r279", "r281" ], "lang": { "en-us": { "role": { "documentation": "Identification of the acquiree in a material business combination (or series of individually immaterial business combinations), which may include the name or other type of identification of the acquiree.", "label": "Business Acquisition Acquiree [Domain]", "terseLabel": "Business Acquisition, Acquiree" } } }, "localname": "BusinessAcquisitionAcquireeDomain", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://fulgentdiagnostics.com/20210630/taxonomy/role/DisclosureBusinessCombinationAdditionalInformationDetails", "http://fulgentdiagnostics.com/20210630/taxonomy/role/DisclosureBusinessCombinationSummaryOfConsiderationPaidAndAmountOfAssetsAcquiredAndLiabilitiesAssumedDetails", "http://fulgentdiagnostics.com/20210630/taxonomy/role/DisclosureBusinessCombinationTables", "http://fulgentdiagnostics.com/20210630/taxonomy/role/DisclosureGoodwillAndAcquisitionRelatedIntangiblesAdditionalInformationDetails", "http://fulgentdiagnostics.com/20210630/taxonomy/role/DisclosureGoodwillAndAcquisitionRelatedIntangiblesSummariesOfGoodwillAndAcquisitionsRelatedIntangiblesBalancesDetails", "http://fulgentdiagnostics.com/20210630/taxonomy/role/DisclosureGoodwillAndAcquisitionRelatedIntangiblesSummaryOfAnnualAmortizationExpenseForAcquisitionRelatedIntangiblesDetails", "http://fulgentdiagnostics.com/20210630/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_BusinessAcquisitionAxis": { "auth_ref": [ "r279", "r281", "r336", "r337" ], "lang": { "en-us": { "role": { "documentation": "Information by business combination or series of individually immaterial business combinations.", "label": "Business Acquisition [Axis]", "terseLabel": "Business Acquisition" } } }, "localname": "BusinessAcquisitionAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://fulgentdiagnostics.com/20210630/taxonomy/role/DisclosureBusinessCombinationAdditionalInformationDetails", "http://fulgentdiagnostics.com/20210630/taxonomy/role/DisclosureBusinessCombinationSummaryOfConsiderationPaidAndAmountOfAssetsAcquiredAndLiabilitiesAssumedDetails", "http://fulgentdiagnostics.com/20210630/taxonomy/role/DisclosureBusinessCombinationTables", "http://fulgentdiagnostics.com/20210630/taxonomy/role/DisclosureGoodwillAndAcquisitionRelatedIntangiblesAdditionalInformationDetails", "http://fulgentdiagnostics.com/20210630/taxonomy/role/DisclosureGoodwillAndAcquisitionRelatedIntangiblesSummariesOfGoodwillAndAcquisitionsRelatedIntangiblesBalancesDetails", "http://fulgentdiagnostics.com/20210630/taxonomy/role/DisclosureGoodwillAndAcquisitionRelatedIntangiblesSummaryOfAnnualAmortizationExpenseForAcquisitionRelatedIntangiblesDetails", "http://fulgentdiagnostics.com/20210630/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_BusinessAcquisitionLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Business Acquisition [Line Items]", "terseLabel": "Business Acquisition [Line Items]" } } }, "localname": "BusinessAcquisitionLineItems", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://fulgentdiagnostics.com/20210630/taxonomy/role/DisclosureBusinessCombinationAdditionalInformationDetails", "http://fulgentdiagnostics.com/20210630/taxonomy/role/DisclosureBusinessCombinationSummaryOfConsiderationPaidAndAmountOfAssetsAcquiredAndLiabilitiesAssumedDetails", "http://fulgentdiagnostics.com/20210630/taxonomy/role/DisclosureBusinessCombinationTables" ], "xbrltype": "stringItemType" }, "us-gaap_BusinessCombinationAcquisitionOfLessThan100PercentNoncontrollingInterestFairValue": { "auth_ref": [ "r340" ], "calculation": { "http://fulgentdiagnostics.com/20210630/taxonomy/role/DisclosureBusinessCombinationSummaryOfConsiderationPaidAndAmountOfAssetsAcquiredAndLiabilitiesAssumedDetails": { "order": 10020.0, "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedLessNoncontrollingInterest", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "This element represents the fair value of the noncontrolling interest in the acquiree at the acquisition date.", "label": "Business Combination Acquisition Of Less Than100 Percent Noncontrolling Interest Fair Value", "negatedLabel": "Noncontrolling interest", "terseLabel": "Business Combination,Fair value of noncontrolling interest" } } }, "localname": "BusinessCombinationAcquisitionOfLessThan100PercentNoncontrollingInterestFairValue", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://fulgentdiagnostics.com/20210630/taxonomy/role/DisclosureBusinessCombinationAdditionalInformationDetails", "http://fulgentdiagnostics.com/20210630/taxonomy/role/DisclosureBusinessCombinationSummaryOfConsiderationPaidAndAmountOfAssetsAcquiredAndLiabilitiesAssumedDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationAcquisitionRelatedCosts": { "auth_ref": [ "r332" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "This element represents acquisition-related costs incurred to effect a business combination which costs have been expensed during the period. Such costs include finder's fees; advisory, legal, accounting, valuation, and other professional or consulting fees; general administrative costs, including the costs of maintaining an internal acquisitions department; and may include costs of registering and issuing debt and equity securities.", "label": "Business Combination Acquisition Related Costs", "terseLabel": "Business Combination, Acquisition Related Costs" } } }, "localname": "BusinessCombinationAcquisitionRelatedCosts", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://fulgentdiagnostics.com/20210630/taxonomy/role/DisclosureBusinessCombinationAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationConsiderationTransferredIncludingEquityInterestInAcquireeHeldPriorToCombination1": { "auth_ref": [ "r333", "r345" ], "calculation": { "http://fulgentdiagnostics.com/20210630/taxonomy/role/DisclosureBusinessCombinationSummaryOfConsiderationPaidAndAmountOfAssetsAcquiredAndLiabilitiesAssumedDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Fair value at acquisition-date of the assets transferred by the acquirer, liabilities incurred by the acquirer, and equity interests issued by the acquirer, including but not limited to, instruments or interests issued or issuable in consideration for the business combination.", "label": "Business Combination Consideration Transferred Including Equity Interest In Acquiree Held Prior To Combination1", "totalLabel": "Total Consideration and fair value of equity interest held before business combination" } } }, "localname": "BusinessCombinationConsiderationTransferredIncludingEquityInterestInAcquireeHeldPriorToCombination1", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://fulgentdiagnostics.com/20210630/taxonomy/role/DisclosureBusinessCombinationSummaryOfConsiderationPaidAndAmountOfAssetsAcquiredAndLiabilitiesAssumedDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationConsiderationTransferredIncludingEquityInterestInAcquireeHeldPriorToCombinationAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Business Combination Consideration Transferred Including Equity Interest In Acquiree Held Prior To Combination [Abstract]", "terseLabel": "Considerations" } } }, "localname": "BusinessCombinationConsiderationTransferredIncludingEquityInterestInAcquireeHeldPriorToCombinationAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://fulgentdiagnostics.com/20210630/taxonomy/role/DisclosureBusinessCombinationSummaryOfConsiderationPaidAndAmountOfAssetsAcquiredAndLiabilitiesAssumedDetails" ], "xbrltype": "stringItemType" }, "us-gaap_BusinessCombinationContingentConsiderationLiability": { "auth_ref": [ "r343", "r344", "r347" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of liability recognized arising from contingent consideration in a business combination.", "label": "Business Combination Contingent Consideration Liability", "terseLabel": "Purchase price for effective investment" } } }, "localname": "BusinessCombinationContingentConsiderationLiability", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://fulgentdiagnostics.com/20210630/taxonomy/role/DisclosureBusinessCombinationAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput": { "auth_ref": [ "r377" ], "lang": { "en-us": { "role": { "documentation": "Value of input used to measure contingent consideration liability from business combination.", "label": "Business Combination Contingent Consideration Liability Measurement Input", "terseLabel": "Business combination, contingent consideration, liability, measurement input" } } }, "localname": "BusinessCombinationContingentConsiderationLiabilityMeasurementInput", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://fulgentdiagnostics.com/20210630/taxonomy/role/DisclosureBusinessCombinationAdditionalInformationDetails" ], "xbrltype": "decimalItemType" }, "us-gaap_BusinessCombinationDisclosureTextBlock": { "auth_ref": [ "r348" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for a business combination (or series of individually immaterial business combinations) completed during the period, including background, timing, and recognized assets and liabilities. The disclosure may include leverage buyout transactions (as applicable).", "label": "Business Combination Disclosure [Text Block]", "terseLabel": "Business Combination" } } }, "localname": "BusinessCombinationDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://fulgentdiagnostics.com/20210630/taxonomy/role/DisclosureBusinessCombination" ], "xbrltype": "textBlockItemType" }, "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesOther": { "auth_ref": [ "r339" ], "calculation": { "http://fulgentdiagnostics.com/20210630/taxonomy/role/DisclosureBusinessCombinationSummaryOfConsiderationPaidAndAmountOfAssetsAcquiredAndLiabilitiesAssumedDetails": { "order": 10090.0, "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of other liabilities due within one year or within the normal operating cycle, if longer, assumed at the acquisition date.", "label": "Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Current Liabilities Other", "negatedLabel": "Other current liabilities" } } }, "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesOther", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://fulgentdiagnostics.com/20210630/taxonomy/role/DisclosureBusinessCombinationSummaryOfConsiderationPaidAndAmountOfAssetsAcquiredAndLiabilitiesAssumedDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedFinancialAssets": { "auth_ref": [ "r338", "r339", "r388" ], "calculation": { "http://fulgentdiagnostics.com/20210630/taxonomy/role/DisclosureBusinessCombinationSummaryOfConsiderationPaidAndAmountOfAssetsAcquiredAndLiabilitiesAssumedDetails": { "order": 10040.0, "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The amount of financial assets (as defined) recognized as of the acquisition date.", "label": "Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Financial Assets", "terseLabel": "Financial assets" } } }, "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedFinancialAssets", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://fulgentdiagnostics.com/20210630/taxonomy/role/DisclosureBusinessCombinationSummaryOfConsiderationPaidAndAmountOfAssetsAcquiredAndLiabilitiesAssumedDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles": { "auth_ref": [ "r338", "r339" ], "calculation": { "http://fulgentdiagnostics.com/20210630/taxonomy/role/DisclosureBusinessCombinationSummaryOfConsiderationPaidAndAmountOfAssetsAcquiredAndLiabilitiesAssumedDetails": { "order": 10080.0, "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The amount of identifiable intangible assets recognized as of the acquisition date.", "label": "Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Intangibles", "terseLabel": "Identified intangible assets assumed", "verboseLabel": "Identifiable intangible assets" } } }, "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://fulgentdiagnostics.com/20210630/taxonomy/role/DisclosureBusinessCombinationAdditionalInformationDetails", "http://fulgentdiagnostics.com/20210630/taxonomy/role/DisclosureBusinessCombinationSummaryOfConsiderationPaidAndAmountOfAssetsAcquiredAndLiabilitiesAssumedDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet": { "auth_ref": [ "r338", "r339" ], "calculation": { "http://fulgentdiagnostics.com/20210630/taxonomy/role/DisclosureBusinessCombinationSummaryOfConsiderationPaidAndAmountOfAssetsAcquiredAndLiabilitiesAssumedDetails": { "order": 10010.0, "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedLessNoncontrollingInterest", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount recognized as of the acquisition date for the identifiable assets acquired in excess of (less than) the aggregate liabilities assumed.", "label": "Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Net", "totalLabel": "Recognized amounts of identifiable assets acquired and liabilities assumed, net" } } }, "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://fulgentdiagnostics.com/20210630/taxonomy/role/DisclosureBusinessCombinationSummaryOfConsiderationPaidAndAmountOfAssetsAcquiredAndLiabilitiesAssumedDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesLongTermDebt": { "auth_ref": [ "r339" ], "calculation": { "http://fulgentdiagnostics.com/20210630/taxonomy/role/DisclosureBusinessCombinationSummaryOfConsiderationPaidAndAmountOfAssetsAcquiredAndLiabilitiesAssumedDetails": { "order": 10100.0, "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of long-term debt due after one year or the normal operating cycle, if longer, assumed at the acquisition date.", "label": "Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Noncurrent Liabilities Long Term Debt", "negatedLabel": "Notes payable" } } }, "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesLongTermDebt", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://fulgentdiagnostics.com/20210630/taxonomy/role/DisclosureBusinessCombinationSummaryOfConsiderationPaidAndAmountOfAssetsAcquiredAndLiabilitiesAssumedDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment": { "auth_ref": [ "r338", "r339" ], "calculation": { "http://fulgentdiagnostics.com/20210630/taxonomy/role/DisclosureBusinessCombinationSummaryOfConsiderationPaidAndAmountOfAssetsAcquiredAndLiabilitiesAssumedDetails": { "order": 10060.0, "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The amount of property, plant, and equipment recognized as of the acquisition date.", "label": "Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Property Plant And Equipment", "terseLabel": "Fixed assets" } } }, "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://fulgentdiagnostics.com/20210630/taxonomy/role/DisclosureBusinessCombinationSummaryOfConsiderationPaidAndAmountOfAssetsAcquiredAndLiabilitiesAssumedDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedLessNoncontrollingInterest": { "auth_ref": [ "r339" ], "calculation": { "http://fulgentdiagnostics.com/20210630/taxonomy/role/DisclosureBusinessCombinationSummaryOfConsiderationPaidAndAmountOfAssetsAcquiredAndLiabilitiesAssumedDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount recognized as of the acquisition date for the assets, including goodwill, in excess of (less than) the aggregate liabilities assumed, less the noncontrolling interest in the acquiree.", "label": "Business Combination Recognized Identifiable Assets Acquired Goodwill And Liabilities Assumed Less Noncontrolling Interest", "totalLabel": "Total" } } }, "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedLessNoncontrollingInterest", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://fulgentdiagnostics.com/20210630/taxonomy/role/DisclosureBusinessCombinationSummaryOfConsiderationPaidAndAmountOfAssetsAcquiredAndLiabilitiesAssumedDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedLessNoncontrollingInterestAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Business Combination Recognized Identifiable Assets Acquired Goodwill And Liabilities Assumed Less Noncontrolling Interest [Abstract]", "terseLabel": "Recognized amounts of identifiable assets acquired and liabilities assumed" } } }, "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedLessNoncontrollingInterestAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://fulgentdiagnostics.com/20210630/taxonomy/role/DisclosureBusinessCombinationSummaryOfConsiderationPaidAndAmountOfAssetsAcquiredAndLiabilitiesAssumedDetails" ], "xbrltype": "stringItemType" }, "us-gaap_BusinessCombinationStepAcquisitionEquityInterestInAcquireeFairValue1": { "auth_ref": [ "r334" ], "calculation": { "http://fulgentdiagnostics.com/20210630/taxonomy/role/DisclosureBusinessCombinationSummaryOfConsiderationPaidAndAmountOfAssetsAcquiredAndLiabilitiesAssumedDetails": { "order": 10120.0, "parentTag": "us-gaap_BusinessCombinationConsiderationTransferredIncludingEquityInterestInAcquireeHeldPriorToCombination1", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Fair value at acquisition-date of the equity interest in the acquiree held by the acquirer, immediately before the acquisition date for businesses combined in stages.", "label": "Business Combination Step Acquisition Equity Interest In Acquiree Fair Value1", "terseLabel": "Fair value of the Company\u2019s 30% equity interest held before the business combination" } } }, "localname": "BusinessCombinationStepAcquisitionEquityInterestInAcquireeFairValue1", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://fulgentdiagnostics.com/20210630/taxonomy/role/DisclosureBusinessCombinationSummaryOfConsiderationPaidAndAmountOfAssetsAcquiredAndLiabilitiesAssumedDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationStepAcquisitionEquityInterestInAcquireePercentage": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Percentage of equity in the acquiree held by the acquirer immediately before the acquisition date in a business combination.", "label": "Business Combination Step Acquisition Equity Interest In Acquiree Percentage", "terseLabel": "Percentage of preexisting equity interest" } } }, "localname": "BusinessCombinationStepAcquisitionEquityInterestInAcquireePercentage", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://fulgentdiagnostics.com/20210630/taxonomy/role/DisclosureBusinessCombinationAdditionalInformationDetails" ], "xbrltype": "percentItemType" }, "us-gaap_BusinessCombinationStepAcquisitionEquityInterestInAcquireeRemeasurementGain": { "auth_ref": [ "r335" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "In a business combination achieved in stages, this element represents the amount of gain recognized by the entity as a result of remeasuring to fair value the equity interest in the acquiree it held before the business combination.", "label": "Business Combination Step Acquisition Equity Interest In Acquiree Remeasurement Gain", "terseLabel": "Gain recognized on preexisting investment" } } }, "localname": "BusinessCombinationStepAcquisitionEquityInterestInAcquireeRemeasurementGain", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://fulgentdiagnostics.com/20210630/taxonomy/role/DisclosureBusinessCombinationAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Business Combinations [Abstract]" } } }, "localname": "BusinessCombinationsAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "xbrltype": "stringItemType" }, "us-gaap_BusinessCombinationsPolicy": { "auth_ref": [ "r97", "r331" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for completed business combinations (purchase method, acquisition method or combination of entities under common control). This accounting policy may include a general discussion of the purchase method or acquisition method of accounting (including for example, the treatment accorded contingent consideration, the identification of assets and liabilities, the purchase price allocation process, how the fair values of acquired assets and liabilities are determined) and the entity's specific application thereof. An entity that acquires another entity in a leveraged buyout transaction generally discloses the accounting policy followed by the acquiring entity in determining the basis used to value its interest in the acquired entity, and the rationale for that accounting policy.", "label": "Business Combinations Policy", "terseLabel": "Business Combination" } } }, "localname": "BusinessCombinationsPolicy", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://fulgentdiagnostics.com/20210630/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock": { "auth_ref": [ "r1", "r105", "r147" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for the business description and basis of presentation concepts. Business description describes the nature and type of organization including but not limited to organizational structure as may be applicable to holding companies, parent and subsidiary relationships, business divisions, business units, business segments, affiliates and information about significant ownership of the reporting entity. Basis of presentation describes the underlying basis used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).", "label": "Business Description And Basis Of Presentation [Text Block]", "terseLabel": "Overview and Basis of Presentation" } } }, "localname": "BusinessDescriptionAndBasisOfPresentationTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://fulgentdiagnostics.com/20210630/taxonomy/role/DisclosureOverviewAndBasisOfPresentation" ], "xbrltype": "textBlockItemType" }, "us-gaap_CashAndCashEquivalentsAtCarryingValue": { "auth_ref": [ "r2", "r28", "r91" ], "calculation": { "http://fulgentdiagnostics.com/20210630/taxonomy/role/StatementCondensedConsolidatedBalanceSheets": { "order": 10270.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.", "label": "Cash And Cash Equivalents At Carrying Value", "terseLabel": "Cash and cash equivalents" } } }, "localname": "CashAndCashEquivalentsAtCarryingValue", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://fulgentdiagnostics.com/20210630/taxonomy/role/DisclosureMarketableSecuritiesSummaryOfMarketableSecuritiesDetails", "http://fulgentdiagnostics.com/20210630/taxonomy/role/StatementCondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashAndCashEquivalentsFairValueDisclosure": { "auth_ref": [], "calculation": { "http://fulgentdiagnostics.com/20210630/taxonomy/role/DisclosureFairValueMeasurementsInformationAboutFinancialAssetsMeasuredAtFairValueOnRecurringBasisBasedOnThreeTierFairValueHierarchyDetails": { "order": 10070.0, "parentTag": "us-gaap_AssetsFairValueDisclosure", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Fair value portion of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "Cash And Cash Equivalents Fair Value Disclosure", "terseLabel": "Cash and cash equivalents fair value disclosure", "verboseLabel": "Cash and cash equivalents fair value disclosure" } } }, "localname": "CashAndCashEquivalentsFairValueDisclosure", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://fulgentdiagnostics.com/20210630/taxonomy/role/DisclosureFairValueMeasurementsInformationAboutFinancialAssetsMeasuredAtFairValueOnRecurringBasisBasedOnThreeTierFairValueHierarchyDetails", "http://fulgentdiagnostics.com/20210630/taxonomy/role/DisclosureMarketableSecuritiesSummaryOfMarketableSecuritiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": { "auth_ref": [ "r85", "r91", "r96" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents", "periodEndLabel": "Cash and cash equivalents at end of period", "periodStartLabel": "Cash and cash equivalents at beginning of period" } } }, "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://fulgentdiagnostics.com/20210630/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": { "auth_ref": [ "r85", "r391" ], "calculation": { "http://fulgentdiagnostics.com/20210630/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect", "totalLabel": "Net increase (decrease) in cash and cash equivalents" } } }, "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://fulgentdiagnostics.com/20210630/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashEquivalentsAtCarryingValue": { "auth_ref": [ "r28" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.", "label": "Cash Equivalents At Carrying Value", "negatedLabel": "Less: Cash equivalents" } } }, "localname": "CashEquivalentsAtCarryingValue", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://fulgentdiagnostics.com/20210630/taxonomy/role/DisclosureMarketableSecuritiesSummaryOfMarketableSecuritiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashEquivalentsMember": { "auth_ref": [ "r12" ], "lang": { "en-us": { "role": { "documentation": "Short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "Cash Equivalents [Member]", "terseLabel": "Cash Equivalents" } } }, "localname": "CashEquivalentsMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://fulgentdiagnostics.com/20210630/taxonomy/role/DisclosureMarketableSecuritiesSummaryOfMarketableSecuritiesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted": { "auth_ref": [ "r110", "r194", "r195", "r196", "r197", "r198", "r294", "r295", "r296", "r315", "r371", "r387", "r405", "r448", "r449", "r510", "r511" ], "lang": { "en-us": { "role": { "documentation": "Indicates (true false) whether accounting standards update was adopted.", "label": "Change In Accounting Principle Accounting Standards Update Adopted", "terseLabel": "Accounting standards update, adopted" } } }, "localname": "ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://fulgentdiagnostics.com/20210630/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails" ], "xbrltype": "booleanItemType" }, "us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateImmaterialEffect": { "auth_ref": [ "r111", "r122", "r201", "r301", "r319" ], "lang": { "en-us": { "role": { "documentation": "Indicates (true false) whether effect from applying amendment to accounting standards is immaterial.", "label": "Change In Accounting Principle Accounting Standards Update Immaterial Effect", "terseLabel": "Accounting standards update, immaterial effect" } } }, "localname": "ChangeInAccountingPrincipleAccountingStandardsUpdateImmaterialEffect", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://fulgentdiagnostics.com/20210630/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails" ], "xbrltype": "booleanItemType" }, "us-gaap_CommitmentsAndContingencies": { "auth_ref": [ "r41", "r238", "r471", "r496" ], "calculation": { "http://fulgentdiagnostics.com/20210630/taxonomy/role/StatementCondensedConsolidatedBalanceSheets": { "order": 10020.0, "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.", "label": "Commitments And Contingencies", "terseLabel": "Commitments and contingencies (Note 8)" } } }, "localname": "CommitmentsAndContingencies", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://fulgentdiagnostics.com/20210630/taxonomy/role/StatementCondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_CommonStockMember": { "auth_ref": [ "r106", "r107" ], "lang": { "en-us": { "role": { "documentation": "Stock that is subordinate to all other stock of the issuer.", "label": "Common Stock [Member]", "terseLabel": "Stockholders' Equity" } } }, "localname": "CommonStockMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://fulgentdiagnostics.com/20210630/taxonomy/role/DisclosureEquityDistributionAgreementAdditionalInformationDetails", "http://fulgentdiagnostics.com/20210630/taxonomy/role/StatementCondensedConsolidatedStatementsOfStockholdersEquityUnaudited" ], "xbrltype": "domainItemType" }, "us-gaap_CommonStockParOrStatedValuePerShare": { "auth_ref": [ "r19" ], "lang": { "en-us": { "role": { "documentation": "Face amount or stated value per share of common stock.", "label": "Common Stock Par Or Stated Value Per Share", "terseLabel": "Common stock, par value" } } }, "localname": "CommonStockParOrStatedValuePerShare", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://fulgentdiagnostics.com/20210630/taxonomy/role/StatementCondensedConsolidatedBalanceSheetsParenthetical" ], "xbrltype": "perShareItemType" }, "us-gaap_CommonStockSharesAuthorized": { "auth_ref": [ "r19" ], "lang": { "en-us": { "role": { "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws.", "label": "Common Stock Shares Authorized", "terseLabel": "Common stock, shares authorized" } } }, "localname": "CommonStockSharesAuthorized", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://fulgentdiagnostics.com/20210630/taxonomy/role/StatementCondensedConsolidatedBalanceSheetsParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockSharesIssued": { "auth_ref": [ "r19" ], "lang": { "en-us": { "role": { "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.", "label": "Common Stock Shares Issued", "periodEndLabel": "Ending Balance, Shares", "periodStartLabel": "Beginning Balance, Shares", "terseLabel": "Common stock, shares issued" } } }, "localname": "CommonStockSharesIssued", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://fulgentdiagnostics.com/20210630/taxonomy/role/StatementCondensedConsolidatedBalanceSheetsParenthetical", "http://fulgentdiagnostics.com/20210630/taxonomy/role/StatementCondensedConsolidatedStatementsOfStockholdersEquityUnaudited" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockSharesOutstanding": { "auth_ref": [ "r19", "r240" ], "lang": { "en-us": { "role": { "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.", "label": "Common Stock Shares Outstanding", "terseLabel": "Common stock, shares outstanding" } } }, "localname": "CommonStockSharesOutstanding", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://fulgentdiagnostics.com/20210630/taxonomy/role/StatementCondensedConsolidatedBalanceSheetsParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockValue": { "auth_ref": [ "r19" ], "calculation": { "http://fulgentdiagnostics.com/20210630/taxonomy/role/StatementCondensedConsolidatedBalanceSheets": { "order": 10060.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.", "label": "Common Stock Value", "terseLabel": "Common stock, $0.0001 par value per share, 50,000 shares authorized, 29,513 and 28,178 shares issued and outstanding at June 30, 2021 and December 31, 2020, respectively" } } }, "localname": "CommonStockValue", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://fulgentdiagnostics.com/20210630/taxonomy/role/StatementCondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_ComprehensiveIncomeNetOfTax": { "auth_ref": [ "r56", "r58", "r59", "r68", "r479", "r503" ], "calculation": { "http://fulgentdiagnostics.com/20210630/taxonomy/role/StatementCondensedConsolidatedStatementsOfComprehensiveIncomeLossUnaudited": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.", "label": "Comprehensive Income Net Of Tax", "totalLabel": "Comprehensive income attributable to Fulgent" } } }, "localname": "ComprehensiveIncomeNetOfTax", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://fulgentdiagnostics.com/20210630/taxonomy/role/StatementCondensedConsolidatedStatementsOfComprehensiveIncomeLossUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest": { "auth_ref": [ "r56", "r58", "r67", "r353", "r354", "r367", "r478", "r502" ], "calculation": { "http://fulgentdiagnostics.com/20210630/taxonomy/role/StatementCondensedConsolidatedStatementsOfComprehensiveIncomeLossUnaudited": { "order": 10020.0, "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income (loss) and other comprehensive income (loss), attributable to noncontrolling interests. Excludes changes in equity resulting from investments by owners and distributions to owners.", "label": "Comprehensive Income Net Of Tax Attributable To Noncontrolling Interest", "negatedTotalLabel": "Comprehensive loss attributable to noncontrolling interest" } } }, "localname": "ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://fulgentdiagnostics.com/20210630/taxonomy/role/StatementCondensedConsolidatedStatementsOfComprehensiveIncomeLossUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest": { "auth_ref": [ "r56", "r58", "r66", "r352", "r367", "r477", "r501" ], "calculation": { "http://fulgentdiagnostics.com/20210630/taxonomy/role/StatementCondensedConsolidatedStatementsOfComprehensiveIncomeLossUnaudited": { "order": 10010.0, "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income. Excludes changes in equity resulting from investments by owners and distributions to owners.", "label": "Comprehensive Income Net Of Tax Including Portion Attributable To Noncontrolling Interest", "totalLabel": "Comprehensive income from consolidated operations" } } }, "localname": "ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://fulgentdiagnostics.com/20210630/taxonomy/role/StatementCondensedConsolidatedStatementsOfComprehensiveIncomeLossUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_ComputerEquipmentMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Long lived, depreciable assets that are used in the creation, maintenance and utilization of information systems.", "label": "Computer Equipment [Member]", "terseLabel": "Computer Hardware" } } }, "localname": "ComputerEquipmentMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://fulgentdiagnostics.com/20210630/taxonomy/role/DisclosureFixedAssetsMajorClassesOfFixedAssetsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ConcentrationRiskBenchmarkDomain": { "auth_ref": [ "r142", "r143", "r179", "r384", "r385" ], "lang": { "en-us": { "role": { "documentation": "The denominator in a calculation of a disclosed concentration risk percentage.", "label": "Concentration Risk Benchmark [Domain]", "terseLabel": "Concentration Risk Benchmark" } } }, "localname": "ConcentrationRiskBenchmarkDomain", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://fulgentdiagnostics.com/20210630/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ConcentrationRiskByBenchmarkAxis": { "auth_ref": [ "r142", "r143", "r179", "r384", "r385", "r523" ], "lang": { "en-us": { "role": { "documentation": "Information by benchmark of concentration risk.", "label": "Concentration Risk By Benchmark [Axis]", "terseLabel": "Concentration Risk Benchmark" } } }, "localname": "ConcentrationRiskByBenchmarkAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://fulgentdiagnostics.com/20210630/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ConcentrationRiskByTypeAxis": { "auth_ref": [ "r142", "r143", "r179", "r384", "r385", "r523" ], "lang": { "en-us": { "role": { "documentation": "Information by type of concentration risk, for example, but not limited to, asset, liability, net assets, geographic, customer, employees, supplier, lender.", "label": "Concentration Risk By Type [Axis]", "terseLabel": "Concentration Risk Type" } } }, "localname": "ConcentrationRiskByTypeAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://fulgentdiagnostics.com/20210630/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ConcentrationRiskCreditRisk": { "auth_ref": [ "r138", "r486" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for credit risk.", "label": "Concentration Risk Credit Risk", "terseLabel": "Concentration of Customers" } } }, "localname": "ConcentrationRiskCreditRisk", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://fulgentdiagnostics.com/20210630/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_ConcentrationRiskPercentage1": { "auth_ref": [ "r142", "r143", "r179", "r384", "r385" ], "lang": { "en-us": { "role": { "documentation": "For an entity that discloses a concentration risk in relation to quantitative amount, which serves as the \"benchmark\" (or denominator) in the equation, this concept represents the concentration percentage derived from the division.", "label": "Concentration Risk Percentage1", "terseLabel": "Concentration risk, percentage" } } }, "localname": "ConcentrationRiskPercentage1", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://fulgentdiagnostics.com/20210630/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails" ], "xbrltype": "percentItemType" }, "us-gaap_ConcentrationRiskTypeDomain": { "auth_ref": [ "r142", "r143", "r179", "r384", "r385" ], "lang": { "en-us": { "role": { "documentation": "For an entity that discloses a concentration risk as a percentage of some financial balance or benchmark, identifies the type (for example, asset, liability, net assets, geographic, customer, employees, supplier, lender) of the concentration.", "label": "Concentration Risk Type [Domain]", "terseLabel": "Concentration Risk Type" } } }, "localname": "ConcentrationRiskTypeDomain", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://fulgentdiagnostics.com/20210630/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ContractWithCustomerAssetNet": { "auth_ref": [ "r244", "r246", "r258" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount, after allowance for credit loss, of right to consideration in exchange for good or service transferred to customer when right is conditioned on something other than passage of time.", "label": "Contract With Customer Asset Net", "terseLabel": "Contract assets from contract with customers" } } }, "localname": "ContractWithCustomerAssetNet", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://fulgentdiagnostics.com/20210630/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ContractWithCustomerAssetNetCurrent": { "auth_ref": [ "r244", "r246", "r258" ], "calculation": { "http://fulgentdiagnostics.com/20210630/taxonomy/role/DisclosureOtherSignificantBalanceSheetAccountsScheduleOfOtherCurrentAssetsDetails": { "order": 10050.0, "parentTag": "us-gaap_OtherAssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount, after allowance for credit loss, of right to consideration in exchange for good or service transferred to customer when right is conditioned on something other than passage of time, classified as current.", "label": "Contract With Customer Asset Net Current", "terseLabel": "Contract assets" } } }, "localname": "ContractWithCustomerAssetNetCurrent", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://fulgentdiagnostics.com/20210630/taxonomy/role/DisclosureOtherSignificantBalanceSheetAccountsScheduleOfOtherCurrentAssetsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ContractWithCustomerLiabilityCurrent": { "auth_ref": [ "r244", "r245", "r258" ], "calculation": { "http://fulgentdiagnostics.com/20210630/taxonomy/role/StatementCondensedConsolidatedBalanceSheets": { "order": 10170.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as current.", "label": "Contract With Customer Liability Current", "terseLabel": "Contract liabilities", "verboseLabel": "Contract liability" } } }, "localname": "ContractWithCustomerLiabilityCurrent", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://fulgentdiagnostics.com/20210630/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails", "http://fulgentdiagnostics.com/20210630/taxonomy/role/StatementCondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_ContractWithCustomerLiabilityRevenueRecognized": { "auth_ref": [ "r259" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of revenue recognized that was previously included in balance of obligation to transfer good or service to customer for which consideration from customer has been received or is due.", "label": "Contract With Customer Liability Revenue Recognized", "terseLabel": "Contract with customer liability, revenue recognized" } } }, "localname": "ContractWithCustomerLiabilityRevenueRecognized", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://fulgentdiagnostics.com/20210630/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_CorporateDebtSecuritiesMember": { "auth_ref": [ "r270", "r278", "r522" ], "lang": { "en-us": { "role": { "documentation": "Debt securities issued by domestic or foreign corporate business, banks and other entities with a promise of repayment.", "label": "Corporate Debt Securities [Member]", "terseLabel": "Corporate Debt Securities" } } }, "localname": "CorporateDebtSecuritiesMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://fulgentdiagnostics.com/20210630/taxonomy/role/DisclosureFairValueMeasurementsInformationAboutFinancialAssetsMeasuredAtFairValueOnRecurringBasisBasedOnThreeTierFairValueHierarchyDetails", "http://fulgentdiagnostics.com/20210630/taxonomy/role/DisclosureMarketableSecuritiesSummaryOfMarketableSecuritiesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_CostOfRevenue": { "auth_ref": [ "r74", "r99", "r192", "r386" ], "calculation": { "http://fulgentdiagnostics.com/20210630/taxonomy/role/StatementCondensedConsolidatedStatementsOfOperationsUnaudited": { "order": 10160.0, "parentTag": "us-gaap_GrossProfit", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The aggregate cost of goods produced and sold and services rendered during the reporting period.", "label": "Cost Of Revenue", "terseLabel": "Cost of revenue" } } }, "localname": "CostOfRevenue", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://fulgentdiagnostics.com/20210630/taxonomy/role/StatementCondensedConsolidatedStatementsOfOperationsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_CostOfSalesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Primary financial statement caption encompassing cost of sales.", "label": "Cost Of Sales [Member]", "terseLabel": "Cost of Revenue" } } }, "localname": "CostOfSalesMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://fulgentdiagnostics.com/20210630/taxonomy/role/DisclosureEquityBasedCompensationSummaryOfEquityBasedCompensationExpensesAsPartOfCostOfRevenueAndOperatingExpensesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_CreditFacilityAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Information by type of credit facility. Credit facilities provide capital to borrowers without the need to structure a loan for each borrowing.", "label": "Credit Facility [Axis]", "terseLabel": "Credit Facility" } } }, "localname": "CreditFacilityAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://fulgentdiagnostics.com/20210630/taxonomy/role/DisclosureMarketableSecuritiesAdditionalInformationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_CreditFacilityDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Type of credit facility. Credit facilities provide capital to borrowers without the need to structure a loan for each borrowing.", "label": "Credit Facility [Domain]", "terseLabel": "Credit Facility" } } }, "localname": "CreditFacilityDomain", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://fulgentdiagnostics.com/20210630/taxonomy/role/DisclosureMarketableSecuritiesAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_CustomerConcentrationRiskMember": { "auth_ref": [ "r141", "r179" ], "lang": { "en-us": { "role": { "documentation": "Reflects the percentage that revenues in the period from one or more significant customers is to net revenues, as defined by the entity, such as total net revenues, product line revenues, segment revenues. The risk is the materially adverse effects of loss of a significant customer.", "label": "Customer Concentration Risk [Member]", "terseLabel": "Customer Concentration Risk" } } }, "localname": "CustomerConcentrationRiskMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://fulgentdiagnostics.com/20210630/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_CustomerRelationshipsMember": { "auth_ref": [ "r342" ], "lang": { "en-us": { "role": { "documentation": "Customer relationship that exists between an entity and its customer, for example, but not limited to, tenant relationships.", "label": "Customer Relationships [Member]", "terseLabel": "Customer Relationships" } } }, "localname": "CustomerRelationshipsMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://fulgentdiagnostics.com/20210630/taxonomy/role/DisclosureBusinessCombinationAdditionalInformationDetails", "http://fulgentdiagnostics.com/20210630/taxonomy/role/DisclosureGoodwillAndAcquisitionRelatedIntangiblesSummariesOfGoodwillAndAcquisitionsRelatedIntangiblesBalancesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_DebtInstrumentAxis": { "auth_ref": [ "r15", "r16", "r17", "r466", "r467", "r487" ], "lang": { "en-us": { "role": { "documentation": "Information by type of debt instrument, including, but not limited to, draws against credit facilities.", "label": "Debt Instrument [Axis]", "terseLabel": "Debt Instrument" } } }, "localname": "DebtInstrumentAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://fulgentdiagnostics.com/20210630/taxonomy/role/DisclosureDebtCommitmentsAndContingenciesAdditionalInformationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DebtInstrumentDescription": { "auth_ref": [ "r15", "r17", "r241", "r466", "r467", "r485", "r487" ], "lang": { "en-us": { "role": { "documentation": "Identification of the lender and information about a contractual promise to repay a short-term or long-term obligation, which includes borrowings under lines of credit, notes payable, commercial paper, bonds payable, debentures, and other contractual obligations for payment. This may include rationale for entering into the arrangement, significant terms of the arrangement, which may include amount, repayment terms, priority, collateral required, debt covenants, borrowing capacity, call features, participation rights, conversion provisions, sinking-fund requirements, voting rights, basis for conversion if convertible and remarketing provisions. The description may be provided for individual debt instruments, rational groupings of debt instruments, or by debt in total.", "label": "Debt Instrument Description", "terseLabel": "Debt instrument, interest rate terms" } } }, "localname": "DebtInstrumentDescription", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://fulgentdiagnostics.com/20210630/taxonomy/role/DisclosureDebtCommitmentsAndContingenciesAdditionalInformationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DebtInstrumentInterestRateEffectivePercentage": { "auth_ref": [ "r38", "r239", "r403" ], "lang": { "en-us": { "role": { "documentation": "Effective interest rate for the funds borrowed under the debt agreement considering interest compounding and original issue discount or premium.", "label": "Debt Instrument Interest Rate Effective Percentage", "terseLabel": "Debt instrument, interest rate" } } }, "localname": "DebtInstrumentInterestRateEffectivePercentage", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://fulgentdiagnostics.com/20210630/taxonomy/role/DisclosureDebtCommitmentsAndContingenciesAdditionalInformationDetails" ], "xbrltype": "percentItemType" }, "us-gaap_DebtInstrumentNameDomain": { "auth_ref": [ "r39" ], "lang": { "en-us": { "role": { "documentation": "The name for the particular debt instrument or borrowing that distinguishes it from other debt instruments or borrowings, including draws against credit facilities.", "label": "Debt Instrument Name [Domain]", "terseLabel": "Debt Instrument, Name" } } }, "localname": "DebtInstrumentNameDomain", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://fulgentdiagnostics.com/20210630/taxonomy/role/DisclosureDebtCommitmentsAndContingenciesAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLoss": { "auth_ref": [ "r189", "r208", "r209", "r210" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of allowance for credit loss on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).", "label": "Debt Securities Available For Sale Allowance For Credit Loss", "terseLabel": "Credit losses" } } }, "localname": "DebtSecuritiesAvailableForSaleAllowanceForCreditLoss", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://fulgentdiagnostics.com/20210630/taxonomy/role/DisclosureMarketableSecuritiesAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredIncomeTaxExpenseBenefit": { "auth_ref": [ "r89", "r100", "r314", "r322", "r323", "r324" ], "calculation": { "http://fulgentdiagnostics.com/20210630/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited": { "order": 10230.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of deferred income tax expense (benefit) pertaining to income (loss) from continuing operations.", "label": "Deferred Income Tax Expense Benefit", "terseLabel": "Deferred taxes" } } }, "localname": "DeferredIncomeTaxExpenseBenefit", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://fulgentdiagnostics.com/20210630/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_Depreciation": { "auth_ref": [ "r89", "r227" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.", "label": "Depreciation", "verboseLabel": "Depreciation expense on fixed assets" } } }, "localname": "Depreciation", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://fulgentdiagnostics.com/20210630/taxonomy/role/DisclosureFixedAssetsAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DepreciationDepletionAndAmortization": { "auth_ref": [ "r89", "r155" ], "calculation": { "http://fulgentdiagnostics.com/20210630/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited": { "order": 10180.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.", "label": "Depreciation Depletion And Amortization", "terseLabel": "Depreciation and amortization" } } }, "localname": "DepreciationDepletionAndAmortization", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://fulgentdiagnostics.com/20210630/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_DisaggregationOfRevenueLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Disaggregation Of Revenue [Line Items]", "terseLabel": "Disaggregation Of Revenue [Line Items]" } } }, "localname": "DisaggregationOfRevenueLineItems", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://fulgentdiagnostics.com/20210630/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesSummaryOfRevenueFromContractsWithCustomersByPayorTypeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DisaggregationOfRevenueTable": { "auth_ref": [ "r257", "r260", "r261", "r262", "r263", "r264", "r265", "r266" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of information about disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor.", "label": "Disaggregation Of Revenue [Table]", "terseLabel": "Disaggregation Of Revenue [Table]" } } }, "localname": "DisaggregationOfRevenueTable", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://fulgentdiagnostics.com/20210630/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesSummaryOfRevenueFromContractsWithCustomersByPayorTypeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DisaggregationOfRevenueTableTextBlock": { "auth_ref": [ "r257" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor.", "label": "Disaggregation Of Revenue Table [Text Block]", "terseLabel": "Summary of Revenue from Contracts with Customers by Payor Type" } } }, "localname": "DisaggregationOfRevenueTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://fulgentdiagnostics.com/20210630/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock": { "auth_ref": [ "r305" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for share-based payment arrangement.", "label": "Disclosure Of Compensation Related Costs Share Based Payments [Text Block]", "terseLabel": "Equity-Based Compensation" } } }, "localname": "DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://fulgentdiagnostics.com/20210630/taxonomy/role/DisclosureEquityBasedCompensation" ], "xbrltype": "textBlockItemType" }, "us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Disclosure Of Compensation Related Costs Sharebased Payments [Abstract]" } } }, "localname": "DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "xbrltype": "stringItemType" }, "us-gaap_DueToRelatedPartiesCurrent": { "auth_ref": [ "r33", "r104", "r428" ], "calculation": { "http://fulgentdiagnostics.com/20210630/taxonomy/role/DisclosureOtherSignificantBalanceSheetAccountsScheduleOfOtherCurrentLiabilitiesDetails": { "order": 10040.0, "parentTag": "us-gaap_OtherLiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying amount as of the balance sheet date of obligations due all related parties. For classified balance sheets, represents the current portion of such liabilities (due within one year or within the normal operating cycle if longer).", "label": "Due To Related Parties Current", "terseLabel": "Due to related parties" } } }, "localname": "DueToRelatedPartiesCurrent", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://fulgentdiagnostics.com/20210630/taxonomy/role/DisclosureOtherSignificantBalanceSheetAccountsScheduleOfOtherCurrentLiabilitiesDetails", "http://fulgentdiagnostics.com/20210630/taxonomy/role/DisclosureRelatedPartiesAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_EarningsPerShareAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Earnings Per Share [Abstract]" } } }, "localname": "EarningsPerShareAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "xbrltype": "stringItemType" }, "us-gaap_EarningsPerShareBasicAndDilutedAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Earnings Per Share Basic And Diluted [Abstract]", "terseLabel": "Net income per common share attributable to Fulgent:" } } }, "localname": "EarningsPerShareBasicAndDilutedAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://fulgentdiagnostics.com/20210630/taxonomy/role/StatementCondensedConsolidatedStatementsOfOperationsUnaudited" ], "xbrltype": "stringItemType" }, "us-gaap_EarningsPerShareBasicAndDilutedOtherDisclosuresAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Earnings Per Share Basic And Diluted Other Disclosures [Abstract]", "terseLabel": "Weighted-average common shares:" } } }, "localname": "EarningsPerShareBasicAndDilutedOtherDisclosuresAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://fulgentdiagnostics.com/20210630/taxonomy/role/StatementCondensedConsolidatedStatementsOfOperationsUnaudited" ], "xbrltype": "stringItemType" }, "us-gaap_EarningsPerShareTextBlock": { "auth_ref": [ "r130", "r131", "r132", "r133" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for earnings per share.", "label": "Earnings Per Share [Text Block]", "terseLabel": "Income per Share" } } }, "localname": "EarningsPerShareTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://fulgentdiagnostics.com/20210630/taxonomy/role/DisclosureIncomePerShare" ], "xbrltype": "textBlockItemType" }, "us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": { "auth_ref": [ "r391" ], "calculation": { "http://fulgentdiagnostics.com/20210630/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited": { "order": 10040.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) from effect of exchange rate changes on cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; held in foreign currencies. Excludes amounts for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents", "terseLabel": "Effect of exchange rate changes on cash and cash equivalents" } } }, "localname": "EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://fulgentdiagnostics.com/20210630/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_EffectiveIncomeTaxRateContinuingOperations": { "auth_ref": [ "r309" ], "lang": { "en-us": { "role": { "documentation": "Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.", "label": "Effective Income Tax Rate Continuing Operations", "terseLabel": "Effective income tax rate" } } }, "localname": "EffectiveIncomeTaxRateContinuingOperations", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://fulgentdiagnostics.com/20210630/taxonomy/role/DisclosureProvisionForBenefitFromIncomeTaxesAdditionalInformationDetails" ], "xbrltype": "percentItemType" }, "us-gaap_EmployeeStockOptionMember": { "auth_ref": [ "r289" ], "lang": { "en-us": { "role": { "documentation": "Share-based payment arrangement granting right, subject to vesting and other restrictions, to purchase or sell certain number of shares at predetermined price for specified period of time.", "label": "Employee Stock Option [Member]", "terseLabel": "Options" } } }, "localname": "EmployeeStockOptionMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://fulgentdiagnostics.com/20210630/taxonomy/role/DisclosureIncomePerShareAntiDilutiveSecuritiesExcludedFromCalculationOfDilutedIncomePerShareDetails" ], "xbrltype": "domainItemType" }, "us-gaap_EquityAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Equity [Abstract]" } } }, "localname": "EquityAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "xbrltype": "stringItemType" }, "us-gaap_EquityComponentDomain": { "auth_ref": [ "r106", "r107", "r108", "r112", "r119", "r121", "r135", "r200", "r240", "r242", "r298", "r299", "r300", "r317", "r318", "r393", "r394", "r395", "r396", "r397", "r399", "r512", "r513", "r514" ], "lang": { "en-us": { "role": { "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc.", "label": "Equity Component [Domain]", "terseLabel": "Equity Component" } } }, "localname": "EquityComponentDomain", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://fulgentdiagnostics.com/20210630/taxonomy/role/DisclosureEquityDistributionAgreementAdditionalInformationDetails", "http://fulgentdiagnostics.com/20210630/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails", "http://fulgentdiagnostics.com/20210630/taxonomy/role/StatementCondensedConsolidatedStatementsOfStockholdersEquityUnaudited" ], "xbrltype": "domainItemType" }, "us-gaap_EquityMethodInvestmentOwnershipPercentage": { "auth_ref": [ "r191" ], "lang": { "en-us": { "role": { "documentation": "The percentage of ownership of common stock or equity participation in the investee accounted for under the equity method of accounting.", "label": "Equity Method Investment Ownership Percentage", "verboseLabel": "Equity interest to be made in joint venture" } } }, "localname": "EquityMethodInvestmentOwnershipPercentage", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://fulgentdiagnostics.com/20210630/taxonomy/role/DisclosureBusinessCombinationAdditionalInformationDetails" ], "xbrltype": "percentItemType" }, "us-gaap_EquitySecuritiesFvNi": { "auth_ref": [ "r383" ], "calculation": { "http://fulgentdiagnostics.com/20210630/taxonomy/role/DisclosureFairValueMeasurementsInformationAboutFinancialAssetsMeasuredAtFairValueOnRecurringBasisBasedOnThreeTierFairValueHierarchyDetails": { "order": 10010.0, "parentTag": "us-gaap_AssetsFairValueDisclosure", "weight": 1.0 }, "http://fulgentdiagnostics.com/20210630/taxonomy/role/DisclosureMarketableSecuritiesSummaryOfMarketableSecuritiesDetails": { "order": 10060.0, "parentTag": "us-gaap_EquitySecuritiesFvNiCost", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI).", "label": "Equity Securities Fv Ni", "terseLabel": "Marketable securities, Aggregate Fair Value", "verboseLabel": "Total equity trading securities" } } }, "localname": "EquitySecuritiesFvNi", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://fulgentdiagnostics.com/20210630/taxonomy/role/DisclosureFairValueMeasurementsInformationAboutFinancialAssetsMeasuredAtFairValueOnRecurringBasisBasedOnThreeTierFairValueHierarchyDetails", "http://fulgentdiagnostics.com/20210630/taxonomy/role/DisclosureMarketableSecuritiesSummaryOfMarketableSecuritiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_EquitySecuritiesFvNiCost": { "auth_ref": [], "calculation": { "http://fulgentdiagnostics.com/20210630/taxonomy/role/DisclosureMarketableSecuritiesSummaryOfMarketableSecuritiesDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Cost of investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI). Excludes equity method investment and investment in equity security without readily determinable fair value.", "label": "Equity Securities Fv Ni Cost", "totalLabel": "Marketable securities, Amortized Cost Basis" } } }, "localname": "EquitySecuritiesFvNiCost", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://fulgentdiagnostics.com/20210630/taxonomy/role/DisclosureMarketableSecuritiesSummaryOfMarketableSecuritiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ExchangeTradedFundsMember": { "auth_ref": [ "r270", "r379" ], "lang": { "en-us": { "role": { "documentation": "Investment that follows an index, commodity or basket of assets that trades similar to a stock on an exchange.", "label": "Exchange Traded Funds [Member]", "terseLabel": "Exchange Traded Funds" } } }, "localname": "ExchangeTradedFundsMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://fulgentdiagnostics.com/20210630/taxonomy/role/DisclosureFairValueMeasurementsInformationAboutFinancialAssetsMeasuredAtFairValueOnRecurringBasisBasedOnThreeTierFairValueHierarchyDetails", "http://fulgentdiagnostics.com/20210630/taxonomy/role/DisclosureMarketableSecuritiesSummaryOfMarketableSecuritiesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]", "terseLabel": "Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]" } } }, "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://fulgentdiagnostics.com/20210630/taxonomy/role/DisclosureFairValueMeasurementsInformationAboutFinancialAssetsMeasuredAtFairValueOnRecurringBasisBasedOnThreeTierFairValueHierarchyDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable": { "auth_ref": [ "r372", "r373", "r374", "r380" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of information about asset and liability measured at fair value on recurring and nonrecurring basis.", "label": "Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Table]", "terseLabel": "Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Table]" } } }, "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://fulgentdiagnostics.com/20210630/taxonomy/role/DisclosureFairValueMeasurementsInformationAboutFinancialAssetsMeasuredAtFairValueOnRecurringBasisBasedOnThreeTierFairValueHierarchyDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock": { "auth_ref": [ "r372", "r373" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of assets, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, by class that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).", "label": "Fair Value Assets Measured On Recurring Basis [Text Block]", "terseLabel": "Information about Financial Assets Measured at Fair Value on Recurring Basis Based on Three-Tier Fair Value Hierarchy" } } }, "localname": "FairValueAssetsMeasuredOnRecurringBasisTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://fulgentdiagnostics.com/20210630/taxonomy/role/DisclosureFairValueMeasurementsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain": { "auth_ref": [ "r378" ], "lang": { "en-us": { "role": { "documentation": "Class of asset.", "label": "Fair Value Assets Measured On Recurring Basis Unobservable Input Reconciliation By Asset Class [Domain]", "terseLabel": "Asset Class" } } }, "localname": "FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://fulgentdiagnostics.com/20210630/taxonomy/role/DisclosureFairValueMeasurementsInformationAboutFinancialAssetsMeasuredAtFairValueOnRecurringBasisBasedOnThreeTierFairValueHierarchyDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueByAssetClassAxis": { "auth_ref": [ "r372", "r380" ], "lang": { "en-us": { "role": { "documentation": "Information by class of asset.", "label": "Fair Value By Asset Class [Axis]", "terseLabel": "Asset Class" } } }, "localname": "FairValueByAssetClassAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://fulgentdiagnostics.com/20210630/taxonomy/role/DisclosureFairValueMeasurementsInformationAboutFinancialAssetsMeasuredAtFairValueOnRecurringBasisBasedOnThreeTierFairValueHierarchyDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueByFairValueHierarchyLevelAxis": { "auth_ref": [ "r270", "r271", "r272", "r273", "r274", "r275", "r276", "r278", "r373", "r436", "r437", "r438" ], "lang": { "en-us": { "role": { "documentation": "Information by level within fair value hierarchy and fair value measured at net asset value per share as practical expedient.", "label": "Fair Value By Fair Value Hierarchy Level [Axis]", "terseLabel": "Fair Value Hierarchy and NAV" } } }, "localname": "FairValueByFairValueHierarchyLevelAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://fulgentdiagnostics.com/20210630/taxonomy/role/DisclosureFairValueMeasurementsInformationAboutFinancialAssetsMeasuredAtFairValueOnRecurringBasisBasedOnThreeTierFairValueHierarchyDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueByMeasurementFrequencyAxis": { "auth_ref": [ "r372", "r373", "r376", "r377", "r381" ], "lang": { "en-us": { "role": { "documentation": "Information by measurement frequency.", "label": "Fair Value By Measurement Frequency [Axis]", "terseLabel": "Measurement Frequency" } } }, "localname": "FairValueByMeasurementFrequencyAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://fulgentdiagnostics.com/20210630/taxonomy/role/DisclosureFairValueMeasurementsInformationAboutFinancialAssetsMeasuredAtFairValueOnRecurringBasisBasedOnThreeTierFairValueHierarchyDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueDisclosuresAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Fair Value Disclosures [Abstract]" } } }, "localname": "FairValueDisclosuresAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "xbrltype": "stringItemType" }, "us-gaap_FairValueInputsLevel1Member": { "auth_ref": [ "r270", "r271", "r276", "r278", "r373", "r436" ], "lang": { "en-us": { "role": { "documentation": "Quoted prices in active markets for identical assets or liabilities that the reporting entity can access at the measurement date.", "label": "Fair Value Inputs Level1 [Member]", "terseLabel": "Level 1" } } }, "localname": "FairValueInputsLevel1Member", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://fulgentdiagnostics.com/20210630/taxonomy/role/DisclosureFairValueMeasurementsInformationAboutFinancialAssetsMeasuredAtFairValueOnRecurringBasisBasedOnThreeTierFairValueHierarchyDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueInputsLevel2Member": { "auth_ref": [ "r270", "r271", "r276", "r278", "r373", "r437" ], "lang": { "en-us": { "role": { "documentation": "Inputs other than quoted prices included within level 1 that are observable for an asset or liability, either directly or indirectly, including, but not limited to, quoted prices for similar assets or liabilities in active markets, or quoted prices for identical or similar assets or liabilities in inactive markets.", "label": "Fair Value Inputs Level2 [Member]", "terseLabel": "Level 2" } } }, "localname": "FairValueInputsLevel2Member", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://fulgentdiagnostics.com/20210630/taxonomy/role/DisclosureFairValueMeasurementsInformationAboutFinancialAssetsMeasuredAtFairValueOnRecurringBasisBasedOnThreeTierFairValueHierarchyDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueInputsLevel3Member": { "auth_ref": [ "r270", "r271", "r272", "r273", "r274", "r275", "r276", "r278", "r373", "r438" ], "lang": { "en-us": { "role": { "documentation": "Unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.", "label": "Fair Value Inputs Level3 [Member]", "terseLabel": "Level 3" } } }, "localname": "FairValueInputsLevel3Member", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://fulgentdiagnostics.com/20210630/taxonomy/role/DisclosureFairValueMeasurementsInformationAboutFinancialAssetsMeasuredAtFairValueOnRecurringBasisBasedOnThreeTierFairValueHierarchyDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueMeasurementFrequencyDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Measurement frequency.", "label": "Fair Value Measurement Frequency [Domain]", "terseLabel": "Measurement Frequency" } } }, "localname": "FairValueMeasurementFrequencyDomain", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://fulgentdiagnostics.com/20210630/taxonomy/role/DisclosureFairValueMeasurementsInformationAboutFinancialAssetsMeasuredAtFairValueOnRecurringBasisBasedOnThreeTierFairValueHierarchyDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueMeasurementInputsDisclosureTextBlock": { "auth_ref": [ "r382" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure of the fair value measurement of assets and liabilities, which includes financial instruments measured at fair value that are classified in shareholders' equity, which may be measured on a recurring or nonrecurring basis.", "label": "Fair Value Measurement Inputs Disclosure [Text Block]", "terseLabel": "Fair Value Measurements" } } }, "localname": "FairValueMeasurementInputsDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://fulgentdiagnostics.com/20210630/taxonomy/role/DisclosureFairValueMeasurements" ], "xbrltype": "textBlockItemType" }, "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue": { "auth_ref": [ "r378" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Fair value of financial instrument classified as an asset measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.", "label": "Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Asset Value", "terseLabel": "Fair value asset, investments measured using unobservable inputs" } } }, "localname": "FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://fulgentdiagnostics.com/20210630/taxonomy/role/DisclosureFairValueMeasurementsAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FairValueMeasurementsFairValueHierarchyDomain": { "auth_ref": [ "r270", "r271", "r272", "r273", "r274", "r275", "r276", "r278", "r436", "r437", "r438" ], "lang": { "en-us": { "role": { "documentation": "Categories used to prioritize the inputs to valuation techniques to measure fair value.", "label": "Fair Value Measurements Fair Value Hierarchy [Domain]", "terseLabel": "Fair Value Hierarchy and NAV" } } }, "localname": "FairValueMeasurementsFairValueHierarchyDomain", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://fulgentdiagnostics.com/20210630/taxonomy/role/DisclosureFairValueMeasurementsInformationAboutFinancialAssetsMeasuredAtFairValueOnRecurringBasisBasedOnThreeTierFairValueHierarchyDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueMeasurementsRecurringMember": { "auth_ref": [ "r379", "r381" ], "lang": { "en-us": { "role": { "documentation": "Frequent fair value measurement. Includes, but is not limited to, fair value adjustment for impairment of asset, liability or equity, frequently measured at fair value.", "label": "Fair Value Measurements Recurring [Member]", "terseLabel": "Fair Value Measurements Recurring" } } }, "localname": "FairValueMeasurementsRecurringMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://fulgentdiagnostics.com/20210630/taxonomy/role/DisclosureFairValueMeasurementsInformationAboutFinancialAssetsMeasuredAtFairValueOnRecurringBasisBasedOnThreeTierFairValueHierarchyDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization": { "auth_ref": [ "r221" ], "calculation": { "http://fulgentdiagnostics.com/20210630/taxonomy/role/DisclosureGoodwillAndAcquisitionRelatedIntangiblesSummariesOfGoodwillAndAcquisitionsRelatedIntangiblesBalancesDetails": { "order": 10020.0, "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Accumulated amount of amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.", "label": "Finite Lived Intangible Assets Accumulated Amortization", "negatedLabel": "Less: accumulated amortization" } } }, "localname": "FiniteLivedIntangibleAssetsAccumulatedAmortization", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://fulgentdiagnostics.com/20210630/taxonomy/role/DisclosureGoodwillAndAcquisitionRelatedIntangiblesSummariesOfGoodwillAndAcquisitionsRelatedIntangiblesBalancesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive": { "auth_ref": [], "calculation": { "http://fulgentdiagnostics.com/20210630/taxonomy/role/DisclosureGoodwillAndAcquisitionRelatedIntangiblesSummaryOfAnnualAmortizationExpenseForAcquisitionRelatedIntangiblesDetails": { "order": 10070.0, "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of amortization for asset, excluding financial asset and goodwill, lacking physical substance with finite life expected to be recognized after fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Finite Lived Intangible Assets Amortization Expense After Year Five", "terseLabel": "Thereafter" } } }, "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://fulgentdiagnostics.com/20210630/taxonomy/role/DisclosureGoodwillAndAcquisitionRelatedIntangiblesSummaryOfAnnualAmortizationExpenseForAcquisitionRelatedIntangiblesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths": { "auth_ref": [ "r222" ], "calculation": { "http://fulgentdiagnostics.com/20210630/taxonomy/role/DisclosureGoodwillAndAcquisitionRelatedIntangiblesSummaryOfAnnualAmortizationExpenseForAcquisitionRelatedIntangiblesDetails": { "order": 10020.0, "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Finite Lived Intangible Assets Amortization Expense Next Twelve Months", "terseLabel": "2022" } } }, "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://fulgentdiagnostics.com/20210630/taxonomy/role/DisclosureGoodwillAndAcquisitionRelatedIntangiblesSummaryOfAnnualAmortizationExpenseForAcquisitionRelatedIntangiblesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear": { "auth_ref": [], "calculation": { "http://fulgentdiagnostics.com/20210630/taxonomy/role/DisclosureGoodwillAndAcquisitionRelatedIntangiblesSummaryOfAnnualAmortizationExpenseForAcquisitionRelatedIntangiblesDetails": { "order": 10010.0, "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in remainder of current fiscal year.", "label": "Finite Lived Intangible Assets Amortization Expense Remainder Of Fiscal Year", "terseLabel": "2021 (remaining 6 months)" } } }, "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://fulgentdiagnostics.com/20210630/taxonomy/role/DisclosureGoodwillAndAcquisitionRelatedIntangiblesSummaryOfAnnualAmortizationExpenseForAcquisitionRelatedIntangiblesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of amortization expense of assets, excluding financial assets, that lack physical substance, having a limited useful life.", "label": "Finite Lived Intangible Assets Amortization Expense Table [Text Block]", "terseLabel": "Summary of Annual Amortization Expense For Acquisition-Related Intangibles" } } }, "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://fulgentdiagnostics.com/20210630/taxonomy/role/DisclosureGoodwillAndAcquisitionRelatedIntangiblesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive": { "auth_ref": [ "r222" ], "calculation": { "http://fulgentdiagnostics.com/20210630/taxonomy/role/DisclosureGoodwillAndAcquisitionRelatedIntangiblesSummaryOfAnnualAmortizationExpenseForAcquisitionRelatedIntangiblesDetails": { "order": 10060.0, "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Finite Lived Intangible Assets Amortization Expense Year Five", "terseLabel": "2026" } } }, "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearFive", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://fulgentdiagnostics.com/20210630/taxonomy/role/DisclosureGoodwillAndAcquisitionRelatedIntangiblesSummaryOfAnnualAmortizationExpenseForAcquisitionRelatedIntangiblesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour": { "auth_ref": [ "r222" ], "calculation": { "http://fulgentdiagnostics.com/20210630/taxonomy/role/DisclosureGoodwillAndAcquisitionRelatedIntangiblesSummaryOfAnnualAmortizationExpenseForAcquisitionRelatedIntangiblesDetails": { "order": 10050.0, "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Finite Lived Intangible Assets Amortization Expense Year Four", "terseLabel": "2025" } } }, "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearFour", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://fulgentdiagnostics.com/20210630/taxonomy/role/DisclosureGoodwillAndAcquisitionRelatedIntangiblesSummaryOfAnnualAmortizationExpenseForAcquisitionRelatedIntangiblesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree": { "auth_ref": [ "r222" ], "calculation": { "http://fulgentdiagnostics.com/20210630/taxonomy/role/DisclosureGoodwillAndAcquisitionRelatedIntangiblesSummaryOfAnnualAmortizationExpenseForAcquisitionRelatedIntangiblesDetails": { "order": 10040.0, "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Finite Lived Intangible Assets Amortization Expense Year Three", "terseLabel": "2024" } } }, "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearThree", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://fulgentdiagnostics.com/20210630/taxonomy/role/DisclosureGoodwillAndAcquisitionRelatedIntangiblesSummaryOfAnnualAmortizationExpenseForAcquisitionRelatedIntangiblesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo": { "auth_ref": [ "r222" ], "calculation": { "http://fulgentdiagnostics.com/20210630/taxonomy/role/DisclosureGoodwillAndAcquisitionRelatedIntangiblesSummaryOfAnnualAmortizationExpenseForAcquisitionRelatedIntangiblesDetails": { "order": 10030.0, "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Finite Lived Intangible Assets Amortization Expense Year Two", "terseLabel": "2023" } } }, "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://fulgentdiagnostics.com/20210630/taxonomy/role/DisclosureGoodwillAndAcquisitionRelatedIntangiblesSummaryOfAnnualAmortizationExpenseForAcquisitionRelatedIntangiblesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis": { "auth_ref": [ "r217", "r219", "r221", "r223", "r447", "r451" ], "lang": { "en-us": { "role": { "documentation": "Information by major type or class of finite-lived intangible assets.", "label": "Finite Lived Intangible Assets By Major Class [Axis]", "terseLabel": "Finite-Lived Intangible Assets by Major Class" } } }, "localname": "FiniteLivedIntangibleAssetsByMajorClassAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://fulgentdiagnostics.com/20210630/taxonomy/role/DisclosureBusinessCombinationAdditionalInformationDetails", "http://fulgentdiagnostics.com/20210630/taxonomy/role/DisclosureGoodwillAndAcquisitionRelatedIntangiblesSummariesOfGoodwillAndAcquisitionsRelatedIntangiblesBalancesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FiniteLivedIntangibleAssetsGross": { "auth_ref": [ "r221", "r451" ], "calculation": { "http://fulgentdiagnostics.com/20210630/taxonomy/role/DisclosureGoodwillAndAcquisitionRelatedIntangiblesSummariesOfGoodwillAndAcquisitionsRelatedIntangiblesBalancesDetails": { "order": 10010.0, "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount before amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.", "label": "Finite Lived Intangible Assets Gross", "positiveLabel": "Intangibles", "terseLabel": "Acquisitions-related intangibles, gross" } } }, "localname": "FiniteLivedIntangibleAssetsGross", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://fulgentdiagnostics.com/20210630/taxonomy/role/DisclosureGoodwillAndAcquisitionRelatedIntangiblesAdditionalInformationDetails", "http://fulgentdiagnostics.com/20210630/taxonomy/role/DisclosureGoodwillAndAcquisitionRelatedIntangiblesSummariesOfGoodwillAndAcquisitionsRelatedIntangiblesBalancesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FiniteLivedIntangibleAssetsLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Finite Lived Intangible Assets [Line Items]", "terseLabel": "Finite Lived Intangible Assets [Line Items]" } } }, "localname": "FiniteLivedIntangibleAssetsLineItems", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://fulgentdiagnostics.com/20210630/taxonomy/role/DisclosureGoodwillAndAcquisitionRelatedIntangiblesSummaryOfAnnualAmortizationExpenseForAcquisitionRelatedIntangiblesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain": { "auth_ref": [ "r217", "r220" ], "lang": { "en-us": { "role": { "documentation": "The major class of finite-lived intangible asset (for example, patents, trademarks, copyrights, etc.) A major class is composed of intangible assets that can be grouped together because they are similar, either by their nature or by their use in the operations of a company.", "label": "Finite Lived Intangible Assets Major Class Name [Domain]", "terseLabel": "Finite-Lived Intangible Assets, Major Class Name" } } }, "localname": "FiniteLivedIntangibleAssetsMajorClassNameDomain", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://fulgentdiagnostics.com/20210630/taxonomy/role/DisclosureBusinessCombinationAdditionalInformationDetails", "http://fulgentdiagnostics.com/20210630/taxonomy/role/DisclosureGoodwillAndAcquisitionRelatedIntangiblesSummariesOfGoodwillAndAcquisitionsRelatedIntangiblesBalancesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FiniteLivedIntangibleAssetsNet": { "auth_ref": [ "r221", "r447" ], "calculation": { "http://fulgentdiagnostics.com/20210630/taxonomy/role/DisclosureGoodwillAndAcquisitionRelatedIntangiblesSummariesOfGoodwillAndAcquisitionsRelatedIntangiblesBalancesDetails": { "order": null, "parentTag": null, "root": true, "weight": null }, "http://fulgentdiagnostics.com/20210630/taxonomy/role/DisclosureGoodwillAndAcquisitionRelatedIntangiblesSummaryOfAnnualAmortizationExpenseForAcquisitionRelatedIntangiblesDetails": { "order": null, "parentTag": null, "root": true, "weight": null }, "http://fulgentdiagnostics.com/20210630/taxonomy/role/StatementCondensedConsolidatedBalanceSheets": { "order": 10240.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.", "label": "Finite Lived Intangible Assets Net", "terseLabel": "Acquisition-related intangible assets, net", "totalLabel": "Acquisitions-related intangibles, net" } } }, "localname": "FiniteLivedIntangibleAssetsNet", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://fulgentdiagnostics.com/20210630/taxonomy/role/DisclosureGoodwillAndAcquisitionRelatedIntangiblesSummariesOfGoodwillAndAcquisitionsRelatedIntangiblesBalancesDetails", "http://fulgentdiagnostics.com/20210630/taxonomy/role/DisclosureGoodwillAndAcquisitionRelatedIntangiblesSummaryOfAnnualAmortizationExpenseForAcquisitionRelatedIntangiblesDetails", "http://fulgentdiagnostics.com/20210630/taxonomy/role/StatementCondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock": { "auth_ref": [ "r97", "r401" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for (1) transactions denominated in a currency other than the reporting enterprise's functional currency, (2) translating foreign currency financial statements that are incorporated into the financial statements of the reporting enterprise by consolidation, combination, or the equity method of accounting, and (3) remeasurement of the financial statements of a foreign reporting enterprise in a hyperinflationary economy.", "label": "Foreign Currency Transactions And Translations Policy [Text Block]", "terseLabel": "Foreign Currency Translation and Foreign Currency Transactions" } } }, "localname": "ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://fulgentdiagnostics.com/20210630/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_FurnitureAndFixturesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Equipment commonly used in offices and stores that have no permanent connection to the structure of a building or utilities. Examples include, but are not limited to, desks, chairs, tables, and bookcases.", "label": "Furniture And Fixtures [Member]", "terseLabel": "Furniture and Fixtures" } } }, "localname": "FurnitureAndFixturesMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://fulgentdiagnostics.com/20210630/taxonomy/role/DisclosureFixedAssetsMajorClassesOfFixedAssetsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_GainLossOnDispositionOfAssets": { "auth_ref": [ "r89", "r226", "r231" ], "calculation": { "http://fulgentdiagnostics.com/20210630/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited": { "order": 10200.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of gain (loss) on sale or disposal of property, plant and equipment assets, excluding oil and gas property and timber property.", "label": "Gain Loss On Disposition Of Assets", "negatedLabel": "Loss on disposal of fixed asset" } } }, "localname": "GainLossOnDispositionOfAssets", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://fulgentdiagnostics.com/20210630/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_GeneralAndAdministrativeExpense": { "auth_ref": [ "r75" ], "calculation": { "http://fulgentdiagnostics.com/20210630/taxonomy/role/StatementCondensedConsolidatedStatementsOfOperationsUnaudited": { "order": 10140.0, "parentTag": "us-gaap_OperatingExpenses", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.", "label": "General And Administrative Expense", "terseLabel": "General and administrative" } } }, "localname": "GeneralAndAdministrativeExpense", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://fulgentdiagnostics.com/20210630/taxonomy/role/StatementCondensedConsolidatedStatementsOfOperationsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_GeneralAndAdministrativeExpenseMember": { "auth_ref": [ "r70" ], "lang": { "en-us": { "role": { "documentation": "Primary financial statement caption encompassing general and administrative expense.", "label": "General And Administrative Expense [Member]", "terseLabel": "General and Administrative" } } }, "localname": "GeneralAndAdministrativeExpenseMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://fulgentdiagnostics.com/20210630/taxonomy/role/DisclosureBusinessCombinationAdditionalInformationDetails", "http://fulgentdiagnostics.com/20210630/taxonomy/role/DisclosureEquityBasedCompensationSummaryOfEquityBasedCompensationExpensesAsPartOfCostOfRevenueAndOperatingExpensesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_Goodwill": { "auth_ref": [ "r214", "r215", "r464" ], "calculation": { "http://fulgentdiagnostics.com/20210630/taxonomy/role/DisclosureBusinessCombinationSummaryOfConsiderationPaidAndAmountOfAssetsAcquiredAndLiabilitiesAssumedDetails": { "order": 10030.0, "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedLessNoncontrollingInterest", "weight": 1.0 }, "http://fulgentdiagnostics.com/20210630/taxonomy/role/StatementCondensedConsolidatedBalanceSheets": { "order": 10250.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.", "label": "Goodwill", "terseLabel": "Goodwill" } } }, "localname": "Goodwill", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://fulgentdiagnostics.com/20210630/taxonomy/role/DisclosureBusinessCombinationAdditionalInformationDetails", "http://fulgentdiagnostics.com/20210630/taxonomy/role/DisclosureBusinessCombinationSummaryOfConsiderationPaidAndAmountOfAssetsAcquiredAndLiabilitiesAssumedDetails", "http://fulgentdiagnostics.com/20210630/taxonomy/role/DisclosureGoodwillAndAcquisitionRelatedIntangiblesAdditionalInformationDetails", "http://fulgentdiagnostics.com/20210630/taxonomy/role/DisclosureGoodwillAndAcquisitionRelatedIntangiblesSummariesOfGoodwillAndAcquisitionsRelatedIntangiblesBalancesDetails", "http://fulgentdiagnostics.com/20210630/taxonomy/role/StatementCondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Goodwill And Intangible Assets Disclosure [Abstract]" } } }, "localname": "GoodwillAndIntangibleAssetsDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "xbrltype": "stringItemType" }, "us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock": { "auth_ref": [ "r224" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for goodwill and intangible assets.", "label": "Goodwill And Intangible Assets Disclosure [Text Block]", "terseLabel": "Goodwill and Acquisition-Related Intangibles" } } }, "localname": "GoodwillAndIntangibleAssetsDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://fulgentdiagnostics.com/20210630/taxonomy/role/DisclosureGoodwillAndAcquisitionRelatedIntangibles" ], "xbrltype": "textBlockItemType" }, "us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy": { "auth_ref": [ "r97", "r216" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for goodwill. This accounting policy also may address how an entity assesses and measures impairment of goodwill, how reporting units are determined, how goodwill is allocated to such units, and how the fair values of the reporting units are determined.", "label": "Goodwill And Intangible Assets Goodwill Policy", "terseLabel": "Goodwill" } } }, "localname": "GoodwillAndIntangibleAssetsGoodwillPolicy", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://fulgentdiagnostics.com/20210630/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_GrossProfit": { "auth_ref": [ "r73", "r99", "r158", "r162", "r166", "r169", "r172", "r192", "r386" ], "calculation": { "http://fulgentdiagnostics.com/20210630/taxonomy/role/StatementCondensedConsolidatedStatementsOfOperationsUnaudited": { "order": 10100.0, "parentTag": "us-gaap_OperatingIncomeLoss", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Aggregate revenue less cost of goods and services sold or operating expenses directly attributable to the revenue generation activity.", "label": "Gross Profit", "totalLabel": "Gross profit" } } }, "localname": "GrossProfit", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://fulgentdiagnostics.com/20210630/taxonomy/role/StatementCondensedConsolidatedStatementsOfOperationsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments": { "auth_ref": [ "r103", "r158", "r162", "r166", "r169", "r172" ], "calculation": { "http://fulgentdiagnostics.com/20210630/taxonomy/role/StatementCondensedConsolidatedStatementsOfOperationsUnaudited": { "order": 10060.0, "parentTag": "flgt_IncomeBeforeGainOnEquityMethodInvestmentAndEquityLossInInvestee", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of income (loss) from continuing operations before deduction of income tax expense (benefit) and income (loss) attributable to noncontrolling interest, and addition of income (loss) from equity method investments.", "label": "Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments", "totalLabel": "Income before income taxes, gain on equity method investment and equity loss in investee" } } }, "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://fulgentdiagnostics.com/20210630/taxonomy/role/StatementCondensedConsolidatedStatementsOfOperationsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeLossFromContinuingOperationsPerBasicShare": { "auth_ref": [ "r61", "r69", "r111", "r115", "r116", "r117", "r118", "r125", "r127", "r128", "r472", "r474", "r480", "r498" ], "lang": { "en-us": { "role": { "documentation": "The amount of net income (loss) from continuing operations per each share of common stock or unit outstanding during the reporting period.", "label": "Income Loss From Continuing Operations Per Basic Share", "terseLabel": "Basic", "verboseLabel": "Net income per common share, basic" } } }, "localname": "IncomeLossFromContinuingOperationsPerBasicShare", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://fulgentdiagnostics.com/20210630/taxonomy/role/DisclosureIncomePerShareReconciliationOfBasicAndDilutedIncomePerShareComputationsDetails", "http://fulgentdiagnostics.com/20210630/taxonomy/role/StatementCondensedConsolidatedStatementsOfOperationsUnaudited" ], "xbrltype": "perShareItemType" }, "us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare": { "auth_ref": [ "r61", "r69", "r111", "r115", "r116", "r117", "r118", "r125", "r127", "r128", "r129", "r480", "r498", "r500", "r504" ], "lang": { "en-us": { "role": { "documentation": "The amount of net income (loss) derived from continuing operations during the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.", "label": "Income Loss From Continuing Operations Per Diluted Share", "terseLabel": "Diluted", "verboseLabel": "Net income per common share, diluted" } } }, "localname": "IncomeLossFromContinuingOperationsPerDilutedShare", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://fulgentdiagnostics.com/20210630/taxonomy/role/DisclosureIncomePerShareReconciliationOfBasicAndDilutedIncomePerShareComputationsDetails", "http://fulgentdiagnostics.com/20210630/taxonomy/role/StatementCondensedConsolidatedStatementsOfOperationsUnaudited" ], "xbrltype": "perShareItemType" }, "us-gaap_IncomeLossFromEquityMethodInvestments": { "auth_ref": [ "r63", "r89", "r156", "r190", "r473", "r497" ], "calculation": { "http://fulgentdiagnostics.com/20210630/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited": { "order": 10260.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 }, "http://fulgentdiagnostics.com/20210630/taxonomy/role/StatementCondensedConsolidatedStatementsOfOperationsUnaudited": { "order": 10050.0, "parentTag": "us-gaap_ProfitLoss", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of income (loss) for proportionate share of equity method investee's income (loss).", "label": "Income Loss From Equity Method Investments", "negatedLabel": "Equity loss in investee", "terseLabel": "Equity loss in investee" } } }, "localname": "IncomeLossFromEquityMethodInvestments", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://fulgentdiagnostics.com/20210630/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited", "http://fulgentdiagnostics.com/20210630/taxonomy/role/StatementCondensedConsolidatedStatementsOfOperationsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeStatementAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Income Statement [Abstract]" } } }, "localname": "IncomeStatementAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "xbrltype": "stringItemType" }, "us-gaap_IncomeStatementLocationAxis": { "auth_ref": [ "r232" ], "lang": { "en-us": { "role": { "documentation": "Information by location in the income statement.", "label": "Income Statement Location [Axis]", "terseLabel": "Income Statement Location" } } }, "localname": "IncomeStatementLocationAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://fulgentdiagnostics.com/20210630/taxonomy/role/DisclosureBusinessCombinationAdditionalInformationDetails", "http://fulgentdiagnostics.com/20210630/taxonomy/role/DisclosureEquityBasedCompensationSummaryOfEquityBasedCompensationExpensesAsPartOfCostOfRevenueAndOperatingExpensesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_IncomeStatementLocationDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Location in the income statement.", "label": "Income Statement Location [Domain]", "terseLabel": "Income Statement Location" } } }, "localname": "IncomeStatementLocationDomain", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://fulgentdiagnostics.com/20210630/taxonomy/role/DisclosureBusinessCombinationAdditionalInformationDetails", "http://fulgentdiagnostics.com/20210630/taxonomy/role/DisclosureEquityBasedCompensationSummaryOfEquityBasedCompensationExpensesAsPartOfCostOfRevenueAndOperatingExpensesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_IncomeTaxDisclosureAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Income Tax Disclosure [Abstract]" } } }, "localname": "IncomeTaxDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "xbrltype": "stringItemType" }, "us-gaap_IncomeTaxDisclosureTextBlock": { "auth_ref": [ "r310", "r312", "r313", "r320", "r325", "r328", "r329", "r330" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.", "label": "Income Tax Disclosure [Text Block]", "terseLabel": "Provision for (Benefit from) Income Taxes" } } }, "localname": "IncomeTaxDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://fulgentdiagnostics.com/20210630/taxonomy/role/DisclosureProvisionForBenefitFromIncomeTaxes" ], "xbrltype": "textBlockItemType" }, "us-gaap_IncomeTaxEffectsAllocatedDirectlyToEquityCumulativeEffectOfChangeInAccountingPrinciple": { "auth_ref": [ "r321", "r326" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cumulative tax effect on beginning retained earnings from change in accounting principle.", "label": "Income Tax Effects Allocated Directly To Equity Cumulative Effect Of Change In Accounting Principle", "positiveLabel": "Cumulative tax effect", "terseLabel": "Cumulative tax effect of accounting change" } } }, "localname": "IncomeTaxEffectsAllocatedDirectlyToEquityCumulativeEffectOfChangeInAccountingPrinciple", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://fulgentdiagnostics.com/20210630/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails", "http://fulgentdiagnostics.com/20210630/taxonomy/role/StatementCondensedConsolidatedStatementsOfStockholdersEquityUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeTaxExpenseBenefit": { "auth_ref": [ "r100", "r120", "r121", "r157", "r308", "r321", "r327", "r505" ], "calculation": { "http://fulgentdiagnostics.com/20210630/taxonomy/role/StatementCondensedConsolidatedStatementsOfOperationsUnaudited": { "order": 10070.0, "parentTag": "flgt_IncomeBeforeGainOnEquityMethodInvestmentAndEquityLossInInvestee", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.", "label": "Income Tax Expense Benefit", "terseLabel": "Provision for (benefit from) income taxes" } } }, "localname": "IncomeTaxExpenseBenefit", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://fulgentdiagnostics.com/20210630/taxonomy/role/DisclosureProvisionForBenefitFromIncomeTaxesAdditionalInformationDetails", "http://fulgentdiagnostics.com/20210630/taxonomy/role/StatementCondensedConsolidatedStatementsOfOperationsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeTaxesPaid": { "auth_ref": [ "r86", "r92" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The amount of cash paid during the current period to foreign, federal, state, and local authorities as taxes on income.", "label": "Income Taxes Paid", "terseLabel": "Income taxes paid" } } }, "localname": "IncomeTaxesPaid", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://fulgentdiagnostics.com/20210630/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInAccountsPayable": { "auth_ref": [ "r88" ], "calculation": { "http://fulgentdiagnostics.com/20210630/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited": { "order": 10310.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.", "label": "Increase Decrease In Accounts Payable", "terseLabel": "Accounts payable" } } }, "localname": "IncreaseDecreaseInAccountsPayable", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://fulgentdiagnostics.com/20210630/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInAccountsReceivable": { "auth_ref": [ "r88" ], "calculation": { "http://fulgentdiagnostics.com/20210630/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited": { "order": 10290.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.", "label": "Increase Decrease In Accounts Receivable", "negatedLabel": "Trade accounts receivable" } } }, "localname": "IncreaseDecreaseInAccountsReceivable", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://fulgentdiagnostics.com/20210630/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities": { "auth_ref": [ "r88" ], "calculation": { "http://fulgentdiagnostics.com/20210630/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited": { "order": 10320.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in accrued expenses, and obligations classified as other.", "label": "Increase Decrease In Accrued Liabilities And Other Operating Liabilities", "terseLabel": "Accrued liabilities and other liabilities" } } }, "localname": "IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://fulgentdiagnostics.com/20210630/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInContractWithCustomerLiability": { "auth_ref": [ "r88" ], "calculation": { "http://fulgentdiagnostics.com/20210630/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited": { "order": 10340.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in obligation to transfer good or service to customer for which consideration has been received or is receivable.", "label": "Increase Decrease In Contract With Customer Liability", "terseLabel": "Contract liabilities" } } }, "localname": "IncreaseDecreaseInContractWithCustomerLiability", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://fulgentdiagnostics.com/20210630/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInIncomeTaxesPayableNetOfIncomeTaxesReceivable": { "auth_ref": [ "r88" ], "calculation": { "http://fulgentdiagnostics.com/20210630/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited": { "order": 10330.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The increase (decrease) during the reporting period in the amounts payable to taxing authorities for taxes that are based on the reporting entity's earnings, net of amounts receivable from taxing authorities for refunds of overpayments or recoveries of income taxes.", "label": "Increase Decrease In Income Taxes Payable Net Of Income Taxes Receivable", "terseLabel": "Income tax payable" } } }, "localname": "IncreaseDecreaseInIncomeTaxesPayableNetOfIncomeTaxesReceivable", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://fulgentdiagnostics.com/20210630/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Increase Decrease In Operating Capital [Abstract]", "terseLabel": "Changes in operating assets and liabilities:" } } }, "localname": "IncreaseDecreaseInOperatingCapitalAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://fulgentdiagnostics.com/20210630/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "xbrltype": "stringItemType" }, "us-gaap_IncreaseDecreaseInOtherOperatingAssets": { "auth_ref": [ "r88" ], "calculation": { "http://fulgentdiagnostics.com/20210630/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited": { "order": 10300.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in operating assets classified as other.", "label": "Increase Decrease In Other Operating Assets", "negatedLabel": "Other current and long-term assets" } } }, "localname": "IncreaseDecreaseInOtherOperatingAssets", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://fulgentdiagnostics.com/20210630/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_InterestAndOtherIncome": { "auth_ref": [], "calculation": { "http://fulgentdiagnostics.com/20210630/taxonomy/role/StatementCondensedConsolidatedStatementsOfOperationsUnaudited": { "order": 10090.0, "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The amount of interest income and other income recognized during the period. Included in this element is interest derived from investments in debt securities, cash and cash equivalents, and other investments which reflect the time value of money or transactions in which the payments are for the use or forbearance of money and other income from ancillary business-related activities (that is, excluding major activities considered part of the normal operations of the business).", "label": "Interest And Other Income", "terseLabel": "Interest and other income, net" } } }, "localname": "InterestAndOtherIncome", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://fulgentdiagnostics.com/20210630/taxonomy/role/StatementCondensedConsolidatedStatementsOfOperationsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_InterestExpense": { "auth_ref": [ "r62", "r154", "r402", "r404", "r481" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of the cost of borrowed funds accounted for as interest expense.", "label": "Interest Expense", "terseLabel": "Interest expense" } } }, "localname": "InterestExpense", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://fulgentdiagnostics.com/20210630/taxonomy/role/DisclosureDebtCommitmentsAndContingenciesAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_InvestmentIncomeAmortizationOfPremium": { "auth_ref": [ "r76" ], "calculation": { "http://fulgentdiagnostics.com/20210630/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited": { "order": 10210.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of amortization of purchase premium on nonoperating securities.", "label": "Investment Income Amortization Of Premium", "terseLabel": "Amortization of premium of marketable securities" } } }, "localname": "InvestmentIncomeAmortizationOfPremium", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://fulgentdiagnostics.com/20210630/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_InvestmentSecondaryCategorizationAxis": { "auth_ref": [ "r527", "r531", "r535" ], "lang": { "en-us": { "role": { "documentation": "Information by second categorization of investments, which may include, but is not limited to industry.", "label": "Investment Secondary Categorization [Axis]", "terseLabel": "Investment Secondary Categorization" } } }, "localname": "InvestmentSecondaryCategorizationAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://fulgentdiagnostics.com/20210630/taxonomy/role/DisclosureMarketableSecuritiesSummaryOfMarketableSecuritiesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_InvestmentTypeAxis": { "auth_ref": [ "r526", "r528", "r529", "r530", "r532", "r533", "r534", "r536", "r537", "r538", "r539", "r540", "r541", "r542", "r543" ], "lang": { "en-us": { "role": { "documentation": "Information by type of investments.", "label": "Investment Type [Axis]", "terseLabel": "Investment Type" } } }, "localname": "InvestmentTypeAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://fulgentdiagnostics.com/20210630/taxonomy/role/DisclosureFairValueMeasurementsInformationAboutFinancialAssetsMeasuredAtFairValueOnRecurringBasisBasedOnThreeTierFairValueHierarchyDetails", "http://fulgentdiagnostics.com/20210630/taxonomy/role/DisclosureMarketableSecuritiesSummaryOfMarketableSecuritiesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_InvestmentTypeCategorizationMember": { "auth_ref": [ "r526", "r528", "r529", "r530", "r532", "r533", "r534", "r536", "r537", "r538", "r539", "r540", "r541", "r542", "r543" ], "lang": { "en-us": { "role": { "documentation": "Asset obtained to generate income or appreciate in value.", "label": "Investment Type Categorization [Member]", "terseLabel": "Investments" } } }, "localname": "InvestmentTypeCategorizationMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://fulgentdiagnostics.com/20210630/taxonomy/role/DisclosureFairValueMeasurementsInformationAboutFinancialAssetsMeasuredAtFairValueOnRecurringBasisBasedOnThreeTierFairValueHierarchyDetails", "http://fulgentdiagnostics.com/20210630/taxonomy/role/DisclosureMarketableSecuritiesSummaryOfMarketableSecuritiesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_InvestmentsBySecondaryCategorizationDomain": { "auth_ref": [ "r525", "r527", "r531", "r535" ], "lang": { "en-us": { "role": { "documentation": "Investments in the \"Investment Holdings [Table]\" and the \"Summary of Investment Holdings [Table]\" are often categorized at two levels. The first categorization is the investment type. The second categorization can vary. The usual secondary categorizations are industry, country or geography.", "label": "Investments By Secondary Categorization [Domain]", "terseLabel": "Investments by Secondary Categorization" } } }, "localname": "InvestmentsBySecondaryCategorizationDomain", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://fulgentdiagnostics.com/20210630/taxonomy/role/DisclosureMarketableSecuritiesSummaryOfMarketableSecuritiesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Investments Debt And Equity Securities [Abstract]" } } }, "localname": "InvestmentsDebtAndEquitySecuritiesAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "xbrltype": "stringItemType" }, "us-gaap_InvestmentsInDebtAndEquityInstrumentsCashAndCashEquivalentsUnrealizedAndRealizedGainsLossesTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for cash, cash equivalents, investments in debt and equity instruments (including cost and equity investees and related income statement amounts), equity and cost method investments, investments in joint ventures and any other investment.", "label": "Investments In Debt And Equity Instruments Cash And Cash Equivalents Unrealized And Realized Gains Losses [Text Block]", "terseLabel": "Marketable Securities" } } }, "localname": "InvestmentsInDebtAndEquityInstrumentsCashAndCashEquivalentsUnrealizedAndRealizedGainsLossesTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://fulgentdiagnostics.com/20210630/taxonomy/role/DisclosureMarketableSecurities" ], "xbrltype": "textBlockItemType" }, "us-gaap_LandImprovementsMember": { "auth_ref": [ "r9" ], "lang": { "en-us": { "role": { "documentation": "Additions or improvements to real estate held.", "label": "Land Improvements [Member]", "terseLabel": "Land Improvements" } } }, "localname": "LandImprovementsMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://fulgentdiagnostics.com/20210630/taxonomy/role/DisclosureFixedAssetsMajorClassesOfFixedAssetsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_LandMember": { "auth_ref": [ "r260" ], "lang": { "en-us": { "role": { "documentation": "Part of earth's surface not covered by water.", "label": "Land [Member]", "terseLabel": "Land" } } }, "localname": "LandMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://fulgentdiagnostics.com/20210630/taxonomy/role/DisclosureFixedAssetsMajorClassesOfFixedAssetsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_LeaseCost": { "auth_ref": [ "r417", "r419" ], "calculation": { "http://fulgentdiagnostics.com/20210630/taxonomy/role/DisclosureLeasesScheduleOfOperatingLeaseExpenseDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of lease cost recognized by lessee for lease contract.", "label": "Lease Cost", "totalLabel": "Total lease cost" } } }, "localname": "LeaseCost", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://fulgentdiagnostics.com/20210630/taxonomy/role/DisclosureLeasesScheduleOfOperatingLeaseExpenseDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LeaseCostTableTextBlock": { "auth_ref": [ "r417" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of lessee's lease cost. Includes, but is not limited to, interest expense for finance lease, amortization of right-of-use asset for finance lease, operating lease cost, short-term lease cost, variable lease cost and sublease income.", "label": "Lease Cost Table [Text Block]", "terseLabel": "Schedule of Operating Lease Expense" } } }, "localname": "LeaseCostTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://fulgentdiagnostics.com/20210630/taxonomy/role/DisclosureLeasesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_LeaseholdImprovementsMember": { "auth_ref": [ "r228" ], "lang": { "en-us": { "role": { "documentation": "Additions or improvements to assets held under a lease arrangement.", "label": "Leasehold Improvements [Member]", "terseLabel": "Leasehold Improvements" } } }, "localname": "LeaseholdImprovementsMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://fulgentdiagnostics.com/20210630/taxonomy/role/DisclosureFixedAssetsMajorClassesOfFixedAssetsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_LeasesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Leases [Abstract]" } } }, "localname": "LeasesAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "xbrltype": "stringItemType" }, "us-gaap_LesseeLeaseDescriptionLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Lessee Lease Description [Line Items]", "terseLabel": "Lessee Lease Description [Line Items]" } } }, "localname": "LesseeLeaseDescriptionLineItems", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://fulgentdiagnostics.com/20210630/taxonomy/role/DisclosureLeasesAdditionalInformationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_LesseeLeaseDescriptionTable": { "auth_ref": [ "r411" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of information about lessee's leases.", "label": "Lessee Lease Description [Table]", "terseLabel": "Lessee Lease Description [Table]" } } }, "localname": "LesseeLeaseDescriptionTable", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://fulgentdiagnostics.com/20210630/taxonomy/role/DisclosureLeasesAdditionalInformationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_LesseeLeasesPolicyTextBlock": { "auth_ref": [ "r409" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for leasing arrangement entered into by lessee.", "label": "Lessee Leases Policy [Text Block]", "terseLabel": "Leases" } } }, "localname": "LesseeLeasesPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://fulgentdiagnostics.com/20210630/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock": { "auth_ref": [ "r418" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position.", "label": "Lessee Operating Lease Liability Maturity Table [Text Block]", "terseLabel": "Schedule of Maturity Analysis of Operating Lease Liabilities using Undiscounted Cash Flows on an Annual Basis" } } }, "localname": "LesseeOperatingLeaseLiabilityMaturityTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://fulgentdiagnostics.com/20210630/taxonomy/role/DisclosureLeasesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue": { "auth_ref": [ "r418" ], "calculation": { "http://fulgentdiagnostics.com/20210630/taxonomy/role/DisclosureLeasesScheduleOfMaturityAnalysisOfOperatingLeaseLiabilitiesUsingUndiscountedCashFlowsOnAnnualBasisDetails": { "order": null, "parentTag": null, "root": true, "weight": null }, "http://fulgentdiagnostics.com/20210630/taxonomy/role/DisclosureLeasesScheduleOfMaturityAnalysisOfOperatingLeaseLiabilitiesUsingUndiscountedCashFlowsOnAnnualBasisDetails2": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease.", "label": "Lessee Operating Lease Liability Payments Due", "totalLabel": "Total lease payments" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsDue", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://fulgentdiagnostics.com/20210630/taxonomy/role/DisclosureLeasesScheduleOfMaturityAnalysisOfOperatingLeaseLiabilitiesUsingUndiscountedCashFlowsOnAnnualBasisDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive": { "auth_ref": [ "r418" ], "calculation": { "http://fulgentdiagnostics.com/20210630/taxonomy/role/DisclosureLeasesScheduleOfMaturityAnalysisOfOperatingLeaseLiabilitiesUsingUndiscountedCashFlowsOnAnnualBasisDetails": { "order": 10070.0, "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease due after fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Lessee Operating Lease Liability Payments Due After Year Five", "terseLabel": "Thereafter" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://fulgentdiagnostics.com/20210630/taxonomy/role/DisclosureLeasesScheduleOfMaturityAnalysisOfOperatingLeaseLiabilitiesUsingUndiscountedCashFlowsOnAnnualBasisDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths": { "auth_ref": [ "r418" ], "calculation": { "http://fulgentdiagnostics.com/20210630/taxonomy/role/DisclosureLeasesScheduleOfMaturityAnalysisOfOperatingLeaseLiabilitiesUsingUndiscountedCashFlowsOnAnnualBasisDetails": { "order": 10020.0, "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Lessee Operating Lease Liability Payments Due Next Twelve Months", "terseLabel": "2022" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://fulgentdiagnostics.com/20210630/taxonomy/role/DisclosureLeasesScheduleOfMaturityAnalysisOfOperatingLeaseLiabilitiesUsingUndiscountedCashFlowsOnAnnualBasisDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive": { "auth_ref": [ "r418" ], "calculation": { "http://fulgentdiagnostics.com/20210630/taxonomy/role/DisclosureLeasesScheduleOfMaturityAnalysisOfOperatingLeaseLiabilitiesUsingUndiscountedCashFlowsOnAnnualBasisDetails": { "order": 10060.0, "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Lessee Operating Lease Liability Payments Due Year Five", "terseLabel": "2026" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearFive", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://fulgentdiagnostics.com/20210630/taxonomy/role/DisclosureLeasesScheduleOfMaturityAnalysisOfOperatingLeaseLiabilitiesUsingUndiscountedCashFlowsOnAnnualBasisDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour": { "auth_ref": [ "r418" ], "calculation": { "http://fulgentdiagnostics.com/20210630/taxonomy/role/DisclosureLeasesScheduleOfMaturityAnalysisOfOperatingLeaseLiabilitiesUsingUndiscountedCashFlowsOnAnnualBasisDetails": { "order": 10050.0, "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Lessee Operating Lease Liability Payments Due Year Four", "terseLabel": "2025" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearFour", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://fulgentdiagnostics.com/20210630/taxonomy/role/DisclosureLeasesScheduleOfMaturityAnalysisOfOperatingLeaseLiabilitiesUsingUndiscountedCashFlowsOnAnnualBasisDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree": { "auth_ref": [ "r418" ], "calculation": { "http://fulgentdiagnostics.com/20210630/taxonomy/role/DisclosureLeasesScheduleOfMaturityAnalysisOfOperatingLeaseLiabilitiesUsingUndiscountedCashFlowsOnAnnualBasisDetails": { "order": 10040.0, "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Lessee Operating Lease Liability Payments Due Year Three", "terseLabel": "2024" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearThree", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://fulgentdiagnostics.com/20210630/taxonomy/role/DisclosureLeasesScheduleOfMaturityAnalysisOfOperatingLeaseLiabilitiesUsingUndiscountedCashFlowsOnAnnualBasisDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo": { "auth_ref": [ "r418" ], "calculation": { "http://fulgentdiagnostics.com/20210630/taxonomy/role/DisclosureLeasesScheduleOfMaturityAnalysisOfOperatingLeaseLiabilitiesUsingUndiscountedCashFlowsOnAnnualBasisDetails": { "order": 10030.0, "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Lessee Operating Lease Liability Payments Due Year Two", "terseLabel": "2023" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearTwo", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://fulgentdiagnostics.com/20210630/taxonomy/role/DisclosureLeasesScheduleOfMaturityAnalysisOfOperatingLeaseLiabilitiesUsingUndiscountedCashFlowsOnAnnualBasisDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear": { "auth_ref": [ "r418" ], "calculation": { "http://fulgentdiagnostics.com/20210630/taxonomy/role/DisclosureLeasesScheduleOfMaturityAnalysisOfOperatingLeaseLiabilitiesUsingUndiscountedCashFlowsOnAnnualBasisDetails": { "order": 10010.0, "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease having initial or remaining lease term in excess of one year to be paid in remainder of current fiscal year.", "label": "Lessee Operating Lease Liability Payments Remainder Of Fiscal Year", "terseLabel": "2021 (remaining 6 months)" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://fulgentdiagnostics.com/20210630/taxonomy/role/DisclosureLeasesScheduleOfMaturityAnalysisOfOperatingLeaseLiabilitiesUsingUndiscountedCashFlowsOnAnnualBasisDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount": { "auth_ref": [ "r418" ], "calculation": { "http://fulgentdiagnostics.com/20210630/taxonomy/role/DisclosureLeasesScheduleOfMaturityAnalysisOfOperatingLeaseLiabilitiesUsingUndiscountedCashFlowsOnAnnualBasisDetails2": { "order": 10010.0, "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease.", "label": "Lessee Operating Lease Liability Undiscounted Excess Amount", "negatedLabel": "Less imputed interest" } } }, "localname": "LesseeOperatingLeaseLiabilityUndiscountedExcessAmount", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://fulgentdiagnostics.com/20210630/taxonomy/role/DisclosureLeasesScheduleOfMaturityAnalysisOfOperatingLeaseLiabilitiesUsingUndiscountedCashFlowsOnAnnualBasisDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseRenewalTerm": { "auth_ref": [ "r410" ], "lang": { "en-us": { "role": { "documentation": "Term of lessee's operating lease renewal, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.", "label": "Lessee Operating Lease Renewal Term", "terseLabel": "Operating leases, renewal term" } } }, "localname": "LesseeOperatingLeaseRenewalTerm", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://fulgentdiagnostics.com/20210630/taxonomy/role/DisclosureLeasesAdditionalInformationDetails" ], "xbrltype": "durationItemType" }, "us-gaap_LessorOperatingLeasePaymentsToBeReceived": { "auth_ref": [ "r421" ], "calculation": { "http://fulgentdiagnostics.com/20210630/taxonomy/role/DisclosureLeasesScheduleOfFutureFixedLeasePaymentsFromTenantsForAllNoncancelableOperatingLeasesDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of lease payments to be received by lessor for operating lease.", "label": "Lessor Operating Lease Payments To Be Received", "totalLabel": "Total" } } }, "localname": "LessorOperatingLeasePaymentsToBeReceived", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://fulgentdiagnostics.com/20210630/taxonomy/role/DisclosureLeasesScheduleOfFutureFixedLeasePaymentsFromTenantsForAllNoncancelableOperatingLeasesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LessorOperatingLeasePaymentsToBeReceivedMaturityTableTextBlock": { "auth_ref": [ "r421" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of maturity of undiscounted cash flows to be received by lessor on annual basis for operating lease.", "label": "Lessor Operating Lease Payments To Be Received Maturity Table [Text Block]", "terseLabel": "Schedule of Future Fixed Lease Payments from Tenants for All Noncancelable Operating Leases" } } }, "localname": "LessorOperatingLeasePaymentsToBeReceivedMaturityTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://fulgentdiagnostics.com/20210630/taxonomy/role/DisclosureLeasesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_LessorOperatingLeasePaymentsToBeReceivedNextTwelveMonths": { "auth_ref": [ "r421" ], "calculation": { "http://fulgentdiagnostics.com/20210630/taxonomy/role/DisclosureLeasesScheduleOfFutureFixedLeasePaymentsFromTenantsForAllNoncancelableOperatingLeasesDetails": { "order": 10020.0, "parentTag": "us-gaap_LessorOperatingLeasePaymentsToBeReceived", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of lease payment to be received by lessor for operating lease in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Lessor Operating Lease Payments To Be Received Next Twelve Months", "terseLabel": "2022" } } }, "localname": "LessorOperatingLeasePaymentsToBeReceivedNextTwelveMonths", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://fulgentdiagnostics.com/20210630/taxonomy/role/DisclosureLeasesScheduleOfFutureFixedLeasePaymentsFromTenantsForAllNoncancelableOperatingLeasesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LessorOperatingLeasePaymentsToBeReceivedRemainderOfFiscalYear": { "auth_ref": [ "r421" ], "calculation": { "http://fulgentdiagnostics.com/20210630/taxonomy/role/DisclosureLeasesScheduleOfFutureFixedLeasePaymentsFromTenantsForAllNoncancelableOperatingLeasesDetails": { "order": 10010.0, "parentTag": "us-gaap_LessorOperatingLeasePaymentsToBeReceived", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of lease payment to be received by lessor for operating lease in remainder of current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Lessor Operating Lease Payments To Be Received Remainder Of Fiscal Year", "terseLabel": "2021 (remaining 6 months)" } } }, "localname": "LessorOperatingLeasePaymentsToBeReceivedRemainderOfFiscalYear", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://fulgentdiagnostics.com/20210630/taxonomy/role/DisclosureLeasesScheduleOfFutureFixedLeasePaymentsFromTenantsForAllNoncancelableOperatingLeasesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LessorOperatingLeasePaymentsToBeReceivedThreeYears": { "auth_ref": [ "r421" ], "calculation": { "http://fulgentdiagnostics.com/20210630/taxonomy/role/DisclosureLeasesScheduleOfFutureFixedLeasePaymentsFromTenantsForAllNoncancelableOperatingLeasesDetails": { "order": 10040.0, "parentTag": "us-gaap_LessorOperatingLeasePaymentsToBeReceived", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of lease payment to be received by lessor for operating lease in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Lessor Operating Lease Payments To Be Received Three Years", "terseLabel": "2024" } } }, "localname": "LessorOperatingLeasePaymentsToBeReceivedThreeYears", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://fulgentdiagnostics.com/20210630/taxonomy/role/DisclosureLeasesScheduleOfFutureFixedLeasePaymentsFromTenantsForAllNoncancelableOperatingLeasesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LessorOperatingLeasePaymentsToBeReceivedTwoYears": { "auth_ref": [ "r421" ], "calculation": { "http://fulgentdiagnostics.com/20210630/taxonomy/role/DisclosureLeasesScheduleOfFutureFixedLeasePaymentsFromTenantsForAllNoncancelableOperatingLeasesDetails": { "order": 10030.0, "parentTag": "us-gaap_LessorOperatingLeasePaymentsToBeReceived", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of lease payment to be received by lessor for operating lease in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Lessor Operating Lease Payments To Be Received Two Years", "terseLabel": "2023" } } }, "localname": "LessorOperatingLeasePaymentsToBeReceivedTwoYears", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://fulgentdiagnostics.com/20210630/taxonomy/role/DisclosureLeasesScheduleOfFutureFixedLeasePaymentsFromTenantsForAllNoncancelableOperatingLeasesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_Liabilities": { "auth_ref": [ "r35", "r99", "r164", "r192", "r356", "r363", "r364", "r386" ], "calculation": { "http://fulgentdiagnostics.com/20210630/taxonomy/role/StatementCondensedConsolidatedBalanceSheets": { "order": 10010.0, "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.", "label": "Liabilities", "totalLabel": "Total liabilities" } } }, "localname": "Liabilities", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://fulgentdiagnostics.com/20210630/taxonomy/role/StatementCondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesAndStockholdersEquity": { "auth_ref": [ "r27", "r99", "r192", "r386", "r469", "r493" ], "calculation": { "http://fulgentdiagnostics.com/20210630/taxonomy/role/StatementCondensedConsolidatedBalanceSheets": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.", "label": "Liabilities And Stockholders Equity", "totalLabel": "Total liabilities and stockholders\u2019 equity" } } }, "localname": "LiabilitiesAndStockholdersEquity", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://fulgentdiagnostics.com/20210630/taxonomy/role/StatementCondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesAndStockholdersEquityAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Liabilities And Stockholders Equity [Abstract]", "terseLabel": "Liabilities and Stockholders\u2019 Equity" } } }, "localname": "LiabilitiesAndStockholdersEquityAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://fulgentdiagnostics.com/20210630/taxonomy/role/StatementCondensedConsolidatedBalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_LiabilitiesCurrent": { "auth_ref": [ "r37", "r99", "r192", "r356", "r363", "r364", "r386" ], "calculation": { "http://fulgentdiagnostics.com/20210630/taxonomy/role/StatementCondensedConsolidatedBalanceSheets": { "order": 10110.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.", "label": "Liabilities Current", "totalLabel": "Total current liabilities" } } }, "localname": "LiabilitiesCurrent", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://fulgentdiagnostics.com/20210630/taxonomy/role/StatementCondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesCurrentAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Liabilities Current [Abstract]", "terseLabel": "Current liabilities" } } }, "localname": "LiabilitiesCurrentAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://fulgentdiagnostics.com/20210630/taxonomy/role/StatementCondensedConsolidatedBalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_LongTermInvestments": { "auth_ref": [ "r29" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The total amount of investments that are intended to be held for an extended period of time (longer than one operating cycle).", "label": "Long Term Investments", "terseLabel": "Investment" } } }, "localname": "LongTermInvestments", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://fulgentdiagnostics.com/20210630/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LongTermNotesPayable": { "auth_ref": [ "r39" ], "calculation": { "http://fulgentdiagnostics.com/20210630/taxonomy/role/StatementCondensedConsolidatedBalanceSheets": { "order": 10120.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying value as of the balance sheet date of notes payable (with maturities initially due after one year or beyond the operating cycle if longer), excluding current portion.", "label": "Long Term Notes Payable", "terseLabel": "Notes payable" } } }, "localname": "LongTermNotesPayable", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://fulgentdiagnostics.com/20210630/taxonomy/role/StatementCondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_MarketableSecuritiesPolicy": { "auth_ref": [ "r484" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for investment classified as marketable security.", "label": "Marketable Securities Policy", "terseLabel": "Marketable Securities" } } }, "localname": "MarketableSecuritiesPolicy", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://fulgentdiagnostics.com/20210630/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_MeasurementInputDiscountForLackOfMarketabilityMember": { "auth_ref": [ "r375" ], "lang": { "en-us": { "role": { "documentation": "Measurement input using amount by which value of business ownership interest is reduced to reflect lack of ability to convert business interest into cash quickly.", "label": "Measurement Input Discount For Lack Of Marketability [Member]", "terseLabel": "Discount for Lack of Marketability" } } }, "localname": "MeasurementInputDiscountForLackOfMarketabilityMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://fulgentdiagnostics.com/20210630/taxonomy/role/DisclosureBusinessCombinationAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_MeasurementInputDiscountRateMember": { "auth_ref": [ "r375" ], "lang": { "en-us": { "role": { "documentation": "Measurement input using interest rate to determine present value of future cash flows.", "label": "Measurement Input Discount Rate [Member]", "terseLabel": "Discount" } } }, "localname": "MeasurementInputDiscountRateMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://fulgentdiagnostics.com/20210630/taxonomy/role/DisclosureBusinessCombinationAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_MeasurementInputTypeAxis": { "auth_ref": [ "r375" ], "lang": { "en-us": { "role": { "documentation": "Information by type of measurement input used to determine value of asset and liability.", "label": "Measurement Input Type [Axis]", "terseLabel": "Measurement Input Type" } } }, "localname": "MeasurementInputTypeAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://fulgentdiagnostics.com/20210630/taxonomy/role/DisclosureBusinessCombinationAdditionalInformationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_MeasurementInputTypeDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Measurement input used to determine value of asset and liability.", "label": "Measurement Input Type [Domain]", "terseLabel": "Measurement Input Type" } } }, "localname": "MeasurementInputTypeDomain", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://fulgentdiagnostics.com/20210630/taxonomy/role/DisclosureBusinessCombinationAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_MinorityInterest": { "auth_ref": [ "r43", "r99", "r192", "r386", "r468", "r492" ], "calculation": { "http://fulgentdiagnostics.com/20210630/taxonomy/role/StatementCondensedConsolidatedBalanceSheets": { "order": 10050.0, "parentTag": "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which is directly or indirectly attributable to that ownership interest in subsidiary equity which is not attributable to the parent (that is, noncontrolling interest, previously referred to as minority interest).", "label": "Minority Interest", "terseLabel": "Noncontrolling interest" } } }, "localname": "MinorityInterest", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://fulgentdiagnostics.com/20210630/taxonomy/role/StatementCondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_MinorityInterestOwnershipPercentageByParent": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The parent entity's interest in net assets of the subsidiary, expressed as a percentage.", "label": "Minority Interest Ownership Percentage By Parent", "terseLabel": "Minority interest ownership percentage" } } }, "localname": "MinorityInterestOwnershipPercentageByParent", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://fulgentdiagnostics.com/20210630/taxonomy/role/DisclosureBusinessCombinationAdditionalInformationDetails" ], "xbrltype": "percentItemType" }, "us-gaap_MoneyMarketFundsMember": { "auth_ref": [ "r270" ], "lang": { "en-us": { "role": { "documentation": "Fund that invests in short-term money-market instruments, for example, but not limited to, commercial paper, banker's acceptances, repurchase agreements, government securities, certificates of deposit, and other highly liquid securities.", "label": "Money Market Funds [Member]", "terseLabel": "Money Market Accounts" } } }, "localname": "MoneyMarketFundsMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://fulgentdiagnostics.com/20210630/taxonomy/role/DisclosureFairValueMeasurementsInformationAboutFinancialAssetsMeasuredAtFairValueOnRecurringBasisBasedOnThreeTierFairValueHierarchyDetails", "http://fulgentdiagnostics.com/20210630/taxonomy/role/DisclosureMarketableSecuritiesSummaryOfMarketableSecuritiesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_MunicipalBondsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Long-term debt securities issued by state, city or local governments or the agencies operated by state, city or local governments.", "label": "Municipal Bonds [Member]", "terseLabel": "Municipal Bonds" } } }, "localname": "MunicipalBondsMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://fulgentdiagnostics.com/20210630/taxonomy/role/DisclosureFairValueMeasurementsInformationAboutFinancialAssetsMeasuredAtFairValueOnRecurringBasisBasedOnThreeTierFairValueHierarchyDetails", "http://fulgentdiagnostics.com/20210630/taxonomy/role/DisclosureMarketableSecuritiesSummaryOfMarketableSecuritiesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_NetCashProvidedByUsedInFinancingActivities": { "auth_ref": [ "r85" ], "calculation": { "http://fulgentdiagnostics.com/20210630/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited": { "order": 10030.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.", "label": "Net Cash Provided By Used In Financing Activities", "totalLabel": "Net cash provided by (used in) financing activities" } } }, "localname": "NetCashProvidedByUsedInFinancingActivities", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://fulgentdiagnostics.com/20210630/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Net Cash Provided By Used In Financing Activities [Abstract]", "terseLabel": "Cash flow from financing activities:" } } }, "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://fulgentdiagnostics.com/20210630/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "xbrltype": "stringItemType" }, "us-gaap_NetCashProvidedByUsedInInvestingActivities": { "auth_ref": [ "r85" ], "calculation": { "http://fulgentdiagnostics.com/20210630/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited": { "order": 10020.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.", "label": "Net Cash Provided By Used In Investing Activities", "totalLabel": "Net cash used in investing activities" } } }, "localname": "NetCashProvidedByUsedInInvestingActivities", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://fulgentdiagnostics.com/20210630/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Net Cash Provided By Used In Investing Activities [Abstract]", "terseLabel": "Cash flow from investing activities:" } } }, "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://fulgentdiagnostics.com/20210630/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "xbrltype": "stringItemType" }, "us-gaap_NetCashProvidedByUsedInOperatingActivities": { "auth_ref": [ "r85", "r87", "r90" ], "calculation": { "http://fulgentdiagnostics.com/20210630/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited": { "order": 10010.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0 } }, "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.", "label": "Net Cash Provided By Used In Operating Activities", "totalLabel": "Net cash provided by (used in) operating activities" } } }, "localname": "NetCashProvidedByUsedInOperatingActivities", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://fulgentdiagnostics.com/20210630/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Net Cash Provided By Used In Operating Activities [Abstract]", "terseLabel": "Cash flow from operating activities:" } } }, "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://fulgentdiagnostics.com/20210630/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "xbrltype": "stringItemType" }, "us-gaap_NetIncomeLoss": { "auth_ref": [ "r0", "r54", "r57", "r64", "r90", "r99", "r111", "r115", "r116", "r117", "r118", "r120", "r121", "r126", "r158", "r162", "r166", "r169", "r172", "r192", "r386", "r475", "r499" ], "calculation": { "http://fulgentdiagnostics.com/20210630/taxonomy/role/StatementCondensedConsolidatedStatementsOfOperationsUnaudited": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.", "label": "Net Income Loss", "positiveVerboseLabel": "Net income attributable to Fulgent", "totalLabel": "Net income attributable to Fulgent" } } }, "localname": "NetIncomeLoss", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://fulgentdiagnostics.com/20210630/taxonomy/role/DisclosureIncomePerShareReconciliationOfBasicAndDilutedIncomePerShareComputationsDetails", "http://fulgentdiagnostics.com/20210630/taxonomy/role/StatementCondensedConsolidatedStatementsOfOperationsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetIncomeLossAttributableToNoncontrollingInterest": { "auth_ref": [ "r54", "r57", "r120", "r121", "r358", "r366" ], "calculation": { "http://fulgentdiagnostics.com/20210630/taxonomy/role/StatementCondensedConsolidatedStatementsOfComprehensiveIncomeLossUnaudited": { "order": 10030.0, "parentTag": "us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest", "weight": 1.0 }, "http://fulgentdiagnostics.com/20210630/taxonomy/role/StatementCondensedConsolidatedStatementsOfOperationsUnaudited": { "order": 10020.0, "parentTag": "us-gaap_NetIncomeLoss", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of Net Income (Loss) attributable to noncontrolling interest.", "label": "Net Income Loss Attributable To Noncontrolling Interest", "negatedLabel": "Net loss attributable to noncontrolling interests" } } }, "localname": "NetIncomeLossAttributableToNoncontrollingInterest", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://fulgentdiagnostics.com/20210630/taxonomy/role/StatementCondensedConsolidatedStatementsOfComprehensiveIncomeLossUnaudited", "http://fulgentdiagnostics.com/20210630/taxonomy/role/StatementCondensedConsolidatedStatementsOfOperationsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.", "label": "New Accounting Pronouncements Policy Policy [Text Block]", "terseLabel": "Recent Accounting and Recently Adopted Accounting Pronouncements" } } }, "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://fulgentdiagnostics.com/20210630/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_NonUsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Countries excluding the United States of America (US).", "label": "Non Us [Member]", "terseLabel": "Foreign" } } }, "localname": "NonUsMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://fulgentdiagnostics.com/20210630/taxonomy/role/DisclosureReportingSegmentAndGeographicalInformationSummaryOfRevenueByGeographicRegionDetails" ], "xbrltype": "domainItemType" }, "us-gaap_NoncashInvestingAndFinancingItemsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Noncash Investing And Financing Items [Abstract]", "terseLabel": "Supplemental disclosures of non-cash investing and financing activities:" } } }, "localname": "NoncashInvestingAndFinancingItemsAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://fulgentdiagnostics.com/20210630/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "xbrltype": "stringItemType" }, "us-gaap_NoncashOrPartNoncashAcquisitionFixedAssetsAcquired1": { "auth_ref": [ "r93", "r94", "r95" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The amount of fixed assets that an Entity acquires in a noncash (or part noncash) acquisition. Noncash is defined as information about all investing and financing activities of an enterprise during a period that affect recognized assets or liabilities but that do not result in cash receipts or cash payments in the period. \"Part noncash\" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.", "label": "Noncash Or Part Noncash Acquisition Fixed Assets Acquired1", "terseLabel": "Purchases of fixed assets in accounts payable" } } }, "localname": "NoncashOrPartNoncashAcquisitionFixedAssetsAcquired1", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://fulgentdiagnostics.com/20210630/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_NoncontrollingInterestIncreaseFromBusinessCombination": { "auth_ref": [ "r243", "r340", "r360" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of increase in noncontrolling interest from a business combination.", "label": "Noncontrolling Interest Increase From Business Combination", "terseLabel": "Noncontrolling interest assumed related to acquisitions" } } }, "localname": "NoncontrollingInterestIncreaseFromBusinessCombination", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://fulgentdiagnostics.com/20210630/taxonomy/role/StatementCondensedConsolidatedStatementsOfStockholdersEquityUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_NoncontrollingInterestMember": { "auth_ref": [ "r106", "r107", "r108", "r242", "r350" ], "lang": { "en-us": { "role": { "documentation": "This element represents that portion of equity (net assets) in a subsidiary not attributable, directly or indirectly, to the parent. A noncontrolling interest is sometimes called a minority interest.", "label": "Noncontrolling Interest [Member]", "terseLabel": "Noncontrolling Interest" } } }, "localname": "NoncontrollingInterestMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://fulgentdiagnostics.com/20210630/taxonomy/role/StatementCondensedConsolidatedStatementsOfStockholdersEquityUnaudited" ], "xbrltype": "domainItemType" }, "us-gaap_NotesPayable": { "auth_ref": [ "r17", "r467", "r489" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Including the current and noncurrent portions, aggregate carrying amount of all types of notes payable, as of the balance sheet date, with initial maturities beyond one year or beyond the normal operating cycle, if longer.", "label": "Notes Payable", "terseLabel": "Notes payable" } } }, "localname": "NotesPayable", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://fulgentdiagnostics.com/20210630/taxonomy/role/DisclosureDebtCommitmentsAndContingenciesAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_NumberOfReportableSegments": { "auth_ref": [ "r149" ], "lang": { "en-us": { "role": { "documentation": "Number of segments reported by the entity. A reportable segment is a component of an entity for which there is an accounting requirement to report separate financial information on that component in the entity's financial statements.", "label": "Number Of Reportable Segments", "terseLabel": "Number of reporting segments" } } }, "localname": "NumberOfReportableSegments", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://fulgentdiagnostics.com/20210630/taxonomy/role/DisclosureReportingSegmentAndGeographicalInformationAdditionalInformationDetails" ], "xbrltype": "integerItemType" }, "us-gaap_OperatingExpenses": { "auth_ref": [], "calculation": { "http://fulgentdiagnostics.com/20210630/taxonomy/role/StatementCondensedConsolidatedStatementsOfOperationsUnaudited": { "order": 10110.0, "parentTag": "us-gaap_OperatingIncomeLoss", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.", "label": "Operating Expenses", "totalLabel": "Total operating expenses" } } }, "localname": "OperatingExpenses", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://fulgentdiagnostics.com/20210630/taxonomy/role/StatementCondensedConsolidatedStatementsOfOperationsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingExpensesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Operating Expenses [Abstract]", "terseLabel": "Operating expenses:" } } }, "localname": "OperatingExpensesAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://fulgentdiagnostics.com/20210630/taxonomy/role/StatementCondensedConsolidatedStatementsOfOperationsUnaudited" ], "xbrltype": "stringItemType" }, "us-gaap_OperatingIncomeLoss": { "auth_ref": [ "r158", "r162", "r166", "r169", "r172" ], "calculation": { "http://fulgentdiagnostics.com/20210630/taxonomy/role/StatementCondensedConsolidatedStatementsOfOperationsUnaudited": { "order": 10080.0, "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The net result for the period of deducting operating expenses from operating revenues.", "label": "Operating Income Loss", "totalLabel": "Operating income" } } }, "localname": "OperatingIncomeLoss", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://fulgentdiagnostics.com/20210630/taxonomy/role/StatementCondensedConsolidatedStatementsOfOperationsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseCost": { "auth_ref": [ "r412", "r419" ], "calculation": { "http://fulgentdiagnostics.com/20210630/taxonomy/role/DisclosureLeasesScheduleOfOperatingLeaseExpenseDetails": { "order": 10010.0, "parentTag": "us-gaap_LeaseCost", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of single lease cost, calculated by allocation of remaining cost of lease over remaining lease term. Includes, but is not limited to, single lease cost, after impairment of right-of-use asset, calculated by amortization of remaining right-of-use asset and accretion of lease liability.", "label": "Operating Lease Cost", "terseLabel": "Operating lease cost" } } }, "localname": "OperatingLeaseCost", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://fulgentdiagnostics.com/20210630/taxonomy/role/DisclosureLeasesScheduleOfOperatingLeaseExpenseDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseLeaseIncome": { "auth_ref": [ "r134", "r420", "r424" ], "calculation": { "http://fulgentdiagnostics.com/20210630/taxonomy/role/DisclosureLeasesScheduleOfLeaseIncomeDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of operating lease income from lease payments and variable lease payments paid and payable to lessor. Includes, but is not limited to, variable lease payments not included in measurement of lease receivable.", "label": "Operating Lease Lease Income", "terseLabel": "Lease income", "totalLabel": "Total lease income" } } }, "localname": "OperatingLeaseLeaseIncome", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://fulgentdiagnostics.com/20210630/taxonomy/role/DisclosureLeasesAdditionalInformationDetails", "http://fulgentdiagnostics.com/20210630/taxonomy/role/DisclosureLeasesScheduleOfLeaseIncomeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseLeaseIncomeLeasePayments": { "auth_ref": [ "r134", "r422" ], "calculation": { "http://fulgentdiagnostics.com/20210630/taxonomy/role/DisclosureLeasesScheduleOfLeaseIncomeDetails": { "order": 10010.0, "parentTag": "us-gaap_OperatingLeaseLeaseIncome", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of operating lease income from lease payments paid and payable to lessor. Excludes variable lease payments not included in measurement of lease receivable.", "label": "Operating Lease Lease Income Lease Payments", "terseLabel": "Lease income" } } }, "localname": "OperatingLeaseLeaseIncomeLeasePayments", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://fulgentdiagnostics.com/20210630/taxonomy/role/DisclosureLeasesScheduleOfLeaseIncomeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseLeaseIncomeTableTextBlock": { "auth_ref": [ "r134", "r424" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of components of income from operating lease.", "label": "Operating Lease Lease Income Table [Text Block]", "terseLabel": "Schedule of Lease Income" } } }, "localname": "OperatingLeaseLeaseIncomeTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://fulgentdiagnostics.com/20210630/taxonomy/role/DisclosureLeasesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_OperatingLeaseLiability": { "auth_ref": [ "r407" ], "calculation": { "http://fulgentdiagnostics.com/20210630/taxonomy/role/DisclosureLeasesScheduleOfMaturityAnalysisOfOperatingLeaseLiabilitiesUsingUndiscountedCashFlowsOnAnnualBasisDetails2": { "order": 10020.0, "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease.", "label": "Operating Lease Liability", "terseLabel": "Total" } } }, "localname": "OperatingLeaseLiability", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://fulgentdiagnostics.com/20210630/taxonomy/role/DisclosureLeasesScheduleOfMaturityAnalysisOfOperatingLeaseLiabilitiesUsingUndiscountedCashFlowsOnAnnualBasisDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseLiabilityCurrent": { "auth_ref": [ "r407" ], "calculation": { "http://fulgentdiagnostics.com/20210630/taxonomy/role/DisclosureOtherSignificantBalanceSheetAccountsScheduleOfOtherCurrentLiabilitiesDetails": { "order": 10030.0, "parentTag": "us-gaap_OtherLiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.", "label": "Operating Lease Liability Current", "terseLabel": "Operating lease liabilities" } } }, "localname": "OperatingLeaseLiabilityCurrent", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://fulgentdiagnostics.com/20210630/taxonomy/role/DisclosureLeasesScheduleOfLeaseRightOfUseAssetShortTermLeaseLiabilitiesAndLongTermLeaseLiabilitiesDetails", "http://fulgentdiagnostics.com/20210630/taxonomy/role/DisclosureOtherSignificantBalanceSheetAccountsScheduleOfOtherCurrentLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList": { "auth_ref": [ "r408" ], "lang": { "en-us": { "role": { "documentation": "Indicates line item in statement of financial position that includes current operating lease liability.", "label": "Operating Lease Liability Current Statement Of Financial Position Extensible List", "terseLabel": "Operating lease, liability, current, statement of financial position [Extensible List]" } } }, "localname": "OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://fulgentdiagnostics.com/20210630/taxonomy/role/DisclosureLeasesScheduleOfLeaseRightOfUseAssetShortTermLeaseLiabilitiesAndLongTermLeaseLiabilitiesDetails" ], "xbrltype": "extensibleListItemType" }, "us-gaap_OperatingLeaseLiabilityNoncurrent": { "auth_ref": [ "r407" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.", "label": "Operating Lease Liability Noncurrent", "terseLabel": "Operating lease liabilities, long term" } } }, "localname": "OperatingLeaseLiabilityNoncurrent", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://fulgentdiagnostics.com/20210630/taxonomy/role/DisclosureLeasesScheduleOfLeaseRightOfUseAssetShortTermLeaseLiabilitiesAndLongTermLeaseLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList": { "auth_ref": [ "r408" ], "lang": { "en-us": { "role": { "documentation": "Indicates line item in statement of financial position that includes noncurrent operating lease liability.", "label": "Operating Lease Liability Noncurrent Statement Of Financial Position Extensible List", "terseLabel": "Operating lease, liability, noncurrent, statement of financial position [Extensible List]" } } }, "localname": "OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://fulgentdiagnostics.com/20210630/taxonomy/role/DisclosureLeasesScheduleOfLeaseRightOfUseAssetShortTermLeaseLiabilitiesAndLongTermLeaseLiabilitiesDetails" ], "xbrltype": "extensibleListItemType" }, "us-gaap_OperatingLeaseRightOfUseAsset": { "auth_ref": [ "r406" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's right to use underlying asset under operating lease.", "label": "Operating Lease Right Of Use Asset", "terseLabel": "Operating lease right-of-use asset" } } }, "localname": "OperatingLeaseRightOfUseAsset", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://fulgentdiagnostics.com/20210630/taxonomy/role/DisclosureLeasesScheduleOfLeaseRightOfUseAssetShortTermLeaseLiabilitiesAndLongTermLeaseLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList": { "auth_ref": [ "r408" ], "lang": { "en-us": { "role": { "documentation": "Indicates line item in statement of financial position that includes operating lease right-of-use asset.", "label": "Operating Lease Right Of Use Asset Statement Of Financial Position Extensible List", "terseLabel": "Operating lease, right-of-use asset, statement of financial position [Extensible List]" } } }, "localname": "OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://fulgentdiagnostics.com/20210630/taxonomy/role/DisclosureLeasesScheduleOfLeaseRightOfUseAssetShortTermLeaseLiabilitiesAndLongTermLeaseLiabilitiesDetails" ], "xbrltype": "extensibleListItemType" }, "us-gaap_OperatingLeaseVariableLeaseIncome": { "auth_ref": [ "r134", "r423" ], "calculation": { "http://fulgentdiagnostics.com/20210630/taxonomy/role/DisclosureLeasesScheduleOfLeaseIncomeDetails": { "order": 10020.0, "parentTag": "us-gaap_OperatingLeaseLeaseIncome", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of operating lease income from variable lease payments paid and payable to lessor, excluding amount included in measurement of lease receivable.", "label": "Operating Lease Variable Lease Income", "terseLabel": "Variable lease income" } } }, "localname": "OperatingLeaseVariableLeaseIncome", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://fulgentdiagnostics.com/20210630/taxonomy/role/DisclosureLeasesScheduleOfLeaseIncomeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent": { "auth_ref": [ "r416", "r419" ], "lang": { "en-us": { "role": { "documentation": "Weighted average discount rate for operating lease calculated at point in time.", "label": "Operating Lease Weighted Average Discount Rate Percent", "verboseLabel": "Weighted average discount rate - operating leases" } } }, "localname": "OperatingLeaseWeightedAverageDiscountRatePercent", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://fulgentdiagnostics.com/20210630/taxonomy/role/DisclosureLeasesScheduleOfSupplementalInformationRelatedToLeasesDetails" ], "xbrltype": "percentItemType" }, "us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1": { "auth_ref": [ "r415", "r419" ], "lang": { "en-us": { "role": { "documentation": "Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.", "label": "Operating Lease Weighted Average Remaining Lease Term1", "terseLabel": "Weighted average remaining lease term - operating leases" } } }, "localname": "OperatingLeaseWeightedAverageRemainingLeaseTerm1", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://fulgentdiagnostics.com/20210630/taxonomy/role/DisclosureLeasesScheduleOfSupplementalInformationRelatedToLeasesDetails" ], "xbrltype": "durationItemType" }, "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Organization Consolidation And Presentation Of Financial Statements [Abstract]" } } }, "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "xbrltype": "stringItemType" }, "us-gaap_OtherAssetsCurrent": { "auth_ref": [ "r44" ], "calculation": { "http://fulgentdiagnostics.com/20210630/taxonomy/role/DisclosureOtherSignificantBalanceSheetAccountsScheduleOfOtherCurrentAssetsDetails": { "order": null, "parentTag": null, "root": true, "weight": null }, "http://fulgentdiagnostics.com/20210630/taxonomy/role/StatementCondensedConsolidatedBalanceSheets": { "order": 10300.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of current assets classified as other.", "label": "Other Assets Current", "terseLabel": "Other current assets", "totalLabel": "Total" } } }, "localname": "OtherAssetsCurrent", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://fulgentdiagnostics.com/20210630/taxonomy/role/DisclosureOtherSignificantBalanceSheetAccountsScheduleOfOtherCurrentAssetsDetails", "http://fulgentdiagnostics.com/20210630/taxonomy/role/StatementCondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherAssetsNoncurrent": { "auth_ref": [ "r32" ], "calculation": { "http://fulgentdiagnostics.com/20210630/taxonomy/role/StatementCondensedConsolidatedBalanceSheets": { "order": 10260.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of noncurrent assets classified as other.", "label": "Other Assets Noncurrent", "terseLabel": "Other long-term assets" } } }, "localname": "OtherAssetsNoncurrent", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://fulgentdiagnostics.com/20210630/taxonomy/role/StatementCondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToNoncontrollingInterest": { "auth_ref": [ "r352", "r353", "r361" ], "calculation": { "http://fulgentdiagnostics.com/20210630/taxonomy/role/StatementCondensedConsolidatedStatementsOfComprehensiveIncomeLossUnaudited": { "order": 10040.0, "parentTag": "us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount after tax and reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature, attributable to noncontrolling interests.", "label": "Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Noncontrolling Interest", "negatedLabel": "Foreign currency translation gain attributable to noncontrolling interest" } } }, "localname": "OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToNoncontrollingInterest", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://fulgentdiagnostics.com/20210630/taxonomy/role/StatementCondensedConsolidatedStatementsOfComprehensiveIncomeLossUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax": { "auth_ref": [ "r47", "r50", "r389", "r390", "r392" ], "calculation": { "http://fulgentdiagnostics.com/20210630/taxonomy/role/StatementCondensedConsolidatedStatementsOfComprehensiveIncomeLossUnaudited": { "order": 10060.0, "parentTag": "us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount after tax, before reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature.", "label": "Other Comprehensive Income Foreign Currency Transaction And Translation Gain Loss Arising During Period Net Of Tax", "terseLabel": "Foreign currency translation gain (loss)" } } }, "localname": "OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://fulgentdiagnostics.com/20210630/taxonomy/role/StatementCondensedConsolidatedStatementsOfComprehensiveIncomeLossUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherComprehensiveIncomeLossNetOfTax": { "auth_ref": [ "r55", "r58", "r60", "r65", "r240", "r393", "r398", "r399", "r476", "r500" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount after tax and reclassification adjustments of other comprehensive income (loss).", "label": "Other Comprehensive Income Loss Net Of Tax", "terseLabel": "Other comprehensive gain (loss)" } } }, "localname": "OtherComprehensiveIncomeLossNetOfTax", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://fulgentdiagnostics.com/20210630/taxonomy/role/StatementCondensedConsolidatedStatementsOfStockholdersEquityUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Other Comprehensive Income Loss Net Of Tax Period Increase Decrease [Abstract]", "terseLabel": "Other comprehensive income (loss):" } } }, "localname": "OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://fulgentdiagnostics.com/20210630/taxonomy/role/StatementCondensedConsolidatedStatementsOfComprehensiveIncomeLossUnaudited" ], "xbrltype": "stringItemType" }, "us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax": { "auth_ref": [ "r48", "r50" ], "calculation": { "http://fulgentdiagnostics.com/20210630/taxonomy/role/StatementCondensedConsolidatedStatementsOfComprehensiveIncomeLossUnaudited": { "order": 10070.0, "parentTag": "us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount, after tax and before adjustment, of unrealized holding gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale). Excludes unrealized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity) from transfer to available-for-sale.", "label": "Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax", "terseLabel": "Net unrealized gain (loss) on marketable securities, net of tax" } } }, "localname": "OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://fulgentdiagnostics.com/20210630/taxonomy/role/StatementCondensedConsolidatedStatementsOfComprehensiveIncomeLossUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherCurrentAssetsMember": { "auth_ref": [ "r368", "r370" ], "lang": { "en-us": { "role": { "documentation": "Primary financial statement caption encompassing other current assets.", "label": "Other Current Assets [Member]", "terseLabel": "Other Current Assets" } } }, "localname": "OtherCurrentAssetsMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://fulgentdiagnostics.com/20210630/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_OtherCurrentLiabilitiesTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of other current liabilities.", "label": "Other Current Liabilities Table [Text Block]", "terseLabel": "Schedule of Other Current Liabilities" } } }, "localname": "OtherCurrentLiabilitiesTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://fulgentdiagnostics.com/20210630/taxonomy/role/DisclosureOtherSignificantBalanceSheetAccountsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_OtherLiabilitiesCurrent": { "auth_ref": [ "r10", "r11", "r36" ], "calculation": { "http://fulgentdiagnostics.com/20210630/taxonomy/role/DisclosureOtherSignificantBalanceSheetAccountsScheduleOfOtherCurrentLiabilitiesDetails": { "order": null, "parentTag": null, "root": true, "weight": null }, "http://fulgentdiagnostics.com/20210630/taxonomy/role/StatementCondensedConsolidatedBalanceSheets": { "order": 10200.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of liabilities classified as other, due within one year or the normal operating cycle, if longer.", "label": "Other Liabilities Current", "terseLabel": "Other current liabilities", "totalLabel": "Total" } } }, "localname": "OtherLiabilitiesCurrent", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://fulgentdiagnostics.com/20210630/taxonomy/role/DisclosureOtherSignificantBalanceSheetAccountsScheduleOfOtherCurrentLiabilitiesDetails", "http://fulgentdiagnostics.com/20210630/taxonomy/role/StatementCondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherLiabilitiesNoncurrent": { "auth_ref": [ "r40" ], "calculation": { "http://fulgentdiagnostics.com/20210630/taxonomy/role/StatementCondensedConsolidatedBalanceSheets": { "order": 10140.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer.", "label": "Other Liabilities Noncurrent", "terseLabel": "Other long-term liabilities" } } }, "localname": "OtherLiabilitiesNoncurrent", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://fulgentdiagnostics.com/20210630/taxonomy/role/StatementCondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherNoncashIncomeExpense": { "auth_ref": [ "r90" ], "calculation": { "http://fulgentdiagnostics.com/20210630/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited": { "order": 10280.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of income (expense) included in net income that results in no cash inflow (outflow), classified as other.", "label": "Other Noncash Income Expense", "negatedLabel": "Other" } } }, "localname": "OtherNoncashIncomeExpense", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://fulgentdiagnostics.com/20210630/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherNoncurrentAssetsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Primary financial statement caption encompassing other noncurrent assets.", "label": "Other Noncurrent Assets [Member]", "terseLabel": "Other Long-Term Assets" } } }, "localname": "OtherNoncurrentAssetsMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://fulgentdiagnostics.com/20210630/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_OtherReceivablesNetCurrent": { "auth_ref": [], "calculation": { "http://fulgentdiagnostics.com/20210630/taxonomy/role/DisclosureOtherSignificantBalanceSheetAccountsScheduleOfOtherCurrentAssetsDetails": { "order": 10040.0, "parentTag": "us-gaap_OtherAssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount, after allowance, of receivables classified as other, due within one year or the operating cycle, if longer.", "label": "Other Receivables Net Current", "terseLabel": "Other receivable" } } }, "localname": "OtherReceivablesNetCurrent", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://fulgentdiagnostics.com/20210630/taxonomy/role/DisclosureOtherSignificantBalanceSheetAccountsScheduleOfOtherCurrentAssetsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ParentMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Portion of equity, or net assets, in the consolidated entity attributable, directly or indirectly, to the parent. Excludes noncontrolling interests.", "label": "Parent [Member]", "terseLabel": "Fulgent Stockholders' Equity" } } }, "localname": "ParentMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://fulgentdiagnostics.com/20210630/taxonomy/role/StatementCondensedConsolidatedStatementsOfStockholdersEquityUnaudited" ], "xbrltype": "domainItemType" }, "us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation": { "auth_ref": [ "r83" ], "calculation": { "http://fulgentdiagnostics.com/20210630/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited": { "order": 10080.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of cash outflow to satisfy grantee's tax withholding obligation for award under share-based payment arrangement.", "label": "Payments Related To Tax Withholding For Share Based Compensation", "negatedLabel": "Common stock withholding for employee tax obligations" } } }, "localname": "PaymentsRelatedToTaxWithholdingForShareBasedCompensation", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://fulgentdiagnostics.com/20210630/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsToAcquireBusinessesGross": { "auth_ref": [ "r78", "r346" ], "calculation": { "http://fulgentdiagnostics.com/20210630/taxonomy/role/DisclosureBusinessCombinationSummaryOfConsiderationPaidAndAmountOfAssetsAcquiredAndLiabilitiesAssumedDetails": { "order": 10110.0, "parentTag": "us-gaap_BusinessCombinationConsiderationTransferredIncludingEquityInterestInAcquireeHeldPriorToCombination1", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cash outflow associated with the acquisition of business during the period. The cash portion only of the acquisition price.", "label": "Payments To Acquire Businesses Gross", "terseLabel": "Cash" } } }, "localname": "PaymentsToAcquireBusinessesGross", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://fulgentdiagnostics.com/20210630/taxonomy/role/DisclosureBusinessCombinationSummaryOfConsiderationPaidAndAmountOfAssetsAcquiredAndLiabilitiesAssumedDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired": { "auth_ref": [ "r78" ], "calculation": { "http://fulgentdiagnostics.com/20210630/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited": { "order": 10150.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cash outflow associated with the acquisition of a business, net of the cash acquired from the purchase.", "label": "Payments To Acquire Businesses Net Of Cash Acquired", "negatedLabel": "Acquisition of businesses, net of cash acquired" } } }, "localname": "PaymentsToAcquireBusinessesNetOfCashAcquired", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://fulgentdiagnostics.com/20210630/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsToAcquireMarketableSecurities": { "auth_ref": [ "r186" ], "calculation": { "http://fulgentdiagnostics.com/20210630/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited": { "order": 10120.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of cash outflow for purchase of marketable security.", "label": "Payments To Acquire Marketable Securities", "negatedLabel": "Purchase of marketable securities" } } }, "localname": "PaymentsToAcquireMarketableSecurities", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://fulgentdiagnostics.com/20210630/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment": { "auth_ref": [ "r79" ], "calculation": { "http://fulgentdiagnostics.com/20210630/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited": { "order": 10100.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.", "label": "Payments To Acquire Property Plant And Equipment", "negatedLabel": "Purchases of fixed assets" } } }, "localname": "PaymentsToAcquirePropertyPlantAndEquipment", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://fulgentdiagnostics.com/20210630/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_PreferredStockParOrStatedValuePerShare": { "auth_ref": [ "r18" ], "lang": { "en-us": { "role": { "documentation": "Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.", "label": "Preferred Stock Par Or Stated Value Per Share", "terseLabel": "Preferred stock, par value" } } }, "localname": "PreferredStockParOrStatedValuePerShare", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://fulgentdiagnostics.com/20210630/taxonomy/role/StatementCondensedConsolidatedBalanceSheetsParenthetical" ], "xbrltype": "perShareItemType" }, "us-gaap_PreferredStockSharesAuthorized": { "auth_ref": [ "r18" ], "lang": { "en-us": { "role": { "documentation": "The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.", "label": "Preferred Stock Shares Authorized", "terseLabel": "Preferred stock, shares authorized" } } }, "localname": "PreferredStockSharesAuthorized", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://fulgentdiagnostics.com/20210630/taxonomy/role/StatementCondensedConsolidatedBalanceSheetsParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_PreferredStockSharesIssued": { "auth_ref": [ "r18" ], "lang": { "en-us": { "role": { "documentation": "Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.", "label": "Preferred Stock Shares Issued", "terseLabel": "Preferred stock, shares issued" } } }, "localname": "PreferredStockSharesIssued", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://fulgentdiagnostics.com/20210630/taxonomy/role/StatementCondensedConsolidatedBalanceSheetsParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_PreferredStockSharesOutstanding": { "auth_ref": [ "r18" ], "lang": { "en-us": { "role": { "documentation": "Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.", "label": "Preferred Stock Shares Outstanding", "terseLabel": "Preferred stock, shares outstanding" } } }, "localname": "PreferredStockSharesOutstanding", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://fulgentdiagnostics.com/20210630/taxonomy/role/StatementCondensedConsolidatedBalanceSheetsParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_PreferredStockValue": { "auth_ref": [ "r18" ], "calculation": { "http://fulgentdiagnostics.com/20210630/taxonomy/role/StatementCondensedConsolidatedBalanceSheets": { "order": 10070.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.", "label": "Preferred Stock Value", "terseLabel": "Preferred stock, $0.0001 par value per share, 1,000 shares authorized, no shares issued or outstanding at June 30, 2021 and December 31, 2020" } } }, "localname": "PreferredStockValue", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://fulgentdiagnostics.com/20210630/taxonomy/role/StatementCondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_PrepaidExpenseCurrent": { "auth_ref": [ "r4", "r7", "r212", "r213" ], "calculation": { "http://fulgentdiagnostics.com/20210630/taxonomy/role/DisclosureOtherSignificantBalanceSheetAccountsScheduleOfOtherCurrentAssetsDetails": { "order": 10020.0, "parentTag": "us-gaap_OtherAssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits within a future period of one year or the normal operating cycle, if longer.", "label": "Prepaid Expense Current", "terseLabel": "Prepaid expenses" } } }, "localname": "PrepaidExpenseCurrent", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://fulgentdiagnostics.com/20210630/taxonomy/role/DisclosureOtherSignificantBalanceSheetAccountsScheduleOfOtherCurrentAssetsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_PrepaidTaxes": { "auth_ref": [ "r5", "r7", "r211", "r213" ], "calculation": { "http://fulgentdiagnostics.com/20210630/taxonomy/role/DisclosureOtherSignificantBalanceSheetAccountsScheduleOfOtherCurrentAssetsDetails": { "order": 10060.0, "parentTag": "us-gaap_OtherAssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of asset related to consideration paid in advance for income and other taxes that provide economic benefits within a future period of one year or the normal operating cycle, if longer.", "label": "Prepaid Taxes", "terseLabel": "Prepaid income taxes" } } }, "localname": "PrepaidTaxes", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://fulgentdiagnostics.com/20210630/taxonomy/role/DisclosureOtherSignificantBalanceSheetAccountsScheduleOfOtherCurrentAssetsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromIssuanceOfCommonStock": { "auth_ref": [ "r80" ], "calculation": { "http://fulgentdiagnostics.com/20210630/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited": { "order": 10050.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The cash inflow from the additional capital contribution to the entity.", "label": "Proceeds From Issuance Of Common Stock", "terseLabel": "Proceeds from (payment for) public offerings of common stock, net of issuance costs" } } }, "localname": "ProceedsFromIssuanceOfCommonStock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://fulgentdiagnostics.com/20210630/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromIssuanceOfDebt": { "auth_ref": [ "r81" ], "calculation": { "http://fulgentdiagnostics.com/20210630/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited": { "order": 10090.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The cash inflow during the period from additional borrowings in aggregate debt. Includes proceeds from short-term and long-term debt.", "label": "Proceeds From Issuance Of Debt", "terseLabel": "Borrowing under margin account" } } }, "localname": "ProceedsFromIssuanceOfDebt", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://fulgentdiagnostics.com/20210630/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromMinorityShareholders": { "auth_ref": [ "r82" ], "calculation": { "http://fulgentdiagnostics.com/20210630/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited": { "order": 10060.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow from a noncontrolling interest. Includes, but is not limited to, purchase of additional shares or other increase in noncontrolling interest ownership.", "label": "Proceeds From Minority Shareholders", "terseLabel": "Proceeds from noncontrolling interest" } } }, "localname": "ProceedsFromMinorityShareholders", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://fulgentdiagnostics.com/20210630/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities": { "auth_ref": [], "calculation": { "http://fulgentdiagnostics.com/20210630/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited": { "order": 10140.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The cash inflow associated with the aggregate amount received by the entity through sale or maturity of marketable securities (held-to-maturity or available-for-sale) during the period.", "label": "Proceeds From Sale And Maturity Of Marketable Securities", "terseLabel": "Maturities of marketable securities" } } }, "localname": "ProceedsFromSaleAndMaturityOfMarketableSecurities", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://fulgentdiagnostics.com/20210630/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment": { "auth_ref": [ "r77" ], "calculation": { "http://fulgentdiagnostics.com/20210630/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited": { "order": 10110.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The cash inflow from the sale of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale.", "label": "Proceeds From Sale Of Property Plant And Equipment", "terseLabel": "Proceeds from sale of fixed assets" } } }, "localname": "ProceedsFromSaleOfPropertyPlantAndEquipment", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://fulgentdiagnostics.com/20210630/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromStockOptionsExercised": { "auth_ref": [ "r80", "r293" ], "calculation": { "http://fulgentdiagnostics.com/20210630/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited": { "order": 10070.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow from exercise of option under share-based payment arrangement.", "label": "Proceeds From Stock Options Exercised", "terseLabel": "Proceeds from exercise of stock options" } } }, "localname": "ProceedsFromStockOptionsExercised", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://fulgentdiagnostics.com/20210630/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProfitLoss": { "auth_ref": [ "r0", "r54", "r57", "r84", "r99", "r111", "r120", "r121", "r158", "r162", "r166", "r169", "r172", "r192", "r352", "r357", "r359", "r366", "r367", "r386", "r482" ], "calculation": { "http://fulgentdiagnostics.com/20210630/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited": { "order": 10160.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 }, "http://fulgentdiagnostics.com/20210630/taxonomy/role/StatementCondensedConsolidatedStatementsOfComprehensiveIncomeLossUnaudited": { "order": 10050.0, "parentTag": "us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest", "weight": 1.0 }, "http://fulgentdiagnostics.com/20210630/taxonomy/role/StatementCondensedConsolidatedStatementsOfOperationsUnaudited": { "order": 10010.0, "parentTag": "us-gaap_NetIncomeLoss", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.", "label": "Profit Loss", "terseLabel": "Net income from consolidated operations", "totalLabel": "Net income from consolidated operations", "verboseLabel": "Net income (loss)" } } }, "localname": "ProfitLoss", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://fulgentdiagnostics.com/20210630/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited", "http://fulgentdiagnostics.com/20210630/taxonomy/role/StatementCondensedConsolidatedStatementsOfComprehensiveIncomeLossUnaudited", "http://fulgentdiagnostics.com/20210630/taxonomy/role/StatementCondensedConsolidatedStatementsOfOperationsUnaudited", "http://fulgentdiagnostics.com/20210630/taxonomy/role/StatementCondensedConsolidatedStatementsOfStockholdersEquityUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_PropertyPlantAndEquipmentAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Property Plant And Equipment [Abstract]" } } }, "localname": "PropertyPlantAndEquipmentAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "xbrltype": "stringItemType" }, "us-gaap_PropertyPlantAndEquipmentByTypeAxis": { "auth_ref": [ "r31", "r230" ], "lang": { "en-us": { "role": { "documentation": "Information by type of long-lived, physical assets used to produce goods and services and not intended for resale.", "label": "Property Plant And Equipment By Type [Axis]", "terseLabel": "Long-Lived Tangible Asset" } } }, "localname": "PropertyPlantAndEquipmentByTypeAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://fulgentdiagnostics.com/20210630/taxonomy/role/DisclosureFixedAssetsMajorClassesOfFixedAssetsDetails", "http://fulgentdiagnostics.com/20210630/taxonomy/role/DisclosureLeasesAdditionalInformationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock": { "auth_ref": [ "r233", "r545", "r546", "r547" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.", "label": "Property Plant And Equipment Disclosure [Text Block]", "terseLabel": "Fixed Assets" } } }, "localname": "PropertyPlantAndEquipmentDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://fulgentdiagnostics.com/20210630/taxonomy/role/DisclosureFixedAssets" ], "xbrltype": "textBlockItemType" }, "us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives": { "auth_ref": [ "r97", "r225" ], "lang": { "en-us": { "role": { "documentation": "Describes the periods of time over which an entity anticipates to receive utility from its property, plant and equipment (that is, the periods of time over which an entity allocates the initial cost of its property, plant and equipment).", "label": "Property Plant And Equipment Estimated Useful Lives", "terseLabel": "Useful life in years" } } }, "localname": "PropertyPlantAndEquipmentEstimatedUsefulLives", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://fulgentdiagnostics.com/20210630/taxonomy/role/DisclosureFixedAssetsMajorClassesOfFixedAssetsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_PropertyPlantAndEquipmentGross": { "auth_ref": [ "r30", "r228" ], "calculation": { "http://fulgentdiagnostics.com/20210630/taxonomy/role/DisclosureFixedAssetsMajorClassesOfFixedAssetsDetails": { "order": 10010.0, "parentTag": "us-gaap_PropertyPlantAndEquipmentNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.", "label": "Property Plant And Equipment Gross", "terseLabel": "Fixed assets, gross" } } }, "localname": "PropertyPlantAndEquipmentGross", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://fulgentdiagnostics.com/20210630/taxonomy/role/DisclosureFixedAssetsMajorClassesOfFixedAssetsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_PropertyPlantAndEquipmentLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Property Plant And Equipment [Line Items]", "terseLabel": "Property Plant And Equipment [Line Items]" } } }, "localname": "PropertyPlantAndEquipmentLineItems", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://fulgentdiagnostics.com/20210630/taxonomy/role/DisclosureFixedAssetsMajorClassesOfFixedAssetsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_PropertyPlantAndEquipmentNet": { "auth_ref": [ "r13", "r14", "r230", "r495" ], "calculation": { "http://fulgentdiagnostics.com/20210630/taxonomy/role/DisclosureFixedAssetsMajorClassesOfFixedAssetsDetails": { "order": null, "parentTag": null, "root": true, "weight": null }, "http://fulgentdiagnostics.com/20210630/taxonomy/role/StatementCondensedConsolidatedBalanceSheets": { "order": 10230.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.", "label": "Property Plant And Equipment Net", "terseLabel": "Fixed assets, net", "totalLabel": "Fixed assets, net" } } }, "localname": "PropertyPlantAndEquipmentNet", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://fulgentdiagnostics.com/20210630/taxonomy/role/DisclosureFixedAssetsMajorClassesOfFixedAssetsDetails", "http://fulgentdiagnostics.com/20210630/taxonomy/role/StatementCondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_PropertyPlantAndEquipmentTextBlock": { "auth_ref": [ "r13", "r230" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.", "label": "Property Plant And Equipment [Text Block]", "terseLabel": "Major Classes of Fixed Assets" } } }, "localname": "PropertyPlantAndEquipmentTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://fulgentdiagnostics.com/20210630/taxonomy/role/DisclosureFixedAssetsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_PropertyPlantAndEquipmentTypeDomain": { "auth_ref": [ "r13", "r228" ], "lang": { "en-us": { "role": { "documentation": "Listing of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale. Examples include land, buildings, machinery and equipment, and other types of furniture and equipment including, but not limited to, office equipment, furniture and fixtures, and computer equipment and software.", "label": "Property Plant And Equipment Type [Domain]", "terseLabel": "Long-Lived Tangible Asset" } } }, "localname": "PropertyPlantAndEquipmentTypeDomain", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://fulgentdiagnostics.com/20210630/taxonomy/role/DisclosureFixedAssetsMajorClassesOfFixedAssetsDetails", "http://fulgentdiagnostics.com/20210630/taxonomy/role/DisclosureLeasesAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_PropertyPlantAndEquipmentUsefulLife": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment.", "label": "Property Plant And Equipment Useful Life", "verboseLabel": "Useful life in years" } } }, "localname": "PropertyPlantAndEquipmentUsefulLife", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://fulgentdiagnostics.com/20210630/taxonomy/role/DisclosureFixedAssetsMajorClassesOfFixedAssetsDetails" ], "xbrltype": "durationItemType" }, "us-gaap_ProvisionForDoubtfulAccounts": { "auth_ref": [ "r71", "r206" ], "calculation": { "http://fulgentdiagnostics.com/20210630/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited": { "order": 10220.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of expense (reversal of expense) for expected credit loss on accounts receivable.", "label": "Provision For Doubtful Accounts", "terseLabel": "Provision for credit losses", "verboseLabel": "Provision for credit losses for accounts receivable" } } }, "localname": "ProvisionForDoubtfulAccounts", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://fulgentdiagnostics.com/20210630/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails", "http://fulgentdiagnostics.com/20210630/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_PurchaseObligation": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Minimum amount of purchase arrangement in which the entity has agreed to expend funds to procure goods or services from a supplier.", "label": "Purchase Obligation", "terseLabel": "Non-cancelable purchase obligations" } } }, "localname": "PurchaseObligation", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://fulgentdiagnostics.com/20210630/taxonomy/role/DisclosureDebtCommitmentsAndContingenciesAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_RecordedUnconditionalPurchaseObligationByCategoryOfItemPurchasedAxis": { "auth_ref": [ "r237" ], "lang": { "en-us": { "role": { "documentation": "Pertinent information about recorded unconditional purchase arrangements to acquire goods or services, by category of goods or services.", "label": "Recorded Unconditional Purchase Obligation By Category Of Item Purchased [Axis]", "terseLabel": "Recorded Unconditional Purchase Obligation by Category of Item Purchased" } } }, "localname": "RecordedUnconditionalPurchaseObligationByCategoryOfItemPurchasedAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://fulgentdiagnostics.com/20210630/taxonomy/role/DisclosureDebtCommitmentsAndContingenciesAdditionalInformationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_RecordedUnconditionalPurchaseObligationDueInNextRollingTwelveMonths": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of the recorded unconditional purchase obligation maturing in the next rolling twelve months following the latest balance sheet. For interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.", "label": "Recorded Unconditional Purchase Obligation Due In Next Rolling Twelve Months", "terseLabel": "Non-cancelable purchase obligations, payable within twelve months" } } }, "localname": "RecordedUnconditionalPurchaseObligationDueInNextRollingTwelveMonths", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://fulgentdiagnostics.com/20210630/taxonomy/role/DisclosureDebtCommitmentsAndContingenciesAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_RelatedPartyCosts": { "auth_ref": [ "r74", "r104" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Direct costs arising from transactions with related parties who are not affiliates or joint Ventures. These costs are categorized as cost of goods sold.", "label": "Related Party Costs", "terseLabel": "Related party costs" } } }, "localname": "RelatedPartyCosts", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://fulgentdiagnostics.com/20210630/taxonomy/role/DisclosureRelatedPartiesAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_RelatedPartyDomain": { "auth_ref": [ "r277", "r427", "r428" ], "lang": { "en-us": { "role": { "documentation": "Related parties include affiliates; other entities for which investments are accounted for by the equity method by the entity; trusts for benefit of employees; and principal owners, management, and members of immediate families. It also may include other parties with which the entity may control or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests.", "label": "Related Party [Domain]", "terseLabel": "Related Party" } } }, "localname": "RelatedPartyDomain", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://fulgentdiagnostics.com/20210630/taxonomy/role/DisclosureDebtCommitmentsAndContingenciesAdditionalInformationDetails", "http://fulgentdiagnostics.com/20210630/taxonomy/role/DisclosureRelatedPartiesAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_RelatedPartyTransactionAxis": { "auth_ref": [ "r277", "r427", "r428", "r430" ], "lang": { "en-us": { "role": { "documentation": "Information by type of related party transaction.", "label": "Related Party Transaction [Axis]", "terseLabel": "Related Party Transaction" } } }, "localname": "RelatedPartyTransactionAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://fulgentdiagnostics.com/20210630/taxonomy/role/DisclosureRelatedPartiesAdditionalInformationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_RelatedPartyTransactionDomain": { "auth_ref": [ "r277" ], "lang": { "en-us": { "role": { "documentation": "Transaction between related party.", "label": "Related Party Transaction [Domain]", "terseLabel": "Related Party Transaction" } } }, "localname": "RelatedPartyTransactionDomain", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://fulgentdiagnostics.com/20210630/taxonomy/role/DisclosureRelatedPartiesAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty": { "auth_ref": [ "r427" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Expenses recognized resulting from transactions (excluding transactions that are eliminated in consolidated or combined financial statements) with related party.", "label": "Related Party Transaction Expenses From Transactions With Related Party", "terseLabel": "Expenses to transport employees and supplies" } } }, "localname": "RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://fulgentdiagnostics.com/20210630/taxonomy/role/DisclosureRelatedPartiesAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_RelatedPartyTransactionLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Related Party Transaction [Line Items]", "terseLabel": "Related Party Transaction [Line Items]" } } }, "localname": "RelatedPartyTransactionLineItems", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://fulgentdiagnostics.com/20210630/taxonomy/role/DisclosureRelatedPartiesAdditionalInformationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_RelatedPartyTransactionsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Related Party Transactions [Abstract]" } } }, "localname": "RelatedPartyTransactionsAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "xbrltype": "stringItemType" }, "us-gaap_RelatedPartyTransactionsByRelatedPartyAxis": { "auth_ref": [ "r277", "r427", "r430", "r452", "r453", "r454", "r455", "r456", "r457", "r458", "r459", "r460", "r461", "r462", "r463" ], "lang": { "en-us": { "role": { "documentation": "Information by type of related party. Related parties include, but not limited to, affiliates; other entities for which investments are accounted for by the equity method by the entity; trusts for benefit of employees; and principal owners, management, and members of immediate families. It also may include other parties with which the entity may control or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests.", "label": "Related Party Transactions By Related Party [Axis]", "terseLabel": "Related Party" } } }, "localname": "RelatedPartyTransactionsByRelatedPartyAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://fulgentdiagnostics.com/20210630/taxonomy/role/DisclosureDebtCommitmentsAndContingenciesAdditionalInformationDetails", "http://fulgentdiagnostics.com/20210630/taxonomy/role/DisclosureRelatedPartiesAdditionalInformationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_RelatedPartyTransactionsDisclosureTextBlock": { "auth_ref": [ "r425", "r426", "r428", "r431", "r432" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.", "label": "Related Party Transactions Disclosure [Text Block]", "terseLabel": "Related Parties" } } }, "localname": "RelatedPartyTransactionsDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://fulgentdiagnostics.com/20210630/taxonomy/role/DisclosureRelatedParties" ], "xbrltype": "textBlockItemType" }, "us-gaap_ResearchAndDevelopmentExpense": { "auth_ref": [ "r306", "r557" ], "calculation": { "http://fulgentdiagnostics.com/20210630/taxonomy/role/StatementCondensedConsolidatedStatementsOfOperationsUnaudited": { "order": 10120.0, "parentTag": "us-gaap_OperatingExpenses", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.", "label": "Research And Development Expense", "terseLabel": "Research and development" } } }, "localname": "ResearchAndDevelopmentExpense", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://fulgentdiagnostics.com/20210630/taxonomy/role/StatementCondensedConsolidatedStatementsOfOperationsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_ResearchAndDevelopmentExpenseMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Primary financial statement caption in which the reported facts about research and development expense have been included.", "label": "Research And Development Expense [Member]", "terseLabel": "Research and Development" } } }, "localname": "ResearchAndDevelopmentExpenseMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://fulgentdiagnostics.com/20210630/taxonomy/role/DisclosureEquityBasedCompensationSummaryOfEquityBasedCompensationExpensesAsPartOfCostOfRevenueAndOperatingExpensesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_RestrictedStockUnitsRSUMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Share instrument which is convertible to stock or an equivalent amount of cash, after a specified period of time or when specified performance conditions are met.", "label": "Restricted Stock Units R S U [Member]", "terseLabel": "Restricted Stock Units" } } }, "localname": "RestrictedStockUnitsRSUMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://fulgentdiagnostics.com/20210630/taxonomy/role/DisclosureIncomePerShareAntiDilutiveSecuritiesExcludedFromCalculationOfDilutedIncomePerShareDetails" ], "xbrltype": "domainItemType" }, "us-gaap_RetainedEarningsAccumulatedDeficit": { "auth_ref": [ "r23", "r242", "r301", "r491", "r516", "r521" ], "calculation": { "http://fulgentdiagnostics.com/20210630/taxonomy/role/StatementCondensedConsolidatedBalanceSheets": { "order": 10100.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.", "label": "Retained Earnings Accumulated Deficit", "terseLabel": "Retained earnings" } } }, "localname": "RetainedEarningsAccumulatedDeficit", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://fulgentdiagnostics.com/20210630/taxonomy/role/StatementCondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_RetainedEarningsMember": { "auth_ref": [ "r106", "r107", "r108", "r112", "r119", "r121", "r200", "r298", "r299", "r300", "r317", "r318", "r512", "r514" ], "lang": { "en-us": { "role": { "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.", "label": "Retained Earnings [Member]", "terseLabel": "Retained Earnings (Accumulated Deficit)" } } }, "localname": "RetainedEarningsMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://fulgentdiagnostics.com/20210630/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails", "http://fulgentdiagnostics.com/20210630/taxonomy/role/StatementCondensedConsolidatedStatementsOfStockholdersEquityUnaudited" ], "xbrltype": "domainItemType" }, "us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax": { "auth_ref": [ "r152", "r153", "r161", "r167", "r168", "r174", "r175", "r179", "r256", "r257", "r446" ], "calculation": { "http://fulgentdiagnostics.com/20210630/taxonomy/role/StatementCondensedConsolidatedStatementsOfOperationsUnaudited": { "order": 10150.0, "parentTag": "us-gaap_GrossProfit", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.", "label": "Revenue From Contract With Customer Excluding Assessed Tax", "terseLabel": "Revenue", "verboseLabel": "Revenue from contracts with customers by payor type" } } }, "localname": "RevenueFromContractWithCustomerExcludingAssessedTax", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://fulgentdiagnostics.com/20210630/taxonomy/role/DisclosureReportingSegmentAndGeographicalInformationSummaryOfRevenueByGeographicRegionDetails", "http://fulgentdiagnostics.com/20210630/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesSummaryOfRevenueFromContractsWithCustomersByPayorTypeDetails", "http://fulgentdiagnostics.com/20210630/taxonomy/role/StatementCondensedConsolidatedStatementsOfOperationsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_RevenueFromContractWithCustomerPolicyTextBlock": { "auth_ref": [ "r98", "r248", "r249", "r250", "r251", "r252", "r253", "r254", "r255", "r268" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for revenue from contract with customer.", "label": "Revenue From Contract With Customer Policy [Text Block]", "terseLabel": "Revenue from Contracts with Customers" } } }, "localname": "RevenueFromContractWithCustomerPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://fulgentdiagnostics.com/20210630/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_RevenueFromExternalCustomersByGeographicAreasTableTextBlock": { "auth_ref": [ "r177" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of revenue from external customers by geographic areas attributed to the entity's country of domicile and to foreign countries from which the entity derives revenue.", "label": "Revenue From External Customers By Geographic Areas Table [Text Block]", "terseLabel": "Summary of Revenue by Geographic Region" } } }, "localname": "RevenueFromExternalCustomersByGeographicAreasTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://fulgentdiagnostics.com/20210630/taxonomy/role/DisclosureReportingSegmentAndGeographicInformationTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_RevenueFromRelatedParties": { "auth_ref": [ "r72", "r524" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of revenue, fees and commissions earned from transactions between (a) a parent company and its subsidiaries; (b) subsidiaries of a common parent; (c) an entity and trusts for the benefit of employees, for example, but not limited to, pension and profit-sharing trusts that are managed by or under the trusteeship of the entity's management; (d) an entity and its principal, owners, management, or members of their immediate families; and (e) affiliates.", "label": "Revenue From Related Parties", "terseLabel": "Revenue from related parties" } } }, "localname": "RevenueFromRelatedParties", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://fulgentdiagnostics.com/20210630/taxonomy/role/DisclosureRelatedPartiesAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_RevenuePracticalExpedientRemainingPerformanceObligation": { "auth_ref": [ "r247" ], "lang": { "en-us": { "role": { "documentation": "Indicates (true false) whether optional exemption was applied not to disclose amount of transaction price allocated to and explanation of expected timing of revenue recognition for remaining performance obligation, when contract has expected duration of one year or less or right to consideration corresponds directly to performance completed.", "label": "Revenue Practical Expedient Remaining Performance Obligation", "terseLabel": "Practical expedient not to disclose amount of transaction price allocated to unsatisfied performance obligations" } } }, "localname": "RevenuePracticalExpedientRemainingPerformanceObligation", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://fulgentdiagnostics.com/20210630/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails" ], "xbrltype": "booleanItemType" }, "us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability": { "auth_ref": [ "r414", "r419" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of increase in right-of-use asset obtained in exchange for operating lease liability.", "label": "Right Of Use Asset Obtained In Exchange For Operating Lease Liability", "terseLabel": "Operating lease right-of-use assets obtained in exchange for lease liabilities" } } }, "localname": "RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://fulgentdiagnostics.com/20210630/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The number of shares issued or sold by the subsidiary or equity method investee per stock transaction.", "label": "Sale Of Stock Number Of Shares Issued In Transaction", "terseLabel": "Number of shares purchased" } } }, "localname": "SaleOfStockNumberOfSharesIssuedInTransaction", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://fulgentdiagnostics.com/20210630/taxonomy/role/DisclosureEquityDistributionAgreementAdditionalInformationDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_SaleOfStockPricePerShare": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Per share amount received by subsidiary or equity investee for each share of common stock issued or sold in the stock transaction.", "label": "Sale Of Stock Price Per Share", "terseLabel": "Selling price per share" } } }, "localname": "SaleOfStockPricePerShare", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://fulgentdiagnostics.com/20210630/taxonomy/role/StatementCondensedConsolidatedStatementsOfStockholdersEquityUnauditedParenthetical" ], "xbrltype": "perShareItemType" }, "us-gaap_SalesRevenueNetMember": { "auth_ref": [ "r142", "r179" ], "lang": { "en-us": { "role": { "documentation": "Revenue from sale of product and rendering of service and other sources of income, when it serves as benchmark in concentration of risk calculation.", "label": "Sales Revenue Net [Member]", "terseLabel": "Revenue" } } }, "localname": "SalesRevenueNetMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://fulgentdiagnostics.com/20210630/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable": { "auth_ref": [ "r130" ], "lang": { "en-us": { "role": { "documentation": "Schedule for securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by Antidilutive Securities.", "label": "Schedule Of Antidilutive Securities Excluded From Computation Of Earnings Per Share [Table]", "terseLabel": "Schedule Of Antidilutive Securities Excluded From Computation Of Earnings Per Share [Table]" } } }, "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://fulgentdiagnostics.com/20210630/taxonomy/role/DisclosureIncomePerShareAntiDilutiveSecuritiesExcludedFromCalculationOfDilutedIncomePerShareDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock": { "auth_ref": [ "r130" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities.", "label": "Schedule Of Antidilutive Securities Excluded From Computation Of Earnings Per Share [Text Block]", "terseLabel": "Anti-dilutive Securities Excluded from Calculation of Diluted Income Per Share" } } }, "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://fulgentdiagnostics.com/20210630/taxonomy/role/DisclosureIncomePerShareTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable": { "auth_ref": [ "r336", "r337" ], "lang": { "en-us": { "role": { "documentation": "Schedule reflecting each material business combination (or series of individually immaterial business combinations) completed during the period, including background, timing, and recognized assets and liabilities.", "label": "Schedule Of Business Acquisitions By Acquisition [Table]", "terseLabel": "Schedule Of Business Acquisitions By Acquisition [Table]" } } }, "localname": "ScheduleOfBusinessAcquisitionsByAcquisitionTable", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://fulgentdiagnostics.com/20210630/taxonomy/role/DisclosureBusinessCombinationAdditionalInformationDetails", "http://fulgentdiagnostics.com/20210630/taxonomy/role/DisclosureBusinessCombinationSummaryOfConsiderationPaidAndAmountOfAssetsAcquiredAndLiabilitiesAssumedDetails", "http://fulgentdiagnostics.com/20210630/taxonomy/role/DisclosureBusinessCombinationTables" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock": { "auth_ref": [ "r336", "r337" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of a material business combination completed during the period, including background, timing, and recognized assets and liabilities. This table does not include leveraged buyouts.", "label": "Schedule Of Business Acquisitions By Acquisition [Text Block]", "terseLabel": "Summary of Consideration Paid and Amount of Assets Acquired and Liabilities Assumed" } } }, "localname": "ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://fulgentdiagnostics.com/20210630/taxonomy/role/DisclosureBusinessCombinationTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock": { "auth_ref": [ "r129" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations.", "label": "Schedule Of Earnings Per Share Basic And Diluted Table [Text Block]", "terseLabel": "Reconciliation of the Basic and Diluted Income Per Share Computations" } } }, "localname": "ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://fulgentdiagnostics.com/20210630/taxonomy/role/DisclosureIncomePerShareTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock": { "auth_ref": [ "r285", "r290", "r302" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement.", "label": "Schedule Of Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Text Block]", "terseLabel": "Summary of Equity-Based Compensation" } } }, "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://fulgentdiagnostics.com/20210630/taxonomy/role/DisclosureEquityBasedCompensationTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable": { "auth_ref": [ "r217", "r220", "r447" ], "lang": { "en-us": { "role": { "documentation": "Schedule of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.", "label": "Schedule Of Finite Lived Intangible Assets [Table]", "terseLabel": "Schedule Of Finite Lived Intangible Assets [Table]" } } }, "localname": "ScheduleOfFiniteLivedIntangibleAssetsTable", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://fulgentdiagnostics.com/20210630/taxonomy/role/DisclosureGoodwillAndAcquisitionRelatedIntangiblesSummaryOfAnnualAmortizationExpenseForAcquisitionRelatedIntangiblesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock": { "auth_ref": [ "r216" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of goodwill and intangible assets, which may be broken down by segment or major class.", "label": "Schedule Of Intangible Assets And Goodwill Table [Text Block]", "terseLabel": "Summaries of Goodwill and Acquisitions-Related Intangibles Balances" } } }, "localname": "ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://fulgentdiagnostics.com/20210630/taxonomy/role/DisclosureGoodwillAndAcquisitionRelatedIntangiblesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfOtherCurrentAssetsTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the carrying amounts of other current assets.", "label": "Schedule Of Other Current Assets Table [Text Block]", "terseLabel": "Schedule of Other Current Assets" } } }, "localname": "ScheduleOfOtherCurrentAssetsTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://fulgentdiagnostics.com/20210630/taxonomy/role/DisclosureOtherSignificantBalanceSheetAccountsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfPropertyPlantAndEquipmentTable": { "auth_ref": [ "r31", "r230" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of information about physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.", "label": "Schedule Of Property Plant And Equipment [Table]", "terseLabel": "Schedule Of Property Plant And Equipment [Table]" } } }, "localname": "ScheduleOfPropertyPlantAndEquipmentTable", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://fulgentdiagnostics.com/20210630/taxonomy/role/DisclosureFixedAssetsMajorClassesOfFixedAssetsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable": { "auth_ref": [ "r102", "r429", "r430" ], "lang": { "en-us": { "role": { "documentation": "Schedule of quantitative and qualitative information pertaining to related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.", "label": "Schedule Of Related Party Transactions By Related Party [Table]", "terseLabel": "Schedule Of Related Party Transactions By Related Party [Table]" } } }, "localname": "ScheduleOfRelatedPartyTransactionsByRelatedPartyTable", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://fulgentdiagnostics.com/20210630/taxonomy/role/DisclosureRelatedPartiesAdditionalInformationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable": { "auth_ref": [ "r158", "r159", "r165", "r216" ], "lang": { "en-us": { "role": { "documentation": "A table disclosing the profit or loss and total assets for each reportable segment of the entity. An entity discloses certain information on each reportable segment if the amounts (a) are included in the measure of segment profit or loss reviewed by the chief operating decision maker or (b) are otherwise regularly provided to the chief operating decision maker, even if not included in that measure of segment profit or loss.", "label": "Schedule Of Segment Reporting Information By Segment [Table]", "terseLabel": "Schedule Of Segment Reporting Information By Segment [Table]" } } }, "localname": "ScheduleOfSegmentReportingInformationBySegmentTable", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://fulgentdiagnostics.com/20210630/taxonomy/role/DisclosureReportingSegmentAndGeographicalInformationSummaryOfRevenueByGeographicRegionDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfTradingSecuritiesAndOtherTradingAssetsLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Schedule Of Trading Securities And Other Trading Assets [Line Items]", "terseLabel": "Schedule Of Trading Securities And Other Trading Assets [Line Items]" } } }, "localname": "ScheduleOfTradingSecuritiesAndOtherTradingAssetsLineItems", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://fulgentdiagnostics.com/20210630/taxonomy/role/DisclosureMarketableSecuritiesSummaryOfMarketableSecuritiesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfTradingSecuritiesAndOtherTradingAssetsTable": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Disclosure of information about investment in debt security measured at fair value with change in fair value recognized in net income (trading) and investment in equity security with change in fair value recognized in net income (FV-NI).", "label": "Schedule Of Trading Securities And Other Trading Assets [Table]", "terseLabel": "Schedule Of Trading Securities And Other Trading Assets [Table]" } } }, "localname": "ScheduleOfTradingSecuritiesAndOtherTradingAssetsTable", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://fulgentdiagnostics.com/20210630/taxonomy/role/DisclosureMarketableSecuritiesSummaryOfMarketableSecuritiesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_SegmentReportingAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Segment Reporting [Abstract]" } } }, "localname": "SegmentReportingAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "xbrltype": "stringItemType" }, "us-gaap_SegmentReportingDisclosureTextBlock": { "auth_ref": [ "r148", "r150", "r151", "r158", "r160", "r166", "r170", "r171", "r172", "r173", "r174", "r178", "r179", "r180" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for reporting segments including data and tables. Reportable segments include those that meet any of the following quantitative thresholds a) it's reported revenue, including sales to external customers and intersegment sales or transfers is 10 percent or more of the combined revenue, internal and external, of all operating segments b) the absolute amount of its reported profit or loss is 10 percent or more of the greater, in absolute amount of 1) the combined reported profit of all operating segments that did not report a loss or 2) the combined reported loss of all operating segments that did report a loss c) its assets are 10 percent or more of the combined assets of all operating segments.", "label": "Segment Reporting Disclosure [Text Block]", "terseLabel": "Reporting Segment and Geographic Information" } } }, "localname": "SegmentReportingDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://fulgentdiagnostics.com/20210630/taxonomy/role/DisclosureReportingSegmentAndGeographicInformation" ], "xbrltype": "textBlockItemType" }, "us-gaap_SegmentReportingInformationLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Segment Reporting Information [Line Items]", "terseLabel": "Segment Reporting Information [Line Items]" } } }, "localname": "SegmentReportingInformationLineItems", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://fulgentdiagnostics.com/20210630/taxonomy/role/DisclosureReportingSegmentAndGeographicalInformationSummaryOfRevenueByGeographicRegionDetails" ], "xbrltype": "stringItemType" }, "us-gaap_SellingAndMarketingExpense": { "auth_ref": [], "calculation": { "http://fulgentdiagnostics.com/20210630/taxonomy/role/StatementCondensedConsolidatedStatementsOfOperationsUnaudited": { "order": 10130.0, "parentTag": "us-gaap_OperatingExpenses", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The aggregate total amount of expenses directly related to the marketing or selling of products or services.", "label": "Selling And Marketing Expense", "terseLabel": "Selling and marketing" } } }, "localname": "SellingAndMarketingExpense", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://fulgentdiagnostics.com/20210630/taxonomy/role/StatementCondensedConsolidatedStatementsOfOperationsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_SellingAndMarketingExpenseMember": { "auth_ref": [ "r70" ], "lang": { "en-us": { "role": { "documentation": "Primary financial statement caption encompassing selling and marketing expense.", "label": "Selling And Marketing Expense [Member]", "terseLabel": "Selling and Marketing" } } }, "localname": "SellingAndMarketingExpenseMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://fulgentdiagnostics.com/20210630/taxonomy/role/DisclosureEquityBasedCompensationSummaryOfEquityBasedCompensationExpensesAsPartOfCostOfRevenueAndOperatingExpensesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ShareBasedCompensation": { "auth_ref": [ "r88" ], "calculation": { "http://fulgentdiagnostics.com/20210630/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited": { "order": 10170.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of noncash expense for share-based payment arrangement.", "label": "Share Based Compensation", "terseLabel": "Equity-based compensation" } } }, "localname": "ShareBasedCompensation", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://fulgentdiagnostics.com/20210630/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_ShareBasedCompensationAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Share Based Compensation [Abstract]" } } }, "localname": "ShareBasedCompensationAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "xbrltype": "stringItemType" }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": { "auth_ref": [ "r284", "r287" ], "lang": { "en-us": { "role": { "documentation": "Award under share-based payment arrangement.", "label": "Share Based Compensation Arrangements By Share Based Payment Award Award Type And Plan Name [Domain]", "terseLabel": "Award Type" } } }, "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://fulgentdiagnostics.com/20210630/taxonomy/role/DisclosureIncomePerShareAntiDilutiveSecuritiesExcludedFromCalculationOfDilutedIncomePerShareDetails" ], "xbrltype": "domainItemType" }, "us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of shares used to settle grantee's tax withholding obligation for award under share-based payment arrangement.", "label": "Shares Paid For Tax Withholding For Share Based Compensation", "negatedLabel": "Common stock withholding for employee tax obligations, Shares" } } }, "localname": "SharesPaidForTaxWithholdingForShareBasedCompensation", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://fulgentdiagnostics.com/20210630/taxonomy/role/StatementCondensedConsolidatedStatementsOfStockholdersEquityUnaudited" ], "xbrltype": "sharesItemType" }, "us-gaap_ShortTermLeaseCost": { "auth_ref": [ "r413", "r419" ], "calculation": { "http://fulgentdiagnostics.com/20210630/taxonomy/role/DisclosureLeasesScheduleOfOperatingLeaseExpenseDetails": { "order": 10020.0, "parentTag": "us-gaap_LeaseCost", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of short-term lease cost, excluding expense for lease with term of one month or less.", "label": "Short Term Lease Cost", "terseLabel": "Short-term lease cost" } } }, "localname": "ShortTermLeaseCost", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://fulgentdiagnostics.com/20210630/taxonomy/role/DisclosureLeasesScheduleOfOperatingLeaseExpenseDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_SignificantAccountingPoliciesTextBlock": { "auth_ref": [ "r105" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for all significant accounting policies of the reporting entity.", "label": "Significant Accounting Policies [Text Block]", "terseLabel": "Summary of Significant Accounting Policies" } } }, "localname": "SignificantAccountingPoliciesTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://fulgentdiagnostics.com/20210630/taxonomy/role/DisclosureSummaryOfSignificantAccountingPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_SoftwareDevelopmentMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Internally developed software for sale, licensing or long-term internal use.", "label": "Software Development [Member]", "terseLabel": "Computer Software" } } }, "localname": "SoftwareDevelopmentMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://fulgentdiagnostics.com/20210630/taxonomy/role/DisclosureFixedAssetsMajorClassesOfFixedAssetsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_StatementEquityComponentsAxis": { "auth_ref": [ "r42", "r106", "r107", "r108", "r112", "r119", "r121", "r135", "r200", "r240", "r242", "r298", "r299", "r300", "r317", "r318", "r393", "r394", "r395", "r396", "r397", "r399", "r512", "r513", "r514" ], "lang": { "en-us": { "role": { "documentation": "Information by component of equity.", "label": "Statement Equity Components [Axis]", "terseLabel": "Equity Components" } } }, "localname": "StatementEquityComponentsAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://fulgentdiagnostics.com/20210630/taxonomy/role/DisclosureEquityDistributionAgreementAdditionalInformationDetails", "http://fulgentdiagnostics.com/20210630/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails", "http://fulgentdiagnostics.com/20210630/taxonomy/role/StatementCondensedConsolidatedStatementsOfStockholdersEquityUnaudited" ], "xbrltype": "stringItemType" }, "us-gaap_StatementLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Statement [Line Items]", "terseLabel": "Statement [Line Items]" } } }, "localname": "StatementLineItems", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://fulgentdiagnostics.com/20210630/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesTables", "http://fulgentdiagnostics.com/20210630/taxonomy/role/StatementCondensedConsolidatedStatementsOfStockholdersEquityUnaudited", "http://fulgentdiagnostics.com/20210630/taxonomy/role/StatementCondensedConsolidatedStatementsOfStockholdersEquityUnauditedParenthetical" ], "xbrltype": "stringItemType" }, "us-gaap_StatementOfCashFlowsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Statement Of Cash Flows [Abstract]" } } }, "localname": "StatementOfCashFlowsAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "xbrltype": "stringItemType" }, "us-gaap_StatementOfFinancialPositionAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Statement Of Financial Position [Abstract]" } } }, "localname": "StatementOfFinancialPositionAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "xbrltype": "stringItemType" }, "us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Statement Of Income And Comprehensive Income [Abstract]" } } }, "localname": "StatementOfIncomeAndComprehensiveIncomeAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "xbrltype": "stringItemType" }, "us-gaap_StatementOfStockholdersEquityAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Statement Of Stockholders Equity [Abstract]" } } }, "localname": "StatementOfStockholdersEquityAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "xbrltype": "stringItemType" }, "us-gaap_StatementTable": { "auth_ref": [ "r106", "r107", "r108", "r135", "r446" ], "lang": { "en-us": { "role": { "documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed.", "label": "Statement [Table]", "terseLabel": "Statement [Table]" } } }, "localname": "StatementTable", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://fulgentdiagnostics.com/20210630/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesTables", "http://fulgentdiagnostics.com/20210630/taxonomy/role/StatementCondensedConsolidatedStatementsOfStockholdersEquityUnaudited", "http://fulgentdiagnostics.com/20210630/taxonomy/role/StatementCondensedConsolidatedStatementsOfStockholdersEquityUnauditedParenthetical" ], "xbrltype": "stringItemType" }, "us-gaap_StockIssuedDuringPeriodSharesNewIssues": { "auth_ref": [ "r18", "r19", "r240", "r242" ], "lang": { "en-us": { "role": { "documentation": "Number of new stock issued during the period.", "label": "Stock Issued During Period Shares New Issues", "terseLabel": "Issuance of common stock, Shares" } } }, "localname": "StockIssuedDuringPeriodSharesNewIssues", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://fulgentdiagnostics.com/20210630/taxonomy/role/StatementCondensedConsolidatedStatementsOfStockholdersEquityUnaudited" ], "xbrltype": "sharesItemType" }, "us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures": { "auth_ref": [ "r18", "r19", "r240", "r242" ], "lang": { "en-us": { "role": { "documentation": "Number of shares issued during the period related to Restricted Stock Awards, net of any shares forfeited.", "label": "Stock Issued During Period Shares Restricted Stock Award Net Of Forfeitures", "terseLabel": "Restricted stock awards, Shares" } } }, "localname": "StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://fulgentdiagnostics.com/20210630/taxonomy/role/StatementCondensedConsolidatedStatementsOfStockholdersEquityUnaudited" ], "xbrltype": "sharesItemType" }, "us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised": { "auth_ref": [ "r18", "r19", "r240", "r242", "r288" ], "lang": { "en-us": { "role": { "documentation": "Number of share options (or share units) exercised during the current period.", "label": "Stock Issued During Period Shares Stock Options Exercised", "terseLabel": "Exercise of common stock options, Shares" } } }, "localname": "StockIssuedDuringPeriodSharesStockOptionsExercised", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://fulgentdiagnostics.com/20210630/taxonomy/role/StatementCondensedConsolidatedStatementsOfStockholdersEquityUnaudited" ], "xbrltype": "sharesItemType" }, "us-gaap_StockIssuedDuringPeriodValueAcquisitions": { "auth_ref": [ "r42", "r240", "r242" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Value of stock issued pursuant to acquisitions during the period.", "label": "Stock Issued During Period Value Acquisitions", "terseLabel": "Acquisition of issued and outstanding common stock value" } } }, "localname": "StockIssuedDuringPeriodValueAcquisitions", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://fulgentdiagnostics.com/20210630/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockIssuedDuringPeriodValueNewIssues": { "auth_ref": [ "r18", "r19", "r240", "r242" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.", "label": "Stock Issued During Period Value New Issues", "terseLabel": "Issuance of common stock" } } }, "localname": "StockIssuedDuringPeriodValueNewIssues", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://fulgentdiagnostics.com/20210630/taxonomy/role/StatementCondensedConsolidatedStatementsOfStockholdersEquityUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures": { "auth_ref": [ "r240", "r242" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Value of stock related to Restricted Stock Awards issued during the period, net of the stock value of such awards forfeited.", "label": "Stock Issued During Period Value Restricted Stock Award Net Of Forfeitures", "terseLabel": "Restricted stock awards" } } }, "localname": "StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://fulgentdiagnostics.com/20210630/taxonomy/role/StatementCondensedConsolidatedStatementsOfStockholdersEquityUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised": { "auth_ref": [ "r42", "r240", "r242" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Value of stock issued as a result of the exercise of stock options.", "label": "Stock Issued During Period Value Stock Options Exercised", "terseLabel": "Exercise of common stock options" } } }, "localname": "StockIssuedDuringPeriodValueStockOptionsExercised", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://fulgentdiagnostics.com/20210630/taxonomy/role/StatementCondensedConsolidatedStatementsOfStockholdersEquityUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockRepurchasedDuringPeriodShares": { "auth_ref": [ "r18", "r19", "r240", "r242" ], "lang": { "en-us": { "role": { "documentation": "Number of shares that have been repurchased during the period and have not been retired and are not held in treasury. Some state laws may govern the circumstances under which an entity may acquire its own stock and prescribe the accounting treatment therefore. This element is used when state law does not recognize treasury stock.", "label": "Stock Repurchased During Period Shares", "negatedLabel": "Repurchases of capital stock, Shares" } } }, "localname": "StockRepurchasedDuringPeriodShares", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://fulgentdiagnostics.com/20210630/taxonomy/role/StatementCondensedConsolidatedStatementsOfStockholdersEquityUnaudited" ], "xbrltype": "sharesItemType" }, "us-gaap_StockRepurchasedDuringPeriodValue": { "auth_ref": [ "r18", "r19", "r240", "r242" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Equity impact of the value of stock that has been repurchased during the period and has not been retired and is not held in treasury. Some state laws may mandate the circumstances under which an entity may acquire its own stock and prescribe the accounting treatment therefore. This element is used when state law does not recognize treasury stock.", "label": "Stock Repurchased During Period Value", "negatedLabel": "Repurchases of capital stock" } } }, "localname": "StockRepurchasedDuringPeriodValue", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://fulgentdiagnostics.com/20210630/taxonomy/role/StatementCondensedConsolidatedStatementsOfStockholdersEquityUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockholdersEquity": { "auth_ref": [ "r19", "r25", "r26", "r99", "r184", "r192", "r386" ], "calculation": { "http://fulgentdiagnostics.com/20210630/taxonomy/role/StatementCondensedConsolidatedBalanceSheets": { "order": 10040.0, "parentTag": "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.", "label": "Stockholders Equity", "positiveLabel": "Stockholders' equity", "totalLabel": "Total Fulgent stockholders' equity" } } }, "localname": "StockholdersEquity", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://fulgentdiagnostics.com/20210630/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails", "http://fulgentdiagnostics.com/20210630/taxonomy/role/StatementCondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest": { "auth_ref": [ "r99", "r106", "r107", "r108", "r112", "r119", "r192", "r200", "r242", "r298", "r299", "r300", "r317", "r318", "r350", "r351", "r365", "r386", "r393", "r394", "r399", "r513", "r514" ], "calculation": { "http://fulgentdiagnostics.com/20210630/taxonomy/role/StatementCondensedConsolidatedBalanceSheets": { "order": 10030.0, "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of stockholders' equity (deficit), net of receivables from officers, directors, owners, and affiliates of the entity, attributable to both the parent and noncontrolling interests. Amount excludes temporary equity. Alternate caption for the concept is permanent equity.", "label": "Stockholders Equity Including Portion Attributable To Noncontrolling Interest", "periodEndLabel": "Ending Balance", "periodStartLabel": "Beginning Balance", "totalLabel": "Total stockholders\u2019 equity" } } }, "localname": "StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://fulgentdiagnostics.com/20210630/taxonomy/role/StatementCondensedConsolidatedBalanceSheets", "http://fulgentdiagnostics.com/20210630/taxonomy/role/StatementCondensedConsolidatedStatementsOfStockholdersEquityUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Stockholders Equity Including Portion Attributable To Noncontrolling Interest [Abstract]", "terseLabel": "Stockholders\u2019 equity" } } }, "localname": "StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://fulgentdiagnostics.com/20210630/taxonomy/role/StatementCondensedConsolidatedBalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_SubsequentEventLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Detail information of subsequent event by type. User is expected to use existing line items from elsewhere in the taxonomy as the primary line items for this disclosure, which is further associated with dimension and member elements pertaining to a subsequent event.", "label": "Subsequent Event [Line Items]", "terseLabel": "Subsequent Event [Line Items]" } } }, "localname": "SubsequentEventLineItems", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://fulgentdiagnostics.com/20210630/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_SubsequentEventMember": { "auth_ref": [ "r400", "r434" ], "lang": { "en-us": { "role": { "documentation": "Identifies event that occurred after the balance sheet date but before financial statements are issued or available to be issued.", "label": "Subsequent Event [Member]", "terseLabel": "Subsequent Events [Member]" } } }, "localname": "SubsequentEventMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://fulgentdiagnostics.com/20210630/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_SubsequentEventTable": { "auth_ref": [ "r400", "r434" ], "lang": { "en-us": { "role": { "documentation": "Discloses pertinent information about one or more significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued.", "label": "Subsequent Event [Table]", "terseLabel": "Subsequent Event [Table]" } } }, "localname": "SubsequentEventTable", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://fulgentdiagnostics.com/20210630/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_SubsequentEventTypeAxis": { "auth_ref": [ "r400", "r434" ], "lang": { "en-us": { "role": { "documentation": "Information by event that occurred after the balance sheet date but before financial statements are issued or available to be issued.", "label": "Subsequent Event Type [Axis]", "terseLabel": "Subsequent Event Type" } } }, "localname": "SubsequentEventTypeAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://fulgentdiagnostics.com/20210630/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_SubsequentEventTypeDomain": { "auth_ref": [ "r400", "r434" ], "lang": { "en-us": { "role": { "documentation": "Event that occurred after the balance sheet date but before financial statements are issued or available to be issued.", "label": "Subsequent Event Type [Domain]", "terseLabel": "Subsequent Event Type" } } }, "localname": "SubsequentEventTypeDomain", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://fulgentdiagnostics.com/20210630/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_SubsequentEventsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Subsequent Events [Abstract]" } } }, "localname": "SubsequentEventsAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "xbrltype": "stringItemType" }, "us-gaap_SubsequentEventsTextBlock": { "auth_ref": [ "r433", "r435" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.", "label": "Subsequent Events [Text Block]", "terseLabel": "Subsequent Events" } } }, "localname": "SubsequentEventsTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://fulgentdiagnostics.com/20210630/taxonomy/role/DisclosureSubsequentEvents" ], "xbrltype": "textBlockItemType" }, "us-gaap_SupplementalBalanceSheetDisclosuresTextBlock": { "auth_ref": [ "r46" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for supplemental balance sheet disclosures, including descriptions and amounts for assets, liabilities, and equity.", "label": "Supplemental Balance Sheet Disclosures [Text Block]", "terseLabel": "Significant Balance Sheet Accounts" } } }, "localname": "SupplementalBalanceSheetDisclosuresTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://fulgentdiagnostics.com/20210630/taxonomy/role/DisclosureOtherSignificantBalanceSheetAccounts" ], "xbrltype": "textBlockItemType" }, "us-gaap_SupplementalCashFlowInformationAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Supplemental Cash Flow Information [Abstract]", "terseLabel": "Supplemental disclosures of cash flow information:" } } }, "localname": "SupplementalCashFlowInformationAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://fulgentdiagnostics.com/20210630/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "xbrltype": "stringItemType" }, "us-gaap_TaxesPayableCurrent": { "auth_ref": [ "r34" ], "calculation": { "http://fulgentdiagnostics.com/20210630/taxonomy/role/StatementCondensedConsolidatedBalanceSheets": { "order": 10160.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable for statutory income, sales, use, payroll, excise, real, property and other taxes. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "label": "Taxes Payable Current", "terseLabel": "Income tax payable" } } }, "localname": "TaxesPayableCurrent", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://fulgentdiagnostics.com/20210630/taxonomy/role/StatementCondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_TechnologyBasedIntangibleAssetsMember": { "auth_ref": [ "r341" ], "lang": { "en-us": { "role": { "documentation": "Technology-based intangible assets, including, but not limited to, patented technology, unpatented technology, and developed technology rights.", "label": "Technology Based Intangible Assets [Member]", "terseLabel": "Royalty-Free Technology" } } }, "localname": "TechnologyBasedIntangibleAssetsMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://fulgentdiagnostics.com/20210630/taxonomy/role/DisclosureBusinessCombinationAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_TypeOfAdoptionMember": { "auth_ref": [ "r111", "r112", "r113", "r114", "r197", "r198", "r199", "r200", "r202", "r203", "r294", "r295", "r296", "r297", "r298", "r299", "r300", "r301", "r315", "r316", "r317", "r318", "r448", "r449", "r450", "r510", "r511", "r512", "r513", "r514", "r515", "r516", "r517", "r518", "r519", "r520", "r521" ], "lang": { "en-us": { "role": { "documentation": "Amendment to accounting standards.", "label": "Type Of Adoption [Member]", "terseLabel": "Accounting Standards Update" } } }, "localname": "TypeOfAdoptionMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://fulgentdiagnostics.com/20210630/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails", "http://fulgentdiagnostics.com/20210630/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesSummaryOfRevenueFromContractsWithCustomersByPayorTypeDetails", "http://fulgentdiagnostics.com/20210630/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesTables" ], "xbrltype": "domainItemType" }, "us-gaap_TypeOfArrangementAxis": { "auth_ref": [ "r349" ], "lang": { "en-us": { "role": { "documentation": "Information by collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.", "label": "Type Of Arrangement [Axis]", "terseLabel": "Collaborative Arrangement and Arrangement Other than Collaborative" } } }, "localname": "TypeOfArrangementAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://fulgentdiagnostics.com/20210630/taxonomy/role/DisclosureEquityDistributionAgreementAdditionalInformationDetails", "http://fulgentdiagnostics.com/20210630/taxonomy/role/StatementCondensedConsolidatedStatementsOfStockholdersEquityUnauditedParenthetical" ], "xbrltype": "stringItemType" }, "us-gaap_TypeOfRevenueExtensibleList": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicates type of revenue from product and service. Includes, but is not limited to, revenue from contract with customer and other sources.", "label": "Type Of Revenue Extensible List", "terseLabel": "Type of Revenue [Extensible List]" } } }, "localname": "TypeOfRevenueExtensibleList", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://fulgentdiagnostics.com/20210630/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesSummaryOfRevenueFromContractsWithCustomersByPayorTypeDetails" ], "xbrltype": "extensibleListItemType" }, "us-gaap_USGovernmentAgenciesDebtSecuritiesMember": { "auth_ref": [ "r270", "r483" ], "lang": { "en-us": { "role": { "documentation": "Debentures, notes, and other debt securities issued by US government agencies, for example, but not limited to, Government National Mortgage Association (GNMA or Ginnie Mae). Excludes US treasury securities and debt issued by government-sponsored Enterprises (GSEs), for example, but is not limited to, Federal Home Loan Mortgage Corporation (FHLMC or Freddie Mac), Federal National Mortgage Association (FNMA or Fannie Mae), and the Federal Home Loan Bank (FHLB).", "label": "U S Government Agencies Debt Securities [Member]", "terseLabel": "U.S. Government Agency Debt Securities" } } }, "localname": "USGovernmentAgenciesDebtSecuritiesMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://fulgentdiagnostics.com/20210630/taxonomy/role/DisclosureFairValueMeasurementsInformationAboutFinancialAssetsMeasuredAtFairValueOnRecurringBasisBasedOnThreeTierFairValueHierarchyDetails", "http://fulgentdiagnostics.com/20210630/taxonomy/role/DisclosureMarketableSecuritiesSummaryOfMarketableSecuritiesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_UnconditionalPurchaseObligationCategoryOfGoodsOrServicesAcquiredDomain": { "auth_ref": [ "r234", "r235", "r236", "r237" ], "lang": { "en-us": { "role": { "documentation": "General description of the goods or services to be purchased from the counterparty to the unconditional purchase arrangement.", "label": "Unconditional Purchase Obligation Category Of Goods Or Services Acquired [Domain]", "terseLabel": "Unconditional Purchase Obligation, Category of Goods or Services Acquired" } } }, "localname": "UnconditionalPurchaseObligationCategoryOfGoodsOrServicesAcquiredDomain", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://fulgentdiagnostics.com/20210630/taxonomy/role/DisclosureDebtCommitmentsAndContingenciesAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_UnrecognizedTaxBenefits": { "auth_ref": [ "r307", "r311" ], "calculation": { "http://fulgentdiagnostics.com/20210630/taxonomy/role/StatementCondensedConsolidatedBalanceSheets": { "order": 10130.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of unrecognized tax benefits.", "label": "Unrecognized Tax Benefits", "terseLabel": "Unrecognized tax benefits" } } }, "localname": "UnrecognizedTaxBenefits", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://fulgentdiagnostics.com/20210630/taxonomy/role/StatementCondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_UseOfEstimates": { "auth_ref": [ "r136", "r137", "r139", "r140", "r144", "r145", "r146" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.", "label": "Use Of Estimates", "terseLabel": "Use of Estimates" } } }, "localname": "UseOfEstimates", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://fulgentdiagnostics.com/20210630/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": { "auth_ref": [ "r124", "r129" ], "lang": { "en-us": { "role": { "documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.", "label": "Weighted Average Number Of Diluted Shares Outstanding", "terseLabel": "Diluted", "verboseLabel": "Weighted-average common shares\u2014outstanding, diluted" } } }, "localname": "WeightedAverageNumberOfDilutedSharesOutstanding", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://fulgentdiagnostics.com/20210630/taxonomy/role/DisclosureIncomePerShareReconciliationOfBasicAndDilutedIncomePerShareComputationsDetails", "http://fulgentdiagnostics.com/20210630/taxonomy/role/StatementCondensedConsolidatedStatementsOfOperationsUnaudited" ], "xbrltype": "sharesItemType" }, "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": { "auth_ref": [ "r123", "r129" ], "lang": { "en-us": { "role": { "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.", "label": "Weighted Average Number Of Shares Outstanding Basic", "terseLabel": "Basic", "verboseLabel": "Weighted-average common shares\u2014outstanding, basic" } } }, "localname": "WeightedAverageNumberOfSharesOutstandingBasic", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://fulgentdiagnostics.com/20210630/taxonomy/role/DisclosureIncomePerShareReconciliationOfBasicAndDilutedIncomePerShareComputationsDetails", "http://fulgentdiagnostics.com/20210630/taxonomy/role/StatementCondensedConsolidatedStatementsOfOperationsUnaudited" ], "xbrltype": "sharesItemType" } }, "unitCount": 7 } }, "std_ref": { "r0": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "205", "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721683-107760" }, "r1": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "205", "URI": "http://asc.fasb.org/topic&trid=2122149" }, "r10": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6904-107765" }, "r100": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(h))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r101": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(k)(1))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r102": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(k))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r103": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08.(h)(1)(i))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r104": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08.(k)(1))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r105": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "235", "URI": "http://asc.fasb.org/topic&trid=2122369" }, "r106": { "Name": "Accounting Standards Codification", "Paragraph": "23", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=115929471&loc=d3e21914-107793" }, "r107": { "Name": "Accounting Standards Codification", "Paragraph": "24", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=115929471&loc=d3e21930-107793" }, "r108": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=115929471&loc=d3e21711-107793" }, "r109": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=115929471&loc=d3e21728-107793" }, "r11": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6911-107765" }, "r110": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22499-107794" }, "r111": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)(2)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22499-107794" }, "r112": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)(3)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22499-107794" }, "r113": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)(4)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22499-107794" }, "r114": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22499-107794" }, "r115": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22694-107794" }, "r116": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22694-107794" }, "r117": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22583-107794" }, "r118": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22595-107794" }, "r119": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22644-107794" }, "r12": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(1))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r120": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22658-107794" }, "r121": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22663-107794" }, "r122": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=112272810&loc=d3e31010-122693" }, "r123": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=d3e1448-109256" }, "r124": { "Name": "Accounting Standards Codification", "Paragraph": "16", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=d3e1505-109256" }, "r125": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=d3e1252-109256" }, "r126": { "Name": "Accounting Standards Codification", "Paragraph": "60B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=SL5780133-109256" }, "r127": { "Name": "Accounting Standards Codification", "Paragraph": "60B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=SL5780133-109256" }, "r128": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=d3e1337-109256" }, "r129": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257" }, "r13": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(13))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r130": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257" }, "r131": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=6371337&loc=d3e3630-109257" }, "r132": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=109243012&loc=SL65017193-207537" }, "r133": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "260", "URI": "http://asc.fasb.org/topic&trid=2144383" }, "r134": { "Name": "Accounting Standards Codification", "Paragraph": "6A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "270", "URI": "http://asc.fasb.org/extlink&oid=121640914&loc=SL77927221-108306" }, "r135": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "272", "URI": "http://asc.fasb.org/extlink&oid=6828210&loc=d3e70191-108054" }, "r136": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592" }, "r137": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592" }, "r138": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592" }, "r139": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6161-108592" }, "r14": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(14))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r140": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6191-108592" }, "r141": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6351-108592" }, "r142": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6351-108592" }, "r143": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6404-108592" }, "r144": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6061-108592" }, "r145": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6132-108592" }, "r146": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6143-108592" }, "r147": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "275", "URI": "http://asc.fasb.org/topic&trid=2134479" }, "r148": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8657-108599" }, "r149": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8672-108599" }, "r15": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(19))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r150": { "Name": "Accounting Standards Codification", "Paragraph": "21", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8721-108599" }, "r151": { "Name": "Accounting Standards Codification", "Paragraph": "21", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8721-108599" }, "r152": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599" }, "r153": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599" }, "r154": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599" }, "r155": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599" }, "r156": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(g)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599" }, "r157": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599" }, "r158": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599" }, "r159": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8813-108599" }, "r16": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(20))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r160": { "Name": "Accounting Standards Codification", "Paragraph": "26", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8844-108599" }, "r161": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8906-108599" }, "r162": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8906-108599" }, "r163": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8906-108599" }, "r164": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8906-108599" }, "r165": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8906-108599" }, "r166": { "Name": "Accounting Standards Codification", "Paragraph": "31", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8924-108599" }, "r167": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599" }, "r168": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599" }, "r169": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599" }, "r17": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(22))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r170": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599" }, "r171": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599" }, "r172": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599" }, "r173": { "Name": "Accounting Standards Codification", "Paragraph": "34", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8981-108599" }, "r174": { "Name": "Accounting Standards Codification", "Paragraph": "40", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e9031-108599" }, "r175": { "Name": "Accounting Standards Codification", "Paragraph": "41", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e9038-108599" }, "r176": { "Name": "Accounting Standards Codification", "Paragraph": "41", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e9038-108599" }, "r177": { "Name": "Accounting Standards Codification", "Paragraph": "41", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "a", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e9038-108599" }, "r178": { "Name": "Accounting Standards Codification", "Paragraph": "41", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e9038-108599" }, "r179": { "Name": "Accounting Standards Codification", "Paragraph": "42", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e9054-108599" }, "r18": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(28))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r180": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "280", "URI": "http://asc.fasb.org/topic&trid=2134510" }, "r181": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "310", "URI": "http://asc.fasb.org/extlink&oid=121593590&loc=d3e4428-111522" }, "r182": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "310", "URI": "http://asc.fasb.org/extlink&oid=121593590&loc=d3e4531-111522" }, "r183": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "310", "URI": "http://asc.fasb.org/extlink&oid=121611835&loc=d3e5074-111524" }, "r184": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 4.E)", "Topic": "310", "URI": "http://asc.fasb.org/extlink&oid=27010918&loc=d3e74512-122707" }, "r185": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "320", "URI": "http://asc.fasb.org/extlink&oid=121553693&loc=d3e26610-111562" }, "r186": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "320", "URI": "http://asc.fasb.org/extlink&oid=121553693&loc=d3e26853-111562" }, "r187": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "320", "URI": "http://asc.fasb.org/extlink&oid=121553693&loc=d3e26626-111562" }, "r188": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(aa)", "Topic": "320", "URI": "http://asc.fasb.org/extlink&oid=121645371&loc=d3e27161-111563" }, "r189": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(aaa)", "Topic": "320", "URI": "http://asc.fasb.org/extlink&oid=121645371&loc=d3e27161-111563" }, "r19": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(29))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r190": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "323", "URI": "http://asc.fasb.org/extlink&oid=109237563&loc=d3e33749-111570" }, "r191": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(1)", "Topic": "323", "URI": "http://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571" }, "r192": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "323", "URI": "http://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571" }, "r193": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=121646688&loc=SL82887624-210437" }, "r194": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=121646688&loc=SL120254519-210437" }, "r195": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=121646688&loc=SL120320025-210437" }, "r196": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=121646688&loc=SL120320025-210437" }, "r197": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=121646688&loc=SL121648383-210437" }, "r198": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=121646688&loc=SL121648383-210437" }, "r199": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=121646688&loc=SL121648383-210437" }, "r2": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6676-107765" }, "r20": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(3)(a)(2))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r200": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=121646688&loc=SL121648383-210437" }, "r201": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(e)(1)", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=121646688&loc=SL121648383-210437" }, "r202": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(e)(3)", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=121646688&loc=SL121648383-210437" }, "r203": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(e)(4)", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=121646688&loc=SL121648383-210437" }, "r204": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=121599878&loc=SL82895884-210446" }, "r205": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=121599337&loc=SL82919249-210447" }, "r206": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=121599337&loc=SL82919249-210447" }, "r207": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(f)", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=121599337&loc=SL82919249-210447" }, "r208": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=121558606&loc=SL82898722-210454" }, "r209": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=121582814&loc=SL82922900-210455" }, "r21": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(3))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r210": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(i)", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=121582814&loc=SL82922900-210455" }, "r211": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "05", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "340", "URI": "http://asc.fasb.org/extlink&oid=68074540&loc=d3e5879-108316" }, "r212": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "05", "SubTopic": "10", "Topic": "340", "URI": "http://asc.fasb.org/extlink&oid=68074540&loc=d3e5879-108316" }, "r213": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "340", "URI": "http://asc.fasb.org/extlink&oid=6387103&loc=d3e6435-108320" }, "r214": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=99380562&loc=d3e13770-109266" }, "r215": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=120320667&loc=SL49117168-202975" }, "r216": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267" }, "r217": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275" }, "r218": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)(3)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275" }, "r219": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(d)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275" }, "r22": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30)(a)(1))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r220": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275" }, "r221": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)(1)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275" }, "r222": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)(3)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275" }, "r223": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(d)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275" }, "r224": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "350", "URI": "http://asc.fasb.org/topic&trid=2144416" }, "r225": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "35", "SubTopic": "10", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=68071081&loc=d3e1205-110223" }, "r226": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=109226348&loc=d3e2443-110228" }, "r227": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229" }, "r228": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229" }, "r229": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229" }, "r23": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30)(a)(3))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r230": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229" }, "r231": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230" }, "r232": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230" }, "r233": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "360", "URI": "http://asc.fasb.org/topic&trid=2155823" }, "r234": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "440", "URI": "http://asc.fasb.org/extlink&oid=121559207&loc=d3e25336-109308" }, "r235": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "440", "URI": "http://asc.fasb.org/extlink&oid=121559207&loc=d3e25336-109308" }, "r236": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "440", "URI": "http://asc.fasb.org/extlink&oid=121559207&loc=d3e25336-109308" }, "r237": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "440", "URI": "http://asc.fasb.org/extlink&oid=121559207&loc=d3e25383-109308" }, "r238": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "450", "URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14326-108349" }, "r239": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=120520924&loc=SL6036836-161870" }, "r24": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30)(a)(4))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r240": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21463-112644" }, "r241": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21475-112644" }, "r242": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.3-04)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770" }, "r243": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770" }, "r244": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=121556615&loc=SL49130531-203044" }, "r245": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=121556615&loc=SL49130532-203044" }, "r246": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=121556615&loc=SL49130533-203044" }, "r247": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130558-203045" }, "r248": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130561-203045" }, "r249": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130563-203045" }, "r25": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r250": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130563-203045" }, "r251": { "Name": "Accounting Standards Codification", "Paragraph": "19", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130564-203045" }, "r252": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130566-203045" }, "r253": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130566-203045" }, "r254": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130566-203045" }, "r255": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130566-203045" }, "r256": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130543-203045" }, "r257": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130545-203045" }, "r258": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130549-203045" }, "r259": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130549-203045" }, "r26": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(31))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r260": { "Name": "Accounting Standards Codification", "Paragraph": "91", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=121551570&loc=SL49130690-203046-203046" }, "r261": { "Name": "Accounting Standards Codification", "Paragraph": "91", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=121551570&loc=SL49130690-203046-203046" }, "r262": { "Name": "Accounting Standards Codification", "Paragraph": "91", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=121551570&loc=SL49130690-203046-203046" }, "r263": { "Name": "Accounting Standards Codification", "Paragraph": "91", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=121551570&loc=SL49130690-203046-203046" }, "r264": { "Name": "Accounting Standards Codification", "Paragraph": "91", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=121551570&loc=SL49130690-203046-203046" }, "r265": { "Name": "Accounting Standards Codification", "Paragraph": "91", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=121551570&loc=SL49130690-203046-203046" }, "r266": { "Name": "Accounting Standards Codification", "Paragraph": "91", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Subparagraph": "(g)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=121551570&loc=SL49130690-203046-203046" }, "r267": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=113356391&loc=SL49131195-203048" }, "r268": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "606", "URI": "http://asc.fasb.org/topic&trid=49130388" }, "r269": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(i)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920" }, "r27": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(32))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r270": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(ii)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920" }, "r271": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(01)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920" }, "r272": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(02)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920" }, "r273": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(02)(A)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920" }, "r274": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(02)(B)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920" }, "r275": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(02)(C)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920" }, "r276": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(03)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920" }, "r277": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(n)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920" }, "r278": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118257860&loc=d3e4179-114921" }, "r279": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "80", "Subparagraph": "(a)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450702-114947" }, "r28": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.1)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r280": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "80", "Subparagraph": "(d)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450657-114947" }, "r281": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "80", "Subparagraph": "(a)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450673-114947" }, "r282": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "55", "SubTopic": "80", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=35742348&loc=SL14450788-114948" }, "r283": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "35", "SubTopic": "10", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=121326096&loc=d3e4534-113899" }, "r284": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901" }, "r285": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901" }, "r286": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901" }, "r287": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a),(g)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r288": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(2)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r289": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(g)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r29": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.12)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r290": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)(1)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r291": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)(1)(i)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r292": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r293": { "Name": "Accounting Standards Codification", "Paragraph": "2A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=SL79508275-113901" }, "r294": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333" }, "r295": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333" }, "r296": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333" }, "r297": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333" }, "r298": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333" }, "r299": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(f)(1)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333" }, "r3": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6676-107765" }, "r30": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.13)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r300": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(f)(2)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333" }, "r301": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(g)(2)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333" }, "r302": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 14.F)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=115993241&loc=d3e301413-122809" }, "r303": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120383193&loc=d3e11149-113907" }, "r304": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120383193&loc=d3e11178-113907" }, "r305": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "718", "URI": "http://asc.fasb.org/topic&trid=2228938" }, "r306": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "730", "URI": "http://asc.fasb.org/extlink&oid=6420194&loc=d3e21568-108373" }, "r307": { "Name": "Accounting Standards Codification", "Paragraph": "10B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=120406818&loc=SL37586934-109318" }, "r308": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32672-109319" }, "r309": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32687-109319" }, "r31": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.14)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r310": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32705-109319" }, "r311": { "Name": "Accounting Standards Codification", "Paragraph": "15A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=SL6600010-109319" }, "r312": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32809-109319" }, "r313": { "Name": "Accounting Standards Codification", "Paragraph": "21", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32857-109319" }, "r314": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32639-109319" }, "r315": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "740" }, "r316": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "740" }, "r317": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)(2)", "Topic": "740" }, "r318": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)(3)", "Topic": "740" }, "r319": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(e)(3)", "Topic": "740" }, "r32": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.17)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r320": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB TOPIC 6.I.5.Q1)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=116825942&loc=d3e330036-122817" }, "r321": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB TOPIC 6.I.7)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=116825942&loc=d3e330036-122817" }, "r322": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 6.I.7)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=116825942&loc=d3e330036-122817" }, "r323": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 6.I.Fact.1)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=116825942&loc=d3e330036-122817" }, "r324": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 6.I.Fact.2)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=116825942&loc=d3e330036-122817" }, "r325": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 11.C)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=116825942&loc=d3e330215-122817" }, "r326": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=120385591&loc=d3e39076-109324" }, "r327": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=120385591&loc=d3e38679-109324" }, "r328": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "270", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=6424409&loc=d3e44925-109338" }, "r329": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=6424122&loc=d3e41874-109331" }, "r33": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19(a))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r330": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "740", "URI": "http://asc.fasb.org/topic&trid=2144680" }, "r331": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "05", "SubTopic": "10", "Subparagraph": "(a)-(d)", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=6909625&loc=d3e227-128457" }, "r332": { "Name": "Accounting Standards Codification", "Paragraph": "23", "Publisher": "FASB", "Section": "25", "SubTopic": "10", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=116868678&loc=d3e1043-128460" }, "r333": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(g)", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=79982066&loc=d3e1392-128463" }, "r334": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(g)(1)", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=79982066&loc=d3e1392-128463" }, "r335": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(g)(2)", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=79982066&loc=d3e1392-128463" }, "r336": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=79982066&loc=d3e1392-128463" }, "r337": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=79982066&loc=d3e1486-128463" }, "r338": { "Name": "Accounting Standards Codification", "Paragraph": "37", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=121600890&loc=d3e2207-128464" }, "r339": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=121647850&loc=d3e4845-128472" }, "r34": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19,20)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r340": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(e)(1)", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=121647850&loc=d3e4845-128472" }, "r341": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=121598580&loc=d3e5227-128473" }, "r342": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=121598580&loc=d3e5333-128473" }, "r343": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "25", "SubTopic": "30", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=6911189&loc=d3e6408-128476" }, "r344": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "35", "SubTopic": "30", "Subparagraph": "(b)", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=116859824&loc=d3e6819-128478" }, "r345": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(b)", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=120321790&loc=d3e6927-128479" }, "r346": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(b)(1)", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=120321790&loc=d3e6927-128479" }, "r347": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(c)(1)", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=120321790&loc=d3e6927-128479" }, "r348": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "805", "URI": "http://asc.fasb.org/topic&trid=2303972" }, "r349": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "808", "URI": "http://asc.fasb.org/extlink&oid=6931272&loc=SL5834143-161434" }, "r35": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19-26)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r350": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=108774443&loc=SL4568447-111683" }, "r351": { "Name": "Accounting Standards Codification", "Paragraph": "16", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=108774443&loc=SL4568740-111683" }, "r352": { "Name": "Accounting Standards Codification", "Paragraph": "19", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=108774443&loc=SL4569616-111683" }, "r353": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=108774443&loc=SL4569643-111683" }, "r354": { "Name": "Accounting Standards Codification", "Paragraph": "21", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=108774443&loc=SL4613674-111683" }, "r355": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988" }, "r356": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988" }, "r357": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(1)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684" }, "r358": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(2)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684" }, "r359": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684" }, "r36": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.20)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r360": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684" }, "r361": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(3)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684" }, "r362": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c),(3)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684" }, "r363": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(bb)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=121559654&loc=d3e5710-111685" }, "r364": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=121559654&loc=d3e5710-111685" }, "r365": { "Name": "Accounting Standards Codification", "Paragraph": "4I", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=120409616&loc=SL4590271-111686" }, "r366": { "Name": "Accounting Standards Codification", "Paragraph": "4J", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=120409616&loc=SL4591551-111686" }, "r367": { "Name": "Accounting Standards Codification", "Paragraph": "4K", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=120409616&loc=SL4591552-111686" }, "r368": { "Name": "Accounting Standards Codification", "Paragraph": "4A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=121590274&loc=SL5618551-113959" }, "r369": { "Name": "Accounting Standards Codification", "Paragraph": "4B", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=121590274&loc=SL5624163-113959" }, "r37": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.21)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r370": { "Name": "Accounting Standards Codification", "Paragraph": "182", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=121582272&loc=SL5629052-113961" }, "r371": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "65", "SubTopic": "20", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=121483254&loc=SL120254523-199619" }, "r372": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258" }, "r373": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258" }, "r374": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(bb)", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258" }, "r375": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(bbb)", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258" }, "r376": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(bbb)(1)", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258" }, "r377": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(bbb)(2)", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258" }, "r378": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258" }, "r379": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258" }, "r38": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.22(a)(1))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r380": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19279-110258" }, "r381": { "Name": "Accounting Standards Codification", "Paragraph": "6A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=SL6742756-110258" }, "r382": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "820", "URI": "http://asc.fasb.org/topic&trid=2155941" }, "r383": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "825", "URI": "http://asc.fasb.org/extlink&oid=99377092&loc=SL75136599-209740" }, "r384": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "825", "URI": "http://asc.fasb.org/extlink&oid=121572278&loc=d3e13531-108611" }, "r385": { "Name": "Accounting Standards Codification", "Paragraph": "21", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "825", "URI": "http://asc.fasb.org/extlink&oid=121572278&loc=d3e13537-108611" }, "r386": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "825", "URI": "http://asc.fasb.org/extlink&oid=75031198&loc=d3e14064-108612" }, "r387": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Topic": "825", "URI": "http://asc.fasb.org/extlink&oid=120240428&loc=SL120254526-165497" }, "r388": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "825", "URI": "http://asc.fasb.org/topic&trid=2134543" }, "r389": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=120253306&loc=d3e28129-110885" }, "r39": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.22)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r390": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "35", "SubTopic": "20", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=121605123&loc=d3e30304-110892" }, "r391": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "230", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=98513438&loc=d3e33268-110906" }, "r392": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32022-110900" }, "r393": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32136-110900" }, "r394": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(a)", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900" }, "r395": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(b)", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900" }, "r396": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(c)", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900" }, "r397": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(d)", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900" }, "r398": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900" }, "r399": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=6450520&loc=d3e32583-110901" }, "r4": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(g)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6676-107765" }, "r40": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.24)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r400": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=6450520&loc=d3e32618-110901" }, "r401": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "830", "URI": "http://asc.fasb.org/topic&trid=2175825" }, "r402": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "835", "URI": "http://asc.fasb.org/extlink&oid=6450988&loc=d3e26243-108391" }, "r403": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "835", "URI": "http://asc.fasb.org/extlink&oid=119993939&loc=d3e28551-108399" }, "r404": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "835", "URI": "http://asc.fasb.org/extlink&oid=119993939&loc=d3e28555-108399" }, "r405": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=121329987&loc=SL120154346-209984" }, "r406": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=121603541&loc=SL77918627-209977" }, "r407": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=121603541&loc=SL77918627-209977" }, "r408": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=121603541&loc=SL77918631-209977" }, "r409": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=121609121&loc=SL77918666-209980" }, "r41": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.25)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r410": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)(3)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=121609121&loc=SL77918673-209980" }, "r411": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=121609121&loc=SL77918673-209980" }, "r412": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=121609121&loc=SL77918686-209980" }, "r413": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=121609121&loc=SL77918686-209980" }, "r414": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(g)(2)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=121609121&loc=SL77918686-209980" }, "r415": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(g)(3)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=121609121&loc=SL77918686-209980" }, "r416": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(g)(4)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=121609121&loc=SL77918686-209980" }, "r417": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=121609121&loc=SL77918686-209980" }, "r418": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=121609121&loc=SL77918701-209980" }, "r419": { "Name": "Accounting Standards Codification", "Paragraph": "53", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=121568110&loc=SL77918982-209971" }, "r42": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.29-31)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r420": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=121561866&loc=SL77919311-209978" }, "r421": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=121576215&loc=SL77919396-209981" }, "r422": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(b)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=121576215&loc=SL77919372-209981" }, "r423": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(c)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=121576215&loc=SL77919372-209981" }, "r424": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=121576215&loc=SL77919372-209981" }, "r425": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "850", "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864" }, "r426": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "850", "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864" }, "r427": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "850", "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864" }, "r428": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "850", "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864" }, "r429": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "850", "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864" }, "r43": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.31)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r430": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "850", "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39603-107864" }, "r431": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "850", "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39691-107864" }, "r432": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "850", "URI": "http://asc.fasb.org/topic&trid=2122745" }, "r433": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "855", "URI": "http://asc.fasb.org/extlink&oid=6842918&loc=SL6314017-165662" }, "r434": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "855", "URI": "http://asc.fasb.org/extlink&oid=6842918&loc=SL6314017-165662" }, "r435": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "855", "URI": "http://asc.fasb.org/topic&trid=2122774" }, "r436": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(bb)(1)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r437": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(bb)(2)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r438": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(bb)(3)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r439": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)(1)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r44": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.8)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r440": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)(2)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r441": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)(3)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r442": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(1)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719" }, "r443": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(2)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719" }, "r444": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(3)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719" }, "r445": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "910", "URI": "http://asc.fasb.org/extlink&oid=119991564&loc=SL119991595-234733" }, "r446": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 11.L)", "Topic": "924", "URI": "http://asc.fasb.org/extlink&oid=6472922&loc=d3e499488-122856" }, "r447": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "926", "URI": "http://asc.fasb.org/extlink&oid=120154696&loc=d3e54445-107959" }, "r448": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "926", "URI": "http://asc.fasb.org/extlink&oid=120154821&loc=SL120154904-197079" }, "r449": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "926", "URI": "http://asc.fasb.org/extlink&oid=120154821&loc=SL120154904-197079" }, "r45": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.9)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r450": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "926", "URI": "http://asc.fasb.org/extlink&oid=120154821&loc=SL120154904-197079" }, "r451": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "340", "Topic": "928", "URI": "http://asc.fasb.org/extlink&oid=6473545&loc=d3e61844-108004" }, "r452": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(a)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=d3e61929-109447" }, "r453": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(b)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=d3e61929-109447" }, "r454": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(a)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=d3e62059-109447" }, "r455": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(b)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=d3e62059-109447" }, "r456": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(a)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=d3e62395-109447" }, "r457": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(b)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=d3e62395-109447" }, "r458": { "Name": "Accounting Standards Codification", "Paragraph": "33", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(a)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=d3e62479-109447" }, "r459": { "Name": "Accounting Standards Codification", "Paragraph": "33", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(b)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=d3e62479-109447" }, "r46": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "210", "URI": "http://asc.fasb.org/topic&trid=2122208" }, "r460": { "Name": "Accounting Standards Codification", "Paragraph": "35A", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(a)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=SL6807758-109447" }, "r461": { "Name": "Accounting Standards Codification", "Paragraph": "35A", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(b)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=SL6807758-109447" }, "r462": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(c)(1)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=d3e61872-109447" }, "r463": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(c)(2)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=d3e61872-109447" }, "r464": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(10)(1))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878" }, "r465": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(11))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878" }, "r466": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(13))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878" }, "r467": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(16))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878" }, "r468": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(22))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878" }, "r469": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(23))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878" }, "r47": { "Name": "Accounting Standards Codification", "Paragraph": "10A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a-c)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669646-108580" }, "r470": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(6))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878" }, "r471": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03.17)", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878" }, "r472": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(19))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260" }, "r473": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(13)(f))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260" }, "r474": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(20))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260" }, "r475": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(22))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260" }, "r476": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(23))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260" }, "r477": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(24))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260" }, "r478": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(25))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260" }, "r479": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(26))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260" }, "r48": { "Name": "Accounting Standards Codification", "Paragraph": "10A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669646-108580" }, "r480": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(27))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260" }, "r481": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04.9)", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260" }, "r482": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "235", "Subparagraph": "(SX 210.9-05(b)(2))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120399901&loc=d3e537907-122884" }, "r483": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "320", "Subparagraph": "(b)", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120252992&loc=d3e62557-112803" }, "r484": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "320", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120252992&loc=d3e62652-112803" }, "r485": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "470", "Subparagraph": "(a)", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=75038535&loc=d3e64711-112823" }, "r486": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "825", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=108315417&loc=d3e61044-112788" }, "r487": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(16))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r488": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(12))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r489": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(16))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r49": { "Name": "Accounting Standards Codification", "Paragraph": "10A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669646-108580" }, "r490": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(23)(a)(3))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r491": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r492": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(24))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r493": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(25))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r494": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(3))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r495": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(8))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r496": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03.(a),19)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r497": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(10))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263" }, "r498": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(11))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263" }, "r499": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(18))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263" }, "r5": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(g)(4)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6676-107765" }, "r50": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=d3e637-108580" }, "r500": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(19))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263" }, "r501": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(20))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263" }, "r502": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(21))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263" }, "r503": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(22))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263" }, "r504": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(23))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263" }, "r505": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(9))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263" }, "r506": { "Name": "Accounting Standards Codification", "Paragraph": "7A", "Publisher": "FASB", "Section": "50", "SubTopic": "40", "Subparagraph": "(d)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=121643868&loc=SL117782755-158439" }, "r507": { "Name": "Accounting Standards Codification", "Paragraph": "13H", "Publisher": "FASB", "Section": "55", "SubTopic": "40", "Subparagraph": "(b)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=121639165&loc=SL117783719-158441" }, "r508": { "Name": "Accounting Standards Codification", "Paragraph": "13H", "Publisher": "FASB", "Section": "55", "SubTopic": "40", "Subparagraph": "(c)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=121639165&loc=SL117783719-158441" }, "r509": { "Name": "Accounting Standards Codification", "Paragraph": "29F", "Publisher": "FASB", "Section": "55", "SubTopic": "40", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=121639165&loc=SL117819544-158441" }, "r51": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=d3e681-108580" }, "r510": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(a)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641" }, "r511": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(b)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641" }, "r512": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(e)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641" }, "r513": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(f)(1)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641" }, "r514": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(f)(2)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641" }, "r515": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(g)(1)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641" }, "r516": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(g)(2)(i)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641" }, "r517": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(g)(2)(ii)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641" }, "r518": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(g)(2)(iii)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641" }, "r519": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(g)(2)(iv)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641" }, "r52": { "Name": "Accounting Standards Codification", "Paragraph": "14A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669686-108580" }, "r520": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(h)(1)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641" }, "r521": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(h)(2)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641" }, "r522": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "80", "Subparagraph": "(e)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=121641442&loc=d3e19393-158473" }, "r523": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "825", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=99380617&loc=SL75241803-196195" }, "r524": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.6-07.1(c))", "Topic": "946", "URI": "http://asc.fasb.org/extlink&oid=120401555&loc=SL114874292-224272" }, "r525": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-12.2(ii))", "Topic": "946", "URI": "http://asc.fasb.org/extlink&oid=120401592&loc=d3e611133-123010" }, "r526": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-12B(Column B)(Footnote 1))", "Topic": "946", "URI": "http://asc.fasb.org/extlink&oid=120401592&loc=d3e611197-123010" }, "r527": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-12B(Column B)(Footnote 2))", "Topic": "946", "URI": "http://asc.fasb.org/extlink&oid=120401592&loc=d3e611197-123010" }, "r528": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-12B(Column B)(Footnote 6))", "Topic": "946", "URI": "http://asc.fasb.org/extlink&oid=120401592&loc=d3e611197-123010" }, "r529": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-12B(Column B)(Footnote 7))", "Topic": "946", "URI": "http://asc.fasb.org/extlink&oid=120401592&loc=d3e611197-123010" }, "r53": { "Name": "Accounting Standards Codification", "Paragraph": "17B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL34724394-108580" }, "r530": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-12B(Column C)(Footnote 1))", "Topic": "946", "URI": "http://asc.fasb.org/extlink&oid=120401592&loc=d3e611197-123010" }, "r531": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-12B(Column C)(Footnote 2))", "Topic": "946", "URI": "http://asc.fasb.org/extlink&oid=120401592&loc=d3e611197-123010" }, "r532": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-12B(Column C)(Footnote 6))", "Topic": "946", "URI": "http://asc.fasb.org/extlink&oid=120401592&loc=d3e611197-123010" }, "r533": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-12B(Column C)(Footnote 7))", "Topic": "946", "URI": "http://asc.fasb.org/extlink&oid=120401592&loc=d3e611197-123010" }, "r534": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-12B(Column D)(Footnote 1))", "Topic": "946", "URI": "http://asc.fasb.org/extlink&oid=120401592&loc=d3e611197-123010" }, "r535": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-12B(Column D)(Footnote 2))", "Topic": "946", "URI": "http://asc.fasb.org/extlink&oid=120401592&loc=d3e611197-123010" }, "r536": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-12B(Column D)(Footnote 6))", "Topic": "946", "URI": "http://asc.fasb.org/extlink&oid=120401592&loc=d3e611197-123010" }, "r537": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-12B(Column D)(Footnote 7))", "Topic": "946", "URI": "http://asc.fasb.org/extlink&oid=120401592&loc=d3e611197-123010" }, "r538": { "Name": "Accounting Standards Codification", "Paragraph": "5D", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-13D(Column B)(Footnote 2))", "Topic": "946", "URI": "http://asc.fasb.org/extlink&oid=120401592&loc=SL120429264-123010" }, "r539": { "Name": "Accounting Standards Codification", "Paragraph": "5D", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-13D(Column C)(Footnote 2))", "Topic": "946", "URI": "http://asc.fasb.org/extlink&oid=120401592&loc=SL120429264-123010" }, "r54": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669619-108580" }, "r540": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-15(Column A))", "Topic": "946", "URI": "http://asc.fasb.org/extlink&oid=120401592&loc=d3e611379-123010" }, "r541": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-15(Column B))", "Topic": "946", "URI": "http://asc.fasb.org/extlink&oid=120401592&loc=d3e611379-123010" }, "r542": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-15(Column C))", "Topic": "946", "URI": "http://asc.fasb.org/extlink&oid=120401592&loc=d3e611379-123010" }, "r543": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-15(Column D))", "Topic": "946", "URI": "http://asc.fasb.org/extlink&oid=120401592&loc=d3e611379-123010" }, "r544": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "310", "Subparagraph": "(SX 210.12-29(Footnote 4))", "Topic": "948", "URI": "http://asc.fasb.org/extlink&oid=120402547&loc=d3e617274-123014" }, "r545": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "360", "Subparagraph": "(d)", "Topic": "958", "URI": "http://asc.fasb.org/extlink&oid=120429125&loc=d3e99779-112916" }, "r546": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "360", "Topic": "958", "URI": "http://asc.fasb.org/extlink&oid=120429125&loc=d3e99893-112916" }, "r547": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "360", "Topic": "958", "URI": "http://asc.fasb.org/extlink&oid=120429125&loc=SL120174063-112916" }, "r548": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column B))", "Topic": "970", "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024" }, "r549": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column C))", "Topic": "970", "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024" }, "r55": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669619-108580" }, "r550": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column D))", "Topic": "970", "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024" }, "r551": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column E))", "Topic": "970", "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024" }, "r552": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column F))", "Topic": "970", "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024" }, "r553": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column G))", "Topic": "970", "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024" }, "r554": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column H))", "Topic": "970", "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024" }, "r555": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column I))", "Topic": "970", "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024" }, "r556": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Footnote 2))", "Topic": "970", "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024" }, "r557": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "985", "URI": "http://asc.fasb.org/extlink&oid=6501960&loc=d3e128462-111756" }, "r558": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b" }, "r559": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "d1-1" }, "r56": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669619-108580" }, "r560": { "Name": "Form 10-Q", "Number": "240", "Publisher": "SEC", "Section": "308", "Subsection": "a" }, "r561": { "Name": "Forms 10-K, 10-Q, 20-F", "Number": "240", "Publisher": "SEC", "Section": "13", "Subsection": "a-1" }, "r562": { "Name": "Regulation 12B", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-2" }, "r563": { "Name": "Regulation S-T", "Number": "232", "Publisher": "SEC", "Section": "405" }, "r564": { "Name": "Securities Act", "Number": "7A", "Publisher": "SEC", "Section": "B", "Subsection": "2" }, "r57": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669625-108580" }, "r58": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669625-108580" }, "r59": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=d3e557-108580" }, "r6": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6676-107765" }, "r60": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=121640130&loc=d3e1436-108581" }, "r61": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(13))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868656-224227" }, "r62": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(210.5-03(11))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227" }, "r63": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(12))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227" }, "r64": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(20))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227" }, "r65": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(21))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227" }, "r66": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(22))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227" }, "r67": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(23))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227" }, "r68": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(24))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227" }, "r69": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(25))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227" }, "r7": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6787-107765" }, "r70": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(4))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227" }, "r71": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(5))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227" }, "r72": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.1(e))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227" }, "r73": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.1,2)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227" }, "r74": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.2)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227" }, "r75": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.4)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227" }, "r76": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.8)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227" }, "r77": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3179-108585" }, "r78": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3213-108585" }, "r79": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3213-108585" }, "r8": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6801-107765" }, "r80": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3255-108585" }, "r81": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3255-108585" }, "r82": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3255-108585" }, "r83": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3291-108585" }, "r84": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3000-108585" }, "r85": { "Name": "Accounting Standards Codification", "Paragraph": "24", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3521-108585" }, "r86": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3536-108585" }, "r87": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3536-108585" }, "r88": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3602-108585" }, "r89": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3602-108585" }, "r9": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6812-107765" }, "r90": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3602-108585" }, "r91": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3044-108585" }, "r92": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=121583591&loc=d3e4297-108586" }, "r93": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=121583591&loc=d3e4304-108586" }, "r94": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=121583591&loc=d3e4313-108586" }, "r95": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=121583591&loc=d3e4332-108586" }, "r96": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=121583591&loc=SL98516268-108586" }, "r97": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=84158767&loc=d3e18780-107790" }, "r98": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=84158767&loc=d3e18823-107790" }, "r99": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(g)(1)(ii))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" } }, "version": "2.1" } ZIP 88 0001564590-21-042834-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001564590-21-042834-xbrl.zip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â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